US8168418B2	NNP	O
-	:	O
Expression	NN	O
of	IN	O
HIV	NNP	O
polypeptides	NNS	O
and	CC	O
production	NN	O
of	IN	O
virus-like	JJ	O
particles	NNS	O
-	:	O
Google	NNP	O
Patents	NNP	O
Info	NNP	O
Links	NNP	O
Images	NNP	O
Classifications	NNP	O
Abstract	NNP	O
Description	NNP	O
CROSS-REFERENCE	NNP	O
TO	NNP	O
RELATED	NNP	O
APPLICATIONS	NNP	O
This	DT	O
application	NN	O
is	VBZ	O
a	DT	O
division	NN	O
of	IN	O
Ser	NNP	O
.	.	O
No	DT	O
.	.	O
12/026,619	CD	O
,	,	O
filed	VBD	O
Feb.	NNP	O
6	CD	O
,	,	O
2008	CD	O
,	,	O
now	RB	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
7,718,401	CD	O
,	,	O
issued	VBN	O
May	NNP	O
18	CD	O
,	,	O
2010	CD	O
,	,	O
which	WDT	O
is	VBZ	O
a	DT	O
division	NN	O
of	IN	O
Ser	NNP	O
.	.	O
No	DT	O
.	.	O
10/387,336	CD	O
filed	VBD	O
Mar	NNP	O
.	.	O
11	CD	O
,	,	O
2003	CD	O
,	,	O
now	RB	O
issued	VBN	O
as	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
7,348,177	CD	O
,	,	O
which	WDT	O
is	VBZ	O
a	DT	O
continuation	NN	O
of	IN	O
Ser	NNP	O
.	.	O
No	DT	O
.	.	O
09/475,515	CD	O
,	,	O
filed	VBN	O
Dec.	NNP	O
30	CD	O
,	,	O
1999	CD	O
,	,	O
now	RB	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
6,602,705	CD	O
,	,	O
and	CC	O
which	WDT	O
claims	VBZ	O
the	DT	O
benefit	NN	O
of	IN	O
Ser	NNP	O
.	.	O
No	DT	O
.	.	O
60/114,495	CD	O
filed	VBN	O
Dec.	NNP	O
31	CD	O
,	,	O
1998	CD	O
and	CC	O
Ser	NNP	O
.	.	O
No	DT	O
.	.	O
60/168,471	CD	O
filed	VBN	O
Dec.	NNP	O
1	CD	O
,	,	O
1999	CD	O
.	.	O
Each	DT	O
of	IN	O
these	DT	O
applications	NNS	O
is	VBZ	O
incorporated	VBN	O
herein	NN	O
by	IN	O
reference	NN	O
in	IN	O
its	PRP$	O
entirety	NN	O
.	.	O
INCORPORATION	NNP	O
OF	NNP	O
SEQUENCE	NNP	O
LISTING	NNP	O
BY	NNP	O
REFERENCE	NNP	O
This	DT	O
application	NN	O
incorporates	VBZ	O
by	IN	O
reference	NN	O
the	DT	O
contents	NNS	O
of	IN	O
a	DT	O
190	CD	O
kb	NN	O
text	NN	O
file	NN	O
created	VBD	O
on	IN	O
Nov.	NNP	O
24	CD	O
,	,	O
2010	CD	O
and	CC	O
named	VBD	O
“	NNP	O
51381.txt	CD	O
,	,	O
”	NN	O
which	WDT	O
is	VBZ	O
the	DT	O
sequence	NN	O
listing	NN	O
for	IN	O
this	DT	O
application	NN	O
.	.	O
TECHNICAL	NNP	O
FIELD	NNP	O
Synthetic	NNP	O
expression	NN	O
cassettes	VBZ	O
encoding	VBG	O
the	DT	O
HIV	NNP	O
polypeptides	NNS	O
(	(	O
e.g.	NN	O
,	,	O
Gag-	NNP	O
,	,	O
pol-	JJ	O
,	,	O
prot-	JJ	O
,	,	O
reverse	JJ	O
transcriptase	NN	O
,	,	O
Env-	NNP	O
or	CC	O
tat-containing	JJ	O
polypeptides	NNS	O
)	)	O
are	VBP	O
described	VBN	O
,	,	O
as	IN	O
are	VBP	O
uses	NNS	O
of	IN	O
the	DT	O
expression	NN	O
cassettes	NNS	O
.	.	O
The	DT	O
present	JJ	O
invention	NN	O
relates	VBZ	O
to	TO	O
the	DT	O
efficient	JJ	O
expression	NN	O
of	IN	O
HIV	NNP	O
polypeptides	NNS	O
in	IN	O
a	DT	O
variety	NN	O
of	IN	O
cell	NN	O
types	NNS	O
.	.	O
Further	RB	O
,	,	O
the	DT	O
invention	NN	O
provides	VBZ	O
methods	NNS	O
of	IN	O
producing	VBG	O
Virus-Like	JJ	O
Particles	NNP	O
(	(	O
VLPs	NNP	O
)	)	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
,	,	O
uses	VBZ	O
of	IN	O
the	DT	O
VLPs	NNP	O
and	CC	O
high	JJ	O
level	NN	O
expression	NN	O
of	IN	O
oligomeric	JJ	O
envelope	NN	O
proteins	NNS	O
.	.	O
BACKGROUND	NNP	O
OF	IN	O
THE	NNP	O
INVENTION	NNP	O
Acquired	NNP	O
immune	JJ	O
deficiency	NN	O
syndrome	NN	O
(	(	O
AIDS	NNP	O
)	)	O
is	VBZ	O
recognized	VBN	O
as	IN	O
one	CD	O
of	IN	O
the	DT	O
greatest	JJS	O
health	NN	O
threats	NNS	O
facing	VBG	O
modern	JJ	O
medicine	NN	O
.	.	O
There	EX	O
is	VBZ	O
,	,	O
as	IN	O
yet	RB	O
,	,	O
no	DT	O
cure	NN	O
for	IN	O
this	DT	O
disease	NN	O
.	.	O
In	IN	O
1983-1984	CD	O
,	,	O
three	CD	O
groups	NNS	O
independently	RB	O
identified	VBD	O
the	DT	O
suspected	JJ	O
etiological	JJ	O
agent	NN	O
of	IN	O
AIDS	NNP	O
.	.	O
See	VB	O
,	,	O
e.g.	VB	O
,	,	O
Barre-Sinoussi	NNP	B
et	FW	I
al	NN	I
.	.	I
(	(	I
1983	CD	I
)	)	I
Science	NNP	I
220:868-871	CD	I
;	:	O
Montagnier	NNP	B
et	FW	I
al.	NN	I
,	,	I
in	IN	I
Human	NNP	I
T-Cell	NNP	I
Leukemia	NNP	I
Viruses	NNP	I
(	(	I
Gallo	NNP	I
,	,	I
Essex	NNP	I
&	CC	I
Gross	NNP	I
,	,	I
eds.	NN	I
,	,	I
1984	CD	I
)	)	I
;	:	O
Vilmer	NNP	B
et	FW	I
al	NN	I
.	.	I
(	(	I
1984	CD	I
)	)	I
The	DT	I
Lancet	NNP	I
1:753	CD	I
;	:	O
Popovic	NNP	B
et	FW	I
al	NN	I
.	.	I
(	(	I
1984	CD	I
)	)	I
Science	NNP	I
224:497-500	CD	I
;	:	O
Levy	NNP	B
et	FW	I
al	NN	I
.	.	I
(	(	I
1984	CD	I
)	)	I
Science	NNP	I
225:840-842	CD	I
.	.	O
These	DT	O
isolates	NNS	O
were	VBD	O
variously	RB	O
called	VBN	O
lymphadenopathy-associated	JJ	O
virus	NN	O
(	(	O
LAV	NNP	O
)	)	O
,	,	O
human	JJ	O
T-cell	NNP	O
lymphotropic	NN	O
virus	NN	O
type	NN	O
III	NNP	O
(	(	O
HTLV-III	NNP	O
)	)	O
,	,	O
or	CC	O
AIDS-associated	JJ	O
retrovirus	NN	O
(	(	O
ARV	NNP	O
)	)	O
.	.	O
All	DT	O
of	IN	O
these	DT	O
isolates	NNS	O
are	VBP	O
strains	NNS	O
of	IN	O
the	DT	O
same	JJ	O
virus	NN	O
,	,	O
and	CC	O
were	VBD	O
later	RB	O
collectively	RB	O
named	VBN	O
Human	NNP	O
Immunodeficiency	NNP	O
Virus	NNP	O
(	(	O
HIV	NNP	O
)	)	O
.	.	O
With	IN	O
the	DT	O
isolation	NN	O
of	IN	O
a	DT	O
related	JJ	O
AIDS-causing	JJ	O
virus	NN	O
,	,	O
the	DT	O
strains	NNS	O
originally	RB	O
called	VBN	O
HIV	NNP	O
are	VBP	O
now	RB	O
termed	VBN	O
HIV-1	NNP	O
and	CC	O
the	DT	O
related	JJ	O
virus	NN	O
is	VBZ	O
called	VBN	O
HIV-2	NNP	O
See	NNP	O
,	,	O
e.g.	RB	O
,	,	O
Guyader	NNP	B
et	CC	I
al	NN	I
.	.	I
(	(	I
1987	CD	I
)	)	I
Nature	NNP	I
326:662-669	JJ	I
;	:	O
Brun-Vezinet	NNP	B
et	FW	I
al	NN	I
.	.	I
(	(	I
1986	CD	I
)	)	I
233:343-346	CD	I
;	:	O
Clavel	NNP	B
et	FW	I
al	NN	I
.	.	I
(	(	I
1986	CD	I
)	)	I
Nature	NN	I
324:691-695	JJ	I
.	.	O
A	DT	O
great	JJ	O
deal	NN	O
of	IN	O
information	NN	O
has	VBZ	O
been	VBN	O
gathered	VBN	O
about	IN	O
the	DT	O
HIV	NNP	O
virus	NN	O
,	,	O
however	RB	O
,	,	O
to	TO	O
date	NN	O
an	DT	O
effective	JJ	O
vaccine	NN	O
has	VBZ	O
not	RB	O
been	VBN	O
identified	VBN	O
.	.	O
Several	JJ	O
targets	NNS	O
for	IN	O
vaccine	NN	O
development	NN	O
have	VBP	O
been	VBN	O
examined	VBN	O
including	VBG	O
the	DT	O
env	NN	O
,	,	O
Gag	NNP	O
,	,	O
poi	NN	O
and	CC	O
tat	JJ	O
gene	NN	O
products	NNS	O
encoded	VBN	O
by	IN	O
HIV	NNP	O
.	.	O
Haas	NNP	B
,	,	I
et	FW	I
al.	NN	I
,	,	I
(	(	I
Current	NNP	I
Biology	NNP	I
6	CD	I
(	(	I
3	CD	I
)	)	I
:315-324	NN	I
,	,	I
1996	CD	I
)	)	I
suggested	VBD	O
that	IN	O
selective	JJ	O
codon	NN	O
usage	NN	O
by	IN	O
HIV-1	NNP	O
appeared	VBD	O
to	TO	O
account	VB	O
for	IN	O
a	DT	O
substantial	JJ	O
fraction	NN	O
of	IN	O
the	DT	O
inefficiency	NN	O
of	IN	O
viral	JJ	O
protein	NN	O
synthesis	NN	O
.	.	O
Andre	NNP	B
,	,	I
et	FW	I
al.	NN	I
,	,	I
(	(	I
J.	NNP	I
Virol	NNP	I
.	.	I
72	CD	I
(	(	I
2	CD	I
)	)	I
:1497-1503	NN	I
,	,	I
1998	CD	I
)	)	I
described	VBD	O
an	DT	O
increased	VBN	O
immune	NN	O
response	NN	O
elicited	VBN	O
by	IN	O
DNA	NNP	O
vaccination	NN	O
employing	VBG	O
a	DT	O
synthetic	JJ	O
gp120	NN	O
sequence	NN	O
with	IN	O
optimized	JJ	O
codon	NN	O
usage	NN	O
.	.	O
Schneider	NNP	B
,	,	I
et	FW	I
al.	NN	I
,	,	I
(	(	I
J.	NNP	I
Virol	NNP	I
.	.	I
71	CD	I
(	(	I
7	CD	I
)	)	I
:4892-4903	NN	I
,	,	I
1997	CD	I
)	)	I
discuss	NN	O
inactivation	NN	O
of	IN	O
inhibitory	NN	O
(	(	O
or	CC	O
instability	NN	O
)	)	O
elements	NNS	O
(	(	O
INS	NNP	O
)	)	O
located	VBD	O
within	IN	O
the	DT	O
coding	VBG	O
sequences	NNS	O
of	IN	O
the	DT	O
Gag	NNP	O
and	CC	O
Gag-protease	NNP	O
coding	NN	O
sequences	NNS	O
.	.	O
The	DT	O
Gag	NNP	O
proteins	NNS	O
of	IN	O
HIV-1	NNP	O
are	VBP	O
necessary	JJ	O
for	IN	O
the	DT	O
assembly	NN	O
of	IN	O
virus-like	JJ	O
particles	NNS	O
.	.	O
HIV-1	NNP	O
Gag	NNP	O
proteins	NNS	O
are	VBP	O
involved	VBN	O
in	IN	O
many	JJ	O
stages	NNS	O
of	IN	O
the	DT	O
life	NN	O
cycle	NN	O
of	IN	O
the	DT	O
virus	NN	O
including	VBG	O
,	,	O
assembly	RB	O
,	,	O
virion	NN	O
maturation	NN	O
after	IN	O
particle	NN	O
release	NN	O
,	,	O
and	CC	O
early	RB	O
post-entry	NN	O
steps	NNS	O
in	IN	O
virus	NN	O
replication	NN	O
.	.	O
The	DT	O
roles	NNS	O
of	IN	O
HIV-1	NNP	O
Gag	NNP	O
proteins	NNS	O
are	VBP	O
numerous	JJ	O
and	CC	O
complex	JJ	O
(	(	O
Freed	NNP	B
,	,	I
E.	NNP	I
O.	NNP	I
,	,	I
Virology	NNP	I
251:1-15	CD	I
,	,	I
1998	CD	I
)	)	O
.	.	O
Wolf	NNP	B
,	,	I
et	FW	I
al.	NN	I
,	,	I
(	(	I
PCT	NNP	I
International	NNP	I
Application	NNP	I
,	,	I
WO	NNP	I
96/30523	CD	I
,	,	I
published	VBD	I
3	CD	I
Oct.	NNP	I
1996	CD	I
;	:	O
European	JJ	B
Patent	NNP	I
Application	NNP	I
,	,	I
Publication	NNP	I
No	NNP	I
.	.	I
0	CD	I
449	CD	I
116	CD	I
A1	NNP	I
,	,	I
published	VBD	I
2	CD	I
Oct.	NNP	I
1991	CD	I
)	)	O
have	VBP	O
described	VBN	O
the	DT	O
use	NN	O
of	IN	O
altered	JJ	O
pr55	NN	O
Gag	NNP	O
of	IN	O
HIV-1	NNP	O
to	TO	O
act	VB	O
as	IN	O
a	DT	O
non-infectious	JJ	O
retroviral-like	JJ	O
particulate	NN	O
carrier	NN	O
,	,	O
in	IN	O
particular	JJ	O
,	,	O
for	IN	O
the	DT	O
presentation	NN	O
of	IN	O
immunologically	RB	O
important	JJ	O
epitopes	NNS	O
.	.	O
Wang	NNP	B
,	,	I
et	FW	I
al.	NN	I
,	,	I
(	(	I
Virology	NNP	I
200:524-534	CD	I
,	,	I
1994	CD	I
)	)	I
describe	VB	O
a	DT	O
system	NN	O
to	TO	O
study	VB	O
assembly	NN	O
of	IN	O
HIV	NNP	O
Gag-β-galactosidase	NNP	O
fusion	NN	O
proteins	VBZ	O
into	IN	O
virions	NNS	O
.	.	O
They	PRP	O
describe	VBP	O
the	DT	O
construction	NN	O
of	IN	O
sequences	NNS	O
encoding	VBG	O
HIV	NNP	O
Gag-β-galactosidase	NNP	O
fusion	NN	O
proteins	NNS	O
,	,	O
the	DT	O
expression	NN	O
of	IN	O
such	JJ	O
sequences	NNS	O
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
HIV	NNP	O
Gag	NNP	O
proteins	VBZ	O
,	,	O
and	CC	O
assembly	RB	O
of	IN	O
these	DT	O
proteins	NNS	O
into	IN	O
virus	NN	O
particles	NNS	O
.	.	O
Recently	RB	O
,	,	O
Shiver	NNP	O
,	,	O
et	FW	O
al.	NN	O
,	,	O
(	(	O
PCT	NNP	O
International	NNP	O
Application	NNP	O
,	,	O
WO	NNP	O
98/34640	CD	O
,	,	O
published	VBN	O
13	CD	O
Aug.	NNP	O
1998	CD	O
)	)	O
described	VBD	O
altering	VBG	O
HIV-1	NNP	O
(	(	O
CAM1	NNP	O
)	)	O
Gag	NNP	O
coding	VBG	O
sequences	NNS	O
to	TO	O
produce	VB	O
synthetic	JJ	O
DNA	NNP	O
molecules	NNS	O
encoding	VBG	O
HIV	NNP	O
Gag	NNP	O
and	CC	O
modifications	NNS	O
of	IN	O
HIV	NNP	O
Gag	NNP	O
.	.	O
The	DT	O
codons	NNS	O
of	IN	O
the	DT	O
synthetic	JJ	O
molecules	NNS	O
were	VBD	O
codons	NNS	O
preferred	VBN	O
by	IN	O
a	DT	O
projected	VBN	O
host	NN	O
cell	NN	O
.	.	O
The	DT	O
envelope	NN	O
protein	NN	O
of	IN	O
HIV-1	NNP	O
is	VBZ	O
a	DT	O
glycoprotein	NN	O
of	IN	O
about	IN	O
160	CD	O
kD	NNS	O
(	(	O
gp160	NN	O
)	)	O
.	.	O
During	IN	O
virus	JJ	O
infection	NN	O
of	IN	O
the	DT	O
host	NN	O
cell	NN	O
,	,	O
gp160	NN	O
is	VBZ	O
cleaved	VBN	O
by	IN	O
host	NN	O
cell	NN	O
proteases	VBZ	O
to	TO	O
form	VB	O
gp120	NN	O
and	CC	O
the	DT	O
integral	JJ	O
membrane	NN	O
protein	NN	O
,	,	O
gp41	NN	O
.	.	O
The	DT	O
gp41	JJ	O
portion	NN	O
is	VBZ	O
anchored	VBN	O
in	IN	O
(	(	O
and	CC	O
spans	NNS	O
)	)	O
the	DT	O
membrane	NN	O
bilayer	NN	O
of	IN	O
virion	NN	O
,	,	O
while	IN	O
the	DT	O
gp120	NN	O
segment	NN	O
protrudes	VBZ	O
into	IN	O
the	DT	O
surrounding	VBG	O
environment	NN	O
.	.	O
As	IN	O
there	EX	O
is	VBZ	O
no	DT	O
covalent	JJ	O
attachment	NN	O
between	IN	O
gp120	NN	O
and	CC	O
gp41	NN	O
,	,	O
free	JJ	O
gp120	NN	O
is	VBZ	O
released	VBN	O
from	IN	O
the	DT	O
surface	NN	O
of	IN	O
virions	NNS	O
and	CC	O
infected	JJ	O
cells	NNS	O
.	.	O
Haas	NNP	B
,	,	I
et	FW	I
al.	NN	I
,	,	I
(	(	I
Current	NNP	I
Biology	NNP	I
6	CD	I
(	(	I
3	CD	I
)	)	I
:315-324	NN	I
,	,	I
1996	CD	I
)	)	I
suggested	VBD	O
that	IN	O
selective	JJ	O
codon	NN	O
usage	NN	O
by	IN	O
HIV-1	NNP	O
appeared	VBD	O
to	TO	O
account	VB	O
for	IN	O
a	DT	O
substantial	JJ	O
fraction	NN	O
of	IN	O
the	DT	O
inefficiency	NN	O
of	IN	O
viral	JJ	O
protein	NN	O
synthesis	NN	O
.	.	O
Andre	NNP	B
,	,	I
et	FW	I
al.	NN	I
,	,	I
(	(	I
J.	NNP	I
Virol	NNP	I
.	.	I
72	CD	I
(	(	I
2	CD	I
)	)	I
:1497-1503	NN	I
,	,	I
1998	CD	I
)	)	I
described	VBD	O
an	DT	O
increased	VBN	O
immune	NN	O
response	NN	O
elicited	VBN	O
by	IN	O
DNA	NNP	O
vaccination	NN	O
employing	VBG	O
a	DT	O
synthetic	JJ	O
gp120	NN	O
sequence	NN	O
with	IN	O
optimized	JJ	O
codon	NN	O
usage	NN	O
.	.	O
SUMMARY	NN	O
OF	IN	O
THE	NNP	O
INVENTION	NNP	O
The	DT	O
present	JJ	O
invention	NN	O
relates	VBZ	O
to	TO	O
improved	JJ	O
expression	NN	O
of	IN	O
HIV	NNP	O
Env-	NNP	O
,	,	O
tat-	JJ	O
,	,	O
pol-	JJ	O
,	,	O
prot-	JJ	O
,	,	O
reverse	JJ	O
transcriptase	NN	O
,	,	O
or	CC	O
Gag-containing	NNP	O
polypeptides	NNS	O
and	CC	O
production	NN	O
of	IN	O
virus-like	JJ	O
particles	NNS	O
.	.	O
In	IN	O
one	CD	O
embodiment	NN	O
the	DT	O
present	JJ	O
invention	NN	O
includes	VBZ	O
an	DT	O
expression	NN	O
cassette	NN	O
,	,	O
comprising	VBG	O
a	DT	O
polynucleotide	NN	O
encoding	VBG	O
an	DT	O
HIV	NNP	O
Gag	NNP	O
polypeptide	IN	O
comprising	VBG	O
a	DT	O
sequence	NN	O
having	VBG	O
at	IN	O
least	JJS	O
90	CD	O
%	NN	O
sequence	NN	O
identity	NN	O
to	TO	O
the	DT	O
sequence	NN	O
presented	VBD	O
as	IN	O
SEQ	NNP	O
ID	NNP	O
NO:20	NNP	O
.	.	O
In	IN	O
certain	JJ	O
embodiments	NNS	O
,	,	O
the	DT	O
polynucleotide	NN	O
sequence	NN	O
encoding	VBG	O
said	VBD	O
Gag	NNP	O
polypeptide	NN	O
comprises	VBZ	O
a	DT	O
sequence	NN	O
having	VBG	O
at	IN	O
least	JJS	O
90	CD	O
%	NN	O
sequence	NN	O
identity	NN	O
to	TO	O
the	DT	O
sequence	NN	O
presented	VBD	O
as	IN	O
SEQ	NNP	O
ID	NNP	O
NO:9	NNP	O
or	CC	O
SEQ	NNP	O
ID	NNP	O
NO:4	NNP	O
.	.	O
The	DT	O
expression	NN	O
cassettes	NNS	O
may	MD	O
further	RB	O
include	VB	O
a	DT	O
polynucleotide	JJ	O
sequence	NN	O
encoding	VBG	O
an	DT	O
HIV	NNP	O
protease	NN	O
polypeptide	NN	O
,	,	O
for	IN	O
example	NN	O
a	DT	O
nucleotide	JJ	O
sequence	NN	O
having	VBG	O
at	IN	O
least	JJS	O
90	CD	O
%	NN	O
sequence	NN	O
identity	NN	O
to	TO	O
a	DT	O
sequence	NN	O
selected	VBN	O
from	IN	O
the	DT	O
group	NN	O
consisting	VBG	O
of	IN	O
:	:	O
SEQ	NNP	O
ID	NNP	O
NO:5	NNP	O
,	,	O
SEQ	NNP	O
ID	NNP	O
NO:78	NNP	O
,	,	O
and	CC	O
SEQ	NNP	O
ID	NNP	O
NO:79	NNP	O
.	.	O
The	DT	O
expression	NN	O
cassettes	NNS	O
may	MD	O
further	RB	O
include	VB	O
a	DT	O
polynucleotide	JJ	O
sequence	NN	O
encoding	VBG	O
an	DT	O
HIV	NNP	O
reverse	NN	O
transcriptase	NN	O
polypeptide	NN	O
,	,	O
for	IN	O
example	NN	O
a	DT	O
sequence	NN	O
having	VBG	O
at	IN	O
least	JJS	O
90	CD	O
%	NN	O
sequence	NN	O
identity	NN	O
to	TO	O
a	DT	O
sequence	NN	O
selected	VBN	O
from	IN	O
the	DT	O
group	NN	O
consisting	VBG	O
of	IN	O
:	:	O
SEQ	NNP	O
ID	NNP	O
NO:80	NNP	O
,	,	O
SEQ	NNP	O
ID	NNP	O
NO:81	NNP	O
,	,	O
SEQ	NNP	O
ID	NNP	O
NO:82	NNP	O
,	,	O
SEQ	NNP	O
ID	NNP	O
NO:83	NNP	O
,	,	O
and	CC	O
SEQ	NNP	O
ID	NNP	O
NO:84	NNP	O
.	.	O
The	DT	O
expression	NN	O
cassettes	NNS	O
may	MD	O
further	RB	O
include	VB	O
a	DT	O
polynucleotide	JJ	O
sequence	NN	O
encoding	VBG	O
an	DT	O
HIV	NNP	O
tat	NN	O
polypeptide	NN	O
,	,	O
for	IN	O
example	NN	O
a	DT	O
sequence	NN	O
selected	VBN	O
from	IN	O
the	DT	O
group	NN	O
consisting	VBG	O
of	IN	O
:	:	O
SEQ	NNP	O
ID	NNP	O
NO:87	NNP	O
,	,	O
SEQ	NNP	O
ID	NNP	O
NO:88	NNP	O
,	,	O
and	CC	O
SEQ	NNP	O
ID	NNP	O
NO:89	NNP	O
.	.	O
The	DT	O
expression	NN	O
cassettes	NNS	O
may	MD	O
further	RB	O
include	VB	O
a	DT	O
polynucleotide	JJ	O
sequence	NN	O
encoding	VBG	O
an	DT	O
HIV	NNP	O
polymerase	NN	O
polypeptide	NN	O
,	,	O
for	IN	O
example	NN	O
a	DT	O
sequence	NN	O
having	VBG	O
at	IN	O
least	JJS	O
90	CD	O
%	NN	O
sequence	NN	O
identity	NN	O
to	TO	O
the	DT	O
sequence	NN	O
presented	VBD	O
as	IN	O
SEQ	NNP	O
ID	NNP	O
NO:6	NNP	O
.	.	O
The	DT	O
expression	NN	O
cassettes	VBZ	O
may	MD	O
include	VB	O
a	DT	O
polynucleotide	JJ	O
sequence	NN	O
encoding	VBG	O
an	DT	O
HIV	NNP	O
polymerase	NN	O
polypeptide	NN	O
,	,	O
wherein	NN	O
(	(	O
i	NN	O
)	)	O
the	DT	O
nucleotide	JJ	O
sequence	NN	O
encoding	NN	O
said	VBD	O
polypeptide	JJ	O
comprises	VBZ	O
a	DT	O
sequence	NN	O
having	VBG	O
at	IN	O
least	JJS	O
90	CD	O
%	NN	O
sequence	NN	O
identity	NN	O
to	TO	O
the	DT	O
sequence	NN	O
presented	VBD	O
as	IN	O
SEQ	NNP	O
ID	NNP	O
NO:4	NNP	O
,	,	O
and	CC	O
(	(	O
ii	NN	O
)	)	O
wherein	VBZ	O
the	DT	O
sequence	NN	O
is	VBZ	O
modified	VBN	O
by	IN	O
deletions	NNS	O
of	IN	O
coding	VBG	O
regions	NNS	O
corresponding	VBG	O
to	TO	O
reverse	VB	O
transcriptase	NN	O
and	CC	O
integrase	NN	O
.	.	O
The	DT	O
expression	NN	O
cassettes	VBZ	O
described	VBN	O
above	IN	O
may	MD	O
preserves	VB	O
T-helper	NNP	O
cell	NN	O
and	CC	O
CTL	NNP	O
epitopes	NNS	O
.	.	O
The	DT	O
expression	NN	O
cassettes	NNS	O
may	MD	O
further	RB	O
include	VB	O
a	DT	O
polynucleotide	JJ	O
sequence	NN	O
encoding	VBG	O
an	DT	O
HCV	NNP	O
core	NN	O
polypeptide	NN	O
,	,	O
for	IN	O
example	NN	O
a	DT	O
sequence	NN	O
having	VBG	O
at	IN	O
least	JJS	O
90	CD	O
%	NN	O
sequence	NN	O
identity	NN	O
to	TO	O
the	DT	O
sequence	NN	O
presented	VBD	O
as	IN	O
SEQ	NNP	O
ID	NNP	O
NO:7	NNP	O
.	.	O
In	IN	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
invention	NN	O
includes	VBZ	O
an	DT	O
expression	NN	O
cassette	NN	O
,	,	O
comprising	VBG	O
a	DT	O
polynucleotide	JJ	O
sequence	NN	O
encoding	VBG	O
a	DT	O
polypeptide	NN	O
including	VBG	O
an	DT	O
HIV	NNP	O
Env	NNP	O
polypeptide	NN	O
,	,	O
wherein	VBP	O
the	DT	O
polynucleotide	NN	O
sequence	NN	O
encoding	VBG	O
said	VBD	O
Env	NNP	O
polypeptide	NN	O
comprises	VBZ	O
a	DT	O
sequence	NN	O
having	VBG	O
at	IN	O
least	JJS	O
90	CD	O
%	NN	O
sequence	NN	O
identity	NN	O
to	TO	O
SEQ	NNP	O
ID	NNP	O
NO:71	NNP	O
(	(	O
FIG	NNP	O
.	.	O
58	CD	O
)	)	O
or	CC	O
SEQ	NNP	O
ID	NNP	O
NO:72	NNP	O
(	(	O
FIG	NNP	O
.	.	O
59	CD	O
)	)	O
.	.	O
In	IN	O
certain	JJ	O
embodiments	NNS	O
,	,	O
the	DT	O
Env	NNP	O
expression	NN	O
cassettes	VBZ	O
includes	VBZ	O
sequences	NNS	O
flanking	VBG	O
a	DT	O
V1	JJ	O
region	NN	O
but	CC	O
have	VBP	O
a	DT	O
deletion	NN	O
in	IN	O
the	DT	O
V1	NNP	O
region	NN	O
itself	PRP	O
,	,	O
for	IN	O
example	NN	O
the	DT	O
sequence	NN	O
presented	VBD	O
as	IN	O
SEQ	NNP	O
ID	NNP	O
NO:65	NNP	O
(	(	O
FIG	NNP	O
.	.	O
52	CD	O
,	,	O
gp160.modUS4.delV1	NN	O
)	)	O
.	.	O
In	IN	O
certain	JJ	O
embodiments	NNS	O
,	,	O
the	DT	O
Env	NNP	O
expression	NN	O
cassettes	NNS	O
,	,	O
include	VBP	O
sequences	NNS	O
flanking	VBG	O
a	DT	O
V2	JJ	O
region	NN	O
but	CC	O
have	VBP	O
a	DT	O
deletion	NN	O
in	IN	O
the	DT	O
V2	NNP	O
region	NN	O
itself	PRP	O
,	,	O
for	IN	O
example	NN	O
the	DT	O
sequences	NNS	O
shown	VBN	O
in	IN	O
SEQ	NNP	O
ID	NNP	O
NO:60	NNP	O
(	(	O
FIG	NNP	O
.	.	O
47	CD	O
)	)	O
;	:	O
SEQ	NNP	O
ID	NNP	O
NO:66	NNP	O
(	(	O
FIG	NNP	O
.	.	O
53	CD	O
)	)	O
;	:	O
SEQ	NNP	O
ID	NNP	O
NO:34	NNP	O
(	(	O
FIG	NNP	O
.	.	O
20	CD	O
)	)	O
;	:	O
SEQ	NNP	O
ID	NNP	O
NO:37	NNP	O
(	(	O
FIG	NNP	O
.	.	O
24	CD	O
)	)	O
;	:	O
SEQ	NNP	O
ID	NNP	O
NO:40	NNP	O
(	(	O
FIG	NNP	O
.	.	O
27	CD	O
)	)	O
;	:	O
SEQ	NNP	O
ID	NNP	O
NO:43	NNP	O
(	(	O
FIG	NNP	O
.	.	O
30	CD	O
)	)	O
;	:	O
SEQ	NNP	O
ID	NNP	O
NO:46	NNP	O
(	(	O
FIG	NNP	O
.	.	O
33	CD	O
)	)	O
;	:	O
SEQ	NNP	O
ID	NNP	O
NO:76	NNP	O
(	(	O
FIG	NNP	O
.	.	O
64	CD	O
)	)	O
and	CC	O
SEQ	NNP	O
ID	NNP	O
NO:49	NNP	O
(	(	O
FIG	NNP	O
.	.	O
36	CD	O
)	)	O
.	.	O
In	IN	O
certain	JJ	O
embodiments	NNS	O
,	,	O
the	DT	O
Env	NNP	O
expression	NN	O
cassettes	NNS	O
include	VBP	O
sequences	NNS	O
flanking	VBG	O
a	DT	O
V1/V2	JJ	O
region	NN	O
but	CC	O
have	VBP	O
a	DT	O
deletion	NN	O
in	IN	O
the	DT	O
V1/V2	NNP	O
region	NN	O
itself	PRP	O
,	,	O
for	IN	O
example	NN	O
,	,	O
SEQ	NNP	O
ID	NNP	O
NO:59	NNP	O
(	(	O
FIG	NNP	O
.	.	O
46	CD	O
)	)	O
;	:	O
SEQ	NNP	O
ID	NNP	O
NO:61	NNP	O
(	(	O
FIG	NNP	O
.	.	O
48	CD	O
)	)	O
;	:	O
SEQ	NNP	O
ID	NNP	O
NO:67	NNP	O
(	(	O
FIG	NNP	O
.	.	O
54	CD	O
)	)	O
;	:	O
SEQ	NNP	O
ID	NNP	O
NO:75	NNP	O
(	(	O
FIG	NNP	O
.	.	O
63	CD	O
)	)	O
;	:	O
SEQ	NNP	O
ID	NNP	O
NO:35	NNP	O
(	(	O
FIG	NNP	O
.	.	O
21	CD	O
)	)	O
;	:	O
SEQ	NNP	O
ID	NNP	O
NO:38	NNP	O
(	(	O
FIG	NNP	O
.	.	O
25	CD	O
)	)	O
;	:	O
SEQ	NNP	O
ID	NNP	O
NO:41	NNP	O
(	(	O
FIG	NNP	O
.	.	O
28	CD	O
)	)	O
;	:	O
SEQ	NNP	O
ID	NNP	O
NO:44	NNP	O
(	(	O
FIG	NNP	O
.	.	O
31	CD	O
)	)	O
;	:	O
SEQ	NNP	O
ID	NNP	O
NO:47	NNP	O
(	(	O
FIG	NNP	O
.	.	O
34	CD	O
)	)	O
and	CC	O
SEQ	NNP	O
ID	NNP	O
NO:50	NNP	O
(	(	O
FIG	NNP	O
.	.	O
37	CD	O
)	)	O
.	.	O
The	DT	O
Env-encoding	JJ	O
expression	NN	O
cassettes	NNS	O
may	MD	O
also	RB	O
include	VB	O
a	DT	O
mutated	JJ	O
cleavage	NN	O
site	NN	O
that	WDT	O
prevents	VBZ	O
the	DT	O
cleavage	NN	O
of	IN	O
a	DT	O
gp140	JJ	O
polypeptide	NN	O
into	IN	O
a	DT	O
gp120	JJ	O
polypeptide	NN	O
and	CC	O
a	DT	O
gp41	NN	O
polypeptide	NN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
SEQ	NNP	O
ID	NNP	O
NO:57	NNP	O
(	(	O
FIG	NNP	O
.	.	O
44	CD	O
)	)	O
;	:	O
SEQ	NNP	O
ID	NNP	O
NO:61	NNP	O
(	(	O
FIG	NNP	O
.	.	O
48	CD	O
)	)	O
;	:	O
SEQ	NNP	O
ID	NNP	O
NO:63	NNP	O
(	(	O
FIG	NNP	O
.	.	O
50	CD	O
)	)	O
;	:	O
SEQ	NNP	O
ID	NNP	O
NO:39	NNP	O
(	(	O
FIG	NNP	O
.	.	O
26	CD	O
)	)	O
;	:	O
SEQ	NNP	O
ID	NNP	O
NO:40	NNP	O
(	(	O
FIG	NNP	O
.	.	O
27	CD	O
)	)	O
;	:	O
SEQ	NNP	O
ID	NNP	O
NO:41	NNP	O
(	(	O
FIG	NNP	O
.	.	O
28	CD	O
)	)	O
;	:	O
SEQ	NNP	O
ID	NNP	O
NO:42	NNP	O
(	(	O
FIG	NNP	O
.	.	O
29	CD	O
)	)	O
;	:	O
SEQ	NNP	O
ID	NNP	O
NO:43	NNP	O
(	(	O
FIG	NNP	O
.	.	O
30	CD	O
)	)	O
;	:	O
SEQ	NNP	O
ID	NNP	O
NO:44	NNP	O
(	(	O
FIG	NNP	O
.	.	O
31	CD	O
)	)	O
;	:	O
SEQ	NNP	O
ID	NNP	O
NO:45	NNP	O
(	(	O
FIG	NNP	O
.	.	O
32	CD	O
)	)	O
;	:	O
SEQ	NNP	O
ID	NNP	O
NO:46	NNP	O
(	(	O
FIG	NNP	O
.	.	O
33	CD	O
)	)	O
;	:	O
and	CC	O
SEQ	NNP	O
ID	NNP	O
NO:47	NNP	O
(	(	O
FIG	NNP	O
.	.	O
34	CD	O
)	)	O
.	.	O
The	DT	O
Env	NNP	O
expression	NN	O
cassettes	NNS	O
may	MD	O
include	VB	O
a	DT	O
gp160	JJ	O
Env	NNP	O
polypeptide	NN	O
or	CC	O
a	DT	O
polypeptide	JJ	O
derived	VBN	O
from	IN	O
a	DT	O
gp160	NN	O
Env	NNP	O
polypeptide	NN	O
,	,	O
for	IN	O
example	NN	O
SEQ	NNP	O
ID	NNP	O
NO:64	NNP	O
(	(	O
FIG	NNP	O
.	.	O
51	CD	O
)	)	O
;	:	O
SEQ	NNP	O
ID	NNP	O
NO:65	NNP	O
(	(	O
FIG	NNP	O
.	.	O
52	CD	O
)	)	O
;	:	O
SEQ	NNP	O
ID	NNP	O
NO:66	NNP	O
(	(	O
FIG	NNP	O
.	.	O
53	CD	O
)	)	O
;	:	O
SEQ	NNP	O
ID	NNP	O
NO:67	NNP	O
(	(	O
FIG	NNP	O
.	.	O
54	CD	O
)	)	O
;	:	O
SEQ	NNP	O
ID	NNP	O
NO:68	NNP	O
(	(	O
FIG	NNP	O
.	.	O
55	CD	O
)	)	O
;	:	O
SEQ	NNP	O
ID	NNP	O
NO:75	NNP	O
(	(	O
FIG	NNP	O
.	.	O
63	CD	O
)	)	O
;	:	O
SEQ	NNP	O
ID	NNP	O
NO:73	NNP	O
(	(	O
FIG	NNP	O
.	.	O
61	CD	O
)	)	O
;	:	O
SEQ	NNP	O
ID	NNP	O
NO:48	NNP	O
(	(	O
FIG	NNP	O
.	.	O
35	CD	O
)	)	O
;	:	O
SEQ	NNP	O
ID	NNP	O
NO:49	NNP	O
(	(	O
FIG	NNP	O
.	.	O
36	CD	O
)	)	O
;	:	O
SEQ	NNP	O
ID	NNP	O
NO:50	NNP	O
(	(	O
FIG	NNP	O
.	.	O
37	CD	O
)	)	O
;	:	O
SEQ	NNP	O
ID	NNP	O
NO:76	NNP	O
(	(	O
FIG	NNP	O
.	.	O
64	CD	O
)	)	O
;	:	O
and	CC	O
SEQ	NNP	O
ID	NNP	O
NO:74	NNP	O
(	(	O
FIG	NNP	O
.	.	O
62	CD	O
)	)	O
.	.	O
The	DT	O
Env	NNP	O
expression	NN	O
cassettes	NNS	O
may	MD	O
include	VB	O
a	DT	O
gp140	JJ	O
Env	NNP	O
polypeptide	NN	O
or	CC	O
a	DT	O
polypeptide	JJ	O
derived	VBN	O
from	IN	O
a	DT	O
gp140	NN	O
Env	NNP	O
polypeptide	NN	O
,	,	O
for	IN	O
example	NN	O
SEQ	NNP	O
ID	NNP	O
NO:56	NNP	O
(	(	O
FIG	NNP	O
.	.	O
43	CD	O
)	)	O
;	:	O
SEQ	NNP	O
ID	NNP	O
NO:57	NNP	O
(	(	O
FIG	NNP	O
.	.	O
44	CD	O
)	)	O
;	:	O
SEQ	NNP	O
ID	NNP	O
NO:58	NNP	O
(	(	O
FIG	NNP	O
.	.	O
45	CD	O
)	)	O
;	:	O
SEQ	NNP	O
ID	NNP	O
NO:59	NNP	O
(	(	O
FIG	NNP	O
.	.	O
46	CD	O
)	)	O
;	:	O
SEQ	NNP	O
ID	NNP	O
NO:60	NNP	O
(	(	O
FIG	NNP	O
.	.	O
47	CD	O
)	)	O
;	:	O
SEQ	NNP	O
ID	NNP	O
NO:61	NNP	O
(	(	O
FIG	NNP	O
.	.	O
48	CD	O
)	)	O
;	:	O
SEQ	NNP	O
ID	NNP	O
NO:62	NNP	O
(	(	O
FIG	NNP	O
.	.	O
49	CD	O
)	)	O
;	:	O
SEQ	NNP	O
ID	NNP	O
NO:63	NNP	O
(	(	O
FIG	NNP	O
.	.	O
50	CD	O
)	)	O
;	:	O
SEQ	NNP	O
ID	NNP	O
NO:36	NNP	O
(	(	O
FIG	NNP	O
.	.	O
23	CD	O
)	)	O
;	:	O
SEQ	NNP	O
ID	NNP	O
NO:37	NNP	O
(	(	O
FIG	NNP	O
.	.	O
24	CD	O
)	)	O
;	:	O
SEQ	NNP	O
ID	NNP	O
NO:38	NNP	O
(	(	O
FIG	NNP	O
.	.	O
25	CD	O
)	)	O
;	:	O
SEQ	NNP	O
ID	NNP	O
NO:39	NNP	O
(	(	O
FIG	NNP	O
.	.	O
26	CD	O
)	)	O
;	:	O
SEQ	NNP	O
ID	NNP	O
NO:40	NNP	O
(	(	O
FIG	NNP	O
.	.	O
27	CD	O
)	)	O
;	:	O
SEQ	NNP	O
ID	NNP	O
NO:41	NNP	O
(	(	O
FIG	NNP	O
.	.	O
28	CD	O
)	)	O
;	:	O
SEQ	NNP	O
ID	NNP	O
NO:42	NNP	O
(	(	O
FIG	NNP	O
.	.	O
29	CD	O
)	)	O
;	:	O
SEQ	NNP	O
ID	NNP	O
NO:43	NNP	O
(	(	O
FIG	NNP	O
.	.	O
30	CD	O
)	)	O
;	:	O
SEQ	NNP	O
ID	NNP	O
NO:44	NNP	O
(	(	O
FIG	NNP	O
.	.	O
31	CD	O
)	)	O
;	:	O
SEQ	NNP	O
ID	NNP	O
NO:45	NNP	O
(	(	O
FIG	NNP	O
.	.	O
32	CD	O
)	)	O
;	:	O
SEQ	NNP	O
ID	NNP	O
NO:46	NNP	O
(	(	O
FIG	NNP	O
.	.	O
33	CD	O
)	)	O
;	:	O
and	CC	O
SEQ	NNP	O
ID	NNP	O
NO:47	NNP	O
(	(	O
FIG	NNP	O
.	.	O
34	CD	O
)	)	O
.	.	O
The	DT	O
Env	NNP	O
expression	NN	O
cassettes	NNS	O
may	MD	O
also	RB	O
include	VB	O
a	DT	O
gp120	JJ	O
Env	NNP	O
polypeptide	NN	O
or	CC	O
a	DT	O
polypeptide	JJ	O
derived	VBN	O
from	IN	O
a	DT	O
gp120	NN	O
Env	NNP	O
polypeptide	NN	O
,	,	O
for	IN	O
example	NN	O
SEQ	NNP	O
ID	NNP	O
NO:54	NNP	O
(	(	O
FIG	NNP	O
.	.	O
41	CD	O
)	)	O
;	:	O
and	CC	O
SEQ	NNP	O
ID	NNP	O
NO:55	NNP	O
(	(	O
FIG	NNP	O
.	.	O
42	CD	O
)	)	O
;	:	O
SEQ	NNP	O
ID	NNP	O
NO:33	NNP	O
(	(	O
FIG	NNP	O
.	.	O
19	CD	O
)	)	O
;	:	O
SEQ	NNP	O
ID	NNP	O
NO:34	NNP	O
(	(	O
FIG	NNP	O
.	.	O
20	CD	O
)	)	O
;	:	O
and	CC	O
SEQ	NNP	O
ID	NNP	O
NO:35	NNP	O
(	(	O
FIG	NNP	O
.	.	O
21	CD	O
)	)	O
.	.	O
The	DT	O
Env	NNP	O
expression	NN	O
cassettes	NNS	O
may	MD	O
include	VB	O
an	DT	O
Env	NNP	O
polypeptide	NN	O
lacking	VBG	O
the	DT	O
amino	NN	O
acids	NNS	O
corresponding	VBG	O
to	TO	O
residues	VB	O
128	CD	O
to	TO	O
about	IN	O
194	CD	O
,	,	O
relative	JJ	O
to	TO	O
strains	VB	O
SF162	NNP	O
or	CC	O
US4	NNP	O
,	,	O
for	IN	O
example	NN	O
,	,	O
SEQ	NNP	O
ID	NNP	O
NO:55	NNP	O
(	(	O
FIG	NNP	O
.	.	O
42	CD	O
)	)	O
;	:	O
SEQ	NNP	O
ID	NNP	O
NO:62	NNP	O
(	(	O
FIG	NNP	O
.	.	O
49	CD	O
)	)	O
;	:	O
SEQ	NNP	O
ID	NNP	O
NO:63	NNP	O
(	(	O
FIG	NNP	O
.	.	O
50	CD	O
)	)	O
;	:	O
and	CC	O
SEQ	NNP	O
ID	NNP	O
NO:68	NNP	O
(	(	O
FIG	NNP	O
.	.	O
55	CD	O
)	)	O
.	.	O
In	IN	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
invention	NN	O
includes	VBZ	O
a	DT	O
recombinant	JJ	O
expression	NN	O
system	NN	O
for	IN	O
use	NN	O
in	IN	O
a	DT	O
selected	VBN	O
host	NN	O
cell	NN	O
,	,	O
comprising	VBG	O
,	,	O
one	CD	O
or	CC	O
more	JJR	O
of	IN	O
the	DT	O
expression	NN	O
cassettes	VBZ	O
described	VBN	O
herein	NN	O
operably	RB	O
linked	VBD	O
to	TO	O
control	VB	O
elements	NNS	O
compatible	JJ	O
with	IN	O
expression	NN	O
in	IN	O
the	DT	O
selected	VBN	O
host	NN	O
cell	NN	O
.	.	O
The	DT	O
expression	NN	O
cassettes	NNS	O
may	MD	O
be	VB	O
included	VBN	O
on	IN	O
one	CD	O
or	CC	O
on	IN	O
multiple	JJ	O
vectors	NNS	O
and	CC	O
may	MD	O
use	VB	O
the	DT	O
same	JJ	O
or	CC	O
different	JJ	O
promoters	NNS	O
.	.	O
Exemplary	JJ	O
control	NN	O
elements	NNS	O
include	VBP	O
a	DT	O
transcription	NN	O
promoter	NN	O
(	(	O
e.g.	UH	O
,	,	O
CMV	NNP	O
,	,	O
CMV+intron	NNP	O
A	NNP	O
,	,	O
SV40	NNP	O
,	,	O
RSV	NNP	O
,	,	O
HIV-Ltr	NNP	O
,	,	O
MMLV-ltr	NNP	O
,	,	O
and	CC	O
metallothionein	NN	O
)	)	O
,	,	O
a	DT	O
transcription	NN	O
enhancer	NN	O
element	NN	O
,	,	O
a	DT	O
transcription	NN	O
termination	NN	O
signal	NN	O
,	,	O
polyadenylation	NN	O
sequences	NNS	O
,	,	O
sequences	NNS	O
for	IN	O
optimization	NN	O
of	IN	O
initiation	NN	O
of	IN	O
translation	NN	O
,	,	O
and	CC	O
translation	NN	O
termination	NN	O
sequences	NNS	O
.	.	O
In	IN	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
invention	NN	O
includes	VBZ	O
a	DT	O
recombinant	JJ	O
expression	NN	O
system	NN	O
for	IN	O
use	NN	O
in	IN	O
a	DT	O
selected	VBN	O
host	NN	O
cell	NN	O
,	,	O
comprising	VBG	O
,	,	O
any	DT	O
one	CD	O
of	IN	O
the	DT	O
expression	NN	O
cassettes	VBZ	O
described	VBN	O
herein	NN	O
operably	RB	O
linked	VBD	O
to	TO	O
control	VB	O
elements	NNS	O
compatible	JJ	O
with	IN	O
expression	NN	O
in	IN	O
the	DT	O
selected	VBN	O
host	NN	O
cell	NN	O
.	.	O
Exemplary	JJ	O
control	NN	O
elements	NNS	O
include	VBP	O
,	,	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
,	,	O
a	DT	O
transcription	NN	O
promoter	NN	O
(	(	O
e.g.	UH	O
,	,	O
CMV	NNP	O
,	,	O
CMV+intron	NNP	O
A	NNP	O
,	,	O
SV40	NNP	O
,	,	O
RSV	NNP	O
,	,	O
HIV-LTR	NNP	O
,	,	O
MMLV-LTR	NNP	O
,	,	O
and	CC	O
metallothionein	NN	O
)	)	O
,	,	O
a	DT	O
transcription	NN	O
enhancer	NN	O
element	NN	O
,	,	O
a	DT	O
transcription	NN	O
termination	NN	O
signal	NN	O
,	,	O
polyadenylation	NN	O
sequences	NNS	O
,	,	O
sequences	NNS	O
for	IN	O
optimization	NN	O
of	IN	O
initiation	NN	O
of	IN	O
translation	NN	O
,	,	O
and	CC	O
translation	NN	O
termination	NN	O
sequences	NNS	O
.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
invention	NN	O
includes	VBZ	O
a	DT	O
cell	NN	O
comprising	VBG	O
one	CD	O
or	CC	O
more	JJR	O
of	IN	O
the	DT	O
expression	NN	O
cassettes	VBZ	O
described	VBN	O
herein	NN	O
operably	RB	O
linked	VBD	O
to	TO	O
control	VB	O
elements	NNS	O
compatible	JJ	O
with	IN	O
expression	NN	O
in	IN	O
the	DT	O
cell	NN	O
.	.	O
The	DT	O
cell	NN	O
can	MD	O
be	VB	O
,	,	O
for	IN	O
example	NN	O
,	,	O
a	DT	O
mammalian	JJ	O
cell	NN	O
(	(	O
e.g.	JJ	O
,	,	O
BHK	NNP	O
,	,	O
VERO	NNP	O
,	,	O
HT1080	NNP	O
,	,	O
293	CD	O
,	,	O
RD	NNP	O
,	,	O
COS-7	NNP	O
,	,	O
or	CC	O
CHO	NNP	O
cells	NNS	O
)	)	O
,	,	O
an	DT	O
insect	NN	O
cell	NN	O
(	(	O
e.g.	JJ	O
,	,	O
Trichoplusia	NNP	O
ni	FW	O
(	(	O
Tn5	NNP	O
)	)	O
or	CC	O
Sf9	NNP	O
)	)	O
,	,	O
a	DT	O
bacterial	JJ	O
cell	NN	O
,	,	O
a	DT	O
plant	NN	O
cell	NN	O
,	,	O
a	DT	O
yeast	NN	O
cell	NN	O
,	,	O
an	DT	O
antigen	NN	O
presenting	NN	O
cell	NN	O
(	(	O
e.g.	JJ	O
,	,	O
primary	JJ	O
,	,	O
immortalized	JJ	O
or	CC	O
tumor-derived	JJ	O
lymphoid	JJ	O
cells	NNS	O
such	JJ	O
as	IN	O
macrophages	NNS	O
,	,	O
monocytes	NNS	O
,	,	O
dendritic	JJ	O
cells	NNS	O
,	,	O
B-cells	NNP	O
,	,	O
T-cells	NNP	O
,	,	O
stem	NN	O
cells	NNS	O
,	,	O
and	CC	O
progenitor	NN	O
cells	NNS	O
thereof	NN	O
)	)	O
.	.	O
In	IN	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
invention	NN	O
includes	VBZ	O
methods	NNS	O
for	IN	O
producing	VBG	O
a	DT	O
polypeptide	NN	O
including	VBG	O
HIV	NNP	O
Gag-	NNP	O
,	,	O
prot-	JJ	O
,	,	O
pol-	JJ	O
,	,	O
reverse	JJ	O
transcriptase	NN	O
,	,	O
Env-	NNP	O
or	CC	O
Tat-containing	NNP	O
polypeptide	NN	O
sequences	NNS	O
,	,	O
said	VBD	O
method	NN	O
comprising	NN	O
,	,	O
incubating	VBG	O
the	DT	O
cells	NNS	O
comprising	VBG	O
one	CD	O
or	CC	O
more	JJR	O
the	DT	O
expression	NN	O
cassettes	VBZ	O
describe	JJ	O
herein	NN	O
,	,	O
under	IN	O
conditions	NNS	O
for	IN	O
producing	VBG	O
said	VBD	O
polypeptide	NN	O
.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
invention	NN	O
includes	VBZ	O
compositions	NNS	O
for	IN	O
generating	VBG	O
an	DT	O
immunological	JJ	O
response	NN	O
,	,	O
comprising	VBG	O
one	CD	O
or	CC	O
more	JJR	O
of	IN	O
the	DT	O
expression	NN	O
cassettes	VBZ	O
described	VBN	O
herein	NNS	O
.	.	O
In	IN	O
certain	JJ	O
embodiments	NNS	O
,	,	O
the	DT	O
compositions	NNS	O
also	RB	O
include	VBP	O
an	DT	O
adjuvant	NN	O
.	.	O
In	IN	O
a	DT	O
still	RB	O
further	JJ	O
aspect	NN	O
,	,	O
the	DT	O
invention	NN	O
includes	VBZ	O
methods	NNS	O
of	IN	O
generating	VBG	O
an	DT	O
immune	JJ	O
response	NN	O
in	IN	O
a	DT	O
subject	NN	O
,	,	O
comprising	VBG	O
introducing	VBG	O
a	DT	O
composition	NN	O
comprising	VBG	O
one	CD	O
or	CC	O
more	JJR	O
of	IN	O
the	DT	O
expression	NN	O
cassettes	VBZ	O
described	VBN	O
herein	RB	O
into	IN	O
the	DT	O
subject	JJ	O
under	IN	O
conditions	NNS	O
that	WDT	O
are	VBP	O
compatible	JJ	O
with	IN	O
expression	NN	O
of	IN	O
said	VBD	O
expression	NN	O
cassette	NN	O
in	IN	O
the	DT	O
subject	NN	O
.	.	O
In	IN	O
certain	JJ	O
embodiments	NNS	O
,	,	O
the	DT	O
expression	NN	O
cassette	NN	O
is	VBZ	O
introduced	VBN	O
using	VBG	O
a	DT	O
gene	NN	O
delivery	NN	O
vector	NN	O
.	.	O
More	JJR	O
than	IN	O
one	CD	O
expression	NN	O
cassette	NN	O
may	MD	O
be	VB	O
introduced	VBN	O
using	VBG	O
one	CD	O
or	CC	O
more	JJR	O
gene	NN	O
delivery	NN	O
vectors	NNS	O
.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
invention	NN	O
includes	VBZ	O
a	DT	O
purified	JJ	O
polynucleotide	NN	O
comprising	VBG	O
a	DT	O
polynucleotide	JJ	O
sequence	NN	O
encoding	VBG	O
a	DT	O
polypeptide	NN	O
including	VBG	O
an	DT	O
HIV	NNP	O
Env	NNP	O
polypeptide	NN	O
,	,	O
wherein	VBP	O
the	DT	O
polynucleotide	NN	O
sequence	NN	O
encoding	VBG	O
said	VBD	O
Env	NNP	O
polypeptide	NN	O
comprises	VBZ	O
a	DT	O
sequence	NN	O
having	VBG	O
at	IN	O
least	JJS	O
90	CD	O
%	NN	O
sequence	NN	O
identity	NN	O
to	TO	O
SEQ	NNP	O
ID	NNP	O
NO:71	NNP	O
(	(	O
FIG	NNP	O
.	.	O
58	CD	O
)	)	O
or	CC	O
SEQ	NNP	O
ID	NNP	O
NO:72	NNP	O
(	(	O
FIG	NNP	O
.	.	O
59	CD	O
)	)	O
.	.	O
Further	RB	O
exemplary	JJ	O
purified	VBD	O
polynucleotide	JJ	O
sequences	NNS	O
were	VBD	O
presented	VBN	O
above	IN	O
.	.	O
The	DT	O
polynucleotides	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
can	MD	O
be	VB	O
produced	VBN	O
by	IN	O
recombinant	NN	O
techniques	NNS	O
,	,	O
synthetic	JJ	O
techniques	NNS	O
,	,	O
or	CC	O
combinations	NNS	O
thereof	VBP	O
.	.	O
In	IN	O
another	DT	O
embodiment	NN	O
,	,	O
the	DT	O
invention	NN	O
includes	VBZ	O
a	DT	O
method	NN	O
for	IN	O
producing	VBG	O
a	DT	O
polypeptide	NN	O
including	VBG	O
HIV	NNP	O
Gag	NNP	O
polypeptide	NN	O
sequences	NNS	O
,	,	O
where	WRB	O
the	DT	O
method	NN	O
comprises	VBZ	O
incubating	VBG	O
any	DT	O
of	IN	O
the	DT	O
above	JJ	O
cells	NNS	O
containing	VBG	O
an	DT	O
expression	NN	O
cassette	NN	O
of	IN	O
interest	NN	O
under	IN	O
conditions	NNS	O
for	IN	O
producing	VBG	O
the	DT	O
polypeptide	NN	O
.	.	O
The	DT	O
invention	NN	O
further	RBR	O
includes	VBZ	O
,	,	O
a	DT	O
method	NN	O
for	IN	O
producing	VBG	O
virus-like	JJ	O
particles	NNS	O
(	(	O
VLPs	NNP	O
)	)	O
where	WRB	O
the	DT	O
method	NN	O
comprises	VBZ	O
incubating	VBG	O
any	DT	O
of	IN	O
the	DT	O
above-described	JJ	O
cells	NNS	O
containing	VBG	O
an	DT	O
expression	NN	O
cassette	NN	O
of	IN	O
interest	NN	O
under	IN	O
conditions	NNS	O
for	IN	O
producing	VBG	O
VLPs	NNP	O
.	.	O
In	IN	O
another	DT	O
aspect	NN	O
the	DT	O
invention	NN	O
includes	VBZ	O
a	DT	O
method	NN	O
for	IN	O
producing	VBG	O
a	DT	O
composition	NN	O
of	IN	O
virus-like	JJ	O
particles	NNS	O
(	(	O
VLPs	NNP	O
)	)	O
where	WRB	O
,	,	O
any	DT	O
of	IN	O
the	DT	O
above-described	JJ	O
cells	NNS	O
containing	VBG	O
an	DT	O
expression	NN	O
cassette	NN	O
of	IN	O
interest	NN	O
are	VBP	O
incubated	VBN	O
under	IN	O
conditions	NNS	O
for	IN	O
producing	VBG	O
VLPs	NNP	O
,	,	O
and	CC	O
the	DT	O
VLPs	NNP	O
are	VBP	O
substantially	RB	O
purified	VBN	O
to	TO	O
produce	VB	O
a	DT	O
composition	NN	O
of	IN	O
VLPs	NNP	O
.	.	O
In	IN	O
a	DT	O
further	JJ	O
embodiment	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
,	,	O
packaging	NN	O
cell	NN	O
lines	NNS	O
are	VBP	O
produced	VBN	O
using	VBG	O
the	DT	O
expression	NN	O
cassettes	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
a	DT	O
cell	NN	O
line	NN	O
useful	JJ	O
for	IN	O
packaging	VBG	O
lentivirus	JJ	O
vectors	NNS	O
comprises	VBZ	O
suitable	JJ	O
host	NN	O
cells	NNS	O
that	WDT	O
have	VBP	O
an	DT	O
expression	NN	O
vector	NN	O
containing	VBG	O
an	DT	O
expression	NN	O
cassette	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
wherein	NN	O
said	VBD	O
polynucleotide	JJ	O
sequence	NN	O
is	VBZ	O
operably	RB	O
linked	VBN	O
to	TO	O
control	VB	O
elements	NNS	O
compatible	JJ	O
with	IN	O
expression	NN	O
in	IN	O
the	DT	O
host	NN	O
cell	NN	O
.	.	O
In	IN	O
a	DT	O
preferred	JJ	O
embodiment	NN	O
,	,	O
such	JJ	O
host	NN	O
cells	NNS	O
may	MD	O
be	VB	O
transfected	VBN	O
with	IN	O
one	CD	O
or	CC	O
more	JJR	O
expression	NN	O
cassettes	VBZ	O
having	VBG	O
a	DT	O
polynucleotide	JJ	O
sequence	NN	O
that	WDT	O
encodes	VBZ	O
an	DT	O
HIV	NNP	O
polymerase	NN	O
polypeptide	NN	O
or	CC	O
polypeptides	NNS	O
derived	VBN	O
therefrom	NNS	O
,	,	O
for	IN	O
example	NN	O
,	,	O
where	WRB	O
the	DT	O
nucleotide	JJ	O
sequence	NN	O
encoding	NN	O
said	VBD	O
polypeptide	JJ	O
comprises	VBZ	O
a	DT	O
sequence	NN	O
having	VBG	O
at	IN	O
least	JJS	O
90	CD	O
%	NN	O
sequence	NN	O
identity	NN	O
to	TO	O
the	DT	O
sequence	NN	O
presented	VBD	O
as	IN	O
SEQ	NNP	O
ID	NNP	O
NO:6	NNP	O
.	.	O
Further	RB	O
,	,	O
the	DT	O
HIV	NNP	O
polymerase	NN	O
polypeptide	NN	O
may	MD	O
be	VB	O
modified	VBN	O
by	IN	O
deletions	NNS	O
of	IN	O
coding	VBG	O
regions	NNS	O
corresponding	VBG	O
to	TO	O
reverse	VB	O
transcriptase	NN	O
and	CC	O
integrase	NN	O
.	.	O
Such	JJ	O
a	DT	O
polynucleotide	JJ	O
sequence	NN	O
may	MD	O
preserve	VB	O
T-helper	NNP	O
cell	NN	O
and	CC	O
CTL	NNP	O
epitopes	NNS	O
,	,	O
for	IN	O
example	NN	O
when	WRB	O
used	VBN	O
in	IN	O
a	DT	O
vaccine	NN	O
application	NN	O
.	.	O
In	IN	O
addition	NN	O
,	,	O
the	DT	O
polynucleotide	JJ	O
sequence	NN	O
may	MD	O
also	RB	O
include	VB	O
other	JJ	O
polypeptides	NNS	O
.	.	O
Further	RB	O
,	,	O
polynucleotide	JJ	O
sequences	NNS	O
encoding	VBG	O
additional	JJ	O
polypeptides	NNS	O
whose	WP$	O
expression	NN	O
are	VBP	O
useful	JJ	O
for	IN	O
packaging	VBG	O
cell	NN	O
line	NN	O
function	NN	O
may	MD	O
also	RB	O
be	VB	O
utilized	VBN	O
.	.	O
In	IN	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
present	JJ	O
invention	NN	O
includes	VBZ	O
a	DT	O
gene	NN	O
delivery	NN	O
or	CC	O
vaccine	NN	O
vector	NN	O
for	IN	O
use	NN	O
in	IN	O
a	DT	O
subject	NN	O
,	,	O
where	WRB	O
the	DT	O
vector	NN	O
is	VBZ	O
a	DT	O
suitable	JJ	O
gene	NN	O
delivery	NN	O
vector	NN	O
for	IN	O
use	NN	O
in	IN	O
the	DT	O
subject	NN	O
,	,	O
and	CC	O
the	DT	O
vector	NN	O
comprises	VBZ	O
one	CD	O
or	CC	O
more	JJR	O
of	IN	O
any	DT	O
of	IN	O
the	DT	O
expression	NN	O
cassettes	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
where	WRB	O
the	DT	O
polynucleotide	NN	O
sequences	NNS	O
of	IN	O
interest	NN	O
are	VBP	O
operably	RB	O
linked	VBN	O
to	TO	O
control	VB	O
elements	NNS	O
compatible	JJ	O
with	IN	O
expression	NN	O
in	IN	O
the	DT	O
subject	NN	O
.	.	O
Such	JJ	O
gene	NN	O
delivery	NN	O
vectors	NNS	O
can	MD	O
be	VB	O
used	VBN	O
in	IN	O
a	DT	O
method	NN	O
of	IN	O
DNA	NNP	O
immunization	NN	O
of	IN	O
a	DT	O
subject	NN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
by	IN	O
introducing	VBG	O
a	DT	O
gene	NN	O
delivery	NN	O
vector	NN	O
into	IN	O
the	DT	O
subject	JJ	O
under	IN	O
conditions	NNS	O
that	WDT	O
are	VBP	O
compatible	JJ	O
with	IN	O
expression	NN	O
of	IN	O
the	DT	O
expression	NN	O
cassette	NN	O
in	IN	O
the	DT	O
subject	NN	O
.	.	O
Gene	NNP	O
delivery	NN	O
vectors	NNS	O
useful	JJ	O
in	IN	O
the	DT	O
practice	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
include	VBP	O
,	,	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
,	,	O
nonviral	JJ	O
vectors	NNS	O
,	,	O
bacterial	JJ	O
plasmid	NN	O
vectors	NNS	O
,	,	O
viral	JJ	O
vectors	NNS	O
,	,	O
particulate	NN	O
carriers	NNS	O
(	(	O
where	WRB	O
the	DT	O
vector	NN	O
is	VBZ	O
coated	VBN	O
on	IN	O
a	DT	O
polylactide	JJ	O
co-glycolide	JJ	O
particles	NNS	O
,	,	O
gold	NN	O
or	CC	O
tungsten	JJ	O
particle	NN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
the	DT	O
coated	JJ	O
particle	NN	O
can	MD	O
be	VB	O
delivered	VBN	O
to	TO	O
a	DT	O
subject	NN	O
cell	NN	O
using	VBG	O
a	DT	O
gene	NN	O
gun	NN	O
)	)	O
,	,	O
liposome	JJ	O
preparations	NNS	O
,	,	O
and	CC	O
viral	JJ	O
vectors	NNS	O
(	(	O
e.g.	NN	O
,	,	O
vectors	NNS	O
derived	VBD	O
from	IN	O
alphaviruses	NNS	O
,	,	O
pox	NN	O
viruses	NNS	O
,	,	O
and	CC	O
vaccinia	NN	O
viruses	NNS	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
,	,	O
retroviral	JJ	O
vectors	NNS	O
,	,	O
including	VBG	O
,	,	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
,	,	O
lentiviral	JJ	O
vectors	NNS	O
)	)	O
.	.	O
Alphavirus-derived	JJ	O
vectors	NNS	O
include	VBP	O
,	,	O
for	IN	O
example	NN	O
,	,	O
an	DT	O
alphavirus	NN	O
cDNA	NN	O
construct	NN	O
,	,	O
a	DT	O
recombinant	JJ	O
alphavirus	NN	O
particle	NN	O
preparation	NN	O
and	CC	O
a	DT	O
eukaryotic	JJ	O
layered	JJ	O
vector	NN	O
initiation	NN	O
system	NN	O
.	.	O
In	IN	O
one	CD	O
embodiment	NN	O
,	,	O
the	DT	O
subject	NN	O
is	VBZ	O
a	DT	O
vertebrate	NN	O
,	,	O
preferably	RB	O
a	DT	O
mammal	NN	O
,	,	O
and	CC	O
in	IN	O
a	DT	O
further	JJ	O
embodiment	NN	O
the	DT	O
subject	NN	O
is	VBZ	O
a	DT	O
human	JJ	O
.	.	O
The	DT	O
invention	NN	O
further	RB	O
includes	VBZ	O
a	DT	O
method	NN	O
of	IN	O
generating	VBG	O
an	DT	O
immune	JJ	O
response	NN	O
in	IN	O
a	DT	O
subject	NN	O
,	,	O
where	WRB	O
cells	NNS	O
of	IN	O
a	DT	O
subject	NN	O
are	VBP	O
transfected	VBN	O
with	IN	O
any	DT	O
of	IN	O
the	DT	O
above-described	JJ	O
gene	NN	O
delivery	NN	O
vectors	NNS	O
(	(	O
e.g.	NN	O
,	,	O
alphavirus	JJ	O
constructs	NNS	O
;	:	O
alphavirus	CC	O
cDNA	NN	O
constructs	NNS	O
;	:	O
eukaryotic	JJ	O
layered	VBD	O
vector	JJ	O
initiation	NN	O
systems	NNS	O
(	(	O
see	VB	O
,	,	O
e.g.	VB	O
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,814,482	CD	O
for	IN	O
description	NN	O
of	IN	O
suitable	JJ	O
eukaryotic	JJ	O
layered	VBD	O
vector	JJ	O
initiation	NN	O
systems	NNS	O
)	)	O
;	:	O
alphavirus	JJ	O
particle	NN	O
preparations	NNS	O
;	:	O
etc	FW	O
.	.	O
)	)	O
under	IN	O
conditions	NNS	O
that	WDT	O
permit	VBP	O
the	DT	O
expression	NN	O
of	IN	O
a	DT	O
selected	VBN	O
polynucleotide	NN	O
and	CC	O
production	NN	O
of	IN	O
a	DT	O
polypeptide	NN	O
of	IN	O
interest	NN	O
(	(	O
i.e.	FW	O
,	,	O
encoded	VBN	O
by	IN	O
any	DT	O
expression	NN	O
cassette	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
)	)	O
,	,	O
thereby	RB	O
eliciting	VBG	O
an	DT	O
immunological	JJ	O
response	NN	O
to	TO	O
the	DT	O
polypeptide	NN	O
.	.	O
Transfection	NN	O
of	IN	O
the	DT	O
cells	NNS	O
may	MD	O
be	VB	O
performed	VBN	O
ex	JJ	O
vivo	NN	O
and	CC	O
the	DT	O
transfected	JJ	O
cells	NNS	O
are	VBP	O
reintroduced	VBN	O
into	IN	O
the	DT	O
subject	NN	O
.	.	O
Alternately	RB	O
,	,	O
or	CC	O
in	IN	O
addition	NN	O
,	,	O
the	DT	O
cells	NNS	O
may	MD	O
be	VB	O
transfected	VBN	O
in	IN	O
vivo	NN	O
in	IN	O
the	DT	O
subject	NN	O
.	.	O
The	DT	O
immune	JJ	O
response	NN	O
may	MD	O
be	VB	O
humoral	JJ	O
and/or	JJ	O
cell-mediated	JJ	O
(	(	O
cellular	JJ	O
)	)	O
.	.	O
Further	JJ	O
embodiments	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
include	VBP	O
purified	VBN	O
polynucleotides	NNS	O
.	.	O
In	IN	O
one	CD	O
embodiment	NN	O
,	,	O
the	DT	O
purified	JJ	O
polynucleotide	NN	O
comprises	VBZ	O
a	DT	O
polynucleotide	NN	O
sequence	NN	O
having	VBG	O
at	IN	O
least	JJS	O
90	CD	O
%	NN	O
sequence	NN	O
identity	NN	O
to	TO	O
the	DT	O
sequence	NN	O
presented	VBD	O
as	IN	O
SEQ	NNP	O
ID	NNP	O
NO:20	NNP	O
,	,	O
and	CC	O
complements	NNS	O
thereof	NN	O
.	.	O
In	IN	O
another	DT	O
embodiment	NN	O
,	,	O
the	DT	O
purified	JJ	O
polynucleotide	NN	O
comprises	VBZ	O
a	DT	O
polynucleotide	JJ	O
sequence	NN	O
encoding	VBG	O
an	DT	O
HIV	NNP	O
Gag	NNP	O
polypeptide	NN	O
,	,	O
wherein	VBP	O
the	DT	O
polynucleotide	NN	O
sequence	NN	O
comprises	VBZ	O
a	DT	O
sequence	NN	O
having	VBG	O
at	IN	O
least	JJS	O
90	CD	O
%	NN	O
sequence	NN	O
identity	NN	O
to	TO	O
the	DT	O
sequence	NN	O
presented	VBD	O
as	IN	O
SEQ	NNP	O
ID	NNP	O
NO:20	NNP	O
,	,	O
and	CC	O
complements	NNS	O
thereof	NN	O
.	.	O
In	IN	O
still	RB	O
another	DT	O
embodiment	NN	O
,	,	O
the	DT	O
purified	JJ	O
polynucleotide	NN	O
comprises	VBZ	O
a	DT	O
polynucleotide	JJ	O
sequence	NN	O
encoding	VBG	O
an	DT	O
HIV	NNP	O
Gag	NNP	O
polypeptide	NN	O
,	,	O
wherein	VBP	O
the	DT	O
polynucleotide	NN	O
sequence	NN	O
comprises	VBZ	O
a	DT	O
sequence	NN	O
having	VBG	O
at	IN	O
least	JJS	O
90	CD	O
%	NN	O
sequence	NN	O
identity	NN	O
to	TO	O
the	DT	O
sequence	NN	O
presented	VBD	O
as	IN	O
SEQ	NNP	O
ID	NNP	O
NO:9	NNP	O
,	,	O
and	CC	O
complements	NNS	O
thereof	NN	O
.	.	O
In	IN	O
further	JJ	O
embodiments	NNS	O
the	DT	O
polynucleotide	NN	O
sequence	NN	O
comprises	VBZ	O
a	DT	O
sequence	NN	O
having	VBG	O
at	IN	O
least	JJS	O
90	CD	O
%	NN	O
sequence	NN	O
identity	NN	O
to	TO	O
one	CD	O
of	IN	O
the	DT	O
following	JJ	O
sequences	NNS	O
:	:	O
SEQ	NNP	O
ID	NNP	O
NO:4	NNP	O
,	,	O
SEQ	NNP	O
ID	NNP	O
NO:5	NNP	O
,	,	O
SEQ	NNP	O
ID	NNP	O
NO:6	NNP	O
,	,	O
SEQ	NNP	O
ID	NNP	O
NO:7	NNP	O
,	,	O
and	CC	O
complements	NNS	O
thereof	NN	O
.	.	O
The	DT	O
polynucleotides	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
can	MD	O
be	VB	O
produced	VBN	O
by	IN	O
recombinant	NN	O
techniques	NNS	O
,	,	O
synthetic	JJ	O
techniques	NNS	O
,	,	O
or	CC	O
combinations	NNS	O
thereof	VBP	O
.	.	O
These	DT	O
and	CC	O
other	JJ	O
embodiments	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
will	MD	O
readily	RB	O
occur	VB	O
to	TO	O
those	DT	O
of	IN	O
ordinary	JJ	O
skill	NN	O
in	IN	O
the	DT	O
art	NN	O
in	IN	O
view	NN	O
of	IN	O
the	DT	O
disclosure	NN	O
herein	NN	O
.	.	O
BRIEF	JJ	O
DESCRIPTION	NNP	O
OF	IN	O
THE	NNP	O
FIGURES	NNP	O
FIG	NNP	O
.	.	O
1	CD	O
shows	VBZ	O
the	DT	O
locations	NNS	O
of	IN	O
the	DT	O
inactivation	NN	O
sites	VBZ	O
for	IN	O
the	DT	O
native	JJ	O
HIV-1SF2	NNP	O
Gag	NNP	O
protein	NN	O
coding	VBG	O
sequence	NN	O
SEQ	NNP	O
ID	NNP	O
NO:1	NNP	O
.	.	O
FIG	NNP	O
.	.	O
2	CD	O
shows	VBZ	O
the	DT	O
locations	NNS	O
of	IN	O
the	DT	O
inactivation	NN	O
sites	VBZ	O
for	IN	O
the	DT	O
native	JJ	O
HIV-1SF2	NNP	O
Gag-protease	NNP	O
protein	NN	O
coding	VBG	O
sequence	NN	O
SEQ	NNP	O
ID	NNP	O
NO:2	NNP	O
.	.	O
FIGS	NNP	O
.	.	O
3A	CD	O
and	CC	O
3B	CD	O
show	NN	O
electron	NN	O
micrographs	NN	O
of	IN	O
virus-like	JJ	O
particles	NNS	O
.	.	O
FIG	NNP	O
.	.	O
3A	CD	O
shows	NNS	O
immature	JJ	O
p55Gag	JJ	O
virus-like	JJ	O
particles	NNS	O
in	IN	O
COS-7	NNP	O
cells	NNS	O
transfected	VBN	O
with	IN	O
a	DT	O
synthetic	JJ	O
HIV-1SF2	NNP	O
gag	NN	O
construct	NN	O
while	IN	O
FIG	NNP	O
.	.	O
3B	CD	O
shows	NNS	O
mature	VBP	O
(	(	O
arrows	NNS	O
)	)	O
and	CC	O
immature	JJ	O
VLP	NNP	O
in	IN	O
cells	NNS	O
transfected	VBN	O
with	IN	O
a	DT	O
modified	JJ	O
HIV-1SF2	JJ	O
gagprotease	NN	O
construct	NN	O
(	(	O
GP2	NNP	O
,	,	O
SEQ	NNP	O
ID	NNP	O
NO:70	NNP	O
)	)	O
.	.	O
Transfected	VBN	O
cells	NNS	O
were	VBD	O
fixed	VBN	O
at	IN	O
24	CD	O
h	NN	O
(	(	O
gag	NN	O
)	)	O
or	CC	O
48	CD	O
h	NN	O
(	(	O
gagprotease	NN	O
)	)	O
post-transfection	NN	O
and	CC	O
subsequently	RB	O
analyzed	VBN	O
by	IN	O
electron	NN	O
microscopy	NN	O
(	(	O
magnification	NN	O
at	IN	O
100,000×	CD	O
)	)	O
.	.	O
Cells	NNS	O
transfected	VBN	O
with	IN	O
vector	NN	O
alone	RB	O
(	(	O
pCMVKm2	NN	O
)	)	O
served	VBD	O
as	IN	O
negative	JJ	O
control	NN	O
(	(	O
data	NNS	O
not	RB	O
shown	VBN	O
)	)	O
.	.	O
FIG	NNP	O
.	.	O
4	CD	O
presents	NNS	O
an	DT	O
image	NN	O
of	IN	O
samples	NNS	O
from	IN	O
a	DT	O
series	NN	O
of	IN	O
fractions	NNS	O
which	WDT	O
were	VBD	O
electrophoresed	VBN	O
on	IN	O
an	DT	O
8-16	JJ	O
%	NN	O
SDS	NNP	O
polyacrylamide	NN	O
gel	NN	O
and	CC	O
the	DT	O
resulting	VBG	O
bands	NNS	O
visualized	VBN	O
by	IN	O
commassie	NN	O
blue	NN	O
staining	NN	O
.	.	O
The	DT	O
results	NNS	O
show	VBP	O
that	IN	O
the	DT	O
native	JJ	O
p55	NN	O
Gag	NNP	O
virus-like	NN	O
particles	NNS	O
(	(	O
VLPs	NNP	O
)	)	O
banded	VBD	O
at	IN	O
a	DT	O
sucrose	JJ	O
density	NN	O
of	IN	O
range	NN	O
of	IN	O
1.15-1.19	JJ	O
g/ml	NN	O
with	IN	O
the	DT	O
peak	NN	O
at	IN	O
approximately	RB	O
1.17	CD	O
g/ml	NNS	O
.	.	O
FIG	NNP	O
.	.	O
5	CD	O
presents	NNS	O
an	DT	O
image	NN	O
similar	JJ	O
to	TO	O
FIG	NNP	O
.	.	O
4	CD	O
where	WRB	O
the	DT	O
analysis	NN	O
was	VBD	O
performed	VBN	O
using	VBG	O
Gag	NNP	O
VLPs	NNP	O
produced	VBN	O
by	IN	O
a	DT	O
synthetic	JJ	O
Gag	NNP	O
expression	NN	O
cassette	NN	O
.	.	O
FIG	NNP	O
.	.	O
6	CD	O
presents	NNS	O
a	DT	O
comparison	NN	O
of	IN	O
the	DT	O
total	JJ	O
amount	NN	O
of	IN	O
purified	JJ	O
HIV	NNP	O
p55	NN	O
Gag	NNP	O
from	IN	O
several	JJ	O
preparations	NNS	O
obtained	VBN	O
from	IN	O
two	CD	O
baculovirus	NN	O
expression	NN	O
cassettes	VBZ	O
encoding	VBG	O
native	JJ	O
and	CC	O
modified	JJ	O
Gag	NNP	O
.	.	O
FIG	NNP	O
.	.	O
7	CD	O
presents	NNS	O
an	DT	O
alignment	NN	O
of	IN	O
modified	JJ	O
coding	VBG	O
sequences	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
including	VBG	O
a	DT	O
synthetic	JJ	O
Gag	NNP	O
expression	NN	O
cassette	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:4	NNP	O
)	)	O
,	,	O
a	DT	O
synthetic	JJ	O
Gag-protease	NNP	O
expression	NN	O
cassette	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:5	NNP	O
)	)	O
,	,	O
and	CC	O
a	DT	O
synthetic	JJ	O
Gag-polymerase	NNP	O
expression	NN	O
cassette	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:6	NNP	O
)	)	O
.	.	O
A	DT	O
common	JJ	O
region	NN	O
(	(	O
Gag-common	NNP	O
;	:	O
SEQ	NNP	O
ID	NNP	O
NO:9	NNP	O
)	)	O
extends	VBZ	O
from	IN	O
position	NN	O
1	CD	O
to	TO	O
position	NN	O
1262	CD	O
.	.	O
FIG	NNP	O
.	.	O
8	CD	O
presents	NNS	O
an	DT	O
image	NN	O
of	IN	O
wild-type	JJ	O
Gag-HCV	NNP	O
core	NN	O
expression	NN	O
samples	NNS	O
from	IN	O
a	DT	O
series	NN	O
of	IN	O
fractions	NNS	O
which	WDT	O
were	VBD	O
electrophoresed	VBN	O
on	IN	O
an	DT	O
8-16	JJ	O
%	NN	O
SDS	NNP	O
polyacrylamide	NN	O
gel	NN	O
and	CC	O
the	DT	O
resulting	VBG	O
bands	NNS	O
visualized	VBN	O
by	IN	O
commassie	NN	O
staining	NN	O
.	.	O
FIG	NNP	O
.	.	O
9	CD	O
shows	VBZ	O
the	DT	O
results	NNS	O
of	IN	O
Western	JJ	O
blot	NN	O
analysis	NN	O
of	IN	O
the	DT	O
gel	NN	O
shown	VBN	O
presented	VBN	O
in	IN	O
FIG	NNP	O
.	.	O
8	CD	O
.	.	O
FIG	NNP	O
.	.	O
10	CD	O
presents	NNS	O
results	NNS	O
similar	JJ	O
to	TO	O
those	DT	O
shown	VBN	O
in	IN	O
FIG	NNP	O
.	.	O
9	CD	O
.	.	O
The	DT	O
results	NNS	O
in	IN	O
FIG	NNP	O
.	.	O
10	CD	O
indicate	NN	O
that	IN	O
the	DT	O
main	JJ	O
HCV	NNP	O
Core-specific	NNP	O
reactivity	NN	O
migrates	NNS	O
at	IN	O
an	DT	O
approximate	JJ	O
molecular	JJ	O
weight	NN	O
of	IN	O
72,000	CD	O
kD	NNS	O
,	,	O
which	WDT	O
is	VBZ	O
in	IN	O
accordance	NN	O
with	IN	O
the	DT	O
predicted	JJ	O
molecular	JJ	O
weight	NN	O
of	IN	O
the	DT	O
Gag-HCV	NNP	O
core	NN	O
chimeric	NN	O
protein	NN	O
.	.	O
FIGS	NNP	O
.	.	O
11A	CD	O
to	TO	O
11D	CD	O
present	NN	O
a	DT	O
comparison	NN	O
of	IN	O
AT	NNP	O
content	NN	O
,	,	O
in	IN	O
percent	NN	O
,	,	O
of	IN	O
cDNAs	NN	O
corresponding	VBG	O
to	TO	O
an	DT	O
unstable	JJ	O
human	JJ	O
mRNA	NN	O
(	(	O
human	JJ	O
IFNγ	NNP	O
mRNA	NN	O
;	:	O
11A	CD	O
)	)	O
,	,	O
wild-type	JJ	O
HIV	NNP	O
Gag	NNP	O
native	JJ	O
RNA	NNP	O
(	(	O
11B	CD	O
)	)	O
,	,	O
a	DT	O
stable	JJ	O
human	JJ	O
mRNA	NN	O
(	(	O
human	JJ	O
GAPDH	NNP	O
mRNA	NN	O
;	:	O
11C	CD	O
)	)	O
,	,	O
and	CC	O
synthetic	JJ	O
HIV	NNP	O
Gag	NNP	O
RNA	NNP	O
(	(	O
11D	CD	O
)	)	O
.	.	O
FIG	NNP	O
.	.	O
12	CD	O
shows	VBZ	O
the	DT	O
location	NN	O
of	IN	O
the	DT	O
inactivation	NN	O
sites	VBZ	O
for	IN	O
the	DT	O
native	JJ	O
HIV-1SF2	NNP	O
Gag-polymerase	NNP	O
sequence	NN	O
SEQ	NNP	O
ID	NNP	O
NO:3	NNP	O
.	.	O
FIG	NNP	O
.	.	O
13A	CD	O
presents	NNS	O
a	DT	O
vector	NN	O
map	NN	O
of	IN	O
pESN2dhfr	NN	O
.	.	O
FIG	NNP	O
.	.	O
13B	CD	O
presents	NNS	O
a	DT	O
map	NN	O
of	IN	O
the	DT	O
pCMVIII	NN	O
vector	NN	O
.	.	O
FIG	NNP	O
.	.	O
14	CD	O
presents	NNS	O
a	DT	O
vector	NN	O
map	NN	O
of	IN	O
pCMV-LINK	NN	O
.	.	O
FIG	NNP	O
.	.	O
15	CD	O
presents	NNS	O
a	DT	O
schematic	JJ	O
diagram	NN	O
showing	VBG	O
the	DT	O
relationships	NNS	O
between	IN	O
the	DT	O
following	VBG	O
forms	NNS	O
of	IN	O
the	DT	O
HIV	NNP	O
Env	NNP	O
polypeptide	NN	O
:	:	O
gp160	NN	O
,	,	O
gp140	NN	O
,	,	O
gp120	NN	O
,	,	O
and	CC	O
gp41	NN	O
.	.	O
FIG	NNP	O
.	.	O
16	CD	O
depicts	VBZ	O
the	DT	O
nucleotide	JJ	O
sequence	NN	O
of	IN	O
wild-type	JJ	O
gp120	NN	O
from	IN	O
SF162	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:30	NNP	O
)	)	O
.	.	O
FIG	NNP	O
.	.	O
17	CD	O
depicts	VBZ	O
the	DT	O
nucleotide	JJ	O
sequence	NN	O
of	IN	O
the	DT	O
wild-type	JJ	O
gp140	NN	O
from	IN	O
SF162	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:31	NNP	O
)	)	O
.	.	O
FIG	NNP	O
.	.	O
18	CD	O
depicts	VBZ	O
the	DT	O
nucleotide	JJ	O
sequence	NN	O
of	IN	O
the	DT	O
wild-type	JJ	O
gp160	NN	O
from	IN	O
SF162	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:32	NNP	O
)	)	O
.	.	O
FIG	NNP	O
.	.	O
19	CD	O
depicts	VBZ	O
the	DT	O
nucleotide	JJ	O
sequence	NN	O
of	IN	O
the	DT	O
construct	NN	O
designated	VBN	O
gp120.modSF162	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:33	NNP	O
)	)	O
.	.	O
FIG	NNP	O
.	.	O
20	CD	O
depicts	VBZ	O
the	DT	O
nucleotide	JJ	O
sequence	NN	O
of	IN	O
the	DT	O
construct	NN	O
designated	VBN	O
gp120.modSF162.delV2	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:34	NNP	O
)	)	O
.	.	O
FIG	NNP	O
.	.	O
21	CD	O
depicts	VBZ	O
the	DT	O
nucleotide	JJ	O
sequence	NN	O
of	IN	O
the	DT	O
construct	NN	O
designated	VBN	O
gp120.modSF162.delV1/V2	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:35	NNP	O
)	)	O
.	.	O
FIGS	NNP	O
.	.	O
22A-H	JJ	O
show	NN	O
the	DT	O
percent	NN	O
A-T	NNP	O
content	NN	O
over	IN	O
the	DT	O
length	NN	O
of	IN	O
the	DT	O
sequences	NNS	O
for	IN	O
IFNγ	NNP	O
(	(	O
FIGS	NNP	O
.	.	O
2C	CD	O
and	CC	O
2G	CD	O
)	)	O
;	:	O
native	JJ	O
gp160	NN	O
Env	NNP	O
US4	NNP	O
and	CC	O
SF162	NNP	O
(	(	O
FIGS	NNP	O
.	.	O
2A	CD	O
and	CC	O
2E	CD	O
,	,	O
respectively	RB	O
)	)	O
;	:	O
GAPDH	NNP	O
(	(	O
FIGS	NNP	O
.	.	O
2D	CD	O
and	CC	O
2H	CD	O
)	)	O
;	:	O
and	CC	O
the	DT	O
synthetic	JJ	O
gp160	NN	O
Env	NNP	O
for	IN	O
US4	NNP	O
and	CC	O
SF162	NNP	O
(	(	O
FIGS	NNP	O
.	.	O
2B	CD	O
and	CC	O
2F	CD	O
,	,	O
respectively	RB	O
)	)	O
.	.	O
FIG	NNP	O
.	.	O
23	CD	O
depicts	VBZ	O
the	DT	O
nucleotide	JJ	O
sequence	NN	O
of	IN	O
the	DT	O
construct	NN	O
designated	VBN	O
gp140.modSF162	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:36	NNP	O
)	)	O
.	.	O
FIG	NNP	O
.	.	O
24	CD	O
depicts	VBZ	O
the	DT	O
nucleotide	JJ	O
sequence	NN	O
of	IN	O
the	DT	O
construct	NN	O
designated	VBN	O
gp140.modSF162.delV2	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:37	NNP	O
)	)	O
.	.	O
FIG	NNP	O
.	.	O
25	CD	O
depicts	VBZ	O
the	DT	O
nucleotide	JJ	O
sequence	NN	O
of	IN	O
the	DT	O
construct	NN	O
designated	VBN	O
gp140.modSF162.delV1/V2	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:38	NNP	O
)	)	O
.	.	O
FIG	NNP	O
.	.	O
26	CD	O
depicts	VBZ	O
the	DT	O
nucleotide	JJ	O
sequence	NN	O
of	IN	O
the	DT	O
construct	NN	O
designated	VBN	O
gp140.mut.modSF162	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:39	NNP	O
)	)	O
.	.	O
FIG	NNP	O
.	.	O
27	CD	O
depicts	VBZ	O
the	DT	O
nucleotide	JJ	O
sequence	NN	O
of	IN	O
the	DT	O
construct	NN	O
designated	VBN	O
gp140.mut.modSF162.delV2	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:40	NNP	O
)	)	O
.	.	O
FIG	NNP	O
.	.	O
28	CD	O
depicts	VBZ	O
the	DT	O
nucleotide	JJ	O
sequence	NN	O
of	IN	O
the	DT	O
construct	NN	O
designated	VBN	O
gp140.mut.modSF162.delV1/V2	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:41	NNP	O
)	)	O
.	.	O
FIG	NNP	O
.	.	O
29	CD	O
depicts	VBZ	O
the	DT	O
nucleotide	JJ	O
sequence	NN	O
of	IN	O
the	DT	O
construct	NN	O
designated	VBN	O
gp140.mut7.modSF162	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:42	NNP	O
)	)	O
.	.	O
FIG	NNP	O
.	.	O
30	CD	O
depicts	VBZ	O
the	DT	O
nucleotide	JJ	O
sequence	NN	O
of	IN	O
the	DT	O
construct	NN	O
designated	VBN	O
gp140.mut7.modSF162.delV2	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:43	NNP	O
)	)	O
.	.	O
FIG	NNP	O
.	.	O
31	CD	O
depicts	VBZ	O
the	DT	O
nucleotide	JJ	O
sequence	NN	O
of	IN	O
the	DT	O
construct	NN	O
designated	VBN	O
gp140.mut7.modSF162.delV1/V2	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:44	NNP	O
)	)	O
.	.	O
FIG	NNP	O
.	.	O
32	CD	O
depicts	VBZ	O
the	DT	O
nucleotide	JJ	O
sequence	NN	O
of	IN	O
the	DT	O
construct	NN	O
designated	VBN	O
gp140.mut8.modSF162	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:45	NNP	O
)	)	O
.	.	O
FIG	NNP	O
.	.	O
33	CD	O
depicts	VBZ	O
the	DT	O
nucleotide	JJ	O
sequence	NN	O
of	IN	O
the	DT	O
construct	NN	O
designated	VBN	O
gp140.mut8.modSF162.delV2	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:46	NNP	O
)	)	O
.	.	O
FIG	NNP	O
.	.	O
34	CD	O
depicts	VBZ	O
the	DT	O
nucleotide	JJ	O
sequence	NN	O
of	IN	O
the	DT	O
construct	NN	O
designated	VBN	O
gp140.mut8.modSF162.delV1/V2	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:47	NNP	O
)	)	O
.	.	O
FIG	NNP	O
.	.	O
35	CD	O
depicts	VBZ	O
the	DT	O
nucleotide	JJ	O
sequence	NN	O
of	IN	O
the	DT	O
construct	NN	O
designated	VBN	O
gp160.modSF162	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:48	NNP	O
)	)	O
.	.	O
FIG	NNP	O
.	.	O
36	CD	O
depicts	VBZ	O
the	DT	O
nucleotide	JJ	O
sequence	NN	O
of	IN	O
the	DT	O
construct	NN	O
designated	VBN	O
gp160.modSF162.delV2	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:49	NNP	O
)	)	O
.	.	O
FIG	NNP	O
.	.	O
37	CD	O
depicts	VBZ	O
the	DT	O
nucleotide	JJ	O
sequence	NN	O
of	IN	O
the	DT	O
construct	NN	O
designated	VBN	O
gp160.modSF162.delV1/V2	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:50	NNP	O
)	)	O
.	.	O
FIG	NNP	O
.	.	O
38	CD	O
depicts	VBZ	O
the	DT	O
nucleotide	JJ	O
sequence	NN	O
of	IN	O
the	DT	O
wild-type	JJ	O
gp120	NN	O
from	IN	O
US4	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:51	NNP	O
)	)	O
.	.	O
FIG	NNP	O
.	.	O
39	CD	O
depicts	VBZ	O
the	DT	O
nucleotide	JJ	O
sequence	NN	O
of	IN	O
the	DT	O
wild-type	JJ	O
gp140	NN	O
from	IN	O
US4	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:52	NNP	O
)	)	O
.	.	O
FIG	NNP	O
.	.	O
40	CD	O
depicts	VBZ	O
the	DT	O
nucleotide	JJ	O
sequence	NN	O
of	IN	O
the	DT	O
wild-type	JJ	O
gp160	NN	O
from	IN	O
US4	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:53	NNP	O
)	)	O
.	.	O
FIG	NNP	O
.	.	O
41	CD	O
depicts	VBZ	O
the	DT	O
nucleotide	JJ	O
sequence	NN	O
of	IN	O
the	DT	O
construct	NN	O
designated	VBN	O
gp120.modUS4	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:54	NNP	O
)	)	O
.	.	O
FIG	NNP	O
.	.	O
42	CD	O
depicts	VBZ	O
the	DT	O
nucleotide	JJ	O
sequence	NN	O
of	IN	O
the	DT	O
construct	NN	O
designated	VBN	O
gp120.modUS4.del	JJ	O
128-194	JJ	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:55	NNP	O
)	)	O
.	.	O
FIG	NNP	O
.	.	O
43	CD	O
depicts	VBZ	O
the	DT	O
nucleotide	JJ	O
sequence	NN	O
of	IN	O
the	DT	O
construct	NN	O
designated	VBN	O
gp140.modUS4	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:56	NNP	O
)	)	O
.	.	O
FIG	NNP	O
.	.	O
44	CD	O
depicts	VBZ	O
the	DT	O
nucleotide	JJ	O
sequence	NN	O
of	IN	O
the	DT	O
construct	NN	O
designated	VBN	O
gp140.mut.modUS4	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:57	NNP	O
)	)	O
.	.	O
FIG	NNP	O
.	.	O
45	CD	O
depicts	VBZ	O
the	DT	O
nucleotide	JJ	O
sequence	NN	O
of	IN	O
the	DT	O
construct	NN	O
designated	VBN	O
gp140.TM.modUS4	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:58	NNP	O
)	)	O
.	.	O
FIG	NNP	O
.	.	O
46	CD	O
depicts	VBZ	O
the	DT	O
nucleotide	JJ	O
sequence	NN	O
of	IN	O
the	DT	O
construct	NN	O
designated	VBN	O
gp140.modUS4.delV1/V2	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:59	NNP	O
)	)	O
.	.	O
FIG	NNP	O
.	.	O
47	CD	O
depicts	VBZ	O
the	DT	O
nucleotide	JJ	O
sequence	NN	O
of	IN	O
the	DT	O
construct	NN	O
designated	VBN	O
gp140.modUS4.delV2	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:60	NNP	O
)	)	O
.	.	O
FIG	NNP	O
.	.	O
48	CD	O
depicts	VBZ	O
the	DT	O
nucleotide	JJ	O
sequence	NN	O
of	IN	O
the	DT	O
construct	NN	O
designated	VBN	O
gp140.mut.modUS4.delV1/V2	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:61	NNP	O
)	)	O
.	.	O
FIG	NNP	O
.	.	O
49	CD	O
depicts	VBZ	O
the	DT	O
nucleotide	JJ	O
sequence	NN	O
of	IN	O
the	DT	O
construct	NN	O
designated	VBN	O
gp140.modUS4.del	JJ	O
128-194	JJ	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:62	NNP	O
)	)	O
.	.	O
FIG	NNP	O
.	.	O
50	CD	O
depicts	VBZ	O
the	DT	O
nucleotide	JJ	O
sequence	NN	O
of	IN	O
the	DT	O
construct	NN	O
designated	VBN	O
gp140.mut.modUS4.del	JJ	O
128-194	JJ	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:63	NNP	O
)	)	O
.	.	O
FIG	NNP	O
.	.	O
51	CD	O
depicts	VBZ	O
the	DT	O
nucleotide	JJ	O
sequence	NN	O
of	IN	O
the	DT	O
construct	NN	O
designated	VBN	O
gp160.modUS4	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:64	NNP	O
)	)	O
.	.	O
FIG	NNP	O
.	.	O
52	CD	O
depicts	VBZ	O
the	DT	O
nucleotide	JJ	O
sequence	NN	O
of	IN	O
the	DT	O
construct	NN	O
designated	VBN	O
gp160.modUS4.delV1	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:65	NNP	O
)	)	O
.	.	O
FIG	NNP	O
.	.	O
53	CD	O
depicts	VBZ	O
the	DT	O
nucleotide	JJ	O
sequence	NN	O
of	IN	O
the	DT	O
construct	NN	O
designated	VBN	O
gp160.modUS4.delV2	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:66	NNP	O
)	)	O
.	.	O
FIG	NNP	O
.	.	O
54	CD	O
depicts	VBZ	O
the	DT	O
nucleotide	JJ	O
sequence	NN	O
of	IN	O
the	DT	O
construct	NN	O
designated	VBN	O
gp160.modUS4.delV1/V2	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:67	NNP	O
)	)	O
.	.	O
FIG	NNP	O
.	.	O
55	CD	O
depicts	VBZ	O
the	DT	O
nucleotide	JJ	O
sequence	NN	O
of	IN	O
the	DT	O
construct	NN	O
designated	VBN	O
gp160.modUS4.del	JJ	O
128-194	JJ	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:68	NNP	O
)	)	O
.	.	O
FIG	NNP	O
.	.	O
56	CD	O
depicts	VBZ	O
the	DT	O
nucleotide	JJ	O
sequence	NN	O
of	IN	O
the	DT	O
common	JJ	O
region	NN	O
of	IN	O
Env	NNP	O
from	IN	O
wild-type	JJ	O
US4	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:69	NNP	O
)	)	O
.	.	O
FIG	NNP	O
.	.	O
57	CD	O
depicts	VBZ	O
the	DT	O
nucleotide	JJ	O
sequence	NN	O
of	IN	O
the	DT	O
common	JJ	O
region	NN	O
of	IN	O
Env	NNP	O
from	IN	O
wild-type	JJ	O
SF162	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:70	NNP	O
)	)	O
.	.	O
FIG	NNP	O
.	.	O
58	CD	O
depicts	VBZ	O
the	DT	O
nucleotide	JJ	O
sequence	NN	O
of	IN	O
synthetic	JJ	O
sequences	NNS	O
corresponding	VBG	O
to	TO	O
the	DT	O
common	JJ	O
region	NN	O
of	IN	O
Env	NNP	O
from	IN	O
US4	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:71	NNP	O
)	)	O
.	.	O
FIG	NNP	O
.	.	O
59	CD	O
depicts	VBZ	O
the	DT	O
nucleotide	JJ	O
sequence	NN	O
of	IN	O
synthetic	JJ	O
sequences	NNS	O
corresponding	VBG	O
to	TO	O
the	DT	O
common	JJ	O
region	NN	O
of	IN	O
Env	NNP	O
from	IN	O
SF162	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:72	NNP	O
)	)	O
.	.	O
FIG	NNP	O
.	.	O
60	CD	O
presents	NNS	O
a	DT	O
schematic	JJ	O
representation	NN	O
of	IN	O
an	DT	O
Env	NNP	O
polypeptide	NN	O
purification	NN	O
strategy	NN	O
.	.	O
FIG	NNP	O
.	.	O
61	CD	O
depicts	VBZ	O
the	DT	O
nucleotide	JJ	O
sequence	NN	O
of	IN	O
the	DT	O
bicistronic	JJ	O
construct	NN	O
designated	VBN	O
gp160.modUS4.Gag.modSF2	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:73	NNP	O
)	)	O
.	.	O
FIG	NNP	O
.	.	O
62	CD	O
depicts	VBZ	O
the	DT	O
nucleotide	JJ	O
sequence	NN	O
of	IN	O
the	DT	O
bicistronic	JJ	O
construct	NN	O
designated	VBN	O
gp160.modSF162.Gag.modSF2	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:74	NNP	O
)	)	O
.	.	O
FIG	NNP	O
.	.	O
63	CD	O
depicts	VBZ	O
the	DT	O
nucleotide	JJ	O
sequence	NN	O
of	IN	O
the	DT	O
bicistronic	JJ	O
construct	NN	O
designated	VBN	O
gp160.modUS4.-delV1/V2.Gag.modSF2	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:75	NNP	O
)	)	O
.	.	O
FIG	NNP	O
.	.	O
64	CD	O
depicts	VBZ	O
the	DT	O
nucleotide	JJ	O
sequence	NN	O
of	IN	O
the	DT	O
bicistronic	JJ	O
construct	NN	O
designated	VBN	O
gp160.modSF162.delV2.Gag.modSF2	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:76	NNP	O
)	)	O
.	.	O
FIGS	NNP	O
.	.	O
65A-65F	JJ	O
show	NN	O
micrographs	NN	O
of	IN	O
293T	CD	O
cells	NNS	O
transfected	VBN	O
with	IN	O
the	DT	O
following	JJ	O
polypeptide	NN	O
encoding	VBG	O
sequences	NNS	O
:	:	O
FIG	NNP	O
.	.	O
65A	CD	O
,	,	O
gag.modSF2	NN	O
;	:	O
FIG	NNP	O
.	.	O
65B	CD	O
,	,	O
gp160.modUS4	NN	O
;	:	O
FIG	NNP	O
.	.	O
65C	CD	O
,	,	O
gp160.modUS4.delV1/V2.gag.modSF2	NN	O
(	(	O
bicistronic	JJ	O
Env	NNP	O
and	CC	O
Gag	NNP	O
)	)	O
;	:	O
FIGS	NNP	O
.	.	O
65D	CD	O
and	CC	O
65E	CD	O
,	,	O
gp160.modUS4.delV1/V2	NN	O
and	CC	O
gag.modSF2	NN	O
;	:	O
and	CC	O
FIG	NNP	O
.	.	O
65F	CD	O
,	,	O
gp120.modSF162.delV2	NN	O
and	CC	O
gag.modSF2	NN	O
.	.	O
FIGS	NNP	O
.	.	O
66A	CD	O
and	CC	O
66B	CD	O
present	JJ	O
alignments	NNS	O
of	IN	O
selected	VBN	O
modified	JJ	O
coding	VBG	O
sequences	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
including	VBG	O
a	DT	O
common	JJ	O
region	NN	O
defined	VBN	O
for	IN	O
each	DT	O
group	NN	O
of	IN	O
synthetic	JJ	O
Env	NNP	O
expression	NN	O
cassettes	NNS	O
.	.	O
FIG	NNP	O
.	.	O
66A	CD	O
presents	NNS	O
alignments	NNS	O
of	IN	O
modified	JJ	O
SF162	NNP	O
sequences	NNS	O
.	.	O
gp160.modSF162	NN	O
,	,	O
SEQ	NNP	O
ID	NNP	O
NO:48	NNP	O
;	:	O
gp160.modSF162.delV2	NN	O
,	,	O
SEQ	NNP	O
ID	NNP	O
NO:49	NNP	O
;	:	O
gp160.modSF162.delV1V2	NN	O
,	,	O
SEQ	NNP	O
ID	NNP	O
NO:50	NNP	O
;	:	O
gp140.mut.modSF162	NN	O
,	,	O
SEQ	NNP	O
ID	NNP	O
NO:39	NNP	O
;	:	O
gp140.mut7.modSF162	NN	O
,	,	O
SEQ	NNP	O
ID	NNP	O
NO:42	NNP	O
;	:	O
gp140.mut8.modSF162	NN	O
,	,	O
SEQ	NNP	O
ID	NNP	O
NO:45	NNP	O
;	:	O
gp120.modSF162	NN	O
,	,	O
SEQ	NNP	O
ID	NNP	O
NO:33	NNP	O
.	.	O
FIG	NNP	O
.	.	O
66B	CD	O
presents	NNS	O
alignments	NNS	O
of	IN	O
modified	JJ	O
US4	NNP	O
sequences	NNS	O
.	.	O
gp160	NN	O
,	,	O
SEQ	NNP	O
ID	NNP	O
NO:53	NNP	O
;	:	O
gp160	JJ	O
del	NN	O
V1	NNP	O
,	,	O
SEQ	NNP	O
ID	NNP	O
NO:65	NNP	O
;	:	O
gp160	JJ	O
del	NN	O
V2	NNP	O
,	,	O
SEQ	NNP	O
ID	NNP	O
NO:66	NNP	O
;	:	O
gp160	JJ	O
del	FW	O
128-194	JJ	O
,	,	O
SEQ	NNP	O
ID	NNP	O
NO:63	NNP	O
;	:	O
gp140™	NN	O
,	,	O
SEQ	NNP	O
ID	NNP	O
NO:58	NNP	O
;	:	O
gp140	NN	O
,	,	O
SEQ	NNP	O
ID	NNP	O
NO:52	NNP	O
;	:	O
gp140mut	NN	O
,	,	O
SEQ	NNP	O
ID	NNP	O
NO:57	NNP	O
;	:	O
gp120	NN	O
,	,	O
SEQ	NNP	O
ID	NNP	O
NO:51	NNP	O
.	.	O
The	DT	O
SEQ	NNP	O
ID	NNP	O
NOs	NNP	O
for	IN	O
these	DT	O
sequences	NNS	O
are	VBP	O
presented	VBN	O
in	IN	O
Tables	NNP	O
1A	CD	O
and	CC	O
1B	CD	O
.	.	O
FIG	NNP	O
.	.	O
67	CD	O
shows	VBZ	O
the	DT	O
ELISA	NNP	O
titers	NNS	O
(	(	O
binding	VBG	O
antibodies	NNS	O
)	)	O
obtained	VBN	O
in	IN	O
two	CD	O
rhesus	NN	O
macaques	NNS	O
(	(	O
H445	NNP	O
,	,	O
lines	NNS	O
with	IN	O
solid	JJ	O
black	JJ	O
dots	NNS	O
;	:	O
and	CC	O
J408	NNP	O
,	,	O
lines	NNS	O
with	IN	O
open	JJ	O
squares	NNS	O
)	)	O
.	.	O
The	DT	O
y-axis	NN	O
is	VBZ	O
the	DT	O
end-point	JJ	O
gp140	NN	O
ELISA	NNP	O
titers	NNS	O
and	CC	O
the	DT	O
x-axis	JJ	O
shows	NNS	O
weeks	NNS	O
post-immunization	NN	O
.	.	O
The	DT	O
dashed	JJ	O
lines	NNS	O
at	IN	O
0	CD	O
,	,	O
4	CD	O
,	,	O
and	CC	O
8	CD	O
weeks	NNS	O
represent	JJ	O
DNA	NNP	O
immunizations	NNS	O
.	.	O
The	DT	O
alternating	NN	O
dash/dotted	VBD	O
line	NN	O
at	IN	O
27	CD	O
weeks	NNS	O
indicates	VBZ	O
a	DT	O
DNA	NN	O
plus	CC	O
protein	NN	O
boost	NN	O
immunization	NN	O
.	.	O
FIG	NNP	O
.	.	O
68	CD	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:77	NNP	O
)	)	O
depicts	VBZ	O
the	DT	O
wild-type	JJ	O
nucleotide	JJ	O
sequence	NN	O
of	IN	O
Gag	NNP	O
reverse	NN	O
transcriptase	NN	O
from	IN	O
SF2	NNP	O
.	.	O
FIG	NNP	O
.	.	O
69	CD	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:78	NNP	O
)	)	O
depicts	VBZ	O
the	DT	O
nucleotide	JJ	O
sequence	NN	O
of	IN	O
the	DT	O
construct	NN	O
designated	VBN	O
GP1	NNP	O
.	.	O
FIG	NNP	O
.	.	O
70	CD	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:79	NNP	O
)	)	O
depicts	VBZ	O
the	DT	O
nucleotide	JJ	O
sequence	NN	O
of	IN	O
the	DT	O
construct	NN	O
designated	VBN	O
GP2	NNP	O
.	.	O
FIG	NNP	O
.	.	O
71	CD	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:80	NNP	O
)	)	O
depicts	VBZ	O
the	DT	O
nucleotide	JJ	O
sequence	NN	O
of	IN	O
the	DT	O
construct	NN	O
designated	VBN	O
FS	NNP	O
(	(	O
+	NNP	O
)	)	O
.protinact_RTopt.YM	NN	O
.	.	O
FS	NNP	O
(	(	O
+	NNP	O
)	)	O
indicates	VBZ	O
that	IN	O
there	EX	O
is	VBZ	O
a	DT	O
frameshift	NN	O
in	IN	O
the	DT	O
GagPol	NNP	O
coding	NN	O
sequence	NN	O
.	.	O
FIG	NNP	O
.	.	O
72	CD	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:81	NNP	O
)	)	O
depicts	VBZ	O
the	DT	O
nucleotide	JJ	O
sequence	NN	O
of	IN	O
the	DT	O
construct	NN	O
designated	VBN	O
FS	NNP	O
(	(	O
+	NNP	O
)	)	O
.protinact.RTopt.YMWM	NN	O
.	.	O
FIG	NNP	O
.	.	O
73	CD	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:82	NNP	O
)	)	O
depicts	VBZ	O
the	DT	O
nucleotide	JJ	O
sequence	NN	O
of	IN	O
the	DT	O
construct	NN	O
designated	VBN	O
FS	NNP	O
(	(	O
−	NNP	O
)	)	O
.protmod.RTopt.YM	NN	O
.	.	O
FS	NNP	O
(	(	O
−	NNP	O
)	)	O
indicates	VBZ	O
that	IN	O
there	EX	O
is	VBZ	O
no	DT	O
frameshift	NN	O
in	IN	O
the	DT	O
GagPol	NNP	O
coding	NN	O
sequence	NN	O
.	.	O
FIG	NNP	O
.	.	O
74	CD	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:83	NNP	O
)	)	O
depicts	VBZ	O
the	DT	O
nucleotide	JJ	O
sequence	NN	O
of	IN	O
the	DT	O
construct	NN	O
designated	VBN	O
FS	NNP	O
(	(	O
−	NNP	O
)	)	O
.protmod.RTopt.YMWM	NN	O
.	.	O
FIG	NNP	O
.	.	O
75	CD	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:84	NNP	O
)	)	O
depicts	VBZ	O
the	DT	O
nucleotide	JJ	O
sequence	NN	O
of	IN	O
the	DT	O
construct	NN	O
designated	VBN	O
FS	NNP	O
(	(	O
−	NNP	O
)	)	O
.protmod.RTopt	NNP	O
(	(	O
+	NNP	O
)	)	O
.	.	O
FIG	NNP	O
.	.	O
76	CD	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:85	NNP	O
)	)	O
depicts	VBZ	O
the	DT	O
nucleotide	JJ	O
sequence	NN	O
of	IN	O
wild	JJ	O
type	JJ	O
Tat	NN	O
from	IN	O
isolate	JJ	O
SF162	NNP	O
.	.	O
FIG	NNP	O
.	.	O
77	CD	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:86	NNP	O
)	)	O
depicts	VBZ	O
the	DT	O
amino	NN	O
acid	JJ	O
sequence	NN	O
of	IN	O
the	DT	O
tat	JJ	O
polypeptide	NN	O
.	.	O
FIG	NNP	O
.	.	O
78	CD	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:87	NNP	O
)	)	O
depicts	VBZ	O
the	DT	O
nucleotide	JJ	O
sequence	NN	O
of	IN	O
a	DT	O
synthetic	JJ	O
Tat	NNP	O
construct	NN	O
designated	VBN	O
Tat.SF162.opt	NNP	O
.	.	O
FIG	NNP	O
.	.	O
79	CD	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:88	NNP	O
)	)	O
depicts	VBZ	O
the	DT	O
nucleotide	JJ	O
sequence	NN	O
of	IN	O
a	DT	O
synthetic	JJ	O
Tat	NNP	O
construct	NN	O
designated	VBN	O
tat.cys22.sf162.opt	NN	O
.	.	O
The	DT	O
construct	NN	O
encodes	VBZ	O
a	DT	O
tat	JJ	O
polypeptide	NN	O
in	IN	O
which	WDT	O
the	DT	O
cystein	NN	O
residue	NN	O
at	IN	O
position	NN	O
22	CD	O
of	IN	O
the	DT	O
wild	JJ	O
type	NN	O
Tat	NNP	O
polypeptide	NN	O
is	VBZ	O
replaced	VBN	O
by	IN	O
a	DT	O
glycine	NN	O
residue	NN	O
.	.	O
FIGS	NNP	O
.	.	O
80A	CD	O
to	TO	O
80E	CD	O
are	VBP	O
an	DT	O
alignment	NN	O
of	IN	O
the	DT	O
nucleotide	JJ	O
sequences	NNS	O
of	IN	O
the	DT	O
constructs	NNS	O
designated	VBN	O
Gag.mod.SF2	NNP	O
,	,	O
GP1	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:78	NNP	O
)	)	O
,	,	O
and	CC	O
GP2	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:79	NNP	O
)	)	O
.	.	O
FIG	NNP	O
.	.	O
81	CD	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:89	NNP	O
)	)	O
depicts	VBZ	O
the	DT	O
nucleotide	JJ	O
sequence	NN	O
of	IN	O
the	DT	O
construct	NN	O
designated	VBN	O
tataminoSF162.opt	NN	O
,	,	O
which	WDT	O
encodes	VBZ	O
the	DT	O
amino	NN	O
terminus	NN	O
of	IN	O
that	DT	O
tat	NN	O
protein	NN	O
.	.	O
The	DT	O
codon	NN	O
encoding	VBG	O
the	DT	O
cystein-22	JJ	O
residue	NN	O
is	VBZ	O
underlined	JJ	O
.	.	O
FIG	NNP	O
.	.	O
82	CD	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:90	NNP	O
)	)	O
depicts	VBZ	O
the	DT	O
amino	NN	O
acid	JJ	O
sequence	NN	O
of	IN	O
the	DT	O
polypeptide	NN	O
encoded	VBN	O
by	IN	O
the	DT	O
construct	NN	O
designated	VBN	O
tat.cys22.5F162.opt	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:88	NNP	O
)	)	O
.	.	O
DETAILED	JJ	O
DESCRIPTION	NNP	O
OF	IN	O
THE	NNP	O
INVENTION	NNP	O
The	DT	O
practice	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
will	MD	O
employ	VB	O
,	,	O
unless	IN	O
otherwise	RB	O
indicated	VBN	O
,	,	O
conventional	JJ	O
methods	NNS	O
of	IN	O
chemistry	NN	O
,	,	O
biochemistry	NN	O
,	,	O
molecular	JJ	O
biology	NN	O
,	,	O
immunology	NN	O
and	CC	O
pharmacology	NN	O
,	,	O
within	IN	O
the	DT	O
skill	NN	O
of	IN	O
the	DT	O
art	NN	O
.	.	O
Such	JJ	O
techniques	NNS	O
are	VBP	O
explained	VBN	O
fully	RB	O
in	IN	O
the	DT	O
literature	NN	O
.	.	O
See	VB	O
,	,	O
e.g.	VB	O
,	,	O
Remington	NNP	B
's	POS	I
Pharmaceutical	NNP	I
Sciences	NNPS	I
,	,	I
18th	CD	I
Edition	NNP	I
(	(	I
Easton	NNP	I
,	,	I
Pa.	NNP	I
:	:	I
Mack	NN	I
Publishing	VBG	I
Company	NNP	I
,	,	I
1990	CD	I
)	)	I
;	:	O
Methods	NNS	B
In	IN	I
Enzymology	NNP	I
(	(	I
S.	NNP	I
Colowick	NNP	I
and	CC	I
N.	NNP	I
Kaplan	NNP	I
,	,	I
eds.	NN	I
,	,	I
Academic	NNP	I
Press	NNP	I
,	,	I
Inc.	NNP	I
)	)	I
;	:	O
and	CC	O
Handbook	NNP	B
of	IN	I
Experimental	NNP	I
Immunology	NNP	I
,	,	I
Vols	NNP	I
.	.	I
I-IV	NNP	I
(	(	I
D.	NNP	I
M.	NNP	I
Weir	NNP	I
and	CC	I
C.	NNP	I
C.	NNP	I
Blackwell	NNP	I
,	,	I
eds.	NN	I
,	,	I
1986	CD	I
,	,	I
Blackwell	NNP	I
Scientific	NNP	I
Publications	NNP	I
)	)	I
;	:	O
Sambrook	NNP	B
,	,	I
et	FW	I
al.	NN	I
,	,	I
Molecular	JJ	I
Cloning	NN	I
:	:	I
A	DT	I
Laboratory	NNP	I
Manual	NNP	I
(	(	I
2nd	CD	I
Edition	NNP	I
,	,	I
1989	CD	I
)	)	I
;	:	O
Short	NNP	B
Protocols	NNP	I
in	IN	I
Molecular	NNP	I
Biology	NNP	I
,	,	I
4th	CD	I
ed	NN	I
.	.	I
(	(	I
Ausubel	NNP	I
et	RB	I
al	RB	I
.	.	I
eds.	NN	I
,	,	I
1999	CD	I
,	,	I
John	NNP	I
Wiley	NNP	I
&	CC	I
Sons	NNP	I
)	)	I
;	:	O
Molecular	NNP	B
Biology	NNP	I
Techniques	NNP	I
:	:	I
An	DT	I
Intensive	JJ	I
Laboratory	NNP	I
Course	NNP	I
,	,	I
(	(	I
Ream	NNP	I
et	RB	I
al.	RB	I
,	,	I
eds.	NN	I
,	,	I
1998	CD	I
,	,	I
Academic	NNP	I
Press	NNP	I
)	)	I
;	:	O
PCR	NNP	B
(	(	I
Introduction	NNP	I
to	TO	I
Biotechniques	NNP	I
Series	NNP	I
)	)	I
,	,	I
2nd	CD	I
ed	NN	I
.	.	I
(	(	I
Newton	NNP	I
&	CC	I
Graham	NNP	I
eds.	NN	I
,	,	I
1997	CD	I
,	,	I
Springer	NNP	I
Verlag	NNP	I
)	)	I
.	.	O
All	DT	O
publications	NNS	O
,	,	O
patents	NNS	O
and	CC	O
patent	NN	O
applications	NNS	O
cited	VBD	O
herein	NN	O
,	,	O
whether	IN	O
supra	NN	O
or	CC	O
infra	NN	O
,	,	O
are	VBP	O
hereby	RB	O
incorporated	VBN	O
by	IN	O
reference	NN	O
in	IN	O
their	PRP$	O
entirety	NN	O
.	.	O
As	IN	O
used	VBN	O
in	IN	O
this	DT	O
specification	NN	O
and	CC	O
the	DT	O
appended	JJ	O
claims	NNS	O
,	,	O
the	DT	O
singular	JJ	O
forms	NNS	O
“	VBP	O
a	DT	O
,	,	O
”	NNP	O
“	NNP	O
an	DT	O
”	NN	O
and	CC	O
“	VB	O
the	DT	O
”	NNP	O
include	VBP	O
plural	JJ	O
references	NNS	O
unless	IN	O
the	DT	O
content	NN	O
clearly	RB	O
dictates	VBZ	O
otherwise	RB	O
.	.	O
Thus	RB	O
,	,	O
for	IN	O
example	NN	O
,	,	O
reference	NN	O
to	TO	O
“	VB	O
an	DT	O
antigen	NN	O
”	NN	O
includes	VBZ	O
a	DT	O
mixture	NN	O
of	IN	O
two	CD	O
or	CC	O
more	JJR	O
such	JJ	O
agents	NNS	O
.	.	O
1	CD	O
.	.	O
Definitions	NNS	O
In	IN	O
describing	VBG	O
the	DT	O
present	JJ	O
invention	NN	O
,	,	O
the	DT	O
following	JJ	O
terms	NNS	O
will	MD	O
be	VB	O
employed	VBN	O
,	,	O
and	CC	O
are	VBP	O
intended	VBN	O
to	TO	O
be	VB	O
defined	VBN	O
as	IN	O
indicated	JJ	O
below	IN	O
.	.	O
“	JJ	O
Synthetic	NNP	O
”	NNP	O
sequences	NNS	O
,	,	O
as	IN	O
used	VBN	O
herein	NN	O
,	,	O
refers	NNS	O
to	TO	O
Env-	NNP	O
,	,	O
tat-	JJ	O
or	CC	O
Gag-encoding	JJ	O
polynucleotides	NNS	O
whose	WP$	O
expression	NN	O
has	VBZ	O
been	VBN	O
optimized	VBN	O
as	IN	O
described	JJ	O
herein	NN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
by	IN	O
codon	JJ	O
substitution	NN	O
,	,	O
deletions	NNS	O
,	,	O
replacements	NNS	O
and/or	VBP	O
inactivation	NN	O
of	IN	O
inhibitory	JJ	O
sequences	NNS	O
.	.	O
“	JJ	O
Wild-type	JJ	O
”	NN	O
or	CC	O
“	JJ	O
native	JJ	O
”	NN	O
sequences	NNS	O
,	,	O
as	IN	O
used	VBN	O
herein	NN	O
,	,	O
refers	NNS	O
to	TO	O
polypeptide	VB	O
encoding	VBG	O
sequences	NNS	O
that	WDT	O
are	VBP	O
essentially	RB	O
as	IN	O
they	PRP	O
are	VBP	O
found	VBN	O
in	IN	O
nature	NN	O
,	,	O
e.g.	NN	O
,	,	O
Gag	NNP	O
encoding	VBG	O
sequences	NNS	O
as	IN	O
found	VBN	O
in	IN	O
the	DT	O
isolate	JJ	O
HIV-1SF2	NNP	O
or	CC	O
Env	NNP	O
encoding	VBG	O
sequences	NNS	O
as	IN	O
found	VBN	O
in	IN	O
the	DT	O
isolates	NNS	O
HIV-1SF162	NNP	O
or	CC	O
HIV1US4	NNP	O
.	.	O
As	IN	O
used	VBN	O
herein	NN	O
,	,	O
the	DT	O
term	NN	O
“	NNP	O
virus-like	JJ	O
particle	NN	O
”	NN	O
or	CC	O
“	VB	O
VLP	NNP	O
”	NNP	O
refers	NNS	O
to	TO	O
a	DT	O
nonreplicating	NN	O
,	,	O
viral	JJ	O
shell	NN	O
,	,	O
derived	VBN	O
from	IN	O
any	DT	O
of	IN	O
several	JJ	O
viruses	NNS	O
discussed	VBD	O
further	RB	O
below	IN	O
.	.	O
VLPs	NN	O
are	VBP	O
generally	RB	O
composed	VBN	O
of	IN	O
one	CD	O
or	CC	O
more	JJR	O
viral	JJ	O
proteins	NNS	O
,	,	O
such	JJ	O
as	IN	O
,	,	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
those	DT	O
proteins	NNS	O
referred	VBD	O
to	TO	O
as	IN	O
capsid	NN	O
,	,	O
coat	NN	O
,	,	O
shell	NN	O
,	,	O
surface	NN	O
and/or	NNS	O
envelope	VBP	O
proteins	NNS	O
,	,	O
or	CC	O
particle-forming	JJ	O
polypeptides	NNS	O
derived	VBN	O
from	IN	O
these	DT	O
proteins	NNS	O
.	.	O
VLPs	NNP	O
can	MD	O
forth	VB	O
spontaneously	RB	O
upon	IN	O
recombinant	JJ	O
expression	NN	O
of	IN	O
the	DT	O
protein	NN	O
in	IN	O
an	DT	O
appropriate	JJ	O
expression	NN	O
system	NN	O
.	.	O
Methods	NNS	O
for	IN	O
producing	VBG	O
particular	JJ	O
VLPs	NNP	O
are	VBP	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
and	CC	O
discussed	VBD	O
more	RBR	O
fully	RB	O
below	IN	O
.	.	O
The	DT	O
presence	NN	O
of	IN	O
VLPs	NNP	O
following	VBG	O
recombinant	JJ	O
expression	NN	O
of	IN	O
viral	JJ	O
proteins	NNS	O
can	MD	O
be	VB	O
detected	VBN	O
using	VBG	O
conventional	JJ	O
techniques	NNS	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
,	,	O
such	JJ	O
as	IN	O
by	IN	O
electron	NN	O
microscopy	NN	O
,	,	O
biophysical	JJ	O
characterization	NN	O
,	,	O
and	CC	O
the	DT	O
like	JJ	O
.	.	O
See	VB	O
,	,	O
e.g.	VB	O
,	,	O
Baker	NNP	B
et	FW	I
al.	NN	I
,	,	I
Biophys	NNP	I
.	.	I
J	NNP	I
.	.	I
(	(	I
1991	CD	I
)	)	I
60:1445-1456	CD	I
;	:	O
Hagensee	NNP	B
et	FW	I
al.	NN	I
,	,	I
J.	NNP	I
Virol	NNP	I
.	.	I
(	(	I
1994	CD	I
)	)	I
68:4503-4505	NN	I
.	.	O
For	IN	O
example	NN	O
,	,	O
VLPs	NNP	O
can	MD	O
be	VB	O
isolated	VBN	O
by	IN	O
density	NN	O
gradient	NN	O
centrifugation	NN	O
and/or	NN	O
identified	VBN	O
by	IN	O
characteristic	JJ	O
density	NN	O
banding	NN	O
(	(	O
e.g.	JJ	O
,	,	O
Example	NNP	O
7	CD	O
)	)	O
.	.	O
Alternatively	RB	O
,	,	O
cryoelectron	NN	O
microscopy	NN	O
can	MD	O
be	VB	O
performed	VBN	O
on	IN	O
vitrified	JJ	O
aqueous	JJ	O
samples	NNS	O
of	IN	O
the	DT	O
VLP	NNP	O
preparation	NN	O
in	IN	O
question	NN	O
,	,	O
and	CC	O
images	NNS	O
recorded	VBN	O
under	IN	O
appropriate	JJ	O
exposure	NN	O
conditions	NNS	O
.	.	O
By	IN	O
“	JJ	O
particle-forming	JJ	O
polypeptide	NN	O
”	NNP	O
derived	VBD	O
from	IN	O
a	DT	O
particular	JJ	O
viral	JJ	O
protein	NN	O
is	VBZ	O
meant	VBN	O
a	DT	O
full-length	NN	O
or	CC	O
near	IN	O
full-length	JJ	O
viral	JJ	O
protein	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
a	DT	O
fragment	NN	O
thereof	NN	O
,	,	O
or	CC	O
a	DT	O
viral	JJ	O
protein	NN	O
with	IN	O
internal	JJ	O
deletions	NNS	O
,	,	O
which	WDT	O
has	VBZ	O
the	DT	O
ability	NN	O
to	TO	O
form	VB	O
VLPs	NNP	O
under	IN	O
conditions	NNS	O
that	WDT	O
favor	VBP	O
VLP	NNP	O
formation	NN	O
.	.	O
Accordingly	RB	O
,	,	O
the	DT	O
polypeptide	NN	O
may	MD	O
comprise	VB	O
the	DT	O
full-length	JJ	O
sequence	NN	O
,	,	O
fragments	NNS	O
,	,	O
truncated	VBN	O
and	CC	O
partial	JJ	O
sequences	NNS	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
analogs	NNS	O
and	CC	O
precursor	NN	O
forms	NNS	O
of	IN	O
the	DT	O
reference	NN	O
molecule	NN	O
.	.	O
The	DT	O
term	NN	O
therefore	RB	O
intends	VBZ	O
deletions	NNS	O
,	,	O
additions	NNS	O
and	CC	O
substitutions	NNS	O
to	TO	O
the	DT	O
sequence	NN	O
,	,	O
so	RB	O
long	RB	O
as	IN	O
the	DT	O
polypeptide	NN	O
retains	VBZ	O
the	DT	O
ability	NN	O
to	TO	O
form	VB	O
a	DT	O
VLP	NNP	O
.	.	O
Thus	RB	O
,	,	O
the	DT	O
term	NN	O
includes	VBZ	O
natural	JJ	O
variations	NNS	O
of	IN	O
the	DT	O
specified	VBN	O
polypeptide	NN	O
since	IN	O
variations	NNS	O
in	IN	O
coat	NN	O
proteins	NNS	O
often	RB	O
occur	VBP	O
between	IN	O
viral	JJ	O
isolates	NNS	O
.	.	O
The	DT	O
term	NN	O
also	RB	O
includes	VBZ	O
deletions	NNS	O
,	,	O
additions	NNS	O
and	CC	O
substitutions	NNS	O
that	WDT	O
do	VBP	O
not	RB	O
naturally	RB	O
occur	VBP	O
in	IN	O
the	DT	O
reference	NN	O
protein	NN	O
,	,	O
so	RB	O
long	RB	O
as	IN	O
the	DT	O
protein	NN	O
retains	VBZ	O
the	DT	O
ability	NN	O
to	TO	O
form	VB	O
a	DT	O
VLP	NNP	O
.	.	O
Preferred	VBN	O
substitutions	NNS	O
are	VBP	O
those	DT	O
which	WDT	O
are	VBP	O
conservative	JJ	O
in	IN	O
nature	NN	O
,	,	O
i.e.	NN	O
,	,	O
those	DT	O
substitutions	NNS	O
that	WDT	O
take	VBP	O
place	NN	O
within	IN	O
a	DT	O
family	NN	O
of	IN	O
amino	NN	O
acids	NNS	O
that	WDT	O
are	VBP	O
related	VBN	O
in	IN	O
their	PRP$	O
side	NN	O
chains	NNS	O
.	.	O
Specifically	RB	O
,	,	O
amino	JJ	O
acids	NNS	O
are	VBP	O
generally	RB	O
divided	VBN	O
into	IN	O
four	CD	O
families	NNS	O
:	:	O
(	(	O
1	CD	O
)	)	O
acidic—aspartate	NN	O
and	CC	O
glutamate	NN	O
;	:	O
(	(	O
2	CD	O
)	)	O
basic—lysine	NN	O
,	,	O
arginine	NN	O
,	,	O
histidine	NN	O
;	:	O
(	(	O
3	CD	O
)	)	O
non-polar—alanine	NN	O
,	,	O
valine	NN	O
,	,	O
leucine	NN	O
,	,	O
isoleucine	NN	O
,	,	O
proline	NN	O
,	,	O
phenylalanine	NN	O
,	,	O
methionine	NN	O
,	,	O
tryptophan	NN	O
;	:	O
and	CC	O
(	(	O
4	CD	O
)	)	O
uncharged	VBD	O
polar—glycine	NN	O
,	,	O
asparagine	NN	O
,	,	O
glutamine	NN	O
,	,	O
cystine	NN	O
,	,	O
serine	JJ	O
threonine	NN	O
,	,	O
tyrosine	NN	O
.	.	O
Phenylalanine	NNP	O
,	,	O
tryptophan	NN	O
,	,	O
and	CC	O
tyrosine	NN	O
are	VBP	O
sometimes	RB	O
classified	VBN	O
as	IN	O
aromatic	JJ	O
amino	NN	O
acids	NNS	O
.	.	O
An	DT	O
“	JJ	O
antigen	NN	O
”	NN	O
refers	NNS	O
to	TO	O
a	DT	O
molecule	NN	O
containing	VBG	O
one	CD	O
or	CC	O
more	JJR	O
epitopes	NNS	O
(	(	O
either	DT	O
linear	NN	O
,	,	O
conformational	NN	O
or	CC	O
both	DT	O
)	)	O
that	WDT	O
will	MD	O
stimulate	VB	O
a	DT	O
host	NN	O
's	POS	O
immune	JJ	O
system	NN	O
to	TO	O
make	VB	O
a	DT	O
humoral	JJ	O
and/or	NN	O
cellular	JJ	O
antigen-specific	JJ	O
response	NN	O
.	.	O
The	DT	O
term	NN	O
is	VBZ	O
used	VBN	O
interchangeably	RB	O
with	IN	O
the	DT	O
term	NN	O
“	NNP	O
immunogen.	NN	O
”	NNP	O
Normally	NNP	O
,	,	O
a	DT	O
B-cell	NNP	O
epitope	NN	O
will	MD	O
include	VB	O
at	IN	O
least	JJS	O
about	IN	O
5	CD	O
amino	JJ	O
acids	NNS	O
but	CC	O
can	MD	O
be	VB	O
as	RB	O
small	JJ	O
as	IN	O
3-4	JJ	O
amino	NN	O
acids	NNS	O
.	.	O
A	DT	O
T-cell	NNP	O
epitope	NN	O
,	,	O
such	JJ	O
as	IN	O
a	DT	O
CTL	NNP	O
epitope	NN	O
,	,	O
will	MD	O
include	VB	O
at	IN	O
least	JJS	O
about	IN	O
7-9	JJ	O
amino	NN	O
acids	NNS	O
,	,	O
and	CC	O
a	DT	O
helper	JJ	O
T-cell	NNP	O
epitope	NN	O
at	IN	O
least	JJS	O
about	IN	O
12-20	JJ	O
amino	NN	O
acids	NNS	O
.	.	O
Normally	RB	O
,	,	O
an	DT	O
epitope	NN	O
will	MD	O
include	VB	O
between	IN	O
about	RB	O
7	CD	O
and	CC	O
15	CD	O
amino	NN	O
acids	NNS	O
,	,	O
such	JJ	O
as	IN	O
,	,	O
9	CD	O
,	,	O
10	CD	O
,	,	O
12	CD	O
or	CC	O
15	CD	O
amino	JJ	O
acids	NNS	O
.	.	O
The	DT	O
term	NN	O
“	NNP	O
antigen	NN	O
”	NN	O
denotes	VBZ	O
both	DT	O
subunit	NN	O
antigens	VBZ	O
,	,	O
(	(	O
i.e.	FW	O
,	,	O
antigens	NNS	O
which	WDT	O
are	VBP	O
separate	JJ	O
and	CC	O
discrete	JJ	O
from	IN	O
a	DT	O
whole	JJ	O
organism	NN	O
with	IN	O
which	WDT	O
the	DT	O
antigen	NN	O
is	VBZ	O
associated	VBN	O
in	IN	O
nature	NN	O
)	)	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
,	,	O
killed	VBD	O
,	,	O
attenuated	VBD	O
or	CC	O
inactivated	JJ	O
bacteria	NNS	O
,	,	O
viruses	NNS	O
,	,	O
fungi	NNS	O
,	,	O
parasites	NNS	O
or	CC	O
other	JJ	O
microbes	NNS	O
.	.	O
Antibodies	NNS	O
such	JJ	O
as	IN	O
anti-idiotype	JJ	O
antibodies	NNS	O
,	,	O
or	CC	O
fragments	NNS	O
thereof	CC	O
,	,	O
and	CC	O
synthetic	JJ	O
peptide	NN	O
mimotopes	NNS	O
,	,	O
which	WDT	O
can	MD	O
mimic	VB	O
an	DT	O
antigen	NN	O
or	CC	O
antigenic	JJ	O
determinant	NN	O
,	,	O
are	VBP	O
also	RB	O
captured	VBN	O
under	IN	O
the	DT	O
definition	NN	O
of	IN	O
antigen	NN	O
as	IN	O
used	VBN	O
herein	NN	O
.	.	O
Similarly	RB	O
,	,	O
an	DT	O
oligonucleotide	NN	O
or	CC	O
polynucleotide	NN	O
which	WDT	O
expresses	VBZ	O
an	DT	O
antigen	NN	O
or	CC	O
antigenic	JJ	O
determinant	NN	O
in	IN	O
vivo	NN	O
,	,	O
such	JJ	O
as	IN	O
in	IN	O
gene	NN	O
therapy	NN	O
and	CC	O
DNA	NNP	O
immunization	NN	O
applications	NNS	O
,	,	O
is	VBZ	O
also	RB	O
included	VBN	O
in	IN	O
the	DT	O
definition	NN	O
of	IN	O
antigen	NN	O
herein	NN	O
.	.	O
For	IN	O
purposes	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
,	,	O
antigens	NNS	O
can	MD	O
be	VB	O
derived	VBN	O
from	IN	O
any	DT	O
of	IN	O
several	JJ	O
known	VBN	O
viruses	NNS	O
,	,	O
bacteria	NNS	O
,	,	O
parasites	NNS	O
and	CC	O
fungi	NNS	O
,	,	O
as	IN	O
described	VBN	O
more	RBR	O
fully	RB	O
below	IN	O
.	.	O
The	DT	O
term	NN	O
also	RB	O
intends	VBZ	O
any	DT	O
of	IN	O
the	DT	O
various	JJ	O
tumor	NN	O
antigens	NNS	O
.	.	O
Furthermore	RB	O
,	,	O
for	IN	O
purposes	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
,	,	O
an	DT	O
“	JJ	O
antigen	NN	O
”	NN	O
refers	NNS	O
to	TO	O
a	DT	O
protein	NN	O
which	WDT	O
includes	VBZ	O
modifications	NNS	O
,	,	O
such	JJ	O
as	IN	O
deletions	NNS	O
,	,	O
additions	NNS	O
and	CC	O
substitutions	NNS	O
(	(	O
generally	RB	O
conservative	JJ	O
in	IN	O
nature	NN	O
)	)	O
,	,	O
to	TO	O
the	DT	O
native	JJ	O
sequence	NN	O
,	,	O
so	RB	O
long	RB	O
as	IN	O
the	DT	O
protein	NN	O
maintains	VBZ	O
the	DT	O
ability	NN	O
to	TO	O
elicit	VB	O
an	DT	O
immunological	JJ	O
response	NN	O
,	,	O
as	IN	O
defined	VBN	O
herein	NN	O
.	.	O
These	DT	O
modifications	NNS	O
may	MD	O
be	VB	O
deliberate	NN	O
,	,	O
as	IN	O
through	IN	O
site-directed	JJ	O
mutagenesis	NN	O
,	,	O
or	CC	O
may	MD	O
be	VB	O
accidental	JJ	O
,	,	O
such	JJ	O
as	IN	O
through	IN	O
mutations	NNS	O
of	IN	O
hosts	NNS	O
which	WDT	O
produce	VBP	O
the	DT	O
antigens	NNS	O
.	.	O
An	DT	O
“	JJ	O
immunological	JJ	O
response	NN	O
”	NN	O
to	TO	O
an	DT	O
antigen	NN	O
or	CC	O
composition	NN	O
is	VBZ	O
the	DT	O
development	NN	O
in	IN	O
a	DT	O
subject	NN	O
of	IN	O
a	DT	O
humoral	JJ	O
and/or	NN	O
a	DT	O
cellular	JJ	O
immune	NN	O
response	NN	O
to	TO	O
an	DT	O
antigen	NN	O
present	NN	O
in	IN	O
the	DT	O
composition	NN	O
of	IN	O
interest	NN	O
.	.	O
For	IN	O
purposes	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
,	,	O
a	DT	O
“	JJ	O
humoral	JJ	O
immune	NN	O
response	NN	O
”	NN	O
refers	NNS	O
to	TO	O
an	DT	O
immune	JJ	O
response	NN	O
mediated	VBN	O
by	IN	O
antibody	NN	O
molecules	NNS	O
,	,	O
while	IN	O
a	DT	O
“	JJ	O
cellular	JJ	O
immune	NN	O
response	NN	O
”	NN	O
is	VBZ	O
one	CD	O
mediated	VBN	O
by	IN	O
T-lymphocytes	NNP	O
and/or	NN	O
other	JJ	O
white	JJ	O
blood	NN	O
cells	NNS	O
.	.	O
One	CD	O
important	JJ	O
aspect	NN	O
of	IN	O
cellular	JJ	O
immunity	NN	O
involves	VBZ	O
an	DT	O
antigen-specific	JJ	O
response	NN	O
by	IN	O
cytolytic	JJ	O
T-cells	NNP	O
(	(	O
“	NNP	O
CTL	NNP	O
”	NNP	O
s	NN	O
)	)	O
.	.	O
CTLs	NNP	O
have	VBP	O
specificity	NN	O
for	IN	O
peptide	NN	O
antigens	NNS	O
that	WDT	O
are	VBP	O
presented	VBN	O
in	IN	O
association	NN	O
with	IN	O
proteins	NNS	O
encoded	VBN	O
by	IN	O
the	DT	O
major	JJ	O
histocompatibility	NN	O
complex	NN	O
(	(	O
MHC	NNP	O
)	)	O
and	CC	O
expressed	VBN	O
on	IN	O
the	DT	O
surfaces	NNS	O
of	IN	O
cells	NNS	O
.	.	O
CTLs	NNP	O
help	NN	O
induce	NN	O
and	CC	O
promote	VB	O
the	DT	O
destruction	NN	O
of	IN	O
intracellular	JJ	O
microbes	NNS	O
,	,	O
or	CC	O
the	DT	O
lysis	NN	O
of	IN	O
cells	NNS	O
infected	VBN	O
with	IN	O
such	JJ	O
microbes	NNS	O
.	.	O
Another	DT	O
aspect	NN	O
of	IN	O
cellular	JJ	O
immunity	NN	O
involves	VBZ	O
an	DT	O
antigen-specific	JJ	O
response	NN	O
by	IN	O
helper	JJR	O
T-cells	NNS	O
.	.	O
Helper	NNP	O
T-cells	NNP	O
act	NN	O
to	TO	O
help	VB	O
stimulate	VB	O
the	DT	O
function	NN	O
,	,	O
and	CC	O
focus	VB	O
the	DT	O
activity	NN	O
of	IN	O
,	,	O
nonspecific	JJ	O
effector	NN	O
cells	NNS	O
against	IN	O
cells	NNS	O
displaying	VBG	O
peptide	NN	O
antigens	NNS	O
in	IN	O
association	NN	O
with	IN	O
MHC	NNP	O
molecules	NNS	O
on	IN	O
their	PRP$	O
surface	NN	O
.	.	O
A	DT	O
“	JJ	O
cellular	JJ	O
immune	NN	O
response	NN	O
”	NNP	O
also	RB	O
refers	VBZ	O
to	TO	O
the	DT	O
production	NN	O
of	IN	O
cytokines	NNS	O
,	,	O
chemokines	NNS	O
and	CC	O
other	JJ	O
such	JJ	O
molecules	NNS	O
produced	VBN	O
by	IN	O
activated	JJ	O
T-cells	NNP	O
and/or	NN	O
other	JJ	O
white	JJ	O
blood	NN	O
cells	NNS	O
,	,	O
including	VBG	O
those	DT	O
derived	VBN	O
from	IN	O
CD4+	NNP	O
and	CC	O
CD8+	NNP	O
T-cells	NNP	O
.	.	O
A	DT	O
composition	NN	O
or	CC	O
vaccine	NN	O
that	IN	O
elicits	VBZ	O
a	DT	O
cellular	JJ	O
immune	JJ	O
response	NN	O
may	MD	O
serve	VB	O
to	TO	O
sensitize	VB	O
a	DT	O
vertebrate	NN	O
subject	NN	O
by	IN	O
the	DT	O
presentation	NN	O
of	IN	O
antigen	NN	O
in	IN	O
association	NN	O
with	IN	O
MHC	NNP	O
molecules	NNS	O
at	IN	O
the	DT	O
cell	NN	O
surface	NN	O
.	.	O
The	DT	O
cell-mediated	JJ	O
immune	JJ	O
response	NN	O
is	VBZ	O
directed	VBN	O
at	IN	O
,	,	O
or	CC	O
near	IN	O
,	,	O
cells	NNS	O
presenting	VBG	O
antigen	NN	O
at	IN	O
their	PRP$	O
surface	NN	O
.	.	O
In	IN	O
addition	NN	O
,	,	O
antigen-specific	JJ	O
T-lymphocytes	NNS	O
can	MD	O
be	VB	O
generated	VBN	O
to	TO	O
allow	VB	O
for	IN	O
the	DT	O
future	JJ	O
protection	NN	O
of	IN	O
an	DT	O
immunized	JJ	O
host	NN	O
.	.	O
The	DT	O
ability	NN	O
of	IN	O
a	DT	O
particular	JJ	O
antigen	NN	O
to	TO	O
stimulate	VB	O
a	DT	O
cell-mediated	JJ	O
immunological	JJ	O
response	NN	O
may	MD	O
be	VB	O
determined	VBN	O
by	IN	O
a	DT	O
number	NN	O
of	IN	O
assays	NNS	O
,	,	O
such	JJ	O
as	IN	O
by	IN	O
lymphoproliferation	NN	O
(	(	O
lymphocyte	JJ	O
activation	NN	O
)	)	O
assays	VBZ	O
,	,	O
CTL	NNP	O
cytotoxic	NN	O
cell	NN	O
assays	NNS	O
,	,	O
or	CC	O
by	IN	O
assaying	VBG	O
for	IN	O
T-lymphocytes	NNP	O
specific	NN	O
for	IN	O
the	DT	O
antigen	NN	O
in	IN	O
a	DT	O
sensitized	JJ	O
subject	NN	O
.	.	O
Such	JJ	O
assays	NNS	O
are	VBP	O
well	RB	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
See	VB	O
,	,	O
e.g.	VB	O
,	,	O
Erickson	NNP	B
et	FW	I
al.	NN	I
,	,	I
J.	NNP	I
Immunol	NNP	I
.	.	I
(	(	I
1993	CD	I
)	)	I
151:4189-4199	CD	I
;	:	O
Doe	NNP	B
et	FW	I
al.	NN	I
,	,	I
Eur	NNP	I
.	.	I
J.	NNP	I
Immunol	NNP	I
.	.	I
(	(	I
1994	CD	I
)	)	I
24:2369-2376	CD	I
.	.	O
Recent	JJ	O
methods	NNS	O
of	IN	O
measuring	VBG	O
cell-mediated	JJ	O
immune	JJ	O
response	NN	O
include	VBP	O
measurement	NN	O
of	IN	O
intracellular	JJ	O
cytokines	NNS	O
or	CC	O
cytokine	JJ	O
secretion	NN	O
by	IN	O
T-cell	NNP	O
populations	NNS	O
,	,	O
or	CC	O
by	IN	O
measurement	NN	O
of	IN	O
epitope	NN	O
specific	JJ	O
T-cells	NNP	O
(	(	O
e.g.	NN	O
,	,	O
by	IN	O
the	DT	O
tetramer	NN	O
technique	NN	O
)	)	O
(	(	O
reviewed	VBN	O
by	IN	O
McMichael	NNP	B
,	,	I
A.	NNP	I
J.	NNP	I
,	,	I
and	CC	I
O'Callaghan	NNP	I
,	,	I
C.	NNP	I
A.	NN	I
,	,	I
J.	NNP	I
Exp	NNP	I
.	.	I
Med	NNP	I
.	.	I
187	CD	I
(	(	I
9	CD	I
)	)	I
1367-1371	CD	I
,	,	I
1998	CD	I
;	:	O
Mcheyzer-Williams	NNP	B
,	,	I
M.	NNP	I
G.	NNP	I
,	,	I
et	FW	I
al	NN	I
,	,	I
Immunol	NNP	I
.	.	I
Rev	NNP	I
.	.	I
150:5-21	CD	I
,	,	I
1996	CD	I
;	:	O
Lalvani	NNP	B
,	,	I
A.	NNP	I
,	,	I
et	FW	I
al	NN	I
,	,	I
J.	NNP	I
Exp	NNP	I
.	.	I
Med	NNP	I
.	.	I
186:859-865	CD	I
,	,	I
1997	CD	I
)	)	O
.	.	O
Thus	RB	O
,	,	O
an	DT	O
immunological	JJ	O
response	NN	O
as	IN	O
used	VBN	O
herein	NN	O
may	MD	O
be	VB	O
one	CD	O
which	WDT	O
stimulates	VBZ	O
the	DT	O
production	NN	O
of	IN	O
CTLs	NNP	O
,	,	O
and/or	VBZ	O
the	DT	O
production	NN	O
or	CC	O
activation	NN	O
of	IN	O
helper	JJ	O
T-cells	NNP	O
.	.	O
The	DT	O
antigen	NN	O
of	IN	O
interest	NN	O
may	MD	O
also	RB	O
elicit	VB	O
an	DT	O
antibody-mediated	JJ	O
immune	NN	O
response	NN	O
.	.	O
Hence	NNP	O
,	,	O
an	DT	O
immunological	JJ	O
response	NN	O
may	MD	O
include	VB	O
one	CD	O
or	CC	O
more	JJR	O
of	IN	O
the	DT	O
following	JJ	O
effects	NNS	O
:	:	O
the	DT	O
production	NN	O
of	IN	O
antibodies	NNS	O
by	IN	O
B-cells	NNP	O
;	:	O
and/or	VBZ	O
the	DT	O
activation	NN	O
of	IN	O
suppressor	NN	O
T-cells	NNP	O
and/or	NN	O
γδ	NNP	O
T-cells	NNP	O
directed	VBD	O
specifically	RB	O
to	TO	O
an	DT	O
antigen	NN	O
or	CC	O
antigens	NNS	O
present	JJ	O
in	IN	O
the	DT	O
composition	NN	O
or	CC	O
vaccine	NN	O
of	IN	O
interest	NN	O
.	.	O
These	DT	O
responses	NNS	O
may	MD	O
serve	VB	O
to	TO	O
neutralize	VB	O
infectivity	NN	O
,	,	O
and/or	JJ	O
mediate	NN	O
antibody-complement	NN	O
,	,	O
or	CC	O
antibody	NN	O
dependent	JJ	O
cell	NN	O
cytotoxicity	NN	O
(	(	O
ADCC	NNP	O
)	)	O
to	TO	O
provide	VB	O
protection	NN	O
to	TO	O
an	DT	O
immunized	JJ	O
host	NN	O
.	.	O
Such	JJ	O
responses	NNS	O
can	MD	O
be	VB	O
determined	VBN	O
using	VBG	O
standard	JJ	O
immunoassays	NNS	O
and	CC	O
neutralization	NN	O
assays	NNS	O
,	,	O
well	RB	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
An	DT	O
“	JJ	O
immunogenic	JJ	O
composition	NN	O
”	NN	O
is	VBZ	O
a	DT	O
composition	NN	O
that	WDT	O
comprises	VBZ	O
an	DT	O
antigenic	JJ	O
molecule	NN	O
where	WRB	O
administration	NN	O
of	IN	O
the	DT	O
composition	NN	O
to	TO	O
a	DT	O
subject	JJ	O
results	NNS	O
in	IN	O
the	DT	O
development	NN	O
in	IN	O
the	DT	O
subject	NN	O
of	IN	O
a	DT	O
humoral	JJ	O
and/or	NN	O
a	DT	O
cellular	JJ	O
immune	NN	O
response	NN	O
to	TO	O
the	DT	O
antigenic	JJ	O
molecule	NN	O
of	IN	O
interest	NN	O
.	.	O
By	IN	O
“	NNP	O
subunit	NN	O
vaccine	NN	O
”	NN	O
is	VBZ	O
meant	VBN	O
a	DT	O
vaccine	NN	O
composition	NN	O
which	WDT	O
includes	VBZ	O
one	CD	O
or	CC	O
more	JJR	O
selected	VBN	O
antigens	NNS	O
but	CC	O
not	RB	O
all	DT	O
antigens	NNS	O
,	,	O
derived	VBN	O
from	IN	O
or	CC	O
homologous	JJ	O
to	TO	O
,	,	O
an	DT	O
antigen	NN	O
from	IN	O
a	DT	O
pathogen	NN	O
of	IN	O
interest	NN	O
such	JJ	O
as	IN	O
from	IN	O
a	DT	O
virus	NN	O
,	,	O
bacterium	NN	O
,	,	O
parasite	NN	O
or	CC	O
fungus	NN	O
.	.	O
Such	JJ	O
a	DT	O
composition	NN	O
is	VBZ	O
substantially	RB	O
free	JJ	O
of	IN	O
intact	JJ	O
pathogen	NN	O
cells	NNS	O
or	CC	O
pathogenic	JJ	O
particles	NNS	O
,	,	O
or	CC	O
the	DT	O
lysate	NN	O
of	IN	O
such	JJ	O
cells	NNS	O
or	CC	O
particles	NNS	O
.	.	O
Thus	RB	O
,	,	O
a	DT	O
“	JJ	O
subunit	NN	O
vaccine	NN	O
”	NN	O
can	MD	O
be	VB	O
prepared	VBN	O
from	IN	O
at	IN	O
least	JJS	O
partially	RB	O
purified	VBN	O
(	(	O
preferably	RB	O
substantially	RB	O
purified	VBN	O
)	)	O
immunogenic	JJ	O
polypeptides	NNS	O
from	IN	O
the	DT	O
pathogen	NN	O
,	,	O
or	CC	O
analogs	NNS	O
thereof	NNS	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
obtaining	VBG	O
an	DT	O
antigen	NN	O
included	VBD	O
in	IN	O
the	DT	O
subunit	NN	O
vaccine	NN	O
can	MD	O
thus	RB	O
include	VB	O
standard	JJ	O
purification	NN	O
techniques	NNS	O
,	,	O
recombinant	JJ	O
production	NN	O
,	,	O
or	CC	O
synthetic	JJ	O
production	NN	O
.	.	O
“	NNS	O
Substantially	RB	O
purified	VBD	O
”	NNP	O
general	JJ	O
refers	NNS	O
to	TO	O
isolation	NN	O
of	IN	O
a	DT	O
substance	NN	O
(	(	O
compound	NN	O
,	,	O
polynucleotide	RB	O
,	,	O
protein	NN	O
,	,	O
polypeptide	NN	O
,	,	O
polypeptide	JJ	O
composition	NN	O
)	)	O
such	PDT	O
that	IN	O
the	DT	O
substance	NN	O
comprises	VBZ	O
the	DT	O
majority	NN	O
percent	NN	O
of	IN	O
the	DT	O
sample	NN	O
in	IN	O
which	WDT	O
it	PRP	O
resides	VBZ	O
.	.	O
Typically	RB	O
in	IN	O
a	DT	O
sample	NN	O
a	DT	O
substantially	RB	O
purified	VBN	O
component	NN	O
comprises	VBZ	O
50	CD	O
%	NN	O
,	,	O
preferably	RB	O
80	CD	O
%	NN	O
-85	CD	O
%	NN	O
,	,	O
more	JJR	O
preferably	RB	O
90-95	CD	O
%	NN	O
of	IN	O
the	DT	O
sample	NN	O
.	.	O
Techniques	NNS	O
for	IN	O
purifying	VBG	O
polynucleotides	NNS	O
and	CC	O
polypeptides	NNS	O
of	IN	O
interest	NN	O
are	VBP	O
well-known	JJ	O
in	IN	O
the	DT	O
art	NN	O
and	CC	O
include	VBP	O
,	,	O
for	IN	O
example	NN	O
,	,	O
ion-exchange	JJ	O
chromatography	NN	O
,	,	O
affinity	NN	O
chromatography	NN	O
and	CC	O
sedimentation	NN	O
according	VBG	O
to	TO	O
density	NN	O
.	.	O
A	DT	O
“	JJ	O
coding	NN	O
sequence	NN	O
”	NN	O
or	CC	O
a	DT	O
sequence	NN	O
which	WDT	O
“	NNP	O
encodes	VBZ	O
”	FW	O
a	DT	O
selected	VBN	O
polypeptide	NN	O
,	,	O
is	VBZ	O
a	DT	O
nucleic	JJ	O
acid	NN	O
molecule	NN	O
which	WDT	O
is	VBZ	O
transcribed	VBN	O
(	(	O
in	IN	O
the	DT	O
case	NN	O
of	IN	O
DNA	NNP	O
)	)	O
and	CC	O
translated	VBN	O
(	(	O
in	IN	O
the	DT	O
case	NN	O
of	IN	O
mRNA	NN	O
)	)	O
into	IN	O
a	DT	O
polypeptide	NN	O
in	IN	O
vivo	NN	O
when	WRB	O
placed	VBN	O
under	IN	O
the	DT	O
control	NN	O
of	IN	O
appropriate	JJ	O
regulatory	JJ	O
sequences	NNS	O
(	(	O
or	CC	O
“	VB	O
control	NN	O
elements	NNS	O
”	VBP	O
)	)	O
.	.	O
The	DT	O
boundaries	NNS	O
of	IN	O
the	DT	O
coding	NN	O
sequence	NN	O
are	VBP	O
determined	VBN	O
by	IN	O
a	DT	O
start	NN	O
codon	NN	O
at	IN	O
the	DT	O
5′	CD	O
(	(	O
amino	NN	O
)	)	O
terminus	NN	O
and	CC	O
a	DT	O
translation	NN	O
stop	NN	O
codon	NN	O
at	IN	O
the	DT	O
3′	CD	O
(	(	O
carboxy	NN	O
)	)	O
terminus	NN	O
.	.	O
A	DT	O
coding	VBG	O
sequence	NN	O
can	MD	O
include	VB	O
,	,	O
but	CC	O
is	VBZ	O
not	RB	O
limited	VBN	O
to	TO	O
,	,	O
cDNA	NN	O
from	IN	O
viral	JJ	O
,	,	O
procaryotic	JJ	O
or	CC	O
eucaryotic	JJ	O
mRNA	NN	O
,	,	O
genomic	JJ	O
DNA	NN	O
sequences	NNS	O
from	IN	O
viral	JJ	O
or	CC	O
procaryotic	JJ	O
DNA	NN	O
,	,	O
and	CC	O
even	RB	O
synthetic	JJ	O
DNA	NNP	O
sequences	NNS	O
.	.	O
A	DT	O
transcription	NN	O
termination	NN	O
sequence	NN	O
may	MD	O
be	VB	O
located	VBN	O
3′	CD	O
to	TO	O
the	DT	O
coding	VBG	O
sequence	NN	O
.	.	O
Typical	JJ	O
“	NNP	O
control	NN	O
elements	VBZ	O
”	JJ	O
,	,	O
include	VBP	O
,	,	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
,	,	O
transcription	NN	O
promoters	NNS	O
,	,	O
transcription	NN	O
enhancer	NN	O
elements	NNS	O
,	,	O
transcription	NN	O
termination	NN	O
signals	NNS	O
,	,	O
polyadenylation	NN	O
sequences	NNS	O
(	(	O
located	VBN	O
3′	CD	O
to	TO	O
the	DT	O
translation	NN	O
stop	VB	O
codon	NN	O
)	)	O
,	,	O
sequences	NNS	O
for	IN	O
optimization	NN	O
of	IN	O
initiation	NN	O
of	IN	O
translation	NN	O
(	(	O
located	VBN	O
5′	CD	O
to	TO	O
the	DT	O
coding	VBG	O
sequence	NN	O
)	)	O
,	,	O
and	CC	O
translation	NN	O
termination	NN	O
sequences	NNS	O
,	,	O
see	VBP	O
e.g.	RB	O
,	,	O
McCaughan	NNP	B
et	VBZ	I
al	NN	I
.	.	I
(	(	I
1995	CD	I
)	)	I
PNAS	NNP	I
USA	NNP	I
92:5431-5435	CD	I
;	:	O
Kochetov	NNP	B
et	FW	I
al	NN	I
(	(	I
1998	CD	I
)	)	I
FEBS	NNP	I
Letts	NNP	I
.	.	I
440:351-355	JJ	I
.	.	O
A	DT	O
“	JJ	O
nucleic	JJ	O
acid	NN	O
”	NN	O
molecule	NN	O
can	MD	O
include	VB	O
,	,	O
but	CC	O
is	VBZ	O
not	RB	O
limited	VBN	O
to	TO	O
,	,	O
procaryotic	JJ	O
sequences	NNS	O
,	,	O
eucaryotic	JJ	O
mRNA	NN	O
,	,	O
cDNA	NN	O
from	IN	O
eucaryotic	JJ	O
mRNA	NN	O
,	,	O
genomic	JJ	O
DNA	NN	O
sequences	NNS	O
from	IN	O
eucaryotic	JJ	O
(	(	O
e.g.	JJ	O
,	,	O
mammalian	JJ	O
)	)	O
DNA	NN	O
,	,	O
and	CC	O
even	RB	O
synthetic	JJ	O
DNA	NNP	O
sequences	NNS	O
.	.	O
The	DT	O
term	NN	O
also	RB	O
captures	VBZ	O
sequences	NNS	O
that	WDT	O
include	VBP	O
any	DT	O
of	IN	O
the	DT	O
known	JJ	O
base	NN	O
analogs	NN	O
of	IN	O
DNA	NNP	O
and	CC	O
RNA	NNP	O
.	.	O
“	NN	O
Operably	RB	O
linked	VBD	O
”	JJ	O
refers	NNS	O
to	TO	O
an	DT	O
arrangement	NN	O
of	IN	O
elements	NNS	O
wherein	VBP	O
the	DT	O
components	NNS	O
so	RB	O
described	VBN	O
are	VBP	O
configured	VBN	O
so	RB	O
as	IN	O
to	TO	O
perform	VB	O
their	PRP$	O
usual	JJ	O
function	NN	O
.	.	O
Thus	RB	O
,	,	O
a	DT	O
given	VBN	O
promoter	NN	O
operably	RB	O
linked	VBD	O
to	TO	O
a	DT	O
coding	NN	O
sequence	NN	O
is	VBZ	O
capable	JJ	O
of	IN	O
effecting	VBG	O
the	DT	O
expression	NN	O
of	IN	O
the	DT	O
coding	VBG	O
sequence	NN	O
when	WRB	O
the	DT	O
proper	JJ	O
enzymes	NNS	O
are	VBP	O
present	JJ	O
.	.	O
The	DT	O
promoter	NN	O
need	MD	O
not	RB	O
be	VB	O
contiguous	JJ	O
with	IN	O
the	DT	O
coding	VBG	O
sequence	NN	O
,	,	O
so	RB	O
long	RB	O
as	IN	O
it	PRP	O
functions	VBZ	O
to	TO	O
direct	VB	O
the	DT	O
expression	NN	O
thereof	NN	O
.	.	O
Thus	RB	O
,	,	O
for	IN	O
example	NN	O
,	,	O
intervening	VBG	O
untranslated	JJ	O
yet	RB	O
transcribed	VBN	O
sequences	NNS	O
can	MD	O
be	VB	O
present	JJ	O
between	IN	O
the	DT	O
promoter	NN	O
sequence	NN	O
and	CC	O
the	DT	O
coding	NN	O
sequence	NN	O
and	CC	O
the	DT	O
promoter	NN	O
sequence	NN	O
can	MD	O
still	RB	O
be	VB	O
considered	VBN	O
“	NNP	O
operably	RB	O
linked	VBD	O
”	UH	O
to	TO	O
the	DT	O
coding	VBG	O
sequence	NN	O
.	.	O
“	NN	O
Recombinant	NNP	O
”	NNP	O
as	IN	O
used	VBN	O
herein	NN	O
to	TO	O
describe	VB	O
a	DT	O
nucleic	JJ	O
acid	NN	O
molecule	NN	O
means	VBZ	O
a	DT	O
polynucleotide	NN	O
of	IN	O
genomic	JJ	O
,	,	O
cDNA	NN	O
,	,	O
semisynthetic	JJ	O
,	,	O
or	CC	O
synthetic	JJ	O
origin	NN	O
which	WDT	O
,	,	O
by	IN	O
virtue	NN	O
of	IN	O
its	PRP$	O
origin	NN	O
or	CC	O
manipulation	NN	O
:	:	O
(	(	O
1	CD	O
)	)	O
is	VBZ	O
not	RB	O
associated	VBN	O
with	IN	O
all	DT	O
or	CC	O
a	DT	O
portion	NN	O
of	IN	O
the	DT	O
polynucleotide	NN	O
with	IN	O
which	WDT	O
it	PRP	O
is	VBZ	O
associated	VBN	O
in	IN	O
nature	NN	O
;	:	O
and/or	CC	O
(	(	O
2	CD	O
)	)	O
is	VBZ	O
linked	VBN	O
to	TO	O
a	DT	O
polynucleotide	NN	O
other	JJ	O
than	IN	O
that	DT	O
to	TO	O
which	WDT	O
it	PRP	O
is	VBZ	O
linked	VBN	O
in	IN	O
nature	NN	O
.	.	O
The	DT	O
term	NN	O
“	NNP	O
re-combinant	JJ	O
”	NN	O
as	IN	O
used	VBN	O
with	IN	O
respect	NN	O
to	TO	O
a	DT	O
protein	NN	O
or	CC	O
polypeptide	NN	O
means	VBZ	O
a	DT	O
polypeptide	NN	O
produced	VBN	O
by	IN	O
expression	NN	O
of	IN	O
a	DT	O
recombinant	JJ	O
polynucleotide	NN	O
.	.	O
“	NN	O
Recombinant	NNP	O
host	NN	O
cells	NNS	O
,	,	O
”	NNP	O
“	NNP	O
host	NN	O
cells	NNS	O
,	,	O
”	NNP	O
“	NNP	O
cells	NNS	O
,	,	O
”	NNP	O
“	NNP	O
cell	NN	O
lines	NNS	O
,	,	O
”	NNP	O
“	NNP	O
cell	NN	O
cultures	NNS	O
,	,	O
”	NNP	O
and	CC	O
other	JJ	O
such	JJ	O
terms	NNS	O
denoting	VBG	O
procaryotic	JJ	O
microorganisms	NNS	O
or	CC	O
eucaryotic	JJ	O
cell	NN	O
lines	NNS	O
cultured	VBD	O
as	IN	O
unicellular	JJ	O
entities	NNS	O
,	,	O
are	VBP	O
used	VBN	O
interchangeably	RB	O
,	,	O
and	CC	O
refer	VBP	O
to	TO	O
cells	NNS	O
which	WDT	O
can	MD	O
be	VB	O
,	,	O
or	CC	O
have	VBP	O
been	VBN	O
,	,	O
used	VBN	O
as	IN	O
recipients	NNS	O
for	IN	O
recombinant	JJ	O
vectors	NNS	O
or	CC	O
other	JJ	O
transfer	NN	O
DNA	NNP	O
,	,	O
and	CC	O
include	VBP	O
the	DT	O
progeny	NN	O
of	IN	O
the	DT	O
original	JJ	O
cell	NN	O
which	WDT	O
has	VBZ	O
been	VBN	O
transfected	VBN	O
.	.	O
It	PRP	O
is	VBZ	O
understood	JJ	O
that	IN	O
the	DT	O
progeny	NN	O
of	IN	O
a	DT	O
single	JJ	O
parental	NN	O
cell	NN	O
may	MD	O
not	RB	O
necessarily	RB	O
be	VB	O
completely	RB	O
identical	JJ	O
in	IN	O
morphology	NN	O
or	CC	O
in	IN	O
genomic	JJ	O
or	CC	O
total	JJ	O
DNA	NNP	O
complement	NN	O
to	TO	O
the	DT	O
original	JJ	O
parent	NN	O
,	,	O
due	JJ	O
to	TO	O
accidental	JJ	O
or	CC	O
deliberate	JJ	O
mutation	NN	O
.	.	O
Progeny	NNP	O
of	IN	O
the	DT	O
parental	NN	O
cell	NN	O
which	WDT	O
are	VBP	O
sufficiently	RB	O
similar	JJ	O
to	TO	O
the	DT	O
parent	NN	O
to	TO	O
be	VB	O
characterized	VBN	O
by	IN	O
the	DT	O
relevant	JJ	O
property	NN	O
,	,	O
such	JJ	O
as	IN	O
the	DT	O
presence	NN	O
of	IN	O
a	DT	O
nucleotide	JJ	O
sequence	NN	O
encoding	VBG	O
a	DT	O
desired	JJ	O
peptide	NN	O
,	,	O
are	VBP	O
included	VBN	O
in	IN	O
the	DT	O
progeny	NN	O
intended	VBN	O
by	IN	O
this	DT	O
definition	NN	O
,	,	O
and	CC	O
are	VBP	O
covered	VBN	O
by	IN	O
the	DT	O
above	NN	O
terms	NNS	O
.	.	O
Techniques	NNS	O
for	IN	O
determining	VBG	O
amino	NN	O
acid	JJ	O
sequence	NN	O
“	NNP	O
similarity	NN	O
”	NN	O
are	VBP	O
well	RB	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
In	IN	O
general	JJ	O
,	,	O
“	JJ	O
similarity	NN	O
”	NN	O
means	VBZ	O
the	DT	O
exact	JJ	O
amino	NN	O
acid	NN	O
to	TO	O
amino	VB	O
acid	JJ	O
comparison	NN	O
of	IN	O
two	CD	O
or	CC	O
more	JJR	O
polypeptides	NNS	O
at	IN	O
the	DT	O
appropriate	JJ	O
place	NN	O
,	,	O
where	WRB	O
amino	NN	O
acids	NNS	O
are	VBP	O
identical	JJ	O
or	CC	O
possess	JJ	O
similar	JJ	O
chemical	NN	O
and/or	NN	O
physical	JJ	O
properties	NNS	O
such	JJ	O
as	IN	O
charge	NN	O
or	CC	O
hydrophobicity	NN	O
.	.	O
A	DT	O
so-termed	JJ	O
“	NN	O
percent	NN	O
similarity	NN	O
”	NNP	O
then	RB	O
can	MD	O
be	VB	O
determined	VBN	O
between	IN	O
the	DT	O
compared	VBN	O
polypeptide	NN	O
sequences	NNS	O
.	.	O
Techniques	NNS	O
for	IN	O
determining	VBG	O
nucleic	JJ	O
acid	NN	O
and	CC	O
amino	NN	O
acid	VBP	O
sequence	NN	O
identity	NN	O
also	RB	O
are	VBP	O
well	RB	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
and	CC	O
include	VBP	O
determining	VBG	O
the	DT	O
nucleotide	JJ	O
sequence	NN	O
of	IN	O
the	DT	O
mRNA	NN	O
for	IN	O
that	DT	O
gene	NN	O
(	(	O
usually	RB	O
via	IN	O
a	DT	O
cDNA	JJ	O
intermediate	NN	O
)	)	O
and	CC	O
determining	VBG	O
the	DT	O
amino	NN	O
acid	JJ	O
sequence	NN	O
encoded	VBD	O
thereby	RB	O
,	,	O
and	CC	O
comparing	VBG	O
this	DT	O
to	TO	O
a	DT	O
second	JJ	O
amino	NN	O
acid	NN	O
sequence	NN	O
.	.	O
In	IN	O
general	JJ	O
,	,	O
“	JJ	O
identity	NN	O
”	NN	O
refers	NNS	O
to	TO	O
an	DT	O
exact	JJ	O
nucleotide	NN	O
to	TO	O
nucleotide	VB	O
or	CC	O
amino	VB	O
acid	NN	O
to	TO	O
amino	VB	O
acid	JJ	O
correspondence	NN	O
of	IN	O
two	CD	O
polynucleotides	NNS	O
or	CC	O
polypeptide	NN	O
sequences	NNS	O
,	,	O
respectively	RB	O
.	.	O
Two	CD	O
or	CC	O
more	JJR	O
polynucleotide	JJ	O
sequences	NNS	O
can	MD	O
be	VB	O
compared	VBN	O
by	IN	O
determining	VBG	O
their	PRP$	O
“	JJ	O
percent	NN	O
identity.	NN	O
”	CD	O
Two	CD	O
or	CC	O
more	JJR	O
amino	JJ	O
acid	NN	O
sequences	NNS	O
likewise	VBP	O
can	MD	O
be	VB	O
compared	VBN	O
by	IN	O
determining	VBG	O
their	PRP$	O
“	JJ	O
percent	NN	O
identity.	NN	O
”	VBD	O
The	DT	O
percent	NN	O
identity	NN	O
of	IN	O
two	CD	O
sequences	NNS	O
,	,	O
whether	IN	O
nucleic	JJ	O
acid	NN	O
or	CC	O
peptide	NN	O
sequences	NNS	O
,	,	O
is	VBZ	O
generally	RB	O
described	VBN	O
as	IN	O
the	DT	O
number	NN	O
of	IN	O
exact	JJ	O
matches	NNS	O
between	IN	O
two	CD	O
aligned	VBD	O
sequences	NNS	O
divided	VBN	O
by	IN	O
the	DT	O
length	NN	O
of	IN	O
the	DT	O
shorter	JJR	O
sequence	NN	O
and	CC	O
multiplied	VBN	O
by	IN	O
100	CD	O
.	.	O
An	DT	O
approximate	JJ	O
alignment	NN	O
for	IN	O
nucleic	JJ	O
acid	NN	O
sequences	NNS	O
is	VBZ	O
provided	VBN	O
by	IN	O
the	DT	O
local	JJ	O
homology	NN	O
algorithm	NN	O
of	IN	O
Smith	NNP	B
and	CC	I
Waterman	NNP	I
,	,	I
Advances	NNP	I
in	IN	I
Applied	NNP	I
Mathematics	NNP	I
2:482-489	CD	I
(	(	I
1981	CD	I
)	)	I
.	.	O
This	DT	O
algorithm	NN	O
can	MD	O
be	VB	O
extended	VBN	O
to	TO	O
use	VB	O
with	IN	O
peptide	JJ	O
sequences	NNS	O
using	VBG	O
the	DT	O
scoring	VBG	O
matrix	NN	O
developed	VBN	O
by	IN	O
Dayhoff	NNP	B
,	,	I
Atlas	NNP	I
of	IN	I
Protein	NNP	I
Sequences	NNPS	I
and	CC	I
Structure	NNP	I
,	,	I
M.	NNP	I
O.	NNP	I
Dayhoff	NNP	I
ed.	NN	I
,	,	I
5	CD	I
suppl	NN	I
.	.	I
3:353-358	JJ	I
,	,	I
National	NNP	I
Biomedical	NNP	I
Research	NNP	I
Foundation	NNP	I
,	,	I
Washington	NNP	I
,	,	I
D.C.	NNP	I
,	,	I
USA	NNP	I
,	,	O
and	CC	O
normalized	VBN	O
by	IN	O
Gribskov	NNP	B
,	,	I
Nucl	NNP	I
.	.	I
Acids	NNP	I
Res	NNP	I
.	.	I
14	CD	I
(	(	I
6	CD	I
)	)	I
:6745-6763	NN	I
(	(	I
1986	CD	I
)	)	I
.	.	O
An	DT	O
implementation	NN	O
of	IN	O
this	DT	O
algorithm	NN	O
for	IN	O
nucleic	JJ	O
acid	NN	O
and	CC	O
peptide	NN	O
sequences	NNS	O
is	VBZ	O
provided	VBN	O
by	IN	O
the	DT	O
Genetics	NNP	O
Computer	NNP	O
Group	NNP	O
(	(	O
Madison	NNP	O
,	,	O
Wis.	NNP	O
)	)	O
in	IN	O
their	PRP$	O
BestFit	NNP	O
utility	NN	O
application	NN	O
.	.	O
The	DT	O
default	NN	O
parameters	NNS	O
for	IN	O
this	DT	O
method	NN	O
are	VBP	O
described	VBN	O
in	IN	O
the	DT	O
Wisconsin	NNP	O
Sequence	NNP	O
Analysis	NNP	O
Package	NNP	O
Program	NNP	O
Manual	NNP	O
,	,	O
Version	NNP	O
8	CD	O
(	(	O
1995	CD	O
)	)	O
(	(	O
available	JJ	O
from	IN	O
Genetics	NNP	O
Computer	NNP	O
Group	NNP	O
,	,	O
Madison	NNP	O
,	,	O
Wis.	NNP	O
)	)	O
.	.	O
Other	JJ	O
equally	RB	O
suitable	JJ	O
programs	NNS	O
for	IN	O
calculating	VBG	O
the	DT	O
percent	NN	O
identity	NN	O
or	CC	O
similarity	NN	O
between	IN	O
sequences	NNS	O
are	VBP	O
generally	RB	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
percent	NN	O
identity	NN	O
of	IN	O
a	DT	O
particular	JJ	O
nucleotide	NN	O
sequence	NN	O
to	TO	O
a	DT	O
reference	NN	O
sequence	NN	O
can	MD	O
be	VB	O
determined	VBN	O
using	VBG	O
the	DT	O
homology	NN	O
algorithm	NN	O
of	IN	O
Smith	NNP	O
and	CC	O
Waterman	NNP	O
with	IN	O
a	DT	O
default	NN	O
scoring	VBG	O
table	NN	O
and	CC	O
a	DT	O
gap	NN	O
penalty	NN	O
of	IN	O
six	CD	O
nucleotide	JJ	O
positions	NNS	O
.	.	O
Another	DT	O
method	NN	O
of	IN	O
establishing	VBG	O
percent	NN	O
identity	NN	O
in	IN	O
the	DT	O
context	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
is	VBZ	O
to	TO	O
use	VB	O
the	DT	O
MPSRCH	NNP	O
package	NN	O
of	IN	O
programs	NNS	O
copyrighted	VBN	O
by	IN	O
the	DT	O
University	NNP	O
of	IN	O
Edinburgh	NNP	O
,	,	O
developed	VBN	O
by	IN	O
John	NNP	O
F.	NNP	O
Collins	NNP	O
and	CC	O
Shane	NNP	O
S.	NNP	O
Sturrok	NNP	O
,	,	O
and	CC	O
distributed	VBN	O
by	IN	O
IntelliGenetics	NNP	O
,	,	O
Inc.	NNP	O
(	(	O
Mountain	NNP	O
View	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
.	.	O
From	IN	O
this	DT	O
suite	NN	O
of	IN	O
packages	NNS	O
,	,	O
the	DT	O
Smith-Waterman	NNP	O
algorithm	NN	O
can	MD	O
be	VB	O
employed	VBN	O
where	WRB	O
default	NN	O
parameters	NNS	O
are	VBP	O
used	VBN	O
for	IN	O
the	DT	O
scoring	NN	O
table	NN	O
(	(	O
for	IN	O
example	NN	O
,	,	O
gap	NN	O
open	JJ	O
penalty	NN	O
of	IN	O
12	CD	O
,	,	O
gap	NN	O
extension	NN	O
penalty	NN	O
of	IN	O
one	CD	O
,	,	O
and	CC	O
a	DT	O
gap	NN	O
of	IN	O
six	CD	O
)	)	O
.	.	O
From	IN	O
the	DT	O
data	NN	O
generated	VBD	O
,	,	O
the	DT	O
“	NNP	O
Match	NNP	O
”	NNP	O
value	NN	O
reflects	VBZ	O
“	JJ	O
sequence	NN	O
identity.	NN	O
”	VBZ	O
Other	JJ	O
suitable	JJ	O
programs	NNS	O
for	IN	O
calculating	VBG	O
the	DT	O
percent	NN	O
identity	NN	O
or	CC	O
similarity	NN	O
between	IN	O
sequences	NNS	O
are	VBP	O
generally	RB	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
,	,	O
such	JJ	O
as	IN	O
the	DT	O
alignment	JJ	O
program	NN	O
BLAST	NNP	O
,	,	O
which	WDT	O
can	MD	O
also	RB	O
be	VB	O
used	VBN	O
with	IN	O
default	NN	O
parameters	NNS	O
.	.	O
For	IN	O
example	NN	O
,	,	O
BLASTN	NNP	O
and	CC	O
BLASTP	NNP	O
can	MD	O
be	VB	O
used	VBN	O
with	IN	O
the	DT	O
following	VBG	O
default	NN	O
parameters	NNS	O
:	:	O
genetic	JJ	O
code=standard	NN	O
;	:	O
filter=none	NN	O
;	:	O
strand=both	CC	O
;	:	O
cutoff=60	NN	O
;	:	O
expect=10	CC	O
;	:	O
Matrix=BLOSUM62	NNP	O
;	:	O
Descriptions=50	NNP	O
sequences	NNS	O
;	:	O
sort	VB	O
by=HIGH	NN	O
SCORE	NNP	O
;	:	O
Databases=non-redundant	NNP	O
,	,	O
GenBank+EMBL+DDBJ+PDB+GenBank	NNP	O
CDS	NNP	O
translations+Swiss	JJ	O
protein+Spupdate+PIR	NN	O
.	.	O
Details	NNS	O
of	IN	O
these	DT	O
programs	NNS	O
can	MD	O
be	VB	O
found	VBN	O
at	IN	O
the	DT	O
following	JJ	O
internet	NN	O
address	NN	O
:	:	O
http	NN	O
:	:	O
//www.ncbi.nlm.gov/cgi-bin/BLAST	NN	O
.	.	O
One	CD	O
of	IN	O
skill	NN	O
in	IN	O
the	DT	O
art	NN	O
can	MD	O
readily	RB	O
determine	VB	O
the	DT	O
proper	JJ	O
search	NN	O
parameters	NNS	O
to	TO	O
use	VB	O
for	IN	O
a	DT	O
given	VBN	O
sequence	NN	O
in	IN	O
the	DT	O
above	JJ	O
programs	NNS	O
.	.	O
For	IN	O
example	NN	O
,	,	O
the	DT	O
search	NN	O
parameters	NNS	O
may	MD	O
vary	VB	O
based	VBN	O
on	IN	O
the	DT	O
size	NN	O
of	IN	O
the	DT	O
sequence	NN	O
in	IN	O
question	NN	O
.	.	O
Thus	RB	O
,	,	O
for	IN	O
example	NN	O
,	,	O
a	DT	O
representative	JJ	O
embodiment	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
would	MD	O
include	VB	O
an	DT	O
isolated	JJ	O
polynucleotide	NN	O
having	VBG	O
X	NNP	O
contiguous	JJ	O
nucleotides	NNS	O
,	,	O
wherein	NN	O
(	(	O
i	NN	O
)	)	O
the	DT	O
X	NNP	O
contiguous	JJ	O
nucleotides	NNS	O
have	VBP	O
at	IN	O
least	JJS	O
about	IN	O
50	CD	O
%	NN	O
identity	NN	O
to	TO	O
Y	NNP	O
contiguous	JJ	O
nucleotides	NNS	O
derived	VBN	O
from	IN	O
any	DT	O
of	IN	O
the	DT	O
sequences	NNS	O
described	VBD	O
herein	NN	O
,	,	O
(	(	O
ii	NN	O
)	)	O
X	NN	O
equals	NNS	O
Y	NNP	O
,	,	O
and	CC	O
(	(	O
iii	NN	O
)	)	O
X	NN	O
is	VBZ	O
greater	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
6	CD	O
nucleotides	NNS	O
and	CC	O
up	RB	O
to	TO	O
5000	CD	O
nucleotides	NNS	O
,	,	O
preferably	RB	O
greater	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
8	CD	O
nucleotides	NNS	O
and	CC	O
up	RB	O
to	TO	O
5000	CD	O
nucleotides	NNS	O
,	,	O
more	JJR	O
preferably	RB	O
10-12	JJ	O
nucleotides	NNS	O
and	CC	O
up	RB	O
to	TO	O
5000	CD	O
nucleotides	NNS	O
,	,	O
and	CC	O
even	RB	O
more	JJR	O
preferably	RB	O
15-20	JJ	O
nucleotides	NNS	O
,	,	O
up	RB	O
to	TO	O
the	DT	O
number	NN	O
of	IN	O
nucleotides	JJ	O
present	NN	O
in	IN	O
the	DT	O
full-length	JJ	O
sequences	NNS	O
described	VBN	O
herein	NN	O
(	(	O
e.g.	JJ	O
,	,	O
see	VB	O
the	DT	O
Sequence	NNP	O
Listing	NNP	O
and	CC	O
claims	NNS	O
)	)	O
,	,	O
including	VBG	O
all	DT	O
integer	NN	O
values	NNS	O
falling	VBG	O
within	IN	O
the	DT	O
above-described	JJ	O
ranges	NNS	O
.	.	O
The	DT	O
synthetic	JJ	O
expression	NN	O
cassettes	NNS	O
(	(	O
and	CC	O
purified	VBN	O
polynucleotides	NNS	O
)	)	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
include	VBP	O
related	VBN	O
polynucleotide	JJ	O
sequences	NNS	O
having	VBG	O
about	RB	O
80	CD	O
%	NN	O
to	TO	O
100	CD	O
%	NN	O
,	,	O
greater	JJR	O
than	IN	O
80-85	CD	O
%	NN	O
,	,	O
preferably	RB	O
greater	JJR	O
than	IN	O
90-92	CD	O
%	NN	O
,	,	O
more	JJR	O
preferably	RB	O
greater	JJR	O
than	IN	O
95	CD	O
%	NN	O
,	,	O
and	CC	O
most	JJS	O
preferably	RB	O
greater	JJR	O
than	IN	O
98	CD	O
%	NN	O
sequence	NN	O
(	(	O
including	VBG	O
all	DT	O
integer	NN	O
values	NNS	O
falling	VBG	O
within	IN	O
these	DT	O
described	VBN	O
ranges	NNS	O
)	)	O
identity	NN	O
to	TO	O
the	DT	O
synthetic	JJ	O
expression	NN	O
cassette	NN	O
sequences	NNS	O
disclosed	VBD	O
herein	NN	O
(	(	O
for	IN	O
example	NN	O
,	,	O
to	TO	O
the	DT	O
sequences	NNS	O
presented	VBN	O
in	IN	O
Tables	NNP	O
1A	CD	O
and	CC	O
1B	CD	O
)	)	O
when	WRB	O
the	DT	O
sequences	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
are	VBP	O
used	VBN	O
as	IN	O
the	DT	O
query	NN	O
sequence	NN	O
.	.	O
Two	CD	O
nucleic	JJ	O
acid	NN	O
fragments	NNS	O
are	VBP	O
considered	VBN	O
to	TO	O
“	VB	O
selectively	RB	O
hybridize	JJ	O
”	NN	O
as	IN	O
described	JJ	O
herein	NN	O
.	.	O
The	DT	O
degree	NN	O
of	IN	O
sequence	NN	O
identity	NN	O
between	IN	O
two	CD	O
nucleic	JJ	O
acid	NN	O
molecules	NNS	O
affects	VBZ	O
the	DT	O
efficiency	NN	O
and	CC	O
strength	NN	O
of	IN	O
hybridization	NN	O
events	NNS	O
between	IN	O
such	JJ	O
molecules	NNS	O
.	.	O
A	DT	O
partially	RB	O
identical	JJ	O
nucleic	NN	O
acid	NN	O
sequence	NN	O
will	MD	O
at	IN	O
least	JJS	O
partially	RB	O
inhibit	VB	O
a	DT	O
completely	RB	O
identical	JJ	O
sequence	NN	O
from	IN	O
hybridizing	VBG	O
to	TO	O
a	DT	O
target	NN	O
molecule	NN	O
.	.	O
Inhibition	NN	O
of	IN	O
hybridization	NN	O
of	IN	O
the	DT	O
completely	RB	O
identical	JJ	O
sequence	NN	O
can	MD	O
be	VB	O
assessed	VBN	O
using	VBG	O
hybridization	NN	O
assays	NNS	O
that	WDT	O
are	VBP	O
well	RB	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
(	(	O
e.g.	UH	O
,	,	O
Southern	JJ	O
blot	NN	O
,	,	O
Northern	NNP	O
blot	NN	O
,	,	O
solution	NN	O
hybridization	NN	O
,	,	O
or	CC	O
the	DT	O
like	JJ	O
,	,	O
see	VB	O
Sambrook	NNP	B
,	,	I
et	FW	I
al.	NN	I
,	,	I
Molecular	JJ	I
Cloning	NN	I
:	:	I
A	DT	I
Laboratory	NNP	I
Manual	NNP	I
,	,	I
Second	NNP	I
Edition	NNP	I
,	,	I
(	(	I
1989	CD	I
)	)	I
Cold	NNP	I
Spring	NNP	I
Harbor	NNP	I
,	,	I
N	NNP	I
.	.	I
Y	NNP	I
.	.	I
)	)	O
.	.	O
Such	JJ	O
assays	NNS	O
can	MD	O
be	VB	O
conducted	VBN	O
using	VBG	O
varying	VBG	O
degrees	NNS	O
of	IN	O
selectivity	NN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
using	VBG	O
conditions	NNS	O
varying	VBG	O
from	IN	O
low	JJ	O
to	TO	O
high	JJ	O
stringency	NN	O
.	.	O
If	IN	O
conditions	NNS	O
of	IN	O
low	JJ	O
stringency	NN	O
are	VBP	O
employed	VBN	O
,	,	O
the	DT	O
absence	NN	O
of	IN	O
non-specific	JJ	O
binding	NN	O
can	MD	O
be	VB	O
assessed	VBN	O
using	VBG	O
a	DT	O
secondary	JJ	O
probe	NN	O
that	IN	O
lacks	VBZ	O
even	RB	O
a	DT	O
partial	JJ	O
degree	NN	O
of	IN	O
sequence	NN	O
identity	NN	O
(	(	O
for	IN	O
example	NN	O
,	,	O
a	DT	O
probe	NN	O
having	VBG	O
less	JJR	O
than	IN	O
about	RB	O
30	CD	O
%	NN	O
sequence	NN	O
identity	NN	O
with	IN	O
the	DT	O
target	NN	O
molecule	NN	O
)	)	O
,	,	O
such	JJ	O
that	IN	O
,	,	O
in	IN	O
the	DT	O
absence	NN	O
of	IN	O
non-specific	JJ	O
binding	NN	O
events	NNS	O
,	,	O
the	DT	O
secondary	JJ	O
probe	NN	O
will	MD	O
not	RB	O
hybridize	VB	O
to	TO	O
the	DT	O
target	NN	O
.	.	O
When	WRB	O
utilizing	VBG	O
a	DT	O
hybridization-based	JJ	O
detection	NN	O
system	NN	O
,	,	O
a	DT	O
nucleic	JJ	O
acid	NN	O
probe	NN	O
is	VBZ	O
chosen	VBN	O
that	IN	O
is	VBZ	O
complementary	JJ	O
to	TO	O
a	DT	O
target	NN	O
nucleic	JJ	O
acid	JJ	O
sequence	NN	O
,	,	O
and	CC	O
then	RB	O
by	IN	O
selection	NN	O
of	IN	O
appropriate	JJ	O
conditions	NNS	O
the	DT	O
probe	NN	O
and	CC	O
the	DT	O
target	NN	O
sequence	NN	O
“	NNP	O
selectively	RB	O
hybridize	VB	O
,	,	O
”	FW	O
or	CC	O
bind	VB	O
,	,	O
to	TO	O
each	DT	O
other	JJ	O
to	TO	O
form	VB	O
a	DT	O
hybrid	JJ	O
molecule	NN	O
.	.	O
A	DT	O
nucleic	JJ	O
acid	NN	O
molecule	NN	O
that	WDT	O
is	VBZ	O
capable	JJ	O
of	IN	O
hybridizing	VBG	O
selectively	RB	O
to	TO	O
a	DT	O
target	NN	O
sequence	NN	O
under	IN	O
“	NNP	O
moderately	RB	O
stringent	JJ	O
”	NNP	O
typically	RB	O
hybridizes	VBZ	O
under	IN	O
conditions	NNS	O
that	WDT	O
allow	VBP	O
detection	NN	O
of	IN	O
a	DT	O
target	NN	O
nucleic	JJ	O
acid	JJ	O
sequence	NN	O
of	IN	O
at	IN	O
least	JJS	O
about	IN	O
10-14	JJ	O
nucleotides	NNS	O
in	IN	O
length	NN	O
having	VBG	O
at	IN	O
least	JJS	O
approximately	RB	O
70	CD	O
%	NN	O
sequence	NN	O
identity	NN	O
with	IN	O
the	DT	O
sequence	NN	O
of	IN	O
the	DT	O
selected	VBN	O
nucleic	NN	O
acid	NN	O
probe	NN	O
.	.	O
Stringent	JJ	O
hybridization	NN	O
conditions	NNS	O
typically	RB	O
allow	VBP	O
detection	NN	O
of	IN	O
target	NN	O
nucleic	JJ	O
acid	JJ	O
sequences	NNS	O
of	IN	O
at	IN	O
least	JJS	O
about	IN	O
10-14	JJ	O
nucleotides	NNS	O
in	IN	O
length	NN	O
having	VBG	O
a	DT	O
sequence	NN	O
identity	NN	O
of	IN	O
greater	JJR	O
than	IN	O
about	RB	O
90-95	CD	O
%	NN	O
with	IN	O
the	DT	O
sequence	NN	O
of	IN	O
the	DT	O
selected	VBN	O
nucleic	NN	O
acid	NN	O
probe	NN	O
.	.	O
Hybridization	NNP	O
conditions	NNS	O
useful	JJ	O
for	IN	O
probe/target	NN	O
hybridization	NN	O
where	WRB	O
the	DT	O
probe	NN	O
and	CC	O
target	NN	O
have	VBP	O
a	DT	O
specific	JJ	O
degree	NN	O
of	IN	O
sequence	NN	O
identity	NN	O
,	,	O
can	MD	O
be	VB	O
determined	VBN	O
as	IN	O
is	VBZ	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
(	(	O
see	VB	O
,	,	O
for	IN	O
example	NN	O
,	,	O
Nucleic	NNP	B
Acid	NNP	I
Hybridization	NNP	I
:	:	I
A	DT	I
Practical	NNP	I
Approach	NNP	I
,	,	I
editors	NNS	I
B.	NNP	I
D.	NNP	I
Hames	NNP	I
and	CC	I
S.	NNP	I
J.	NNP	I
Higgins	NNP	I
,	,	I
(	(	I
1985	CD	I
)	)	I
Oxford	NNP	I
;	:	I
Washington	NNP	I
,	,	I
D.C.	NNP	I
;	:	I
IRL	NNP	I
Press	NNP	I
)	)	O
.	.	O
With	IN	O
respect	NN	O
to	TO	O
stringency	VB	O
conditions	NNS	O
for	IN	O
hybridization	NN	O
,	,	O
it	PRP	O
is	VBZ	O
well	RB	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
that	WDT	O
numerous	JJ	O
equivalent	JJ	O
conditions	NNS	O
can	MD	O
be	VB	O
employed	VBN	O
to	TO	O
establish	VB	O
a	DT	O
particular	JJ	O
stringency	NN	O
by	IN	O
varying	VBG	O
,	,	O
for	IN	O
example	NN	O
,	,	O
the	DT	O
following	JJ	O
factors	NNS	O
:	:	O
the	DT	O
length	NN	O
and	CC	O
nature	NN	O
of	IN	O
probe	NN	O
and	CC	O
target	NN	O
sequences	NNS	O
,	,	O
base	NN	O
composition	NN	O
of	IN	O
the	DT	O
various	JJ	O
sequences	NNS	O
,	,	O
concentrations	NNS	O
of	IN	O
salts	NNS	O
and	CC	O
other	JJ	O
hybridization	NN	O
solution	NN	O
components	NNS	O
,	,	O
the	DT	O
presence	NN	O
or	CC	O
absence	NN	O
of	IN	O
blocking	VBG	O
agents	NNS	O
in	IN	O
the	DT	O
hybridization	NN	O
solutions	NNS	O
(	(	O
e.g.	NN	O
,	,	O
formamide	RB	O
,	,	O
dextran	JJ	O
sulfate	NN	O
,	,	O
and	CC	O
polyethylene	VB	O
glycol	NN	O
)	)	O
,	,	O
hybridization	NN	O
reaction	NN	O
temperature	NN	O
and	CC	O
time	NN	O
parameters	NNS	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
,	,	O
varying	VBG	O
wash	JJ	O
conditions	NNS	O
.	.	O
The	DT	O
selection	NN	O
of	IN	O
a	DT	O
particular	JJ	O
set	NN	O
of	IN	O
hybridization	NN	O
conditions	NNS	O
is	VBZ	O
selected	VBN	O
following	VBG	O
standard	JJ	O
methods	NNS	O
in	IN	O
the	DT	O
art	NN	O
(	(	O
see	VB	O
,	,	O
for	IN	O
example	NN	O
,	,	O
Sambrook	NNP	B
,	,	I
et	FW	I
al.	NN	I
,	,	I
Molecular	JJ	I
Cloning	NN	I
:	:	I
A	DT	I
Laboratory	NNP	I
Manual	NNP	I
,	,	I
Second	NNP	I
Edition	NNP	I
,	,	I
(	(	I
1989	CD	I
)	)	I
Cold	NNP	I
Spring	NNP	I
Harbor	NNP	I
,	,	I
N	NNP	I
.	.	I
Y	NNP	I
.	.	I
)	)	O
.	.	O
A	DT	O
first	JJ	O
polynucleotide	NN	O
is	VBZ	O
“	JJ	O
derived	VBN	O
from	IN	O
”	JJ	O
second	JJ	O
polynucleotide	NN	O
if	IN	O
it	PRP	O
has	VBZ	O
the	DT	O
same	JJ	O
or	CC	O
substantially	RB	O
the	DT	O
same	JJ	O
basepair	NN	O
sequence	NN	O
as	IN	O
a	DT	O
region	NN	O
of	IN	O
the	DT	O
second	JJ	O
polynucleotide	NN	O
,	,	O
its	PRP$	O
cDNA	NN	O
,	,	O
complements	NNS	O
thereof	VBP	O
,	,	O
or	CC	O
if	IN	O
it	PRP	O
displays	VBZ	O
sequence	NN	O
identity	NN	O
as	IN	O
described	VBN	O
above	IN	O
.	.	O
A	DT	O
first	JJ	O
polypeptide	NN	O
is	VBZ	O
“	JJ	O
derived	VBN	O
from	IN	O
”	VBG	O
a	DT	O
second	JJ	O
polypeptide	NN	O
if	IN	O
it	PRP	O
is	VBZ	O
(	(	O
i	NN	O
)	)	O
encoded	VBN	O
by	IN	O
a	DT	O
first	JJ	O
polynucleotide	NN	O
derived	VBN	O
from	IN	O
a	DT	O
second	JJ	O
polynucleotide	NN	O
,	,	O
or	CC	O
(	(	O
ii	NN	O
)	)	O
displays	VBZ	O
sequence	NN	O
identity	NN	O
to	TO	O
the	DT	O
second	JJ	O
polypeptides	NNS	O
as	IN	O
described	VBN	O
above	IN	O
.	.	O
Generally	RB	O
,	,	O
a	DT	O
viral	JJ	O
polypeptide	NN	O
is	VBZ	O
“	JJ	O
derived	VBN	O
from	IN	O
”	VBG	O
a	DT	O
particular	JJ	O
polypeptide	NN	O
of	IN	O
a	DT	O
virus	NN	O
(	(	O
viral	JJ	O
polypeptide	NN	O
)	)	O
if	IN	O
it	PRP	O
is	VBZ	O
(	(	O
i	NN	O
)	)	O
encoded	VBN	O
by	IN	O
an	DT	O
open	JJ	O
reading	NN	O
frame	NN	O
of	IN	O
a	DT	O
polynucleotide	NN	O
of	IN	O
that	DT	O
virus	NN	O
(	(	O
viral	JJ	O
polynucleotide	NN	O
)	)	O
,	,	O
or	CC	O
(	(	O
ii	NN	O
)	)	O
displays	VBZ	O
sequence	NN	O
identity	NN	O
to	TO	O
polypeptides	NNS	O
of	IN	O
that	DT	O
virus	NN	O
as	IN	O
described	VBN	O
above	IN	O
.	.	O
“	NN	O
Encoded	VBN	O
by	IN	O
”	JJ	O
refers	NNS	O
to	TO	O
a	DT	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
which	WDT	O
codes	VBZ	O
for	IN	O
a	DT	O
polypeptide	JJ	O
sequence	NN	O
,	,	O
wherein	VBP	O
the	DT	O
polypeptide	NN	O
sequence	NN	O
or	CC	O
a	DT	O
portion	NN	O
thereof	NN	O
contains	VBZ	O
an	DT	O
amino	NN	O
acid	JJ	O
sequence	NN	O
of	IN	O
at	IN	O
least	JJS	O
3	CD	O
to	TO	O
5	CD	O
amino	NN	O
acids	NNS	O
,	,	O
more	JJR	O
preferably	RB	O
at	IN	O
least	JJS	O
8	CD	O
to	TO	O
10	CD	O
amino	NN	O
acids	NNS	O
,	,	O
and	CC	O
even	RB	O
more	JJR	O
preferably	RB	O
at	IN	O
least	JJS	O
15	CD	O
to	TO	O
20	CD	O
amino	NN	O
acids	NNS	O
from	IN	O
a	DT	O
polypeptide	NN	O
encoded	VBN	O
by	IN	O
the	DT	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
.	.	O
Also	RB	O
encompassed	VBN	O
are	VBP	O
polypeptide	JJ	O
sequences	NNS	O
which	WDT	O
are	VBP	O
immunologically	RB	O
identifiable	JJ	O
with	IN	O
a	DT	O
polypeptide	NN	O
encoded	VBN	O
by	IN	O
the	DT	O
sequence	NN	O
.	.	O
“	NNS	O
Purified	VBD	O
polynucleotide	JJ	O
”	NNP	O
refers	NNS	O
to	TO	O
a	DT	O
polynucleotide	NN	O
of	IN	O
interest	NN	O
or	CC	O
fragment	NN	O
thereof	NN	O
which	WDT	O
is	VBZ	O
essentially	RB	O
free	JJ	O
,	,	O
e.g.	JJ	O
,	,	O
contains	VBZ	O
less	JJR	O
than	IN	O
about	RB	O
50	CD	O
%	NN	O
,	,	O
preferably	RB	O
less	JJR	O
than	IN	O
about	RB	O
70	CD	O
%	NN	O
,	,	O
and	CC	O
more	JJR	O
preferably	RB	O
less	RBR	O
than	IN	O
about	RB	O
90	CD	O
%	NN	O
,	,	O
of	IN	O
the	DT	O
protein	NN	O
with	IN	O
which	WDT	O
the	DT	O
polynucleotide	NN	O
is	VBZ	O
naturally	RB	O
associated	VBN	O
.	.	O
Techniques	NNS	O
for	IN	O
purifying	VBG	O
polynucleotides	NNS	O
of	IN	O
interest	NN	O
are	VBP	O
well-known	JJ	O
in	IN	O
the	DT	O
art	NN	O
and	CC	O
include	VBP	O
,	,	O
for	IN	O
example	NN	O
,	,	O
disruption	NN	O
of	IN	O
the	DT	O
cell	NN	O
containing	VBG	O
the	DT	O
polynucleotide	NN	O
with	IN	O
a	DT	O
chaotropic	NN	O
agent	NN	O
and	CC	O
separation	NN	O
of	IN	O
the	DT	O
polynucleotide	NN	O
(	(	O
s	NN	O
)	)	O
and	CC	O
proteins	NNS	O
by	IN	O
ion-exchange	JJ	O
chromatography	NN	O
,	,	O
affinity	NN	O
chromatography	NN	O
and	CC	O
sedimentation	NN	O
according	VBG	O
to	TO	O
density	NN	O
.	.	O
By	IN	O
“	NNP	O
nucleic	JJ	O
acid	NN	O
immunization	NN	O
”	NN	O
is	VBZ	O
meant	VBN	O
the	DT	O
introduction	NN	O
of	IN	O
a	DT	O
nucleic	JJ	O
acid	NN	O
molecule	NN	O
encoding	VBG	O
one	CD	O
or	CC	O
more	JJR	O
selected	VBN	O
antigens	NNS	O
into	IN	O
a	DT	O
host	NN	O
cell	NN	O
,	,	O
for	IN	O
the	DT	O
in	IN	O
vivo	JJ	O
expression	NN	O
of	IN	O
an	DT	O
antigen	NN	O
,	,	O
antigens	NNS	O
,	,	O
an	DT	O
epitope	NN	O
,	,	O
or	CC	O
epitopes	NNS	O
.	.	O
The	DT	O
nucleic	JJ	O
acid	NN	O
molecule	NN	O
can	MD	O
be	VB	O
introduced	VBN	O
directly	RB	O
into	IN	O
a	DT	O
recipient	NN	O
subject	NN	O
,	,	O
such	JJ	O
as	IN	O
by	IN	O
injection	NN	O
,	,	O
inhalation	NN	O
,	,	O
oral	JJ	O
,	,	O
intranasal	JJ	O
and	CC	O
mucosal	JJ	O
administration	NN	O
,	,	O
or	CC	O
the	DT	O
like	JJ	O
,	,	O
or	CC	O
can	MD	O
be	VB	O
introduced	VBN	O
ex	JJ	O
vivo	NN	O
,	,	O
into	IN	O
cells	NNS	O
which	WDT	O
have	VBP	O
been	VBN	O
removed	VBN	O
from	IN	O
the	DT	O
host	NN	O
.	.	O
In	IN	O
the	DT	O
latter	JJ	O
case	NN	O
,	,	O
the	DT	O
transformed	JJ	O
cells	NNS	O
are	VBP	O
reintroduced	VBN	O
into	IN	O
the	DT	O
subject	NN	O
where	WRB	O
an	DT	O
immune	JJ	O
response	NN	O
can	MD	O
be	VB	O
mounted	VBN	O
against	IN	O
the	DT	O
antigen	NN	O
encoded	VBN	O
by	IN	O
the	DT	O
nucleic	JJ	O
acid	NN	O
molecule	NN	O
.	.	O
“	JJ	O
Gene	NNP	O
transfer	NN	O
”	NN	O
or	CC	O
“	JJ	O
gene	NN	O
delivery	NN	O
”	NN	O
refers	NNS	O
to	TO	O
methods	NNS	O
or	CC	O
systems	NNS	O
for	IN	O
reliably	RB	O
inserting	VBG	O
DNA	NNP	O
or	CC	O
RNA	NNP	O
of	IN	O
interest	NN	O
into	IN	O
a	DT	O
host	NN	O
cell	NN	O
.	.	O
Such	JJ	O
methods	NNS	O
can	MD	O
result	VB	O
in	IN	O
transient	JJ	O
expression	NN	O
of	IN	O
non-integrated	JJ	O
transferred	JJ	O
DNA	NNP	O
,	,	O
extrachromosomal	JJ	O
replication	NN	O
and	CC	O
expression	NN	O
of	IN	O
transferred	JJ	O
replicons	NNS	O
(	(	O
e.g.	NN	O
,	,	O
episomes	RB	O
)	)	O
,	,	O
or	CC	O
integration	NN	O
of	IN	O
transferred	VBN	O
genetic	JJ	O
material	NN	O
into	IN	O
the	DT	O
genomic	JJ	O
DNA	NN	O
of	IN	O
host	NN	O
cells	NNS	O
.	.	O
Gene	NNP	O
delivery	NN	O
expression	NN	O
vectors	NNS	O
include	VBP	O
,	,	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
,	,	O
vectors	NNS	O
derived	VBD	O
from	IN	O
bacterial	JJ	O
plasmid	NN	O
vectors	NNS	O
,	,	O
viral	JJ	O
vectors	NNS	O
,	,	O
non-viral	JJ	O
vectors	NNS	O
,	,	O
alphaviruses	NNS	O
,	,	O
pox	NN	O
viruses	NNS	O
and	CC	O
vaccinia	NN	O
viruses	NNS	O
.	.	O
When	WRB	O
used	VBN	O
for	IN	O
immunization	NN	O
,	,	O
such	JJ	O
gene	NN	O
delivery	NN	O
expression	NN	O
vectors	NNS	O
may	MD	O
be	VB	O
referred	VBN	O
to	TO	O
as	IN	O
vaccines	NNS	O
or	CC	O
vaccine	NN	O
vectors	NNS	O
.	.	O
“	JJ	O
T	NNP	O
lymphocytes	VBZ	O
”	CD	O
or	CC	O
“	VB	O
T	NNP	O
cells	NNS	O
”	EX	O
are	VBP	O
non-antibody	JJ	O
producing	VBG	O
lymphocytes	NNS	O
that	IN	O
constitute	VBP	O
a	DT	O
part	NN	O
of	IN	O
the	DT	O
cell-mediated	JJ	O
arm	NN	O
of	IN	O
the	DT	O
immune	NN	O
system	NN	O
.	.	O
T	NNP	O
cells	NNS	O
arise	VBP	O
from	IN	O
immature	NN	O
lymphocytes	VBZ	O
that	IN	O
migrate	NN	O
from	IN	O
the	DT	O
bone	NN	O
marrow	NN	O
to	TO	O
the	DT	O
thymus	NN	O
,	,	O
where	WRB	O
they	PRP	O
undergo	VBP	O
a	DT	O
maturation	NN	O
process	NN	O
under	IN	O
the	DT	O
direction	NN	O
of	IN	O
thymic	JJ	O
hormones	NNS	O
.	.	O
Here	RB	O
,	,	O
the	DT	O
mature	NN	O
lymphocytes	VBZ	O
rapidly	RB	O
divide	JJ	O
increasing	VBG	O
to	TO	O
very	RB	O
large	JJ	O
numbers	NNS	O
.	.	O
The	DT	O
maturing	VBG	O
T	NNP	O
cells	NNS	O
become	VBP	O
immunocompetent	JJ	O
based	VBN	O
on	IN	O
their	PRP$	O
ability	NN	O
to	TO	O
recognize	VB	O
and	CC	O
bind	VB	O
a	DT	O
specific	JJ	O
antigen	NN	O
.	.	O
Activation	NN	O
of	IN	O
immunocompetent	JJ	O
T	NNP	O
cells	NNS	O
is	VBZ	O
triggered	VBN	O
when	WRB	O
an	DT	O
antigen	NN	O
binds	VBZ	O
to	TO	O
the	DT	O
lymphocyte	NN	O
's	POS	O
surface	NN	O
receptors	NNS	O
.	.	O
The	DT	O
term	NN	O
“	NNP	O
transfection	NN	O
”	NN	O
is	VBZ	O
used	VBN	O
to	TO	O
refer	VB	O
to	TO	O
the	DT	O
uptake	NN	O
of	IN	O
foreign	JJ	O
DNA	NNP	O
by	IN	O
a	DT	O
cell	NN	O
.	.	O
A	DT	O
cell	NN	O
has	VBZ	O
been	VBN	O
“	NNP	O
transfected	VBD	O
”	RP	O
when	WRB	O
exogenous	JJ	O
DNA	NN	O
has	VBZ	O
been	VBN	O
introduced	VBN	O
inside	IN	O
the	DT	O
cell	NN	O
membrane	NN	O
.	.	O
A	DT	O
number	NN	O
of	IN	O
transfection	NN	O
techniques	NNS	O
are	VBP	O
generally	RB	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
See	VB	O
,	,	O
e.g.	VB	O
,	,	O
Graham	NNP	B
et	CC	I
al	NN	I
.	.	I
(	(	I
1973	CD	I
)	)	I
Virology	NNP	I
,	,	I
52:456	CD	I
,	,	O
Sambrook	NNP	B
et	CC	I
al	NN	I
.	.	I
(	(	I
1989	CD	I
)	)	I
Molecular	NNP	I
Cloning	NNP	I
,	,	I
a	DT	I
laboratory	NN	I
manual	JJ	I
,	,	I
Cold	NNP	I
Spring	NNP	I
Harbor	NNP	I
Laboratories	NNPS	I
,	,	I
New	NNP	I
York	NNP	I
,	,	O
Davis	NNP	B
et	CC	I
al	NN	I
.	.	I
(	(	I
1986	CD	I
)	)	I
Basic	NNP	I
Methods	NNP	I
in	IN	I
Molecular	NNP	I
Biology	NNP	I
,	,	I
Elsevier	NNP	I
,	,	I
and	CC	I
Chu	NNP	I
et	VBP	I
al	NN	I
.	.	I
(	(	I
1981	CD	I
)	)	I
Gene	NNP	I
13:197	CD	I
.	.	O
Such	JJ	O
techniques	NNS	O
can	MD	O
be	VB	O
used	VBN	O
to	TO	O
introduce	VB	O
one	CD	O
or	CC	O
more	JJR	O
exogenous	JJ	O
DNA	NN	O
moieties	NNS	O
into	IN	O
suitable	JJ	O
host	NN	O
cells	NNS	O
.	.	O
The	DT	O
term	NN	O
refers	NNS	O
to	TO	O
both	DT	O
stable	JJ	O
and	CC	O
transient	JJ	O
uptake	NN	O
of	IN	O
the	DT	O
genetic	JJ	O
material	NN	O
,	,	O
and	CC	O
includes	VBZ	O
uptake	NN	O
of	IN	O
peptide-	JJ	O
or	CC	O
antibody-linked	JJ	O
DNAs	NNP	O
.	.	O
A	DT	O
“	JJ	O
vector	NN	O
”	NN	O
is	VBZ	O
capable	JJ	O
of	IN	O
transferring	VBG	O
gene	NN	O
sequences	NNS	O
to	TO	O
target	VB	O
cells	NNS	O
(	(	O
e.g.	NN	O
,	,	O
bacterial	JJ	O
plasmid	NN	O
vectors	NNS	O
,	,	O
viral	JJ	O
vectors	NNS	O
,	,	O
non-viral	JJ	O
vectors	NNS	O
,	,	O
particulate	NN	O
carriers	NNS	O
,	,	O
and	CC	O
liposomes	RB	O
)	)	O
.	.	O
Typically	RB	O
,	,	O
“	NNP	O
vector	NN	O
construct	NN	O
,	,	O
”	NNP	O
“	NNP	O
expression	NN	O
vector	NN	O
,	,	O
”	NNP	O
and	CC	O
“	NNP	O
gene	NN	O
transfer	NN	O
vector	NN	O
,	,	O
”	JJ	O
mean	VBP	O
any	DT	O
nucleic	JJ	O
acid	NN	O
construct	NN	O
capable	JJ	O
of	IN	O
directing	VBG	O
the	DT	O
expression	NN	O
of	IN	O
a	DT	O
gene	NN	O
of	IN	O
interest	NN	O
and	CC	O
which	WDT	O
can	MD	O
transfer	VB	O
gene	NN	O
sequences	NNS	O
to	TO	O
target	VB	O
cells	NNS	O
.	.	O
Thus	RB	O
,	,	O
the	DT	O
term	NN	O
includes	VBZ	O
cloning	NN	O
and	CC	O
expression	NN	O
vehicles	NNS	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
viral	JJ	O
vectors	NNS	O
.	.	O
Transfer	NN	O
of	IN	O
a	DT	O
“	NNP	O
suicide	NN	O
gene	NN	O
”	NNP	O
(	(	O
e.g.	NN	O
,	,	O
a	DT	O
drug-susceptibility	JJ	O
gene	NN	O
)	)	O
to	TO	O
a	DT	O
target	NN	O
cell	NN	O
renders	VBZ	O
the	DT	O
cell	NN	O
sensitive	JJ	O
to	TO	O
compounds	NNS	O
or	CC	O
compositions	NNS	O
that	WDT	O
are	VBP	O
relatively	RB	O
nontoxic	JJ	O
to	TO	O
normal	JJ	O
cells	NNS	O
.	.	O
Moolten	NNP	B
,	,	I
F.	NNP	I
L.	NNP	I
(	(	I
1994	CD	I
)	)	I
Cancer	NNP	I
Gene	NNP	I
Ther	NNP	I
.	.	I
1:279-287	JJ	I
.	.	O
Examples	NNS	O
of	IN	O
suicide	NN	O
genes	NNS	O
are	VBP	O
thymidine	JJ	O
kinase	NN	O
of	IN	O
herpes	NNS	O
simplex	JJ	O
virus	NN	O
(	(	O
HSV-tk	NNP	O
)	)	O
,	,	O
cytochrome	JJ	O
P450	NNP	O
(	(	O
Manome	NNP	B
et	RB	I
al	RB	I
.	.	I
(	(	I
1996	CD	I
)	)	I
Gene	NNP	I
Therapy	NNP	I
3:513-520	CD	I
)	)	O
,	,	O
human	JJ	O
deoxycytidine	NN	O
kinase	NN	O
(	(	O
Manome	NNP	B
et	RB	I
al	RB	I
.	.	I
(	(	I
1996	CD	I
)	)	I
Nature	NNP	I
Medicine	NNP	I
2	CD	I
(	(	I
5	CD	I
)	)	I
:567-573	NN	I
)	)	O
and	CC	O
the	DT	O
bacterial	JJ	O
enzyme	NN	O
cytosine	NN	O
deaminase	NN	O
(	(	O
Dong	NNP	B
et	RB	I
al	RB	I
.	.	I
(	(	I
1996	CD	I
)	)	I
Human	NNP	I
Gene	NNP	I
Therapy	NNP	I
7:713-720	NNP	I
)	)	O
.	.	O
Cells	NNS	O
which	WDT	O
express	VBP	O
these	DT	O
genes	NNS	O
are	VBP	O
rendered	VBN	O
sensitive	JJ	O
to	TO	O
the	DT	O
effects	NNS	O
of	IN	O
the	DT	O
relatively	RB	O
nontoxic	JJ	O
prodrugs	NNS	O
ganciclovir	NN	O
(	(	O
HSV-tk	NNP	O
)	)	O
,	,	O
cyclophosphamide	NN	O
(	(	O
cytochrome	JJ	O
P450	NNP	O
2B1	CD	O
)	)	O
,	,	O
cytosine	JJ	O
arabinoside	NN	O
(	(	O
human	JJ	O
deoxycytidine	NN	O
kinase	NN	O
)	)	O
or	CC	O
5-fluorocytosine	JJ	O
(	(	O
bacterial	JJ	O
cytosine	NN	O
deaminase	NN	O
)	)	O
.	.	O
Culver	NNP	B
et	CC	I
al	NN	I
.	.	I
(	(	I
1992	CD	I
)	)	I
Science	NNP	I
256:1550-1552	CD	I
,	,	O
Huber	NNP	B
et	CC	I
al	NN	I
.	.	I
(	(	I
1994	CD	I
)	)	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
USA	NNP	I
91:8302-8306	CD	I
.	.	O
A	DT	O
“	NN	O
selectable	JJ	O
marker	NN	O
”	NN	O
or	CC	O
“	JJ	O
reporter	NN	O
marker	NN	O
”	VBZ	O
refers	NNS	O
to	TO	O
a	DT	O
nucleotide	JJ	O
sequence	NN	O
included	VBD	O
in	IN	O
a	DT	O
gene	NN	O
transfer	NN	O
vector	NN	O
that	WDT	O
has	VBZ	O
no	DT	O
therapeutic	JJ	O
activity	NN	O
,	,	O
but	CC	O
rather	RB	O
is	VBZ	O
included	VBN	O
to	TO	O
allow	VB	O
for	IN	O
simpler	JJR	O
preparation	NN	O
,	,	O
manufacturing	NN	O
,	,	O
characterization	NN	O
or	CC	O
testing	NN	O
of	IN	O
the	DT	O
gene	NN	O
transfer	NN	O
vector	NN	O
.	.	O
A	DT	O
“	NN	O
specific	JJ	O
binding	VBG	O
agent	JJ	O
”	JJ	O
refers	NNS	O
to	TO	O
a	DT	O
member	NN	O
of	IN	O
a	DT	O
specific	JJ	O
binding	VBG	O
pair	NN	O
of	IN	O
molecules	NNS	O
wherein	VBP	O
one	CD	O
of	IN	O
the	DT	O
molecules	NNS	O
specifically	RB	O
binds	VBZ	O
to	TO	O
the	DT	O
second	JJ	O
molecule	NN	O
through	IN	O
chemical	NN	O
and/or	NN	O
physical	JJ	O
means	NNS	O
.	.	O
One	CD	O
example	NN	O
of	IN	O
a	DT	O
specific	JJ	O
binding	NN	O
agent	NN	O
is	VBZ	O
an	DT	O
antibody	NN	O
directed	VBN	O
against	IN	O
a	DT	O
selected	VBN	O
antigen	NN	O
.	.	O
By	IN	O
“	NNP	O
subject	JJ	O
”	NNP	O
is	VBZ	O
meant	VBN	O
any	DT	O
member	NN	O
of	IN	O
the	DT	O
subphylum	NN	O
chordata	NN	O
,	,	O
including	VBG	O
,	,	O
without	IN	O
limitation	NN	O
,	,	O
humans	NNS	O
and	CC	O
other	JJ	O
primates	NNS	O
,	,	O
including	VBG	O
non-human	JJ	O
primates	NNS	O
such	JJ	O
as	IN	O
chimpanzees	NNS	O
and	CC	O
other	JJ	O
apes	NNS	O
and	CC	O
monkey	JJ	O
species	NNS	O
;	:	O
farm	NN	O
animals	NNS	O
such	JJ	O
as	IN	O
cattle	NNS	O
,	,	O
sheep	NN	O
,	,	O
pigs	NNS	O
,	,	O
goats	NNS	O
and	CC	O
horses	NNS	O
;	:	O
domestic	JJ	O
mammals	NNS	O
such	JJ	O
as	IN	O
dogs	NNS	O
and	CC	O
cats	NNS	O
;	:	O
laboratory	NN	O
animals	NNS	O
including	VBG	O
rodents	NNS	O
such	JJ	O
as	IN	O
mice	NNS	O
,	,	O
rats	NNS	O
and	CC	O
guinea	NN	O
pigs	NNS	O
;	:	O
birds	NNS	O
,	,	O
including	VBG	O
domestic	JJ	O
,	,	O
wild	JJ	O
and	CC	O
game	NN	O
birds	NNS	O
such	JJ	O
as	IN	O
chickens	NNS	O
,	,	O
turkeys	NNS	O
and	CC	O
other	JJ	O
gallinaceous	JJ	O
birds	NNS	O
,	,	O
ducks	NNS	O
,	,	O
geese	JJ	O
,	,	O
and	CC	O
the	DT	O
like	JJ	O
.	.	O
The	DT	O
term	NN	O
does	VBZ	O
not	RB	O
denote	VB	O
a	DT	O
particular	JJ	O
age	NN	O
.	.	O
Thus	RB	O
,	,	O
both	DT	O
adult	NN	O
and	CC	O
newborn	JJ	O
individuals	NNS	O
are	VBP	O
intended	VBN	O
to	TO	O
be	VB	O
covered	VBN	O
.	.	O
The	DT	O
system	NN	O
described	VBN	O
above	IN	O
is	VBZ	O
intended	VBN	O
for	IN	O
use	NN	O
in	IN	O
any	DT	O
of	IN	O
the	DT	O
above	JJ	O
vertebrate	NN	O
species	NNS	O
,	,	O
since	IN	O
the	DT	O
immune	JJ	O
systems	NNS	O
of	IN	O
all	DT	O
of	IN	O
these	DT	O
vertebrates	NNS	O
operate	VBP	O
similarly	RB	O
.	.	O
By	IN	O
“	NNP	O
pharmaceutically	RB	O
acceptable	JJ	O
”	NN	O
or	CC	O
“	VB	O
pharmacologically	RB	O
acceptable	JJ	O
”	NN	O
is	VBZ	O
meant	VBN	O
a	DT	O
material	NN	O
which	WDT	O
is	VBZ	O
not	RB	O
biologically	RB	O
or	CC	O
otherwise	RB	O
undesirable	JJ	O
,	,	O
i.e.	FW	O
,	,	O
the	DT	O
material	NN	O
may	MD	O
be	VB	O
administered	VBN	O
to	TO	O
an	DT	O
individual	NN	O
in	IN	O
a	DT	O
formulation	NN	O
or	CC	O
composition	NN	O
without	IN	O
causing	VBG	O
any	DT	O
undesirable	JJ	O
biological	JJ	O
effects	NNS	O
or	CC	O
interacting	VBG	O
in	IN	O
a	DT	O
deleterious	JJ	O
manner	NN	O
with	IN	O
any	DT	O
of	IN	O
the	DT	O
components	NNS	O
of	IN	O
the	DT	O
composition	NN	O
in	IN	O
which	WDT	O
it	PRP	O
is	VBZ	O
contained	VBN	O
.	.	O
By	IN	O
“	NNP	O
physiological	JJ	O
pH	NN	O
”	NN	O
or	CC	O
a	DT	O
“	JJ	O
pH	NN	O
in	IN	O
the	DT	O
physiological	JJ	O
range	NN	O
”	NN	O
is	VBZ	O
meant	VBN	O
a	DT	O
pH	NN	O
in	IN	O
the	DT	O
range	NN	O
of	IN	O
approximately	RB	O
7.2	CD	O
to	TO	O
8.0	CD	O
inclusive	NN	O
,	,	O
more	RBR	O
typically	RB	O
in	IN	O
the	DT	O
range	NN	O
of	IN	O
approximately	RB	O
7.2	CD	O
to	TO	O
7.6	CD	O
inclusive	NN	O
.	.	O
As	IN	O
used	VBN	O
herein	NN	O
,	,	O
“	NNP	O
treatment	NN	O
”	NN	O
refers	NNS	O
to	TO	O
any	DT	O
of	IN	O
(	(	O
I	PRP	O
)	)	O
the	DT	O
prevention	NN	O
of	IN	O
infection	NN	O
or	CC	O
reinfection	NN	O
,	,	O
as	IN	O
in	IN	O
a	DT	O
traditional	JJ	O
vaccine	NN	O
,	,	O
(	(	O
ii	NN	O
)	)	O
the	DT	O
reduction	NN	O
or	CC	O
elimination	NN	O
of	IN	O
symptoms	NNS	O
,	,	O
and	CC	O
(	(	O
iii	NN	O
)	)	O
the	DT	O
substantial	JJ	O
or	CC	O
complete	JJ	O
elimination	NN	O
of	IN	O
the	DT	O
pathogen	NN	O
in	IN	O
question	NN	O
.	.	O
Treatment	NN	O
may	MD	O
be	VB	O
effected	VBN	O
prophylactically	RB	O
(	(	O
prior	JJ	O
to	TO	O
infection	NN	O
)	)	O
or	CC	O
therapeutically	RB	O
(	(	O
following	VBG	O
infection	NN	O
)	)	O
.	.	O
“	JJ	O
Lentiviral	NNP	O
vector	NN	O
”	NN	O
,	,	O
and	CC	O
“	NNP	O
recombinant	JJ	O
lentiviral	JJ	O
vector	NN	O
”	NN	O
are	VBP	O
derived	VBN	O
from	IN	O
the	DT	O
subset	NN	O
of	IN	O
retroviral	JJ	O
vectors	NNS	O
known	VBN	O
as	IN	O
lentiviruses	NNS	O
.	.	O
Lentiviral	JJ	O
vectors	NNS	O
refer	VBP	O
to	TO	O
a	DT	O
nucleic	JJ	O
acid	NN	O
construct	NN	O
which	WDT	O
carries	VBZ	O
,	,	O
and	CC	O
within	IN	O
certain	JJ	O
embodiments	NNS	O
,	,	O
is	VBZ	O
capable	JJ	O
of	IN	O
directing	VBG	O
the	DT	O
expression	NN	O
of	IN	O
a	DT	O
nucleic	JJ	O
acid	NN	O
molecule	NN	O
of	IN	O
interest	NN	O
.	.	O
The	DT	O
lentiviral	JJ	O
vector	NN	O
includes	VBZ	O
at	IN	O
least	JJS	O
one	CD	O
transcriptional	JJ	O
promoter/enhancer	NN	O
or	CC	O
locus	NN	O
defining	VBG	O
element	NN	O
(	(	O
s	NN	O
)	)	O
,	,	O
or	CC	O
other	JJ	O
elements	NNS	O
which	WDT	O
control	VBP	O
gene	NN	O
expression	NN	O
by	IN	O
other	JJ	O
means	NNS	O
such	JJ	O
as	IN	O
alternate	NN	O
splicing	NN	O
,	,	O
nuclear	JJ	O
RNA	NNP	O
export	NN	O
,	,	O
post-translational	JJ	O
modification	NN	O
of	IN	O
messenger	NN	O
,	,	O
or	CC	O
post-transcriptional	JJ	O
modification	NN	O
of	IN	O
protein	NN	O
.	.	O
Such	JJ	O
vector	NN	O
constructs	NNS	O
must	MD	O
also	RB	O
include	VB	O
a	DT	O
packaging	JJ	O
signal	NN	O
,	,	O
long	JJ	O
terminal	JJ	O
repeats	NNS	O
(	(	O
LTRS	NNP	O
)	)	O
or	CC	O
portion	NN	O
thereof	NN	O
,	,	O
and	CC	O
positive	JJ	O
and	CC	O
negative	JJ	O
strand	NN	O
primer	NN	O
binding	VBG	O
sites	NNS	O
appropriate	VBP	O
to	TO	O
the	DT	O
lentiviral	JJ	O
vector	NN	O
used	VBN	O
(	(	O
if	IN	O
these	DT	O
are	VBP	O
not	RB	O
already	RB	O
present	JJ	O
in	IN	O
the	DT	O
retroviral	JJ	O
vector	NN	O
)	)	O
.	.	O
Optionally	RB	O
,	,	O
the	DT	O
recombinant	JJ	O
lentiviral	JJ	O
vector	NN	O
may	MD	O
also	RB	O
include	VB	O
a	DT	O
signal	NN	O
which	WDT	O
directs	VBZ	O
polyadenylation	NN	O
,	,	O
selectable	JJ	O
markers	NNS	O
such	JJ	O
as	IN	O
Neo	NNP	O
,	,	O
TK	NNP	O
,	,	O
hygromycin	NN	O
,	,	O
phleomycin	NN	O
,	,	O
histidinol	NN	O
,	,	O
or	CC	O
DHFR	NNP	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
one	CD	O
or	CC	O
more	JJR	O
restriction	NN	O
sites	NNS	O
and	CC	O
a	DT	O
translation	NN	O
termination	NN	O
sequence	NN	O
.	.	O
By	IN	O
way	NN	O
of	IN	O
example	NN	O
,	,	O
such	JJ	O
vectors	NNS	O
typically	RB	O
include	VBP	O
a	DT	O
5′	CD	O
LTR	NNP	O
,	,	O
a	DT	O
tRNA	NN	O
binding	VBG	O
site	NN	O
,	,	O
a	DT	O
packaging	NN	O
signal	NN	O
,	,	O
an	DT	O
origin	NN	O
of	IN	O
second	JJ	O
strand	NN	O
DNA	NNP	O
synthesis	NN	O
,	,	O
and	CC	O
a	DT	O
3′LTR	CD	O
or	CC	O
a	DT	O
portion	NN	O
thereof	NN	O
.	.	O
“	JJ	O
Lentiviral	NNP	O
vector	NN	O
particle	NN	O
”	NNP	O
as	IN	O
utilized	JJ	O
within	IN	O
the	DT	O
present	JJ	O
invention	NN	O
refers	NNS	O
to	TO	O
a	DT	O
lentivirus	NN	O
which	WDT	O
carries	VBZ	O
at	IN	O
least	JJS	O
one	CD	O
gene	NN	O
of	IN	O
interest	NN	O
.	.	O
The	DT	O
retrovirus	NN	O
may	MD	O
also	RB	O
contain	VB	O
a	DT	O
selectable	JJ	O
marker	NN	O
.	.	O
The	DT	O
recombinant	JJ	O
lentivirus	NN	O
is	VBZ	O
capable	JJ	O
of	IN	O
reverse	NN	O
transcribing	VBG	O
its	PRP$	O
genetic	JJ	O
material	NN	O
(	(	O
RNA	NNP	O
)	)	O
into	IN	O
DNA	NN	O
and	CC	O
incorporating	VBG	O
this	DT	O
genetic	JJ	O
material	NN	O
into	IN	O
a	DT	O
host	NN	O
cell	NN	O
's	POS	O
DNA	NNP	O
upon	IN	O
infection	NN	O
.	.	O
Lentiviral	JJ	O
vector	NN	O
particles	NNS	O
may	MD	O
have	VB	O
a	DT	O
lentiviral	JJ	O
envelope	NN	O
,	,	O
a	DT	O
non-lentiviral	JJ	O
envelope	NN	O
(	(	O
e.g.	NN	O
,	,	O
an	DT	O
ampho	NN	O
or	CC	O
VSV-G	NNP	O
envelope	NN	O
)	)	O
,	,	O
or	CC	O
a	DT	O
chimeric	JJ	O
envelope	NN	O
.	.	O
“	JJ	O
Nucleic	NNP	O
acid	NN	O
expression	NN	O
vector	NN	O
”	NN	O
or	CC	O
“	JJ	O
Expression	NNP	O
cassette	NN	O
”	NN	O
refers	NNS	O
to	TO	O
an	DT	O
assembly	NN	O
which	WDT	O
is	VBZ	O
capable	JJ	O
of	IN	O
directing	VBG	O
the	DT	O
expression	NN	O
of	IN	O
a	DT	O
sequence	NN	O
or	CC	O
gene	NN	O
of	IN	O
interest	NN	O
.	.	O
The	DT	O
nucleic	JJ	O
acid	JJ	O
expression	NN	O
vector	NN	O
includes	VBZ	O
a	DT	O
promoter	NN	O
which	WDT	O
is	VBZ	O
operably	RB	O
linked	VBN	O
to	TO	O
the	DT	O
sequences	NNS	O
or	CC	O
gene	NN	O
(	(	O
s	JJ	O
)	)	O
of	IN	O
interest	NN	O
.	.	O
Other	JJ	O
control	NN	O
elements	NNS	O
may	MD	O
be	VB	O
present	JJ	O
as	RB	O
well	RB	O
.	.	O
Expression	NN	O
cassettes	NNS	O
described	VBD	O
herein	NN	O
may	MD	O
be	VB	O
contained	VBN	O
within	IN	O
a	DT	O
plasmid	JJ	O
construct	NN	O
.	.	O
In	IN	O
addition	NN	O
to	TO	O
the	DT	O
components	NNS	O
of	IN	O
the	DT	O
expression	NN	O
cassette	NN	O
,	,	O
the	DT	O
plasmid	JJ	O
construct	NN	O
may	MD	O
also	RB	O
include	VB	O
a	DT	O
bacterial	JJ	O
origin	NN	O
of	IN	O
replication	NN	O
,	,	O
one	CD	O
or	CC	O
more	JJR	O
selectable	JJ	O
markers	NNS	O
,	,	O
a	DT	O
signal	NN	O
which	WDT	O
allows	VBZ	O
the	DT	O
plasmid	JJ	O
construct	NN	O
to	TO	O
exist	VB	O
as	IN	O
single-stranded	JJ	O
DNA	NNP	O
(	(	O
e.g.	NN	O
,	,	O
a	DT	O
M13	NNP	O
origin	NN	O
of	IN	O
replication	NN	O
)	)	O
,	,	O
a	DT	O
multiple	JJ	O
cloning	NN	O
site	NN	O
,	,	O
and	CC	O
a	DT	O
“	JJ	O
mammalian	JJ	O
”	NNP	O
origin	NN	O
of	IN	O
replication	NN	O
(	(	O
e.g.	NN	O
,	,	O
a	DT	O
SV40	NNP	O
or	CC	O
adenovirus	JJ	O
origin	NN	O
of	IN	O
replication	NN	O
)	)	O
.	.	O
“	JJ	O
Packaging	NNP	O
cell	NN	O
”	NNP	O
refers	NNS	O
to	TO	O
a	DT	O
cell	NN	O
which	WDT	O
contains	VBZ	O
those	DT	O
elements	NNS	O
necessary	JJ	O
for	IN	O
production	NN	O
of	IN	O
infectious	JJ	O
recombinant	JJ	O
retrovirus	NN	O
(	(	O
e.g.	JJ	O
,	,	O
lentivirus	NN	O
)	)	O
which	WDT	O
are	VBP	O
lacking	VBG	O
in	IN	O
a	DT	O
recombinant	JJ	O
retroviral	JJ	O
vector	NN	O
.	.	O
Typically	RB	O
,	,	O
such	JJ	O
packaging	NN	O
cells	NNS	O
contain	VBP	O
one	CD	O
or	CC	O
more	JJR	O
expression	NN	O
cassettes	NNS	O
which	WDT	O
are	VBP	O
capable	JJ	O
of	IN	O
expressing	VBG	O
proteins	NNS	O
which	WDT	O
encode	VBP	O
Gag	NNP	O
,	,	O
pol	NN	O
and	CC	O
env	JJ	O
proteins	NNS	O
.	.	O
“	JJ	O
Producer	NNP	O
cell	NN	O
”	NNP	O
or	CC	O
“	NNP	O
vector	NN	O
producing	VBG	O
cell	NN	O
”	FW	O
refers	NNS	O
to	TO	O
a	DT	O
cell	NN	O
which	WDT	O
contains	VBZ	O
all	DT	O
elements	NNS	O
necessary	JJ	O
for	IN	O
production	NN	O
of	IN	O
recombinant	JJ	O
retroviral	JJ	O
vector	NN	O
particles	NNS	O
.	.	O
2	CD	O
.	.	O
Modes	NNS	O
of	IN	O
Carrying	VBG	O
Out	RP	O
the	DT	O
Invention	NN	O
Before	IN	O
describing	VBG	O
the	DT	O
present	JJ	O
invention	NN	O
in	IN	O
detail	NN	O
,	,	O
it	PRP	O
is	VBZ	O
to	TO	O
be	VB	O
understood	JJ	O
that	IN	O
this	DT	O
invention	NN	O
is	VBZ	O
not	RB	O
limited	VBN	O
to	TO	O
particular	JJ	O
formulations	NNS	O
or	CC	O
process	NN	O
parameters	NNS	O
as	IN	O
such	JJ	O
may	MD	O
,	,	O
of	IN	O
course	NN	O
,	,	O
vary	JJ	O
.	.	O
It	PRP	O
is	VBZ	O
also	RB	O
to	TO	O
be	VB	O
understood	JJ	O
that	IN	O
the	DT	O
terminology	NN	O
used	VBN	O
herein	NN	O
is	VBZ	O
for	IN	O
the	DT	O
purpose	NN	O
of	IN	O
describing	VBG	O
particular	JJ	O
embodiments	NNS	O
of	IN	O
the	DT	O
invention	NN	O
only	RB	O
,	,	O
and	CC	O
is	VBZ	O
not	RB	O
intended	VBN	O
to	TO	O
be	VB	O
limiting	VBG	O
.	.	O
Although	IN	O
a	DT	O
number	NN	O
of	IN	O
methods	NNS	O
and	CC	O
materials	NNS	O
similar	JJ	O
or	CC	O
equivalent	JJ	O
to	TO	O
those	DT	O
described	VBN	O
herein	NNS	O
can	MD	O
be	VB	O
used	VBN	O
in	IN	O
the	DT	O
practice	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
,	,	O
the	DT	O
preferred	JJ	O
materials	NNS	O
and	CC	O
methods	NNS	O
are	VBP	O
described	VBN	O
herein	NNS	O
.	.	O
2.1	CD	O
Synthetic	JJ	O
Expression	NNP	O
Cassettes	VBZ	O
2.1.1	CD	O
Modification	NN	O
of	IN	O
HIV-1	NNP	O
Gag	NNP	O
Nucleic	NNP	O
Acid	NNP	O
Coding	NNP	O
Sequences	NNP	O
One	NNP	O
aspect	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
is	VBZ	O
the	DT	O
generation	NN	O
of	IN	O
HIV-1	NNP	O
Gag	NNP	O
protein	NN	O
coding	VBG	O
sequences	NNS	O
,	,	O
and	CC	O
related	JJ	O
sequences	NNS	O
,	,	O
having	VBG	O
improved	VBN	O
expression	NN	O
relative	NN	O
to	TO	O
the	DT	O
corresponding	JJ	O
wild-type	JJ	O
sequence	NN	O
.	.	O
An	DT	O
exemplary	JJ	O
embodiment	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
is	VBZ	O
illustrated	VBN	O
herein	RB	O
modifying	VBG	O
the	DT	O
Gag	NNP	O
protein	NN	O
wild-type	JJ	O
sequences	NNS	O
obtained	VBN	O
from	IN	O
the	DT	O
HIV-1SF2	NNP	O
strain	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:1	NNP	O
;	:	O
Sanchez-Pescador	NNP	B
,	,	I
R.	NNP	I
,	,	I
et	FW	I
al.	NN	I
,	,	I
Science	NNP	I
227	CD	I
(	(	I
4686	CD	I
)	)	I
:	:	I
484-492	CD	I
,	,	I
1985	CD	I
;	:	O
Luciw	NNP	B
,	,	I
P.	NNP	I
A.	NN	I
,	,	I
et	CC	I
al	NN	I
.	.	I
U.S.	NNP	I
Pat	NNP	I
.	.	I
No	DT	I
.	.	I
5,156,949	CD	I
,	,	I
issued	VBN	I
Oct.	NNP	I
20	CD	I
,	,	I
1992	CD	I
,	,	O
herein	RB	O
incorporated	VBN	O
by	IN	O
reference	NN	O
;	:	O
Luciw	NNP	B
,	,	I
P.	NNP	I
A.	NN	I
,	,	I
et	FW	I
al.	NN	I
,	,	I
U.S.	NNP	I
Pat	NNP	I
.	.	I
No	DT	I
.	.	I
5,688,688	CD	I
,	,	I
Nov.	NNP	I
18	CD	I
,	,	I
1997	CD	I
,	,	O
herein	RB	O
incorporated	VBN	O
by	IN	O
reference	NN	O
)	)	O
.	.	O
Gag	NNP	O
sequence	NN	O
obtained	VBN	O
from	IN	O
other	JJ	O
HIV	NNP	O
variants	NNS	O
may	MD	O
be	VB	O
manipulated	VBN	O
in	IN	O
similar	JJ	O
fashion	NN	O
following	VBG	O
the	DT	O
teachings	NNS	O
of	IN	O
the	DT	O
present	JJ	O
specification	NN	O
.	.	O
Such	JJ	O
other	JJ	O
variants	NNS	O
include	VBP	O
,	,	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
,	,	O
Gag	NNP	O
protein	VBZ	O
encoding	VBG	O
sequences	NNS	O
obtained	VBN	O
from	IN	O
the	DT	O
isolates	NNS	O
.	.	O
HIVIIIb	NNP	O
,	,	O
HIVSF2	NNP	O
,	,	O
HIV-1SF162	NNP	O
,	,	O
HIV-1SF170	NNP	O
,	,	O
HIVLAV	NNP	O
,	,	O
HIVLAI	NNP	O
,	,	O
HIVMN	NNP	O
,	,	O
HIV-1CM235	NNP	O
,	,	O
HIV-1US4	NNP	O
,	,	O
other	JJ	O
HIV-1	JJ	O
strains	NNS	O
from	IN	O
diverse	JJ	O
subtypes	NNS	O
(	(	O
e.g.	NN	O
,	,	O
subtypes	NNS	O
,	,	O
A	NNP	O
through	IN	O
G	NNP	O
,	,	O
and	CC	O
O	NNP	O
)	)	O
,	,	O
HIV-2	NNP	O
strains	NNS	O
and	CC	O
diverse	JJ	O
subtypes	NNS	O
(	(	O
e.g.	NN	O
,	,	O
HIV-2UC1	NNP	O
and	CC	O
HIV-2UC2	NNP	O
)	)	O
,	,	O
and	CC	O
simian	JJ	O
immunodeficiency	NN	O
virus	NN	O
(	(	O
Sly	NNP	O
)	)	O
.	.	O
(	(	O
See	VB	O
,	,	O
e.g.	VB	O
,	,	O
Virology	NNP	B
,	,	I
3rd	CD	I
Edition	NNP	I
(	(	I
W.	NNP	I
K.	NNP	I
Joklik	NNP	I
ed	NN	I
.	.	I
1988	CD	I
)	)	I
;	:	O
Fundamental	NNP	B
Virology	NNP	I
,	,	I
2nd	CD	I
Edition	NNP	I
(	(	I
B.	NNP	I
N.	NNP	I
Fields	NNP	I
and	CC	I
D.	NNP	I
M.	NNP	I
Knipe	NNP	I
,	,	I
eds	VBZ	I
.	.	I
1991	CD	I
)	)	I
;	:	O
Virology	NNP	B
,	,	I
3rd	CD	I
Edition	NNP	I
(	(	I
Fields	NNP	I
,	,	I
B	NNP	I
N	NNP	I
,	,	I
D	NNP	I
M	NNP	I
Knipe	NNP	I
,	,	I
P	NNP	I
M	NNP	I
Howley	NNP	I
,	,	I
Editors	NNP	I
,	,	I
1996	CD	I
,	,	I
Lippincott-Raven	NNP	I
,	,	I
Philadelphia	NNP	I
,	,	I
Pa.	NNP	I
;	:	O
for	IN	O
a	DT	O
description	NN	O
of	IN	O
these	DT	O
and	CC	O
other	JJ	O
related	JJ	O
viruses	NNS	O
)	)	O
.	.	O
First	RB	O
,	,	O
the	DT	O
HIV-1	NNP	O
codon	NN	O
usage	NN	O
pattern	NN	O
was	VBD	O
modified	VBN	O
so	RB	O
that	IN	O
the	DT	O
resulting	VBG	O
nucleic	JJ	O
acid	NN	O
coding	VBG	O
sequence	NN	O
was	VBD	O
comparable	JJ	O
to	TO	O
codon	VB	O
usage	NN	O
found	VBN	O
in	IN	O
highly	RB	O
expressed	VBN	O
human	JJ	O
genes	NNS	O
(	(	O
Example	NNP	O
1	CD	O
)	)	O
.	.	O
The	DT	O
HIV	NNP	O
codon	NN	O
usage	NN	O
reflects	VBZ	O
a	DT	O
high	JJ	O
content	NN	O
of	IN	O
the	DT	O
nucleotides	NNS	O
A	NNP	O
or	CC	O
T	NNP	O
of	IN	O
the	DT	O
codon-triplet	NN	O
.	.	O
The	DT	O
effect	NN	O
of	IN	O
the	DT	O
HIV-1	NNP	O
codon	NN	O
usage	NN	O
is	VBZ	O
a	DT	O
high	JJ	O
AT	NNP	O
content	NN	O
in	IN	O
the	DT	O
DNA	NN	O
sequence	NN	O
that	WDT	O
results	NNS	O
in	IN	O
a	DT	O
decreased	JJ	O
translation	NN	O
ability	NN	O
and	CC	O
instability	NN	O
of	IN	O
the	DT	O
mRNA	NN	O
.	.	O
In	IN	O
comparison	NN	O
,	,	O
highly	RB	O
expressed	VBN	O
human	JJ	O
codons	NNS	O
prefer	VBP	O
the	DT	O
nucleotides	NNS	O
G	NNP	O
or	CC	O
C.	NNP	O
The	DT	O
Gag	NNP	O
coding	NN	O
sequences	NNS	O
were	VBD	O
modified	VBN	O
to	TO	O
be	VB	O
comparable	JJ	O
to	TO	O
codon	VB	O
usage	NN	O
found	VBN	O
in	IN	O
highly	RB	O
expressed	VBN	O
human	JJ	O
genes	NNS	O
.	.	O
In	IN	O
FIG	NNP	O
.	.	O
11	CD	O
(	(	O
Example	NNP	O
1	CD	O
)	)	O
,	,	O
the	DT	O
percent	NN	O
A-T	NNP	O
content	NN	O
of	IN	O
cDNA	NN	O
sequences	NNS	O
corresponding	VBG	O
to	TO	O
the	DT	O
mRNA	NN	O
for	IN	O
a	DT	O
known	VBN	O
unstable	JJ	O
mRNA	NN	O
and	CC	O
a	DT	O
known	VBN	O
stable	JJ	O
mRNA	NN	O
are	VBP	O
compared	VBN	O
to	TO	O
the	DT	O
percent	NN	O
A-T	NNP	O
content	NN	O
of	IN	O
native	JJ	O
HIV-1SF2	NNP	O
Gag	NNP	O
cDNA	NN	O
and	CC	O
to	TO	O
the	DT	O
synthetic	JJ	O
Gag	NNP	O
cDNA	NN	O
sequence	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
.	.	O
Experiments	NNS	O
performed	VBN	O
in	IN	O
support	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
showed	VBD	O
that	IN	O
the	DT	O
synthetic	JJ	O
Gag	NNP	O
sequences	NNS	O
were	VBD	O
capable	JJ	O
of	IN	O
higher	JJR	O
level	NN	O
of	IN	O
protein	JJ	O
production	NN	O
(	(	O
see	VB	O
the	DT	O
Examples	NNP	O
)	)	O
relative	VBP	O
to	TO	O
the	DT	O
native	JJ	O
Gag	NNP	O
sequences	NNS	O
.	.	O
The	DT	O
data	NN	O
in	IN	O
FIG	NNP	O
.	.	O
11	CD	O
suggest	JJS	O
that	IN	O
one	CD	O
reason	NN	O
for	IN	O
this	DT	O
increased	VBN	O
production	NN	O
is	VBZ	O
increased	VBN	O
stability	NN	O
of	IN	O
the	DT	O
mRNA	NN	O
corresponding	VBG	O
to	TO	O
the	DT	O
synthetic	JJ	O
Gag	NNP	O
coding	NN	O
sequences	NNS	O
versus	VBP	O
the	DT	O
mRNA	NN	O
corresponding	VBG	O
to	TO	O
the	DT	O
native	JJ	O
Gag	NNP	O
coding	NN	O
sequences	NNS	O
.	.	O
Second	JJ	O
,	,	O
there	EX	O
are	VBP	O
inhibitory	JJ	O
(	(	O
or	CC	O
instability	NN	O
)	)	O
elements	NNS	O
(	(	O
INS	NNP	O
)	)	O
located	VBD	O
within	IN	O
the	DT	O
coding	VBG	O
sequences	NNS	O
of	IN	O
the	DT	O
Gag	NNP	O
coding	NN	O
sequences	NNS	O
(	(	O
Example	NNP	O
1	CD	O
)	)	O
.	.	O
The	DT	O
RRE	NNP	O
is	VBZ	O
a	DT	O
secondary	JJ	O
RNA	NNP	O
structure	NN	O
that	WDT	O
interacts	VBZ	O
with	IN	O
the	DT	O
HIV	NNP	O
encoded	VBD	O
Rev-protein	NNP	O
to	TO	O
overcome	VB	O
the	DT	O
expression	NN	O
down-regulating	JJ	O
effects	NNS	O
of	IN	O
the	DT	O
INS	NNP	O
.	.	O
To	TO	O
overcome	VB	O
the	DT	O
post-transcriptional	JJ	O
activating	NN	O
mechanisms	NNS	O
of	IN	O
RRE	NNP	O
and	CC	O
Rev	NNP	O
,	,	O
the	DT	O
instability	NN	O
elements	NNS	O
were	VBD	O
inactivated	VBN	O
by	IN	O
introducing	VBG	O
multiple	JJ	O
point	NN	O
mutations	NNS	O
that	WDT	O
did	VBD	O
not	RB	O
alter	VB	O
the	DT	O
reading	NN	O
frame	NN	O
of	IN	O
the	DT	O
encoded	JJ	O
proteins	NNS	O
.	.	O
FIG	NNP	O
.	.	O
1	CD	O
shows	VBZ	O
the	DT	O
original	JJ	O
SF2	NNP	O
Gag	NNP	O
sequence	NN	O
,	,	O
the	DT	O
location	NN	O
of	IN	O
the	DT	O
INS	NNP	O
sequences	NNS	O
,	,	O
and	CC	O
the	DT	O
modifications	NNS	O
made	VBN	O
to	TO	O
the	DT	O
INS	NNP	O
sequences	NNS	O
to	TO	O
reduce	VB	O
their	PRP$	O
effects	NNS	O
.	.	O
The	DT	O
resulting	VBG	O
modified	JJ	O
coding	NN	O
sequences	NNS	O
are	VBP	O
presented	VBN	O
as	IN	O
a	DT	O
synthetic	JJ	O
Gag	NNP	O
expression	NN	O
cassette	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:4	NNP	O
)	)	O
.	.	O
Modification	NN	O
of	IN	O
the	DT	O
Gag	NNP	O
polypeptide	NN	O
coding	VBG	O
sequences	NNS	O
resulted	VBD	O
in	IN	O
improved	JJ	O
expression	NN	O
relative	NN	O
to	TO	O
the	DT	O
wild-type	JJ	O
coding	NN	O
sequences	NNS	O
in	IN	O
a	DT	O
number	NN	O
of	IN	O
mammalian	JJ	O
cell	NN	O
lines	NNS	O
(	(	O
as	RB	O
well	RB	O
as	IN	O
other	JJ	O
types	NNS	O
of	IN	O
cell	NN	O
lines	NNS	O
,	,	O
including	VBG	O
,	,	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
,	,	O
insect	VB	O
cells	NNS	O
)	)	O
.	.	O
Further	RB	O
,	,	O
expression	NN	O
of	IN	O
the	DT	O
sequences	NNS	O
resulted	VBD	O
in	IN	O
production	NN	O
of	IN	O
virus-like	JJ	O
particles	NNS	O
(	(	O
VLPs	NNP	O
)	)	O
by	IN	O
these	DT	O
cell	NN	O
lines	NNS	O
(	(	O
see	VB	O
below	IN	O
)	)	O
.	.	O
Similar	JJ	O
Gag	NNP	O
polypeptide	NN	O
coding	VBG	O
sequences	NNS	O
can	MD	O
be	VB	O
obtained	VBN	O
from	IN	O
a	DT	O
variety	NN	O
of	IN	O
isolates	NNS	O
(	(	O
families	NNS	O
,	,	O
sub-types	NNS	O
,	,	O
strains	NNS	O
,	,	O
etc	FW	O
.	.	O
)	)	O
including	VBG	O
,	,	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
such	JJ	O
other	JJ	O
variants	NNS	O
include	VBP	O
,	,	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
,	,	O
Gag	NNP	O
polypeptide	IN	O
encoding	VBG	O
sequences	NNS	O
obtained	VBN	O
from	IN	O
the	DT	O
isolates	NNS	O
HIVIIIb	NNP	O
,	,	O
HIVSF2	NNP	O
,	,	O
HIV-1SF162	NNP	O
,	,	O
HIV-1SF170	NNP	O
,	,	O
HIVLAV	NNP	O
,	,	O
HIVLAI	NNP	O
,	,	O
HIVMN	NNP	O
,	,	O
HIV-1CM235	NNP	O
,	,	O
HIV-1US4	NNP	O
,	,	O
other	JJ	O
HIV-1	JJ	O
strains	NNS	O
from	IN	O
diverse	JJ	O
subtypes	NNS	O
(	(	O
e.g.	NN	O
,	,	O
subtypes	NNS	O
,	,	O
A	NNP	O
through	IN	O
G	NNP	O
,	,	O
and	CC	O
O	NNP	O
)	)	O
,	,	O
HIV-2	NNP	O
strains	NNS	O
and	CC	O
diverse	JJ	O
subtypes	NNS	O
(	(	O
e.g.	NN	O
,	,	O
HIV-2UC1	NNP	O
and	CC	O
HIV-2UC2	NNP	O
)	)	O
,	,	O
and	CC	O
simian	JJ	O
immunodeficiency	NN	O
virus	NN	O
(	(	O
SIV	NNP	O
)	)	O
.	.	O
(	(	O
See	VB	O
,	,	O
e.g.	VB	O
,	,	O
Virology	NNP	B
,	,	I
3rd	CD	I
Edition	NNP	I
(	(	I
W.	NNP	I
K.	NNP	I
Joklik	NNP	I
ed	NN	I
.	.	I
1988	CD	I
)	)	I
;	:	O
Fundamental	NNP	B
Virology	NNP	I
,	,	I
2nd	CD	I
Edition	NNP	I
(	(	I
B.	NNP	I
N.	NNP	I
Fields	NNP	I
and	CC	I
D.	NNP	I
M.	NNP	I
Knipe	NNP	I
,	,	I
eds	VBZ	I
.	.	I
1991	CD	I
;	:	O
Virology	NNP	B
,	,	I
3rd	CD	I
Edition	NNP	I
(	(	I
Fields	NNP	I
,	,	I
B	NNP	I
N	NNP	I
,	,	I
D	NNP	I
M	NNP	I
Knipe	NNP	I
,	,	I
P	NNP	I
M	NNP	I
Howley	NNP	I
,	,	I
Editors	NNP	I
,	,	I
1996	CD	I
,	,	I
Lippincott-Raven	NNP	I
,	,	I
Philadelphia	NNP	I
,	,	I
Pa.	NNP	I
)	)	I
.	.	O
Gag	NNP	O
polypeptide	NN	O
encoding	VBG	O
sequences	NNS	O
derived	VBN	O
from	IN	O
these	DT	O
variants	NNS	O
can	MD	O
be	VB	O
optimized	VBN	O
and	CC	O
tested	VBN	O
for	IN	O
improved	JJ	O
expression	NN	O
in	IN	O
mammals	NNS	O
by	IN	O
following	VBG	O
the	DT	O
teachings	NNS	O
of	IN	O
the	DT	O
present	JJ	O
specification	NN	O
(	(	O
see	VB	O
the	DT	O
Examples	NNP	O
,	,	O
in	IN	O
particular	JJ	O
Example	NNP	O
1	CD	O
)	)	O
.	.	O
2.1.2	CD	O
Further	JJ	O
Modification	NN	O
of	IN	O
Sequences	NNS	O
Including	VBG	O
HIV-1	NNP	O
Gag	NNP	O
Nucleic	NNP	O
Acid	NNP	O
Coding	NNP	O
Sequences	NNP	O
Experiments	NNP	O
performed	VBD	O
in	IN	O
support	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
have	VBP	O
shown	VBN	O
that	IN	O
similar	JJ	O
modifications	NNS	O
of	IN	O
HIV-1	NNP	O
Gag-protease	NNP	O
,	,	O
Gag-reverse	NNP	O
transcriptase	NN	O
and	CC	O
Gag-polymerase	NNP	O
sequences	NNS	O
also	RB	O
result	VBP	O
in	IN	O
improved	JJ	O
expression	NN	O
of	IN	O
the	DT	O
polyproteins	NNS	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
,	,	O
the	DT	O
production	NN	O
of	IN	O
VLPs	NNP	O
formed	VBN	O
by	IN	O
polypeptides	NNS	O
produced	VBN	O
from	IN	O
such	JJ	O
modified	VBN	O
coding	NN	O
sequences	NNS	O
.	.	O
For	IN	O
the	DT	O
Gag-protease	NNP	O
sequence	NN	O
(	(	O
wild	JJ	O
type	NN	O
,	,	O
SEQ	NNP	O
ID	NNP	O
NO:2	NNP	O
;	:	O
modified	VBN	O
,	,	O
SEQ	NNP	O
ID	NNP	O
NOs:5	NNP	O
,	,	O
78	CD	O
,	,	O
79	CD	O
)	)	O
,	,	O
the	DT	O
changes	NNS	O
in	IN	O
codon	NN	O
usage	NN	O
were	VBD	O
restricted	VBN	O
to	TO	O
the	DT	O
regions	NNS	O
upstream	NN	O
of	IN	O
the	DT	O
−1	NNP	O
frameshift	NN	O
(	(	O
FIG	NNP	O
.	.	O
2	CD	O
)	)	O
.	.	O
Further	RB	O
,	,	O
inhibitory	NN	O
(	(	O
or	CC	O
instability	NN	O
)	)	O
elements	NNS	O
(	(	O
INS	NNP	O
)	)	O
located	VBD	O
within	IN	O
the	DT	O
coding	VBG	O
sequences	NNS	O
of	IN	O
the	DT	O
Gag-protease	NNP	O
polypeptide	NN	O
coding	VBG	O
sequence	NN	O
were	VBD	O
altered	VBN	O
as	RB	O
well	RB	O
(	(	O
indicated	VBN	O
in	IN	O
FIG	NNP	O
.	.	O
2	CD	O
)	)	O
.	.	O
Exemplary	JJ	O
constructs	NNS	O
(	(	O
which	WDT	O
include	VBP	O
the	DT	O
−1	NNP	O
frameshift	NN	O
)	)	O
encoding	VBG	O
modified	VBN	O
Gag-protease	NNP	O
sequences	NNS	O
include	VBP	O
those	DT	O
shown	VBN	O
in	IN	O
SEQ	NNP	O
ID	NNP	O
NOs:78	NNP	O
and	CC	O
79	CD	O
(	(	O
FIGS	NNP	O
.	.	O
69	CD	O
and	CC	O
70	CD	O
)	)	O
.	.	O
These	DT	O
are	VBP	O
:	:	O
GP1	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:78	NNP	O
)	)	O
in	IN	O
which	WDT	O
the	DT	O
protease	NN	O
region	NN	O
was	VBD	O
also	RB	O
codon	JJ	O
optimized	VBN	O
and	CC	O
INS	NNP	O
inactivated	VBD	O
and	CC	O
GP2	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:79	NNP	O
)	)	O
,	,	O
in	IN	O
which	WDT	O
the	DT	O
protease	NN	O
region	NN	O
was	VBD	O
only	RB	O
subjected	VBN	O
to	TO	O
INS	NNP	O
inactivation	NN	O
.	.	O
For	IN	O
other	JJ	O
Gag-containing	JJ	O
sequences	NNS	O
,	,	O
for	IN	O
example	NN	O
the	DT	O
Gag-polymerase	NNP	O
sequence	NN	O
(	(	O
wild	JJ	O
type	NN	O
,	,	O
SEQ	NNP	O
ID	NNP	O
NO:3	NNP	O
;	:	O
modified	VBN	O
,	,	O
SEQ	NNP	O
ID	NNP	O
NO:6	NNP	O
)	)	O
or	CC	O
Gag-reverse	JJ	O
transcriptase	NN	O
(	(	O
wild	JJ	O
type	NN	O
,	,	O
SEQ	NNP	O
ID	NNP	O
NO:77	NNP	O
;	:	O
modified	VBD	O
SEQ	NNP	O
ID	NNP	O
NOs:80-84	NNP	O
)	)	O
,	,	O
the	DT	O
changes	NNS	O
in	IN	O
codon	NN	O
usage	NN	O
are	VBP	O
similar	JJ	O
to	TO	O
those	DT	O
for	IN	O
the	DT	O
Gag-protease	NNP	O
sequence	NN	O
.	.	O
Those	DT	O
expression	NN	O
cassettes	NNS	O
which	WDT	O
contain	VBP	O
a	DT	O
frameshift	NN	O
in	IN	O
the	DT	O
GagPol	NNP	O
coding	NN	O
sequence	NN	O
are	VBP	O
designated	VBN	O
“	JJ	O
FS	NNP	O
(	(	O
+	NNP	O
)	)	O
”	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NOs:80	NNP	O
and	CC	O
81	CD	O
,	,	O
FIGS	NNP	O
.	.	O
71	CD	O
and	CC	O
72	CD	O
)	)	O
while	IN	O
the	DT	O
designation	NN	O
“	NNP	O
FS	NNP	O
(	(	O
−	NNP	O
)	)	O
”	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
Nos	NNP	O
:	:	O
82	CD	O
,	,	O
83	CD	O
and	CC	O
84	CD	O
,	,	O
FIGS	NNP	O
.	.	O
73	CD	O
,	,	O
74	CD	O
and	CC	O
75	CD	O
)	)	O
indicates	VBZ	O
that	IN	O
there	EX	O
is	VBZ	O
no	DT	O
frameshift	NN	O
utilized	VBN	O
in	IN	O
this	DT	O
coding	NN	O
sequence	NN	O
.	.	O
In	IN	O
addition	NN	O
to	TO	O
polyproteins	NNS	O
containing	VBG	O
HIV-related	JJ	O
sequences	NNS	O
,	,	O
the	DT	O
various	JJ	O
Gag-	NNP	O
,	,	O
Gag-prot	NNP	O
,	,	O
Gag-pol	NNP	O
,	,	O
Gag-reverse	NNP	O
transcriptase	NN	O
encoding	VBG	O
sequences	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
can	MD	O
be	VB	O
fused	VBN	O
to	TO	O
other	JJ	O
polypeptides	NNS	O
(	(	O
creating	VBG	O
chimeric	RB	O
polypeptides	NNS	O
)	)	O
for	IN	O
which	WDT	O
an	DT	O
immunogenic	JJ	O
response	NN	O
is	VBZ	O
desired	VBN	O
.	.	O
An	DT	O
example	NN	O
of	IN	O
such	PDT	O
a	DT	O
chimeric	JJ	O
protein	NN	O
is	VBZ	O
the	DT	O
joining	NN	O
of	IN	O
the	DT	O
improved	JJ	O
expression	NN	O
Gag	NNP	O
encoding	VBG	O
sequences	NNS	O
to	TO	O
the	DT	O
Hepatitis	NNP	O
C	NNP	O
Virus	NNP	O
(	(	O
HCV	NNP	O
)	)	O
core	NN	O
protein	NN	O
.	.	O
In	IN	O
this	DT	O
case	NN	O
,	,	O
the	DT	O
HCV-core	NNP	O
encoding	NN	O
sequences	NNS	O
were	VBD	O
placed	VBN	O
in-frame	JJ	O
with	IN	O
the	DT	O
HIV-Gag	NNP	O
encoding	NN	O
sequences	NNS	O
,	,	O
resulting	VBG	O
in	IN	O
the	DT	O
Gag/HCV-core	NNP	O
encoding	NN	O
sequence	NN	O
presented	VBD	O
as	IN	O
SEQ	NNP	O
ID	NNP	O
NO:7	NNP	O
(	(	O
wild	JJ	O
type	NN	O
sequence	NN	O
presented	VBD	O
as	IN	O
SEQ	NNP	O
ID	NNP	O
NO:8	NNP	O
)	)	O
.	.	O
Further	JJ	O
sequences	NNS	O
useful	JJ	O
in	IN	O
the	DT	O
practice	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
include	VBP	O
,	,	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
,	,	O
sequences	NNS	O
encoding	VBG	O
viral	JJ	O
epitopes/antigens	NNS	O
{	(	O
including	VBG	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
,	,	O
HCV	NNP	O
antigens	VBZ	O
(	(	O
e.g.	NN	O
,	,	O
E1	NNP	O
,	,	O
E2	NNP	O
;	:	O
Houghton	NNP	B
,	,	I
M.	NNP	I
,	,	I
et	FW	I
al.	NN	I
,	,	I
U.S.	NNP	I
Pat	NNP	I
.	.	I
No	DT	I
.	.	I
5,714,596	CD	I
,	,	O
issued	VBN	O
Feb.	NNP	O
3	CD	O
,	,	O
1998	CD	O
;	:	O
Houghton	NNP	O
,	,	O
M.	NNP	O
,	,	O
et	FW	O
al.	NN	O
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,712,088	CD	O
,	,	O
issued	VBD	O
Jan.	NNP	O
27	CD	O
,	,	O
1998	CD	O
;	:	O
Houghton	NNP	O
,	,	O
M.	NNP	O
,	,	O
et	FW	O
al.	NN	O
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,683,864	CD	O
,	,	O
issued	VBD	O
Nov.	NNP	O
4	CD	O
,	,	O
1997	CD	O
;	:	O
Weiner	NNP	O
,	,	O
A.	NNP	O
J.	NNP	O
,	,	O
et	FW	O
al.	NN	O
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,728,520	CD	O
,	,	O
issued	VBN	O
Mar	NNP	O
.	.	O
17	CD	O
,	,	O
1998	CD	O
;	:	O
Weiner	NNP	O
,	,	O
A.	NNP	O
J.	NNP	O
,	,	O
et	FW	O
al.	NN	O
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,766,845	CD	O
,	,	O
issued	VBN	O
Jun	NNP	O
.	.	O
16	CD	O
,	,	O
1998	CD	O
;	:	O
Weiner	NNP	O
,	,	O
A.	NNP	O
J.	NNP	O
,	,	O
et	FW	O
al.	NN	O
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,670,152	CD	O
,	,	O
issued	VBN	O
Sep.	NNP	O
23	CD	O
,	,	O
1997	CD	O
;	:	O
all	DT	O
herein	NN	O
incorporated	VBN	O
by	IN	O
reference	NN	O
)	)	O
,	,	O
HIV	NNP	O
antigens	VBZ	O
(	(	O
e.g.	NN	O
,	,	O
derived	VBN	O
from	IN	O
nef	NN	O
,	,	O
tat	NN	O
,	,	O
rev	NN	O
,	,	O
vpu	NN	O
,	,	O
vif	NN	O
,	,	O
vpr	FW	O
and/or	FW	O
env	NN	O
)	)	O
;	:	O
and	CC	O
sequences	NNS	O
encoding	VBG	O
tumor	NN	O
antigens/epitopes	NNS	O
.	.	O
Additional	JJ	O
sequences	NNS	O
are	VBP	O
described	VBN	O
below	IN	O
.	.	O
Also	RB	O
,	,	O
variations	NNS	O
on	IN	O
the	DT	O
orientation	NN	O
of	IN	O
the	DT	O
Gag	NNP	O
and	CC	O
other	JJ	O
coding	NN	O
sequences	NNS	O
,	,	O
relative	JJ	O
to	TO	O
each	DT	O
other	JJ	O
,	,	O
are	VBP	O
also	RB	O
described	VBN	O
below	IN	O
.	.	O
Gag	NNP	O
,	,	O
Gag-protease	NNP	O
,	,	O
Gag-reverse	NNP	O
transcriptase	NN	O
and/or	VBZ	O
Gag-polymerase	NNP	O
polypeptide	NN	O
coding	VBG	O
sequences	NNS	O
can	MD	O
be	VB	O
obtained	VBN	O
from	IN	O
any	DT	O
HIV	NNP	O
isolates	NNS	O
(	(	O
different	JJ	O
families	NNS	O
,	,	O
subtypes	NNS	O
,	,	O
and	CC	O
strains	NNS	O
)	)	O
including	VBG	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
the	DT	O
isolates	NNS	O
HIVIIIb	NNP	O
,	,	O
HIVSF2	NNP	O
,	,	O
HIVSF162	NNP	O
,	,	O
HIVus4	NNP	O
,	,	O
HIVcm235	NNP	O
,	,	O
HIVLAV	NNP	O
,	,	O
HIVMN	NNP	O
)	)	O
(	(	O
see	VB	O
,	,	O
e.g.	VB	O
,	,	O
Myers	NNP	B
et	VBP	I
al	NN	I
.	.	I
Los	NNP	I
Alamos	NNP	I
Database	NNP	I
,	,	I
Los	NNP	I
Alamos	NNP	I
National	NNP	I
Laboratory	NNP	I
,	,	I
Los	NNP	I
Alamos	NNP	I
,	,	I
N.	NNP	I
Mex	NNP	I
.	.	I
(	(	I
1992	CD	I
)	)	I
;	:	O
Myers	NNP	B
et	FW	I
al.	NN	I
,	,	I
Human	NNP	I
Retroviruses	NNP	I
and	CC	I
Aids	NNP	I
,	,	I
1997	CD	I
,	,	I
Los	NNP	I
Alamos	NNP	I
,	,	I
N	NNP	I
.	.	I
Mex	NNP	I
.	.	I
:	:	I
Los	NNP	I
Alamos	NNP	I
National	NNP	I
Laboratory	NNP	I
)	)	O
.	.	O
Synthetic	JJ	O
expression	NN	O
cassettes	NNS	O
can	MD	O
be	VB	O
generated	VBN	O
using	VBG	O
such	JJ	O
coding	JJ	O
sequences	NNS	O
as	IN	O
starting	VBG	O
material	NN	O
by	IN	O
following	VBG	O
the	DT	O
teachings	NNS	O
of	IN	O
the	DT	O
present	JJ	O
specification	NN	O
(	(	O
e.g.	JJ	O
,	,	O
see	VBP	O
Example	JJ	O
1	CD	O
)	)	O
.	.	O
Further	RB	O
,	,	O
the	DT	O
synthetic	JJ	O
expression	NN	O
cassettes	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
include	VBP	O
related	VBN	O
Gag	NNP	O
polypeptide	IN	O
coding	VBG	O
sequences	NNS	O
having	VBG	O
greater	JJR	O
than	IN	O
75	CD	O
%	NN	O
,	,	O
preferably	RB	O
greater	JJR	O
than	IN	O
80-85	CD	O
%	NN	O
,	,	O
more	JJR	O
preferably	RB	O
greater	JJR	O
than	IN	O
90-95	CD	O
%	NN	O
,	,	O
and	CC	O
most	JJS	O
preferably	RB	O
greater	JJR	O
than	IN	O
98	CD	O
%	NN	O
sequence	NN	O
identity	NN	O
(	(	O
or	CC	O
any	DT	O
integer	JJ	O
value	NN	O
within	IN	O
these	DT	O
ranges	NNS	O
)	)	O
to	TO	O
the	DT	O
synthetic	JJ	O
expression	NN	O
cassette	NN	O
sequences	NNS	O
disclosed	VBD	O
herein	NN	O
(	(	O
for	IN	O
example	NN	O
,	,	O
SEQ	NNP	O
ID	NNP	O
NO:4	NNP	O
;	:	O
SEQ	NNP	O
ID	NNP	O
NO:5	NNP	O
;	:	O
SEQ	NNP	O
ID	NNP	O
NO:6	NNP	O
;	:	O
and	CC	O
SEQ	NNP	O
ID	NNP	O
NO:20	NNP	O
,	,	O
the	DT	O
Gag	NNP	O
Major	NNP	O
Homology	NNP	O
Region	NNP	O
)	)	O
.	.	O
2.1.3	CD	O
Expression	NN	O
of	IN	O
Synthetic	JJ	O
Sequences	NNS	O
Encoding	VBG	O
HIV-1	NNP	O
Gag	NNP	O
and	CC	O
Related	NNP	O
Polypeptides	NNP	O
Several	NNP	O
synthetic	JJ	O
Gag-encoding	NNP	O
sequences	NNS	O
(	(	O
expression	NN	O
cassettes	NNS	O
)	)	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
were	VBD	O
cloned	VBN	O
into	IN	O
a	DT	O
number	NN	O
of	IN	O
different	JJ	O
expression	NN	O
vectors	NNS	O
(	(	O
Example	NNP	O
1	CD	O
)	)	O
to	TO	O
evaluate	VB	O
levels	NNS	O
of	IN	O
expression	NN	O
and	CC	O
production	NN	O
of	IN	O
VLPs	NNP	O
.	.	O
Two	CD	O
modified	VBD	O
synthetic	JJ	O
coding	NN	O
sequences	NNS	O
are	VBP	O
presented	VBN	O
as	IN	O
a	DT	O
synthetic	JJ	O
Gag	NNP	O
expression	NN	O
cassette	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:4	NNP	O
)	)	O
and	CC	O
a	DT	O
synthetic	JJ	O
Gag-protease	NNP	O
expression	NN	O
cassette	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NOs:78	NNP	O
and	CC	O
79	CD	O
)	)	O
.	.	O
Other	JJ	O
synthetic	JJ	O
Gag-encoding	JJ	O
proteins	NNS	O
are	VBP	O
presented	VBN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
as	IN	O
SEQ	NNP	O
ID	NNP	O
NOs:80	NNP	O
through	IN	O
84	CD	O
.	.	O
The	DT	O
synthetic	JJ	O
DNA	NN	O
fragments	NNS	O
for	IN	O
Gag-encoding	NNP	O
polypeptides	NNS	O
(	(	O
e.g.	NN	O
,	,	O
Gag	NNP	O
,	,	O
Gag-protease	NNP	O
,	,	O
Gag-polymerase	NNP	O
,	,	O
Gag-reverse	NNP	O
transcriptase	NN	O
)	)	O
were	VBD	O
cloned	VBN	O
into	IN	O
expression	NN	O
vectors	NNS	O
described	VBD	O
in	IN	O
Example	NNP	O
1	CD	O
,	,	O
including	VBG	O
,	,	O
a	DT	O
transient	JJ	O
expression	NN	O
vector	NN	O
,	,	O
CMV-promoter-based	JJ	O
mammalian	JJ	O
vectors	NNS	O
,	,	O
and	CC	O
a	DT	O
shuttle	JJ	O
vector	NN	O
for	IN	O
use	NN	O
in	IN	O
baculovirus	JJ	O
expression	NN	O
systems	NNS	O
.	.	O
Corresponding	VBG	O
wild-type	JJ	O
sequences	NNS	O
were	VBD	O
cloned	VBN	O
into	IN	O
the	DT	O
same	JJ	O
vectors	NNS	O
.	.	O
These	DT	O
vectors	NNS	O
were	VBD	O
then	RB	O
transfected	VBN	O
into	IN	O
a	DT	O
several	JJ	O
different	JJ	O
cell	NN	O
types	NNS	O
,	,	O
including	VBG	O
a	DT	O
variety	NN	O
of	IN	O
mammalian	JJ	O
cell	NN	O
lines	NNS	O
,	,	O
(	(	O
293	CD	O
,	,	O
RD	NNP	O
,	,	O
COS-7	NNP	O
,	,	O
and	CC	O
CHO	NNP	O
,	,	O
cell	NN	O
lines	NNS	O
available	JJ	O
,	,	O
for	IN	O
example	NN	O
,	,	O
from	IN	O
the	DT	O
A.T.C.C	NNP	O
.	.	O
)	)	O
.	.	O
The	DT	O
cell	NN	O
lines	NNS	O
were	VBD	O
cultured	VBN	O
under	IN	O
appropriate	JJ	O
conditions	NNS	O
and	CC	O
the	DT	O
levels	NNS	O
of	IN	O
p24	NN	O
(	(	O
Gag	NNP	O
)	)	O
expression	NN	O
in	IN	O
supernatants	NNS	O
were	VBD	O
evaluated	VBN	O
(	(	O
Example	NNP	O
2	CD	O
)	)	O
.	.	O
The	DT	O
results	NNS	O
of	IN	O
these	DT	O
assays	NNS	O
demonstrated	VBD	O
that	IN	O
expression	NN	O
of	IN	O
synthetic	JJ	O
Gag-encoding	JJ	O
sequences	NNS	O
were	VBD	O
significantly	RB	O
higher	JJR	O
than	IN	O
corresponding	VBG	O
wild-type	JJ	O
sequences	NNS	O
(	(	O
Example	JJ	O
2	CD	O
;	:	O
Table	NNP	O
2	CD	O
)	)	O
.	.	O
Further	RB	O
,	,	O
Western	JJ	O
Blot	NNP	O
analysis	NN	O
showed	VBD	O
that	IN	O
cells	NNS	O
containing	VBG	O
the	DT	O
synthetic	JJ	O
Gag	NNP	O
expression	NN	O
cassette	NN	O
produced	VBD	O
the	DT	O
expected	JJ	O
55	CD	O
kD	NN	O
(	(	O
p55	NN	O
)	)	O
protein	NN	O
at	IN	O
higher	JJR	O
per-cell	NN	O
concentrations	NNS	O
than	IN	O
cells	NNS	O
containing	VBG	O
the	DT	O
native	JJ	O
expression	NN	O
cassette	NN	O
.	.	O
The	DT	O
Gag	NNP	O
p55	NN	O
protein	NN	O
was	VBD	O
seen	VBN	O
in	IN	O
both	DT	O
cell	NN	O
lysates	NNS	O
and	CC	O
supernatants	NNS	O
.	.	O
The	DT	O
levels	NNS	O
of	IN	O
production	NN	O
were	VBD	O
significantly	RB	O
higher	JJR	O
in	IN	O
cell	NN	O
supernatants	NNS	O
for	IN	O
cells	NNS	O
transfected	VBN	O
with	IN	O
the	DT	O
synthetic	JJ	O
Gag	NNP	O
expression	NN	O
cassette	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
.	.	O
Experiments	NNS	O
performed	VBN	O
in	IN	O
support	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
suggest	VBP	O
that	IN	O
cells	NNS	O
containing	VBG	O
the	DT	O
synthetic	JJ	O
Gag-prot	NNP	O
expression	NN	O
cassettes	NNS	O
produced	VBD	O
the	DT	O
expected	VBN	O
Gag-prot	NNP	O
protein	NN	O
at	IN	O
comparably	RB	O
higher	JJR	O
per-cell	NN	O
concentrations	NNS	O
than	IN	O
cells	NNS	O
containing	VBG	O
the	DT	O
wild-type	JJ	O
expression	NN	O
cassette	NN	O
.	.	O
Fractionation	NN	O
of	IN	O
the	DT	O
supernatants	NNS	O
from	IN	O
mammalian	JJ	O
cells	NNS	O
transfected	VBN	O
with	IN	O
the	DT	O
synthetic	JJ	O
Gag	NNP	O
expression	NN	O
cassette	NN	O
showed	VBD	O
that	IN	O
it	PRP	O
provides	VBZ	O
superior	JJ	O
production	NN	O
of	IN	O
both	DT	O
p55	JJ	O
protein	NN	O
and	CC	O
VLPs	NNP	O
,	,	O
relative	JJ	O
to	TO	O
the	DT	O
wild-type	JJ	O
Gag	NNP	O
sequences	NNS	O
(	(	O
Examples	NNP	O
6	CD	O
and	CC	O
7	CD	O
)	)	O
.	.	O
Efficient	JJ	O
expression	NN	O
of	IN	O
these	DT	O
Gag-containing	NNP	O
polypeptides	NNS	O
in	IN	O
mammalian	JJ	O
cell	NN	O
lines	NNS	O
provides	VBZ	O
the	DT	O
following	JJ	O
benefits	NNS	O
:	:	O
the	DT	O
Gag	NNP	O
polypeptides	NNS	O
are	VBP	O
free	JJ	O
of	IN	O
baculovirus	NN	O
contaminants	NNS	O
;	:	O
production	NN	O
by	IN	O
established	VBN	O
methods	NNS	O
approved	VBN	O
by	IN	O
the	DT	O
FDA	NNP	O
;	:	O
increased	VBD	O
purity	NN	O
;	:	O
greater	JJR	O
yields	NNS	O
(	(	O
relative	JJ	O
to	TO	O
native	JJ	O
coding	NN	O
sequences	NNS	O
)	)	O
;	:	O
and	CC	O
a	DT	O
novel	JJ	O
method	NN	O
of	IN	O
producing	VBG	O
the	DT	O
Gag-containing	NNP	O
polypeptides	NNS	O
in	IN	O
CHO	NNP	O
or	CC	O
other	JJ	O
mammalian	JJ	O
cells	NNS	O
which	WDT	O
is	VBZ	O
not	RB	O
feasible	JJ	O
in	IN	O
the	DT	O
absence	NN	O
of	IN	O
the	DT	O
increased	VBN	O
expression	NN	O
obtained	VBN	O
using	VBG	O
the	DT	O
constructs	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
.	.	O
Exemplary	JJ	O
Mammalian	NNP	O
cell	NN	O
lines	NNS	O
include	VBP	O
,	,	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
,	,	O
BHK	NNP	O
,	,	O
VERO	NNP	O
,	,	O
HT1080	NNP	O
,	,	O
293	CD	O
,	,	O
293T	CD	O
,	,	O
RD	NNP	O
,	,	O
COS-7	NNP	O
,	,	O
CHO	NNP	O
,	,	O
Jurkat	NNP	O
,	,	O
HUT	NNP	O
,	,	O
SUPT	NNP	O
,	,	O
C8166	NNP	O
,	,	O
MOLT4/clone8	NNP	O
,	,	O
MT-2	NNP	O
,	,	O
MT-4	NNP	O
,	,	O
H9	NNP	O
,	,	O
PM1	NNP	O
,	,	O
CEM	NNP	O
,	,	O
myeloma	NN	O
cells	NNS	O
(	(	O
e.g.	NN	O
,	,	O
SB20	NNP	O
cells	NNS	O
)	)	O
and	CC	O
CEMX174	NNP	O
,	,	O
such	JJ	O
cell	NN	O
lines	NNS	O
are	VBP	O
available	JJ	O
,	,	O
for	IN	O
example	NN	O
,	,	O
from	IN	O
the	DT	O
A.T.C.C	NNP	O
.	.	O
)	)	O
.	.	O
A	DT	O
synthetic	JJ	O
Gag	NNP	O
expression	NN	O
cassette	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
also	RB	O
demonstrated	VBD	O
high	JJ	O
levels	NNS	O
of	IN	O
expression	NN	O
and	CC	O
VLP	NNP	O
production	NN	O
when	WRB	O
transfected	VBN	O
into	IN	O
insect	JJ	O
cells	NNS	O
(	(	O
Example	NNP	O
7	CD	O
)	)	O
.	.	O
Further	RB	O
,	,	O
in	IN	O
addition	NN	O
to	TO	O
a	DT	O
higher	JJR	O
total	JJ	O
protein	JJ	O
yield	NN	O
,	,	O
the	DT	O
final	JJ	O
product	NN	O
from	IN	O
the	DT	O
synthetic	JJ	O
p55-expressed	JJ	O
Gag	NNP	O
consistently	RB	O
contained	VBD	O
lower	JJR	O
amounts	NNS	O
of	IN	O
contaminating	VBG	O
baculovirus	NN	O
proteins	NNS	O
than	IN	O
the	DT	O
final	JJ	O
purified	JJ	O
product	NN	O
from	IN	O
the	DT	O
native	JJ	O
p55-expressed	JJ	O
Gag	NNP	O
.	.	O
Further	RB	O
,	,	O
synthetic	JJ	O
Gag	NNP	O
expression	NN	O
cassettes	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
have	VBP	O
also	RB	O
been	VBN	O
introduced	VBN	O
into	IN	O
yeast	NN	O
vectors	NNS	O
which	WDT	O
were	VBD	O
transformed	VBN	O
into	IN	O
and	CC	O
efficiently	RB	O
expressed	VBN	O
by	IN	O
yeast	NN	O
cells	NNS	O
(	(	O
Saccharomyces	NNPS	O
cerevisea	NN	O
;	:	O
using	VBG	O
vectors	NNS	O
as	IN	O
described	VBN	O
in	IN	O
Rosenberg	NNP	B
,	,	I
S.	NNP	I
and	CC	I
Tekamp-Olson	NNP	I
,	,	I
P.	NNP	I
,	,	I
U.S.	NNP	I
Pat	NNP	I
.	.	I
No	DT	I
.	.	I
RE35,749	NNP	I
,	,	I
issued	VBN	I
,	,	I
Mar	NNP	I
.	.	I
17	CD	I
,	,	I
1998	CD	I
,	,	O
herein	RB	O
incorporated	VBN	O
by	IN	O
reference	NN	O
)	)	O
.	.	O
In	IN	O
addition	NN	O
to	TO	O
the	DT	O
mammalian	JJ	O
and	CC	O
insect	JJ	O
vectors	NNS	O
described	VBN	O
in	IN	O
the	DT	O
Examples	NNP	O
,	,	O
the	DT	O
synthetic	JJ	O
expression	NN	O
cassettes	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
can	MD	O
be	VB	O
incorporated	VBN	O
into	IN	O
a	DT	O
variety	NN	O
of	IN	O
expression	NN	O
vectors	NNS	O
using	VBG	O
selected	VBN	O
expression	NN	O
control	NN	O
elements	NNS	O
.	.	O
Appropriate	JJ	O
vectors	NNS	O
and	CC	O
control	NN	O
elements	NNS	O
for	IN	O
any	DT	O
given	VBN	O
cell	NN	O
type	NN	O
can	MD	O
be	VB	O
selected	VBN	O
by	IN	O
one	CD	O
having	VBG	O
ordinary	JJ	O
skill	NN	O
in	IN	O
the	DT	O
art	NN	O
in	IN	O
view	NN	O
of	IN	O
the	DT	O
teachings	NNS	O
of	IN	O
the	DT	O
present	JJ	O
specification	NN	O
and	CC	O
information	NN	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
about	IN	O
expression	NN	O
vectors	NNS	O
.	.	O
For	IN	O
example	NN	O
,	,	O
a	DT	O
synthetic	JJ	O
Gag	NNP	O
expression	NN	O
cassette	NN	O
can	MD	O
be	VB	O
inserted	VBN	O
into	IN	O
a	DT	O
vector	NN	O
which	WDT	O
includes	VBZ	O
control	NN	O
elements	NNS	O
operably	RB	O
linked	VBN	O
to	TO	O
the	DT	O
desired	VBN	O
coding	NN	O
sequence	NN	O
,	,	O
which	WDT	O
allow	VBP	O
for	IN	O
the	DT	O
expression	NN	O
of	IN	O
the	DT	O
gene	NN	O
in	IN	O
a	DT	O
selected	VBN	O
cell-type	NN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
typical	JJ	O
promoters	NNS	O
for	IN	O
mammalian	JJ	O
cell	NN	O
expression	NN	O
include	VBP	O
the	DT	O
SV40	NNP	O
early	JJ	O
promoter	NN	O
,	,	O
a	DT	O
CMV	NNP	O
promoter	NN	O
such	JJ	O
as	IN	O
the	DT	O
CMV	NNP	O
immediate	VBP	O
early	JJ	O
promoter	NN	O
(	(	O
a	DT	O
CMV	NNP	O
promoter	NN	O
can	MD	O
include	VB	O
intron	VB	O
A	NNP	O
)	)	O
,	,	O
RSV	NNP	O
,	,	O
HIV-LTR	NNP	O
,	,	O
the	DT	O
mouse	NN	O
mammary	JJ	O
tumor	NN	O
virus	NN	O
LTR	NNP	O
promoter	NN	O
(	(	O
MMLV-LTR	NNP	O
)	)	O
,	,	O
FIV-LTR	NNP	O
,	,	O
the	DT	O
adenovirus	NN	O
major	JJ	O
late	JJ	O
promoter	NN	O
(	(	O
Ad	NNP	O
MLP	NNP	O
)	)	O
,	,	O
and	CC	O
the	DT	O
herpes	NNS	O
simplex	JJ	O
virus	NN	O
promoter	NN	O
,	,	O
among	IN	O
others	NNS	O
.	.	O
Other	JJ	O
nonviral	JJ	O
promoters	NNS	O
,	,	O
such	JJ	O
as	IN	O
a	DT	O
promoter	NN	O
derived	VBN	O
from	IN	O
the	DT	O
murine	NN	O
metallothionein	NN	O
gene	NN	O
,	,	O
will	MD	O
also	RB	O
find	VB	O
use	NN	O
for	IN	O
mammalian	JJ	O
expression	NN	O
.	.	O
Typically	RB	O
,	,	O
transcription	NN	O
termination	NN	O
and	CC	O
polyadenylation	NN	O
sequences	NNS	O
will	MD	O
also	RB	O
be	VB	O
present	JJ	O
,	,	O
located	VBN	O
3′	CD	O
to	TO	O
the	DT	O
translation	NN	O
stop	NN	O
codon	NN	O
.	.	O
Preferably	RB	O
,	,	O
a	DT	O
sequence	NN	O
for	IN	O
optimization	NN	O
of	IN	O
initiation	NN	O
of	IN	O
translation	NN	O
,	,	O
located	VBN	O
5′	CD	O
to	TO	O
the	DT	O
coding	VBG	O
sequence	NN	O
,	,	O
is	VBZ	O
also	RB	O
present	JJ	O
.	.	O
Examples	NNS	O
of	IN	O
transcription	NN	O
terminator/polyadenylation	NN	O
signals	NNS	O
include	VBP	O
those	DT	O
derived	VBN	O
from	IN	O
SV40	NNP	O
,	,	O
as	IN	O
described	VBN	O
in	IN	O
Sambrook	NNP	O
,	,	O
et	FW	O
al.	NN	O
,	,	O
supra	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
a	DT	O
bovine	NN	O
growth	NN	O
hormone	NN	O
terminator	NN	O
sequence	NN	O
.	.	O
Introns	NNS	O
,	,	O
containing	VBG	O
splice	NN	O
donor	NN	O
and	CC	O
acceptor	NN	O
sites	NNS	O
,	,	O
may	MD	O
also	RB	O
be	VB	O
designed	VBN	O
into	IN	O
the	DT	O
constructs	NNS	O
for	IN	O
use	NN	O
with	IN	O
the	DT	O
present	JJ	O
invention	NN	O
(	(	O
Chapman	NNP	B
et	VBZ	I
al.	NN	I
,	,	I
Nuc	NNP	I
.	.	I
Acids	NNP	I
Res	NNP	I
.	.	I
(	(	I
1991	CD	I
)	)	I
19:3979-3986	CD	I
)	)	O
.	.	O
Enhancer	NNP	O
elements	NNS	O
may	MD	O
also	RB	O
be	VB	O
used	VBN	O
herein	NN	O
to	TO	O
increase	VB	O
expression	NN	O
levels	NNS	O
of	IN	O
the	DT	O
mammalian	JJ	O
constructs	NNS	O
.	.	O
Examples	NNS	O
include	VBP	O
the	DT	O
SV40	NNP	O
early	JJ	O
gene	NN	O
enhancer	NN	O
,	,	O
as	IN	O
described	VBN	O
in	IN	O
Dijkema	NNP	B
et	CC	I
al.	NN	I
,	,	I
EMBO	NNP	I
J	NNP	I
.	.	I
(	(	I
1985	CD	I
)	)	I
4:761	CD	I
,	,	O
the	DT	O
enhancer/promoter	NN	O
derived	VBN	O
from	IN	O
the	DT	O
long	JJ	O
terminal	JJ	O
repeat	NN	O
(	(	O
LTR	NNP	O
)	)	O
of	IN	O
the	DT	O
Rous	NNP	O
Sarcoma	NNP	O
Virus	NNP	O
,	,	O
as	IN	O
described	VBN	O
in	IN	O
Gorman	NNP	B
et	CC	I
al.	NN	I
,	,	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
USA	NNP	I
(	(	I
1982b	CD	I
)	)	I
79:6777	CD	I
and	CC	O
elements	NNS	O
derived	VBN	O
from	IN	O
human	JJ	O
CMV	NNP	O
,	,	O
as	IN	O
described	VBN	O
in	IN	O
Boshart	NNP	B
et	FW	I
al.	NN	I
,	,	I
Cell	NNP	I
(	(	I
1985	CD	I
)	)	I
41:521	CD	I
,	,	O
such	JJ	O
as	IN	O
elements	NNS	O
included	VBN	O
in	IN	O
the	DT	O
CMV	NNP	O
intron	NN	O
A	NNP	O
sequence	NN	O
(	(	O
Chapman	NNP	B
at	IN	I
al.	NN	I
,	,	I
Nuc	NNP	I
.	.	I
Acids	NNP	I
Res	NNP	I
.	.	I
(	(	I
1991	CD	I
)	)	I
19:3979-3986	CD	I
)	)	O
.	.	O
The	DT	O
desired	VBN	O
synthetic	JJ	O
Gag	NNP	O
polypeptide	NN	O
encoding	VBG	O
sequences	NNS	O
can	MD	O
be	VB	O
cloned	VBN	O
into	IN	O
any	DT	O
number	NN	O
of	IN	O
commercially	RB	O
available	JJ	O
vectors	NNS	O
to	TO	O
generate	VB	O
expression	NN	O
of	IN	O
the	DT	O
polypeptide	NN	O
in	IN	O
an	DT	O
appropriate	JJ	O
host	NN	O
system	NN	O
.	.	O
These	DT	O
systems	NNS	O
include	VBP	O
,	,	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
,	,	O
the	DT	O
following	NN	O
:	:	O
baculovirus	JJ	O
expression	NN	O
{	(	O
Reilly	RB	B
,	,	I
P.	NNP	I
R.	NNP	I
,	,	I
et	FW	I
al.	NN	I
,	,	I
BACULOVIRUS	NNP	I
EXPRESSION	NNP	I
VECTORS	NNP	I
:	:	I
A	DT	I
LABORATORY	NNP	I
MANUAL	NNP	I
(	(	I
1992	CD	I
)	)	I
;	:	O
Beames	NNP	B
,	,	I
et	FW	I
al.	NN	I
,	,	I
Biotechniques	NNP	I
11:378	CD	I
(	(	I
1991	CD	I
)	)	I
;	:	O
Pharmingen	NNP	B
;	:	O
Clontech	NNP	B
,	,	I
Palo	NNP	I
Alto	NNP	I
,	,	I
Calif.	NNP	I
)	)	O
}	)	O
,	,	O
vaccinia	JJ	O
expression	NN	O
{	(	O
Earl	NNP	B
,	,	I
P.	NNP	I
L.	NNP	I
,	,	I
et	FW	I
al.	NN	I
,	,	I
“	JJ	I
Expression	NNP	I
of	IN	I
proteins	NNS	I
in	IN	I
mammalian	JJ	I
cells	NNS	I
using	VBG	I
vaccinia	NN	I
”	NN	I
In	IN	I
Current	NNP	I
Protocols	NNP	I
in	IN	I
Molecular	NNP	I
Biology	NNP	I
(	(	I
F.	NNP	I
M.	NNP	I
Ausubel	NNP	I
,	,	I
et	RB	I
al	NN	I
.	.	I
Eds	NNP	I
.	.	I
)	)	I
,	,	I
Greene	NNP	I
Publishing	NNP	I
Associates	NNPS	I
&	CC	I
Wiley	NNP	I
Interscience	NNP	I
,	,	I
New	NNP	I
York	NNP	I
(	(	I
1991	CD	I
)	)	I
;	:	O
Moss	NNP	O
,	,	O
B.	NNP	O
,	,	O
et	FW	O
al.	NN	O
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,135,855	CD	O
,	,	O
issued	VBD	O
4	CD	O
Aug.	NNP	O
1992	CD	O
}	)	O
,	,	O
expression	NN	O
in	IN	O
bacteria	NNS	O
{	(	O
Ausubel	NNP	B
,	,	I
F.	NNP	I
M.	NNP	I
,	,	I
et	FW	I
al.	RB	I
,	,	I
CURRENT	NNP	I
PROTOCOLS	NNP	I
IN	NNP	I
MOLECULAR	NNP	I
BIOLOGY	NNP	I
,	,	I
John	NNP	I
Wiley	NNP	I
and	CC	I
Sons	NNP	I
,	,	I
Inc.	NNP	I
,	,	I
Media	NNP	I
PA	NNP	I
;	:	O
Clontech	NNP	B
}	)	O
,	,	O
expression	NN	O
in	IN	O
yeast	NN	O
{	(	O
Rosenberg	NNP	B
,	,	I
S.	NNP	I
and	CC	I
Tekamp-Olson	NNP	I
,	,	I
P.	NNP	I
,	,	I
U.S.	NNP	I
Pat	NNP	I
.	.	I
No	DT	I
.	.	I
RE35,749	NNP	I
,	,	I
issued	VBN	I
,	,	I
Mar	NNP	I
.	.	I
17	CD	I
,	,	I
1998	CD	I
,	,	O
herein	RB	O
incorporated	VBN	O
by	IN	O
reference	NN	O
;	:	O
Shuster	NNP	O
,	,	O
J.	NNP	O
R.	NNP	O
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,629,203	CD	O
,	,	O
issued	VBN	O
May	NNP	O
13	CD	O
,	,	O
1997	CD	O
,	,	O
herein	RB	O
incorporated	VBN	O
by	IN	O
reference	NN	O
;	:	O
Gellissen	NNP	B
,	,	I
G.	NNP	I
,	,	I
et	FW	I
al.	NN	I
,	,	I
Antonie	NNP	I
Van	NNP	I
Leeuwenhoek	NNP	I
,	,	I
62	CD	I
(	(	I
1-2	JJ	I
)	)	I
:79-93	NN	I
(	(	I
1992	CD	I
)	)	I
;	:	O
Romanos	NNP	B
,	,	I
M.	NNP	I
A.	NN	I
,	,	I
at	IN	I
al.	NN	I
,	,	I
Yeast	NNP	I
8	CD	I
(	(	I
6	CD	I
)	)	I
:423-488	NN	I
(	(	I
1992	CD	I
)	)	I
;	:	O
Goeddel	NNP	B
,	,	I
D.	NNP	I
V.	NNP	I
,	,	I
Methods	NNP	I
in	IN	I
Enzymology	NNP	I
185	CD	I
(	(	I
1990	CD	I
)	)	I
;	:	O
Guthrie	NNP	B
,	,	I
C.	NNP	I
,	,	I
and	CC	I
G.	NNP	I
R.	NNP	I
Fink	NNP	I
,	,	I
Methods	NNP	I
in	IN	I
Enzymology	NNP	I
194	CD	I
(	(	I
1991	CD	I
)	)	I
}	)	O
,	,	O
expression	NN	O
in	IN	O
mammalian	JJ	O
cells	NNS	O
{	(	O
Clontech	NNP	B
;	:	O
Gibco-BRL	NNP	B
,	,	I
Ground	NNP	I
Island	NNP	I
,	,	I
N.	NNP	I
Y.	NNP	I
;	:	O
e.g.	NN	O
,	,	O
Chinese	JJ	O
hamster	NN	O
ovary	JJ	O
(	(	O
CHO	NNP	O
)	)	O
cell	NN	O
lines	NNS	O
(	(	O
Haynes	NNPS	B
,	,	I
J.	NNP	I
,	,	I
et	FW	I
al.	NN	I
,	,	I
Nuc	NNP	I
.	.	I
Acid	NNP	I
.	.	I
Res	NNP	I
.	.	I
11:687-706	CD	I
(	(	I
1983	CD	I
)	)	I
;	:	O
1983	CD	B
,	,	I
Lau	NNP	I
,	,	I
Y.	NNP	I
F.	NNP	I
,	,	I
et	NN	I
al.	NN	I
,	,	I
Mol	NNP	I
.	.	I
Cell	NNP	I
.	.	I
Biol	NNP	I
.	.	I
4:1469-1475	CD	I
(	(	I
1984	CD	I
)	)	I
;	:	O
Kaufman	NNP	B
,	,	I
R.	NNP	I
J.	NNP	I
,	,	I
“	NNP	I
Selection	NNP	I
and	CC	I
coamplification	NN	I
of	IN	I
heterologous	JJ	I
genes	NNS	I
in	IN	I
mammalian	JJ	I
cells	NNS	I
,	,	I
”	NN	I
in	IN	I
Methods	NNP	I
in	IN	I
Enzymology	NNP	I
,	,	I
vol	NN	I
.	.	I
185	CD	I
,	,	I
pp	JJ	I
537-566	JJ	I
.	.	I
Academic	NNP	I
Press	NNP	I
,	,	I
Inc.	NNP	I
,	,	I
San	NNP	I
Diego	NNP	I
Calif.	NNP	I
(	(	I
1991	CD	I
)	)	I
}	)	O
,	,	O
and	CC	O
expression	NN	O
in	IN	O
plant	NN	O
cells	NNS	O
{	(	O
plant	NN	B
cloning	VBG	I
vectors	NNS	I
,	,	I
Clontech	NNP	I
Laboratories	NNP	I
,	,	I
Inc.	NNP	I
,	,	I
Palo	NNP	I
Alto	NNP	I
,	,	I
Calif.	NNP	I
,	,	I
and	CC	I
Pharmacia	NNP	I
LKB	NNP	I
Biotechnology	NNP	I
,	,	I
Inc.	NNP	I
,	,	I
Pistcataway	NNP	I
,	,	I
N.J.	NNP	I
;	:	O
Hood	NNP	B
,	,	I
E.	NNP	I
,	,	I
et	FW	I
al.	NN	I
,	,	I
J.	NNP	I
Bacteriol	NNP	I
.	.	I
168:1291-1301	CD	I
(	(	I
1986	CD	I
)	)	I
;	:	O
Nagel	NNP	B
,	,	I
R.	NNP	I
,	,	I
et	FW	I
al.	NN	I
,	,	I
FEMS	NNP	I
Microbiol	NNP	I
.	.	I
Lett	NNP	I
.	.	I
67:325	CD	I
(	(	I
1990	CD	I
)	)	I
;	:	O
An	DT	B
,	,	I
et	NN	I
al.	NN	I
,	,	I
“	NNP	I
Binary	NNP	I
Vectors	NNP	I
”	NNP	I
,	,	I
and	CC	I
others	NNS	I
in	IN	I
Plant	NNP	I
Molecular	NNP	I
Biology	NNP	I
Manual	NNP	I
A3:1-19	NNP	I
(	(	I
1988	CD	I
)	)	I
;	:	O
Miki	NNP	B
,	,	I
B.	NNP	I
L.	NNP	I
A.	NN	I
,	,	I
et	FW	I
al.	NN	I
,	,	I
pp	NN	I
.	.	I
249-265	JJ	I
,	,	O
and	CC	O
others	NNS	O
in	IN	O
Plant	NNP	B
DNA	NNP	I
Infectious	NNP	I
Agents	NNP	I
(	(	I
Hohn	NNP	I
,	,	I
T.	NNP	I
,	,	I
et	FW	I
al.	NN	I
,	,	I
eds	NNS	I
.	.	I
)	)	I
Springer-Verlag	NNP	I
,	,	I
Wien	NNP	I
,	,	I
Austria	NNP	I
,	,	I
(	(	I
1987	CD	I
)	)	I
;	:	O
Plant	NNP	B
Molecular	NNP	I
Biology	NNP	I
:	:	I
Essential	JJ	I
Techniques	NNP	I
,	,	I
P.	NNP	I
G.	NNP	I
Jones	NNP	I
and	CC	I
J.	NNP	I
M.	NNP	I
Sutton	NNP	I
,	,	I
New	NNP	I
York	NNP	I
,	,	I
J.	NNP	I
Wiley	NNP	I
,	,	I
1997	CD	I
;	:	O
Miglani	NNP	B
,	,	I
Gurbachan	NNP	I
Dictionary	NNP	I
of	IN	I
Plant	NNP	I
Genetics	NNP	I
and	CC	I
Molecular	NNP	I
Biology	NNP	I
,	,	I
New	NNP	I
York	NNP	I
,	,	I
Food	NNP	I
Products	NNP	I
Press	NNP	I
,	,	I
1998	CD	I
;	:	O
Henry	NNP	B
,	,	I
R.	NNP	I
J.	NNP	I
,	,	I
Practical	NNP	I
Applications	NNP	I
of	IN	I
Plant	NNP	I
Molecular	NNP	I
Biology	NNP	I
,	,	I
New	NNP	I
York	NNP	I
,	,	I
Chapman	NNP	I
&	CC	I
Hall	NNP	I
,	,	I
1997	CD	I
}	)	O
.	.	O
Also	RB	O
included	VBN	O
in	IN	O
the	DT	O
invention	NN	O
is	VBZ	O
an	DT	O
expression	NN	O
vector	NN	O
,	,	O
such	JJ	O
as	IN	O
the	DT	O
CMV	NNP	O
promoter-containing	JJ	O
vectors	NNS	O
described	VBN	O
in	IN	O
Example	NNP	O
1	CD	O
,	,	O
containing	VBG	O
coding	VBG	O
sequences	NNS	O
and	CC	O
expression	NN	O
control	NN	O
elements	VBZ	O
which	WDT	O
allow	JJ	O
expression	NN	O
of	IN	O
the	DT	O
coding	NN	O
regions	NNS	O
in	IN	O
a	DT	O
suitable	JJ	O
host	NN	O
.	.	O
The	DT	O
control	NN	O
elements	VBZ	O
generally	RB	O
include	VBP	O
a	DT	O
promoter	NN	O
,	,	O
translation	NN	O
initiation	NN	O
codon	NN	O
,	,	O
and	CC	O
translation	NN	O
and	CC	O
transcription	NN	O
termination	NN	O
sequences	NNS	O
,	,	O
and	CC	O
an	DT	O
insertion	NN	O
site	NN	O
for	IN	O
introducing	VBG	O
the	DT	O
insert	NN	O
into	IN	O
the	DT	O
vector	NN	O
.	.	O
Translational	NNP	O
control	NN	O
elements	NNS	O
have	VBP	O
been	VBN	O
reviewed	VBN	O
by	IN	O
M.	NNP	O
Kozak	NNP	O
(	(	O
e.g.	NN	O
,	,	O
Kozak	NNP	B
,	,	I
M.	NNP	I
,	,	I
Mamm	NNP	I
.	.	I
Genome	NNP	I
7	CD	I
(	(	I
8	CD	I
)	)	I
:563-574	NN	I
,	,	I
1996	CD	I
;	:	O
Kozak	NNP	B
,	,	I
M.	NNP	I
,	,	I
Biochimie	NNP	I
76	CD	I
(	(	I
9	CD	I
)	)	I
:815-821	NN	I
,	,	I
1994	CD	I
;	:	O
Kozak	NNP	B
,	,	I
M.	NNP	I
,	,	I
J	NNP	I
Cell	NNP	I
Biol	NNP	I
108	CD	I
(	(	I
2	CD	I
)	)	I
:229-241	NN	I
,	,	I
1989	CD	I
;	:	O
Kozak	NNP	B
,	,	I
M.	NNP	I
,	,	I
and	CC	I
Shatkin	NNP	I
,	,	I
A.	NNP	I
J.	NNP	I
,	,	I
Methods	NNP	I
Enzymol	NNP	I
60:360-375	CD	I
,	,	I
1979	CD	I
)	)	O
.	.	O
Expression	NN	O
in	IN	O
yeast	NN	O
systems	NNS	O
has	VBZ	O
the	DT	O
advantage	NN	O
of	IN	O
commercial	JJ	O
production	NN	O
.	.	O
Recombinant	JJ	O
protein	NN	O
production	NN	O
by	IN	O
vaccinia	NN	O
and	CC	O
CHO	NNP	O
cell	VBP	O
line	NN	O
have	VBP	O
the	DT	O
advantage	NN	O
of	IN	O
being	VBG	O
mammalian	JJ	O
expression	NN	O
systems	NNS	O
.	.	O
Further	RB	O
,	,	O
vaccinia	FW	O
virus	NN	O
expression	NN	O
has	VBZ	O
several	JJ	O
advantages	NNS	O
including	VBG	O
the	DT	O
following	NN	O
:	:	O
(	(	O
i	NN	O
)	)	O
its	PRP$	O
wide	JJ	O
host	NN	O
range	NN	O
;	:	O
(	(	O
ii	NN	O
)	)	O
faithful	JJ	O
post-transcriptional	JJ	O
modification	NN	O
,	,	O
processing	NN	O
,	,	O
folding	NN	O
,	,	O
transport	NN	O
,	,	O
secretion	NN	O
,	,	O
and	CC	O
assembly	RB	O
of	IN	O
recombinant	JJ	O
proteins	NNS	O
;	:	O
(	(	O
iii	NN	O
)	)	O
high	JJ	O
level	NN	O
expression	NN	O
of	IN	O
relatively	RB	O
soluble	JJ	O
recombinant	JJ	O
proteins	NNS	O
;	:	O
and	CC	O
(	(	O
iv	NN	O
)	)	O
a	DT	O
large	JJ	O
capacity	NN	O
to	TO	O
accommodate	VB	O
foreign	JJ	O
DNA	NNP	O
.	.	O
The	DT	O
recombinantly	RB	O
expressed	VBN	O
polypeptides	NNS	O
from	IN	O
synthetic	JJ	O
Gag-encoding	NNP	O
expression	NN	O
cassettes	NNS	O
are	VBP	O
typically	RB	O
isolated	VBN	O
from	IN	O
lysed	JJ	O
cells	NNS	O
or	CC	O
culture	NN	O
media	NNS	O
.	.	O
Purification	NN	O
can	MD	O
be	VB	O
carried	VBN	O
out	RP	O
by	IN	O
methods	NNS	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
including	VBG	O
salt	NN	O
fractionation	NN	O
,	,	O
ion	NN	O
exchange	NN	O
chromatography	NN	O
,	,	O
gel	JJ	O
filtration	NN	O
,	,	O
size-exclusion	NN	O
chromatography	NN	O
,	,	O
size-fractionation	NN	O
,	,	O
and	CC	O
affinity	NN	O
chromatography	NN	O
.	.	O
Immunoaffinity	NNP	O
chromatography	NN	O
can	MD	O
be	VB	O
employed	VBN	O
using	VBG	O
antibodies	NNS	O
generated	VBD	O
based	VBN	O
on	IN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
Gag	NNP	O
antigens	VBZ	O
.	.	O
Advantages	NNS	O
of	IN	O
expressing	VBG	O
the	DT	O
Gag-containing	JJ	O
proteins	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
using	VBG	O
mammalian	JJ	O
cells	NNS	O
include	VBP	O
,	,	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
,	,	O
the	DT	O
following	JJ	O
:	:	O
well-established	JJ	O
protocols	NNS	O
for	IN	O
scale-up	JJ	O
production	NN	O
;	:	O
the	DT	O
ability	NN	O
to	TO	O
produce	VB	O
VLPs	NNP	O
;	:	O
cell	NN	O
lines	NNS	O
are	VBP	O
suitable	JJ	O
to	TO	O
meet	VB	O
good	JJ	O
manufacturing	NN	O
process	NN	O
(	(	O
GMP	NNP	O
)	)	O
standards	NNS	O
;	:	O
culture	NN	O
conditions	NNS	O
for	IN	O
mammalian	JJ	O
cells	NNS	O
are	VBP	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
2.1.4	CD	O
Modification	NN	O
of	IN	O
HIV-1	NNP	O
Env	NNP	O
Nucleic	NNP	O
Acid	NNP	O
Coding	NNP	O
Sequences	NNP	O
One	NNP	O
aspect	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
is	VBZ	O
the	DT	O
generation	NN	O
of	IN	O
HIV-1	NNP	O
Env	NNP	O
protein	NN	O
coding	VBG	O
sequences	NNS	O
,	,	O
and	CC	O
related	JJ	O
sequences	NNS	O
,	,	O
having	VBG	O
improved	VBN	O
expression	NN	O
relative	NN	O
to	TO	O
the	DT	O
corresponding	JJ	O
wild-type	JJ	O
sequence	NN	O
.	.	O
Exemplary	JJ	O
embodiments	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
are	VBP	O
illustrated	VBN	O
herein	JJ	O
modifying	VBG	O
the	DT	O
Env	NNP	O
protein	NN	O
wild-type	JJ	O
sequences	NNS	O
obtained	VBN	O
from	IN	O
the	DT	O
HIV-1	NNP	O
subtype	NN	O
B	NNP	O
strains	VBZ	O
HIV-1US4	NNP	O
and	CC	O
HIV-1SF162	NNP	O
(	(	O
Myers	NNP	B
et	VBP	I
al.	NN	I
,	,	I
Los	NNP	I
Alamos	NNP	I
Database	NNP	I
,	,	I
Los	NNP	I
Alamos	NNP	I
National	NNP	I
Laboratory	NNP	I
,	,	I
Los	NNP	I
Alamos	NNP	I
,	,	I
N.	NNP	I
Mex	NNP	I
.	.	I
(	(	I
1992	CD	I
)	)	I
;	:	O
Myers	NNP	B
et	FW	I
al.	NN	I
,	,	I
Human	NNP	I
Retroviruses	NNP	I
and	CC	I
Aids	NNP	I
,	,	I
1997	CD	I
,	,	I
Los	NNP	I
Alamos	NNP	I
,	,	I
N	NNP	I
.	.	I
Mex	NNP	I
.	.	I
:	:	I
Los	NNP	I
Alamos	NNP	I
National	NNP	I
Laboratory	NNP	I
)	)	O
.	.	O
Env	NNP	O
sequence	NN	O
obtained	VBN	O
from	IN	O
other	JJ	O
HIV	NNP	O
variants	NNS	O
may	MD	O
be	VB	O
manipulated	VBN	O
in	IN	O
similar	JJ	O
fashion	NN	O
following	VBG	O
the	DT	O
teachings	NNS	O
of	IN	O
the	DT	O
present	JJ	O
specification	NN	O
.	.	O
Such	JJ	O
other	JJ	O
variants	NNS	O
include	VBP	O
those	DT	O
described	VBN	O
above	IN	O
in	IN	O
Section	NN	O
2.1.1	CD	O
and	CC	O
on	IN	O
the	DT	O
World	NNP	O
Wide	NNP	O
Web	NNP	O
(	(	O
Internet	NNP	O
)	)	O
,	,	O
for	IN	O
example	NN	O
at	IN	O
http	NN	O
:	:	O
//hiv-web.lan1.gov/cgi-bin/hivDB3/public/wdb/ssampublic	JJ	O
and	CC	O
http	JJ	O
:	:	O
//hiv-web.lan1.gov	NN	O
.	.	O
First	RB	O
,	,	O
the	DT	O
HIV-1	NNP	O
codon	NN	O
usage	NN	O
pattern	NN	O
was	VBD	O
modified	VBN	O
so	RB	O
that	IN	O
the	DT	O
resulting	VBG	O
nucleic	JJ	O
acid	NN	O
coding	VBG	O
sequence	NN	O
was	VBD	O
comparable	JJ	O
to	TO	O
codon	VB	O
usage	NN	O
found	VBN	O
in	IN	O
highly	RB	O
expressed	VBN	O
human	JJ	O
genes	NNS	O
(	(	O
Example	NNP	O
1	CD	O
)	)	O
.	.	O
The	DT	O
HIV	NNP	O
codon	NN	O
usage	NN	O
reflects	VBZ	O
a	DT	O
high	JJ	O
content	NN	O
of	IN	O
the	DT	O
nucleotides	NNS	O
A	NNP	O
or	CC	O
T	NNP	O
of	IN	O
the	DT	O
codon-triplet	NN	O
.	.	O
The	DT	O
effect	NN	O
of	IN	O
the	DT	O
HIV-1	NNP	O
codon	NN	O
usage	NN	O
is	VBZ	O
a	DT	O
high	JJ	O
AT	NNP	O
content	NN	O
in	IN	O
the	DT	O
DNA	NN	O
sequence	NN	O
that	WDT	O
results	NNS	O
in	IN	O
a	DT	O
decreased	JJ	O
translation	NN	O
ability	NN	O
and	CC	O
instability	NN	O
of	IN	O
the	DT	O
mRNA	NN	O
.	.	O
In	IN	O
comparison	NN	O
,	,	O
highly	RB	O
expressed	VBN	O
human	JJ	O
codons	NNS	O
prefer	VBP	O
the	DT	O
nucleotides	NNS	O
G	NNP	O
or	CC	O
C.	NNP	O
The	DT	O
Env	NNP	O
coding	NN	O
sequences	NNS	O
were	VBD	O
modified	VBN	O
to	TO	O
be	VB	O
comparable	JJ	O
to	TO	O
codon	VB	O
usage	NN	O
found	VBN	O
in	IN	O
highly	RB	O
expressed	VBN	O
human	JJ	O
genes	NNS	O
.	.	O
Experiments	NNS	O
performed	VBN	O
in	IN	O
support	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
showed	VBD	O
that	IN	O
the	DT	O
synthetic	JJ	O
Env	NNP	O
sequences	NNS	O
were	VBD	O
capable	JJ	O
of	IN	O
higher	JJR	O
level	NN	O
of	IN	O
protein	JJ	O
production	NN	O
(	(	O
see	VB	O
the	DT	O
Examples	NNP	O
)	)	O
relative	VBP	O
to	TO	O
the	DT	O
native	JJ	O
Env	NNP	O
sequences	NNS	O
.	.	O
One	CD	O
reason	NN	O
for	IN	O
this	DT	O
increased	VBN	O
production	NN	O
may	MD	O
be	VB	O
increased	VBN	O
stability	NN	O
of	IN	O
the	DT	O
mRNA	NN	O
corresponding	VBG	O
to	TO	O
the	DT	O
synthetic	JJ	O
Env	NNP	O
coding	NN	O
sequences	NNS	O
versus	VBP	O
the	DT	O
mRNA	NN	O
corresponding	VBG	O
to	TO	O
the	DT	O
native	JJ	O
Env	NNP	O
coding	NN	O
sequences	NNS	O
.	.	O
Modification	NN	O
of	IN	O
the	DT	O
Env	NNP	O
polypeptide	NN	O
coding	VBG	O
sequences	NNS	O
resulted	VBD	O
in	IN	O
improved	JJ	O
expression	NN	O
relative	NN	O
to	TO	O
the	DT	O
wild-type	JJ	O
coding	NN	O
sequences	NNS	O
in	IN	O
a	DT	O
number	NN	O
of	IN	O
mammalian	JJ	O
cell	NN	O
lines	NNS	O
.	.	O
Similar	JJ	O
Env	NNP	O
polypeptide	NN	O
coding	VBG	O
sequences	NNS	O
can	MD	O
be	VB	O
obtained	VBN	O
from	IN	O
a	DT	O
variety	NN	O
of	IN	O
isolates	NNS	O
(	(	O
families	NNS	O
,	,	O
sub-types	NNS	O
,	,	O
etc	FW	O
.	.	O
)	)	O
.	.	O
Env	NNP	O
polypeptide	NN	O
encoding	VBG	O
sequences	NNS	O
derived	VBN	O
from	IN	O
these	DT	O
variants	NNS	O
can	MD	O
be	VB	O
optimized	VBN	O
and	CC	O
tested	VBN	O
for	IN	O
improved	JJ	O
expression	NN	O
in	IN	O
mammals	NNS	O
by	IN	O
following	VBG	O
the	DT	O
teachings	NNS	O
of	IN	O
the	DT	O
present	JJ	O
specification	NN	O
(	(	O
see	VB	O
the	DT	O
Examples	NNP	O
,	,	O
in	IN	O
particular	JJ	O
Example	NNP	O
2	CD	O
)	)	O
.	.	O
2.1.5	CD	O
Further	JJ	O
Modification	NN	O
of	IN	O
HIV-1	NNP	O
Env	NNP	O
Nucleic	NNP	O
Acid	NNP	O
Coding	NNP	O
Sequences	NNPS	O
In	IN	O
addition	NN	O
to	TO	O
proteins	NNS	O
containing	VBG	O
HIV-related	JJ	O
sequences	NNS	O
,	,	O
the	DT	O
Env	NNP	O
encoding	VBG	O
sequences	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
can	MD	O
be	VB	O
fused	VBN	O
to	TO	O
other	JJ	O
polypeptides	NNS	O
(	(	O
creating	VBG	O
chimeric	RB	O
polypeptides	NNS	O
)	)	O
.	.	O
Also	RB	O
,	,	O
variations	NNS	O
on	IN	O
the	DT	O
orientation	NN	O
of	IN	O
the	DT	O
Env	NNP	O
and	CC	O
other	JJ	O
coding	NN	O
sequences	NNS	O
,	,	O
relative	JJ	O
to	TO	O
each	DT	O
other	JJ	O
,	,	O
are	VBP	O
contemplated	VBN	O
.	.	O
Further	RB	O
,	,	O
the	DT	O
HIV	NNP	O
protein	NN	O
encoding	VBG	O
cassettes	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
can	MD	O
be	VB	O
co-expressed	JJ	O
using	VBG	O
one	CD	O
vector	NN	O
or	CC	O
multiple	JJ	O
vectors	NNS	O
.	.	O
In	IN	O
addition	NN	O
,	,	O
the	DT	O
polyproteins	NNS	O
can	MD	O
be	VB	O
operably	RB	O
linked	VBN	O
to	TO	O
the	DT	O
same	JJ	O
or	CC	O
different	JJ	O
promoters	NNS	O
.	.	O
Env	NNP	O
polypeptide	NN	O
coding	VBG	O
sequences	NNS	O
can	MD	O
be	VB	O
obtained	VBN	O
from	IN	O
any	DT	O
HIV	NNP	O
isolates	NNS	O
(	(	O
different	JJ	O
families	NNS	O
,	,	O
subtypes	NNS	O
,	,	O
and	CC	O
strains	NNS	O
)	)	O
including	VBG	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
the	DT	O
isolates	NNS	O
HIVIIIb	NNP	O
,	,	O
HIVSF2	NNP	O
,	,	O
HIVus4	NNP	O
,	,	O
HIVCM235	NNP	O
,	,	O
HIVSF162	NNP	O
,	,	O
HIVLAV	NNP	O
,	,	O
HIVLAI	NNP	O
,	,	O
HIVMN	NNP	O
)	)	O
(	(	O
see	VB	O
,	,	O
e.g.	VB	O
,	,	O
Myers	NNP	B
et	VBP	I
al.	NN	I
,	,	I
Los	NNP	I
Alamos	NNP	I
Database	NNP	I
,	,	I
Los	NNP	I
Alamos	NNP	I
National	NNP	I
Laboratory	NNP	I
,	,	I
Los	NNP	I
Alamos	NNP	I
,	,	I
N.	NNP	I
Mex	NNP	I
.	.	I
(	(	I
1992	CD	I
)	)	I
;	:	O
Myers	NNP	B
et	FW	I
al.	NN	I
,	,	I
Human	NNP	I
Retroviruses	NNP	I
and	CC	I
Aids	NNP	I
,	,	I
1997	CD	I
,	,	I
Los	NNP	I
Alamos	NNP	I
,	,	I
N	NNP	I
.	.	I
Mex	NNP	I
.	.	I
:	:	I
Los	NNP	I
Alamos	NNP	I
National	NNP	I
Laboratory	NNP	I
)	)	O
.	.	O
Synthetic	JJ	O
expression	NN	O
cassettes	NNS	O
can	MD	O
be	VB	O
generated	VBN	O
using	VBG	O
such	JJ	O
coding	JJ	O
sequences	NNS	O
as	IN	O
starting	VBG	O
material	NN	O
by	IN	O
following	VBG	O
the	DT	O
teachings	NNS	O
of	IN	O
the	DT	O
present	JJ	O
specification	NN	O
(	(	O
e.g.	JJ	O
,	,	O
see	VBP	O
Example	JJ	O
1	CD	O
)	)	O
.	.	O
Further	RB	O
,	,	O
the	DT	O
synthetic	JJ	O
expression	NN	O
cassettes	NNS	O
(	(	O
and	CC	O
purified	VBN	O
polynucleotides	NNS	O
)	)	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
include	VBP	O
related	VBN	O
Env	NNP	O
polypeptide	IN	O
coding	VBG	O
sequences	NNS	O
having	VBG	O
greater	JJR	O
than	IN	O
90	CD	O
%	NN	O
,	,	O
preferably	RB	O
greater	JJR	O
than	IN	O
92	CD	O
%	NN	O
,	,	O
more	JJR	O
preferably	RB	O
greater	JJR	O
than	IN	O
95	CD	O
%	NN	O
,	,	O
and	CC	O
most	JJS	O
preferably	RB	O
greater	JJR	O
than	IN	O
98	CD	O
%	NN	O
sequence	NN	O
identity	NN	O
to	TO	O
the	DT	O
synthetic	JJ	O
expression	NN	O
cassette	NN	O
sequences	NNS	O
disclosed	VBD	O
herein	NN	O
(	(	O
for	IN	O
example	NN	O
,	,	O
SEQ	NNP	O
ID	NNP	O
NOs:71-72	NNP	O
;	:	O
and/or	VBZ	O
the	DT	O
sequences	NNS	O
presented	VBN	O
in	IN	O
Tables	NNP	O
1A	CD	O
and	CC	O
1B	CD	O
)	)	O
when	WRB	O
the	DT	O
sequences	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
are	VBP	O
used	VBN	O
as	IN	O
the	DT	O
query	NN	O
sequence	NN	O
.	.	O
2.1.6	CD	O
Expression	NN	O
of	IN	O
Synthetic	JJ	O
Sequences	NNS	O
Encoding	VBG	O
HIV-1	NNP	O
Env	NNP	O
and	CC	O
Related	NNP	O
Polypeptides	NNP	O
Several	NNP	O
synthetic	JJ	O
Env-encoding	JJ	O
sequences	NNS	O
(	(	O
expression	NN	O
cassettes	NNS	O
)	)	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
were	VBD	O
cloned	VBN	O
into	IN	O
a	DT	O
number	NN	O
of	IN	O
different	JJ	O
expression	NN	O
vectors	NNS	O
(	(	O
Example	NNP	O
1	CD	O
)	)	O
to	TO	O
evaluate	VB	O
levels	NNS	O
of	IN	O
expression	NN	O
and	CC	O
production	NN	O
of	IN	O
Env	NNP	O
polypeptide	NN	O
.	.	O
A	DT	O
modified	VBN	O
synthetic	JJ	O
coding	NN	O
sequence	NN	O
is	VBZ	O
presented	VBN	O
as	IN	O
synthetic	JJ	O
Env	NNP	O
expression	NN	O
cassettes	NNS	O
(	(	O
Example	JJ	O
1	CD	O
,	,	O
e.g.	NN	O
,	,	O
Tables	VBZ	O
1A	CD	O
and	CC	O
1B	CD	O
)	)	O
.	.	O
The	DT	O
synthetic	JJ	O
DNA	NN	O
fragments	NNS	O
for	IN	O
Env	NNP	O
were	VBD	O
cloned	VBN	O
into	IN	O
eucaryotic	JJ	O
expression	NN	O
vectors	NNS	O
described	VBD	O
in	IN	O
Example	NNP	O
1	CD	O
and	CC	O
in	IN	O
Section	NNP	O
2.1.3	CD	O
above	IN	O
,	,	O
including	VBG	O
,	,	O
a	DT	O
transient	JJ	O
expression	NN	O
vector	NN	O
and	CC	O
CMV-promoter-based	JJ	O
mammalian	JJ	O
vectors	NNS	O
.	.	O
Corresponding	VBG	O
wild-type	JJ	O
sequences	NNS	O
were	VBD	O
cloned	VBN	O
into	IN	O
the	DT	O
same	JJ	O
vectors	NNS	O
.	.	O
These	DT	O
vectors	NNS	O
were	VBD	O
then	RB	O
transfected	VBN	O
into	IN	O
a	DT	O
several	JJ	O
different	JJ	O
cell	NN	O
types	NNS	O
,	,	O
including	VBG	O
a	DT	O
variety	NN	O
of	IN	O
mammalian	JJ	O
cell	NN	O
lines	NNS	O
,	,	O
(	(	O
293	CD	O
,	,	O
RD	NNP	O
,	,	O
COS-7	NNP	O
,	,	O
and	CC	O
CHO	NNP	O
,	,	O
cell	NN	O
lines	NNS	O
available	JJ	O
,	,	O
for	IN	O
example	NN	O
,	,	O
from	IN	O
the	DT	O
A.T.C.C	NNP	O
.	.	O
)	)	O
.	.	O
The	DT	O
cell	NN	O
lines	NNS	O
were	VBD	O
cultured	VBN	O
under	IN	O
appropriate	JJ	O
conditions	NNS	O
and	CC	O
the	DT	O
levels	NNS	O
of	IN	O
gp120	NN	O
,	,	O
gp140	NN	O
and	CC	O
gp160	NN	O
Env	NNP	O
expression	NN	O
in	IN	O
supernatants	NNS	O
were	VBD	O
evaluated	VBN	O
(	(	O
Example	NNP	O
2	CD	O
)	)	O
.	.	O
Env	NNP	O
polypeptides	NNS	O
include	VBP	O
,	,	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
,	,	O
for	IN	O
example	NN	O
,	,	O
native	JJ	O
gp160	NN	O
,	,	O
oligomeric	JJ	O
gp140	NN	O
,	,	O
monomeric	JJ	O
gp120	NN	O
as	RB	O
well	RB	O
as	IN	O
modified	JJ	O
sequences	NNS	O
of	IN	O
these	DT	O
polypeptides	NNS	O
.	.	O
The	DT	O
results	NNS	O
of	IN	O
these	DT	O
assays	NNS	O
demonstrated	VBD	O
that	IN	O
expression	NN	O
of	IN	O
synthetic	JJ	O
Env	NNP	O
encoding	VBG	O
sequences	NNS	O
were	VBD	O
significantly	RB	O
higher	JJR	O
than	IN	O
corresponding	VBG	O
wild-type	JJ	O
sequences	NNS	O
(	(	O
Example	JJ	O
2	CD	O
;	:	O
Tables	NNP	O
3	CD	O
and	CC	O
4	CD	O
)	)	O
.	.	O
Further	RB	O
,	,	O
Western	JJ	O
Blot	NNP	O
analysis	NN	O
showed	VBD	O
that	IN	O
cells	NNS	O
containing	VBG	O
the	DT	O
synthetic	JJ	O
Env	NNP	O
expression	NN	O
cassette	NN	O
produced	VBD	O
the	DT	O
expected	VBN	O
protein	NN	O
(	(	O
gp120	NN	O
,	,	O
gp140	NN	O
or	CC	O
gp160	NN	O
)	)	O
at	IN	O
higher	JJR	O
per-cell	NN	O
concentrations	NNS	O
than	IN	O
cells	NNS	O
containing	VBG	O
the	DT	O
native	JJ	O
expression	NN	O
cassette	NN	O
.	.	O
The	DT	O
Env	NNP	O
proteins	NNS	O
were	VBD	O
seen	VBN	O
in	IN	O
both	DT	O
cell	NN	O
lysates	NNS	O
and	CC	O
supernatants	NNS	O
.	.	O
The	DT	O
levels	NNS	O
of	IN	O
production	NN	O
were	VBD	O
significantly	RB	O
higher	JJR	O
in	IN	O
cell	NN	O
supernatants	NNS	O
for	IN	O
cells	NNS	O
transfected	VBN	O
with	IN	O
the	DT	O
synthetic	JJ	O
Env	NNP	O
expression	NN	O
cassettes	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
as	IN	O
compared	VBN	O
to	TO	O
wild	VB	O
type	NN	O
.	.	O
Fractionation	NN	O
of	IN	O
the	DT	O
supernatants	NNS	O
from	IN	O
mammalian	JJ	O
cells	NNS	O
transfected	VBN	O
with	IN	O
the	DT	O
synthetic	JJ	O
Env	NNP	O
expression	NN	O
cassettes	NNS	O
showed	VBD	O
that	IN	O
it	PRP	O
provides	VBZ	O
superior	JJ	O
production	NN	O
of	IN	O
Env	NNP	O
proteins	NNS	O
,	,	O
relative	JJ	O
to	TO	O
the	DT	O
wild-type	JJ	O
Env	NNP	O
sequences	NNS	O
(	(	O
Examples	NNP	O
2	CD	O
and	CC	O
3	CD	O
)	)	O
.	.	O
Efficient	JJ	O
expression	NN	O
of	IN	O
these	DT	O
Env-containing	NNP	O
polypeptides	NNS	O
in	IN	O
mammalian	JJ	O
cell	NN	O
lines	NNS	O
provides	VBZ	O
the	DT	O
following	JJ	O
benefits	NNS	O
:	:	O
the	DT	O
Env	NNP	O
polypeptides	NNS	O
are	VBP	O
free	JJ	O
of	IN	O
baculovirus	NN	O
or	CC	O
other	JJ	O
viral	JJ	O
contaminants	NNS	O
;	:	O
production	NN	O
by	IN	O
established	VBN	O
methods	NNS	O
approved	VBN	O
by	IN	O
the	DT	O
FDA	NNP	O
;	:	O
increased	VBD	O
purity	NN	O
;	:	O
greater	JJR	O
yields	NNS	O
(	(	O
relative	JJ	O
to	TO	O
native	JJ	O
coding	NN	O
sequences	NNS	O
)	)	O
;	:	O
and	CC	O
a	DT	O
novel	JJ	O
method	NN	O
of	IN	O
producing	VBG	O
the	DT	O
Env-containing	JJ	O
polypeptides	NNS	O
in	IN	O
CHO	NNP	O
cells	NNS	O
which	WDT	O
is	VBZ	O
less	RBR	O
feasible	JJ	O
in	IN	O
the	DT	O
absence	NN	O
of	IN	O
the	DT	O
increased	VBN	O
expression	NN	O
obtained	VBN	O
using	VBG	O
the	DT	O
constructs	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
.	.	O
Exemplary	NNP	O
cell	NN	O
lines	NNS	O
(	(	O
e.g.	NN	O
,	,	O
mammalian	JJ	O
,	,	O
yeast	RB	O
,	,	O
insect	NN	O
,	,	O
etc	FW	O
.	.	O
)	)	O
include	VBP	O
those	DT	O
described	VBN	O
above	IN	O
in	IN	O
Section	NN	O
2.1.3	CD	O
for	IN	O
Gag-containing	JJ	O
constructs	NNS	O
.	.	O
Further	RB	O
,	,	O
appropriate	JJ	O
vectors	NNS	O
and	CC	O
control	NN	O
elements	NNS	O
(	(	O
e.g.	NN	O
,	,	O
promoters	NNS	O
,	,	O
enhancers	NNS	O
,	,	O
polyadenylation	NN	O
sequences	NNS	O
,	,	O
etc	FW	O
.	.	O
)	)	O
for	IN	O
any	DT	O
given	VBN	O
cell	NN	O
type	NN	O
can	MD	O
be	VB	O
selected	VBN	O
,	,	O
as	IN	O
described	VBN	O
above	IN	O
in	IN	O
Section	NN	O
2.1.3	CD	O
,	,	O
by	IN	O
one	CD	O
having	VBG	O
ordinary	JJ	O
skill	NN	O
in	IN	O
the	DT	O
art	NN	O
in	IN	O
view	NN	O
of	IN	O
the	DT	O
teachings	NNS	O
of	IN	O
the	DT	O
present	JJ	O
specification	NN	O
and	CC	O
information	NN	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
about	IN	O
expression	NN	O
vectors	NNS	O
.	.	O
In	IN	O
addition	NN	O
,	,	O
the	DT	O
recombinantly	RB	O
expressed	VBN	O
polypeptides	NNS	O
from	IN	O
synthetic	JJ	O
Env-encoding	JJ	O
expression	NN	O
cassettes	NNS	O
are	VBP	O
typically	RB	O
isolated	JJ	O
and	CC	O
purified	VBN	O
from	IN	O
lysed	JJ	O
cells	NNS	O
or	CC	O
culture	NN	O
media	NNS	O
,	,	O
as	IN	O
described	VBN	O
above	IN	O
for	IN	O
Gag-encoding	NNP	O
expression	NN	O
cassettes	NNS	O
.	.	O
An	DT	O
exemplary	JJ	O
purification	NN	O
is	VBZ	O
described	VBN	O
in	IN	O
Example	NNP	O
4	CD	O
and	CC	O
shown	VBN	O
in	IN	O
FIG	NNP	O
.	.	O
60	CD	O
.	.	O
2.1.7	CD	O
Modification	NN	O
of	IN	O
HIV-1	NNP	O
Tat	NNP	O
Nucleic	NNP	O
Acid	NNP	O
Coding	NNP	O
Sequences	NNP	O
Another	DT	O
aspect	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
is	VBZ	O
the	DT	O
generation	NN	O
of	IN	O
HIV-1	NNP	O
tat	NN	O
protein	NN	O
coding	VBG	O
sequences	NNS	O
,	,	O
and	CC	O
related	JJ	O
sequences	NNS	O
,	,	O
having	VBG	O
improved	VBN	O
expression	NN	O
relative	NN	O
to	TO	O
the	DT	O
corresponding	JJ	O
wild-type	JJ	O
sequence	NN	O
.	.	O
Exemplary	JJ	O
embodiments	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
are	VBP	O
illustrated	VBN	O
herein	JJ	O
modifying	VBG	O
the	DT	O
tat	JJ	O
wild-type	JJ	O
nucleotide	JJ	O
sequence	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:85	NNP	O
,	,	O
FIG	NNP	O
.	.	O
76	CD	O
)	)	O
obtained	VBN	O
from	IN	O
SF162	NNP	O
as	IN	O
described	VBN	O
above	IN	O
.	.	O
Exemplary	NNP	O
synthetic	JJ	O
tat	NN	O
constructs	NNS	O
are	VBP	O
shown	VBN	O
in	IN	O
SEQ	NNP	O
ID	NNP	O
NO:87	NNP	O
,	,	O
which	WDT	O
depicts	VBZ	O
a	DT	O
tat	JJ	O
construct	NN	O
encoding	VBG	O
a	DT	O
full-length	JJ	O
tat	NN	O
polypeptide	NN	O
from	IN	O
strain	NN	O
SF162	NNP	O
;	:	O
SEQ	NNP	O
ID	NNP	O
NO:88	NNP	O
,	,	O
which	WDT	O
depicts	VBZ	O
a	DT	O
tat	JJ	O
construct	NN	O
encoding	VBG	O
a	DT	O
tat	NN	O
polypeptide	NN	O
having	VBG	O
the	DT	O
cystein	NN	O
residue	NN	O
at	IN	O
position	NN	O
22	CD	O
changed	VBD	O
;	:	O
and	CC	O
SEQ	NNP	O
ID	NNP	O
NO:89	NNP	O
,	,	O
which	WDT	O
depicts	VBZ	O
a	DT	O
tat	JJ	O
construct	NN	O
encoding	VBG	O
the	DT	O
amino	JJ	O
terminal	JJ	O
portion	NN	O
of	IN	O
a	DT	O
tat	JJ	O
polypeptide	NN	O
from	IN	O
strain	NN	O
SF162	NNP	O
.	.	O
The	DT	O
amino	JJ	O
portion	NN	O
of	IN	O
the	DT	O
tat	NN	O
protein	NN	O
appears	VBZ	O
to	TO	O
contain	VB	O
many	JJ	O
of	IN	O
the	DT	O
epitopes	NNS	O
that	WDT	O
induce	VBP	O
an	DT	O
immune	JJ	O
response	NN	O
.	.	O
In	IN	O
addition	NN	O
,	,	O
further	JJ	O
modifications	NNS	O
include	VBP	O
replacement	NN	O
or	CC	O
deletion	NN	O
of	IN	O
the	DT	O
cystein	NN	O
residue	NN	O
at	IN	O
position	NN	O
22	CD	O
,	,	O
for	IN	O
example	NN	O
with	IN	O
a	DT	O
valine	NN	O
residue	NN	O
,	,	O
an	DT	O
alanine	NN	O
residue	NN	O
or	CC	O
a	DT	O
glycine	NN	O
residue	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
Nos	NNP	O
:	:	O
88	CD	O
and	CC	O
89	CD	O
,	,	O
FIGS	NNP	O
.	.	O
79	CD	O
and	CC	O
81	CD	O
)	)	O
,	,	O
see	VBP	O
,	,	O
e.g.	FW	O
,	,	O
Caputo	NNP	B
et	CC	I
al	NN	I
.	.	I
(	(	I
1996	CD	I
)	)	I
Gene	NNP	I
Ther	NNP	I
.	.	I
3:235	CD	I
.	.	O
In	IN	O
FIG	NNP	O
.	.	O
81	CD	O
,	,	O
which	WDT	O
depicts	VBZ	O
a	DT	O
tat	JJ	O
construct	NN	O
encoding	VBG	O
the	DT	O
amino	JJ	O
terminal	JJ	O
portion	NN	O
of	IN	O
a	DT	O
tat	JJ	O
polypeptide	NN	O
,	,	O
the	DT	O
nucleotides	NNS	O
(	(	O
nucleotides	IN	O
64-66	NNP	O
)	)	O
encoding	VBG	O
the	DT	O
cystein	NN	O
residues	NNS	O
are	VBP	O
underlined	JJ	O
.	.	O
The	DT	O
design	NN	O
and	CC	O
construction	NN	O
of	IN	O
suitable	JJ	O
construct	NN	O
can	MD	O
be	VB	O
readily	RB	O
done	VBN	O
using	VBG	O
the	DT	O
teachings	NNS	O
of	IN	O
the	DT	O
present	JJ	O
specification	NN	O
.	.	O
As	IN	O
with	IN	O
Gag	NNP	O
,	,	O
pol	NN	O
,	,	O
prot	NN	O
and	CC	O
Env	NNP	O
,	,	O
tat	JJ	O
polypeptide	IN	O
coding	VBG	O
sequences	NNS	O
can	MD	O
be	VB	O
obtained	VBN	O
from	IN	O
a	DT	O
variety	NN	O
of	IN	O
isolates	NNS	O
(	(	O
families	NNS	O
,	,	O
sub-types	NNS	O
,	,	O
etc	FW	O
.	.	O
)	)	O
.	.	O
Modification	NN	O
of	IN	O
the	DT	O
tat	NN	O
polypeptide	IN	O
coding	VBG	O
sequences	NNS	O
result	NN	O
in	IN	O
improved	JJ	O
expression	NN	O
relative	NN	O
to	TO	O
the	DT	O
wild-type	JJ	O
coding	NN	O
sequences	NNS	O
in	IN	O
a	DT	O
number	NN	O
of	IN	O
cell	NN	O
lines	NNS	O
(	(	O
e.g.	NN	O
,	,	O
mammalian	JJ	O
,	,	O
yeast	RB	O
,	,	O
bacterial	JJ	O
and	CC	O
insect	JJ	O
cells	NNS	O
)	)	O
.	.	O
Tat	NNP	O
polypeptide	NN	O
encoding	VBG	O
sequences	NNS	O
derived	VBN	O
from	IN	O
these	DT	O
variants	NNS	O
can	MD	O
be	VB	O
optimized	VBN	O
and	CC	O
tested	VBN	O
for	IN	O
improved	JJ	O
expression	NN	O
in	IN	O
mammals	NNS	O
by	IN	O
following	VBG	O
the	DT	O
teachings	NNS	O
of	IN	O
the	DT	O
present	JJ	O
specification	NN	O
(	(	O
see	VB	O
the	DT	O
Examples	NNP	O
,	,	O
in	IN	O
particular	JJ	O
Example	NNP	O
2	CD	O
)	)	O
.	.	O
Various	JJ	O
forms	NNS	O
of	IN	O
the	DT	O
different	JJ	O
embodiments	NNS	O
of	IN	O
the	DT	O
invention	NN	O
,	,	O
described	VBN	O
herein	NNS	O
,	,	O
may	MD	O
be	VB	O
combined	VBN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
polynucleotides	NNS	O
may	MD	O
be	VB	O
derived	VBN	O
from	IN	O
the	DT	O
polynucleotide	JJ	O
sequences	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
,	,	O
including	VBG	O
,	,	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
,	,	O
coding	VBG	O
sequences	NNS	O
for	IN	O
Gag	NNP	O
polypeptides	NNS	O
,	,	O
Env	NNP	O
polypeptides	VBZ	O
,	,	O
polymerase	NN	O
polypeptides	NNS	O
,	,	O
protease	NN	O
polypeptides	NNS	O
,	,	O
tat	NN	O
polypeptides	NNS	O
,	,	O
and	CC	O
reverse	VB	O
transcriptase	NN	O
polypeptides	NNS	O
.	.	O
Further	RB	O
,	,	O
the	DT	O
polynucleotide	NN	O
coding	VBG	O
sequences	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
may	MD	O
be	VB	O
combined	VBN	O
into	IN	O
multi-cistronic	JJ	O
expression	NN	O
cassettes	NNS	O
where	WRB	O
typically	RB	O
each	DT	O
coding	VBG	O
sequence	NN	O
for	IN	O
each	DT	O
polypeptide	NN	O
is	VBZ	O
preceded	VBN	O
by	IN	O
IRES	NNP	O
sequences	NNS	O
.	.	O
2.2	CD	O
Production	NN	O
of	IN	O
Virus-Like	NNP	O
Particles	NNP	O
and	CC	O
Use	NNP	O
of	IN	O
the	DT	O
Constructs	NNP	O
of	IN	O
the	DT	O
Present	JJ	O
Invention	NNP	O
to	TO	O
Create	VB	O
Packaging	NNP	O
Cell	NNP	O
Lines	VBZ	O
The	DT	O
group-specific	JJ	O
antigens	NNS	O
(	(	O
Gag	NNP	O
)	)	O
of	IN	O
human	JJ	O
immunodeficiency	NN	O
virus	NN	O
type-1	NN	O
(	(	O
HIV-1	NNP	O
)	)	O
self-assemble	JJ	O
into	IN	O
noninfectious	JJ	O
virus-like	JJ	O
particles	NNS	O
(	(	O
VLP	NNP	O
)	)	O
that	WDT	O
are	VBP	O
released	VBN	O
from	IN	O
various	JJ	O
eucaryotic	JJ	O
cells	NNS	O
by	IN	O
budding	VBG	O
(	(	O
reviewed	VBN	O
by	IN	O
Freed	NNP	B
,	,	I
E.	NNP	I
O.	NNP	I
,	,	I
Virology	NNP	I
251:1-15	CD	I
,	,	I
1998	CD	I
)	)	O
.	.	O
The	DT	O
synthetic	JJ	O
expression	NN	O
cassettes	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
provide	VBP	O
efficient	NN	O
means	NNS	O
for	IN	O
the	DT	O
production	NN	O
of	IN	O
HIV-Gag	NNP	O
virus-like	JJ	O
particles	NNS	O
(	(	O
VLPs	NNP	O
)	)	O
using	VBG	O
a	DT	O
variety	NN	O
of	IN	O
different	JJ	O
cell	NN	O
types	NNS	O
,	,	O
including	VBG	O
,	,	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
,	,	O
mammalian	JJ	O
cells	NNS	O
.	.	O
Viral	JJ	O
particles	NNS	O
can	MD	O
be	VB	O
used	VBN	O
as	IN	O
a	DT	O
matrix	NN	O
for	IN	O
the	DT	O
proper	JJ	O
presentation	NN	O
of	IN	O
an	DT	O
antigen	NN	O
entrapped	VBD	O
or	CC	O
associated	VBN	O
therewith	NN	O
to	TO	O
the	DT	O
immune	JJ	O
system	NN	O
of	IN	O
the	DT	O
host	NN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
4,722,840	CD	O
describes	NNS	O
hybrid	JJ	O
particles	NNS	O
comprised	VBN	O
of	IN	O
a	DT	O
particle-forming	JJ	O
fragment	NN	O
of	IN	O
a	DT	O
structural	JJ	O
protein	NN	O
from	IN	O
a	DT	O
virus	NN	O
,	,	O
such	JJ	O
as	IN	O
a	DT	O
particle-forming	JJ	O
fragment	NN	O
of	IN	O
hepatitis	NN	O
B	NNP	O
virus	NN	O
(	(	O
HBV	NNP	O
)	)	O
surface	NN	O
antigen	NN	O
(	(	O
HBsAg	NNP	O
)	)	O
,	,	O
fused	VBN	O
to	TO	O
a	DT	O
heterologous	JJ	O
polypeptide	NN	O
.	.	O
Tindle	NNP	B
et	CC	I
al.	NN	I
,	,	I
Virology	NNP	I
(	(	I
1994	CD	I
)	)	I
200:547-557	CD	I
,	,	O
describes	VBZ	O
the	DT	O
production	NN	O
and	CC	O
use	NN	O
of	IN	O
chimeric	JJ	O
HBV	NNP	O
core	NN	O
antigen	NN	O
particles	NNS	O
containing	VBG	O
epitopes	NNS	O
of	IN	O
human	JJ	O
papillomavirus	NN	O
(	(	O
HPV	NNP	O
)	)	O
type	VBD	O
16	CD	O
E7	NNP	O
transforming	VBG	O
protein	NN	O
.	.	O
Adams	NNP	B
et	CC	I
al.	NN	I
,	,	I
Nature	NNP	I
(	(	I
1987	CD	I
)	)	I
329:68-70	CD	I
,	,	O
describes	VBZ	O
the	DT	O
recombinant	JJ	O
production	NN	O
of	IN	O
hybrid	JJ	O
HIVgp120	NNP	O
:	:	O
Ty	NNP	O
VLPs	NNP	O
in	IN	O
yeast	NN	O
and	CC	O
Brown	NNP	B
et	FW	I
al.	NN	I
,	,	I
Virology	NNP	I
(	(	I
1994	CD	I
)	)	I
198:477-488	CD	I
,	,	O
the	DT	O
production	NN	O
of	IN	O
chimeric	JJ	O
proteins	NNS	O
consisting	VBG	O
of	IN	O
the	DT	O
VP2	NNP	O
protein	NN	O
of	IN	O
human	JJ	O
parvovirus	NN	O
B19	NNP	O
and	CC	O
epitopes	NNS	O
from	IN	O
human	JJ	O
herpes	NNS	O
simplex	JJ	O
virus	NN	O
type	NN	O
1	CD	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
mouse	NN	O
hepatitis	NN	O
virus	NN	O
A59	NNP	O
.	.	O
Wagner	NNP	B
et	CC	I
al.	NN	I
,	,	I
(	(	I
Virology	NNP	I
(	(	I
1994	CD	I
)	)	I
200:162-175	CD	I
,	,	O
Brand	NNP	B
et	FW	I
al.	NN	I
,	,	I
J.	NNP	I
Virol	NNP	I
.	.	I
Meth	NNP	I
.	.	I
(	(	I
1995	CD	I
)	)	I
51:153-168	CD	I
;	:	O
Virology	NNP	B
(	(	I
1996	CD	I
)	)	I
220:128-140	CD	I
)	)	O
and	CC	O
Wolf	NNP	B
,	,	I
et	FW	I
al.	NN	I
,	,	I
(	(	I
EP	NNP	I
0	CD	I
449	CD	I
116	CD	I
A1	NNP	I
,	,	I
published	VBD	I
2	CD	I
Oct.	NNP	I
1991	CD	I
;	:	I
WO	NNP	I
96/30523	CD	I
,	,	I
published	VBD	I
3	CD	I
Oct.	NNP	I
1996	CD	I
)	)	I
describe	VB	O
the	DT	O
assembly	NN	O
of	IN	O
chimeric	JJ	O
HIV-1	NNP	O
p55Gag	NN	O
particles	NNS	O
.	.	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,503,833	CD	O
describes	VBZ	O
the	DT	O
use	NN	O
of	IN	O
rotavirus	NN	O
VP6	NNP	O
spheres	VBZ	O
for	IN	O
encapsulating	VBG	O
and	CC	O
delivering	VBG	O
therapeutic	JJ	O
agents	NNS	O
.	.	O
2.2.1	CD	O
VLP	NNP	O
Production	NNP	O
Using	VBG	O
the	DT	O
Synthetic	JJ	O
Expression	NNP	O
Cassettes	NNP	O
of	IN	O
the	DT	O
Present	JJ	O
Invention	NNP	O
Experiments	NNP	O
performed	VBD	O
in	IN	O
support	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
have	VBP	O
demonstrated	VBN	O
that	IN	O
the	DT	O
synthetic	JJ	O
expression	NN	O
cassettes	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
provide	NN	O
superior	JJ	O
production	NN	O
of	IN	O
both	DT	O
protein	NN	O
and	CC	O
VLPs	NNP	O
,	,	O
relative	JJ	O
to	TO	O
native	JJ	O
coding	NN	O
sequences	NNS	O
(	(	O
Examples	NNP	O
7	CD	O
and	CC	O
15	CD	O
)	)	O
.	.	O
Further	RB	O
,	,	O
electron	FW	O
microscopic	FW	O
evaluation	NN	O
of	IN	O
VLP	NNP	O
production	NN	O
(	(	O
Examples	NNP	O
6	CD	O
and	CC	O
15	CD	O
,	,	O
FIGS	NNP	O
.	.	O
3A-B	JJ	O
and	CC	O
65A-F	JJ	O
)	)	O
showed	VBD	O
that	IN	O
free	JJ	O
and	CC	O
budding	JJ	O
immature	NN	O
virus	NN	O
particles	NNS	O
of	IN	O
the	DT	O
expected	JJ	O
size	NN	O
were	VBD	O
produced	VBN	O
by	IN	O
cells	NNS	O
containing	VBG	O
the	DT	O
synthetic	JJ	O
expression	NN	O
cassettes	NNS	O
.	.	O
Using	VBG	O
the	DT	O
synthetic	JJ	O
expression	NN	O
cassettes	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
,	,	O
rather	RB	O
than	IN	O
native	JJ	O
coding	NN	O
sequences	NNS	O
,	,	O
for	IN	O
the	DT	O
production	NN	O
of	IN	O
virus-like	JJ	O
particles	NNS	O
provide	IN	O
several	JJ	O
advantages	NNS	O
.	.	O
First	RB	O
,	,	O
VLPs	NNP	O
can	MD	O
be	VB	O
produced	VBN	O
in	IN	O
enhanced	JJ	O
quantity	NN	O
making	VBG	O
isolation	NN	O
and	CC	O
purification	NN	O
of	IN	O
the	DT	O
VLPs	NNP	O
easier	JJR	O
.	.	O
Second	JJ	O
,	,	O
VLPs	NNP	O
can	MD	O
be	VB	O
produced	VBN	O
in	IN	O
a	DT	O
variety	NN	O
of	IN	O
cell	NN	O
types	NNS	O
using	VBG	O
the	DT	O
synthetic	JJ	O
expression	NN	O
cassettes	NNS	O
,	,	O
in	IN	O
particular	JJ	O
,	,	O
mammalian	JJ	O
cell	NN	O
lines	NNS	O
can	MD	O
be	VB	O
used	VBN	O
for	IN	O
VLP	NNP	O
production	NN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
CHO	NNP	O
cells	NNS	O
.	.	O
Production	NN	O
using	VBG	O
CHO	NNP	O
cells	NNS	O
provides	VBZ	O
(	(	O
i	NN	O
)	)	O
VLP	NNP	O
formation	NN	O
;	:	O
(	(	O
ii	NN	O
)	)	O
correct	VBP	O
myristylation	NN	O
and	CC	O
budding	NN	O
;	:	O
(	(	O
iii	NN	O
)	)	O
absence	NN	O
of	IN	O
non-mammalian	JJ	O
cell	NN	O
contaminants	NNS	O
(	(	O
e.g.	NN	O
,	,	O
insect	JJ	O
viruses	NNS	O
and/or	VBP	O
cells	NNS	O
)	)	O
;	:	O
and	CC	O
(	(	O
iv	NN	O
)	)	O
ease	NN	O
of	IN	O
purification	NN	O
.	.	O
The	DT	O
synthetic	JJ	O
expression	NN	O
cassettes	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
are	VBP	O
also	RB	O
useful	JJ	O
for	IN	O
enhanced	JJ	O
expression	NN	O
in	IN	O
cell-types	NNS	O
other	JJ	O
than	IN	O
mammalian	JJ	O
cell	NN	O
lines	NNS	O
.	.	O
For	IN	O
example	NN	O
,	,	O
infection	NN	O
of	IN	O
insect	JJ	O
cells	NNS	O
with	IN	O
baculovirus	NN	O
vectors	NNS	O
encoding	VBG	O
the	DT	O
synthetic	JJ	O
expression	NN	O
cassettes	NNS	O
resulted	VBD	O
in	IN	O
higher	JJR	O
levels	NNS	O
of	IN	O
total	JJ	O
protein	JJ	O
yield	NN	O
and	CC	O
higher	JJR	O
levels	NNS	O
of	IN	O
VLP	NNP	O
production	NN	O
(	(	O
relative	JJ	O
to	TO	O
wild-type	JJ	O
coding	NN	O
sequences	NNS	O
)	)	O
.	.	O
Further	RB	O
,	,	O
the	DT	O
final	JJ	O
product	NN	O
from	IN	O
insect	JJ	O
cells	NNS	O
infected	VBN	O
with	IN	O
the	DT	O
baculovirus-Gag	JJ	O
synthetic	JJ	O
expression	NN	O
cassettes	NNS	O
consistently	RB	O
contained	VBD	O
lower	JJR	O
amounts	NNS	O
of	IN	O
contaminating	VBG	O
insect	JJ	O
proteins	NNS	O
than	IN	O
the	DT	O
final	JJ	O
product	NN	O
when	WRB	O
wild-type	JJ	O
coding	NN	O
sequences	NNS	O
were	VBD	O
used	VBN	O
(	(	O
Examples	NNP	O
)	)	O
.	.	O
VLPs	NNP	O
can	MD	O
spontaneously	RB	O
form	VB	O
when	WRB	O
the	DT	O
particle-forming	JJ	O
polypeptide	NN	O
of	IN	O
interest	NN	O
is	VBZ	O
recombinantly	RB	O
expressed	VBN	O
in	IN	O
an	DT	O
appropriate	JJ	O
host	NN	O
cell	NN	O
.	.	O
Thus	RB	O
,	,	O
the	DT	O
VLPs	NNP	O
produced	VBD	O
using	VBG	O
the	DT	O
synthetic	JJ	O
expression	NN	O
cassettes	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
are	VBP	O
conveniently	RB	O
prepared	JJ	O
using	VBG	O
recombinant	JJ	O
techniques	NNS	O
.	.	O
As	IN	O
discussed	VBN	O
below	IN	O
,	,	O
the	DT	O
Gag	NNP	O
polypeptide	NN	O
encoding	VBG	O
synthetic	JJ	O
expression	NN	O
cassettes	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
can	MD	O
include	VB	O
other	JJ	O
polypeptide	JJ	O
coding	VBG	O
sequences	NNS	O
of	IN	O
interest	NN	O
(	(	O
for	IN	O
example	NN	O
,	,	O
Env	NNP	O
,	,	O
tat	NN	O
,	,	O
rev	NN	O
,	,	O
HIV	NNP	O
protease	NN	O
,	,	O
HIV	NNP	O
polymerase	NN	O
,	,	O
HCV	NNP	O
core	NN	O
;	:	O
see	VB	O
,	,	O
Example	NNP	O
1	CD	O
)	)	O
.	.	O
Expression	NN	O
of	IN	O
such	JJ	O
synthetic	JJ	O
expression	NN	O
cassettes	NNS	O
yields	NNS	O
VLPs	NNP	O
comprising	VBG	O
the	DT	O
product	NN	O
of	IN	O
the	DT	O
synthetic	JJ	O
expression	NN	O
cassette	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
,	,	O
the	DT	O
polypeptide	NN	O
of	IN	O
interest	NN	O
.	.	O
Once	RB	O
coding	VBG	O
sequences	NNS	O
for	IN	O
the	DT	O
desired	JJ	O
particle-forming	NN	O
polypeptides	NNS	O
have	VBP	O
been	VBN	O
isolated	VBN	O
or	CC	O
synthesized	VBN	O
,	,	O
they	PRP	O
can	MD	O
be	VB	O
cloned	VBN	O
into	IN	O
any	DT	O
suitable	JJ	O
vector	NN	O
or	CC	O
replicon	NN	O
for	IN	O
expression	NN	O
.	.	O
Numerous	JJ	O
cloning	VBG	O
vectors	NNS	O
are	VBP	O
known	VBN	O
to	TO	O
those	DT	O
of	IN	O
skill	NN	O
in	IN	O
the	DT	O
art	NN	O
,	,	O
and	CC	O
the	DT	O
selection	NN	O
of	IN	O
an	DT	O
appropriate	JJ	O
cloning	NN	O
vector	NN	O
is	VBZ	O
a	DT	O
matter	NN	O
of	IN	O
choice	NN	O
.	.	O
See	VB	O
,	,	O
generally	RB	O
,	,	O
Ausubel	NNP	B
et	FW	I
al	NN	I
,	,	I
supra	NN	I
or	CC	O
Sambrook	NNP	B
et	CC	I
al	NN	I
,	,	I
supra	NN	I
.	.	O
The	DT	O
vector	NN	O
is	VBZ	O
then	RB	O
used	VBN	O
to	TO	O
transform	VB	O
an	DT	O
appropriate	JJ	O
host	NN	O
cell	NN	O
.	.	O
Suitable	JJ	O
recombinant	JJ	O
expression	NN	O
systems	NNS	O
include	VBP	O
,	,	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
,	,	O
bacterial	JJ	O
,	,	O
mammalian	JJ	O
,	,	O
baculovirus/insect	JJ	O
,	,	O
vaccinia	NN	O
,	,	O
Semliki	NNP	O
Forest	NNP	O
virus	NN	O
(	(	O
SFV	NNP	O
)	)	O
,	,	O
Alphaviruses	NNP	O
(	(	O
such	JJ	O
as	IN	O
,	,	O
Sindbis	NNP	O
,	,	O
Venezuelan	NNP	O
Equine	NNP	O
Encephalitis	NNP	O
(	(	O
VEE	NNP	O
)	)	O
)	)	O
,	,	O
mammalian	JJ	O
,	,	O
yeast	NN	O
and	CC	O
Xenopus	NNP	O
expression	NN	O
systems	NNS	O
,	,	O
well	RB	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
Particularly	RB	O
preferred	JJ	O
expression	NN	O
systems	NNS	O
are	VBP	O
mammalian	JJ	O
cell	NN	O
lines	NNS	O
,	,	O
vaccinia	NN	O
,	,	O
Sindbis	NNP	O
,	,	O
insect	NN	O
and	CC	O
yeast	JJ	O
systems	NNS	O
.	.	O
For	IN	O
example	NN	O
,	,	O
a	DT	O
number	NN	O
of	IN	O
mammalian	JJ	O
cell	NN	O
lines	NNS	O
are	VBP	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
and	CC	O
include	VBP	O
immortalized	VBN	O
cell	NN	O
lines	NNS	O
available	JJ	O
from	IN	O
the	DT	O
American	JJ	O
Type	NNP	O
Culture	NNP	O
Collection	NNP	O
(	(	O
A.T.C.C	NNP	O
.	.	O
)	)	O
,	,	O
such	JJ	O
as	IN	O
,	,	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
,	,	O
Chinese	JJ	O
hamster	NN	O
ovary	JJ	O
(	(	O
CHO	NNP	O
)	)	O
cells	NNS	O
,	,	O
293	CD	O
cells	NNS	O
,	,	O
HeLa	NNP	O
cells	NNS	O
,	,	O
baby	NN	O
hamster	NN	O
kidney	NN	O
(	(	O
BHK	NNP	O
)	)	O
cells	NNS	O
,	,	O
mouse	NN	O
myeloma	NN	O
(	(	O
SB20	NNP	O
)	)	O
,	,	O
monkey	JJ	O
kidney	NN	O
cells	NNS	O
(	(	O
COS	NNP	O
)	)	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
others	NNS	O
.	.	O
Similarly	RB	O
,	,	O
bacterial	JJ	O
hosts	NNS	O
such	JJ	O
as	IN	O
E.	NNP	O
coli	NNS	O
,	,	O
Bacillus	NNP	O
subtilis	NNS	O
,	,	O
and	CC	O
Streptococcus	NNP	O
spp.	NN	O
,	,	O
will	MD	O
find	VB	O
use	NN	O
with	IN	O
the	DT	O
present	JJ	O
expression	NN	O
constructs	NNS	O
.	.	O
Yeast	JJ	O
hosts	NNS	O
useful	JJ	O
in	IN	O
the	DT	O
present	JJ	O
invention	NN	O
include	VBP	O
inter	NN	O
alia	NN	O
,	,	O
Saccharomyces	NNP	O
cerevisiae	NN	O
,	,	O
Candida	NNP	O
albicans	VBZ	O
,	,	O
Candida	NNP	O
maltose	NN	O
,	,	O
Hansenula	NNP	O
polymorpha	NN	O
,	,	O
Kluyveromyces	NNP	O
fragilis	NN	O
,	,	O
Kluyveromyces	NNP	O
lactis	NN	O
,	,	O
Pichia	NNP	O
guillerimondii	NN	O
,	,	O
Pichia	NNP	O
pastoris	NN	O
,	,	O
Schizosaccharomyces	NNP	O
pombe	NN	O
and	CC	O
Yarrowia	NNP	O
lipolytica	NN	O
.	.	O
Insect	NNP	O
cells	NNS	O
for	IN	O
use	NN	O
with	IN	O
baculovirus	JJ	O
expression	NN	O
vectors	NNS	O
include	VBP	O
,	,	O
inter	JJ	O
alia	NN	O
,	,	O
Aedes	NNP	O
aegypti	NN	O
,	,	O
Autographa	NNP	O
californica	NN	O
,	,	O
Bombyx	NNP	O
mori	FW	O
,	,	O
Drosophila	NNP	O
melanogaster	NN	O
,	,	O
Spodoptera	NNP	O
frugiperda	NN	O
,	,	O
and	CC	O
Trichoplusia	NNP	O
ni	NN	O
.	.	O
See	VB	O
,	,	O
e.g.	VB	O
,	,	O
Summers	NNPS	B
and	CC	I
Smith	NNP	I
,	,	I
Texas	NNP	I
Agricultural	NNP	I
Experiment	NNP	I
Station	NNP	I
Bulletin	NNP	I
No	NNP	I
.	.	I
1555	CD	I
(	(	I
1987	CD	I
)	)	I
.	.	O
Fungal	JJ	O
hosts	NNS	O
include	VBP	O
,	,	O
for	IN	O
example	NN	O
,	,	O
Aspergillus	NNP	O
.	.	O
Viral	JJ	O
vectors	NNS	O
can	MD	O
be	VB	O
used	VBN	O
for	IN	O
the	DT	O
production	NN	O
of	IN	O
particles	NNS	O
in	IN	O
eucaryotic	JJ	O
cells	NNS	O
,	,	O
such	JJ	O
as	IN	O
those	DT	O
derived	VBN	O
from	IN	O
the	DT	O
pox	JJ	O
family	NN	O
of	IN	O
viruses	NNS	O
,	,	O
including	VBG	O
vaccinia	NN	O
virus	NN	O
and	CC	O
avian	JJ	O
poxvirus	NN	O
.	.	O
Additionally	RB	O
,	,	O
a	DT	O
vaccinia	NN	O
based	VBN	O
infection/transfection	NN	O
system	NN	O
,	,	O
as	IN	O
described	VBN	O
in	IN	O
Tomei	NNP	B
et	CC	I
al.	NN	I
,	,	I
J.	NNP	I
Virol	NNP	I
.	.	I
(	(	I
1993	CD	I
)	)	I
67:4017-4026	CD	I
and	CC	O
Selby	NNP	B
et	VBP	I
al.	NN	I
,	,	I
J.	NNP	I
Gen.	NNP	I
Virol	NNP	I
.	.	I
(	(	I
1993	CD	I
)	)	I
74:1103-1113	CD	I
,	,	O
will	MD	O
also	RB	O
find	VB	O
use	NN	O
with	IN	O
the	DT	O
present	JJ	O
invention	NN	O
.	.	O
In	IN	O
this	DT	O
system	NN	O
,	,	O
cells	NNS	O
are	VBP	O
first	RB	O
infected	VBN	O
in	IN	O
vitro	NN	O
with	IN	O
a	DT	O
vaccinia	NN	O
virus	NN	O
recombinant	NN	O
that	WDT	O
encodes	VBZ	O
the	DT	O
bacteriophage	NN	O
T7	NNP	O
RNA	NNP	O
polymerase	NN	O
.	.	O
This	DT	O
polymerase	NN	O
displays	VBZ	O
exquisite	JJ	O
specificity	NN	O
in	IN	O
that	DT	O
it	PRP	O
only	RB	O
transcribes	VBZ	O
templates	NNS	O
bearing	VBG	O
T7	NNP	O
promoters	NNS	O
.	.	O
Following	VBG	O
infection	NN	O
,	,	O
cells	NNS	O
are	VBP	O
transfected	VBN	O
with	IN	O
the	DT	O
DNA	NN	O
of	IN	O
interest	NN	O
,	,	O
driven	VBN	O
by	IN	O
a	DT	O
T7	NNP	O
promoter	NN	O
.	.	O
The	DT	O
polymerase	NN	O
expressed	VBN	O
in	IN	O
the	DT	O
cytoplasm	NN	O
from	IN	O
the	DT	O
vaccinia	NN	O
virus	NN	O
recombinant	NN	O
transcribes	VBZ	O
the	DT	O
transfected	JJ	O
DNA	NNP	O
into	IN	O
RNA	NNP	O
which	WDT	O
is	VBZ	O
then	RB	O
translated	VBN	O
into	IN	O
protein	NN	O
by	IN	O
the	DT	O
host	NN	O
translational	JJ	O
machinery	NN	O
.	.	O
Alternately	RB	O
,	,	O
T7	NNP	O
can	MD	O
be	VB	O
added	VBN	O
as	IN	O
a	DT	O
purified	JJ	O
protein	NN	O
or	CC	O
enzyme	NN	O
as	IN	O
in	IN	O
the	DT	O
“	NNP	O
Progenitor	NNP	O
”	NNP	O
system	NN	O
(	(	O
Studier	NNP	B
and	CC	I
Moffatt	NNP	I
,	,	I
J.	NNP	I
Mol	NNP	I
.	.	I
Biol	NNP	I
.	.	I
(	(	I
1986	CD	I
)	)	I
189:113-130	CD	I
)	)	O
.	.	O
The	DT	O
method	NN	O
provides	VBZ	O
for	IN	O
high	JJ	O
level	NN	O
,	,	O
transient	NN	O
,	,	O
cytoplasmic	JJ	O
production	NN	O
of	IN	O
large	JJ	O
quantities	NNS	O
of	IN	O
RNA	NNP	O
and	CC	O
its	PRP$	O
translation	NN	O
product	NN	O
(	(	O
s	JJ	O
)	)	O
.	.	O
Depending	VBG	O
on	IN	O
the	DT	O
expression	NN	O
system	NN	O
and	CC	O
host	NN	O
selected	VBN	O
,	,	O
the	DT	O
VLPS	NNP	O
are	VBP	O
produced	VBN	O
by	IN	O
growing	VBG	O
host	NN	O
cells	NNS	O
transformed	VBN	O
by	IN	O
an	DT	O
expression	NN	O
vector	NN	O
under	IN	O
conditions	NNS	O
whereby	VBP	O
the	DT	O
particle-forming	JJ	O
polypeptide	NN	O
is	VBZ	O
expressed	VBN	O
and	CC	O
VLPs	NNP	O
can	MD	O
be	VB	O
formed	VBN	O
.	.	O
The	DT	O
selection	NN	O
of	IN	O
the	DT	O
appropriate	JJ	O
growth	NN	O
conditions	NNS	O
is	VBZ	O
within	IN	O
the	DT	O
skill	NN	O
of	IN	O
the	DT	O
art	NN	O
.	.	O
If	IN	O
the	DT	O
VLPs	NNP	O
are	VBP	O
formed	VBN	O
intracellularly	RB	O
,	,	O
the	DT	O
cells	NNS	O
are	VBP	O
then	RB	O
disrupted	VBN	O
,	,	O
using	VBG	O
chemical	NN	O
,	,	O
physical	JJ	O
or	CC	O
mechanical	JJ	O
means	NNS	O
,	,	O
which	WDT	O
lyse	VBZ	O
the	DT	O
cells	NNS	O
yet	RB	O
keep	VBP	O
the	DT	O
VLPs	NNP	O
substantially	RB	O
intact	JJ	O
.	.	O
Such	JJ	O
methods	NNS	O
are	VBP	O
known	VBN	O
to	TO	O
those	DT	O
of	IN	O
skill	NN	O
in	IN	O
the	DT	O
art	NN	O
and	CC	O
are	VBP	O
described	VBN	O
in	IN	O
,	,	O
e.g.	NN	O
,	,	O
Protein	NNP	B
Purification	NNP	I
Applications	NNP	I
:	:	I
A	DT	I
Practical	NNP	I
Approach	NNP	I
,	,	I
(	(	I
E.	NNP	I
L.	NNP	I
V.	NNP	I
Harris	NNP	I
and	CC	I
S.	NNP	I
Angal	NNP	I
,	,	I
Eds.	NNP	I
,	,	I
1990	CD	I
)	)	I
.	.	O
The	DT	O
particles	NNS	O
are	VBP	O
then	RB	O
isolated	VBN	O
(	(	O
or	CC	O
substantially	RB	O
purified	VBN	O
)	)	O
using	VBG	O
methods	NNS	O
that	WDT	O
preserve	VBP	O
the	DT	O
integrity	NN	O
thereof	NN	O
,	,	O
such	JJ	O
as	IN	O
,	,	O
by	IN	O
density	NN	O
gradient	NN	O
centrifugation	NN	O
,	,	O
e.g.	NN	O
,	,	O
sucrose	JJ	O
gradients	NNS	O
,	,	O
PEG-precipitation	NNP	O
,	,	O
pelleting	NN	O
,	,	O
and	CC	O
the	DT	O
like	JJ	O
(	(	O
see	VB	O
,	,	O
e.g.	VB	O
,	,	O
Kirnbauer	NNP	B
et	CC	I
al	NN	I
.	.	I
J.	NNP	I
Virol	NNP	I
.	.	I
(	(	I
1993	CD	I
)	)	I
67:6929-6936	NN	I
)	)	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
standard	JJ	O
purification	NN	O
techniques	NNS	O
including	VBG	O
,	,	O
e.g.	NN	O
,	,	O
ion	NN	O
exchange	NN	O
and	CC	O
gel	JJ	O
filtration	NN	O
chromatography	NN	O
.	.	O
VLPs	NNP	O
produced	VBN	O
by	IN	O
cells	NNS	O
containing	VBG	O
the	DT	O
synthetic	JJ	O
expression	NN	O
cassettes	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
can	MD	O
be	VB	O
used	VBN	O
to	TO	O
elicit	VB	O
an	DT	O
immune	JJ	O
response	NN	O
when	WRB	O
administered	VBN	O
to	TO	O
a	DT	O
subject	NN	O
.	.	O
One	CD	O
advantage	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
is	VBZ	O
that	IN	O
VLPs	NNP	O
can	MD	O
be	VB	O
produced	VBN	O
by	IN	O
mammalian	JJ	O
cells	NNS	O
carrying	VBG	O
the	DT	O
synthetic	JJ	O
expression	NN	O
cassettes	NNS	O
at	IN	O
levels	NNS	O
previously	RB	O
not	RB	O
possible	JJ	O
.	.	O
As	IN	O
discussed	VBN	O
above	IN	O
,	,	O
the	DT	O
VLPs	NNP	O
can	MD	O
comprise	VB	O
a	DT	O
variety	NN	O
of	IN	O
antigens	NNS	O
in	IN	O
addition	NN	O
to	TO	O
the	DT	O
Gag	NNP	O
polypeptides	NNS	O
(	(	O
e.g.	NN	O
,	,	O
Env	NNP	O
,	,	O
tat	NN	O
,	,	O
Gag-protease	NNP	O
,	,	O
Gag-polymerase	NNP	O
,	,	O
Gag-HCV-core	NNP	O
)	)	O
.	.	O
Purified	NNP	O
VLPs	NNP	O
,	,	O
produced	VBD	O
using	VBG	O
the	DT	O
synthetic	JJ	O
expression	NN	O
cassettes	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
,	,	O
can	MD	O
be	VB	O
administered	VBN	O
to	TO	O
a	DT	O
vertebrate	NN	O
subject	NN	O
,	,	O
usually	RB	O
in	IN	O
the	DT	O
form	NN	O
of	IN	O
vaccine	JJ	O
compositions	NNS	O
.	.	O
Combination	NNP	O
vaccines	NNS	O
may	MD	O
also	RB	O
be	VB	O
used	VBN	O
,	,	O
where	WRB	O
such	JJ	O
vaccines	NNS	O
contain	VBP	O
,	,	O
for	IN	O
example	NN	O
,	,	O
other	JJ	O
subunit	NN	O
proteins	NNS	O
derived	VBN	O
from	IN	O
HIV	NNP	O
or	CC	O
other	JJ	O
organisms	NNS	O
(	(	O
e.g.	NN	O
,	,	O
env	NN	O
)	)	O
or	CC	O
gene	NN	O
delivery	NN	O
vaccines	NNS	O
encoding	VBG	O
such	JJ	O
antigens	NNS	O
.	.	O
Administration	NN	O
can	MD	O
take	VB	O
place	NN	O
using	VBG	O
the	DT	O
VLPs	NNP	O
formulated	VBD	O
alone	RB	O
or	CC	O
formulated	VBN	O
with	IN	O
other	JJ	O
antigens	NNS	O
.	.	O
Further	RB	O
,	,	O
the	DT	O
VLPs	NNP	O
can	MD	O
be	VB	O
administered	VBN	O
prior	RB	O
to	TO	O
,	,	O
concurrent	NN	O
with	IN	O
,	,	O
or	CC	O
subsequent	JJ	O
to	TO	O
,	,	O
delivery	NN	O
of	IN	O
the	DT	O
synthetic	JJ	O
expression	NN	O
cassettes	NNS	O
for	IN	O
DNA	NNP	O
immunization	NN	O
(	(	O
see	VB	O
below	IN	O
)	)	O
and/or	NN	O
delivery	NN	O
of	IN	O
other	JJ	O
vaccines	NNS	O
.	.	O
Also	RB	O
,	,	O
the	DT	O
site	NN	O
of	IN	O
VLP	NNP	O
administration	NN	O
may	MD	O
be	VB	O
the	DT	O
same	JJ	O
or	CC	O
different	JJ	O
as	IN	O
other	JJ	O
vaccine	NN	O
compositions	NNS	O
that	WDT	O
are	VBP	O
being	VBG	O
administered	VBN	O
.	.	O
Gene	NNP	O
delivery	NN	O
can	MD	O
be	VB	O
accomplished	VBN	O
by	IN	O
a	DT	O
number	NN	O
of	IN	O
methods	NNS	O
including	VBG	O
,	,	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
,	,	O
immunization	NN	O
with	IN	O
DNA	NNP	O
,	,	O
alphavirus	NN	O
vectors	NNS	O
,	,	O
pox	NN	O
virus	NN	O
vectors	NNS	O
,	,	O
and	CC	O
vaccinia	NN	O
virus	NN	O
vectors	NNS	O
.	.	O
VLP	NNP	O
immune-stimulating	NN	O
(	(	O
or	CC	O
vaccine	NN	O
)	)	O
compositions	NNS	O
can	MD	O
include	VB	O
various	JJ	O
excipients	NNS	O
,	,	O
adjuvants	NNS	O
,	,	O
carriers	NNS	O
,	,	O
auxiliary	JJ	O
substances	NNS	O
,	,	O
modulating	VBG	O
agents	NNS	O
,	,	O
and	CC	O
the	DT	O
like	JJ	O
.	.	O
The	DT	O
immune	JJ	O
stimulating	NN	O
compositions	NNS	O
will	MD	O
include	VB	O
an	DT	O
amount	NN	O
of	IN	O
the	DT	O
VLP/antigen	NNP	O
sufficient	NN	O
to	TO	O
mount	VB	O
an	DT	O
immunological	JJ	O
response	NN	O
.	.	O
An	DT	O
appropriate	JJ	O
effective	JJ	O
amount	NN	O
can	MD	O
be	VB	O
determined	VBN	O
by	IN	O
one	CD	O
of	IN	O
skill	NN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
Such	JJ	O
an	DT	O
amount	NN	O
will	MD	O
fall	VB	O
in	IN	O
a	DT	O
relatively	RB	O
broad	JJ	O
range	NN	O
that	WDT	O
can	MD	O
be	VB	O
determined	VBN	O
through	IN	O
routine	JJ	O
trials	NNS	O
and	CC	O
will	MD	O
generally	RB	O
be	VB	O
an	DT	O
amount	NN	O
on	IN	O
the	DT	O
order	NN	O
of	IN	O
about	IN	O
0.1	CD	O
μg	NNS	O
to	TO	O
about	IN	O
1000	CD	O
μg	NN	O
,	,	O
more	JJR	O
preferably	RB	O
about	IN	O
1	CD	O
μg	NNS	O
to	TO	O
about	IN	O
300	CD	O
μg	NNS	O
,	,	O
of	IN	O
VLP/antigen	NNP	O
.	.	O
A	DT	O
carrier	NN	O
is	VBZ	O
optionally	RB	O
present	JJ	O
which	WDT	O
is	VBZ	O
a	DT	O
molecule	NN	O
that	WDT	O
does	VBZ	O
not	RB	O
itself	PRP	O
induce	VBP	O
the	DT	O
production	NN	O
of	IN	O
antibodies	NNS	O
harmful	VBP	O
to	TO	O
the	DT	O
individual	JJ	O
receiving	VBG	O
the	DT	O
composition	NN	O
.	.	O
Suitable	JJ	O
carriers	NNS	O
are	VBP	O
typically	RB	O
large	JJ	O
,	,	O
slowly	RB	O
metabolized	VBN	O
macromolecules	NNS	O
such	JJ	O
as	IN	O
proteins	NNS	O
,	,	O
polysaccharides	NNS	O
,	,	O
polylactic	JJ	O
acids	NNS	O
,	,	O
polyglycollic	JJ	O
acids	NNS	O
,	,	O
polymeric	JJ	O
amino	NN	O
acids	NNS	O
,	,	O
amino	JJ	O
acid	NN	O
copolymers	NNS	O
,	,	O
lipid	JJ	O
aggregates	NNS	O
(	(	O
such	JJ	O
as	IN	O
oil	NN	O
droplets	NNS	O
or	CC	O
liposomes	NNS	O
)	)	O
,	,	O
and	CC	O
inactive	JJ	O
virus	NN	O
particles	NNS	O
.	.	O
Examples	NNS	O
of	IN	O
particulate	NN	O
carriers	NNS	O
include	VBP	O
those	DT	O
derived	VBN	O
from	IN	O
polymethyl	NN	O
methacrylate	NN	O
polymers	NNS	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
microparticles	NNS	O
derived	VBN	O
from	IN	O
poly	NN	O
(	(	O
lactides	NNS	O
)	)	O
and	CC	O
poly	JJ	O
(	(	O
lactide-co-glycolides	JJ	O
)	)	O
,	,	O
known	VBN	O
as	IN	O
PLG	NNP	O
.	.	O
See	VB	O
,	,	O
e.g.	VB	O
,	,	O
Jeffery	NNP	B
et	CC	I
al.	NN	I
,	,	I
Pharm	NNP	I
.	.	I
Res	NNP	I
.	.	I
(	(	I
1993	CD	I
)	)	I
10:362-368	CD	I
;	:	O
McGee	NNP	B
J	NNP	I
P	NNP	I
,	,	I
et	FW	I
al.	NN	I
,	,	I
J.	NNP	I
Microencapsul	NNP	I
.	.	I
14	CD	I
(	(	I
2	CD	I
)	)	I
:197-210	NN	I
,	,	I
1997	CD	I
;	:	O
O'Hagan	NNP	B
D	NNP	I
T	NNP	I
,	,	I
et	FW	I
al.	NN	I
,	,	I
Vaccine	NNP	I
11	CD	I
(	(	I
2	CD	I
)	)	I
:149-54	NN	I
,	,	I
1993	CD	I
.	.	O
Such	JJ	O
carriers	NNS	O
are	VBP	O
well	RB	O
known	VBN	O
to	TO	O
those	DT	O
of	IN	O
ordinary	JJ	O
skill	NN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
Additionally	RB	O
,	,	O
these	DT	O
carriers	NNS	O
may	MD	O
function	VB	O
as	IN	O
immunostimulating	VBG	O
agents	NNS	O
(	(	O
“	JJ	O
adjuvants	NNS	O
”	NN	O
)	)	O
.	.	O
Furthermore	RB	O
,	,	O
the	DT	O
antigen	NN	O
may	MD	O
be	VB	O
conjugated	VBN	O
to	TO	O
a	DT	O
bacterial	JJ	O
toxoid	NN	O
,	,	O
such	JJ	O
as	IN	O
toxoid	NN	O
from	IN	O
diphtheria	NN	O
,	,	O
tetanus	NN	O
,	,	O
cholera	NN	O
,	,	O
etc.	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
toxins	NNS	O
derived	VBN	O
from	IN	O
E.	NNP	O
coli	NNS	O
.	.	O
Such	JJ	O
adjuvants	NNS	O
include	VBP	O
,	,	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
:	:	O
(	(	O
1	CD	O
)	)	O
aluminum	NN	O
salts	NNS	O
(	(	O
alum	NN	O
)	)	O
,	,	O
such	JJ	O
as	IN	O
aluminum	NN	O
hydroxide	NN	O
,	,	O
aluminum	NN	O
phosphate	NN	O
,	,	O
aluminum	NN	O
sulfate	NN	O
,	,	O
etc	FW	O
.	.	O
;	:	O
(	(	O
2	CD	O
)	)	O
oil-in-water	NN	O
emulsion	NN	O
formulations	NNS	O
(	(	O
with	IN	O
or	CC	O
without	IN	O
other	JJ	O
specific	JJ	O
immunostimulating	VBG	O
agents	NNS	O
such	JJ	O
as	IN	O
muramyl	NN	O
peptides	NNS	O
(	(	O
see	VB	O
below	IN	O
)	)	O
or	CC	O
bacterial	JJ	O
cell	NN	O
wall	NN	O
components	NNS	O
)	)	O
,	,	O
such	JJ	O
as	IN	O
for	IN	O
example	NN	O
(	(	O
a	DT	O
)	)	O
MF59	NNP	O
(	(	O
International	NNP	O
Publication	NNP	O
No	NNP	O
.	.	O
WO	NNP	O
90/14837	CD	O
)	)	O
,	,	O
containing	VBG	O
5	CD	O
%	NN	O
Squalene	NNP	O
,	,	O
0.5	CD	O
%	NN	O
Tween	NNP	O
80	CD	O
,	,	O
and	CC	O
0.5	CD	O
%	NN	O
Span	NNP	O
85	CD	O
(	(	O
optionally	RB	O
containing	VBG	O
various	JJ	O
amounts	NNS	O
of	IN	O
MTP-PE	NNP	O
(	(	O
see	VB	O
below	IN	O
)	)	O
,	,	O
although	IN	O
not	RB	O
required	VBN	O
)	)	O
formulated	VBN	O
into	IN	O
submicron	NN	O
particles	NNS	O
using	VBG	O
a	DT	O
microfluidizer	NN	O
such	JJ	O
as	IN	O
Model	NNP	O
110Y	CD	O
microfluidizer	NN	O
(	(	O
Microfluidics	NNPS	O
,	,	O
Newton	NNP	O
,	,	O
Mass	NNP	O
.	.	O
)	)	O
,	,	O
(	(	O
b	NN	O
)	)	O
SAF	NNP	O
,	,	O
containing	VBG	O
10	CD	O
%	NN	O
Squalane	NNP	O
,	,	O
0.4	CD	O
%	NN	O
Tween	NNP	O
80	CD	O
,	,	O
5	CD	O
%	NN	O
pluronic-blocked	JJ	O
polymer	NN	O
L121	NNP	O
,	,	O
and	CC	O
thr-MDP	NN	O
(	(	O
see	VB	O
below	IN	O
)	)	O
either	CC	O
microfluidized	VBN	O
into	IN	O
a	DT	O
submicron	JJ	O
emulsion	NN	O
or	CC	O
vortexed	NN	O
to	TO	O
generate	VB	O
a	DT	O
larger	JJR	O
particle	NN	O
size	NN	O
emulsion	NN	O
,	,	O
and	CC	O
(	(	O
c	NN	O
)	)	O
Ribi™	NNP	O
adjuvant	JJ	O
system	NN	O
(	(	O
RAS	NNP	O
)	)	O
,	,	O
(	(	O
Ribi	NNP	O
Immunochem	NNP	O
,	,	O
Hamilton	NNP	O
,	,	O
Mont	NNP	O
.	.	O
)	)	O
containing	VBG	O
2	CD	O
%	NN	O
Squalene	NNP	O
,	,	O
0.2	CD	O
%	NN	O
Tween	NNP	O
80	CD	O
,	,	O
and	CC	O
one	CD	O
or	CC	O
more	JJR	O
bacterial	JJ	O
cell	NN	O
wall	NN	O
components	NNS	O
from	IN	O
the	DT	O
group	NN	O
consisting	VBG	O
of	IN	O
monophosphorylipid	NN	O
A	NNP	O
(	(	O
MPL	NNP	O
)	)	O
,	,	O
trehalose	JJ	O
dimycolate	NN	O
(	(	O
TDM	NNP	O
)	)	O
,	,	O
and	CC	O
cell	NN	O
wall	NN	O
skeleton	NN	O
(	(	O
CWS	NNP	O
)	)	O
,	,	O
preferably	RB	O
MPL+CWS	NNP	O
(	(	O
Detox™	NNP	O
)	)	O
;	:	O
(	(	O
3	CD	O
)	)	O
saponin	NN	O
adjuvants	NNS	O
,	,	O
such	JJ	O
as	IN	O
Stimulon™	NNP	O
(	(	O
Cambridge	NNP	O
Bioscience	NNP	O
,	,	O
Worcester	NNP	O
,	,	O
Mass	NNP	O
.	.	O
)	)	O
may	MD	O
be	VB	O
used	VBN	O
or	CC	O
particle	NN	O
generated	VBN	O
therefrom	NNS	O
such	JJ	O
as	IN	O
ISCOMs	NNP	O
(	(	O
immunostimulating	VBG	O
complexes	NNS	O
)	)	O
;	:	O
(	(	O
4	CD	O
)	)	O
Complete	NNP	O
Freunds	NNP	O
Adjuvant	NNP	O
(	(	O
CFA	NNP	O
)	)	O
and	CC	O
Incomplete	NNP	O
Freunds	NNP	O
Adjuvant	NNP	O
(	(	O
IFA	NNP	O
)	)	O
;	:	O
(	(	O
5	CD	O
)	)	O
cytokines	NNS	O
,	,	O
such	JJ	O
as	IN	O
interleukins	NNS	O
(	(	O
IL-1	NNP	O
,	,	O
IL-2	NNP	O
,	,	O
etc	NN	O
.	.	O
)	)	O
,	,	O
macrophage	NN	O
colony	NN	O
stimulating	VBG	O
factor	NN	O
(	(	O
M-CSF	NNP	O
)	)	O
,	,	O
tumor	JJ	O
necrosis	NN	O
factor	NN	O
(	(	O
TNF	NNP	O
)	)	O
,	,	O
beta	JJ	O
chemokines	NNS	O
(	(	O
MIP	NNP	O
,	,	O
1-alpha	JJ	O
,	,	O
1-beta	JJ	O
Rantes	NNP	O
,	,	O
etc	NN	O
.	.	O
)	)	O
;	:	O
(	(	O
6	CD	O
)	)	O
detoxified	VBD	O
mutants	NNS	O
of	IN	O
a	DT	O
bacterial	JJ	O
ADP-ribosylating	JJ	O
toxin	NN	O
such	JJ	O
as	IN	O
a	DT	O
cholera	NN	O
toxin	NN	O
(	(	O
CT	NNP	O
)	)	O
,	,	O
a	DT	O
pertussis	NN	O
toxin	NN	O
(	(	O
PT	NNP	O
)	)	O
,	,	O
or	CC	O
an	DT	O
E.	NNP	O
coli	NNS	O
heat-labile	JJ	O
toxin	NN	O
(	(	O
LT	NNP	O
)	)	O
,	,	O
particularly	RB	O
LT-K63	NNP	O
(	(	O
where	WRB	O
lysine	NN	O
is	VBZ	O
substituted	VBN	O
for	IN	O
the	DT	O
wild-type	JJ	O
amino	NN	O
acid	NN	O
at	IN	O
position	NN	O
63	CD	O
)	)	O
LT-R72	NN	O
(	(	O
where	WRB	O
arginine	NN	O
is	VBZ	O
substituted	VBN	O
for	IN	O
the	DT	O
wild-type	JJ	O
amino	NN	O
acid	NN	O
at	IN	O
position	NN	O
72	CD	O
)	)	O
,	,	O
CT-S109	NNP	O
(	(	O
where	WRB	O
serine	NN	O
is	VBZ	O
substituted	VBN	O
for	IN	O
the	DT	O
wild-type	JJ	O
amino	NN	O
acid	NN	O
at	IN	O
position	NN	O
109	CD	O
)	)	O
,	,	O
and	CC	O
PT-K9/G129	NNP	O
(	(	O
where	WRB	O
lysine	NN	O
is	VBZ	O
substituted	VBN	O
for	IN	O
the	DT	O
wild-type	JJ	O
amino	NN	O
acid	NN	O
at	IN	O
position	NN	O
9	CD	O
and	CC	O
glycine	NN	O
substituted	VBN	O
at	IN	O
position	NN	O
129	CD	O
)	)	O
(	(	O
see	VB	O
,	,	O
e.g.	VB	O
,	,	O
International	NNP	O
Publication	NNP	O
Nos	NNP	O
.	.	O
WO93/13202	NNP	O
and	CC	O
WO92/19265	NNP	O
)	)	O
;	:	O
and	CC	O
(	(	O
7	CD	O
)	)	O
other	JJ	O
substances	NNS	O
that	WDT	O
act	VBP	O
as	IN	O
immunostimulating	VBG	O
agents	NNS	O
to	TO	O
enhance	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
the	DT	O
composition	NN	O
.	.	O
Muramyl	NNP	O
peptides	NNS	O
include	VBP	O
,	,	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
,	,	O
N-acetyl-muramyl-L-threonyl-D-isoglutamine	NNP	O
(	(	O
thr-MDP	NN	O
)	)	O
,	,	O
N-acteyl-normuramyl-L-alanyl-D-isogluatme	NNP	O
(	(	O
nor-MDP	JJ	O
)	)	O
,	,	O
N-acetylmuramyl-L-alanyl-D-isogluatminyl-L-alanine-2-	NNP	O
(	(	O
1′-2′-dipalmitoyl-sn-glycero-3-huydroxyphosphoryloxy	JJ	O
)	)	O
-ethylamine	NN	O
(	(	O
MTP-PE	NNP	O
)	)	O
,	,	O
etc	FW	O
.	.	O
Dosage	NN	O
treatment	NN	O
with	IN	O
the	DT	O
VLP	NNP	O
composition	NN	O
may	MD	O
be	VB	O
a	DT	O
single	JJ	O
dose	NN	O
schedule	NN	O
or	CC	O
a	DT	O
multiple	JJ	O
dose	NN	O
schedule	NN	O
.	.	O
A	DT	O
multiple	JJ	O
dose	NN	O
schedule	NN	O
is	VBZ	O
one	CD	O
in	IN	O
which	WDT	O
a	DT	O
primary	JJ	O
course	NN	O
of	IN	O
vaccination	NN	O
may	MD	O
be	VB	O
with	IN	O
1-10	JJ	O
separate	JJ	O
doses	NNS	O
,	,	O
followed	VBN	O
by	IN	O
other	JJ	O
doses	NNS	O
given	VBN	O
at	IN	O
subsequent	JJ	O
time	NN	O
intervals	NNS	O
,	,	O
chosen	VBN	O
to	TO	O
maintain	VB	O
and/or	JJ	O
reinforce	VB	O
the	DT	O
immune	JJ	O
response	NN	O
,	,	O
for	IN	O
example	NN	O
at	IN	O
1-4	JJ	O
months	NNS	O
for	IN	O
a	DT	O
second	JJ	O
dose	NN	O
,	,	O
and	CC	O
if	IN	O
needed	VBN	O
,	,	O
a	DT	O
subsequent	JJ	O
dose	NN	O
(	(	O
s	NN	O
)	)	O
after	IN	O
several	JJ	O
months	NNS	O
.	.	O
The	DT	O
dosage	NN	O
regimen	NNS	O
will	MD	O
also	RB	O
,	,	O
at	IN	O
least	JJS	O
in	IN	O
part	NN	O
,	,	O
be	VB	O
determined	VBN	O
by	IN	O
the	DT	O
potency	NN	O
of	IN	O
the	DT	O
modality	NN	O
,	,	O
the	DT	O
vaccine	NN	O
delivery	NN	O
employed	VBN	O
,	,	O
the	DT	O
need	NN	O
of	IN	O
the	DT	O
subject	NN	O
and	CC	O
be	VB	O
dependent	VBN	O
on	IN	O
the	DT	O
judgment	NN	O
of	IN	O
the	DT	O
practitioner	NN	O
.	.	O
If	IN	O
prevention	NN	O
of	IN	O
disease	NN	O
is	VBZ	O
desired	VBN	O
(	(	O
e.g.	NN	O
,	,	O
reduction	NN	O
of	IN	O
symptoms	NNS	O
,	,	O
recurrences	NNS	O
or	CC	O
of	IN	O
disease	JJ	O
progression	NN	O
)	)	O
,	,	O
the	DT	O
antigen	NN	O
carrying	NN	O
VLPs	NNP	O
are	VBP	O
generally	RB	O
administered	VBN	O
prior	RB	O
to	TO	O
primary	JJ	O
infection	NN	O
with	IN	O
the	DT	O
pathogen	NN	O
of	IN	O
interest	NN	O
.	.	O
If	IN	O
treatment	NN	O
is	VBZ	O
desired	VBN	O
,	,	O
e.g.	RB	O
,	,	O
the	DT	O
reduction	NN	O
of	IN	O
symptoms	NNS	O
or	CC	O
recurrences	NNS	O
,	,	O
the	DT	O
VLP	NNP	O
compositions	NNS	O
are	VBP	O
generally	RB	O
administered	VBN	O
subsequent	JJ	O
to	TO	O
primary	JJ	O
infection	NN	O
.	.	O
2.2.2	CD	O
Using	VBG	O
the	DT	O
Synthetic	JJ	O
Expression	NNP	O
Cassettes	NNP	O
of	IN	O
the	DT	O
Present	JJ	O
Invention	NNP	O
to	TO	O
Create	VB	O
Packaging	NNP	O
Cell	NNP	O
Lines	VBZ	O
A	NNP	O
number	NN	O
of	IN	O
viral	JJ	O
based	VBN	O
systems	NNS	O
have	VBP	O
been	VBN	O
developed	VBN	O
for	IN	O
use	NN	O
as	IN	O
gene	NN	O
transfer	NN	O
vectors	NNS	O
for	IN	O
mammalian	JJ	O
host	NN	O
cells	NNS	O
.	.	O
For	IN	O
example	NN	O
,	,	O
retroviruses	VBZ	O
(	(	O
in	IN	O
particular	NN	O
,	,	O
lentiviral	JJ	O
vectors	NNS	O
)	)	O
provide	VBP	O
a	DT	O
convenient	NN	O
platform	NN	O
for	IN	O
gene	NN	O
delivery	NN	O
systems	NNS	O
.	.	O
A	DT	O
coding	VBG	O
sequence	NN	O
of	IN	O
interest	NN	O
(	(	O
for	IN	O
example	NN	O
,	,	O
a	DT	O
sequence	NN	O
useful	JJ	O
for	IN	O
gene	NN	O
therapy	NN	O
applications	NNS	O
)	)	O
can	MD	O
be	VB	O
inserted	VBN	O
into	IN	O
a	DT	O
gene	NN	O
delivery	NN	O
vector	NN	O
and	CC	O
packaged	VBN	O
in	IN	O
retroviral	JJ	O
particles	NNS	O
using	VBG	O
techniques	NNS	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
Recombinant	JJ	O
virus	NN	O
can	MD	O
then	RB	O
be	VB	O
isolated	VBN	O
and	CC	O
delivered	VBN	O
to	TO	O
cells	NNS	O
of	IN	O
the	DT	O
subject	NN	O
either	CC	O
in	IN	O
vivo	NN	O
or	CC	O
ex	NN	O
vivo	NN	O
.	.	O
A	DT	O
number	NN	O
of	IN	O
retroviral	JJ	O
systems	NNS	O
have	VBP	O
been	VBN	O
described	VBN	O
,	,	O
including	VBG	O
,	,	O
for	IN	O
example	NN	O
,	,	O
the	DT	O
following	NN	O
:	:	O
(	(	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,219,740	CD	O
;	:	O
Miller	NNP	B
et	FW	I
al	NN	I
.	.	I
(	(	I
1989	CD	I
)	)	I
Biotechniques	VBZ	I
7:980	CD	I
;	:	O
Miller	NNP	B
,	,	I
A.	NNP	I
D.	NNP	I
(	(	I
1990	CD	I
)	)	I
Human	NNP	I
Gene	NNP	I
Therapy	NNP	I
1:5	CD	I
;	:	O
Scarpa	NNP	B
et	FW	I
al	NN	I
.	.	I
(	(	I
1991	CD	I
)	)	I
Virology	NNP	I
180:849	CD	I
;	:	O
Burns	NNP	B
et	FW	I
al	NN	I
.	.	I
(	(	I
1993	CD	I
)	)	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
USA	NNP	I
90:8033	CD	I
;	:	O
Boris-Lawrie	NNP	B
et	FW	I
al	NN	I
.	.	I
(	(	I
1993	CD	I
)	)	I
Cur	NNP	I
.	.	I
Opin	NNP	I
.	.	I
Genet	NNP	I
.	.	I
Develop	NNP	I
.	.	I
3:102	CD	I
;	:	O
GB	NNP	O
2200651	CD	O
;	:	O
EP	NNP	O
0415731	CD	O
;	:	O
EP	NNP	O
0345242	CD	O
;	:	O
WO	NNP	O
89/02468	CD	O
;	:	O
WO	NNP	O
89/05349	CD	O
;	:	O
WO	NNP	O
89/09271	CD	O
;	:	O
WO	NNP	O
90/02806	CD	O
;	:	O
WO	NNP	O
90/07936	CD	O
;	:	O
WO	NNP	O
90/07936	CD	O
;	:	O
WO	NNP	O
94/03622	CD	O
;	:	O
WO	NNP	O
93/25698	CD	O
;	:	O
WO	NNP	O
93/25234	CD	O
;	:	O
WO	NNP	O
93/11230	CD	O
;	:	O
WO	NNP	O
93/10218	CD	O
;	:	O
WO	NNP	O
91/02805	CD	O
;	:	O
in	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,219,740	CD	O
;	:	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
4,405,712	CD	O
;	:	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
4,861,719	CD	O
;	:	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
4,980,289	CD	O
and	CC	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
4,777,127	CD	O
;	:	O
in	IN	O
U.S.	NNP	O
Ser	NNP	O
.	.	O
No	DT	O
.	.	O
07/800,921	CD	O
;	:	O
and	CC	O
in	IN	O
Vile	NNP	B
(	(	I
1993	CD	I
)	)	I
Cancer	NNP	I
Res	NNP	I
53:3860-3864	CD	I
;	:	O
Vile	NNP	B
(	(	I
1993	CD	I
)	)	I
Cancer	NNP	I
Res	NNP	I
53:962-967	CD	I
;	:	O
Ram	NNP	B
(	(	I
1993	CD	I
)	)	I
Cancer	NNP	I
Res	NNP	I
53:83-88	CD	I
;	:	O
Takamiya	NNP	B
(	(	I
1992	CD	I
)	)	I
Neurosci	NNP	I
Res	NNP	I
33:493-503	CD	I
;	:	O
Baba	NNP	B
(	(	I
1993	CD	I
)	)	I
J	NNP	I
Neurosurg	NNP	I
79:729-735	CD	I
;	:	O
Mann	NNP	B
(	(	I
1983	CD	I
)	)	I
Cell	NNP	I
33:153	CD	I
;	:	O
Cane	NNP	B
(	(	I
1984	CD	I
)	)	I
Proc	NNP	I
Natl	NNP	I
Acad	NNP	I
Sci	NNP	I
USA	NNP	I
81	CD	I
;	:	O
6349	CD	O
;	:	O
and	CC	O
Miller	NNP	B
(	(	I
1990	CD	I
)	)	I
Human	NNP	I
Gene	NNP	I
Therapy	NNP	I
1	CD	I
.	.	O
Sequences	NNS	O
useful	JJ	O
for	IN	O
gene	NN	O
therapy	NN	O
applications	NNS	O
include	VBP	O
,	,	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
,	,	O
the	DT	O
following	NN	O
.	.	O
Factor	NNP	O
VIII	NNP	O
cDNA	NN	O
,	,	O
including	VBG	O
derivatives	NNS	O
and	CC	O
deletions	NNS	O
thereof	NN	O
(	(	O
International	NNP	O
Publication	NNP	O
Nos	NNP	O
.	.	O
WO	NNP	O
96/21035	CD	O
,	,	O
WO	NNP	O
97/03193	CD	O
,	,	O
WO	NNP	O
97/03194	CD	O
,	,	O
WO	NNP	O
97/03195	CD	O
,	,	O
and	CC	O
WO	NNP	O
97/03191	CD	O
,	,	O
all	DT	O
of	IN	O
which	WDT	O
are	VBP	O
hereby	RB	O
incorporated	VBN	O
by	IN	O
reference	NN	O
)	)	O
.	.	O
Factor	NNP	O
IX	NNP	O
cDNA	NN	O
(	(	O
Kurachi	NNP	B
et	RB	I
al	RB	I
.	.	I
(	(	I
1982	CD	I
)	)	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
USA	NNP	I
79:6461-6464	CD	I
)	)	O
.	.	O
Factor	NNP	O
V	NNP	O
cDNA	NN	O
can	MD	O
be	VB	O
obtained	VBN	O
from	IN	O
pMT2-V	NN	O
(	(	O
Jenny	NNP	B
(	(	I
1987	CD	I
)	)	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
USA	NNP	I
84:4846	CD	I
,	,	I
A.T.C.C	NNP	I
.	.	I
Deposit	NN	I
No	DT	I
.	.	I
40515	CD	I
)	)	O
.	.	O
A	DT	O
full-length	JJ	O
factor	NN	O
V	NNP	O
cDNA	NN	O
,	,	O
or	CC	O
a	DT	O
B	NNP	O
domain	NN	O
deletion	NN	O
or	CC	O
B	NNP	O
domain	VBP	O
substitution	NN	O
thereof	NN	O
,	,	O
can	MD	O
be	VB	O
used	VBN	O
.	.	O
B	NNP	O
domain	NN	O
deletions	NNS	O
of	IN	O
factor	NN	O
V	NNP	O
,	,	O
include	VBP	O
those	DT	O
reported	VBN	O
by	IN	O
Marquette	NNP	B
(	(	I
1995	CD	I
)	)	I
Blood	VBD	I
86:3026	CD	I
and	CC	O
Kane	NNP	B
(	(	I
1990	CD	I
)	)	I
Biochemistry	NNP	I
29:6762	CD	I
.	.	O
Antithrombin	NNP	O
III	NNP	O
cDNA	NN	O
(	(	O
Prochownik	NNP	B
(	(	I
1983	CD	I
)	)	I
J.	NNP	I
Biol	NNP	I
.	.	I
Chem	NNP	I
.	.	I
258:8389	CD	I
,	,	I
A.T.C.C	NNP	I
.	.	I
Deposit	NN	I
No	DT	I
.	.	I
57224/57225	CD	I
)	)	O
.	.	O
Protein	NNP	O
C	NNP	O
encoding	VBG	O
cDNA	NN	O
(	(	O
Foster	NNP	B
(	(	I
1984	CD	I
)	)	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
USA	NNP	I
81:4766	CD	I
;	:	O
Beckmann	NNP	B
(	(	I
1985	CD	I
)	)	I
Nucleic	NNP	I
Acids	NNP	I
Res	NNP	I
.	.	I
13:5233	CD	I
)	)	O
.	.	O
Prothrombin	NNP	O
cDNA	NN	O
can	MD	O
be	VB	O
obtained	VBN	O
by	IN	O
restriction	NN	O
enzyme	JJ	O
digestion	NN	O
of	IN	O
a	DT	O
published	VBN	O
vector	NN	O
(	(	O
Degen	NNP	B
(	(	I
1983	CD	I
)	)	I
Biochemistry	NNP	I
22:2087	CD	I
)	)	O
.	.	O
The	DT	O
endothelial	JJ	O
cell	NN	O
surface	NN	O
protein	NN	O
,	,	O
thrombomodulin	NN	O
,	,	O
is	VBZ	O
a	DT	O
necessary	JJ	O
cofactor	NN	O
for	IN	O
the	DT	O
normal	JJ	O
activation	NN	O
of	IN	O
protein	NN	O
C	NNP	O
by	IN	O
thrombin	NN	O
.	.	O
A	DT	O
soluble	JJ	O
recombinant	JJ	O
form	NN	O
has	VBZ	O
been	VBN	O
described	VBN	O
(	(	O
Parkinson	NNP	B
(	(	I
1990	CD	I
)	)	I
J.	NNP	I
Biol	NNP	I
.	.	I
Chem	NNP	I
.	.	I
265:12602	CD	I
;	:	O
Jackman	NNP	B
(	(	I
1987	CD	I
)	)	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
USA	NNP	I
84:6425	CD	I
;	:	O
Shirai	NNP	B
(	(	I
1988	CD	I
)	)	I
J.	NNP	I
Biochem	NNP	I
.	.	I
103:281	CD	I
;	:	O
Wen	NNP	B
(	(	I
1987	CD	I
)	)	I
Biochemistry	NNP	I
26:4350	CD	I
;	:	O
Suzuki	NNP	B
(	(	I
1987	CD	I
)	)	I
EMBO	NNP	I
J	NNP	I
.	.	I
6:1891	CD	I
,	,	I
A.T.C.C	NNP	I
.	.	I
Deposit	NN	I
No	DT	I
.	.	I
61348	CD	I
,	,	I
61349	CD	I
)	)	O
.	.	O
Many	JJ	O
genetic	JJ	O
diseases	NNS	O
caused	VBN	O
by	IN	O
inheritance	NN	O
of	IN	O
defective	JJ	O
genes	NNS	O
result	NN	O
in	IN	O
the	DT	O
failure	NN	O
to	TO	O
produce	VB	O
normal	JJ	O
gene	NN	O
products	NNS	O
,	,	O
for	IN	O
example	NN	O
,	,	O
thalassemia	NN	O
,	,	O
phenylketonuria	NN	O
,	,	O
Lesch-Nyhan	NNP	O
syndrome	NN	O
,	,	O
severe	JJ	O
combined	VBN	O
immunodeficiency	NN	O
(	(	O
SCID	NNP	O
)	)	O
,	,	O
hemophilia	VBZ	O
A	NNP	O
and	CC	O
B	NNP	O
,	,	O
cystic	JJ	O
fibrosis	NN	O
,	,	O
Duchenne	NNP	O
's	POS	O
Muscular	NNP	O
Dystrophy	NNP	O
,	,	O
inherited	VBD	O
emphysema	NN	O
and	CC	O
familial	JJ	O
hypercholesterolemia	NN	O
(	(	O
Mulligan	NNP	B
et	RB	I
al	RB	I
.	.	I
(	(	I
1993	CD	I
)	)	I
Science	NN	I
260:926	CD	I
;	:	O
Anderson	NNP	B
et	FW	I
al	NN	I
.	.	I
(	(	I
1992	CD	I
)	)	I
Science	NN	I
256:808	CD	I
;	:	O
Friedman	NNP	B
et	VBZ	I
al	NN	I
.	.	I
(	(	I
1989	CD	I
)	)	I
Science	NNP	I
244:1275	CD	I
)	)	O
.	.	O
Although	IN	O
genetic	JJ	O
diseases	NNS	O
may	MD	O
result	VB	O
in	IN	O
the	DT	O
absence	NN	O
of	IN	O
a	DT	O
gene	NN	O
product	NN	O
,	,	O
endocrine	JJ	O
disorders	NNS	O
,	,	O
such	JJ	O
as	IN	O
diabetes	NNS	O
and	CC	O
hypopituitarism	NN	O
,	,	O
are	VBP	O
caused	VBN	O
by	IN	O
the	DT	O
inability	NN	O
of	IN	O
the	DT	O
gene	NN	O
to	TO	O
produce	VB	O
adequate	JJ	O
levels	NNS	O
of	IN	O
the	DT	O
appropriate	JJ	O
hormone	NN	O
insulin	NN	O
and	CC	O
human	JJ	O
growth	NN	O
hormone	NN	O
respectively	RB	O
.	.	O
In	IN	O
one	CD	O
aspect	NN	O
,	,	O
gene	NN	O
therapy	NN	O
employing	VBG	O
the	DT	O
constructs	NNS	O
and	CC	O
methods	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
involves	VBZ	O
the	DT	O
introduction	NN	O
of	IN	O
normal	JJ	O
recombinant	JJ	O
genes	NNS	O
into	IN	O
T	NNP	O
cells	NNS	O
so	RB	O
that	IN	O
new	JJ	O
or	CC	O
missing	JJ	O
proteins	NNS	O
are	VBP	O
produced	VBN	O
by	IN	O
the	DT	O
T	NNP	O
cells	NNS	O
after	IN	O
introduction	NN	O
or	CC	O
reintroduction	NN	O
thereof	NN	O
into	IN	O
a	DT	O
patient	NN	O
.	.	O
A	DT	O
number	NN	O
of	IN	O
genetic	JJ	O
diseases	NNS	O
have	VBP	O
been	VBN	O
selected	VBN	O
for	IN	O
treatment	NN	O
with	IN	O
gene	NN	O
therapy	NN	O
,	,	O
including	VBG	O
adenine	JJ	O
deaminase	NN	O
deficiency	NN	O
,	,	O
cystic	JJ	O
fibrosis	NN	O
,	,	O
α1-antitrypsin	JJ	O
deficiency	NN	O
,	,	O
Gaucher	NNP	O
's	POS	O
syndrome	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
non-genetic	JJ	O
diseases	NNS	O
.	.	O
In	IN	O
particular	JJ	O
,	,	O
Gaucher	NNP	O
's	POS	O
syndrome	NN	O
is	VBZ	O
a	DT	O
genetic	JJ	O
disorder	NN	O
characterized	VBN	O
by	IN	O
a	DT	O
deficiency	NN	O
of	IN	O
the	DT	O
enzyme	JJ	O
glucocerebrosidase	NN	O
.	.	O
This	DT	O
enzyme	JJ	O
deficiency	NN	O
leads	VBZ	O
to	TO	O
the	DT	O
accumulation	NN	O
of	IN	O
glucocerebroside	NN	O
in	IN	O
the	DT	O
lysosomes	NNS	O
of	IN	O
all	DT	O
cells	NNS	O
in	IN	O
the	DT	O
body	NN	O
.	.	O
For	IN	O
a	DT	O
review	NN	O
see	NN	O
Science	NNP	B
256:794	CD	I
(	(	I
1992	CD	I
)	)	I
and	CC	O
Scriver	NNP	B
et	VBP	I
al.	NN	I
,	,	I
The	DT	I
Metabolic	NNP	I
Basis	NNP	I
of	IN	I
Inherited	NNP	I
Disease	NNP	I
,	,	I
6th	CD	I
ed.	NN	I
,	,	I
vol	NN	I
.	.	I
2	CD	I
,	,	I
page	NN	I
1677	CD	I
)	)	O
.	.	O
Thus	RB	O
,	,	O
gene	NN	O
transfer	NN	O
vectors	NNS	O
that	WDT	O
express	VBP	O
glucocerebrosidase	NN	O
can	MD	O
be	VB	O
constructed	VBN	O
for	IN	O
use	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
this	DT	O
disorder	NN	O
.	.	O
Likewise	RB	O
,	,	O
gene	NN	O
transfer	NN	O
vectors	NNS	O
encoding	VBG	O
lactase	NN	O
can	MD	O
be	VB	O
used	VBN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
hereditary	JJ	O
lactose	JJ	O
intolerance	NN	O
,	,	O
those	DT	O
expressing	VBG	O
AD	NNP	O
can	MD	O
be	VB	O
used	VBN	O
for	IN	O
treatment	NN	O
of	IN	O
ADA	NNP	O
deficiency	NN	O
,	,	O
and	CC	O
gene	NN	O
transfer	NN	O
vectors	NNS	O
encoding	VBG	O
α1-antitrypsin	NN	O
can	MD	O
be	VB	O
used	VBN	O
to	TO	O
treat	VB	O
α1-antitrypsin	JJ	O
deficiency	NN	O
.	.	O
See	NNP	O
Ledley	NNP	B
,	,	I
F.	NNP	I
D.	NNP	I
(	(	I
1987	CD	I
)	)	I
J.	NNP	I
Pediatrics	NNP	I
110:157-174	JJ	I
,	,	O
Verma	NNP	B
,	,	I
I	PRP	I
.	.	I
(	(	I
November	NNP	I
1987	CD	I
)	)	I
Scientific	FW	I
American	JJ	I
pp	NN	I
.	.	I
68-84	JJ	I
,	,	O
and	CC	O
International	NNP	O
Publication	NNP	O
No	NNP	O
.	.	O
WO	$	O
95/27512	CD	O
entitled	VBN	O
“	JJ	O
Gene	NNP	O
Therapy	NNP	O
Treatment	NNP	O
for	IN	O
a	DT	O
Variety	NNP	O
of	IN	O
Diseases	NNP	O
and	CC	O
Disorders	NNP	O
,	,	O
”	NNP	O
for	IN	O
a	DT	O
description	NN	O
of	IN	O
gene	NN	O
therapy	NN	O
treatment	NN	O
of	IN	O
genetic	JJ	O
diseases	NNS	O
.	.	O
In	IN	O
still	RB	O
further	JJ	O
embodiments	NNS	O
of	IN	O
the	DT	O
invention	NN	O
,	,	O
nucleotide	NN	O
sequences	NNS	O
which	WDT	O
can	MD	O
be	VB	O
incorporated	VBN	O
into	IN	O
a	DT	O
gene	NN	O
transfer	NN	O
vector	NN	O
include	VBP	O
,	,	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
,	,	O
proteins	NNS	O
associated	VBN	O
with	IN	O
enzyme-deficiency	NN	O
disorders	NNS	O
,	,	O
such	JJ	O
as	IN	O
the	DT	O
cystic	JJ	O
fibrosis	NN	O
transmembrane	NN	O
regulator	NN	O
(	(	O
see	VB	O
,	,	O
for	IN	O
example	NN	O
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,240,846	CD	O
and	CC	O
Larrick	NNP	B
et	VBP	I
al	NN	I
.	.	I
(	(	I
1991	CD	I
)	)	I
Gene	NNP	I
Therapy	NNP	I
Applications	NNP	I
of	IN	I
Molecular	NNP	I
Biology	NNP	I
,	,	I
Elsevier	NNP	I
,	,	I
New	NNP	I
York	NNP	I
and	CC	O
adenosine	JJ	O
deaminase	NN	O
(	(	O
ADA	NNP	O
)	)	O
(	(	O
see	VB	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,399,346	CD	O
)	)	O
;	:	O
growth	NN	O
factors	NNS	O
,	,	O
or	CC	O
an	DT	O
agonist	NN	O
or	CC	O
antagonist	NN	O
of	IN	O
a	DT	O
growth	NN	O
factor	NN	O
(	(	O
Bandara	NNP	B
et	RB	I
al	RB	I
.	.	I
(	(	I
1992	CD	I
)	)	I
DNA	NN	I
and	CC	I
Cell	NNP	I
Biology	NNP	I
,	,	I
11:227	CD	I
)	)	O
;	:	O
one	CD	O
or	CC	O
more	JJR	O
tumor	NN	O
suppressor	NN	O
genes	NNS	O
such	JJ	O
as	IN	O
p53	NN	O
,	,	O
Rb	NNP	O
,	,	O
or	CC	O
C-CAMI	NNP	O
(	(	O
Kleinerman	NNP	B
et	VBZ	I
al	NN	I
.	.	I
(	(	I
1995	CD	I
)	)	I
Cancer	NNP	I
Research	NNP	I
55:2831	CD	I
)	)	O
;	:	O
a	DT	O
molecule	NN	O
that	WDT	O
modulates	VBZ	O
the	DT	O
immune	JJ	O
system	NN	O
of	IN	O
an	DT	O
organism	NN	O
,	,	O
such	JJ	O
as	IN	O
a	DT	O
HLA	NNP	O
molecule	NN	O
(	(	O
Nabel	NNP	B
et	RB	I
al	RB	I
.	.	I
(	(	I
1993	CD	I
)	)	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
USA	NNP	I
90:11307	CD	I
)	)	O
;	:	O
a	DT	O
ribozyme	NN	O
(	(	O
Larsson	NNP	B
et	RB	I
al	RB	I
.	.	I
(	(	I
1996	CD	I
)	)	I
Virology	NNP	I
219:161	CD	I
)	)	O
;	:	O
a	DT	O
peptide	NN	O
nucleic	JJ	O
acid	NN	O
(	(	O
Hirshman	NNP	B
et	VBZ	I
al	NN	I
.	.	I
(	(	I
1996	CD	I
)	)	I
J	NNP	I
.	.	I
Invest	NNP	I
.	.	I
Med	NNP	I
.	.	I
44:347	CD	I
)	)	O
;	:	O
an	DT	O
antisense	NN	O
molecule	NN	O
(	(	O
Bordier	NNP	B
et	RB	I
al	RB	I
.	.	I
(	(	I
1995	CD	I
)	)	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
USA	NNP	I
92:9383	CD	I
)	)	O
which	WDT	O
can	MD	O
be	VB	O
used	VBN	O
to	TO	O
down-regulate	VB	O
the	DT	O
expression	NN	O
or	CC	O
synthesis	NN	O
of	IN	O
aberrant	NN	O
or	CC	O
foreign	JJ	O
proteins	NNS	O
,	,	O
such	JJ	O
as	IN	O
HIV	NNP	O
proteins	VBZ	O
or	CC	O
a	DT	O
wide	JJ	O
variety	NN	O
of	IN	O
oncogenes	NNS	O
such	JJ	O
as	IN	O
p53	NN	O
(	(	O
Hesketh	NNP	B
,	,	I
The	DT	I
Oncogene	NNP	I
Facts	NNP	I
Book	NNP	I
,	,	I
Academic	NNP	I
Press	NNP	I
,	,	I
New	NNP	I
York	NNP	I
,	,	I
(	(	I
1995	CD	I
)	)	I
;	:	O
a	DT	O
biopharmaceutical	JJ	O
agent	NN	O
or	CC	O
antisense	NN	O
molecule	NN	O
used	VBN	O
to	TO	O
treat	VB	O
HIV-infection	NNP	O
,	,	O
such	JJ	O
as	IN	O
an	DT	O
inhibitor	NN	O
of	IN	O
p24	NN	O
(	(	O
Nakashima	NNP	B
et	RB	I
al	RB	I
.	.	I
(	(	I
1994	CD	I
)	)	I
Nucleic	NNP	I
Acids	NNP	I
Res	NNP	I
.	.	I
22:5004	CD	I
)	)	O
;	:	O
or	CC	O
reverse-transcriptase	NN	O
(	(	O
see	VB	O
,	,	O
Bordier	NNP	O
,	,	O
supra	NN	O
)	)	O
.	.	O
Other	JJ	O
proteins	NNS	O
of	IN	O
therapeutic	JJ	O
interest	NN	O
can	MD	O
be	VB	O
expressed	VBN	O
in	IN	O
vivo	NN	O
by	IN	O
gene	NN	O
transfer	NN	O
vectors	NNS	O
using	VBG	O
the	DT	O
methods	NNS	O
of	IN	O
the	DT	O
invention	NN	O
.	.	O
For	IN	O
instance	NN	O
sustained	VBN	O
in	IN	O
vivo	JJ	O
expression	NN	O
of	IN	O
tissue	NN	O
factor	NN	O
inhibitory	NN	O
protein	NN	O
(	(	O
TFPI	NNP	O
)	)	O
is	VBZ	O
useful	JJ	O
for	IN	O
treatment	NN	O
of	IN	O
conditions	NNS	O
including	VBG	O
sepsis	NN	O
and	CC	O
DIC	NNP	O
and	CC	O
in	IN	O
preventing	VBG	O
reperfusion	NN	O
injury	NN	O
.	.	O
(	(	O
See	VB	O
International	NNP	O
Publications	NNP	O
Nos	NNP	O
.	.	O
WO	NNP	O
93/24143	CD	O
,	,	O
WO	NNP	O
93/25230	CD	O
and	CC	O
WO	NNP	O
96/06637	CD	O
)	)	O
.	.	O
Nucleic	NNP	O
acid	NN	O
sequences	NNS	O
encoding	VBG	O
various	JJ	O
forms	NNS	O
of	IN	O
TFPI	NNP	O
can	MD	O
be	VB	O
obtained	VBN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
as	IN	O
described	VBN	O
in	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
Nos	NNP	O
.	.	O
4,966,852	CD	O
;	:	O
5,106,833	CD	O
;	:	O
and	CC	O
5,466,783	CD	O
,	,	O
and	CC	O
incorporated	VBN	O
into	IN	O
the	DT	O
gene	NN	O
transfer	NN	O
vectors	NNS	O
described	VBD	O
herein	NN	O
.	.	O
Erythropoietin	NNP	O
(	(	O
EPO	NNP	O
)	)	O
and	CC	O
leptin	NN	O
can	MD	O
also	RB	O
be	VB	O
expressed	VBN	O
in	IN	O
vivo	NN	O
from	IN	O
genetically	RB	O
modified	VBN	O
T	NNP	O
cells	NNS	O
according	VBG	O
to	TO	O
the	DT	O
methods	NNS	O
of	IN	O
the	DT	O
invention	NN	O
.	.	O
For	IN	O
instance	NN	O
EPO	NNP	O
is	VBZ	O
useful	JJ	O
in	IN	O
gene	NN	O
therapy	NN	O
treatment	NN	O
of	IN	O
a	DT	O
variety	NN	O
of	IN	O
disorders	NNS	O
including	VBG	O
anemia	NN	O
(	(	O
see	VB	O
International	NNP	O
Publication	NNP	O
No	NNP	O
.	.	O
WO	$	O
95/13376	CD	O
entitled	VBN	O
“	JJ	O
Gene	NNP	O
Therapy	NNP	O
for	IN	O
Treatment	NNP	O
of	IN	O
Anemia	NNP	O
”	NNP	O
)	)	O
.	.	O
Sustained	JJ	O
delivery	NN	O
of	IN	O
leptin	NN	O
by	IN	O
the	DT	O
methods	NNS	O
of	IN	O
the	DT	O
invention	NN	O
is	VBZ	O
useful	JJ	O
in	IN	O
treatment	NN	O
of	IN	O
obesity	NN	O
.	.	O
See	NNP	O
International	NNP	O
Publication	NNP	O
No	NNP	O
.	.	O
WO	$	O
96/05309	CD	O
for	IN	O
a	DT	O
description	NN	O
of	IN	O
the	DT	O
leptin	JJ	O
gene	NN	O
and	CC	O
the	DT	O
use	NN	O
thereof	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
obesity	NN	O
.	.	O
A	DT	O
variety	NN	O
of	IN	O
other	JJ	O
disorders	NNS	O
can	MD	O
also	RB	O
be	VB	O
treated	VBN	O
by	IN	O
the	DT	O
methods	NNS	O
of	IN	O
the	DT	O
invention	NN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
sustained	VBN	O
in	IN	O
vivo	JJ	O
systemic	JJ	O
production	NN	O
of	IN	O
apolipoprotein	JJ	O
E	NNP	O
or	CC	O
apolipoprotein	VB	O
A	DT	O
from	IN	O
genetically	RB	O
modified	VBN	O
T	NNP	O
cells	NNS	O
can	MD	O
be	VB	O
used	VBN	O
for	IN	O
treatment	NN	O
of	IN	O
hyperlipidemia	NN	O
(	(	O
see	VB	O
Breslow	NNP	B
et	FW	I
al	NN	I
.	.	I
(	(	I
1994	CD	I
)	)	I
Biotechnology	NNP	I
12:365	CD	I
)	)	O
.	.	O
Sustained	VBN	O
production	NN	O
of	IN	O
angiotensin	NN	O
receptor	NN	O
inhibitor	NN	O
(	(	O
Goodfriend	NNP	B
et	VBZ	I
al	NN	I
.	.	I
(	(	I
1996	CD	I
)	)	I
N.	NNP	I
Engl	NNP	I
.	.	I
J.	NNP	I
Med	NNP	I
.	.	I
334:1469	CD	I
)	)	O
can	MD	O
be	VB	O
provided	VBN	O
by	IN	O
the	DT	O
methods	NNS	O
described	VBD	O
herein	NN	O
.	.	O
As	IN	O
yet	RB	O
an	DT	O
additional	JJ	O
example	NN	O
,	,	O
the	DT	O
long	JJ	O
term	NN	O
in	IN	O
vivo	JJ	O
systemic	JJ	O
production	NN	O
of	IN	O
angiostatin	NN	O
is	VBZ	O
useful	JJ	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
a	DT	O
variety	NN	O
of	IN	O
tumors	NNS	O
.	.	O
(	(	O
See	VB	O
O'Reilly	RB	B
et	JJ	I
al	NN	I
.	.	I
(	(	I
1996	CD	I
)	)	I
Nature	NN	I
Med	NNP	I
.	.	I
2:689	CD	I
)	)	O
.	.	O
In	IN	O
other	JJ	O
embodiments	NNS	O
,	,	O
gene	NN	O
transfer	NN	O
vectors	NNS	O
can	MD	O
be	VB	O
constructed	VBN	O
to	TO	O
encode	VB	O
a	DT	O
cytokine	NN	O
or	CC	O
other	JJ	O
immunomodulatory	JJ	O
molecule	NN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
nucleic	JJ	O
acid	NN	O
sequences	NNS	O
encoding	VBG	O
native	JJ	O
IL-2	JJ	O
and	CC	O
gamma-interferon	NN	O
can	MD	O
be	VB	O
obtained	VBN	O
as	IN	O
described	VBN	O
in	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
Nos	NNP	O
.	.	O
4,738,927	CD	O
and	CC	O
5,326,859	CD	O
,	,	O
respectively	RB	O
,	,	O
while	IN	O
useful	JJ	O
muteins	NNS	O
of	IN	O
these	DT	O
proteins	NNS	O
can	MD	O
be	VB	O
obtained	VBN	O
as	IN	O
described	VBN	O
in	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
4,853,332	CD	O
.	.	O
Nucleic	NNP	O
acid	NN	O
sequences	NNS	O
encoding	VBG	O
the	DT	O
short	JJ	O
and	CC	O
long	JJ	O
forms	NNS	O
of	IN	O
mCSF	NN	O
can	MD	O
be	VB	O
obtained	VBN	O
as	IN	O
described	VBN	O
in	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
Nos	NNP	O
.	.	O
4,847,201	CD	O
and	CC	O
4,879,227	CD	O
,	,	O
respectively	RB	O
.	.	O
In	IN	O
particular	JJ	O
aspects	NNS	O
of	IN	O
the	DT	O
invention	NN	O
,	,	O
retroviral	JJ	O
vectors	NNS	O
expressing	VBG	O
cytokine	NN	O
or	CC	O
immunomodulatory	JJ	O
genes	NNS	O
can	MD	O
be	VB	O
produced	VBN	O
as	IN	O
described	JJ	O
herein	NN	O
(	(	O
for	IN	O
example	NN	O
,	,	O
employing	VBG	O
the	DT	O
packaging	NN	O
cell	NN	O
lines	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
)	)	O
and	CC	O
in	IN	O
International	NNP	O
Application	NNP	O
No	NNP	O
.	.	O
PCT	NNP	O
US	NNP	O
94/02951	CD	O
,	,	O
entitled	VBN	O
“	JJ	O
Compositions	NNS	O
and	CC	O
Methods	NNS	O
for	IN	O
Cancer	NNP	O
Immunotherapy.	NNP	O
”	NNP	O
Examples	NNP	O
of	IN	O
suitable	JJ	O
immunomodulatory	NN	O
molecules	NNS	O
for	IN	O
use	NN	O
herein	NN	O
include	VBP	O
the	DT	O
following	JJ	O
:	:	O
IL-1	JJ	O
and	CC	O
IL-2	NNP	O
(	(	O
Karupiah	NNP	B
et	RB	I
al	RB	I
.	.	I
(	(	I
1990	CD	I
)	)	I
J	NNP	I
.	.	I
Immunology	NNP	I
144:290-298	CD	I
,	,	O
Weber	NNP	B
et	CC	I
al	NN	I
.	.	I
(	(	I
1987	CD	I
)	)	I
.	.	I
J.	NNP	I
Exp	NNP	I
.	.	I
Med	NNP	I
.	.	I
166:1716-1733	JJ	I
,	,	O
Gansbacher	NNP	B
et	CC	I
al	NN	I
.	.	I
(	(	I
1990	CD	I
)	)	I
J.	NNP	I
Exp	NNP	I
.	.	I
Med	NNP	I
.	.	I
172:1217-1224	JJ	I
,	,	O
and	CC	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
4,738,927	CD	O
)	)	O
;	:	O
IL-3	JJ	O
and	CC	O
IL-4	NNP	O
(	(	O
Tepper	NNP	B
et	VBZ	I
al	NN	I
.	.	I
(	(	I
1989	CD	I
)	)	I
Cell	NNP	I
57:503-512	CD	I
,	,	O
Golumbek	NNP	B
et	CC	I
al	NN	I
.	.	I
(	(	I
1991	CD	I
)	)	I
Science	NNP	I
254:713-716	JJ	I
,	,	O
and	CC	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,017,691	CD	O
)	)	O
;	:	O
IL-5	JJ	O
and	CC	O
IL-6	NNP	O
(	(	O
Brakenhof	NNP	B
et	RB	I
al	RB	I
.	.	I
(	(	I
1987	CD	I
)	)	I
J.	NNP	I
Immunol	NNP	I
.	.	I
139:4116-4121	JJ	I
,	,	O
and	CC	O
International	NNP	O
Publication	NNP	O
No	NNP	O
.	.	O
WO	NNP	O
90/06370	CD	O
)	)	O
;	:	O
IL-7	NNP	O
(	(	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
4,965,195	CD	O
)	)	O
;	:	O
IL-8	JJ	O
,	,	O
IL-9	NNP	O
,	,	O
IL-10	NNP	O
,	,	O
IL-11	NNP	O
,	,	O
IL-12	NNP	O
,	,	O
and	CC	O
IL-13	NNP	O
(	(	O
Cytokine	NNP	B
Bulletin	NNP	I
,	,	I
Summer	NNP	I
1994	CD	I
)	)	O
;	:	O
IL-14	JJ	O
and	CC	O
IL-15	NNP	O
;	:	O
alpha	JJ	O
interferon	NN	O
(	(	O
Finter	NNP	B
et	RB	I
al	RB	I
.	.	I
(	(	I
1991	CD	I
)	)	I
Drugs	NNP	I
42:749-765	JJ	I
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
Nos	NNP	O
.	.	O
4,892,743	CD	O
and	CC	O
4,966,843	CD	O
,	,	O
International	NNP	O
Publication	NNP	O
No	NNP	O
.	.	O
WO	NNP	O
85/02862	CD	O
,	,	O
Nagata	NNP	B
et	CC	I
al	NN	I
.	.	I
(	(	I
1980	CD	I
)	)	I
Nature	NN	I
284:316-320	JJ	I
,	,	O
Familletti	NNP	B
et	CC	I
al	NN	I
.	.	I
(	(	I
1981	CD	I
)	)	I
Methods	NNS	I
in	IN	I
Enz	NNP	I
.	.	I
78:387-394	JJ	I
,	,	O
Twu	NNP	B
et	CC	I
al	NN	I
.	.	I
(	(	I
1989	CD	I
)	)	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
USA	NNP	I
86:2046-2050	CD	I
,	,	O
and	CC	O
Faktor	NNP	B
et	VBP	I
al	NN	I
.	.	I
(	(	I
1990	CD	I
)	)	I
Oncogene	NNP	I
5:867-872	JJ	I
)	)	I
;	:	O
beta-interferon	NN	O
(	(	O
Seif	NNP	B
et	RB	I
al	RB	I
.	.	I
(	(	I
1991	CD	I
)	)	I
J.	NNP	I
Virol	NNP	I
.	.	I
65:664-671	JJ	I
)	)	O
;	:	O
gamma-interferons	NNS	O
(	(	O
Radford	NNP	B
et	VBZ	I
al	NN	I
.	.	I
(	(	I
1991	CD	I
)	)	I
The	DT	I
American	JJ	I
Society	NNP	I
of	IN	I
Hepatology	NNP	I
20082015	CD	I
,	,	O
Watanabe	NNP	B
et	CC	I
al	NN	I
.	.	I
(	(	I
1989	CD	I
)	)	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
USA	NNP	I
86:9456-9460	CD	I
,	,	O
Gansbacher	NNP	B
et	CC	I
al	NN	I
.	.	I
(	(	I
1990	CD	I
)	)	I
Cancer	NNP	I
Research	NNP	I
50:7820-7825	JJ	I
,	,	O
Maio	NNP	B
et	CC	I
al	NN	I
.	.	I
(	(	I
1989	CD	I
)	)	I
Can	MD	I
.	.	I
Immunol	NNP	I
.	.	I
Immunother	NNP	I
.	.	I
30:34-42	JJ	I
,	,	O
and	CC	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
Nos	NNP	O
.	.	O
4,762,791	CD	O
and	CC	O
4,727,138	CD	O
)	)	O
;	:	O
G-CSF	NNP	O
(	(	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
Nos	NNP	O
.	.	O
4,999,291	CD	O
and	CC	O
4,810,643	CD	O
)	)	O
;	:	O
GM-CSF	NNP	O
(	(	O
International	NNP	O
Publication	NNP	O
No	NNP	O
.	.	O
WO	NNP	O
85/04188	CD	O
)	)	O
;	:	O
tumor	CC	O
necrosis	NN	O
factors	NNS	O
(	(	O
TNFs	NNP	O
)	)	O
(	(	O
Jayaraman	NNP	B
et	VBZ	I
al	NN	I
.	.	I
(	(	I
1990	CD	I
)	)	I
J	NNP	I
.	.	I
Immunology	NNP	I
144:942-951	JJ	I
)	)	O
;	:	O
CD3	NNP	O
(	(	O
Krissanen	NNP	B
et	RB	I
al	RB	I
.	.	I
(	(	I
1987	CD	I
)	)	I
Immunogenetics	NNPS	I
26:258-266	JJ	I
)	)	O
;	:	O
ICAM-1	NNP	O
(	(	O
Altman	NNP	B
et	VBZ	I
al	NN	I
.	.	I
(	(	I
1989	CD	I
)	)	I
Nature	NN	I
338:512-514	JJ	I
,	,	O
Simmons	NNP	B
et	CC	I
al	NN	I
.	.	I
(	(	I
1988	CD	I
)	)	I
Nature	NNP	I
331:624-627	JJ	I
)	)	O
;	:	O
ICAM-2	JJ	O
,	,	O
LFA-1	JJ	O
,	,	O
LFA-3	NNP	O
(	(	O
Wallner	NNP	B
et	RB	I
al	RB	I
.	.	I
(	(	I
1987	CD	I
)	)	I
J.	NNP	I
Exp	NNP	I
.	.	I
Med	NNP	I
.	.	I
166:923-932	JJ	I
)	)	O
;	:	O
MHC	NNP	O
class	NN	O
I	PRP	O
molecules	VBP	O
,	,	O
MHC	NNP	O
class	NN	O
II	NNP	O
molecules	NNS	O
,	,	O
B7.1-.3	NNP	O
,	,	O
β2-microglobulin	NNP	O
(	(	O
Parnes	NNP	B
et	RB	I
al	RB	I
.	.	I
(	(	I
1981	CD	I
)	)	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
USA	NNP	I
78:2253-2257	CD	I
)	)	O
;	:	O
chaperones	NNS	O
such	JJ	O
as	IN	O
calnexin	NN	O
;	:	O
and	CC	O
MHC-linked	JJ	O
transporter	NN	O
proteins	NNS	O
or	CC	O
analogs	NNS	O
thereof	NNS	O
(	(	O
Powis	NNP	B
et	RB	I
al	RB	I
.	.	I
(	(	I
1991	CD	I
)	)	I
Nature	NNP	I
354:528-531	JJ	I
)	)	O
.	.	O
Immunomodulatory	JJ	O
factors	NNS	O
may	MD	O
also	RB	O
be	VB	O
agonists	NNS	O
,	,	O
antagonists	NNS	O
,	,	O
or	CC	O
ligands	VBZ	O
for	IN	O
these	DT	O
molecules	NNS	O
.	.	O
For	IN	O
example	NN	O
,	,	O
soluble	JJ	O
forms	NNS	O
of	IN	O
receptors	NNS	O
can	MD	O
often	RB	O
behave	VB	O
as	IN	O
antagonists	NNS	O
for	IN	O
these	DT	O
types	NNS	O
of	IN	O
factors	NNS	O
,	,	O
as	IN	O
can	MD	O
mutated	VBD	O
forms	NNS	O
of	IN	O
the	DT	O
factors	NNS	O
themselves	PRP	O
.	.	O
Nucleic	NNP	O
acid	NN	O
molecules	NNS	O
that	WDT	O
encode	VBP	O
the	DT	O
above-described	JJ	O
substances	NNS	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
other	JJ	O
nucleic	JJ	O
acid	NN	O
molecules	NNS	O
that	WDT	O
are	VBP	O
advantageous	JJ	O
for	IN	O
use	NN	O
within	IN	O
the	DT	O
present	JJ	O
invention	NN	O
,	,	O
may	MD	O
be	VB	O
readily	RB	O
obtained	VBN	O
from	IN	O
a	DT	O
variety	NN	O
of	IN	O
sources	NNS	O
,	,	O
including	VBG	O
,	,	O
for	IN	O
example	NN	O
,	,	O
depositories	NNS	O
such	JJ	O
as	IN	O
the	DT	O
American	NNP	O
Type	NNP	O
Culture	NNP	O
Collection	NNP	O
,	,	O
or	CC	O
from	IN	O
commercial	JJ	O
sources	NNS	O
such	JJ	O
as	IN	O
British	JJ	O
Bio-Technology	NNP	O
Limited	NNP	O
(	(	O
Cowley	NNP	O
,	,	O
Oxford	NNP	O
England	NNP	O
)	)	O
.	.	O
Representative	JJ	O
examples	NNS	O
include	VBP	O
BBG	NNP	O
12	CD	O
(	(	O
containing	VBG	O
the	DT	O
GM-CSF	NNP	O
gene	NN	O
coding	VBG	O
for	IN	O
the	DT	O
mature	NN	O
protein	NN	O
of	IN	O
127	CD	O
amino	JJ	O
acids	NNS	O
)	)	O
,	,	O
BBG	NNP	O
6	CD	O
(	(	O
which	WDT	O
contains	VBZ	O
sequences	NNS	O
encoding	VBG	O
gamma	NN	O
interferon	NN	O
)	)	O
,	,	O
A.T.C.C	NNP	O
.	.	O
Deposit	NN	O
No	DT	O
.	.	O
39656	CD	O
(	(	O
which	WDT	O
contains	VBZ	O
sequences	NNS	O
encoding	VBG	O
TNF	NNP	O
)	)	O
,	,	O
A.T.C.C	NNP	O
.	.	O
Deposit	NN	O
No	DT	O
.	.	O
20663	CD	O
(	(	O
which	WDT	O
contains	VBZ	O
sequences	NNS	O
encoding	VBG	O
alpha-interferon	NN	O
)	)	O
,	,	O
A.T.C.C	NNP	O
.	.	O
Deposit	NNP	O
Nos	NNP	O
.	.	O
31902	CD	O
,	,	O
31902	CD	O
and	CC	O
39517	CD	O
(	(	O
which	WDT	O
contain	VBP	O
sequences	NNS	O
encoding	VBG	O
beta-interferon	NN	O
)	)	O
,	,	O
A.T.C.C	NNP	O
.	.	O
Deposit	NN	O
No	DT	O
.	.	O
67024	CD	O
(	(	O
which	WDT	O
contains	VBZ	O
a	DT	O
sequence	NN	O
which	WDT	O
encodes	VBZ	O
Interleukin-1b	NNP	O
)	)	O
,	,	O
A.T.C.C	NNP	O
.	.	O
Deposit	NNP	O
Nos	NNP	O
.	.	O
39405	CD	O
,	,	O
39452	CD	O
,	,	O
39516	CD	O
,	,	O
39626	CD	O
and	CC	O
39673	CD	O
(	(	O
which	WDT	O
contain	VBP	O
sequences	NNS	O
encoding	VBG	O
Interleukin-2	NNP	O
)	)	O
,	,	O
A.T.C.C	NNP	O
.	.	O
Deposit	NNP	O
Nos	NNP	O
.	.	O
59399	CD	O
,	,	O
59398	CD	O
,	,	O
and	CC	O
67326	CD	O
(	(	O
which	WDT	O
contain	VBP	O
sequences	NNS	O
encoding	VBG	O
Interleukin-3	NNP	O
)	)	O
,	,	O
A.T.C.C	NNP	O
.	.	O
Deposit	NN	O
No	DT	O
.	.	O
57592	CD	O
(	(	O
which	WDT	O
contains	VBZ	O
sequences	NNS	O
encoding	VBG	O
Interleukin-4	NNP	O
)	)	O
,	,	O
A.T.C.C	NNP	O
.	.	O
Deposit	NNP	O
Nos	NNP	O
.	.	O
59394	CD	O
and	CC	O
59395	CD	O
(	(	O
which	WDT	O
contain	VBP	O
sequences	NNS	O
encoding	VBG	O
Interleukin-5	NNP	O
)	)	O
,	,	O
and	CC	O
A.T.C.C	NNP	O
.	.	O
Deposit	NN	O
No	DT	O
.	.	O
67153	CD	O
(	(	O
which	WDT	O
contains	VBZ	O
sequences	NNS	O
encoding	VBG	O
Interleukin-6	NNP	O
)	)	O
.	.	O
Plasmids	NNS	O
containing	VBG	O
cytokine	NN	O
genes	NNS	O
or	CC	O
immunomodulatory	NN	O
genes	NNS	O
(	(	O
International	NNP	O
Publication	NNP	O
Nos	NNP	O
.	.	O
WO	$	O
94/02951	CD	O
and	CC	O
WO	NNP	O
96/21015	CD	O
,	,	O
both	DT	O
of	IN	O
which	WDT	O
are	VBP	O
incorporated	VBN	O
by	IN	O
reference	NN	O
in	IN	O
their	PRP$	O
entirety	NN	O
)	)	O
can	MD	O
be	VB	O
digested	VBN	O
with	IN	O
appropriate	JJ	O
restriction	NN	O
enzymes	NNS	O
,	,	O
and	CC	O
DNA	NNP	O
fragments	NNS	O
containing	VBG	O
the	DT	O
particular	JJ	O
gene	NN	O
of	IN	O
interest	NN	O
can	MD	O
be	VB	O
inserted	VBN	O
into	IN	O
a	DT	O
gene	NN	O
transfer	NN	O
vector	NN	O
using	VBG	O
standard	JJ	O
molecular	JJ	O
biology	NN	O
techniques	NNS	O
.	.	O
(	(	O
See	VB	O
,	,	O
e.g.	VB	O
,	,	O
Sambrook	NNP	B
et	FW	I
al.	NN	I
,	,	I
supra.	NN	I
,	,	O
or	CC	O
Ausubel	NNP	B
et	CC	I
al	NN	I
.	.	I
(	(	I
eds	NNS	I
)	)	I
Current	NNP	I
Protocols	NNP	I
in	IN	I
Molecular	NNP	I
Biology	NNP	I
,	,	I
Greene	NNP	I
Publishing	NNP	I
and	CC	I
Wiley-Interscience	NNP	I
)	)	O
.	.	O
Exemplary	JJ	O
hormones	NNS	O
,	,	O
growth	NN	O
factors	NNS	O
and	CC	O
other	JJ	O
proteins	NNS	O
which	WDT	O
are	VBP	O
useful	JJ	O
for	IN	O
long	JJ	O
term	NN	O
expression	NN	O
are	VBP	O
described	VBN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
in	IN	O
European	JJ	O
Publication	NNP	O
No	NNP	O
.	.	O
0437478B1	CD	O
,	,	O
entitled	VBN	O
“	JJ	O
Cyclodextrin-Peptide	NNP	O
Complexes.	NNP	O
”	NNP	O
Nucleic	NNP	O
acid	NN	O
sequences	NNS	O
encoding	VBG	O
a	DT	O
variety	NN	O
of	IN	O
hormones	NNS	O
can	MD	O
be	VB	O
used	VBN	O
,	,	O
including	VBG	O
those	DT	O
encoding	VBG	O
human	JJ	O
growth	NN	O
hormone	NN	O
,	,	O
insulin	NN	O
,	,	O
calcitonin	NN	O
,	,	O
prolactin	NN	O
,	,	O
follicle	NN	O
stimulating	VBG	O
hormone	NN	O
(	(	O
FSH	NNP	O
)	)	O
,	,	O
luteinizing	VBG	O
hormone	NN	O
(	(	O
LH	NNP	O
)	)	O
,	,	O
human	JJ	O
chorionic	NN	O
gonadotropin	NN	O
(	(	O
HCG	NNP	O
)	)	O
,	,	O
and	CC	O
thyroid	JJ	O
stimulating	VBG	O
hormone	NN	O
(	(	O
TSH	NNP	O
)	)	O
.	.	O
A	DT	O
variety	NN	O
of	IN	O
different	JJ	O
forms	NNS	O
of	IN	O
IGF-1	NNP	O
and	CC	O
IGF-2	NNP	O
growth	NN	O
factor	NN	O
polypeptides	NNS	O
are	VBP	O
also	RB	O
well	RB	O
known	VBN	O
the	DT	O
art	NN	O
and	CC	O
can	MD	O
be	VB	O
incorporated	VBN	O
into	IN	O
gene	NN	O
transfer	NN	O
vectors	NNS	O
for	IN	O
long	JJ	O
term	NN	O
expression	NN	O
in	IN	O
vivo	NN	O
.	.	O
See	VB	O
,	,	O
e.g.	VB	O
,	,	O
European	JJ	O
Patent	NNP	O
No	NNP	O
.	.	O
0123228B1	CD	O
,	,	O
published	VBN	O
for	IN	O
grant	NN	O
Sep.	NNP	O
19	CD	O
,	,	O
1993	CD	O
,	,	O
entitled	VBD	O
“	JJ	O
Hybrid	NNP	O
DNA	NNP	O
Synthesis	NNP	O
of	IN	O
Mature	NNP	O
Insulin-like	NNP	O
Growth	NNP	O
Factors.	NNP	O
”	NNP	O
As	IN	O
an	DT	O
additional	JJ	O
example	NN	O
,	,	O
the	DT	O
long	JJ	O
term	NN	O
in	IN	O
vivo	JJ	O
expression	NN	O
of	IN	O
different	JJ	O
forms	NNS	O
of	IN	O
fibroblast	JJ	O
growth	NN	O
factor	NN	O
can	MD	O
also	RB	O
be	VB	O
effected	VBN	O
employing	VBG	O
the	DT	O
compositions	NNS	O
and	CC	O
methods	NNS	O
of	IN	O
invention	NN	O
.	.	O
See	VB	O
,	,	O
e.g.	VB	O
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
Nos	NNP	O
.	.	O
5,464,774	CD	O
,	,	O
5,155,214	CD	O
,	,	O
and	CC	O
4,994,559	CD	O
for	IN	O
a	DT	O
description	NN	O
of	IN	O
different	JJ	O
fibroblast	JJ	O
growth	NN	O
factors	NNS	O
.	.	O
Polynucleotide	NNP	O
sequences	NNS	O
coding	VBG	O
for	IN	O
the	DT	O
above-described	JJ	O
molecules	NNS	O
can	MD	O
be	VB	O
obtained	VBN	O
using	VBG	O
recombinant	JJ	O
methods	NNS	O
,	,	O
such	JJ	O
as	IN	O
by	IN	O
screening	VBG	O
cDNA	NN	O
and	CC	O
genomic	JJ	O
libraries	NNS	O
from	IN	O
cells	NNS	O
expressing	VBG	O
the	DT	O
gene	NN	O
,	,	O
or	CC	O
by	IN	O
deriving	VBG	O
the	DT	O
gene	NN	O
from	IN	O
a	DT	O
vector	NN	O
known	VBN	O
to	TO	O
include	VB	O
the	DT	O
same	JJ	O
.	.	O
For	IN	O
example	NN	O
,	,	O
plasmids	NNS	O
which	WDT	O
contain	VBP	O
sequences	NNS	O
that	WDT	O
encode	VBP	O
altered	VBN	O
cellular	JJ	O
products	NNS	O
may	MD	O
be	VB	O
obtained	VBN	O
from	IN	O
a	DT	O
depository	NN	O
such	JJ	O
as	IN	O
the	DT	O
A.T.C.C.	NNP	O
,	,	O
or	CC	O
from	IN	O
commercial	JJ	O
sources	NNS	O
.	.	O
Plasmids	NNS	O
containing	VBG	O
the	DT	O
nucleotide	JJ	O
sequences	NNS	O
of	IN	O
interest	NN	O
can	MD	O
be	VB	O
digested	VBN	O
with	IN	O
appropriate	JJ	O
restriction	NN	O
enzymes	NNS	O
,	,	O
and	CC	O
DNA	NNP	O
fragments	NNS	O
containing	VBG	O
the	DT	O
nucleotide	JJ	O
sequences	NNS	O
can	MD	O
be	VB	O
inserted	VBN	O
into	IN	O
a	DT	O
gene	NN	O
transfer	NN	O
vector	NN	O
using	VBG	O
standard	JJ	O
molecular	JJ	O
biology	NN	O
techniques	NNS	O
.	.	O
Alternatively	RB	O
,	,	O
cDNA	NN	O
sequences	NNS	O
for	IN	O
use	NN	O
with	IN	O
the	DT	O
present	JJ	O
invention	NN	O
may	MD	O
be	VB	O
obtained	VBN	O
from	IN	O
cells	NNS	O
which	WDT	O
express	VBP	O
or	CC	O
contain	VBP	O
the	DT	O
sequences	NNS	O
,	,	O
using	VBG	O
standard	JJ	O
techniques	NNS	O
,	,	O
such	JJ	O
as	IN	O
phenol	JJ	O
extraction	NN	O
and	CC	O
PCR	NNP	O
of	IN	O
cDNA	NN	O
or	CC	O
genomic	JJ	O
DNA	NN	O
.	.	O
See	VB	O
,	,	O
e.g.	VB	O
,	,	O
Sambrook	NNP	O
et	FW	O
al.	NN	O
,	,	O
supra	NN	O
,	,	O
for	IN	O
a	DT	O
description	NN	O
of	IN	O
techniques	NNS	O
used	VBN	O
to	TO	O
obtain	VB	O
and	CC	O
isolate	VB	O
DNA	NNP	O
.	.	O
Briefly	NNP	O
,	,	O
mRNA	NN	O
from	IN	O
a	DT	O
cell	NN	O
which	WDT	O
expresses	VBZ	O
the	DT	O
gene	NN	O
of	IN	O
interest	NN	O
can	MD	O
be	VB	O
reverse	JJ	O
transcribed	VBN	O
with	IN	O
reverse	JJ	O
transcriptase	NN	O
using	VBG	O
oligo-dT	JJ	O
or	CC	O
random	JJ	O
primers	NNS	O
.	.	O
The	DT	O
single	JJ	O
stranded	VBD	O
cDNA	NN	O
may	MD	O
then	RB	O
be	VB	O
amplified	VBN	O
by	IN	O
PCR	NNP	O
(	(	O
see	VB	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
Nos	NNP	O
.	.	O
4,683,202	CD	O
,	,	O
4,683,195	CD	O
and	CC	O
4,800,159	CD	O
,	,	O
see	NN	O
also	RB	O
PCR	NNP	B
Technology	NNP	I
:	:	I
Principles	NNS	I
and	CC	I
Applications	NNS	I
for	IN	I
DNA	NNP	I
Amplification	NNP	I
,	,	I
Erlich	NNP	I
(	(	I
ed	NN	I
.	.	I
)	)	I
,	,	I
Stockton	NNP	I
Press	NNP	I
,	,	I
1989	CD	I
)	)	I
)	)	O
using	VBG	O
oligonucleotide	JJ	O
primers	NNS	O
complementary	VBP	O
to	TO	O
sequences	NNS	O
on	IN	O
either	DT	O
side	NN	O
of	IN	O
desired	JJ	O
sequences	NNS	O
.	.	O
The	DT	O
nucleotide	JJ	O
sequence	NN	O
of	IN	O
interest	NN	O
can	MD	O
also	RB	O
be	VB	O
produced	VBN	O
synthetically	RB	O
,	,	O
rather	RB	O
than	IN	O
cloned	VBN	O
,	,	O
using	VBG	O
a	DT	O
DNA	NN	O
synthesizer	NN	O
(	(	O
e.g.	NN	O
,	,	O
an	DT	O
Applied	NNP	O
Biosystems	NNP	O
Model	NNP	O
392	CD	O
DNA	NNP	O
Synthesizer	NNP	O
,	,	O
available	JJ	O
from	IN	O
ABI	NNP	O
,	,	O
Foster	NNP	O
City	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
.	.	O
The	DT	O
nucleotide	JJ	O
sequence	NN	O
can	MD	O
be	VB	O
designed	VBN	O
with	IN	O
the	DT	O
appropriate	JJ	O
codons	NNS	O
for	IN	O
the	DT	O
expression	NN	O
product	NN	O
desired	VBN	O
.	.	O
The	DT	O
complete	JJ	O
sequence	NN	O
is	VBZ	O
assembled	VBN	O
from	IN	O
overlapping	VBG	O
oligonucleotides	NNS	O
prepared	VBN	O
by	IN	O
standard	JJ	O
methods	NNS	O
and	CC	O
assembled	VBD	O
into	IN	O
a	DT	O
complete	JJ	O
coding	NN	O
sequence	NN	O
.	.	O
See	VB	O
,	,	O
e.g.	VB	O
,	,	O
Edge	NNP	B
(	(	I
1981	CD	I
)	)	I
Nature	NN	I
292:756	CD	I
;	:	O
Nambair	NNP	B
et	FW	I
al	NN	I
.	.	I
(	(	I
1984	CD	I
)	)	I
Science	NN	I
223:1299	CD	I
;	:	O
Jay	NNP	B
et	FW	I
al	NN	I
.	.	I
(	(	I
1984	CD	I
)	)	I
J.	NNP	I
Biol	NNP	I
.	.	I
Chem	NNP	I
.	.	I
259:6311	CD	I
.	.	O
The	DT	O
synthetic	JJ	O
expression	NN	O
cassettes	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
can	MD	O
be	VB	O
employed	VBN	O
in	IN	O
the	DT	O
construction	NN	O
of	IN	O
packaging	NN	O
cell	NN	O
lines	NNS	O
for	IN	O
use	NN	O
with	IN	O
retroviral	JJ	O
vectors	NNS	O
.	.	O
One	CD	O
type	NN	O
of	IN	O
retrovirus	NN	O
,	,	O
the	DT	O
murine	NN	O
leukemia	NN	O
virus	NN	O
,	,	O
or	CC	O
“	VB	O
MLV	NNP	O
”	NNP	O
,	,	O
has	VBZ	O
been	VBN	O
widely	RB	O
utilized	VBN	O
for	IN	O
gene	NN	O
therapy	NN	O
applications	NNS	O
(	(	O
see	VB	O
generally	RB	O
Mann	NNP	B
et	CC	I
al	NN	I
.	.	I
(	(	I
Cell	NNP	I
33:153	CD	I
,	,	I
1993	CD	I
)	)	I
,	,	O
Cane	NNP	B
and	CC	I
Mulligan	NNP	I
(	(	I
Proc	NNP	I
,	,	I
Nat	NNP	I
'	POS	I
l	NN	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
USA	NNP	I
81:6349	CD	I
,	,	I
1984	CD	I
)	)	I
,	,	O
and	CC	O
Miller	NNP	B
et	FW	I
al.	NN	I
,	,	I
Human	NNP	I
Gene	NNP	I
2lerapy	CD	I
1:5-14	CD	I
,	,	I
1990	CD	I
.	.	O
Lentiviral	JJ	O
vectors	NNS	O
typically	RB	O
,	,	O
comprise	VB	O
a	DT	O
5′	CD	O
lentiviral	JJ	O
LTR	NNP	O
,	,	O
a	DT	O
tRNA	NN	O
binding	VBG	O
site	NN	O
,	,	O
a	DT	O
packaging	NN	O
signal	NN	O
,	,	O
a	DT	O
promoter	NN	O
operably	RB	O
linked	VBD	O
to	TO	O
one	CD	O
or	CC	O
more	JJR	O
genes	NNS	O
of	IN	O
interest	NN	O
,	,	O
an	DT	O
origin	NN	O
of	IN	O
second	JJ	O
strand	NN	O
DNA	NNP	O
synthesis	NN	O
and	CC	O
a	DT	O
3′	CD	O
lentiviral	JJ	O
LTR	NNP	O
,	,	O
wherein	VBD	O
the	DT	O
lentiviral	JJ	O
vector	NN	O
contains	VBZ	O
a	DT	O
nuclear	JJ	O
transport	NN	O
element	NN	O
.	.	O
The	DT	O
nuclear	JJ	O
transport	NN	O
element	NN	O
may	MD	O
be	VB	O
located	VBN	O
either	DT	O
upstream	NN	O
(	(	O
5′	CD	O
)	)	O
or	CC	O
downstream	NN	O
(	(	O
3′	CD	O
)	)	O
of	IN	O
a	DT	O
coding	VBG	O
sequence	NN	O
of	IN	O
interest	NN	O
.	.	O
Within	IN	O
certain	JJ	O
embodiments	NNS	O
,	,	O
the	DT	O
nuclear	JJ	O
transport	NN	O
element	NN	O
is	VBZ	O
not	RB	O
RRE	NNP	O
.	.	O
Within	IN	O
one	CD	O
embodiment	NN	O
the	DT	O
packaging	NN	O
signal	NN	O
is	VBZ	O
an	DT	O
extended	JJ	O
packaging	NN	O
signal	NN	O
.	.	O
Within	IN	O
other	JJ	O
embodiments	NNS	O
the	DT	O
promoter	NN	O
is	VBZ	O
a	DT	O
tissue	NN	O
specific	JJ	O
promoter	NN	O
,	,	O
or	CC	O
,	,	O
alternatively	RB	O
,	,	O
a	DT	O
promoter	NN	O
such	JJ	O
as	IN	O
CMV	NNP	O
.	.	O
Within	IN	O
other	JJ	O
embodiments	NNS	O
,	,	O
the	DT	O
lentiviral	JJ	O
vector	NN	O
further	RBR	O
comprises	VBZ	O
an	DT	O
internal	JJ	O
ribosome	NN	O
entry	NN	O
site	NN	O
.	.	O
A	DT	O
wide	JJ	O
variety	NN	O
of	IN	O
lentiviruses	NNS	O
may	MD	O
be	VB	O
utilized	VBN	O
within	IN	O
the	DT	O
context	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
,	,	O
including	VBG	O
for	IN	O
example	NN	O
,	,	O
lentiviruses	VBZ	O
selected	VBN	O
from	IN	O
the	DT	O
group	NN	O
consisting	VBG	O
of	IN	O
HIV	NNP	O
,	,	O
HIV-1	NNP	O
,	,	O
HIV-2	NNP	O
,	,	O
FIV	NNP	O
and	CC	O
SIV	NNP	O
.	.	O
In	IN	O
one	CD	O
embodiment	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
synthetic	JJ	O
Env	NNP	O
and/or	POS	O
Gag-polymerase	NNP	O
expression	NN	O
cassettes	NNS	O
are	VBP	O
provided	VBN	O
comprising	VBG	O
a	DT	O
promoter	NN	O
and	CC	O
a	DT	O
sequence	NN	O
encoding	VBG	O
synthetic	JJ	O
Gag-polymerase	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:6	NNP	O
)	)	O
and	CC	O
at	IN	O
least	JJS	O
one	CD	O
of	IN	O
vpr	NN	O
,	,	O
vpu	NN	O
,	,	O
nef	''	O
or	CC	O
vif	VB	O
,	,	O
wherein	VB	O
the	DT	O
promoter	NN	O
is	VBZ	O
operably	RB	O
linked	VBN	O
to	TO	O
Gag-polymerase	NNP	O
and	CC	O
vpr	NN	O
,	,	O
vpu	NN	O
,	,	O
nef	''	O
or	CC	O
vif	NN	O
.	.	O
Within	IN	O
yet	RB	O
another	DT	O
aspect	NN	O
of	IN	O
the	DT	O
invention	NN	O
,	,	O
host	NN	O
cells	NNS	O
(	(	O
e.g.	NN	O
,	,	O
packaging	NN	O
cell	NN	O
lines	NNS	O
)	)	O
are	VBP	O
provided	VBN	O
which	WDT	O
contain	VBP	O
any	DT	O
of	IN	O
the	DT	O
expression	NN	O
cassettes	VBZ	O
described	VBN	O
herein	NNS	O
.	.	O
For	IN	O
example	NN	O
,	,	O
within	IN	O
one	CD	O
aspect	NN	O
packaging	NN	O
cell	NN	O
line	NN	O
are	VBP	O
provided	VBN	O
comprising	VBG	O
an	DT	O
expression	NN	O
cassette	NN	O
that	WDT	O
comprises	VBZ	O
a	DT	O
sequence	NN	O
encoding	VBG	O
synthetic	JJ	O
Env	NNP	O
and/or	NN	O
Gag-polymerase	NNP	O
,	,	O
and	CC	O
a	DT	O
nuclear	JJ	O
transport	NN	O
element	NN	O
,	,	O
wherein	VBP	O
the	DT	O
promoter	NN	O
is	VBZ	O
operably	RB	O
linked	VBN	O
to	TO	O
the	DT	O
sequence	NN	O
encoding	VBG	O
Env	NNP	O
and/or	JJ	O
Gag-polymerase	NNP	O
.	.	O
Packaging	VBG	O
cell	NN	O
lines	NNS	O
may	MD	O
further	RB	O
comprise	VB	O
a	DT	O
promoter	NN	O
and	CC	O
a	DT	O
sequence	NN	O
encoding	VBG	O
tat	NN	O
,	,	O
rev	NN	O
,	,	O
or	CC	O
an	DT	O
envelope	NN	O
,	,	O
wherein	VBP	O
the	DT	O
promoter	NN	O
is	VBZ	O
operably	RB	O
linked	VBN	O
to	TO	O
the	DT	O
sequence	NN	O
encoding	VBG	O
tat	NN	O
,	,	O
rev	NN	O
,	,	O
or	CC	O
,	,	O
the	DT	O
envelope	NN	O
.	.	O
The	DT	O
packaging	NN	O
cell	NN	O
line	NN	O
may	MD	O
further	RB	O
comprise	VB	O
a	DT	O
sequence	NN	O
encoding	VBG	O
any	DT	O
one	CD	O
or	CC	O
more	JJR	O
of	IN	O
nef	NN	O
,	,	O
vif	NN	O
,	,	O
vpu	NN	O
or	CC	O
vpr	NN	O
.	.	O
In	IN	O
one	CD	O
embodiment	NN	O
,	,	O
the	DT	O
expression	NN	O
cassette	NN	O
(	(	O
carrying	VBG	O
,	,	O
for	IN	O
example	NN	O
,	,	O
the	DT	O
synthetic	JJ	O
Env	NNP	O
,	,	O
synthetic	JJ	O
tat	NN	O
and/or	JJ	O
synthetic	JJ	O
Gag-polymerase	NNP	O
)	)	O
is	VBZ	O
stably	RB	O
integrated	VBN	O
.	.	O
The	DT	O
packaging	NN	O
cell	NN	O
line	NN	O
,	,	O
upon	IN	O
introduction	NN	O
of	IN	O
a	DT	O
lentiviral	JJ	O
vector	NN	O
,	,	O
typically	RB	O
produces	VBZ	O
viral	JJ	O
particles	NNS	O
.	.	O
The	DT	O
promoter	NN	O
regulating	VBG	O
expression	NN	O
of	IN	O
the	DT	O
synthetic	JJ	O
expression	NN	O
cassette	NN	O
may	MD	O
be	VB	O
inducible	JJ	O
.	.	O
Typically	RB	O
,	,	O
the	DT	O
packaging	NN	O
cell	NN	O
line	NN	O
,	,	O
upon	IN	O
introduction	NN	O
of	IN	O
a	DT	O
lentiviral	JJ	O
vector	NN	O
,	,	O
produces	VBZ	O
viral	JJ	O
particles	NNS	O
that	WDT	O
are	VBP	O
essentially	RB	O
free	JJ	O
of	IN	O
replication	NN	O
competent	NN	O
virus	NN	O
.	.	O
Packaging	VBG	O
cell	NN	O
lines	NNS	O
are	VBP	O
provided	VBN	O
comprising	VBG	O
an	DT	O
expression	NN	O
cassette	NN	O
which	WDT	O
directs	VBZ	O
the	DT	O
expression	NN	O
of	IN	O
a	DT	O
synthetic	JJ	O
Env	NNP	O
(	(	O
or	CC	O
Gag-polymerase	NNP	O
)	)	O
gene	NN	O
,	,	O
an	DT	O
expression	NN	O
cassette	NN	O
which	WDT	O
directs	VBZ	O
the	DT	O
expression	NN	O
of	IN	O
a	DT	O
Gag	NNP	O
(	(	O
or	CC	O
Env	NNP	O
)	)	O
gene	NN	O
optimized	VBN	O
for	IN	O
expression	NN	O
(	(	O
e.g.	JJ	O
,	,	O
Andre	NNP	B
,	,	I
S.	NNP	I
,	,	I
et	FW	I
al.	NN	I
,	,	I
Journal	NNP	I
of	IN	I
Virology	NNP	I
72	NNP	I
(	(	I
2	CD	I
)	)	I
:1497-1503	NN	I
,	,	I
1998	CD	I
;	:	O
Haas	NNP	B
,	,	I
J.	NNP	I
,	,	I
et	FW	I
al.	RB	I
,	,	I
Current	NNP	I
Biology	NNP	I
6	CD	I
(	(	I
3	CD	I
)	)	I
:315-324	NN	I
,	,	I
1996	CD	I
)	)	O
.	.	O
A	DT	O
lentiviral	JJ	O
vector	NN	O
is	VBZ	O
introduced	VBN	O
into	IN	O
the	DT	O
packaging	NN	O
cell	NN	O
line	NN	O
to	TO	O
produce	VB	O
a	DT	O
vector	NN	O
particle	NN	O
producing	VBG	O
cell	NN	O
line	NN	O
.	.	O
As	IN	O
noted	VBN	O
above	IN	O
,	,	O
lentiviral	JJ	O
vectors	NNS	O
can	MD	O
be	VB	O
designed	VBN	O
to	TO	O
carry	VB	O
or	CC	O
express	VB	O
a	DT	O
selected	VBN	O
gene	NN	O
(	(	O
s	JJ	O
)	)	O
or	CC	O
sequences	NNS	O
of	IN	O
interest	NN	O
.	.	O
Lentiviral	JJ	O
vectors	NNS	O
may	MD	O
be	VB	O
readily	RB	O
constructed	VBN	O
from	IN	O
a	DT	O
wide	JJ	O
variety	NN	O
of	IN	O
lentiviruses	NNS	O
(	(	O
see	VB	O
RNA	NNP	B
Tumor	NNP	I
Viruses	NNP	I
,	,	I
Second	NNP	I
Edition	NNP	I
,	,	I
Cold	NNP	I
Spring	NNP	I
Harbor	NNP	I
Laboratory	NNP	I
,	,	I
1985	CD	I
)	)	O
.	.	O
Representative	JJ	O
examples	NNS	O
of	IN	O
lentiviruses	NNS	O
included	VBN	O
HIV	NNP	O
,	,	O
HIV-1	NNP	O
,	,	O
HIV-2	NNP	O
,	,	O
FIV	NNP	O
and	CC	O
SIV	NNP	O
.	.	O
Such	JJ	O
lentiviruses	NNS	O
may	MD	O
either	RB	O
be	VB	O
obtained	VBN	O
from	IN	O
patient	JJ	O
isolates	NNS	O
,	,	O
or	CC	O
,	,	O
more	JJR	O
preferably	RB	O
,	,	O
from	IN	O
depositories	NNS	O
or	CC	O
collections	NNS	O
such	JJ	O
as	IN	O
the	DT	O
American	NNP	O
Type	NNP	O
Culture	NNP	O
Collection	NNP	O
,	,	O
or	CC	O
isolated	VBN	O
from	IN	O
known	VBN	O
sources	NNS	O
using	VBG	O
available	JJ	O
techniques	NNS	O
.	.	O
Portions	NNS	O
of	IN	O
the	DT	O
lentiviral	JJ	O
gene	NN	O
delivery	NN	O
vectors	NNS	O
(	(	O
or	CC	O
vehicles	NNS	O
)	)	O
may	MD	O
be	VB	O
derived	VBN	O
from	IN	O
different	JJ	O
viruses	NNS	O
.	.	O
For	IN	O
example	NN	O
,	,	O
in	IN	O
a	DT	O
given	VBN	O
recombinant	JJ	O
lentiviral	JJ	O
vector	NN	O
,	,	O
LTRs	NNP	O
may	MD	O
be	VB	O
derived	VBN	O
from	IN	O
an	DT	O
HIV	NNP	O
,	,	O
a	DT	O
packaging	NN	O
signal	NN	O
from	IN	O
SIV	NNP	O
,	,	O
and	CC	O
an	DT	O
origin	NN	O
of	IN	O
second	JJ	O
strand	NN	O
synthesis	NN	O
from	IN	O
HrV-2	NNP	O
.	.	O
Lentiviral	JJ	O
vector	NN	O
constructs	NNS	O
may	MD	O
comprise	VB	O
a	DT	O
5′	CD	O
lentiviral	JJ	O
LTR	NNP	O
,	,	O
a	DT	O
tRNA	NN	O
binding	VBG	O
site	NN	O
,	,	O
a	DT	O
packaging	NN	O
signal	NN	O
,	,	O
one	CD	O
or	CC	O
more	JJR	O
heterologous	JJ	O
sequences	NNS	O
,	,	O
an	DT	O
origin	NN	O
of	IN	O
second	JJ	O
strand	NN	O
DNA	NNP	O
synthesis	NN	O
and	CC	O
a	DT	O
3′	CD	O
LTR	NNP	O
,	,	O
wherein	NN	O
said	VBD	O
lentiviral	JJ	O
vector	NN	O
contains	VBZ	O
a	DT	O
nuclear	JJ	O
transport	NN	O
element	NN	O
that	WDT	O
is	VBZ	O
not	RB	O
RRE	NNP	O
.	.	O
Briefly	NNP	O
,	,	O
Long	NNP	O
Terminal	NNP	O
Repeats	NNP	O
(	(	O
“	NNP	O
LTRs	NNP	O
”	NNP	O
)	)	O
are	VBP	O
subdivided	VBN	O
into	IN	O
three	CD	O
elements	NNS	O
,	,	O
designated	VBN	O
U5	NNP	O
,	,	O
R	NNP	O
and	CC	O
U3	NNP	O
.	.	O
These	DT	O
elements	NNS	O
contain	VBP	O
a	DT	O
variety	NN	O
of	IN	O
signals	NNS	O
which	WDT	O
are	VBP	O
responsible	JJ	O
for	IN	O
the	DT	O
biological	JJ	O
activity	NN	O
of	IN	O
a	DT	O
retrovirus	NN	O
,	,	O
including	VBG	O
for	IN	O
example	NN	O
,	,	O
promoter	NN	O
and	CC	O
enhancer	NN	O
elements	NNS	O
which	WDT	O
are	VBP	O
located	VBN	O
within	IN	O
U3	NNP	O
.	.	O
LTRs	NNP	O
may	MD	O
be	VB	O
readily	RB	O
identified	VBN	O
in	IN	O
the	DT	O
provirus	NN	O
(	(	O
integrated	JJ	O
DNA	NNP	O
form	NN	O
)	)	O
due	RB	O
to	TO	O
their	PRP$	O
precise	JJ	O
duplication	NN	O
at	IN	O
either	DT	O
end	NN	O
of	IN	O
the	DT	O
genome	NN	O
.	.	O
As	IN	O
utilized	JJ	O
herein	NN	O
,	,	O
a	DT	O
5′	CD	O
LTR	NNP	O
should	MD	O
be	VB	O
understood	JJ	O
to	TO	O
include	VB	O
a	DT	O
5′	CD	O
promoter	NN	O
element	NN	O
and	CC	O
sufficient	JJ	O
LTR	NNP	O
sequence	NN	O
to	TO	O
allow	VB	O
reverse	JJ	O
transcription	NN	O
and	CC	O
integration	NN	O
of	IN	O
the	DT	O
DNA	NNP	O
form	NN	O
of	IN	O
the	DT	O
vector	NN	O
.	.	O
The	DT	O
3′	CD	O
LTR	NNP	O
should	MD	O
be	VB	O
understood	JJ	O
to	TO	O
include	VB	O
a	DT	O
polyadenylation	NN	O
signal	NN	O
,	,	O
and	CC	O
sufficient	JJ	O
LTR	NNP	O
sequence	NN	O
to	TO	O
allow	VB	O
reverse	JJ	O
transcription	NN	O
and	CC	O
integration	NN	O
of	IN	O
the	DT	O
DNA	NNP	O
form	NN	O
of	IN	O
the	DT	O
vector	NN	O
.	.	O
The	DT	O
tRNA	NN	O
binding	VBG	O
site	NN	O
and	CC	O
origin	NN	O
of	IN	O
second	JJ	O
strand	NN	O
DNA	NNP	O
synthesis	NN	O
are	VBP	O
also	RB	O
important	JJ	O
for	IN	O
a	DT	O
retrovirus	NN	O
to	TO	O
be	VB	O
biologically	RB	O
active	JJ	O
,	,	O
and	CC	O
may	MD	O
be	VB	O
readily	RB	O
identified	VBN	O
by	IN	O
one	CD	O
of	IN	O
skill	NN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
retroviral	JJ	O
tRNA	NN	O
binds	NNS	O
to	TO	O
a	DT	O
tRNA	NN	O
binding	VBG	O
site	NN	O
by	IN	O
Watson-Crick	JJ	O
base	NN	O
pairing	NN	O
,	,	O
and	CC	O
is	VBZ	O
carried	VBN	O
with	IN	O
the	DT	O
retrovirus	NN	O
genome	NN	O
into	IN	O
a	DT	O
viral	JJ	O
particle	NN	O
.	.	O
The	DT	O
tRNA	NN	O
is	VBZ	O
then	RB	O
utilized	JJ	O
as	IN	O
a	DT	O
primer	NN	O
for	IN	O
DNA	NNP	O
synthesis	NN	O
by	IN	O
reverse	JJ	O
transcriptase	NN	O
.	.	O
The	DT	O
tRNA	NN	O
binding	VBG	O
site	NN	O
may	MD	O
be	VB	O
readily	RB	O
identified	VBN	O
based	VBN	O
upon	IN	O
its	PRP$	O
location	NN	O
just	RB	O
downstream	NN	O
from	IN	O
the	DT	O
5′LTR	CD	O
.	.	O
Similarly	RB	O
,	,	O
the	DT	O
origin	NN	O
of	IN	O
second	JJ	O
strand	NN	O
DNA	NNP	O
synthesis	NN	O
is	VBZ	O
,	,	O
as	IN	O
its	PRP$	O
name	NN	O
implies	NNS	O
,	,	O
important	JJ	O
for	IN	O
the	DT	O
second	JJ	O
strand	NN	O
DNA	NNP	O
synthesis	NN	O
of	IN	O
a	DT	O
retrovirus	NN	O
.	.	O
This	DT	O
region	NN	O
,	,	O
which	WDT	O
is	VBZ	O
also	RB	O
referred	VBN	O
to	TO	O
as	IN	O
the	DT	O
poly-purine	JJ	O
tract	NN	O
,	,	O
is	VBZ	O
located	VBN	O
just	RB	O
upstream	NN	O
of	IN	O
the	DT	O
3′LTR	CD	O
.	.	O
In	IN	O
addition	NN	O
to	TO	O
a	DT	O
5′	CD	O
and	CC	O
3′	CD	O
LTR	NNP	O
,	,	O
tRNA	NN	O
binding	NN	O
site	NN	O
,	,	O
and	CC	O
origin	NN	O
of	IN	O
second	JJ	O
strand	NN	O
DNA	NNP	O
synthesis	NN	O
,	,	O
recombinant	JJ	O
retroviral	JJ	O
vector	NN	O
constructs	NNS	O
may	MD	O
also	RB	O
comprise	VB	O
a	DT	O
packaging	NN	O
signal	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
one	CD	O
or	CC	O
more	JJR	O
genes	NNS	O
or	CC	O
coding	VBG	O
sequences	NNS	O
of	IN	O
interest	NN	O
.	.	O
In	IN	O
addition	NN	O
,	,	O
the	DT	O
lentiviral	JJ	O
vectors	NNS	O
have	VBP	O
a	DT	O
nuclear	JJ	O
transport	NN	O
element	NN	O
which	WDT	O
,	,	O
in	IN	O
preferred	JJ	O
embodiments	NNS	O
is	VBZ	O
not	RB	O
RRE	NNP	O
.	.	O
Representative	JJ	O
examples	NNS	O
of	IN	O
suitable	JJ	O
nuclear	JJ	O
transport	NN	O
elements	NNS	O
include	VBP	O
the	DT	O
element	NN	O
in	IN	O
Rous	NNP	O
sarcoma	NN	O
virus	NN	O
(	(	O
Ogert	NNP	B
,	,	I
et	FW	I
al.	NN	I
,	,	I
J.	NNP	I
Virol	NNP	I
.	.	I
70	CD	I
,	,	I
3834-3843	CD	I
,	,	I
1996	CD	I
)	)	O
,	,	O
the	DT	O
element	NN	O
in	IN	O
Rous	NNP	O
sarcoma	NN	O
virus	NN	O
(	(	O
Liu	NNP	B
&	CC	I
Mertz	NNP	I
,	,	I
Genes	NNP	I
&	CC	I
Dev.	NNP	I
,	,	I
9	CD	I
,	,	I
1766-1789	CD	I
,	,	I
1995	CD	I
)	)	O
and	CC	O
the	DT	O
element	NN	O
in	IN	O
the	DT	O
genome	NN	O
of	IN	O
simian	JJ	O
retrovirus	NN	O
type	NN	O
I	PRP	O
(	(	O
Zolotukhin	NNP	B
,	,	I
et	FW	I
al.	NN	I
,	,	I
J.	NNP	I
Virol	NNP	I
.	.	I
68	CD	I
,	,	I
7944-7952	CD	I
,	,	I
1994	CD	I
)	)	O
.	.	O
Other	JJ	O
potential	JJ	O
elements	NNS	O
include	VBP	O
the	DT	O
elements	NNS	O
in	IN	O
the	DT	O
histone	NN	O
gene	NN	O
(	(	O
Kedes	NNP	B
,	,	I
Annu	NNP	I
.	.	I
Rev	NNP	I
.	.	I
Biochem	NNP	I
.	.	I
48	CD	I
,	,	I
837-870	CD	I
,	,	I
1970	CD	I
)	)	O
,	,	O
the	DT	O
α-interferon	JJ	O
gene	NN	O
(	(	O
Nagata	NNP	B
et	RB	I
al.	RB	I
,	,	I
Nature	NNP	I
287	CD	I
,	,	I
401-408	CD	I
,	,	I
1980	CD	I
)	)	O
,	,	O
the	DT	O
β-adrenergic	JJ	O
receptor	NN	O
gene	NN	O
(	(	O
Koilka	NNP	B
,	,	I
et	FW	I
al.	NN	I
,	,	I
Nature	NNP	I
329	CD	I
,	,	I
75-79	CD	I
,	,	I
1987	CD	I
)	)	O
,	,	O
and	CC	O
the	DT	O
c-Jun	JJ	O
gene	NN	O
(	(	O
Hattorie	NNP	B
,	,	I
et	FW	I
al.	NN	I
,	,	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
USA	NNP	I
85	CD	I
,	,	I
9148-9152	CD	I
,	,	I
1988	CD	I
)	)	O
.	.	O
Recombinant	JJ	O
lentiviral	JJ	O
vector	NN	O
constructs	NNS	O
typically	RB	O
lack	VBP	O
both	DT	O
Gag-polymerase	NNP	O
and	CC	O
env	VB	O
coding	VBG	O
sequences	NNS	O
.	.	O
Recombinant	JJ	O
lentiviral	JJ	O
vector	NN	O
typically	RB	O
contain	VBZ	O
less	JJR	O
than	IN	O
20	CD	O
,	,	O
preferably	RB	O
15	CD	O
,	,	O
more	JJR	O
preferably	RB	O
10	CD	O
,	,	O
and	CC	O
most	JJS	O
preferably	RB	O
8	CD	O
consecutive	JJ	O
nucleotides	NNS	O
found	VBN	O
in	IN	O
Gag-polymerase	NNP	O
or	CC	O
env	JJ	O
genes	NNS	O
.	.	O
One	CD	O
advantage	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
is	VBZ	O
that	IN	O
the	DT	O
synthetic	JJ	O
Gag-polymerase	NNP	O
expression	NN	O
cassettes	NNS	O
,	,	O
which	WDT	O
can	MD	O
be	VB	O
used	VBN	O
to	TO	O
construct	VB	O
packaging	NN	O
cell	NN	O
lines	NNS	O
for	IN	O
the	DT	O
recombinant	JJ	O
retroviral	JJ	O
vector	NN	O
constructs	NNS	O
,	,	O
have	VBP	O
little	JJ	O
homology	NN	O
to	TO	O
wild-type	JJ	O
Gag-polymerase	NNP	O
sequences	NNS	O
and	CC	O
thus	RB	O
considerably	RB	O
reduce	VB	O
or	CC	O
eliminate	VB	O
the	DT	O
possibility	NN	O
of	IN	O
homologous	JJ	O
recombination	NN	O
between	IN	O
the	DT	O
synthetic	JJ	O
and	CC	O
wild-type	JJ	O
sequences	NNS	O
.	.	O
Lentiviral	JJ	O
vectors	NNS	O
may	MD	O
also	RB	O
include	VB	O
tissue-specific	JJ	O
promoters	NNS	O
to	TO	O
drive	VB	O
expression	NN	O
of	IN	O
one	CD	O
or	CC	O
more	JJR	O
genes	NNS	O
or	CC	O
sequences	NNS	O
of	IN	O
interest	NN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
lentiviral	JJ	O
vector	NN	O
particles	NNS	O
of	IN	O
the	DT	O
invention	NN	O
can	MD	O
contain	VB	O
a	DT	O
liver	NN	O
specific	JJ	O
promoter	NN	O
to	TO	O
maximize	VB	O
the	DT	O
potential	NN	O
for	IN	O
liver	NN	O
specific	JJ	O
expression	NN	O
of	IN	O
the	DT	O
exogenous	JJ	O
DNA	NNP	O
sequence	NN	O
contained	VBD	O
in	IN	O
the	DT	O
vectors	NNS	O
.	.	O
Preferred	VBN	O
liver	NN	O
specific	JJ	O
promoters	NNS	O
include	VBP	O
the	DT	O
hepatitis	NN	O
B	NNP	O
X-gene	NNP	O
promoter	NN	O
and	CC	O
the	DT	O
hepatitis	NN	O
B	NNP	O
core	NN	O
protein	NN	O
promoter	NN	O
.	.	O
These	DT	O
liver	WRB	O
specific	JJ	O
promoters	NNS	O
are	VBP	O
preferably	RB	O
employed	VBN	O
with	IN	O
their	PRP$	O
respective	JJ	O
enhancers	NNS	O
.	.	O
The	DT	O
enhancer	NN	O
element	NN	O
can	MD	O
be	VB	O
linked	VBN	O
at	IN	O
either	CC	O
the	DT	O
5′	CD	O
or	CC	O
the	DT	O
3′	CD	O
end	NN	O
of	IN	O
the	DT	O
nucleic	JJ	O
acid	NN	O
encoding	VBG	O
the	DT	O
sequences	NNS	O
of	IN	O
interest	NN	O
.	.	O
The	DT	O
hepatitis	NN	O
B	NNP	O
X	NNP	O
gene	NN	O
promoter	NN	O
and	CC	O
its	PRP$	O
enhancer	NN	O
can	MD	O
be	VB	O
obtained	VBN	O
from	IN	O
the	DT	O
viral	JJ	O
genome	NN	O
as	IN	O
a	DT	O
332	CD	O
base	NN	O
pair	NN	O
EcoRV-NcoI	NNP	O
DNA	NNP	O
fragment	NN	O
employing	VBG	O
the	DT	O
methods	NNS	O
described	VBN	O
in	IN	O
Twu	NNP	B
,	,	I
et	FW	I
al.	NN	I
,	,	I
J.	NNP	I
Virol	NNP	I
.	.	I
61:3448-3453	CD	I
,	,	I
1987	CD	I
.	.	O
The	DT	O
hepatitis	NN	O
B	NNP	O
core	NN	O
protein	NN	O
promoter	NN	O
can	MD	O
be	VB	O
obtained	VBN	O
from	IN	O
the	DT	O
viral	JJ	O
genome	NN	O
as	IN	O
a	DT	O
584	CD	O
base	NN	O
pair	NN	O
BamHI-BglII	NNP	O
DNA	NNP	O
fragment	NN	O
employing	VBG	O
the	DT	O
methods	NNS	O
described	VBN	O
in	IN	O
Gerlach	NNP	B
,	,	I
et	FW	I
al.	NN	I
,	,	I
Virol	NNP	I
189:59-66	CD	I
,	,	I
1992	CD	I
.	.	O
It	PRP	O
may	MD	O
be	VB	O
necessary	JJ	O
to	TO	O
remove	VB	O
the	DT	O
negative	JJ	O
regulatory	JJ	O
sequence	NN	O
in	IN	O
the	DT	O
BamHI-BglII	NNP	O
fragment	NN	O
prior	RB	O
to	TO	O
inserting	VBG	O
it	PRP	O
.	.	O
Other	JJ	O
liver	NN	O
specific	JJ	O
promoters	NNS	O
include	VBP	O
the	DT	O
AFP	NNP	O
(	(	O
alpha	JJ	O
fetal	JJ	O
protein	NN	O
)	)	O
gene	NN	O
promoter	NN	O
and	CC	O
the	DT	O
albumin	JJ	O
gene	NN	O
promoter	NN	O
,	,	O
as	IN	O
disclosed	VBN	O
in	IN	O
EP	NNP	O
Patent	NNP	O
Publication	NNP	O
0	CD	O
415	CD	O
731	CD	O
,	,	O
the	DT	O
−1	NNP	O
antitrypsin	NN	O
gene	NN	O
promoter	NN	O
,	,	O
as	IN	O
disclosed	VBN	O
in	IN	O
Rettenger	NNP	B
,	,	I
et	FW	I
al.	NN	I
,	,	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
91:1460-1464	CD	I
,	,	I
1994	CD	I
,	,	O
the	DT	O
fibrinogen	NN	O
gene	NN	O
promoter	NN	O
,	,	O
the	DT	O
APO-A1	NNP	O
(	(	O
Apolipoprotein	NNP	O
A1	NNP	O
)	)	O
gene	NN	O
promoter	NN	O
,	,	O
and	CC	O
the	DT	O
promoter	NN	O
genes	NNS	O
for	IN	O
liver	NN	O
transference	NN	O
enzymes	NNS	O
such	JJ	O
as	IN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
SGOT	NNP	O
,	,	O
SGPT	NNP	O
and	CC	O
glutamyle	JJ	O
transferase	NN	O
.	.	O
See	NNP	O
also	RB	O
PCT	NNP	O
Patent	NNP	O
Publications	NNP	O
WO	NNP	O
90/07936	CD	O
and	CC	O
WO	NNP	O
91/02805	CD	O
for	IN	O
a	DT	O
description	NN	O
of	IN	O
the	DT	O
use	NN	O
of	IN	O
liver	NN	O
specific	JJ	O
promoters	NNS	O
in	IN	O
lentiviral	JJ	O
vector	NN	O
particles	NNS	O
.	.	O
Lentiviral	JJ	O
vector	NN	O
constructs	NNS	O
may	MD	O
be	VB	O
generated	VBN	O
such	JJ	O
that	IN	O
more	JJR	O
than	IN	O
one	CD	O
gene	NN	O
of	IN	O
interest	NN	O
is	VBZ	O
expressed	VBN	O
.	.	O
This	DT	O
may	MD	O
be	VB	O
accomplished	VBN	O
through	IN	O
the	DT	O
use	NN	O
of	IN	O
di-	NN	O
or	CC	O
oligo-cistronic	JJ	O
cassettes	NNS	O
(	(	O
e.g.	NN	O
,	,	O
where	WRB	O
the	DT	O
coding	NN	O
regions	NNS	O
are	VBP	O
separated	VBN	O
by	IN	O
80	CD	O
nucleotides	NNS	O
or	CC	O
less	JJR	O
,	,	O
see	VBP	O
generally	RB	O
Levin	NNP	B
et	CC	I
al.	NN	I
,	,	I
Gene	NNP	I
108:167-174	CD	I
,	,	I
1991	CD	I
)	)	O
,	,	O
or	CC	O
through	IN	O
the	DT	O
use	NN	O
of	IN	O
Internal	NNP	O
Ribosome	NNP	O
Entry	NNP	O
Sites	NNP	O
(	(	O
“	JJ	O
IRES	NNP	O
”	NNP	O
)	)	O
.	.	O
Packaging	VBG	O
cell	NN	O
lines	NNS	O
suitable	JJ	O
for	IN	O
use	NN	O
with	IN	O
the	DT	O
above	JJ	O
described	NN	O
recombinant	JJ	O
retroviral	JJ	O
vector	NN	O
constructs	NNS	O
may	MD	O
be	VB	O
readily	RB	O
prepared	JJ	O
given	VBN	O
the	DT	O
disclosure	NN	O
provided	VBD	O
herein	NN	O
.	.	O
Briefly	NNP	O
,	,	O
the	DT	O
parent	NN	O
cell	NN	O
line	NN	O
from	IN	O
which	WDT	O
the	DT	O
packaging	NN	O
cell	NN	O
line	NN	O
is	VBZ	O
derived	VBN	O
can	MD	O
be	VB	O
selected	VBN	O
from	IN	O
a	DT	O
variety	NN	O
of	IN	O
mammalian	JJ	O
cell	NN	O
lines	NNS	O
,	,	O
including	VBG	O
for	IN	O
example	NN	O
,	,	O
293	CD	O
,	,	O
RD	NNP	O
,	,	O
COS-7	NNP	O
,	,	O
CHO	NNP	O
,	,	O
BHK	NNP	O
,	,	O
VERO	NNP	O
,	,	O
HT1080	NNP	O
,	,	O
and	CC	O
myeloma	NN	O
cells	NNS	O
.	.	O
After	IN	O
selection	NN	O
of	IN	O
a	DT	O
suitable	JJ	O
host	NN	O
cell	NN	O
for	IN	O
the	DT	O
generation	NN	O
of	IN	O
a	DT	O
packaging	NN	O
cell	NN	O
line	NN	O
,	,	O
one	CD	O
or	CC	O
more	JJR	O
expression	NN	O
cassettes	NNS	O
are	VBP	O
introduced	VBN	O
into	IN	O
the	DT	O
cell	NN	O
line	NN	O
in	IN	O
order	NN	O
to	TO	O
complement	VB	O
or	CC	O
supply	VB	O
in	IN	O
trans	JJ	O
components	NNS	O
of	IN	O
the	DT	O
vector	NN	O
which	WDT	O
have	VBP	O
been	VBN	O
deleted	VBN	O
.	.	O
Representative	JJ	O
examples	NNS	O
of	IN	O
suitable	JJ	O
expression	NN	O
cassettes	NNS	O
have	VBP	O
been	VBN	O
described	VBN	O
herein	JJ	O
and	CC	O
include	VBP	O
synthetic	JJ	O
Env	NNP	O
,	,	O
tat	NN	O
,	,	O
Gag	NNP	O
,	,	O
synthetic	JJ	O
Gag-protease	NNP	O
,	,	O
synthetic	JJ	O
Gag-reverse	NNP	O
transcriptase	NN	O
and	CC	O
synthetic	JJ	O
Gag-polymerase	NNP	O
expression	NN	O
cassettes	NNS	O
,	,	O
which	WDT	O
comprise	VBP	O
a	DT	O
promoter	NN	O
and	CC	O
a	DT	O
sequence	NN	O
encoding	NN	O
,	,	O
e.g.	NN	O
,	,	O
Env	NNP	O
,	,	O
tat	NN	O
,	,	O
or	CC	O
Gag-polymerase	NNP	O
and	CC	O
at	IN	O
least	JJS	O
one	CD	O
of	IN	O
vpr	NN	O
,	,	O
vpu	NN	O
,	,	O
nef	''	O
or	CC	O
vif	VB	O
,	,	O
wherein	VB	O
the	DT	O
promoter	NN	O
is	VBZ	O
operably	RB	O
linked	VBN	O
to	TO	O
Env	NNP	O
,	,	O
tat	NN	O
or	CC	O
Gag-polymerase	NNP	O
and	CC	O
vpr	NN	O
,	,	O
vpu	NN	O
,	,	O
nef	''	O
or	CC	O
vif	NN	O
.	.	O
As	IN	O
described	VBN	O
above	IN	O
,	,	O
optimized	VBD	O
Env	NNP	O
,	,	O
Gag	NNP	O
and/or	VBZ	O
tat	JJ	O
coding	VBG	O
sequences	NNS	O
may	MD	O
also	RB	O
be	VB	O
utilized	VBN	O
in	IN	O
various	JJ	O
combinations	NNS	O
in	IN	O
the	DT	O
generation	NN	O
of	IN	O
packaging	NN	O
cell	NN	O
lines	NNS	O
.	.	O
Utilizing	VBG	O
the	DT	O
above-described	JJ	O
expression	NN	O
cassettes	NNS	O
,	,	O
a	DT	O
wide	JJ	O
variety	NN	O
of	IN	O
packaging	NN	O
cell	NN	O
lines	NNS	O
can	MD	O
be	VB	O
generated	VBN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
within	IN	O
one	CD	O
aspect	NN	O
packaging	NN	O
cell	NN	O
line	NN	O
are	VBP	O
provided	VBN	O
comprising	VBG	O
an	DT	O
expression	NN	O
cassette	NN	O
that	WDT	O
comprises	VBZ	O
a	DT	O
sequence	NN	O
encoding	VBG	O
synthetic	JJ	O
HIV	NNP	O
(	(	O
e.g.	NN	O
,	,	O
Gag	NNP	O
,	,	O
Env	NNP	O
,	,	O
tat	NN	O
,	,	O
Gag-polymerase	NNP	O
,	,	O
Gag-reverse	NNP	O
transcriptase	NN	O
or	CC	O
Gag-protease	NNP	O
)	)	O
polypeptide	NN	O
,	,	O
and	CC	O
a	DT	O
nuclear	JJ	O
transport	NN	O
element	NN	O
,	,	O
wherein	VBP	O
the	DT	O
promoter	NN	O
is	VBZ	O
operably	RB	O
linked	VBN	O
to	TO	O
the	DT	O
sequence	NN	O
encoding	VBG	O
the	DT	O
HIV	NNP	O
polypeptide	NN	O
.	.	O
Within	IN	O
other	JJ	O
aspects	NNS	O
,	,	O
packaging	NN	O
cell	NN	O
lines	NNS	O
are	VBP	O
provided	VBN	O
comprising	VBG	O
a	DT	O
promoter	NN	O
and	CC	O
a	DT	O
sequence	NN	O
encoding	VBG	O
Gag	NNP	O
,	,	O
tat	NN	O
,	,	O
rev	NN	O
,	,	O
or	CC	O
an	DT	O
envelope	NN	O
(	(	O
e.g.	JJ	O
,	,	O
HIV	NNP	O
env	NN	O
)	)	O
,	,	O
wherein	VBD	O
the	DT	O
promoter	NN	O
is	VBZ	O
operably	RB	O
linked	VBN	O
to	TO	O
the	DT	O
sequence	NN	O
encoding	VBG	O
Gag	NNP	O
,	,	O
tat	NN	O
,	,	O
rev	NN	O
,	,	O
or	CC	O
,	,	O
the	DT	O
envelope	NN	O
.	.	O
Within	IN	O
further	JJ	O
embodiments	NNS	O
,	,	O
the	DT	O
packaging	NN	O
cell	NN	O
line	NN	O
may	MD	O
comprise	VB	O
a	DT	O
sequence	NN	O
encoding	VBG	O
any	DT	O
one	CD	O
or	CC	O
more	JJR	O
of	IN	O
nef	NN	O
,	,	O
vif	NN	O
,	,	O
vpu	NN	O
or	CC	O
vpr	NN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
the	DT	O
packaging	NN	O
cell	NN	O
line	NN	O
may	MD	O
contain	VB	O
only	RB	O
nef	RB	O
,	,	O
vif	NN	O
,	,	O
vpu	NN	O
,	,	O
or	CC	O
vpr	VB	O
alone	RB	O
,	,	O
nef	JJ	O
and	CC	O
vif	NN	O
,	,	O
nef	NN	O
and	CC	O
vpu	NN	O
,	,	O
nef	NN	O
and	CC	O
vpr	NN	O
,	,	O
vif	NN	O
and	CC	O
vpu	NN	O
,	,	O
vif	NN	O
and	CC	O
vpr	NN	O
,	,	O
vpu	NN	O
and	CC	O
vpr	NN	O
,	,	O
nef	JJ	O
vif	NN	O
and	CC	O
vpu	NN	O
,	,	O
nef	JJ	O
vif	NN	O
and	CC	O
vpr	NN	O
,	,	O
nef	JJ	O
vpu	NN	O
and	CC	O
vpr	NN	O
,	,	O
vvir	NN	O
vpu	NN	O
and	CC	O
vpr	NN	O
,	,	O
or	CC	O
,	,	O
all	DT	O
four	CD	O
of	IN	O
nef	NN	O
vif	NN	O
vpu	NN	O
and	CC	O
vpr	NN	O
.	.	O
In	IN	O
one	CD	O
embodiment	NN	O
,	,	O
the	DT	O
expression	NN	O
cassette	NN	O
is	VBZ	O
stably	RB	O
integrated	VBN	O
.	.	O
Within	IN	O
another	DT	O
embodiment	NN	O
,	,	O
the	DT	O
packaging	NN	O
cell	NN	O
line	NN	O
,	,	O
upon	IN	O
introduction	NN	O
of	IN	O
a	DT	O
lentiviral	JJ	O
vector	NN	O
,	,	O
produces	VBZ	O
particles	NNS	O
.	.	O
Within	IN	O
further	JJ	O
embodiments	NNS	O
the	DT	O
promoter	NN	O
is	VBZ	O
inducible	JJ	O
.	.	O
Within	IN	O
certain	JJ	O
preferred	JJ	O
embodiments	NNS	O
of	IN	O
the	DT	O
invention	NN	O
,	,	O
the	DT	O
packaging	NN	O
cell	NN	O
line	NN	O
,	,	O
upon	IN	O
introduction	NN	O
of	IN	O
a	DT	O
lentiviral	JJ	O
vector	NN	O
,	,	O
produces	VBZ	O
particles	NNS	O
that	WDT	O
are	VBP	O
free	JJ	O
of	IN	O
replication	NN	O
competent	NN	O
virus	NN	O
.	.	O
The	DT	O
synthetic	JJ	O
cassettes	NNS	O
containing	VBG	O
optimized	JJ	O
coding	NN	O
sequences	NNS	O
are	VBP	O
transfected	VBN	O
into	IN	O
a	DT	O
selected	VBN	O
cell	NN	O
line	NN	O
.	.	O
Transfected	VBN	O
cells	NNS	O
are	VBP	O
selected	VBN	O
that	IN	O
(	(	O
i	NN	O
)	)	O
carry	NN	O
,	,	O
typically	RB	O
,	,	O
integrated	VBN	O
,	,	O
stable	JJ	O
copies	NNS	O
of	IN	O
the	DT	O
Gag	NNP	O
,	,	O
Pol	NNP	O
,	,	O
and	CC	O
Env	NNP	O
coding	NN	O
sequences	NNS	O
,	,	O
and	CC	O
(	(	O
ii	NN	O
)	)	O
are	VBP	O
expressing	VBG	O
acceptable	JJ	O
levels	NNS	O
of	IN	O
these	DT	O
polypeptides	NNS	O
(	(	O
expression	NN	O
can	MD	O
be	VB	O
evaluated	VBN	O
by	IN	O
methods	NNS	O
known	VBN	O
in	IN	O
the	DT	O
prior	JJ	O
art	NN	O
,	,	O
e.g.	NN	O
,	,	O
see	VBP	O
Examples	NNP	O
1-4	CD	O
)	)	O
.	.	O
The	DT	O
ability	NN	O
of	IN	O
the	DT	O
cell	NN	O
line	NN	O
to	TO	O
produce	VB	O
VLPs	NNP	O
may	MD	O
also	RB	O
be	VB	O
verified	VBN	O
(	(	O
Examples	NNP	O
6	CD	O
,	,	O
7	CD	O
and	CC	O
15	CD	O
)	)	O
.	.	O
A	DT	O
sequence	NN	O
of	IN	O
interest	NN	O
is	VBZ	O
constructed	VBN	O
into	IN	O
a	DT	O
suitable	JJ	O
viral	JJ	O
vector	NN	O
as	IN	O
discussed	VBN	O
above	IN	O
.	.	O
This	DT	O
defective	JJ	O
virus	NN	O
is	VBZ	O
then	RB	O
transfected	VBN	O
into	IN	O
the	DT	O
packaging	NN	O
cell	NN	O
line	NN	O
.	.	O
The	DT	O
packaging	NN	O
cell	NN	O
line	NN	O
provides	VBZ	O
the	DT	O
viral	JJ	O
functions	NNS	O
necessary	JJ	O
for	IN	O
producing	VBG	O
virus-like	JJ	O
particles	NNS	O
into	IN	O
which	WDT	O
the	DT	O
defective	JJ	O
viral	JJ	O
genome	NN	O
,	,	O
containing	VBG	O
the	DT	O
sequence	NN	O
of	IN	O
interest	NN	O
,	,	O
are	VBP	O
packaged	VBN	O
.	.	O
These	DT	O
VLPs	NNP	O
are	VBP	O
then	RB	O
isolated	JJ	O
and	CC	O
can	MD	O
be	VB	O
used	VBN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
in	IN	O
gene	NN	O
delivery	NN	O
or	CC	O
gene	NN	O
therapy	NN	O
.	.	O
Further	RB	O
,	,	O
such	JJ	O
packaging	NN	O
cell	NN	O
lines	NNS	O
can	MD	O
also	RB	O
be	VB	O
used	VBN	O
to	TO	O
produce	VB	O
VLPs	NNP	O
alone	RB	O
,	,	O
which	WDT	O
can	MD	O
,	,	O
for	IN	O
example	NN	O
,	,	O
be	VB	O
used	VBN	O
as	IN	O
adjuvants	NNS	O
for	IN	O
administration	NN	O
with	IN	O
other	JJ	O
antigens	NNS	O
or	CC	O
in	IN	O
vaccine	JJ	O
compositions	NNS	O
.	.	O
Also	RB	O
,	,	O
co-expression	NN	O
of	IN	O
a	DT	O
selected	VBN	O
sequence	NN	O
of	IN	O
interest	NN	O
encoding	VBG	O
a	DT	O
polypeptide	NN	O
(	(	O
for	IN	O
example	NN	O
,	,	O
an	DT	O
antigen	NN	O
)	)	O
in	IN	O
the	DT	O
packaging	NN	O
cell	NN	O
line	NN	O
can	MD	O
also	RB	O
result	VB	O
in	IN	O
the	DT	O
entrapment	NN	O
and/or	NN	O
association	NN	O
of	IN	O
the	DT	O
selected	VBN	O
polypeptide	NN	O
in/with	VBZ	O
the	DT	O
VLPs	NNP	O
.	.	O
2.3	CD	O
DNA	NNP	O
Immunization	NNP	O
and	CC	O
Gene	NNP	O
Delivery	NNP	O
A	NNP	O
variety	NN	O
of	IN	O
polypeptide	JJ	O
antigens	NNS	O
can	MD	O
be	VB	O
used	VBN	O
in	IN	O
the	DT	O
practice	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
.	.	O
Polypeptide	IN	O
antigens	NNS	O
can	MD	O
be	VB	O
included	VBN	O
in	IN	O
DNA	NNP	O
immunization	NN	O
constructs	NNS	O
containing	VBG	O
,	,	O
for	IN	O
example	NN	O
,	,	O
any	DT	O
of	IN	O
the	DT	O
synthetic	JJ	O
expression	NN	O
cassettes	NNS	O
described	VBD	O
herein	NNS	O
fused	VBD	O
in-frame	NN	O
to	TO	O
a	DT	O
coding	NN	O
sequence	NN	O
for	IN	O
the	DT	O
polypeptide	NN	O
antigen	NN	O
,	,	O
where	WRB	O
expression	NN	O
of	IN	O
the	DT	O
construct	NN	O
results	NNS	O
in	IN	O
VLPs	NNP	O
presenting	VBG	O
the	DT	O
antigen	NN	O
of	IN	O
interest	NN	O
.	.	O
Antigens	NNS	O
can	MD	O
be	VB	O
derived	VBN	O
from	IN	O
a	DT	O
wide	JJ	O
variety	NN	O
of	IN	O
viruses	NNS	O
,	,	O
bacteria	NNS	O
,	,	O
fungi	NNS	O
,	,	O
plants	NNS	O
,	,	O
protozoans	NNS	O
and	CC	O
other	JJ	O
parasites	NNS	O
.	.	O
For	IN	O
example	NN	O
,	,	O
the	DT	O
present	JJ	O
invention	NN	O
will	MD	O
find	VB	O
use	NN	O
for	IN	O
stimulating	VBG	O
an	DT	O
immune	JJ	O
response	NN	O
against	IN	O
a	DT	O
wide	JJ	O
variety	NN	O
of	IN	O
proteins	NNS	O
from	IN	O
the	DT	O
herpesvirus	NN	O
family	NN	O
,	,	O
including	VBG	O
proteins	NNS	O
derived	VBN	O
from	IN	O
herpes	NNS	O
simplex	JJ	O
virus	NN	O
(	(	O
HSV	NNP	O
)	)	O
types	VBZ	O
1	CD	O
and	CC	O
2	CD	O
,	,	O
such	JJ	O
as	IN	O
HSV-1	NNP	O
and	CC	O
HSV-2	NNP	O
gB	NN	O
,	,	O
gD	NN	O
,	,	O
gH	NN	O
,	,	O
VP16	NNP	O
and	CC	O
VP22	NNP	O
;	:	O
antigens	VBZ	O
derived	VBN	O
from	IN	O
varicella	NN	O
zoster	NN	O
virus	NN	O
(	(	O
VZV	NNP	O
)	)	O
,	,	O
Epstein-Barr	JJ	O
virus	NN	O
(	(	O
EBV	NNP	O
)	)	O
and	CC	O
cytomegalovirus	NN	O
(	(	O
CMV	NNP	O
)	)	O
including	VBG	O
CMV	NNP	O
gB	NN	O
and	CC	O
gH	NN	O
;	:	O
and	CC	O
antigens	VBZ	O
derived	VBN	O
from	IN	O
other	JJ	O
human	JJ	O
herpesviruses	NNS	O
such	JJ	O
as	IN	O
HHV6	NNP	O
and	CC	O
HHV7	NNP	O
.	.	O
(	(	O
See	VB	O
,	,	O
e.g	VB	O
.	.	O
Chee	NNP	B
et	CC	I
al.	NN	I
,	,	I
Cytomegaloviruses	NNP	I
(	(	I
J.	NNP	I
K.	NNP	I
McDougall	NNP	I
,	,	I
ed.	NN	I
,	,	I
Springer-Verlag	NNP	I
1990	CD	I
)	)	I
pp	NN	I
.	.	I
125-169	JJ	I
,	,	O
for	IN	O
a	DT	O
review	NN	O
of	IN	O
the	DT	O
protein	NN	O
coding	VBG	O
content	NN	O
of	IN	O
cytomegalovirus	NN	O
;	:	O
McGeoch	NNP	B
et	FW	I
al.	NN	I
,	,	I
J.	NNP	I
Gen.	NNP	I
Virol	NNP	I
.	.	I
(	(	I
1988	CD	I
)	)	I
69:1531-1574	CD	I
,	,	O
for	IN	O
a	DT	O
discussion	NN	O
of	IN	O
the	DT	O
various	JJ	O
HSV-1	NNP	O
encoded	VBD	O
proteins	NNS	O
;	:	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,171,568	CD	O
for	IN	O
a	DT	O
discussion	NN	O
of	IN	O
HSV-1	NNP	O
and	CC	O
HSV-2	NNP	O
gB	NN	O
and	CC	O
gD	NN	O
proteins	NNS	O
and	CC	O
the	DT	O
genes	NNS	O
encoding	VBG	O
therefore	RB	O
;	:	O
Baer	NNP	B
et	FW	I
al.	NN	I
,	,	I
Nature	NNP	I
(	(	I
1984	CD	I
)	)	I
310:207-211	CD	I
,	,	O
for	IN	O
the	DT	O
identification	NN	O
of	IN	O
protein	NN	O
coding	VBG	O
sequences	NNS	O
in	IN	O
an	DT	O
EBV	NNP	O
genome	NN	O
;	:	O
and	CC	O
Davison	NNP	B
and	CC	I
Scott	NNP	I
,	,	I
J.	NNP	I
Gen.	NNP	I
Virol	NNP	I
.	.	I
(	(	I
1986	CD	I
)	)	I
67:1759-1816	CD	I
,	,	O
for	IN	O
a	DT	O
review	NN	O
of	IN	O
VZV	NNP	O
.	.	O
)	)	O
Additionally	RB	O
,	,	O
immune	JJ	O
responses	NNS	O
to	TO	O
antigens	NNS	O
from	IN	O
the	DT	O
hepatitis	NN	O
family	NN	O
of	IN	O
viruses	NNS	O
,	,	O
including	VBG	O
hepatitis	NN	O
A	DT	O
virus	NN	O
(	(	O
HAV	NNP	O
)	)	O
,	,	O
hepatitis	NN	O
B	NNP	O
virus	NN	O
(	(	O
HBV	NNP	O
)	)	O
,	,	O
hepatitis	FW	O
C	NNP	O
virus	NN	O
(	(	O
HCV	NNP	O
)	)	O
,	,	O
the	DT	O
delta	NN	O
hepatitis	NN	O
virus	NN	O
(	(	O
HDV	NNP	O
)	)	O
,	,	O
hepatitis	FW	O
E	NNP	O
virus	NN	O
(	(	O
HEV	NNP	O
)	)	O
,	,	O
and	CC	O
hepatitis	NN	O
G	NNP	O
virus	NN	O
,	,	O
can	MD	O
also	RB	O
be	VB	O
stimulated	VBN	O
using	VBG	O
the	DT	O
constructs	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
.	.	O
By	IN	O
way	NN	O
of	IN	O
example	NN	O
,	,	O
the	DT	O
HCV	NNP	O
genome	NN	O
encodes	NNS	O
several	JJ	O
viral	JJ	O
proteins	NNS	O
,	,	O
including	VBG	O
E1	NNP	O
(	(	O
also	RB	O
known	VBN	O
as	IN	O
E	NN	O
)	)	O
and	CC	O
E2	NNP	O
(	(	O
also	RB	O
known	VBN	O
as	IN	O
E2/NSI	NNP	O
)	)	O
,	,	O
which	WDT	O
will	MD	O
find	VB	O
use	NN	O
with	IN	O
the	DT	O
present	JJ	O
invention	NN	O
(	(	O
see	VB	O
,	,	O
Houghton	NNP	B
et	VBZ	I
al	NN	I
.	.	I
Hepatology	NNP	I
(	(	I
1991	CD	I
)	)	I
14:381-388	CD	I
,	,	O
for	IN	O
a	DT	O
discussion	NN	O
of	IN	O
HCV	NNP	O
proteins	NNS	O
,	,	O
including	VBG	O
E1	NNP	O
and	CC	O
E2	NNP	O
)	)	O
.	.	O
The	DT	O
δ-antigen	NN	O
from	IN	O
HDV	NNP	O
can	MD	O
also	RB	O
be	VB	O
used	VBN	O
(	(	O
see	VB	O
,	,	O
e.g.	VB	O
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,389,528	CD	O
,	,	O
for	IN	O
a	DT	O
description	NN	O
of	IN	O
the	DT	O
δ-antigen	NN	O
)	)	O
.	.	O
Similarly	RB	O
,	,	O
influenza	JJ	O
virus	NN	O
is	VBZ	O
another	DT	O
example	NN	O
of	IN	O
a	DT	O
virus	NN	O
for	IN	O
which	WDT	O
the	DT	O
present	JJ	O
invention	NN	O
will	MD	O
be	VB	O
particularly	RB	O
useful	JJ	O
.	.	O
Specifically	RB	O
,	,	O
the	DT	O
envelope	NN	O
glycoproteins	VBZ	O
HA	NNP	O
and	CC	O
NA	NNP	O
of	IN	O
influenza	NN	O
A	DT	O
are	VBP	O
of	IN	O
particular	JJ	O
interest	NN	O
for	IN	O
generating	VBG	O
an	DT	O
immune	JJ	O
response	NN	O
.	.	O
Numerous	JJ	O
HA	NNP	O
subtypes	NNS	O
of	IN	O
influenza	NN	O
A	DT	O
have	VBP	O
been	VBN	O
identified	VBN	O
(	(	O
Kawaoka	NNP	B
et	RB	I
al.	RB	I
,	,	I
Virology	NNP	I
(	(	I
1990	CD	I
)	)	I
179:759-767	CD	I
;	:	O
Webster	NNP	B
et	FW	I
al	NN	I
.	.	I
“	NN	I
Antigenic	NNP	I
variation	NN	I
among	IN	I
type	NN	I
A	NNP	I
influenza	NN	I
viruses	NNS	I
,	,	I
”	JJ	I
p.	NN	I
127-168	JJ	I
.	.	I
In	IN	I
:	:	I
P.	NNP	I
Palese	NNP	I
and	CC	I
D.	NNP	I
W.	NNP	I
Kingsbury	NNP	I
(	(	I
ed	NN	I
.	.	I
)	)	I
,	,	I
Genetics	NNP	I
of	IN	I
influenza	NN	I
viruses	NNS	I
.	.	I
Springer-Verlag	NNP	I
,	,	I
New	NNP	I
York	NNP	I
)	)	O
.	.	O
Other	JJ	O
antigens	NNS	O
of	IN	O
particular	JJ	O
interest	NN	O
to	TO	O
be	VB	O
used	VBN	O
in	IN	O
the	DT	O
practice	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
include	VBP	O
antigens	NNS	O
and	CC	O
polypeptides	NNS	O
derived	VBN	O
therefrom	IN	O
from	IN	O
human	JJ	O
papillomavirus	NN	O
(	(	O
HPV	NNP	O
)	)	O
,	,	O
such	JJ	O
as	IN	O
one	CD	O
or	CC	O
more	JJR	O
of	IN	O
the	DT	O
various	JJ	O
early	JJ	O
proteins	NNS	O
including	VBG	O
E6	NNP	O
and	CC	O
E7	NNP	O
;	:	O
tick-borne	JJ	O
encephalitis	NN	O
viruses	NNS	O
;	:	O
and	CC	O
HIV-1	NNP	O
(	(	O
also	RB	O
known	VBN	O
as	IN	O
HTLV-III	NNP	O
,	,	O
LAV	NNP	O
,	,	O
ARV	NNP	O
,	,	O
etc	NN	O
.	.	O
)	)	O
,	,	O
including	VBG	O
,	,	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
,	,	O
antigens	NNS	O
such	JJ	O
as	IN	O
gp120	NN	O
,	,	O
gp41	NN	O
,	,	O
gp160	NN	O
,	,	O
Gag	NNP	O
and	CC	O
pol	NN	O
from	IN	O
a	DT	O
variety	NN	O
of	IN	O
isolates	NNS	O
including	VBG	O
,	,	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
,	,	O
HIVIIIb	NNP	O
,	,	O
HIVSF2	NNP	O
,	,	O
HIV-1SF162	NNP	O
,	,	O
HIV-1SF170	NNP	O
,	,	O
HIVLAV	NNP	O
,	,	O
HIVLAI	NNP	O
,	,	O
HIVMN	NNP	O
,	,	O
HIV-1CM235	NNP	O
,	,	O
HIV-1US4	NNP	O
,	,	O
other	JJ	O
HIV-1	JJ	O
strains	NNS	O
from	IN	O
diverse	JJ	O
subtypes	NNS	O
(	(	O
e.g.	NN	O
,	,	O
subtypes	NNS	O
,	,	O
A	NNP	O
through	IN	O
G	NNP	O
,	,	O
and	CC	O
O	NNP	O
)	)	O
,	,	O
HIV-2	NNP	O
strains	NNS	O
and	CC	O
diverse	JJ	O
subtypes	NNS	O
(	(	O
e.g.	NN	O
,	,	O
HIV-2UC1	NNP	O
and	CC	O
HIV-2UC2	NNP	O
)	)	O
.	.	O
See	VB	O
,	,	O
e.g.	VB	O
,	,	O
Myers	NNP	B
,	,	I
et	FW	I
al.	NN	I
,	,	I
Los	NNP	I
Alamos	NNP	I
Database	NNP	I
,	,	I
Los	NNP	I
Alamos	NNP	I
National	NNP	I
Laboratory	NNP	I
,	,	I
Los	NNP	I
Alamos	NNP	I
,	,	I
N	NNP	I
.	.	I
Mex	NNP	I
.	.	I
;	:	O
Myers	NNS	B
,	,	I
et	FW	I
al.	NN	I
,	,	I
Human	NNP	I
Retroviruses	NNP	I
and	CC	I
Aids	NNP	I
,	,	I
1990	CD	I
,	,	I
Los	NNP	I
Alamos	NNP	I
,	,	I
N	NNP	I
.	.	I
Mex	NNP	I
.	.	I
:	:	I
Los	NNP	I
Alamos	NNP	I
National	NNP	I
Laboratory	NNP	I
.	.	O
Proteins	NNS	O
derived	VBN	O
from	IN	O
other	JJ	O
viruses	NNS	O
will	MD	O
also	RB	O
find	VB	O
use	NN	O
in	IN	O
the	DT	O
claimed	JJ	O
methods	NNS	O
,	,	O
such	JJ	O
as	IN	O
without	IN	O
limitation	NN	O
,	,	O
proteins	VBZ	O
from	IN	O
members	NNS	O
of	IN	O
the	DT	O
families	NNS	O
Picornaviridae	NNP	O
(	(	O
e.g.	NN	O
,	,	O
polioviruses	NNS	O
,	,	O
etc	FW	O
.	.	O
)	)	O
;	:	O
Caliciviridae	NNP	O
;	:	O
Togaviridae	NNP	O
(	(	O
e.g.	NN	O
,	,	O
rubella	NN	O
virus	NN	O
,	,	O
dengue	NN	O
virus	NN	O
,	,	O
etc	FW	O
.	.	O
)	)	O
;	:	O
Flaviviridae	NNP	O
;	:	O
Coronaviridae	NNP	O
;	:	O
Reoviridae	NNP	O
;	:	O
Birnaviridae	NNP	O
;	:	O
Rhabodoviridae	NNP	O
(	(	O
e.g.	NN	O
,	,	O
rabies	NNS	O
virus	VBP	O
,	,	O
etc	FW	O
.	.	O
)	)	O
;	:	O
Filoviridae	NNP	O
;	:	O
Paramyxoviridae	NNP	O
(	(	O
e.g.	NN	O
,	,	O
mumps	NNS	O
virus	NN	O
,	,	O
measles	NNS	O
virus	VBP	O
,	,	O
respiratory	JJ	O
syncytial	JJ	O
virus	NN	O
,	,	O
etc	FW	O
.	.	O
)	)	O
;	:	O
Orthomyxoviridae	NNP	O
(	(	O
e.g.	NN	O
,	,	O
influenza	JJ	O
virus	NN	O
types	VBZ	O
A	NNP	O
,	,	O
B	NNP	O
and	CC	O
C	NNP	O
,	,	O
etc	FW	O
.	.	O
)	)	O
;	:	O
Bunyaviridae	NNP	O
;	:	O
Arenaviridae	NNP	O
;	:	O
Retroviradae	NNP	O
,	,	O
e.g.	NN	O
,	,	O
HTLV-I	NNP	O
;	:	O
HTLV-II	NNP	O
;	:	O
HIV-1	NNP	O
;	:	O
HIV-2	NNP	O
;	:	O
simian	JJ	O
immunodeficiency	NN	O
virus	NN	O
(	(	O
SIV	NNP	O
)	)	O
among	IN	O
others	NNS	O
.	.	O
See	VB	O
,	,	O
e.g	VB	O
.	.	O
Virology	NNP	B
,	,	I
3rd	CD	I
Edition	NNP	I
(	(	I
W.	NNP	I
K.	NNP	I
Joklik	NNP	I
ed	NN	I
.	.	I
1988	CD	I
)	)	I
;	:	O
Fundamental	NNP	B
Virology	NNP	I
,	,	I
2nd	CD	I
Edition	NNP	I
(	(	I
B.	NNP	I
N.	NNP	I
Fields	NNP	I
and	CC	I
D.	NNP	I
M.	NNP	I
Knipe	NNP	I
,	,	I
eds	VBZ	I
.	.	I
1991	CD	I
;	:	O
Virology	NNP	B
,	,	I
3rd	CD	I
Edition	NNP	I
(	(	I
Fields	NNP	I
,	,	I
B	NNP	I
N	NNP	I
,	,	I
D	NNP	I
M	NNP	I
Knipe	NNP	I
,	,	I
P	NNP	I
M	NNP	I
Howley	NNP	I
,	,	I
Editors	NNP	I
,	,	I
1996	CD	I
,	,	I
Lippincott-Raven	NNP	I
,	,	I
Philadelphia	NNP	I
,	,	I
Pa.	NNP	I
)	)	I
for	IN	O
a	DT	O
description	NN	O
of	IN	O
these	DT	O
and	CC	O
other	JJ	O
viruses	NNS	O
.	.	O
Particularly	RB	O
preferred	VBN	O
bacterial	JJ	O
antigens	NNS	O
are	VBP	O
derived	VBN	O
from	IN	O
organisms	NNS	O
that	WDT	O
cause	VBP	O
diphtheria	NN	O
,	,	O
tetanus	NN	O
,	,	O
pertussis	NN	O
,	,	O
meningitis	NN	O
,	,	O
and	CC	O
other	JJ	O
pathogenic	JJ	O
states	NNS	O
,	,	O
including	VBG	O
,	,	O
without	IN	O
limitation	NN	O
,	,	O
antigens	VBZ	O
derived	VBN	O
from	IN	O
Corynebacterium	NNP	O
diphtheriae	NN	O
,	,	O
Clostridium	NNP	O
tetani	NN	O
,	,	O
Bordetella	NNP	O
pertusis	NN	O
,	,	O
Neisseria	NNP	O
meningitidis	NN	O
,	,	O
including	VBG	O
serotypes	NNS	O
Meningococcus	NNP	O
A	NNP	O
,	,	O
B	NNP	O
,	,	O
C	NNP	O
,	,	O
Y	NNP	O
and	CC	O
WI35	NNP	O
(	(	O
MenA	NNP	O
,	,	O
B	NNP	O
,	,	O
C	NNP	O
,	,	O
Y	NNP	O
and	CC	O
WI35	NNP	O
)	)	O
,	,	O
Haemophilus	NNP	O
influenza	VBP	O
type	NN	O
B	NNP	O
(	(	O
Hib	NNP	O
)	)	O
,	,	O
and	CC	O
Helicobacter	NNP	O
pylori	NN	O
.	.	O
Examples	NNS	O
of	IN	O
parasitic	JJ	O
antigens	NNS	O
include	VBP	O
those	DT	O
derived	VBN	O
from	IN	O
organisms	JJ	O
causing	VBG	O
malaria	NN	O
,	,	O
tuberculosis	NN	O
,	,	O
and	CC	O
Lyme	NNP	O
disease	NN	O
.	.	O
Furthermore	RB	O
,	,	O
the	DT	O
methods	NNS	O
described	VBD	O
herein	JJ	O
provide	NN	O
means	VBZ	O
for	IN	O
treating	VBG	O
a	DT	O
variety	NN	O
of	IN	O
malignant	JJ	O
cancers	NNS	O
.	.	O
For	IN	O
example	NN	O
,	,	O
the	DT	O
system	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
can	MD	O
be	VB	O
used	VBN	O
to	TO	O
enhance	VB	O
both	DT	O
humoral	JJ	O
and	CC	O
cell-mediated	JJ	O
immune	NN	O
responses	NNS	O
to	TO	O
particular	JJ	O
proteins	NNS	O
specific	JJ	O
to	TO	O
a	DT	O
cancer	NN	O
in	IN	O
question	NN	O
,	,	O
such	JJ	O
as	IN	O
an	DT	O
activated	JJ	O
oncogene	NN	O
,	,	O
a	DT	O
fetal	JJ	O
antigen	NN	O
,	,	O
or	CC	O
an	DT	O
activation	NN	O
marker	NN	O
.	.	O
Such	JJ	O
tumor	NN	O
antigens	NNS	O
include	VBP	O
any	DT	O
of	IN	O
the	DT	O
various	JJ	O
MAGEs	NNP	O
(	(	O
melanoma	NN	O
associated	VBN	O
antigen	IN	O
E	NNP	O
)	)	O
,	,	O
including	VBG	O
MAGE	NNP	O
1	CD	O
,	,	O
2	CD	O
,	,	O
3	CD	O
,	,	O
4	CD	O
,	,	O
etc	FW	O
.	.	O
(	(	O
Boon	NNP	B
,	,	I
T.	NNP	I
Scientific	NNP	I
American	NNP	I
(	(	I
March	NNP	I
1993	CD	I
)	)	I
:82-89	NN	I
)	)	O
;	:	O
any	DT	O
of	IN	O
the	DT	O
various	JJ	O
tyrosinases	NNS	O
;	:	O
MART	NNP	O
1	CD	O
(	(	O
melanoma	NN	O
antigen	NN	O
recognized	VBN	O
by	IN	O
T	NNP	O
cells	NNS	O
)	)	O
,	,	O
mutant	JJ	O
ras	NN	O
;	:	O
mutant	JJ	O
p53	NN	O
;	:	O
p97	CC	O
melanoma	VB	O
antigen	NN	O
;	:	O
CEA	NNP	O
(	(	O
carcinoembryonic	JJ	O
antigen	NN	O
)	)	O
,	,	O
among	IN	O
others	NNS	O
.	.	O
DNA	NN	O
immunization	NN	O
using	VBG	O
synthetic	JJ	O
expression	NN	O
cassettes	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
has	VBZ	O
been	VBN	O
demonstrated	VBN	O
to	TO	O
be	VB	O
efficacious	JJ	O
(	(	O
Examples	NNP	O
8	CD	O
and	CC	O
10-12	JJ	O
)	)	O
.	.	O
Animals	NNS	O
were	VBD	O
immunized	VBN	O
with	IN	O
both	DT	O
the	DT	O
synthetic	JJ	O
expression	NN	O
cassette	NN	O
and	CC	O
the	DT	O
wild	JJ	O
type	JJ	O
expression	NN	O
cassette	NN	O
.	.	O
The	DT	O
results	NNS	O
of	IN	O
the	DT	O
immunizations	NNS	O
with	IN	O
plasmid-DNAs	NN	O
showed	VBD	O
that	IN	O
the	DT	O
synthetic	JJ	O
expression	NN	O
cassettes	NNS	O
provide	VBP	O
a	DT	O
clear	JJ	O
improvement	NN	O
of	IN	O
immunogenicity	NN	O
relative	NN	O
to	TO	O
the	DT	O
native	JJ	O
expression	NN	O
cassettes	NNS	O
.	.	O
Also	RB	O
,	,	O
the	DT	O
second	JJ	O
boost	NN	O
immunization	NN	O
induced	VBD	O
a	DT	O
secondary	JJ	O
immune	NN	O
response	NN	O
,	,	O
for	IN	O
example	NN	O
after	IN	O
two	CD	O
to	TO	O
eight	CD	O
weeks	NNS	O
.	.	O
Further	RB	O
,	,	O
the	DT	O
results	NNS	O
of	IN	O
CTL	NNP	O
assays	NNS	O
showed	VBD	O
increased	JJ	O
potency	NN	O
of	IN	O
synthetic	JJ	O
expression	NN	O
cassettes	NNS	O
for	IN	O
induction	NN	O
of	IN	O
cytotoxic	JJ	O
T-lymphocyte	NNP	O
(	(	O
CTL	NNP	O
)	)	O
responses	NNS	O
by	IN	O
DNA	NNP	O
immunization	NN	O
.	.	O
It	PRP	O
is	VBZ	O
readily	RB	O
apparent	JJ	O
that	IN	O
the	DT	O
subject	JJ	O
invention	NN	O
can	MD	O
be	VB	O
used	VBN	O
to	TO	O
mount	VB	O
an	DT	O
immune	JJ	O
response	NN	O
to	TO	O
a	DT	O
wide	JJ	O
variety	NN	O
of	IN	O
antigens	NNS	O
and	CC	O
hence	NN	O
to	TO	O
treat	VB	O
or	CC	O
prevent	VB	O
a	DT	O
large	JJ	O
number	NN	O
of	IN	O
diseases	NNS	O
.	.	O
2.3.1	CD	O
Delivery	NNP	O
of	IN	O
the	DT	O
Synthetic	NNP	O
Expression	NNP	O
Cassettes	NNP	O
of	IN	O
the	DT	O
Present	JJ	O
Invention	NNP	O
Polynucleotide	NNP	O
sequences	VBZ	O
coding	VBG	O
for	IN	O
the	DT	O
above-described	JJ	O
molecules	NNS	O
can	MD	O
be	VB	O
obtained	VBN	O
using	VBG	O
recombinant	JJ	O
methods	NNS	O
,	,	O
such	JJ	O
as	IN	O
by	IN	O
screening	VBG	O
cDNA	NN	O
and	CC	O
genomic	JJ	O
libraries	NNS	O
from	IN	O
cells	NNS	O
expressing	VBG	O
the	DT	O
gene	NN	O
,	,	O
or	CC	O
by	IN	O
deriving	VBG	O
the	DT	O
gene	NN	O
from	IN	O
a	DT	O
vector	NN	O
known	VBN	O
to	TO	O
include	VB	O
the	DT	O
same	JJ	O
.	.	O
The	DT	O
sequences	NNS	O
can	MD	O
be	VB	O
analyzed	VBN	O
by	IN	O
conventional	JJ	O
sequencing	VBG	O
techniques	NNS	O
.	.	O
Furthermore	RB	O
,	,	O
the	DT	O
desired	JJ	O
gene	NN	O
can	MD	O
be	VB	O
isolated	VBN	O
directly	RB	O
from	IN	O
cells	NNS	O
and	CC	O
tissues	NNS	O
containing	VBG	O
the	DT	O
same	JJ	O
,	,	O
using	VBG	O
standard	JJ	O
techniques	NNS	O
,	,	O
such	JJ	O
as	IN	O
phenol	JJ	O
extraction	NN	O
and	CC	O
PCR	NNP	O
of	IN	O
cDNA	NN	O
or	CC	O
genomic	JJ	O
DNA	NN	O
.	.	O
See	VB	O
,	,	O
e.g.	VB	O
,	,	O
Sambrook	NNP	O
et	FW	O
al.	NN	O
,	,	O
supra	NN	O
,	,	O
for	IN	O
a	DT	O
description	NN	O
of	IN	O
techniques	NNS	O
used	VBN	O
to	TO	O
obtain	VB	O
,	,	O
isolate	NN	O
and	CC	O
sequence	NN	O
DNA	NN	O
.	.	O
Once	RB	O
the	DT	O
sequence	NN	O
is	VBZ	O
known	VBN	O
,	,	O
the	DT	O
gene	NN	O
of	IN	O
interest	NN	O
can	MD	O
also	RB	O
be	VB	O
produced	VBN	O
synthetically	RB	O
,	,	O
rather	RB	O
than	IN	O
cloned	VBN	O
.	.	O
The	DT	O
nucleotide	JJ	O
sequence	NN	O
can	MD	O
be	VB	O
designed	VBN	O
with	IN	O
the	DT	O
appropriate	JJ	O
codons	NNS	O
for	IN	O
the	DT	O
particular	JJ	O
amino	NN	O
acid	NN	O
sequence	NN	O
desired	VBD	O
.	.	O
In	IN	O
general	JJ	O
,	,	O
one	CD	O
will	MD	O
select	VB	O
preferred	JJ	O
codons	NNS	O
for	IN	O
the	DT	O
intended	JJ	O
host	NN	O
in	IN	O
which	WDT	O
the	DT	O
sequence	NN	O
will	MD	O
be	VB	O
expressed	VBN	O
.	.	O
The	DT	O
complete	JJ	O
sequence	NN	O
is	VBZ	O
assembled	VBN	O
from	IN	O
overlapping	VBG	O
oligonucleotides	NNS	O
prepared	VBN	O
by	IN	O
standard	JJ	O
methods	NNS	O
and	CC	O
assembled	VBD	O
into	IN	O
a	DT	O
complete	JJ	O
coding	NN	O
sequence	NN	O
.	.	O
See	VB	O
,	,	O
e.g.	VB	O
,	,	O
Edge	NNP	B
,	,	I
Nature	NNP	I
(	(	I
1981	CD	I
)	)	I
292:756	CD	I
;	:	O
Nambair	NNP	B
et	FW	I
al.	NN	I
,	,	I
Science	NNP	I
(	(	I
1984	CD	I
)	)	I
223:1299	CD	I
;	:	O
Jay	NNP	B
et	FW	I
al.	NN	I
,	,	I
J.	NNP	I
Biol	NNP	I
.	.	I
Chem	NNP	I
.	.	I
(	(	I
1984	CD	I
)	)	I
259:6311	CD	I
;	:	O
Stemmer	NNP	B
,	,	I
W	NNP	I
.	.	I
P.C.	NNP	I
,	,	I
(	(	I
1995	CD	I
)	)	I
Gene	NNP	I
164:49-53	JJ	I
.	.	O
Next	RB	O
,	,	O
the	DT	O
gene	NN	O
sequence	NN	O
encoding	VBG	O
the	DT	O
desired	JJ	O
antigen	NN	O
can	MD	O
be	VB	O
inserted	VBN	O
into	IN	O
a	DT	O
vector	NN	O
containing	VBG	O
a	DT	O
synthetic	JJ	O
expression	NN	O
cassette	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
(	(	O
e.g.	JJ	O
,	,	O
see	VBP	O
Example	JJ	O
1	CD	O
for	IN	O
construction	NN	O
of	IN	O
various	JJ	O
exemplary	JJ	O
synthetic	JJ	O
expression	NN	O
cassette	NN	O
)	)	O
.	.	O
The	DT	O
antigen	NN	O
is	VBZ	O
inserted	VBN	O
into	IN	O
the	DT	O
synthetic	JJ	O
coding	NN	O
sequence	NN	O
such	JJ	O
that	IN	O
when	WRB	O
the	DT	O
combined	VBN	O
sequence	NN	O
is	VBZ	O
expressed	VBN	O
it	PRP	O
results	NNS	O
in	IN	O
the	DT	O
production	NN	O
of	IN	O
VLPs	NNP	O
comprising	VBG	O
the	DT	O
polypeptide	NN	O
and/or	IN	O
the	DT	O
antigen	NN	O
of	IN	O
interest	NN	O
.	.	O
Insertions	NNS	O
can	MD	O
be	VB	O
made	VBN	O
within	IN	O
the	DT	O
Gag	NNP	O
coding	VBG	O
sequence	NN	O
or	CC	O
at	IN	O
either	DT	O
end	NN	O
of	IN	O
the	DT	O
coding	VBG	O
sequence	NN	O
(	(	O
5′	CD	O
,	,	O
amino	JJ	O
terminus	NN	O
of	IN	O
the	DT	O
expressed	JJ	O
polypeptide	NN	O
;	:	O
or	CC	O
3′	CD	O
,	,	O
carboxy	JJ	O
terminus	NN	O
of	IN	O
the	DT	O
expressed	JJ	O
polypeptide—e.g.	NN	O
,	,	O
see	VBP	O
Example	JJ	O
1	CD	O
)	)	O
(	(	O
Wagner	NNP	B
,	,	I
R.	NNP	I
,	,	I
et	FW	I
al.	NN	I
,	,	I
Arch	NNP	I
Virol	NNP	I
.	.	I
127:117-137	CD	I
,	,	I
1992	CD	I
;	:	O
Wagner	NNP	B
,	,	I
R.	NNP	I
,	,	I
et	FW	I
al.	NN	I
,	,	I
Virology	NNP	I
200:162-175	CD	I
,	,	I
1994	CD	I
;	:	O
Wu	NNP	B
,	,	I
X.	NNP	I
,	,	I
et	FW	I
al.	NN	I
,	,	I
J.	NNP	I
Virol	NNP	I
.	.	I
69	CD	I
(	(	I
6	CD	I
)	)	I
:3389-3398	NN	I
,	,	I
1995	CD	I
;	:	O
Wang	NNP	B
,	,	I
C-T.	NNP	I
,	,	I
et	FW	I
al.	NN	I
,	,	I
Virology	NNP	I
200:524-534	CD	I
,	,	I
1994	CD	I
;	:	O
Chazal	NNP	B
,	,	I
N.	NNP	I
,	,	I
et	FW	I
al.	NN	I
,	,	I
Virology	NNP	I
68	CD	I
(	(	I
1	CD	I
)	)	I
:111-122	NN	I
,	,	I
1994	CD	I
;	:	O
Griffiths	NNP	B
,	,	I
J.	NNP	I
C.	NNP	I
,	,	I
et	FW	I
al.	NN	I
,	,	I
J.	NNP	I
Virol	NNP	I
.	.	I
67	CD	I
(	(	I
6	CD	I
)	)	I
:3191-3198	NN	I
,	,	I
1993	CD	I
;	:	O
Reicin	NNP	B
,	,	I
A.	NNP	I
S.	NNP	I
,	,	I
et	FW	I
al.	NN	I
,	,	I
J.	NNP	I
Virol	NNP	I
.	.	I
69	CD	I
(	(	I
2	CD	I
)	)	I
:642-650	NN	I
,	,	I
1995	CD	I
)	)	I
.	.	O
Up	RB	O
to	TO	O
50	CD	O
%	NN	O
of	IN	O
the	DT	O
coding	VBG	O
sequences	NNS	O
of	IN	O
p55Gag	NN	O
can	MD	O
be	VB	O
deleted	VBN	O
without	IN	O
affecting	VBG	O
the	DT	O
assembly	NN	O
to	TO	O
virus-like	JJ	O
particles	NNS	O
and	CC	O
expression	NN	O
efficiency	NN	O
(	(	O
Borsetti	NNP	B
,	,	I
A.	NNP	I
,	,	I
et	FW	I
al	NN	I
,	,	I
J.	NNP	I
Virol	NNP	I
.	.	I
72	CD	I
(	(	I
11	CD	I
)	)	I
:9313-9317	NN	I
,	,	I
1998	CD	I
;	:	O
Garnier	NNP	B
,	,	I
L.	NNP	I
,	,	I
et	FW	I
al.	NN	I
,	,	I
J	NNP	I
Virol	NNP	I
72	CD	I
(	(	I
6	CD	I
)	)	I
:4667-4677	NN	I
,	,	I
1998	CD	I
;	:	O
Zhang	NNP	B
,	,	I
Y.	NNP	I
,	,	I
et	FW	I
al.	NN	I
,	,	I
J	NNP	I
Virol	NNP	I
72	CD	I
(	(	I
3	CD	I
)	)	I
:1782-1789	NN	I
,	,	I
1998	CD	I
;	:	O
Wang	NNP	B
,	,	I
C.	NNP	I
,	,	I
et	FW	I
al.	NN	I
,	,	I
J	NNP	I
Virol	NNP	I
72	CD	I
(	(	I
10	CD	I
)	)	I
:	:	I
7950-7959	CD	I
,	,	I
1998	CD	I
)	)	O
.	.	O
In	IN	O
one	CD	O
embodiment	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
,	,	O
immunogenicity	NN	O
of	IN	O
the	DT	O
high	JJ	O
level	NN	O
expressing	VBG	O
synthetic	JJ	O
p55GagMod	NN	O
and	CC	O
p55GagProtMod	JJ	O
expression	NN	O
cassettes	NNS	O
can	MD	O
be	VB	O
increased	VBN	O
by	IN	O
the	DT	O
insertion	NN	O
of	IN	O
different	JJ	O
structural	JJ	O
or	CC	O
non-structural	JJ	O
HIV	NNP	O
antigens	NNS	O
,	,	O
multiepitope	NN	O
cassettes	NNS	O
,	,	O
or	CC	O
cytokine	NN	O
sequences	NNS	O
into	IN	O
deleted	VBN	O
,	,	O
mutated	VBD	O
or	CC	O
truncated	JJ	O
regions	NNS	O
of	IN	O
p55GagMod	JJ	O
sequence	NN	O
.	.	O
In	IN	O
another	DT	O
embodiment	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
,	,	O
immunogenicity	NN	O
of	IN	O
the	DT	O
high	JJ	O
level	NN	O
expressing	VBG	O
synthetic	JJ	O
Env	NNP	O
expression	NN	O
cassettes	NNS	O
can	MD	O
be	VB	O
increased	VBN	O
by	IN	O
the	DT	O
insertion	NN	O
of	IN	O
different	JJ	O
structural	JJ	O
or	CC	O
non-structural	JJ	O
HIV	NNP	O
antigens	NNS	O
,	,	O
multiepitope	NN	O
cassettes	NNS	O
,	,	O
or	CC	O
cytokine	NN	O
sequences	NNS	O
into	IN	O
deleted	JJ	O
regions	NNS	O
of	IN	O
gp120Mod	NN	O
,	,	O
gp140Mod	NN	O
or	CC	O
gp160Mod	NN	O
sequences	NNS	O
.	.	O
Such	JJ	O
deletions	NNS	O
may	MD	O
be	VB	O
generated	VBN	O
following	VBG	O
the	DT	O
teachings	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
and	CC	O
information	NN	O
available	JJ	O
to	TO	O
one	CD	O
of	IN	O
ordinary	JJ	O
skill	NN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
One	CD	O
possible	JJ	O
advantage	NN	O
of	IN	O
this	DT	O
approach	NN	O
,	,	O
relative	JJ	O
to	TO	O
using	VBG	O
full-length	JJ	O
modified	VBN	O
Env	NNP	O
sequences	NNS	O
fused	VBD	O
to	TO	O
heterologous	JJ	O
polypeptides	NNS	O
,	,	O
can	MD	O
be	VB	O
higher	JJR	O
expression/secretion	NN	O
efficiency	NN	O
and/or	IN	O
higher	JJR	O
immunogenicity	NN	O
of	IN	O
the	DT	O
expression	NN	O
product	NN	O
.	.	O
Such	JJ	O
deletions	NNS	O
may	MD	O
be	VB	O
generated	VBN	O
following	VBG	O
the	DT	O
teachings	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
and	CC	O
information	NN	O
available	JJ	O
to	TO	O
one	CD	O
of	IN	O
ordinary	JJ	O
skill	NN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
One	CD	O
possible	JJ	O
advantage	NN	O
of	IN	O
this	DT	O
approach	NN	O
,	,	O
relative	JJ	O
to	TO	O
using	VBG	O
full-length	JJ	O
Env	NNP	O
,	,	O
Gag	NNP	O
or	CC	O
Tat	NNP	O
sequences	NNS	O
fused	VBD	O
to	TO	O
heterologous	JJ	O
polypeptides	NNS	O
,	,	O
can	MD	O
be	VB	O
higher	JJR	O
expression/secretion	NN	O
efficiency	NN	O
and/or	JJ	O
immunogenicity	NN	O
of	IN	O
the	DT	O
expression	NN	O
product	NN	O
.	.	O
When	WRB	O
sequences	NNS	O
are	VBP	O
added	VBN	O
to	TO	O
the	DT	O
amino	NN	O
terminal	JJ	O
end	NN	O
of	IN	O
Gag	NNP	O
(	(	O
for	IN	O
example	NN	O
,	,	O
when	WRB	O
using	VBG	O
the	DT	O
synthetic	JJ	O
p55GagMod	NN	O
expression	NN	O
cassette	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
)	)	O
,	,	O
the	DT	O
polynucleotide	NN	O
can	MD	O
contain	VB	O
coding	JJ	O
sequences	NNS	O
at	IN	O
the	DT	O
5′	CD	O
end	NN	O
that	WDT	O
encode	VBZ	O
a	DT	O
signal	NN	O
for	IN	O
addition	NN	O
of	IN	O
a	DT	O
myristic	JJ	O
moiety	NN	O
to	TO	O
the	DT	O
Gag-containing	NNP	O
polypeptide	NN	O
(	(	O
e.g.	JJ	O
,	,	O
sequences	NNS	O
that	IN	O
encode	VBP	O
Met-Gly	NNP	O
)	)	O
.	.	O
The	DT	O
ability	NN	O
of	IN	O
Gag-containing	NNP	O
polypeptide	NN	O
constructs	NNS	O
to	TO	O
form	VB	O
VLPs	NNP	O
can	MD	O
be	VB	O
empirically	RB	O
determined	VBN	O
following	VBG	O
the	DT	O
teachings	NNS	O
of	IN	O
the	DT	O
present	JJ	O
specification	NN	O
.	.	O
HIV	NNP	O
polypeptide/antigen	NN	O
synthetic	JJ	O
expression	NN	O
cassettes	NNS	O
include	VBP	O
control	JJ	O
elements	NNS	O
operably	RB	O
linked	VBN	O
to	TO	O
the	DT	O
coding	VBG	O
sequence	NN	O
,	,	O
which	WDT	O
allow	VBP	O
for	IN	O
the	DT	O
expression	NN	O
of	IN	O
the	DT	O
gene	NN	O
in	IN	O
vivo	NN	O
in	IN	O
the	DT	O
subject	NN	O
species	NNS	O
.	.	O
For	IN	O
example	NN	O
,	,	O
typical	JJ	O
promoters	NNS	O
for	IN	O
mammalian	JJ	O
cell	NN	O
expression	NN	O
include	VBP	O
the	DT	O
SV40	NNP	O
early	JJ	O
promoter	NN	O
,	,	O
a	DT	O
CMV	NNP	O
promoter	NN	O
such	JJ	O
as	IN	O
the	DT	O
CMV	NNP	O
immediate	VBP	O
early	JJ	O
promoter	NN	O
,	,	O
the	DT	O
mouse	NN	O
mammary	JJ	O
tumor	NN	O
virus	NN	O
LTR	NNP	O
promoter	NN	O
,	,	O
the	DT	O
adenovirus	NN	O
major	JJ	O
late	JJ	O
promoter	NN	O
(	(	O
Ad	NNP	O
MLP	NNP	O
)	)	O
,	,	O
and	CC	O
the	DT	O
herpes	NNS	O
simplex	JJ	O
virus	NN	O
promoter	NN	O
,	,	O
among	IN	O
others	NNS	O
.	.	O
Other	JJ	O
nonviral	JJ	O
promoters	NNS	O
,	,	O
such	JJ	O
as	IN	O
a	DT	O
promoter	NN	O
derived	VBN	O
from	IN	O
the	DT	O
murine	NN	O
metallothionein	NN	O
gene	NN	O
,	,	O
will	MD	O
also	RB	O
find	VB	O
use	NN	O
for	IN	O
mammalian	JJ	O
expression	NN	O
.	.	O
Typically	RB	O
,	,	O
transcription	NN	O
termination	NN	O
and	CC	O
polyadenylation	NN	O
sequences	NNS	O
will	MD	O
also	RB	O
be	VB	O
present	JJ	O
,	,	O
located	VBN	O
3′	CD	O
to	TO	O
the	DT	O
translation	NN	O
stop	NN	O
codon	NN	O
.	.	O
Preferably	RB	O
,	,	O
a	DT	O
sequence	NN	O
for	IN	O
optimization	NN	O
of	IN	O
initiation	NN	O
of	IN	O
translation	NN	O
,	,	O
located	VBN	O
5′	CD	O
to	TO	O
the	DT	O
coding	VBG	O
sequence	NN	O
,	,	O
is	VBZ	O
also	RB	O
present	JJ	O
.	.	O
Examples	NNS	O
of	IN	O
transcription	NN	O
terminator/polyadenylation	NN	O
signals	NNS	O
include	VBP	O
those	DT	O
derived	VBN	O
from	IN	O
SV40	NNP	O
,	,	O
as	IN	O
described	VBN	O
in	IN	O
Sambrook	NNP	B
et	CC	I
al.	NN	I
,	,	I
supra	NN	I
,	,	O
as	RB	O
well	RB	O
as	IN	O
a	DT	O
bovine	NN	O
growth	NN	O
hormone	NN	O
terminator	NN	O
sequence	NN	O
.	.	O
Enhancer	NNP	O
elements	NNS	O
may	MD	O
also	RB	O
be	VB	O
used	VBN	O
herein	NN	O
to	TO	O
increase	VB	O
expression	NN	O
levels	NNS	O
of	IN	O
the	DT	O
mammalian	JJ	O
constructs	NNS	O
.	.	O
Examples	NNS	O
include	VBP	O
the	DT	O
SV40	NNP	O
early	JJ	O
gene	NN	O
enhancer	NN	O
,	,	O
as	IN	O
described	VBN	O
in	IN	O
Dijkema	NNP	B
et	CC	I
al.	NN	I
,	,	I
EMBO	NNP	I
J	NNP	I
.	.	I
(	(	I
1985	CD	I
)	)	I
4:761	CD	I
,	,	O
the	DT	O
enhancer/promoter	NN	O
derived	VBN	O
from	IN	O
the	DT	O
long	JJ	O
terminal	JJ	O
repeat	NN	O
(	(	O
LTR	NNP	O
)	)	O
of	IN	O
the	DT	O
Rous	NNP	O
Sarcoma	NNP	O
Virus	NNP	O
,	,	O
as	IN	O
described	VBN	O
in	IN	O
Gorman	NNP	B
et	CC	I
al.	NN	I
,	,	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
USA	NNP	I
(	(	I
1982b	CD	I
)	)	I
79:6777	CD	I
and	CC	O
elements	NNS	O
derived	VBN	O
from	IN	O
human	JJ	O
CMV	NNP	O
,	,	O
as	IN	O
described	VBN	O
in	IN	O
Boshart	NNP	B
et	FW	I
al.	NN	I
,	,	I
Cell	NNP	I
(	(	I
1985	CD	I
)	)	I
41:521	CD	I
,	,	O
such	JJ	O
as	IN	O
elements	NNS	O
included	VBN	O
in	IN	O
the	DT	O
CMV	NNP	O
intron	NN	O
A	DT	O
sequence	NN	O
.	.	O
Furthermore	RB	O
,	,	O
plasmids	NNS	O
can	MD	O
be	VB	O
constructed	VBN	O
which	WDT	O
include	VBP	O
a	DT	O
chimeric	JJ	O
antigen-coding	JJ	O
gene	NN	O
sequences	NNS	O
,	,	O
encoding	VBG	O
,	,	O
e.g.	NN	O
,	,	O
multiple	JJ	O
antigens/epitopes	NNS	O
of	IN	O
interest	NN	O
,	,	O
for	IN	O
example	NN	O
derived	VBN	O
from	IN	O
a	DT	O
single	JJ	O
or	CC	O
from	IN	O
more	JJR	O
than	IN	O
one	CD	O
viral	JJ	O
isolate	NN	O
.	.	O
Typically	RB	O
the	DT	O
antigen	NN	O
coding	VBG	O
sequences	NNS	O
precede	VBP	O
or	CC	O
follow	VBP	O
the	DT	O
synthetic	JJ	O
coding	NN	O
sequences	NNS	O
and	CC	O
the	DT	O
chimeric	JJ	O
transcription	NN	O
unit	NN	O
will	MD	O
have	VB	O
a	DT	O
single	JJ	O
open	JJ	O
reading	NN	O
frame	NN	O
encoding	VBG	O
both	CC	O
the	DT	O
antigen	NN	O
of	IN	O
interest	NN	O
and	CC	O
the	DT	O
synthetic	JJ	O
Gag	NNP	O
coding	NN	O
sequences	NNS	O
.	.	O
Alternatively	RB	O
,	,	O
multi-cistronic	JJ	O
cassettes	NNS	O
(	(	O
e.g.	NN	O
,	,	O
bi-cistronic	JJ	O
cassettes	NNS	O
)	)	O
can	MD	O
be	VB	O
constructed	VBN	O
allowing	VBG	O
expression	NN	O
of	IN	O
multiple	JJ	O
antigens	NNS	O
from	IN	O
a	DT	O
single	JJ	O
mRNA	NN	O
using	VBG	O
the	DT	O
EMCV	NNP	O
IRES	NNP	O
,	,	O
or	CC	O
the	DT	O
like	JJ	O
.	.	O
Lastly	RB	O
,	,	O
antigens	NNS	O
can	MD	O
be	VB	O
encoded	VBN	O
on	IN	O
separate	JJ	O
transcripts	NNS	O
from	IN	O
independent	JJ	O
promoters	NNS	O
on	IN	O
a	DT	O
single	JJ	O
plasmid	NN	O
or	CC	O
other	JJ	O
vector	NN	O
.	.	O
Once	RB	O
complete	JJ	O
,	,	O
the	DT	O
constructs	NNS	O
are	VBP	O
used	VBN	O
for	IN	O
nucleic	JJ	O
acid	JJ	O
immunization	NN	O
or	CC	O
the	DT	O
like	JJ	O
using	VBG	O
standard	JJ	O
gene	NN	O
delivery	NN	O
protocols	NNS	O
.	.	O
Methods	NNS	O
for	IN	O
gene	NN	O
delivery	NN	O
are	VBP	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
See	VB	O
,	,	O
e.g.	VB	O
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
Nos	NNP	O
.	.	O
5,399,346	CD	O
,	,	O
5,580,859	CD	O
,	,	O
5,589,466	CD	O
.	.	O
Genes	NNS	O
can	MD	O
be	VB	O
delivered	VBN	O
either	DT	O
directly	RB	O
to	TO	O
the	DT	O
vertebrate	NN	O
subject	NN	O
or	CC	O
,	,	O
alternatively	RB	O
,	,	O
delivered	VBD	O
ex	JJ	O
vivo	NN	O
,	,	O
to	TO	O
cells	NNS	O
derived	VBN	O
from	IN	O
the	DT	O
subject	NN	O
and	CC	O
the	DT	O
cells	NNS	O
reimplanted	VBN	O
in	IN	O
the	DT	O
subject	NN	O
.	.	O
A	DT	O
number	NN	O
of	IN	O
viral	JJ	O
based	VBN	O
systems	NNS	O
have	VBP	O
been	VBN	O
developed	VBN	O
for	IN	O
gene	NN	O
transfer	NN	O
into	IN	O
mammalian	JJ	O
cells	NNS	O
.	.	O
For	IN	O
example	NN	O
,	,	O
retroviruses	VBZ	O
provide	VBP	O
a	DT	O
convenient	NN	O
platform	NN	O
for	IN	O
gene	NN	O
delivery	NN	O
systems	NNS	O
.	.	O
Selected	VBN	O
sequences	NNS	O
can	MD	O
be	VB	O
inserted	VBN	O
into	IN	O
a	DT	O
vector	NN	O
and	CC	O
packaged	VBN	O
in	IN	O
retroviral	JJ	O
particles	NNS	O
using	VBG	O
techniques	NNS	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
The	DT	O
recombinant	JJ	O
virus	NN	O
can	MD	O
then	RB	O
be	VB	O
isolated	VBN	O
and	CC	O
delivered	VBN	O
to	TO	O
cells	NNS	O
of	IN	O
the	DT	O
subject	NN	O
either	CC	O
in	IN	O
vivo	NN	O
or	CC	O
ex	NN	O
vivo	NN	O
.	.	O
A	DT	O
number	NN	O
of	IN	O
retroviral	JJ	O
systems	NNS	O
have	VBP	O
been	VBN	O
described	VBN	O
(	(	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,219,740	CD	O
;	:	O
Miller	NNP	B
and	CC	I
Rosman	NNP	I
,	,	I
BioTechniques	NNP	I
(	(	I
1989	CD	I
)	)	I
7:980-990	CD	I
;	:	O
Miller	NNP	B
,	,	I
A.	NNP	I
D.	NNP	I
,	,	I
Human	NNP	I
Gene	NNP	I
Therapy	NNP	I
(	(	I
1990	CD	I
)	)	I
1:5-14	CD	I
;	:	O
Scarpa	NNP	B
et	FW	I
al.	NN	I
,	,	I
Virology	NNP	I
(	(	I
1991	CD	I
)	)	I
180:849-852	CD	I
;	:	O
Burns	NNP	B
et	FW	I
al.	NN	I
,	,	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
USA	NNP	I
(	(	I
1993	CD	I
)	)	I
90:8033-8037	CD	I
;	:	O
and	CC	O
Boris-Lawrie	NNP	B
and	CC	I
Temin	NNP	I
,	,	I
Cur	NNP	I
.	.	I
Opin	NNP	I
.	.	I
Genet	NNP	I
.	.	I
Develop	NNP	I
.	.	I
(	(	I
1993	CD	I
)	)	I
3:102-109	CD	I
.	.	O
A	DT	O
number	NN	O
of	IN	O
adenovirus	JJ	O
vectors	NNS	O
have	VBP	O
also	RB	O
been	VBN	O
described	VBN	O
.	.	O
Unlike	IN	O
retroviruses	NNS	O
which	WDT	O
integrate	VBP	O
into	IN	O
the	DT	O
host	NN	O
genome	NN	O
,	,	O
adenoviruses	VBZ	O
persist	VBP	O
extrachromosomally	RB	O
thus	RB	O
minimizing	VBG	O
the	DT	O
risks	NNS	O
associated	VBN	O
with	IN	O
insertional	JJ	O
mutagenesis	NN	O
(	(	O
Haj-Ahmad	NNP	B
and	CC	I
Graham	NNP	I
,	,	I
J.	NNP	I
Virol	NNP	I
.	.	I
(	(	I
1986	CD	I
)	)	I
57:267-274	CD	I
;	:	O
Bett	NNP	B
et	FW	I
al.	NN	I
,	,	I
J.	NNP	I
Virol	NNP	I
.	.	I
(	(	I
1993	CD	I
)	)	I
67:5911-5921	CD	I
;	:	O
Mittereder	NNP	B
et	FW	I
al.	NN	I
,	,	I
Human	NNP	I
Gene	NNP	I
Therapy	NNP	I
(	(	I
1994	CD	I
)	)	I
5:717-729	CD	I
;	:	O
Seth	NNP	B
et	FW	I
al.	NN	I
,	,	I
J.	NNP	I
Virol	NNP	I
.	.	I
(	(	I
1994	CD	I
)	)	I
68:933-940	CD	I
;	:	O
Barr	NNP	B
et	FW	I
al.	NN	I
,	,	I
Gene	NNP	I
Therapy	NNP	I
(	(	I
1994	CD	I
)	)	I
1:51-58	CD	I
;	:	O
Berkner	NNP	B
,	,	I
K.	NNP	I
L.	NNP	I
BioTechniques	NNP	I
(	(	I
1988	CD	I
)	)	I
6:616-629	CD	I
;	:	O
and	CC	O
Rich	NNP	B
et	VBP	I
al.	NN	I
,	,	I
Human	NNP	I
Gene	NNP	I
Therapy	NNP	I
(	(	I
1993	CD	I
)	)	I
4:461-476	NN	I
)	)	O
.	.	O
Additionally	RB	O
,	,	O
various	JJ	O
adeno-associated	JJ	O
virus	NN	O
(	(	O
AAV	NNP	O
)	)	O
vector	NN	O
systems	NNS	O
have	VBP	O
been	VBN	O
developed	VBN	O
for	IN	O
gene	NN	O
delivery	NN	O
.	.	O
AAV	NNP	O
vectors	NNS	O
can	MD	O
be	VB	O
readily	RB	O
constructed	VBN	O
using	VBG	O
techniques	NNS	O
well	RB	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
See	VB	O
,	,	O
e.g.	VB	O
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
Nos	NNP	O
.	.	O
5,173,414	CD	O
and	CC	O
5,139,941	CD	O
;	:	O
International	NNP	O
Publication	NNP	O
Nos	NNP	O
.	.	O
WO	$	O
92/01070	CD	O
(	(	O
published	VBN	O
23	CD	O
Jan.	NNP	O
1992	CD	O
)	)	O
and	CC	O
WO	$	O
93/03769	CD	O
(	(	O
published	VBN	O
4	CD	O
Mar	NNP	O
.	.	O
1993	CD	O
)	)	O
;	:	O
Lebkowski	NNP	B
et	FW	I
al.	NN	I
,	,	I
Molec	NNP	I
.	.	I
Cell	NNP	I
.	.	I
Biol	NNP	I
.	.	I
(	(	I
1988	CD	I
)	)	I
8:3988-3996	CD	I
;	:	O
Vincent	NNP	B
et	FW	I
al.	NN	I
,	,	I
Vaccines	VBZ	I
90	CD	I
(	(	I
1990	CD	I
)	)	I
(	(	I
Cold	JJ	I
Spring	NN	I
Harbor	NNP	I
Laboratory	NNP	I
Press	NNP	I
)	)	I
;	:	O
Carter	NNP	B
,	,	I
B.	NNP	I
J	NNP	I
.	.	I
Current	JJ	I
Opinion	NN	I
in	IN	I
Biotechnology	NNP	I
(	(	I
1992	CD	I
)	)	I
3:533-539	CD	I
;	:	O
Muzyczka	NNP	B
,	,	I
N.	NNP	I
Current	NNP	I
Topics	NNPS	I
in	IN	I
Microbiol	NNP	I
.	.	I
and	CC	I
Immunol	NNP	I
.	.	I
(	(	I
1992	CD	I
)	)	I
158:97-129	CD	I
;	:	O
Kotin	NNP	B
,	,	I
R.	NNP	I
M.	NNP	I
Human	NNP	I
Gene	NNP	I
Therapy	NNP	I
(	(	I
1994	CD	I
)	)	I
5:793-801	CD	I
;	:	O
Shelling	NNP	B
and	CC	I
Smith	NNP	I
,	,	I
Gene	NNP	I
Therapy	NNP	I
(	(	I
1994	CD	I
)	)	I
1:165-169	CD	I
;	:	O
and	CC	O
Zhou	NNP	B
et	VBP	I
al.	NN	I
,	,	I
J.	NNP	I
Exp	NNP	I
.	.	I
Med	NNP	I
.	.	I
(	(	I
1994	CD	I
)	)	I
179:1867-1875	CD	I
.	.	O
Another	DT	O
vector	NN	O
system	NN	O
useful	JJ	O
for	IN	O
delivering	VBG	O
the	DT	O
polynucleotides	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
is	VBZ	O
the	DT	O
enterically	RB	O
administered	VBN	O
recombinant	JJ	O
poxvirus	NN	O
vaccines	NNS	O
described	VBN	O
by	IN	O
Small	NNP	O
,	,	O
Jr.	NNP	O
,	,	O
P.	NNP	O
A.	NN	O
,	,	O
et	CC	O
al	NN	O
.	.	O
(	(	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,676,950	CD	O
,	,	O
issued	VBN	O
Oct.	NNP	O
14	CD	O
,	,	O
1997	CD	O
,	,	O
herein	RB	O
incorporated	VBN	O
by	IN	O
reference	NN	O
)	)	O
.	.	O
Additional	JJ	O
viral	NN	O
vectors	NNS	O
which	WDT	O
will	MD	O
find	VB	O
use	NN	O
for	IN	O
delivering	VBG	O
the	DT	O
nucleic	JJ	O
acid	NN	O
molecules	NNS	O
encoding	VBG	O
the	DT	O
antigens	NNS	O
of	IN	O
interest	NN	O
include	VBP	O
those	DT	O
derived	VBN	O
from	IN	O
the	DT	O
pox	JJ	O
family	NN	O
of	IN	O
viruses	NNS	O
,	,	O
including	VBG	O
vaccinia	NN	O
virus	NN	O
and	CC	O
avian	JJ	O
poxvirus	NN	O
.	.	O
By	IN	O
way	NN	O
of	IN	O
example	NN	O
,	,	O
vaccinia	FW	O
virus	NN	O
recombinants	NNS	O
expressing	VBG	O
the	DT	O
genes	NNS	O
can	MD	O
be	VB	O
constructed	VBN	O
as	IN	O
follows	VBZ	O
.	.	O
The	DT	O
DNA	NN	O
encoding	VBG	O
the	DT	O
particular	JJ	O
synthetic	JJ	O
Gag/antigen	NNP	O
coding	VBG	O
sequence	NN	O
is	VBZ	O
first	RB	O
inserted	VBN	O
into	IN	O
an	DT	O
appropriate	JJ	O
vector	NN	O
so	IN	O
that	IN	O
it	PRP	O
is	VBZ	O
adjacent	JJ	O
to	TO	O
a	DT	O
vaccinia	NN	O
promoter	NN	O
and	CC	O
flanking	VBG	O
vaccinia	NN	O
DNA	NNP	O
sequences	NNS	O
,	,	O
such	JJ	O
as	IN	O
the	DT	O
sequence	NN	O
encoding	VBG	O
thymidine	JJ	O
kinase	NN	O
(	(	O
TK	NNP	O
)	)	O
.	.	O
This	DT	O
vector	NN	O
is	VBZ	O
then	RB	O
used	VBN	O
to	TO	O
transfect	VB	O
cells	NNS	O
which	WDT	O
are	VBP	O
simultaneously	RB	O
infected	VBN	O
with	IN	O
vaccinia	NN	O
.	.	O
Homologous	JJ	O
recombination	NN	O
serves	NNS	O
to	TO	O
insert	VB	O
the	DT	O
vaccinia	NN	O
promoter	NN	O
plus	CC	O
the	DT	O
gene	NN	O
encoding	VBG	O
the	DT	O
coding	VBG	O
sequences	NNS	O
of	IN	O
interest	NN	O
into	IN	O
the	DT	O
viral	JJ	O
genome	NN	O
.	.	O
The	DT	O
resulting	VBG	O
TK−	NNP	O
recombinant	NN	O
can	MD	O
be	VB	O
selected	VBN	O
by	IN	O
culturing	VBG	O
the	DT	O
cells	NNS	O
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
5-bromodeoxyuridine	JJ	O
and	CC	O
picking	JJ	O
viral	JJ	O
plaques	NNS	O
resistant	JJ	O
thereto	NN	O
.	.	O
Alternatively	RB	O
,	,	O
avipoxviruses	NNS	O
,	,	O
such	JJ	O
as	IN	O
the	DT	O
fowlpox	NN	O
and	CC	O
canarypox	NN	O
viruses	NNS	O
,	,	O
can	MD	O
also	RB	O
be	VB	O
used	VBN	O
to	TO	O
deliver	VB	O
the	DT	O
genes	NNS	O
.	.	O
Recombinant	JJ	O
avipox	NN	O
viruses	NNS	O
,	,	O
expressing	VBG	O
immunogens	NNS	O
from	IN	O
mammalian	JJ	O
pathogens	NNS	O
,	,	O
are	VBP	O
known	VBN	O
to	TO	O
confer	VB	O
protective	JJ	O
immunity	NN	O
when	WRB	O
administered	VBN	O
to	TO	O
non-avian	JJ	O
species	NNS	O
.	.	O
The	DT	O
use	NN	O
of	IN	O
an	DT	O
avipox	JJ	O
vector	NN	O
is	VBZ	O
particularly	RB	O
desirable	JJ	O
in	IN	O
human	JJ	O
and	CC	O
other	JJ	O
mammalian	JJ	O
species	NNS	O
since	IN	O
members	NNS	O
of	IN	O
the	DT	O
avipox	JJ	O
genus	NN	O
can	MD	O
only	RB	O
productively	RB	O
replicate	VB	O
in	IN	O
susceptible	JJ	O
avian	JJ	O
species	NNS	O
and	CC	O
therefore	RB	O
are	VBP	O
not	RB	O
infective	JJ	O
in	IN	O
mammalian	JJ	O
cells	NNS	O
.	.	O
Methods	NNS	O
for	IN	O
producing	VBG	O
recombinant	JJ	O
avipoxviruses	NNS	O
are	VBP	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
and	CC	O
employ	JJ	O
genetic	JJ	O
recombination	NN	O
,	,	O
as	IN	O
described	VBN	O
above	IN	O
with	IN	O
respect	NN	O
to	TO	O
the	DT	O
production	NN	O
of	IN	O
vaccinia	NN	O
viruses	NNS	O
.	.	O
See	VB	O
,	,	O
e.g.	VB	O
,	,	O
WO	NNP	O
91/12882	CD	O
;	:	O
WO	NNP	O
89/03429	CD	O
;	:	O
and	CC	O
WO	NNP	O
92/03545	CD	O
.	.	O
Molecular	JJ	O
conjugate	NN	O
vectors	NNS	O
,	,	O
such	JJ	O
as	IN	O
the	DT	O
adenovirus	NN	O
chimeric	JJ	O
vectors	NNS	O
described	VBD	O
in	IN	O
Michael	NNP	B
et	CC	I
al.	NN	I
,	,	I
J.	NNP	I
Biol	NNP	I
.	.	I
Chem	NNP	I
.	.	I
(	(	I
1993	CD	I
)	)	I
268:6866-6869	CD	I
and	CC	O
Wagner	NNP	B
et	VBP	I
al.	NN	I
,	,	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
USA	NNP	I
(	(	I
1992	CD	I
)	)	I
89:6099-6103	CD	I
,	,	O
can	MD	O
also	RB	O
be	VB	O
used	VBN	O
for	IN	O
gene	NN	O
delivery	NN	O
.	.	O
Members	NNS	O
of	IN	O
the	DT	O
Alphavirus	NNP	O
genus	NN	O
,	,	O
such	JJ	O
as	IN	O
,	,	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
,	,	O
vectors	NNS	O
derived	VBD	O
from	IN	O
the	DT	O
Sindbis	NNP	O
,	,	O
Semliki	NNP	O
Forest	NNP	O
,	,	O
and	CC	O
Venezuelan	NNP	O
Equine	NNP	O
Encephalitis	NNP	O
viruses	NNS	O
,	,	O
will	MD	O
also	RB	O
find	VB	O
use	NN	O
as	IN	O
viral	JJ	O
vectors	NNS	O
for	IN	O
delivering	VBG	O
the	DT	O
polynucleotides	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
(	(	O
for	IN	O
example	NN	O
,	,	O
a	DT	O
synthetic	JJ	O
Gag-	NNP	O
or	CC	O
Env-polypeptide	NNP	O
encoding	VBG	O
expression	NN	O
cassette	NN	O
as	IN	O
described	VBN	O
in	IN	O
Example	NNP	O
14	CD	O
below	IN	O
)	)	O
.	.	O
For	IN	O
a	DT	O
description	NN	O
of	IN	O
Sindbis-virus	NNP	O
derived	VBD	O
vectors	NNS	O
useful	JJ	O
for	IN	O
the	DT	O
practice	NN	O
of	IN	O
the	DT	O
instant	JJ	O
methods	NNS	O
,	,	O
see	VBP	O
,	,	O
Dubensky	NNP	B
et	FW	I
al.	NN	I
,	,	I
J.	NNP	I
Virol	NNP	I
.	.	I
(	(	I
1996	CD	I
)	)	I
70:508-519	CD	I
;	:	O
and	CC	O
International	NNP	O
Publication	NNP	O
Nos	NNP	O
.	.	O
WO	$	O
95/07995	CD	O
and	CC	O
WO	NNP	O
96/17072	CD	O
;	:	O
as	RB	O
well	RB	O
as	IN	O
,	,	O
Dubensky	NNP	O
,	,	O
Jr.	NNP	O
,	,	O
T.	NNP	O
W.	NNP	O
,	,	O
et	FW	O
al.	NN	O
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,843,723	CD	O
,	,	O
issued	VBN	O
Dec.	NNP	O
1	CD	O
,	,	O
1998	CD	O
,	,	O
and	CC	O
Dubensky	NNP	O
,	,	O
Jr.	NNP	O
,	,	O
T.	NNP	O
W.	NNP	O
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,789,245	CD	O
,	,	O
issued	VBN	O
Aug.	NNP	O
4	CD	O
,	,	O
1998	CD	O
,	,	O
both	DT	O
herein	NNS	O
incorporated	VBN	O
by	IN	O
reference	NN	O
.	.	O
A	DT	O
vaccinia	NN	O
based	VBN	O
infection/transfection	NN	O
system	NN	O
can	MD	O
be	VB	O
conveniently	RB	O
used	VBN	O
to	TO	O
provide	VB	O
for	IN	O
inducible	JJ	O
,	,	O
transient	JJ	O
,	,	O
expression	NN	O
of	IN	O
the	DT	O
coding	VBG	O
sequences	NNS	O
of	IN	O
interest	NN	O
(	(	O
for	IN	O
example	NN	O
,	,	O
a	DT	O
synthetic	JJ	O
Gag/HCV-core	NNP	O
expression	NN	O
cassette	NN	O
)	)	O
in	IN	O
a	DT	O
host	NN	O
cell	NN	O
.	.	O
In	IN	O
this	DT	O
system	NN	O
,	,	O
cells	NNS	O
are	VBP	O
first	RB	O
infected	VBN	O
in	IN	O
vitro	NN	O
with	IN	O
a	DT	O
vaccinia	NN	O
virus	NN	O
recombinant	NN	O
that	WDT	O
encodes	VBZ	O
the	DT	O
bacteriophage	NN	O
T7	NNP	O
RNA	NNP	O
polymerase	NN	O
.	.	O
This	DT	O
polymerase	NN	O
displays	VBZ	O
exquisite	JJ	O
specificity	NN	O
in	IN	O
that	DT	O
it	PRP	O
only	RB	O
transcribes	VBZ	O
templates	NNS	O
bearing	VBG	O
T7	NNP	O
promoters	NNS	O
.	.	O
Following	VBG	O
infection	NN	O
,	,	O
cells	NNS	O
are	VBP	O
transfected	VBN	O
with	IN	O
the	DT	O
polynucleotide	NN	O
of	IN	O
interest	NN	O
,	,	O
driven	VBN	O
by	IN	O
a	DT	O
T7	NNP	O
promoter	NN	O
.	.	O
The	DT	O
polymerase	NN	O
expressed	VBN	O
in	IN	O
the	DT	O
cytoplasm	NN	O
from	IN	O
the	DT	O
vaccinia	NN	O
virus	NN	O
recombinant	NN	O
transcribes	VBZ	O
the	DT	O
transfected	JJ	O
DNA	NNP	O
into	IN	O
RNA	NNP	O
which	WDT	O
is	VBZ	O
then	RB	O
translated	VBN	O
into	IN	O
protein	NN	O
by	IN	O
the	DT	O
host	NN	O
translational	JJ	O
machinery	NN	O
.	.	O
The	DT	O
method	NN	O
provides	VBZ	O
for	IN	O
high	JJ	O
level	NN	O
,	,	O
transient	NN	O
,	,	O
cytoplasmic	JJ	O
production	NN	O
of	IN	O
large	JJ	O
quantities	NNS	O
of	IN	O
RNA	NNP	O
and	CC	O
its	PRP$	O
translation	NN	O
products	NNS	O
.	.	O
See	VB	O
,	,	O
e.g.	VB	O
,	,	O
Elroy-Stein	NNP	B
and	CC	I
Moss	NNP	I
,	,	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
USA	NNP	I
(	(	I
1990	CD	I
)	)	I
87:6743-6747	CD	I
;	:	O
Fuerst	NNP	B
et	FW	I
al.	NN	I
,	,	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
USA	NNP	I
(	(	I
1986	CD	I
)	)	I
83:8122-8126	CD	I
.	.	O
As	IN	O
an	DT	O
alternative	JJ	O
approach	NN	O
to	TO	O
infection	NN	O
with	IN	O
vaccinia	NN	O
or	CC	O
avipox	JJ	O
virus	NN	O
recombinants	NNS	O
,	,	O
or	CC	O
to	TO	O
the	DT	O
delivery	NN	O
of	IN	O
genes	NNS	O
using	VBG	O
other	JJ	O
viral	JJ	O
vectors	NNS	O
,	,	O
an	DT	O
amplification	NN	O
system	NN	O
can	MD	O
be	VB	O
used	VBN	O
that	DT	O
will	MD	O
lead	VB	O
to	TO	O
high	JJ	O
level	NN	O
expression	NN	O
following	VBG	O
introduction	NN	O
into	IN	O
host	NN	O
cells	NNS	O
.	.	O
Specifically	RB	O
,	,	O
a	DT	O
T7	NNP	O
RNA	NNP	O
polymerase	NN	O
promoter	NN	O
preceding	VBG	O
the	DT	O
coding	NN	O
region	NN	O
for	IN	O
T7	NNP	O
RNA	NNP	O
polymerase	NN	O
can	MD	O
be	VB	O
engineered	VBN	O
.	.	O
Translation	NN	O
of	IN	O
RNA	NNP	O
derived	VBD	O
from	IN	O
this	DT	O
template	NN	O
will	MD	O
generate	VB	O
T7	NNP	O
RNA	NNP	O
polymerase	NN	O
which	WDT	O
in	IN	O
turn	NN	O
will	MD	O
transcribe	VB	O
more	JJR	O
template	NN	O
.	.	O
Concomitantly	RB	O
,	,	O
there	EX	O
will	MD	O
be	VB	O
a	DT	O
cDNA	NN	O
whose	WP$	O
expression	NN	O
is	VBZ	O
under	IN	O
the	DT	O
control	NN	O
of	IN	O
the	DT	O
T7	NNP	O
promoter	NN	O
.	.	O
Thus	RB	O
,	,	O
some	DT	O
of	IN	O
the	DT	O
T7	NNP	O
RNA	NNP	O
polymerase	NN	O
generated	VBD	O
from	IN	O
translation	NN	O
of	IN	O
the	DT	O
amplification	NN	O
template	NN	O
RNA	NNP	O
will	MD	O
lead	VB	O
to	TO	O
transcription	NN	O
of	IN	O
the	DT	O
desired	JJ	O
gene	NN	O
.	.	O
Because	IN	O
some	DT	O
T7	NNP	O
RNA	NNP	O
polymerase	NN	O
is	VBZ	O
required	VBN	O
to	TO	O
initiate	VB	O
the	DT	O
amplification	NN	O
,	,	O
T7	NNP	O
RNA	NNP	O
polymerase	NN	O
can	MD	O
be	VB	O
introduced	VBN	O
into	IN	O
cells	NNS	O
along	IN	O
with	IN	O
the	DT	O
template	NN	O
(	(	O
s	PRP	O
)	)	O
to	TO	O
prime	VB	O
the	DT	O
transcription	NN	O
reaction	NN	O
.	.	O
The	DT	O
polymerase	NN	O
can	MD	O
be	VB	O
introduced	VBN	O
as	IN	O
a	DT	O
protein	NN	O
or	CC	O
on	IN	O
a	DT	O
plasmid	NN	O
encoding	VBG	O
the	DT	O
RNA	NNP	O
polymerase	NN	O
.	.	O
For	IN	O
a	DT	O
further	JJ	O
discussion	NN	O
of	IN	O
T7	NNP	O
systems	NNS	O
and	CC	O
their	PRP$	O
use	NN	O
for	IN	O
transforming	VBG	O
cells	NNS	O
,	,	O
see	VBP	O
,	,	O
e.g.	FW	O
,	,	O
International	NNP	O
Publication	NNP	O
No	NNP	O
.	.	O
WO	NNP	O
94/26911	CD	O
;	:	O
Studier	NNP	B
and	CC	I
Moffatt	NNP	I
,	,	I
J.	NNP	I
Mol	NNP	I
.	.	I
Biol	NNP	I
.	.	I
(	(	I
1986	CD	I
)	)	I
189:113-130	CD	I
;	:	O
Deng	NNP	B
and	CC	I
Wolff	NNP	I
,	,	I
Gene	NNP	I
(	(	I
1994	CD	I
)	)	I
143:245-249	CD	I
;	:	O
Gao	NNP	B
et	FW	I
al.	NN	I
,	,	I
Biochem	NNP	I
.	.	I
Biophys	NNP	I
.	.	I
Res	NNP	I
.	.	I
Commun	NNP	I
.	.	I
(	(	I
1994	CD	I
)	)	I
200:1201-1206	CD	I
;	:	O
Gao	NNP	B
and	CC	I
Huang	NNP	I
,	,	I
Nuc	NNP	I
.	.	I
Acids	NNP	I
Res	NNP	I
.	.	I
(	(	I
1993	CD	I
)	)	I
21:2867-2872	CD	I
;	:	O
Chen	NNP	B
et	FW	I
al.	NN	I
,	,	I
Nuc	NNP	I
.	.	I
Acids	NNP	I
Res	NNP	I
.	.	I
(	(	I
1994	CD	I
)	)	I
22:2114-2120	CD	I
;	:	O
and	CC	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,135,855	CD	O
.	.	O
The	DT	O
synthetic	JJ	O
expression	NN	O
cassette	NN	O
of	IN	O
interest	NN	O
can	MD	O
also	RB	O
be	VB	O
delivered	VBN	O
without	IN	O
a	DT	O
viral	JJ	O
vector	NN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
the	DT	O
synthetic	JJ	O
expression	NN	O
cassette	NN	O
can	MD	O
be	VB	O
packaged	VBN	O
as	IN	O
DNA	NN	O
or	CC	O
RNA	NNP	O
in	IN	O
liposomes	RB	O
prior	JJ	O
to	TO	O
delivery	NN	O
to	TO	O
the	DT	O
subject	NN	O
or	CC	O
to	TO	O
cells	NNS	O
derived	VBN	O
therefrom	NN	O
.	.	O
Lipid	JJ	O
encapsulation	NN	O
is	VBZ	O
generally	RB	O
accomplished	VBN	O
using	VBG	O
liposomes	NNS	O
which	WDT	O
are	VBP	O
able	JJ	O
to	TO	O
stably	VB	O
bind	NN	O
or	CC	O
entrap	NN	O
and	CC	O
retain	VB	O
nucleic	JJ	O
acid	NN	O
.	.	O
The	DT	O
ratio	NN	O
of	IN	O
condensed	JJ	O
DNA	NN	O
to	TO	O
lipid	JJ	O
preparation	NN	O
can	MD	O
vary	VB	O
but	CC	O
will	MD	O
generally	RB	O
be	VB	O
around	IN	O
1:1	CD	O
(	(	O
mg	JJ	O
DNA	NN	O
:	:	O
micromoles	NNS	O
lipid	VBP	O
)	)	O
,	,	O
or	CC	O
more	JJR	O
of	IN	O
lipid	NN	O
.	.	O
For	IN	O
a	DT	O
review	NN	O
of	IN	O
the	DT	O
use	NN	O
of	IN	O
liposomes	NNS	O
as	IN	O
carriers	NNS	O
for	IN	O
delivery	NN	O
of	IN	O
nucleic	JJ	O
acids	NNS	O
,	,	O
see	VBP	O
,	,	O
Hug	NNP	B
and	CC	I
Sleight	NNP	I
,	,	I
Biochim	NNP	I
.	.	I
Biophys	NNP	I
.	.	I
Acta	NNP	I
.	.	I
(	(	I
1991	CD	I
)	)	I
1097:1-17	CD	I
;	:	O
Straubinger	NNP	B
et	FW	I
al.	NN	I
,	,	I
in	IN	I
Methods	NNP	I
of	IN	I
Enzymology	NNP	I
(	(	I
1983	CD	I
)	)	I
,	,	I
Vol	NNP	I
.	.	I
101	CD	I
,	,	I
pp	NN	I
.	.	I
512-527	JJ	I
.	.	O
Liposomal	JJ	O
preparations	NNS	O
for	IN	O
use	NN	O
in	IN	O
the	DT	O
present	JJ	O
invention	NN	O
include	VBP	O
cationic	JJ	O
(	(	O
positively	RB	O
charged	VBN	O
)	)	O
,	,	O
anionic	JJ	O
(	(	O
negatively	RB	O
charged	VBN	O
)	)	O
and	CC	O
neutral	JJ	O
preparations	NNS	O
,	,	O
with	IN	O
cationic	JJ	O
liposomes	NNS	O
particularly	RB	O
preferred	VBN	O
.	.	O
Cationic	NNP	O
liposomes	NNS	O
have	VBP	O
been	VBN	O
shown	VBN	O
to	TO	O
mediate	VB	O
intracellular	JJ	O
delivery	NN	O
of	IN	O
plasmid	NN	O
DNA	NNP	O
(	(	O
Felgner	NNP	B
et	RB	I
al.	RB	I
,	,	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
USA	NNP	I
(	(	I
1987	CD	I
)	)	I
84:7413-7416	CD	I
)	)	O
;	:	O
mRNA	FW	O
(	(	O
Malone	NNP	B
et	RB	I
al.	RB	I
,	,	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
USA	NNP	I
(	(	I
1989	CD	I
)	)	I
86:6077-6081	CD	I
)	)	O
;	:	O
and	CC	O
purified	JJ	O
transcription	NN	O
factors	NNS	O
(	(	O
Debs	NNP	B
et	RB	I
al.	RB	I
,	,	I
J.	NNP	I
Biol	NNP	I
.	.	I
Chem	NNP	I
.	.	I
(	(	I
1990	CD	I
)	)	I
265:10189-10192	CD	I
)	)	O
,	,	O
in	IN	O
functional	JJ	O
form	NN	O
.	.	O
Cationic	JJ	O
liposomes	NNS	O
are	VBP	O
readily	RB	O
available	JJ	O
.	.	O
For	IN	O
example	NN	O
,	,	O
N	NNP	O
[	NNP	O
1-2,3-dioleyloxy	JJ	O
)	)	O
propyl	NN	O
]	NNP	O
-N	NNP	O
,	,	O
N	NNP	O
,	,	O
N-triethylammonium	NNP	O
(	(	O
DOTMA	NNP	O
)	)	O
liposomes	NNS	O
are	VBP	O
available	JJ	O
under	IN	O
the	DT	O
trademark	NN	O
Lipofectin	NNP	O
,	,	O
from	IN	O
GIBCO	NNP	O
BRL	NNP	O
,	,	O
Grand	NNP	O
Island	NNP	O
,	,	O
N.	NNP	O
Y	NNP	O
.	.	O
(	(	O
See	VB	O
,	,	O
also	RB	O
,	,	O
Feigner	NNP	B
et	CC	I
al.	NN	I
,	,	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
USA	NNP	I
(	(	I
1987	CD	I
)	)	I
84:7413-7416	NN	I
)	)	O
.	.	O
Other	JJ	O
commercially	RB	O
available	JJ	O
lipids	NNS	O
include	VBP	O
(	(	O
DDAB/DOPE	NNP	O
)	)	O
and	CC	O
DOTAP/DOPE	NNP	O
(	(	O
Boerhinger	NNP	O
)	)	O
.	.	O
Other	JJ	O
cationic	JJ	O
liposomes	NNS	O
can	MD	O
be	VB	O
prepared	VBN	O
from	IN	O
readily	RB	O
available	JJ	O
materials	NNS	O
using	VBG	O
techniques	NNS	O
well	RB	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
See	VB	O
,	,	O
e.g.	VB	O
,	,	O
Szoka	NNP	B
et	FW	I
al.	NN	I
,	,	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
USA	NNP	I
(	(	I
1978	CD	I
)	)	I
75:4194-4198	CD	I
;	:	O
PCT	NNP	O
Publication	NNP	O
No	NNP	O
.	.	O
WO	$	O
90/11092	CD	O
for	IN	O
a	DT	O
description	NN	O
of	IN	O
the	DT	O
synthesis	NN	O
of	IN	O
DOTAP	NNP	O
(	(	O
1,2-bis	JJ	O
(	(	O
oleoyloxy	JJ	O
)	)	O
-3-	NN	O
(	(	O
trimethylammonio	NN	O
)	)	O
propane	NN	O
)	)	O
liposomes	VBZ	O
.	.	O
Similarly	RB	O
,	,	O
anionic	JJ	O
and	CC	O
neutral	JJ	O
liposomes	NNS	O
are	VBP	O
readily	RB	O
available	JJ	O
,	,	O
such	JJ	O
as	IN	O
,	,	O
from	IN	O
Avanti	NNP	O
Polar	NNP	O
Lipids	NNP	O
(	(	O
Birmingham	NNP	O
,	,	O
Ala.	NNP	O
)	)	O
,	,	O
or	CC	O
can	MD	O
be	VB	O
easily	RB	O
prepared	JJ	O
using	VBG	O
readily	RB	O
available	JJ	O
materials	NNS	O
.	.	O
Such	JJ	O
materials	NNS	O
include	VBP	O
phosphatidyl	JJ	O
choline	NN	O
,	,	O
cholesterol	NN	O
,	,	O
phosphatidyl	JJ	O
ethanolamine	NN	O
,	,	O
dioleoylphosphatidyl	JJ	O
choline	NN	O
(	(	O
DOPC	NNP	O
)	)	O
,	,	O
dioleoylphosphatidyl	JJ	O
glycerol	NN	O
(	(	O
DOPG	NNP	O
)	)	O
,	,	O
dioleoylphoshatidyl	JJ	O
ethanolamine	NN	O
(	(	O
DOPE	NNP	O
)	)	O
,	,	O
among	IN	O
others	NNS	O
.	.	O
These	DT	O
materials	NNS	O
can	MD	O
also	RB	O
be	VB	O
mixed	JJ	O
with	IN	O
the	DT	O
DOTMA	NNP	O
and	CC	O
DOTAP	NNP	O
starting	VBG	O
materials	NNS	O
in	IN	O
appropriate	JJ	O
ratios	NNS	O
.	.	O
Methods	NNS	O
for	IN	O
making	VBG	O
liposomes	NNS	O
using	VBG	O
these	DT	O
materials	NNS	O
are	VBP	O
well	RB	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
The	DT	O
liposomes	NNS	O
can	MD	O
comprise	VB	O
multilammelar	JJ	O
vesicles	NNS	O
(	(	O
MLVs	NNP	O
)	)	O
,	,	O
small	JJ	O
unilamellar	JJ	O
vesicles	NNS	O
(	(	O
SUVs	NNP	O
)	)	O
,	,	O
or	CC	O
large	JJ	O
unilamellar	JJ	O
vesicles	NNS	O
(	(	O
LUVs	NNP	O
)	)	O
.	.	O
The	DT	O
various	JJ	O
liposome-nucleic	JJ	O
acid	NN	O
complexes	NNS	O
are	VBP	O
prepared	JJ	O
using	VBG	O
methods	NNS	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
See	VB	O
,	,	O
e.g.	VB	O
,	,	O
Straubinger	NNP	B
et	CC	I
al.	NN	I
,	,	I
in	IN	I
METHODS	NNP	I
OF	NNP	I
IMMUNOLOGY	NNP	I
(	(	I
1983	CD	I
)	)	I
,	,	I
Vol	NNP	I
.	.	I
101	CD	I
,	,	I
pp	NN	I
.	.	I
512-527	JJ	I
;	:	O
Szoka	NNP	B
et	FW	I
al.	NN	I
,	,	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
USA	NNP	I
(	(	I
1978	CD	I
)	)	I
75:4194-4198	CD	I
;	:	O
Papahadjopoulos	NNP	B
et	FW	I
al.	NN	I
,	,	I
Biochim	NNP	I
.	.	I
Biophys	NNP	I
.	.	I
Acta	NNP	I
(	(	I
1975	CD	I
)	)	I
394:483	CD	I
;	:	O
Wilson	NNP	B
et	FW	I
al.	NN	I
,	,	I
Cell	NNP	I
(	(	I
1979	CD	I
)	)	I
17:77	CD	I
)	)	I
;	:	O
Deamer	NNP	B
and	CC	I
Bangham	NNP	I
,	,	I
Biochim	NNP	I
.	.	I
Biophys	NNP	I
.	.	I
Acta	NNP	I
(	(	I
1976	CD	I
)	)	I
443:629	CD	I
;	:	O
Ostro	NNP	B
et	FW	I
al.	NN	I
,	,	I
Biochem	NNP	I
.	.	I
Biophys	NNP	I
.	.	I
Res	NNP	I
.	.	I
Commun	NNP	I
.	.	I
(	(	I
1977	CD	I
)	)	I
76:836	CD	I
;	:	O
Fraley	NNP	B
et	FW	I
al.	NN	I
,	,	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
USA	NNP	I
(	(	I
1979	CD	I
)	)	I
76:3348	CD	I
)	)	I
;	:	O
Enoch	NNP	B
and	CC	I
Strittmatter	NNP	I
,	,	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
USA	NNP	I
(	(	I
1979	CD	I
)	)	I
76:145	CD	I
)	)	I
;	:	O
Fraley	NNP	B
et	FW	I
al.	NN	I
,	,	I
J.	NNP	I
Biol	NNP	I
.	.	I
Chem	NNP	I
.	.	I
(	(	I
1980	CD	I
)	)	I
255:10431	CD	I
;	:	O
Szoka	NNP	B
and	CC	I
Papahadjopoulos	NNP	I
,	,	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
USA	NNP	I
(	(	I
1978	CD	I
)	)	I
75:145	CD	I
;	:	O
and	CC	O
Schaefer-Ridder	NNP	B
et	NNP	I
al.	NN	I
,	,	I
Science	NNP	I
(	(	I
1982	CD	I
)	)	I
215:166	CD	I
.	.	O
The	DT	O
DNA	NNP	O
and/or	NN	O
protein	NN	O
antigen	NN	O
(	(	O
s	PRP	O
)	)	O
can	MD	O
also	RB	O
be	VB	O
delivered	VBN	O
in	IN	O
cochleate	NN	O
lipid	JJ	O
compositions	NNS	O
similar	JJ	O
to	TO	O
those	DT	O
described	VBN	O
by	IN	O
Papahadjopoulos	NNP	B
et	FW	I
al.	NN	I
,	,	I
Biochem	NNP	I
.	.	I
Biophys	NNP	I
.	.	I
Acta	NNP	I
.	.	I
(	(	I
1975	CD	I
)	)	I
394:483-491	CD	I
.	.	O
See	NNP	O
,	,	O
also	RB	O
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
Nos	NNP	O
.	.	O
4,663,161	CD	O
and	CC	O
4,871,488	CD	O
.	.	O
The	DT	O
synthetic	JJ	O
expression	NN	O
cassette	NN	O
of	IN	O
interest	NN	O
(	(	O
e.g.	UH	O
,	,	O
any	DT	O
of	IN	O
the	DT	O
synthetic	JJ	O
expression	NN	O
cassettes	NNS	O
described	VBN	O
in	IN	O
Example	NNP	O
1	CD	O
)	)	O
may	MD	O
also	RB	O
be	VB	O
encapsulated	VBN	O
,	,	O
adsorbed	VBN	O
to	TO	O
,	,	O
or	CC	O
associated	VBN	O
with	IN	O
,	,	O
particulate	NN	O
carriers	NNS	O
.	.	O
Such	JJ	O
carriers	NNS	O
present	JJ	O
multiple	JJ	O
copies	NNS	O
of	IN	O
a	DT	O
selected	VBN	O
antigen	NN	O
to	TO	O
the	DT	O
immune	NN	O
system	NN	O
and	CC	O
promote	NN	O
migration	NN	O
,	,	O
trapping	VBG	O
and	CC	O
retention	NN	O
of	IN	O
antigens	NNS	O
in	IN	O
local	JJ	O
lymph	NN	O
nodes	NNS	O
.	.	O
The	DT	O
particles	NNS	O
can	MD	O
be	VB	O
taken	VBN	O
up	RP	O
by	IN	O
profession	NN	O
antigen	NN	O
presenting	VBG	O
cells	NNS	O
such	JJ	O
as	IN	O
macrophages	NNS	O
and	CC	O
dendritic	JJ	O
cells	NNS	O
,	,	O
and/or	NNS	O
can	MD	O
enhance	VB	O
antigen	JJ	O
presentation	NN	O
through	IN	O
other	JJ	O
mechanisms	NNS	O
such	JJ	O
as	IN	O
stimulation	NN	O
of	IN	O
cytokine	NN	O
release	NN	O
.	.	O
Examples	NNS	O
of	IN	O
particulate	NN	O
carriers	NNS	O
include	VBP	O
those	DT	O
derived	VBN	O
from	IN	O
polymethyl	NN	O
methacrylate	NN	O
polymers	NNS	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
microparticles	NNS	O
derived	VBN	O
from	IN	O
poly	NN	O
(	(	O
lactides	NNS	O
)	)	O
and	CC	O
poly	JJ	O
(	(	O
lactide-co-glycolides	JJ	O
)	)	O
,	,	O
known	VBN	O
as	IN	O
PLG	NNP	O
.	.	O
See	VB	O
,	,	O
e.g.	VB	O
,	,	O
Jeffery	NNP	B
et	CC	I
al.	NN	I
,	,	I
Pharm	NNP	I
.	.	I
Res	NNP	I
.	.	I
(	(	I
1993	CD	I
)	)	I
10:362-368	CD	I
;	:	O
McGee	NNP	B
J	NNP	I
P	NNP	I
,	,	I
et	FW	I
al.	NN	I
,	,	I
J.	NNP	I
Microencapsul	NNP	I
.	.	I
14	CD	I
(	(	I
2	CD	I
)	)	I
:197-210	NN	I
,	,	I
1997	CD	I
;	:	O
O'Hagan	NNP	B
D	NNP	I
T	NNP	I
,	,	I
et	FW	I
al.	NN	I
,	,	I
Vaccine	NNP	I
11	CD	I
(	(	I
2	CD	I
)	)	I
:149-54	NN	I
,	,	I
1993	CD	I
.	.	O
Furthermore	RB	O
,	,	O
other	JJ	O
particulate	NN	O
systems	NNS	O
and	CC	O
polymers	NNS	O
can	MD	O
be	VB	O
used	VBN	O
for	IN	O
the	DT	O
in	IN	O
vivo	NN	O
or	CC	O
ex	VB	O
vivo	JJ	O
delivery	NN	O
of	IN	O
the	DT	O
gene	NN	O
of	IN	O
interest	NN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
polymers	NNS	O
such	JJ	O
as	IN	O
polylysine	NN	O
,	,	O
polyarginine	NN	O
,	,	O
polyornithine	NN	O
,	,	O
spermine	NN	O
,	,	O
spermidine	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
conjugates	NNS	O
of	IN	O
these	DT	O
molecules	NNS	O
,	,	O
are	VBP	O
useful	JJ	O
for	IN	O
transferring	VBG	O
a	DT	O
nucleic	JJ	O
acid	NN	O
of	IN	O
interest	NN	O
.	.	O
Similarly	RB	O
,	,	O
DEAE	NNP	O
dextran-mediated	JJ	O
transfection	NN	O
,	,	O
calcium	NN	O
phosphate	NN	O
precipitation	NN	O
or	CC	O
precipitation	NN	O
using	VBG	O
other	JJ	O
insoluble	JJ	O
inorganic	JJ	O
salts	NNS	O
,	,	O
such	JJ	O
as	IN	O
strontium	NN	O
phosphate	NN	O
,	,	O
aluminum	NN	O
silicates	NNS	O
including	VBG	O
bentonite	NN	O
and	CC	O
kaolin	NN	O
,	,	O
chromic	JJ	O
oxide	NN	O
,	,	O
magnesium	NN	O
silicate	NN	O
,	,	O
talc	NN	O
,	,	O
and	CC	O
the	DT	O
like	JJ	O
,	,	O
will	MD	O
find	VB	O
use	NN	O
with	IN	O
the	DT	O
present	JJ	O
methods	NNS	O
.	.	O
See	VB	O
,	,	O
e.g.	VB	O
,	,	O
Feigner	NNP	B
,	,	I
P.	NNP	I
L.	NNP	I
,	,	I
Advanced	NNP	I
Drug	NNP	I
Delivery	NNP	I
Reviews	NNP	I
(	(	I
1990	CD	I
)	)	I
5:163-187	CD	I
,	,	O
for	IN	O
a	DT	O
review	NN	O
of	IN	O
delivery	NN	O
systems	NNS	O
useful	JJ	O
for	IN	O
gene	NN	O
transfer	NN	O
.	.	O
Peptoids	NNS	O
(	(	O
Zuckerman	NNP	B
,	,	I
R.	NNP	I
N.	NNP	I
,	,	I
et	FW	I
al.	NN	I
,	,	I
U.S.	NNP	I
Pat	NNP	I
.	.	I
No	DT	I
.	.	I
5,831,005	CD	I
,	,	I
issued	VBD	I
Nov.	NNP	I
3	CD	I
,	,	I
1998	CD	I
,	,	O
herein	RB	O
incorporated	VBN	O
by	IN	O
reference	NN	O
)	)	O
may	MD	O
also	RB	O
be	VB	O
used	VBN	O
for	IN	O
delivery	NN	O
of	IN	O
a	DT	O
construct	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
.	.	O
Additionally	RB	O
,	,	O
biolistic	JJ	O
delivery	NN	O
systems	NNS	O
employing	VBG	O
particulate	JJ	O
carriers	NNS	O
such	JJ	O
as	IN	O
gold	NN	O
and	CC	O
tungsten	NN	O
,	,	O
are	VBP	O
especially	RB	O
useful	JJ	O
for	IN	O
delivering	VBG	O
synthetic	JJ	O
expression	NN	O
cassettes	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
.	.	O
The	DT	O
particles	NNS	O
are	VBP	O
coated	VBN	O
with	IN	O
the	DT	O
synthetic	JJ	O
expression	NN	O
cassette	NN	O
(	(	O
s	PRP	O
)	)	O
to	TO	O
be	VB	O
delivered	VBN	O
and	CC	O
accelerated	VBN	O
to	TO	O
high	JJ	O
velocity	NN	O
,	,	O
generally	RB	O
under	IN	O
a	DT	O
reduced	VBN	O
atmosphere	NN	O
,	,	O
using	VBG	O
a	DT	O
gun	NN	O
powder	NN	O
discharge	NN	O
from	IN	O
a	DT	O
“	JJ	O
gene	NN	O
gun.	NN	O
”	NNP	O
For	IN	O
a	DT	O
description	NN	O
of	IN	O
such	JJ	O
techniques	NNS	O
,	,	O
and	CC	O
apparatuses	VBZ	O
useful	JJ	O
therefore	RB	O
,	,	O
see	VB	O
,	,	O
e.g.	VB	O
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
Nos	NNP	O
.	.	O
4,945,050	CD	O
;	:	O
5,036,006	CD	O
;	:	O
5,100,792	CD	O
;	:	O
5,179,022	CD	O
;	:	O
5,371,015	CD	O
;	:	O
and	CC	O
5,478,744	CD	O
.	.	O
Also	RB	O
,	,	O
needle-less	JJ	O
injection	NN	O
systems	NNS	O
can	MD	O
be	VB	O
used	VBN	O
(	(	O
Davis	NNP	B
,	,	I
H.	NNP	I
L.	NNP	I
,	,	I
et	FW	I
al	NN	I
,	,	I
Vaccine	NNP	I
12:1503-1509	CD	I
,	,	I
1994	CD	I
;	:	O
Bioject	NNP	B
,	,	I
Inc.	NNP	I
,	,	I
Portland	NNP	I
,	,	I
Oreg	NNP	I
.	.	I
)	)	O
.	.	O
Recombinant	JJ	O
vectors	NNS	O
carrying	VBG	O
a	DT	O
synthetic	JJ	O
expression	NN	O
cassette	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
are	VBP	O
formulated	VBN	O
into	IN	O
compositions	NNS	O
for	IN	O
delivery	NN	O
to	TO	O
the	DT	O
vertebrate	NN	O
subject	NN	O
.	.	O
These	DT	O
compositions	NNS	O
may	MD	O
either	RB	O
be	VB	O
prophylactic	JJ	O
(	(	O
to	TO	O
prevent	VB	O
infection	NN	O
)	)	O
or	CC	O
therapeutic	JJ	O
(	(	O
to	TO	O
treat	VB	O
disease	NN	O
after	IN	O
infection	NN	O
)	)	O
.	.	O
The	DT	O
compositions	NNS	O
will	MD	O
comprise	VB	O
a	DT	O
“	NNP	O
therapeutically	RB	O
effective	JJ	O
amount	NN	O
”	NN	O
of	IN	O
the	DT	O
gene	NN	O
of	IN	O
interest	NN	O
such	JJ	O
that	IN	O
an	DT	O
amount	NN	O
of	IN	O
the	DT	O
antigen	NN	O
can	MD	O
be	VB	O
produced	VBN	O
in	IN	O
vivo	NN	O
so	RB	O
that	IN	O
an	DT	O
immune	JJ	O
response	NN	O
is	VBZ	O
generated	VBN	O
in	IN	O
the	DT	O
individual	NN	O
to	TO	O
which	WDT	O
it	PRP	O
is	VBZ	O
administered	VBN	O
.	.	O
The	DT	O
exact	JJ	O
amount	NN	O
necessary	JJ	O
will	MD	O
vary	VB	O
depending	VBG	O
on	IN	O
the	DT	O
subject	NN	O
being	VBG	O
treated	VBN	O
;	:	O
the	DT	O
age	NN	O
and	CC	O
general	JJ	O
condition	NN	O
of	IN	O
the	DT	O
subject	NN	O
to	TO	O
be	VB	O
treated	VBN	O
;	:	O
the	DT	O
capacity	NN	O
of	IN	O
the	DT	O
subject	NN	O
's	POS	O
immune	NN	O
system	NN	O
to	TO	O
synthesize	VB	O
antibodies	NNS	O
;	:	O
the	DT	O
degree	NN	O
of	IN	O
protection	NN	O
desired	VBN	O
;	:	O
the	DT	O
severity	NN	O
of	IN	O
the	DT	O
condition	NN	O
being	VBG	O
treated	VBN	O
;	:	O
the	DT	O
particular	JJ	O
antigen	NN	O
selected	VBN	O
and	CC	O
its	PRP$	O
mode	NN	O
of	IN	O
administration	NN	O
,	,	O
among	IN	O
other	JJ	O
factors	NNS	O
.	.	O
An	DT	O
appropriate	JJ	O
effective	JJ	O
amount	NN	O
can	MD	O
be	VB	O
readily	RB	O
determined	VBN	O
by	IN	O
one	CD	O
of	IN	O
skill	NN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
Thus	RB	O
,	,	O
a	DT	O
“	NNP	O
therapeutically	RB	O
effective	JJ	O
amount	NN	O
”	NNP	O
will	MD	O
fall	VB	O
in	IN	O
a	DT	O
relatively	RB	O
broad	JJ	O
range	NN	O
that	WDT	O
can	MD	O
be	VB	O
determined	VBN	O
through	IN	O
routine	JJ	O
trials	NNS	O
.	.	O
The	DT	O
compositions	NNS	O
will	MD	O
generally	RB	O
include	VB	O
one	CD	O
or	CC	O
more	JJR	O
“	NNS	O
pharmaceutically	RB	O
acceptable	JJ	O
excipients	NNS	O
or	CC	O
vehicles	NNS	O
”	VBP	O
such	JJ	O
as	IN	O
water	NN	O
,	,	O
saline	NN	O
,	,	O
glycerol	NN	O
,	,	O
polyethyleneglycol	NN	O
,	,	O
hyaluronic	JJ	O
acid	NN	O
,	,	O
ethanol	NN	O
,	,	O
etc	FW	O
.	.	O
Additionally	RB	O
,	,	O
auxiliary	JJ	O
substances	NNS	O
,	,	O
such	JJ	O
as	IN	O
wetting	VBG	O
or	CC	O
emulsifying	VBG	O
agents	NNS	O
,	,	O
pH	NN	O
buffering	NN	O
substances	NNS	O
,	,	O
surfactants	NNS	O
and	CC	O
the	DT	O
like	JJ	O
,	,	O
may	MD	O
be	VB	O
present	JJ	O
in	IN	O
such	JJ	O
vehicles	NNS	O
.	.	O
Certain	NNP	O
facilitators	NNS	O
of	IN	O
immunogenicity	NN	O
or	CC	O
of	IN	O
nucleic	JJ	O
acid	NNS	O
uptake	VBP	O
and/or	JJ	O
expression	NN	O
can	MD	O
also	RB	O
be	VB	O
included	VBN	O
in	IN	O
the	DT	O
compositions	NNS	O
or	CC	O
coadministered	VBN	O
,	,	O
such	JJ	O
as	IN	O
,	,	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
,	,	O
bupivacaine	NN	O
,	,	O
cardiotoxin	NN	O
and	CC	O
sucrose	NN	O
.	.	O
Once	RB	O
formulated	VBN	O
,	,	O
the	DT	O
compositions	NNS	O
of	IN	O
the	DT	O
invention	NN	O
can	MD	O
be	VB	O
administered	VBN	O
directly	RB	O
to	TO	O
the	DT	O
subject	NN	O
(	(	O
e.g.	NN	O
,	,	O
as	IN	O
described	VBN	O
above	IN	O
)	)	O
or	CC	O
,	,	O
alternatively	RB	O
,	,	O
delivered	VBD	O
ex	JJ	O
vivo	NN	O
,	,	O
to	TO	O
cells	NNS	O
derived	VBN	O
from	IN	O
the	DT	O
subject	NN	O
,	,	O
using	VBG	O
methods	NNS	O
such	JJ	O
as	IN	O
those	DT	O
described	VBN	O
above	IN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
methods	NNS	O
for	IN	O
the	DT	O
ex	NN	O
vivo	NN	O
delivery	NN	O
and	CC	O
reimplantation	NN	O
of	IN	O
transformed	JJ	O
cells	NNS	O
into	IN	O
a	DT	O
subject	NN	O
are	VBP	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
and	CC	O
can	MD	O
include	VB	O
,	,	O
e.g.	VB	O
,	,	O
dextran-mediated	JJ	O
transfection	NN	O
,	,	O
calcium	NN	O
phosphate	NN	O
precipitation	NN	O
,	,	O
polybrene	NN	O
mediated	VBD	O
transfection	NN	O
,	,	O
lipofectamine	NN	O
and	CC	O
LT-1	NNP	O
mediated	VBD	O
transfection	NN	O
,	,	O
protoplast	JJ	O
fusion	NN	O
,	,	O
electroporation	NN	O
,	,	O
encapsulation	NN	O
of	IN	O
the	DT	O
polynucleotide	NN	O
(	(	O
s	NN	O
)	)	O
(	(	O
with	IN	O
or	CC	O
without	IN	O
the	DT	O
corresponding	JJ	O
antigen	NN	O
)	)	O
in	IN	O
liposomes	NNS	O
,	,	O
and	CC	O
direct	JJ	O
microinjection	NN	O
of	IN	O
the	DT	O
DNA	NNP	O
into	IN	O
nuclei	NN	O
.	.	O
Direct	JJ	O
delivery	NN	O
of	IN	O
synthetic	JJ	O
expression	NN	O
cassette	NN	O
compositions	NNS	O
in	IN	O
vivo	NN	O
will	MD	O
generally	RB	O
be	VB	O
accomplished	VBN	O
with	IN	O
or	CC	O
without	IN	O
viral	JJ	O
vectors	NNS	O
,	,	O
as	IN	O
described	VBN	O
above	IN	O
,	,	O
by	IN	O
injection	NN	O
using	VBG	O
either	CC	O
a	DT	O
conventional	JJ	O
syringe	NN	O
,	,	O
needless	JJ	O
devices	NNS	O
such	JJ	O
as	IN	O
Bioject®	NNP	O
or	CC	O
a	DT	O
gene	NN	O
gun	NN	O
,	,	O
such	JJ	O
as	IN	O
the	DT	O
Accell®	NNP	O
gene	NN	O
delivery	NN	O
system	NN	O
(	(	O
PowderJect	NNP	O
Technologies	NNP	O
,	,	O
Inc.	NNP	O
,	,	O
Oxford	NNP	O
,	,	O
England	NNP	O
)	)	O
.	.	O
The	DT	O
constructs	NNS	O
can	MD	O
be	VB	O
delivered	VBN	O
(	(	O
e.g.	NN	O
,	,	O
injected	VBN	O
)	)	O
either	DT	O
subcutaneously	RB	O
,	,	O
epidermally	RB	O
,	,	O
intradermally	RB	O
,	,	O
intramuscularly	RB	O
,	,	O
intravenous	JJ	O
,	,	O
intramucosally	RB	O
(	(	O
such	JJ	O
as	IN	O
nasally	RB	O
,	,	O
rectally	RB	O
and	CC	O
vaginally	RB	O
)	)	O
,	,	O
intraperitoneally	RB	O
or	CC	O
orally	RB	O
.	.	O
Delivery	NN	O
of	IN	O
DNA	NNP	O
into	IN	O
cells	NNS	O
of	IN	O
the	DT	O
epidermis	NN	O
is	VBZ	O
particularly	RB	O
preferred	VBN	O
as	IN	O
this	DT	O
mode	NN	O
of	IN	O
administration	NN	O
provides	VBZ	O
access	NN	O
to	TO	O
skin-associated	JJ	O
lymphoid	JJ	O
cells	NNS	O
and	CC	O
provides	VBZ	O
for	IN	O
a	DT	O
transient	JJ	O
presence	NN	O
of	IN	O
DNA	NNP	O
in	IN	O
the	DT	O
recipient	NN	O
.	.	O
Other	JJ	O
modes	NNS	O
of	IN	O
administration	NN	O
include	VBP	O
oral	JJ	O
ingestion	NN	O
and	CC	O
pulmonary	JJ	O
administration	NN	O
,	,	O
suppositories	NNS	O
,	,	O
needle-less	JJ	O
injection	NN	O
,	,	O
transcutaneous	JJ	O
and	CC	O
transdermal	JJ	O
applications	NNS	O
.	.	O
Dosage	NNP	O
treatment	NN	O
may	MD	O
be	VB	O
a	DT	O
single	JJ	O
dose	NN	O
schedule	NN	O
or	CC	O
a	DT	O
multiple	JJ	O
dose	NN	O
schedule	NN	O
.	.	O
2.3.2	CD	O
Ex	NNP	O
Vivo	NNP	O
Delivery	NNP	O
of	IN	O
the	DT	O
Synthetic	NNP	O
Expression	NNP	O
Cassettes	NNP	O
of	IN	O
the	DT	O
Present	JJ	O
Invention	NNP	O
In	IN	O
one	CD	O
embodiment	NN	O
,	,	O
T	NNP	O
cells	NNS	O
,	,	O
and	CC	O
related	VBN	O
cell	NN	O
types	NNS	O
(	(	O
including	VBG	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
antigen	VB	O
presenting	VBG	O
cells	NNS	O
,	,	O
such	JJ	O
as	IN	O
,	,	O
macrophage	NN	O
,	,	O
monocytes	NNS	O
,	,	O
lymphoid	JJ	O
cells	NNS	O
,	,	O
dendritic	JJ	O
cells	NNS	O
,	,	O
B-cells	NNP	O
,	,	O
T-cells	NNP	O
,	,	O
stem	NN	O
cells	NNS	O
,	,	O
and	CC	O
progenitor	NN	O
cells	NNS	O
thereof	NN	O
)	)	O
,	,	O
can	MD	O
be	VB	O
used	VBN	O
for	IN	O
ex	JJ	O
vivo	JJ	O
delivery	NN	O
of	IN	O
the	DT	O
synthetic	JJ	O
expression	NN	O
cassettes	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
.	.	O
T	NNP	O
cells	NNS	O
can	MD	O
be	VB	O
isolated	VBN	O
from	IN	O
peripheral	JJ	O
blood	NN	O
lymphocytes	NNS	O
(	(	O
PBLs	NNP	O
)	)	O
by	IN	O
a	DT	O
variety	NN	O
of	IN	O
procedures	NNS	O
known	VBN	O
to	TO	O
those	DT	O
skilled	VBN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
T	NNP	O
cell	NN	O
populations	NNS	O
can	MD	O
be	VB	O
“	VBN	O
enriched	JJ	O
”	NN	O
from	IN	O
a	DT	O
population	NN	O
of	IN	O
PBLs	NNP	O
through	IN	O
the	DT	O
removal	NN	O
of	IN	O
accessory	NN	O
and	CC	O
B	NNP	O
cells	NNS	O
.	.	O
In	IN	O
particular	JJ	O
,	,	O
T	NNP	O
cell	NN	O
enrichment	NN	O
can	MD	O
be	VB	O
accomplished	VBN	O
by	IN	O
the	DT	O
elimination	NN	O
of	IN	O
non-T	JJ	O
cells	NNS	O
using	VBG	O
anti-MHC	JJ	O
class	NN	O
II	NNP	O
monoclonal	JJ	O
antibodies	NNS	O
.	.	O
Similarly	RB	O
,	,	O
other	JJ	O
antibodies	NNS	O
can	MD	O
be	VB	O
used	VBN	O
to	TO	O
deplete	VB	O
specific	JJ	O
populations	NNS	O
of	IN	O
non-T	JJ	O
cells	NNS	O
.	.	O
For	IN	O
example	NN	O
,	,	O
anti-Ig	JJ	O
antibody	NN	O
molecules	NNS	O
can	MD	O
be	VB	O
used	VBN	O
to	TO	O
deplete	VB	O
B	NNP	O
cells	NNS	O
and	CC	O
anti-MacI	JJ	O
antibody	NN	O
molecules	NNS	O
can	MD	O
be	VB	O
used	VBN	O
to	TO	O
deplete	VB	O
macrophages	NNS	O
.	.	O
T	NNP	O
cells	NNS	O
can	MD	O
be	VB	O
further	RB	O
fractionated	VBN	O
into	IN	O
a	DT	O
number	NN	O
of	IN	O
different	JJ	O
subpopulations	NNS	O
by	IN	O
techniques	NNS	O
known	VBN	O
to	TO	O
those	DT	O
skilled	VBN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
Two	CD	O
major	JJ	O
subpopulations	NNS	O
can	MD	O
be	VB	O
isolated	VBN	O
based	VBN	O
on	IN	O
their	PRP$	O
differential	JJ	O
expression	NN	O
of	IN	O
the	DT	O
cell	NN	O
surface	NN	O
markers	NNS	O
CD4	NNP	O
and	CC	O
CD8	NNP	O
.	.	O
For	IN	O
example	NN	O
,	,	O
following	VBG	O
the	DT	O
enrichment	NN	O
of	IN	O
T	NNP	O
cells	NNS	O
as	IN	O
described	VBN	O
above	IN	O
,	,	O
CD4+	NNP	O
cells	NNS	O
can	MD	O
be	VB	O
enriched	VBN	O
using	VBG	O
antibodies	NNS	O
specific	JJ	O
for	IN	O
CD4	NNP	O
(	(	O
see	VB	O
Coligan	NNP	B
et	FW	I
al.	NN	I
,	,	I
supra	NN	I
)	)	O
.	.	O
The	DT	O
antibodies	NNS	O
may	MD	O
be	VB	O
coupled	VBN	O
to	TO	O
a	DT	O
solid	JJ	O
support	NN	O
such	JJ	O
as	IN	O
magnetic	JJ	O
beads	NNS	O
.	.	O
Conversely	RB	O
,	,	O
CD8+	NNP	O
cells	NNS	O
can	MD	O
be	VB	O
enriched	VBN	O
through	IN	O
the	DT	O
use	NN	O
of	IN	O
antibodies	NNS	O
specific	JJ	O
for	IN	O
CD4	NNP	O
(	(	O
to	TO	O
remove	VB	O
CD4+	NNP	O
cells	NNS	O
)	)	O
,	,	O
or	CC	O
can	MD	O
be	VB	O
isolated	VBN	O
by	IN	O
the	DT	O
use	NN	O
of	IN	O
CD8	NNP	O
antibodies	NNS	O
coupled	VBD	O
to	TO	O
a	DT	O
solid	JJ	O
support	NN	O
.	.	O
CD4	NNP	O
lymphocytes	VBZ	O
from	IN	O
HIV-1	NNP	O
infected	JJ	O
patients	NNS	O
can	MD	O
be	VB	O
expanded	VBN	O
ex	JJ	O
vivo	NNS	O
,	,	O
before	IN	O
or	CC	O
after	IN	O
transduction	NN	O
as	IN	O
described	VBN	O
by	IN	O
Wilson	NNP	B
et	FW	I
.	.	I
al	NN	I
.	.	I
(	(	I
1995	CD	I
)	)	I
J.	NNP	I
Infect	NNP	I
.	.	I
Dis	NNP	I
.	.	I
172:88	CD	I
.	.	O
Following	VBG	O
purification	NN	O
of	IN	O
T	NNP	O
cells	NNS	O
,	,	O
a	DT	O
variety	NN	O
of	IN	O
methods	NNS	O
of	IN	O
genetic	JJ	O
modification	NN	O
known	VBN	O
to	TO	O
those	DT	O
skilled	VBN	O
in	IN	O
the	DT	O
art	NN	O
can	MD	O
be	VB	O
performed	VBN	O
using	VBG	O
non-viral	JJ	O
or	CC	O
viral-based	JJ	O
gene	NN	O
transfer	NN	O
vectors	NNS	O
constructed	VBD	O
as	IN	O
described	JJ	O
herein	NN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
one	CD	O
such	JJ	O
approach	NN	O
involves	VBZ	O
transduction	NN	O
of	IN	O
the	DT	O
purified	JJ	O
T	NNP	O
cell	NN	O
population	NN	O
with	IN	O
vector-containing	JJ	O
supernatant	NN	O
of	IN	O
cultures	NNS	O
derived	VBN	O
from	IN	O
vector	NN	O
producing	VBG	O
cells	NNS	O
.	.	O
A	DT	O
second	JJ	O
approach	NN	O
involves	VBZ	O
co-cultivation	NN	O
of	IN	O
an	DT	O
irradiated	JJ	O
monolayer	NN	O
of	IN	O
vector-producing	JJ	O
cells	NNS	O
with	IN	O
the	DT	O
purified	JJ	O
T	NNP	O
cells	NNS	O
.	.	O
A	DT	O
third	JJ	O
approach	NN	O
involves	VBZ	O
a	DT	O
similar	JJ	O
co-cultivation	NN	O
approach	NN	O
;	:	O
however	RB	O
,	,	O
the	DT	O
purified	JJ	O
T	NNP	O
cells	NNS	O
are	VBP	O
pre-stimulated	JJ	O
with	IN	O
various	JJ	O
cytokines	NNS	O
and	CC	O
cultured	VBD	O
48	CD	O
hours	NNS	O
prior	RB	O
to	TO	O
the	DT	O
co-cultivation	NN	O
with	IN	O
the	DT	O
irradiated	JJ	O
vector	NN	O
producing	VBG	O
cells	NNS	O
.	.	O
Pre-stimulation	NN	O
prior	RB	O
to	TO	O
such	JJ	O
transduction	NN	O
increases	NNS	O
effective	JJ	O
gene	NN	O
transfer	NN	O
(	(	O
Nolta	NNP	B
et	RB	I
al	RB	I
.	.	I
(	(	I
1992	CD	I
)	)	I
Exp	NNP	I
.	.	I
Hematol	NNP	I
.	.	I
20:1065	CD	I
)	)	O
.	.	O
Stimulation	NN	O
of	IN	O
these	DT	O
cultures	NNS	O
to	TO	O
proliferate	VB	O
also	RB	O
provides	VBZ	O
increased	JJ	O
cell	NN	O
populations	NNS	O
for	IN	O
re-infusion	NN	O
into	IN	O
the	DT	O
patient	NN	O
.	.	O
Subsequent	JJ	O
to	TO	O
co-cultivation	NN	O
,	,	O
T	NNP	O
cells	NNS	O
are	VBP	O
collected	VBN	O
from	IN	O
the	DT	O
vector	NN	O
producing	VBG	O
cell	NN	O
monolayer	NN	O
,	,	O
expanded	VBN	O
,	,	O
and	CC	O
frozen	NNS	O
in	IN	O
liquid	JJ	O
nitrogen	NN	O
.	.	O
Gene	NNP	O
transfer	NN	O
vectors	NNS	O
,	,	O
containing	VBG	O
one	CD	O
or	CC	O
more	JJR	O
synthetic	JJ	O
expression	NN	O
cassette	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
(	(	O
associated	VBN	O
with	IN	O
appropriate	JJ	O
control	NN	O
elements	NNS	O
for	IN	O
delivery	NN	O
to	TO	O
the	DT	O
isolated	JJ	O
T	NNP	O
cells	NNS	O
)	)	O
can	MD	O
be	VB	O
assembled	VBN	O
using	VBG	O
known	VBN	O
methods	NNS	O
.	.	O
Selectable	JJ	O
markers	NNS	O
can	MD	O
also	RB	O
be	VB	O
used	VBN	O
in	IN	O
the	DT	O
construction	NN	O
of	IN	O
gene	NN	O
transfer	NN	O
vectors	NNS	O
.	.	O
For	IN	O
example	NN	O
,	,	O
a	DT	O
marker	NN	O
can	MD	O
be	VB	O
used	VBN	O
which	WDT	O
imparts	VBZ	O
to	TO	O
a	DT	O
mammalian	JJ	O
cell	NN	O
transduced	VBD	O
with	IN	O
the	DT	O
gene	NN	O
transfer	NN	O
vector	NN	O
resistance	NN	O
to	TO	O
a	DT	O
cytotoxic	NN	O
agent	NN	O
.	.	O
The	DT	O
cytotoxic	NN	O
agent	NN	O
can	MD	O
be	VB	O
,	,	O
but	CC	O
is	VBZ	O
not	RB	O
limited	VBN	O
to	TO	O
,	,	O
neomycin	RB	O
,	,	O
aminoglycoside	RB	O
,	,	O
tetracycline	NN	O
,	,	O
chloramphenicol	NN	O
,	,	O
sulfonamide	NN	O
,	,	O
actinomycin	NN	O
,	,	O
netropsin	NN	O
,	,	O
distamycin	VB	O
A	NNP	O
,	,	O
anthracycline	NN	O
,	,	O
or	CC	O
pyrazinamide	NN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
neomycin	JJ	O
phosphotransferase	NN	O
II	NNP	O
imparts	VBZ	O
resistance	NN	O
to	TO	O
the	DT	O
neomycin	JJ	O
analogue	NN	O
geneticin	NN	O
(	(	O
G418	NNP	O
)	)	O
.	.	O
The	DT	O
T	NNP	O
cells	NNS	O
can	MD	O
also	RB	O
be	VB	O
maintained	VBN	O
in	IN	O
a	DT	O
medium	NN	O
containing	VBG	O
at	IN	O
least	JJS	O
one	CD	O
type	NN	O
of	IN	O
growth	NN	O
factor	NN	O
prior	RB	O
to	TO	O
being	VBG	O
selected	VBN	O
.	.	O
A	DT	O
variety	NN	O
of	IN	O
growth	NN	O
factors	NNS	O
are	VBP	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
which	WDT	O
sustain	VBP	O
the	DT	O
growth	NN	O
of	IN	O
a	DT	O
particular	JJ	O
cell	NN	O
type	NN	O
.	.	O
Examples	NNS	O
of	IN	O
such	JJ	O
growth	NN	O
factors	NNS	O
are	VBP	O
cytokine	JJ	O
mitogens	NNS	O
such	JJ	O
as	IN	O
rIL-2	JJ	O
,	,	O
IL-10	NNP	O
,	,	O
IL-12	NNP	O
,	,	O
and	CC	O
IL-15	NNP	O
,	,	O
which	WDT	O
promote	VBP	O
growth	NN	O
and	CC	O
activation	NN	O
of	IN	O
lymphocytes	NNS	O
.	.	O
Certain	NNP	O
types	NNS	O
of	IN	O
cells	NNS	O
are	VBP	O
stimulated	VBN	O
by	IN	O
other	JJ	O
growth	NN	O
factors	NNS	O
such	JJ	O
as	IN	O
hormones	NNS	O
,	,	O
including	VBG	O
human	JJ	O
chorionic	JJ	O
gonadotropin	NN	O
(	(	O
hCG	NN	O
)	)	O
and	CC	O
human	JJ	O
growth	NN	O
hormone	NN	O
.	.	O
The	DT	O
selection	NN	O
of	IN	O
an	DT	O
appropriate	JJ	O
growth	NN	O
factor	NN	O
for	IN	O
a	DT	O
particular	JJ	O
cell	NN	O
population	NN	O
is	VBZ	O
readily	RB	O
accomplished	VBN	O
by	IN	O
one	CD	O
of	IN	O
skill	NN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
white	JJ	O
blood	NN	O
cells	NNS	O
such	JJ	O
as	IN	O
differentiated	JJ	O
progenitor	NN	O
and	CC	O
stem	NN	O
cells	NNS	O
are	VBP	O
stimulated	VBN	O
by	IN	O
a	DT	O
variety	NN	O
of	IN	O
growth	NN	O
factors	NNS	O
.	.	O
More	RBR	O
particularly	RB	O
,	,	O
IL-3	NNP	O
,	,	O
IL-4	NNP	O
,	,	O
IL-5	NNP	O
,	,	O
IL-6	NNP	O
,	,	O
IL-9	NNP	O
,	,	O
GM-CSF	NNP	O
,	,	O
M-CSF	NNP	O
,	,	O
and	CC	O
G-CSF	NNP	O
,	,	O
produced	VBN	O
by	IN	O
activated	JJ	O
TH	NNP	O
and	CC	O
activated	VBD	O
macrophages	NNS	O
,	,	O
stimulate	VBP	O
myeloid	JJ	O
stem	NN	O
cells	NNS	O
,	,	O
which	WDT	O
then	RB	O
differentiate	VBP	O
into	IN	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
,	,	O
granulocyte-monocyte	JJ	O
progenitors	NNS	O
,	,	O
eosinophil	JJ	O
progenitors	NNS	O
,	,	O
basophil	NN	O
progenitors	NNS	O
,	,	O
megakaryocytes	NNS	O
,	,	O
and	CC	O
erythroid	JJ	O
progenitors	NNS	O
.	.	O
Differentiation	NN	O
is	VBZ	O
modulated	VBN	O
by	IN	O
growth	NN	O
factors	NNS	O
such	JJ	O
as	IN	O
GM-CSF	NNP	O
,	,	O
IL-3	NNP	O
,	,	O
IL-6	NNP	O
,	,	O
IL-11	NNP	O
,	,	O
and	CC	O
EPO	NNP	O
.	.	O
Pluripotent	JJ	O
stem	NN	O
cells	NNS	O
then	RB	O
differentiate	VB	O
into	IN	O
lymphoid	JJ	O
stem	NN	O
cells	NNS	O
,	,	O
bone	NN	O
marrow	NN	O
stromal	JJ	O
cells	NNS	O
,	,	O
T	NNP	O
cell	NN	O
progenitors	NNS	O
,	,	O
B	NNP	O
cell	NN	O
progenitors	NNS	O
,	,	O
thymocytes	NNS	O
,	,	O
TH	NNP	O
Cells	NNP	O
,	,	O
TC	NNP	O
cells	NNS	O
,	,	O
and	CC	O
B	NNP	O
cells	NNS	O
.	.	O
This	DT	O
differentiation	NN	O
is	VBZ	O
modulated	VBN	O
by	IN	O
growth	NN	O
factors	NNS	O
such	JJ	O
as	IN	O
IL-3	NNP	O
,	,	O
IL-4	NNP	O
,	,	O
IL-6	NNP	O
,	,	O
IL-7	NNP	O
,	,	O
GM-CSF	NNP	O
,	,	O
M-CSF	NNP	O
,	,	O
G-CSF	NNP	O
,	,	O
IL-2	NNP	O
,	,	O
and	CC	O
IL-5	NNP	O
.	.	O
Granulocyte-monocyte	JJ	O
progenitors	NNS	O
differentiate	VBP	O
to	TO	O
monocytes	NNS	O
,	,	O
macrophages	NNS	O
,	,	O
and	CC	O
neutrophils	NNS	O
.	.	O
Such	JJ	O
differentiation	NN	O
is	VBZ	O
modulated	VBN	O
by	IN	O
the	DT	O
growth	NN	O
factors	NNS	O
GM-CSF	NNP	O
,	,	O
M-CSF	NNP	O
,	,	O
and	CC	O
IL-8	NNP	O
.	.	O
Eosinophil	NNP	O
progenitors	NNS	O
differentiate	VBP	O
into	IN	O
eosinophils	NNS	O
.	.	O
This	DT	O
process	NN	O
is	VBZ	O
modulated	VBN	O
by	IN	O
GM-CSF	NNP	O
and	CC	O
IL-5	NNP	O
.	.	O
The	DT	O
differentiation	NN	O
of	IN	O
basophil	NN	O
progenitors	NNS	O
into	IN	O
mast	NN	O
cells	NNS	O
and	CC	O
basophils	NNS	O
is	VBZ	O
modulated	VBN	O
by	IN	O
GM-CSF	NNP	O
,	,	O
IL-4	NNP	O
,	,	O
and	CC	O
IL-9	NNP	O
.	.	O
Megakaryocytes	NNS	O
produce	VBP	O
platelets	NNS	O
in	IN	O
response	NN	O
to	TO	O
GM-CSF	NNP	O
,	,	O
EPO	NNP	O
,	,	O
and	CC	O
IL-6	NNP	O
.	.	O
Erythroid	NNP	O
progenitor	NN	O
cells	NNS	O
differentiate	VBP	O
into	IN	O
red	JJ	O
blood	NN	O
cells	NNS	O
in	IN	O
response	NN	O
to	TO	O
EPO	NNP	O
.	.	O
Thus	RB	O
,	,	O
during	IN	O
activation	NN	O
by	IN	O
the	DT	O
CD3-binding	NNP	O
agent	NN	O
,	,	O
T	NNP	O
cells	NNS	O
can	MD	O
also	RB	O
be	VB	O
contacted	VBN	O
with	IN	O
a	DT	O
mitogen	NN	O
,	,	O
for	IN	O
example	NN	O
a	DT	O
cytokine	NN	O
such	JJ	O
as	IN	O
IL-2	NNP	O
.	.	O
In	IN	O
particularly	RB	O
preferred	JJ	O
embodiments	NNS	O
,	,	O
the	DT	O
IL-2	NNP	O
is	VBZ	O
added	VBN	O
to	TO	O
the	DT	O
population	NN	O
of	IN	O
T	NNP	O
cells	NNS	O
at	IN	O
a	DT	O
concentration	NN	O
of	IN	O
about	RB	O
50	CD	O
to	TO	O
100	CD	O
μg/ml	NNS	O
.	.	O
Activation	NN	O
with	IN	O
the	DT	O
CD3-binding	JJ	O
agent	NN	O
can	MD	O
be	VB	O
carried	VBN	O
out	IN	O
for	IN	O
2	CD	O
to	TO	O
4	CD	O
days	NNS	O
.	.	O
Once	RB	O
suitably	RB	O
activated	VBN	O
,	,	O
the	DT	O
T	NNP	O
cells	NNS	O
are	VBP	O
genetically	RB	O
modified	VBN	O
by	IN	O
contacting	VBG	O
the	DT	O
same	JJ	O
with	IN	O
a	DT	O
suitable	JJ	O
gene	NN	O
transfer	NN	O
vector	NN	O
under	IN	O
conditions	NNS	O
that	WDT	O
allow	VBP	O
for	IN	O
transfection	NN	O
of	IN	O
the	DT	O
vectors	NNS	O
into	IN	O
the	DT	O
T	NNP	O
cells	NNS	O
.	.	O
Genetic	JJ	O
modification	NN	O
is	VBZ	O
carried	VBN	O
out	RP	O
when	WRB	O
the	DT	O
cell	NN	O
density	NN	O
of	IN	O
the	DT	O
T	NNP	O
cell	NN	O
population	NN	O
is	VBZ	O
between	IN	O
about	IN	O
0.1×106	CD	O
and	CC	O
5×106	CD	O
,	,	O
preferably	RB	O
between	IN	O
about	IN	O
0.5×106	CD	O
and	CC	O
2×106	CD	O
.	.	O
A	DT	O
number	NN	O
of	IN	O
suitable	JJ	O
viral	JJ	O
and	CC	O
nonviral-based	JJ	O
gene	NN	O
transfer	NN	O
vectors	NNS	O
have	VBP	O
been	VBN	O
described	VBN	O
for	IN	O
use	NN	O
herein	NN	O
.	.	O
After	IN	O
transduction	NN	O
,	,	O
transduced	JJ	O
cells	NNS	O
are	VBP	O
selected	VBN	O
away	RB	O
from	IN	O
non-transduced	JJ	O
cells	NNS	O
using	VBG	O
known	VBN	O
techniques	NNS	O
.	.	O
For	IN	O
example	NN	O
,	,	O
if	IN	O
the	DT	O
gene	NN	O
transfer	NN	O
vector	NN	O
used	VBN	O
in	IN	O
the	DT	O
transduction	NN	O
includes	VBZ	O
a	DT	O
selectable	JJ	O
marker	NN	O
which	WDT	O
confers	VBZ	O
resistance	NN	O
to	TO	O
a	DT	O
cytotoxic	NN	O
agent	NN	O
,	,	O
the	DT	O
cells	NNS	O
can	MD	O
be	VB	O
contacted	VBN	O
with	IN	O
the	DT	O
appropriate	JJ	O
cytotoxic	NN	O
agent	NN	O
,	,	O
whereby	WRB	O
non-transduced	JJ	O
cells	NNS	O
can	MD	O
be	VB	O
negatively	RB	O
selected	VBN	O
away	RB	O
from	IN	O
the	DT	O
transduced	JJ	O
cells	NNS	O
.	.	O
If	IN	O
the	DT	O
selectable	JJ	O
marker	NN	O
is	VBZ	O
a	DT	O
cell	NN	O
surface	NN	O
marker	NN	O
,	,	O
the	DT	O
cells	NNS	O
can	MD	O
be	VB	O
contacted	VBN	O
with	IN	O
a	DT	O
binding	NN	O
agent	NN	O
specific	NN	O
for	IN	O
the	DT	O
particular	JJ	O
cell	NN	O
surface	NN	O
marker	NN	O
,	,	O
whereby	WRB	O
the	DT	O
transduced	JJ	O
cells	NNS	O
can	MD	O
be	VB	O
positively	RB	O
selected	VBN	O
away	RB	O
from	IN	O
the	DT	O
population	NN	O
.	.	O
The	DT	O
selection	JJ	O
step	NN	O
can	MD	O
also	RB	O
entail	VB	O
fluorescence-activated	JJ	O
cell	NN	O
sorting	VBG	O
(	(	O
FACS	NNP	O
)	)	O
techniques	NNS	O
,	,	O
such	JJ	O
as	IN	O
where	WRB	O
FACS	NNP	O
is	VBZ	O
used	VBN	O
to	TO	O
select	VB	O
cells	NNS	O
from	IN	O
the	DT	O
population	NN	O
containing	VBG	O
a	DT	O
particular	JJ	O
surface	NN	O
marker	NN	O
,	,	O
or	CC	O
the	DT	O
selection	JJ	O
step	NN	O
can	MD	O
entail	VB	O
the	DT	O
use	NN	O
of	IN	O
magnetically	RB	O
responsive	JJ	O
particles	NNS	O
as	IN	O
retrievable	JJ	O
supports	NNS	O
for	IN	O
target	NN	O
cell	NN	O
capture	NN	O
and/or	NN	O
background	NN	O
removal	NN	O
.	.	O
More	RBR	O
particularly	RB	O
,	,	O
positive	JJ	O
selection	NN	O
of	IN	O
the	DT	O
transduced	JJ	O
cells	NNS	O
can	MD	O
be	VB	O
performed	VBN	O
using	VBG	O
a	DT	O
FACS	NNP	O
cell	NN	O
sorter	NN	O
(	(	O
e.g	NN	O
.	.	O
a	DT	O
FACSVantage™	NNP	O
Cell	NNP	O
Sorter	NNP	O
,	,	O
Becton	NNP	O
Dickinson	NNP	O
Immunocytometry	NNP	O
Systems	NNPS	O
,	,	O
San	NNP	O
Jose	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
to	TO	O
sort	VB	O
and	CC	O
collect	VB	O
transduced	JJ	O
cells	NNS	O
expressing	VBG	O
a	DT	O
selectable	JJ	O
cell	NN	O
surface	NN	O
marker	NN	O
.	.	O
Following	VBG	O
transduction	NN	O
,	,	O
the	DT	O
cells	NNS	O
are	VBP	O
stained	VBN	O
with	IN	O
fluorescent-labeled	JJ	O
antibody	NN	O
molecules	NNS	O
directed	VBN	O
against	IN	O
the	DT	O
particular	JJ	O
cell	NN	O
surface	NN	O
marker	NN	O
.	.	O
The	DT	O
amount	NN	O
of	IN	O
bound	NN	O
antibody	NN	O
on	IN	O
each	DT	O
cell	NN	O
can	MD	O
be	VB	O
measured	VBN	O
by	IN	O
passing	VBG	O
droplets	NNS	O
containing	VBG	O
the	DT	O
cells	NNS	O
through	IN	O
the	DT	O
cell	NN	O
sorter	NN	O
.	.	O
By	IN	O
imparting	VBG	O
an	DT	O
electromagnetic	JJ	O
charge	NN	O
to	TO	O
droplets	NNS	O
containing	VBG	O
the	DT	O
stained	JJ	O
cells	NNS	O
,	,	O
the	DT	O
transduced	JJ	O
cells	NNS	O
can	MD	O
be	VB	O
separated	VBN	O
from	IN	O
other	JJ	O
cells	NNS	O
.	.	O
The	DT	O
positively	RB	O
selected	VBN	O
cells	NNS	O
are	VBP	O
then	RB	O
harvested	VBN	O
in	IN	O
sterile	JJ	O
collection	NN	O
vessels	NNS	O
.	.	O
These	DT	O
cell	NN	O
sorting	NN	O
procedures	NNS	O
are	VBP	O
described	VBN	O
in	IN	O
detail	NN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
in	IN	O
the	DT	O
FACSVantage™	NNP	O
Training	NNP	O
Manual	NNP	O
,	,	O
with	IN	O
particular	JJ	O
reference	NN	O
to	TO	O
sections	VB	O
3-11	JJ	O
to	TO	O
3-28	JJ	O
and	CC	O
10-1	JJ	O
to	TO	O
10-17	JJ	O
.	.	O
Positive	JJ	O
selection	NN	O
of	IN	O
the	DT	O
transduced	JJ	O
cells	NNS	O
can	MD	O
also	RB	O
be	VB	O
performed	VBN	O
using	VBG	O
magnetic	JJ	O
separation	NN	O
of	IN	O
cells	NNS	O
based	VBN	O
on	IN	O
expression	NN	O
or	CC	O
a	DT	O
particular	JJ	O
cell	NN	O
surface	NN	O
marker	NN	O
.	.	O
In	IN	O
such	JJ	O
separation	NN	O
techniques	NNS	O
,	,	O
cells	NNS	O
to	TO	O
be	VB	O
positively	RB	O
selected	VBN	O
are	VBP	O
first	JJ	O
contacted	VBN	O
with	IN	O
specific	JJ	O
binding	VBG	O
agent	NN	O
(	(	O
e.g.	NN	O
,	,	O
an	DT	O
antibody	NN	O
or	CC	O
reagent	VB	O
the	DT	O
interacts	NNS	O
specifically	RB	O
with	IN	O
the	DT	O
cell	NN	O
surface	NN	O
marker	NN	O
)	)	O
.	.	O
The	DT	O
cells	NNS	O
are	VBP	O
then	RB	O
contacted	VBN	O
with	IN	O
retrievable	JJ	O
particles	NNS	O
(	(	O
e.g.	NN	O
,	,	O
magnetically	RB	O
responsive	JJ	O
particles	NNS	O
)	)	O
which	WDT	O
are	VBP	O
coupled	VBN	O
with	IN	O
a	DT	O
reagent	NN	O
that	WDT	O
binds	VBZ	O
the	DT	O
specific	JJ	O
binding	NN	O
agent	NN	O
(	(	O
that	WDT	O
has	VBZ	O
bound	VBN	O
to	TO	O
the	DT	O
positive	JJ	O
cells	NNS	O
)	)	O
.	.	O
The	DT	O
cell-binding	JJ	O
agent-particle	NN	O
complex	NN	O
can	MD	O
then	RB	O
be	VB	O
physically	RB	O
separated	VBN	O
from	IN	O
non-labeled	JJ	O
cells	NNS	O
,	,	O
for	IN	O
example	NN	O
using	VBG	O
a	DT	O
magnetic	JJ	O
field	NN	O
.	.	O
When	WRB	O
using	VBG	O
magnetically	RB	O
responsive	JJ	O
particles	NNS	O
,	,	O
the	DT	O
labeled	JJ	O
cells	NNS	O
can	MD	O
be	VB	O
retained	VBN	O
in	IN	O
a	DT	O
container	NN	O
using	VBG	O
a	DT	O
magnetic	JJ	O
filed	VBN	O
while	IN	O
the	DT	O
negative	JJ	O
cells	NNS	O
are	VBP	O
removed	VBN	O
.	.	O
These	DT	O
and	CC	O
similar	JJ	O
separation	NN	O
procedures	NNS	O
are	VBP	O
known	VBN	O
to	TO	O
those	DT	O
of	IN	O
ordinary	JJ	O
skill	NN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
Expression	NN	O
of	IN	O
the	DT	O
vector	NN	O
in	IN	O
the	DT	O
selected	VBN	O
transduced	JJ	O
cells	NNS	O
can	MD	O
be	VB	O
assessed	VBN	O
by	IN	O
a	DT	O
number	NN	O
of	IN	O
assays	NNS	O
known	VBN	O
to	TO	O
those	DT	O
skilled	VBN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
Western	JJ	O
blot	NN	O
or	CC	O
Northern	NNP	O
analysis	NN	O
can	MD	O
be	VB	O
employed	VBN	O
depending	VBG	O
on	IN	O
the	DT	O
nature	NN	O
of	IN	O
the	DT	O
inserted	JJ	O
nucleotide	JJ	O
sequence	NN	O
of	IN	O
interest	NN	O
.	.	O
Once	RB	O
expression	NN	O
has	VBZ	O
been	VBN	O
established	VBN	O
and	CC	O
the	DT	O
transformed	JJ	O
T	NNP	O
cells	NNS	O
have	VBP	O
been	VBN	O
tested	VBN	O
for	IN	O
the	DT	O
presence	NN	O
of	IN	O
the	DT	O
selected	VBN	O
synthetic	JJ	O
expression	NN	O
cassette	NN	O
,	,	O
they	PRP	O
are	VBP	O
ready	JJ	O
for	IN	O
infusion	NN	O
into	IN	O
a	DT	O
patient	NN	O
via	IN	O
the	DT	O
peripheral	JJ	O
blood	NN	O
stream	NN	O
.	.	O
The	DT	O
invention	NN	O
includes	VBZ	O
a	DT	O
kit	NN	O
for	IN	O
genetic	JJ	O
modification	NN	O
of	IN	O
an	DT	O
ex	NN	O
vivo	JJ	O
population	NN	O
of	IN	O
primary	JJ	O
mammalian	JJ	O
cells	NNS	O
.	.	O
The	DT	O
kit	NN	O
typically	RB	O
contains	VBZ	O
a	DT	O
gene	NN	O
transfer	NN	O
vector	NN	O
coding	VBG	O
for	IN	O
at	IN	O
least	JJS	O
one	CD	O
selectable	JJ	O
marker	NN	O
and	CC	O
at	IN	O
least	JJS	O
one	CD	O
synthetic	JJ	O
expression	NN	O
cassette	NN	O
contained	VBN	O
in	IN	O
one	CD	O
or	CC	O
more	JJR	O
containers	NNS	O
,	,	O
ancillary	JJ	O
reagents	NNS	O
or	CC	O
hardware	NN	O
,	,	O
and	CC	O
instructions	NNS	O
for	IN	O
use	NN	O
of	IN	O
the	DT	O
kit	NN	O
.	.	O
EXPERIMENTAL	NNP	O
Below	NNP	O
are	VBP	O
examples	NNS	O
of	IN	O
specific	JJ	O
embodiments	NNS	O
for	IN	O
carrying	VBG	O
out	RP	O
the	DT	O
present	JJ	O
invention	NN	O
.	.	O
The	DT	O
examples	NNS	O
are	VBP	O
offered	VBN	O
for	IN	O
illustrative	JJ	O
purposes	NNS	O
only	RB	O
,	,	O
and	CC	O
are	VBP	O
not	RB	O
intended	VBN	O
to	TO	O
limit	VB	O
the	DT	O
scope	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
in	IN	O
any	DT	O
way	NN	O
.	.	O
Efforts	NNS	O
have	VBP	O
been	VBN	O
made	VBN	O
to	TO	O
ensure	VB	O
accuracy	NN	O
with	IN	O
respect	NN	O
to	TO	O
numbers	NNS	O
used	VBN	O
(	(	O
e.g.	JJ	O
,	,	O
amounts	NNS	O
,	,	O
temperatures	NNS	O
,	,	O
etc	FW	O
.	.	O
)	)	O
,	,	O
but	CC	O
some	DT	O
experimental	JJ	O
error	NN	O
and	CC	O
deviation	NN	O
should	MD	O
,	,	O
of	IN	O
course	NN	O
,	,	O
be	VB	O
allowed	VBN	O
for	IN	O
.	.	O
Example	RB	O
1	CD	O
Generation	NNP	O
of	IN	O
Synthetic	NNP	O
Gag	NNP	O
and	CC	O
Env	NNP	O
Expression	NNP	O
Cassettes	VBZ	O
A	DT	O
.	.	O
Modification	NN	O
of	IN	O
HIV-1	NNP	O
Gag	NNP	O
,	,	O
Gag-Protease	NNP	O
,	,	O
Gag-Reverse	NNP	O
Transcriptase	NNP	O
and	CC	O
Gag-Polymerase	NNP	O
Nucleic	NNP	O
Acid	NNP	O
Coding	NNP	O
Sequences	VBZ	O
The	DT	O
Gag	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:1	NNP	O
)	)	O
,	,	O
Gag-protease	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:2	NNP	O
)	)	O
,	,	O
Gag-polymerase	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:3	NNP	O
)	)	O
,	,	O
and	CC	O
Gag-reverse	JJ	O
transcriptase	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:77	NNP	O
)	)	O
coding	VBG	O
sequences	NNS	O
were	VBD	O
selected	VBN	O
from	IN	O
the	DT	O
HIV-1SF2	NNP	O
strain	NN	O
(	(	O
Sanchez-Pescador	NNP	B
,	,	I
R.	NNP	I
,	,	I
et	FW	I
al.	NN	I
,	,	I
Science	NNP	I
227	CD	I
(	(	I
4686	CD	I
)	)	I
:	:	I
484-492	CD	I
,	,	I
1985	CD	I
;	:	O
Luciw	NNP	B
,	,	I
P.	NNP	I
A.	NN	I
,	,	I
et	CC	I
al	NN	I
.	.	I
U.S.	NNP	I
Pat	NNP	I
.	.	I
No	DT	I
.	.	I
5,156,949	CD	I
,	,	I
issued	VBN	I
Oct.	NNP	I
20	CD	I
,	,	I
1992	CD	I
,	,	O
herein	RB	O
incorporated	VBN	O
by	IN	O
reference	NN	O
;	:	O
Luciw	NNP	B
,	,	I
P.	NNP	I
A.	NN	I
,	,	I
et	FW	I
al.	NN	I
,	,	I
U.S.	NNP	I
Pat	NNP	I
.	.	I
No	DT	I
.	.	I
5,688,688	CD	I
,	,	I
Nov.	NNP	I
18	CD	I
,	,	I
1997	CD	I
)	)	O
.	.	O
These	DT	O
sequences	NNS	O
were	VBD	O
manipulated	VBN	O
to	TO	O
maximize	VB	O
expression	NN	O
of	IN	O
their	PRP$	O
gene	NN	O
products	NNS	O
.	.	O
First	RB	O
,	,	O
the	DT	O
HIV-1	NNP	O
codon	NN	O
usage	NN	O
pattern	NN	O
was	VBD	O
modified	VBN	O
so	RB	O
that	IN	O
the	DT	O
resulting	VBG	O
nucleic	JJ	O
acid	NN	O
coding	VBG	O
sequence	NN	O
was	VBD	O
comparable	JJ	O
to	TO	O
codon	VB	O
usage	NN	O
found	VBN	O
in	IN	O
highly	RB	O
expressed	VBN	O
human	JJ	O
genes	NNS	O
.	.	O
The	DT	O
HIV	NNP	O
codon	NN	O
usage	NN	O
reflects	VBZ	O
a	DT	O
high	JJ	O
content	NN	O
of	IN	O
the	DT	O
nucleotides	NNS	O
A	NNP	O
or	CC	O
T	NNP	O
of	IN	O
the	DT	O
codon-triplet	NN	O
.	.	O
The	DT	O
effect	NN	O
of	IN	O
the	DT	O
HIV-1	NNP	O
codon	NN	O
usage	NN	O
is	VBZ	O
a	DT	O
high	JJ	O
AT	NNP	O
content	NN	O
in	IN	O
the	DT	O
DNA	NN	O
sequence	NN	O
that	WDT	O
results	NNS	O
in	IN	O
a	DT	O
high	JJ	O
AU	NNP	O
content	NN	O
in	IN	O
the	DT	O
RNA	NNP	O
and	CC	O
in	IN	O
a	DT	O
decreased	JJ	O
translation	NN	O
ability	NN	O
and	CC	O
instability	NN	O
of	IN	O
the	DT	O
mRNA	NN	O
.	.	O
In	IN	O
comparison	NN	O
,	,	O
highly	RB	O
expressed	VBN	O
human	JJ	O
codons	NNS	O
prefer	VBP	O
the	DT	O
nucleotides	NNS	O
G	NNP	O
or	CC	O
C.	NNP	O
The	DT	O
Gag-encoding	NNP	O
sequences	NNS	O
were	VBD	O
modified	VBN	O
to	TO	O
be	VB	O
comparable	JJ	O
to	TO	O
codon	VB	O
usage	NN	O
found	VBN	O
in	IN	O
highly	RB	O
expressed	VBN	O
human	JJ	O
genes	NNS	O
.	.	O
FIG	NNP	O
.	.	O
11	CD	O
presents	NNS	O
a	DT	O
comparison	NN	O
of	IN	O
the	DT	O
percent	NN	O
A-T	NNP	O
content	NN	O
for	IN	O
the	DT	O
cDNAs	NN	O
of	IN	O
stable	JJ	O
versus	NN	O
unstable	JJ	O
RNAs	NNP	O
(	(	O
comparison	NN	O
window	NN	O
size=50	NN	O
)	)	O
.	.	O
Human	NNP	O
IFNγ	NNP	O
mRNA	NN	O
is	VBZ	O
known	VBN	O
to	TO	O
(	(	O
i	VB	O
)	)	O
be	VB	O
unstable	JJ	O
,	,	O
(	(	O
ii	NN	O
)	)	O
have	VBP	O
a	DT	O
short	JJ	O
half-life	NN	O
,	,	O
and	CC	O
(	(	O
iii	NN	O
)	)	O
have	VBP	O
a	DT	O
high	JJ	O
A-U	JJ	O
content	NN	O
.	.	O
Human	NNP	O
GAPDH	NNP	O
(	(	O
glyceraldehyde-3-phosphate	JJ	O
dehydrogenase	NN	O
)	)	O
mRNA	NN	O
is	VBZ	O
known	VBN	O
to	TO	O
(	(	O
i	VB	O
)	)	O
be	VB	O
a	DT	O
stable	JJ	O
RNA	NNP	O
,	,	O
and	CC	O
(	(	O
i	NN	O
)	)	O
have	VBP	O
a	DT	O
low	JJ	O
A-U	NNP	O
content	NN	O
.	.	O
In	IN	O
FIG	NNP	O
.	.	O
11	CD	O
,	,	O
the	DT	O
percent	NN	O
A-T	NNP	O
content	NN	O
of	IN	O
these	DT	O
two	CD	O
sequences	NNS	O
are	VBP	O
compared	VBN	O
to	TO	O
the	DT	O
percent	NN	O
A-T	NNP	O
content	NN	O
of	IN	O
native	JJ	O
HIV-1SF2	NNP	O
Gag	NNP	O
cDNA	NN	O
and	CC	O
to	TO	O
the	DT	O
synthetic	JJ	O
Gag	NNP	O
cDNA	NN	O
sequence	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
.	.	O
The	DT	O
top	JJ	O
two	CD	O
panels	NNS	O
of	IN	O
the	DT	O
figure	NN	O
show	VBP	O
the	DT	O
percent	NN	O
A-T	NNP	O
content	NN	O
over	IN	O
the	DT	O
length	NN	O
of	IN	O
the	DT	O
sequences	NNS	O
for	IN	O
IFNγ	NNP	O
and	CC	O
native	JJ	O
Gag	NNP	O
.	.	O
The	DT	O
bottom	JJ	O
two	CD	O
panels	NNS	O
of	IN	O
the	DT	O
figure	NN	O
show	VBP	O
the	DT	O
percent	NN	O
A-T	NNP	O
content	NN	O
over	IN	O
the	DT	O
length	NN	O
of	IN	O
the	DT	O
sequences	NNS	O
for	IN	O
GAPDH	NNP	O
and	CC	O
the	DT	O
synthetic	JJ	O
Gag	NNP	O
.	.	O
Experiments	NNS	O
performed	VBN	O
in	IN	O
support	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
showed	VBD	O
that	IN	O
the	DT	O
synthetic	JJ	O
Gag	NNP	O
sequences	NNS	O
were	VBD	O
capable	JJ	O
of	IN	O
higher	JJR	O
level	NN	O
of	IN	O
protein	JJ	O
production	NN	O
(	(	O
see	VB	O
the	DT	O
Examples	NNP	O
)	)	O
than	IN	O
the	DT	O
native	JJ	O
Gag	NNP	O
sequences	NNS	O
.	.	O
The	DT	O
data	NN	O
in	IN	O
FIG	NNP	O
.	.	O
11	CD	O
suggest	JJS	O
that	IN	O
one	CD	O
reason	NN	O
for	IN	O
this	DT	O
increased	VBN	O
production	NN	O
may	MD	O
be	VB	O
increased	VBN	O
stability	NN	O
of	IN	O
the	DT	O
mRNA	NN	O
corresponding	VBG	O
to	TO	O
the	DT	O
synthetic	JJ	O
Gag	NNP	O
coding	NN	O
sequences	NNS	O
versus	VBP	O
the	DT	O
mRNA	NN	O
corresponding	VBG	O
to	TO	O
the	DT	O
native	JJ	O
Gag	NNP	O
coding	NN	O
sequences	NNS	O
.	.	O
Second	JJ	O
,	,	O
there	EX	O
are	VBP	O
inhibitory	JJ	O
(	(	O
or	CC	O
instability	NN	O
)	)	O
elements	NNS	O
(	(	O
INS	NNP	O
)	)	O
located	VBD	O
within	IN	O
the	DT	O
coding	VBG	O
sequences	NNS	O
of	IN	O
the	DT	O
Gag	NNP	O
and	CC	O
Gag-protease	NNP	O
coding	NN	O
sequences	NNS	O
(	(	O
Schneider	NNP	B
R	NNP	I
,	,	I
et	FW	I
al.	NN	I
,	,	I
J.	NNP	I
Virol	NNP	I
.	.	I
71	CD	I
(	(	I
7	CD	I
)	)	I
:4892-4903	NN	I
,	,	I
1997	CD	I
)	)	O
.	.	O
RRE	NNP	O
is	VBZ	O
a	DT	O
secondary	JJ	O
RNA	NNP	O
structure	NN	O
that	WDT	O
interacts	VBZ	O
with	IN	O
the	DT	O
HIV	NNP	O
encoded	VBD	O
Rev-protein	NNP	O
to	TO	O
overcome	VB	O
the	DT	O
expression	NN	O
down-regulating	JJ	O
effects	NNS	O
of	IN	O
the	DT	O
INS	NNP	O
.	.	O
To	TO	O
overcome	VB	O
the	DT	O
requirement	NN	O
for	IN	O
post-transcriptional	JJ	O
activating	VBG	O
mechanisms	NN	O
of	IN	O
RRE	NNP	O
and	CC	O
Rev	NNP	O
,	,	O
and	CC	O
to	TO	O
enhance	VB	O
independent	JJ	O
expression	NN	O
of	IN	O
the	DT	O
Gag	NNP	O
polypeptide	NN	O
,	,	O
the	DT	O
INS	NNP	O
were	VBD	O
inactivated	VBN	O
by	IN	O
introducing	VBG	O
multiple	JJ	O
point	NN	O
mutations	NNS	O
that	WDT	O
did	VBD	O
not	RB	O
alter	VB	O
the	DT	O
reading	NN	O
frame	NN	O
of	IN	O
the	DT	O
encoded	JJ	O
proteins	NNS	O
.	.	O
FIG	NNP	O
.	.	O
1	CD	O
shows	VBZ	O
the	DT	O
original	JJ	O
SF2	NNP	O
Gag	NNP	O
sequence	NN	O
,	,	O
the	DT	O
location	NN	O
of	IN	O
the	DT	O
INS	NNP	O
sequences	NNS	O
,	,	O
and	CC	O
the	DT	O
modifications	NNS	O
made	VBN	O
to	TO	O
the	DT	O
INS	NNP	O
sequences	NNS	O
to	TO	O
reduce	VB	O
their	PRP$	O
effects	NNS	O
.	.	O
For	IN	O
the	DT	O
Gag-protease	NNP	O
sequence	NN	O
(	(	O
wild	JJ	O
type	NN	O
,	,	O
SEQ	NNP	O
ID	NNP	O
NO:2	NNP	O
;	:	O
synthetic	JJ	O
,	,	O
SEQ	NNP	O
ID	NNP	O
NOs:5	NNP	O
,	,	O
78	CD	O
and	CC	O
79	CD	O
)	)	O
,	,	O
the	DT	O
changes	NNS	O
in	IN	O
codon	NN	O
usage	NN	O
were	VBD	O
restricted	VBN	O
to	TO	O
the	DT	O
regions	NNS	O
up	IN	O
to	TO	O
the	DT	O
−1	NNP	O
frameshift	NN	O
and	CC	O
starting	VBG	O
again	RB	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
Gag	NNP	O
reading	NN	O
frame	NN	O
(	(	O
FIG	NNP	O
.	.	O
2	CD	O
;	:	O
the	DT	O
region	NN	O
indicated	VBD	O
in	IN	O
lower	JJR	O
case	NN	O
letters	NNS	O
in	IN	O
FIG	NNP	O
.	.	O
2	CD	O
is	VBZ	O
the	DT	O
unmodified	JJ	O
region	NN	O
)	)	O
.	.	O
Further	RB	O
,	,	O
inhibitory	NN	O
(	(	O
or	CC	O
instability	NN	O
)	)	O
elements	NNS	O
(	(	O
INS	NNP	O
)	)	O
located	VBD	O
within	IN	O
the	DT	O
coding	VBG	O
sequences	NNS	O
of	IN	O
the	DT	O
Gag-protease	NNP	O
polypeptide	NN	O
coding	VBG	O
sequence	NN	O
were	VBD	O
altered	VBN	O
as	RB	O
well	RB	O
(	(	O
indicated	VBN	O
in	IN	O
FIG	NNP	O
.	.	O
2	CD	O
)	)	O
.	.	O
The	DT	O
synthetic	JJ	O
coding	NN	O
sequences	NNS	O
were	VBD	O
assembled	VBN	O
by	IN	O
the	DT	O
Midland	NNP	O
Certified	NNP	O
Reagent	NNP	O
Company	NNP	O
(	(	O
Midland	NNP	O
,	,	O
Tex	NNP	O
.	.	O
)	)	O
.	.	O
Modification	NN	O
of	IN	O
the	DT	O
Gag-polymerase	NNP	O
sequences	NNS	O
(	(	O
wild	JJ	O
type	NN	O
,	,	O
SEQ	NNP	O
ID	NNP	O
NO:3	NNP	O
;	:	O
synthetic	JJ	O
,	,	O
SEQ	NNP	O
ID	NNP	O
NO:6	NNP	O
)	)	O
and	CC	O
Gag-reverse	JJ	O
transcriptase	NN	O
sequences	NNS	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NOs:80	NNP	O
through	IN	O
84	CD	O
)	)	O
include	VBP	O
similar	JJ	O
modifications	NNS	O
as	IN	O
described	VBN	O
for	IN	O
Gag-protease	NNP	O
in	IN	O
order	NN	O
to	TO	O
preserve	VB	O
the	DT	O
frameshift	JJ	O
region	NN	O
.	.	O
Locations	NNS	O
of	IN	O
the	DT	O
inactivation	NN	O
sites	VBZ	O
and	CC	O
changes	NNS	O
to	TO	O
the	DT	O
sequence	NN	O
to	TO	O
alter	VB	O
the	DT	O
inactivation	NN	O
sites	NNS	O
are	VBP	O
presented	VBN	O
in	IN	O
FIG	NNP	O
.	.	O
12	CD	O
for	IN	O
the	DT	O
native	JJ	O
HIV-1SF2	NNP	O
Gag-polymerase	NNP	O
sequence	NN	O
.	.	O
In	IN	O
one	CD	O
embodiment	NN	O
of	IN	O
the	DT	O
invention	NN	O
,	,	O
the	DT	O
full	JJ	O
length	NN	O
polymerase	NN	O
coding	VBG	O
region	NN	O
of	IN	O
the	DT	O
Gag-polymerase	NNP	O
sequence	NN	O
is	VBZ	O
included	VBN	O
with	IN	O
the	DT	O
synthetic	JJ	O
Gag	NNP	O
sequences	NNS	O
in	IN	O
order	NN	O
to	TO	O
increase	VB	O
the	DT	O
number	NN	O
of	IN	O
epitopes	NNS	O
for	IN	O
virus-like	JJ	O
particles	NNS	O
expressed	VBN	O
by	IN	O
the	DT	O
synthetic	JJ	O
,	,	O
optimized	JJ	O
Gag	NNP	O
expression	NN	O
cassette	NN	O
.	.	O
Because	IN	O
synthetic	JJ	O
HIV-1	NNP	O
Gag-polymerase	NNP	O
expresses	VBZ	O
the	DT	O
potentially	RB	O
deleterious	JJ	O
functional	JJ	O
enzymes	NNS	O
reverse	JJ	O
transcriptase	NN	O
(	(	O
RT	NNP	O
)	)	O
and	CC	O
integrase	NN	O
(	(	O
INT	NNP	O
)	)	O
(	(	O
in	IN	O
addition	NN	O
to	TO	O
the	DT	O
structural	JJ	O
proteins	NNS	O
and	CC	O
protease	NN	O
)	)	O
,	,	O
it	PRP	O
is	VBZ	O
important	JJ	O
to	TO	O
inactivate	VB	O
RT	NNP	O
and	CC	O
INT	NNP	O
functions	NNS	O
.	.	O
Several	JJ	O
in-frame	JJ	O
deletions	NNS	O
in	IN	O
the	DT	O
RT	NNP	O
and	CC	O
INT	NNP	O
reading	NN	O
frame	NN	O
can	MD	O
be	VB	O
made	VBN	O
to	TO	O
achieve	VB	O
catalytic	JJ	O
nonfunctional	JJ	O
enzymes	NNS	O
with	IN	O
respect	NN	O
to	TO	O
their	PRP$	O
RT	NNP	O
and	CC	O
INT	NNP	O
activity	NN	O
.	.	O
{	(	O
Jay	NNP	B
.	.	I
A	DT	I
.	.	I
Levy	NNP	I
(	(	I
Editor	NNP	I
)	)	I
(	(	I
1995	CD	I
)	)	I
The	DT	I
Retroviridae	NNP	I
,	,	I
Plenum	NNP	I
Press	NNP	I
,	,	I
New	NNP	I
York	NNP	I
.	.	I
ISBN	NNP	I
0-306-45033X	NN	I
.	.	I
Pages	NNS	I
215-20	CD	I
;	:	O
Grimison	NNP	B
,	,	I
B.	NNP	I
and	CC	I
Laurence	NNP	I
,	,	I
J	NNP	I
.	.	I
(	(	I
1995	CD	I
)	)	I
,	,	I
Journal	NNP	I
Of	IN	I
Acquired	NNP	I
Immune	NNP	I
Deficiency	NNP	I
Syndromes	NNP	I
and	CC	I
Human	NNP	I
Retrovirology	NNP	I
9	CD	I
(	(	I
1	CD	I
)	)	I
:58-68	NN	I
;	:	O
Wakefield	NNP	B
,	,	I
J.	NNP	I
K.	NNP	I
,	,	I
et	FW	I
al.	NN	I
,	,	I
(	(	I
1992	CD	I
)	)	I
Journal	NNP	I
Of	IN	I
Virology	NNP	I
66	NNP	I
(	(	I
11	CD	I
)	)	I
:6806-6812	NN	I
;	:	O
Esnouf	NNP	B
,	,	I
R.	NNP	I
,	,	I
et	FW	I
al.	NN	I
,	,	I
(	(	I
1995	CD	I
)	)	I
Nature	NNP	I
Structural	NNP	I
Biology	NNP	I
2	CD	I
(	(	I
4	CD	I
)	)	I
:303-308	NN	I
;	:	O
Maignan	NNP	B
,	,	I
S.	NNP	I
,	,	I
et	FW	I
al.	NN	I
,	,	I
(	(	I
1998	CD	I
)	)	I
Journal	NNP	I
Of	IN	I
Molecular	NNP	I
Biology	NNP	I
282	CD	I
(	(	I
2	CD	I
)	)	I
:359-368	NN	I
;	:	O
Katz	NNP	B
,	,	I
R.	NNP	I
A.	NN	I
and	CC	I
Skalka	NNP	I
,	,	I
A.	NNP	I
M.	NNP	I
(	(	I
1994	CD	I
)	)	I
Annual	NNP	I
Review	NNP	I
Of	IN	I
Biochemistry	NNP	I
73	CD	I
(	(	I
1994	CD	I
)	)	I
;	:	O
Jacobo-Molina	NNP	B
,	,	I
A.	NNP	I
,	,	I
et	FW	I
al.	NN	I
,	,	I
(	(	I
1993	CD	I
)	)	I
Proceedings	NNS	I
Of	IN	I
the	DT	I
National	NNP	I
Academy	NNP	I
Of	IN	I
Sciences	NNPS	I
Of	IN	I
the	DT	I
United	NNP	I
States	NNPS	I
Of	IN	I
America	NNP	I
90	CD	I
(	(	I
13	CD	I
)	)	I
:6320-6324	NN	I
;	:	O
Hickman	NNP	B
,	,	I
A	NNP	I
.	.	I
B.	NNP	I
,	,	I
et	FW	I
al.	NN	I
,	,	I
(	(	I
1994	CD	I
)	)	I
Journal	NNP	I
Of	IN	I
Biological	NNP	I
Chemistry	NNP	I
269	CD	I
(	(	I
46	CD	I
)	)	I
:29279-29287	NN	I
;	:	O
Goldgur	NNP	B
,	,	I
Y.	NNP	I
,	,	I
et	FW	I
al.	NN	I
,	,	I
(	(	I
1998	CD	I
)	)	I
Proceedings	NNS	I
Of	IN	I
the	DT	I
National	NNP	I
Academy	NNP	I
Of	IN	I
Sciences	NNPS	I
Of	IN	I
the	DT	I
United	NNP	I
States	NNPS	I
Of	IN	I
America	NNP	I
95	CD	I
(	(	I
16	CD	I
)	)	I
:9150-9154	NN	I
;	:	O
Goette	NNP	B
,	,	I
M.	NNP	I
,	,	I
et	FW	I
al.	NN	I
,	,	I
(	(	I
1998	CD	I
)	)	I
Journal	NNP	I
Of	IN	I
Biological	NNP	I
Chemistry	NNP	I
273	CD	I
(	(	I
17	CD	I
)	)	I
:10139-10146	NN	I
;	:	O
Gorton	NNP	B
,	,	I
J.	NNP	I
L.	NNP	I
,	,	I
et	FW	I
al.	NN	I
,	,	I
(	(	I
1998	CD	I
)	)	I
Journal	NNP	I
of	IN	I
Virology	NNP	I
72	NNP	I
(	(	I
6	CD	I
)	)	I
:5046-5055	NN	I
;	:	O
Engelman	NNP	B
,	,	I
A.	NNP	I
,	,	I
et	FW	I
al.	NN	I
,	,	I
(	(	I
1997	CD	I
)	)	I
Journal	NNP	I
Of	IN	I
Virology	NNP	I
71	NNP	I
(	(	I
5	CD	I
)	)	I
:3507-3514	NN	I
;	:	O
Dyda	NNP	B
,	,	I
F.	NNP	I
,	,	I
et	NN	I
al.	NN	I
,	,	I
Science	NNP	I
266	CD	I
(	(	I
5193	CD	I
)	)	I
:1981-1986	NN	I
;	:	O
Davies	NNP	B
,	,	I
J.	NNP	I
F.	NNP	I
,	,	I
et	NN	I
al.	NN	I
,	,	I
(	(	I
1991	CD	I
)	)	I
Science	NN	I
252	CD	I
(	(	I
5002	CD	I
)	)	I
:88-95	NN	I
;	:	O
Bujacz	NNP	B
,	,	I
G.	NNP	I
,	,	I
et	FW	I
al.	NN	I
,	,	I
(	(	I
1996	CD	I
)	)	I
Febs	NNP	I
Letters	NNP	I
398	CD	I
(	(	I
2-3	CD	I
)	)	I
:175-178	NN	I
;	:	O
Beard	NNP	B
,	,	I
W.	NNP	I
A.	NN	I
,	,	I
et	FW	I
al.	NN	I
,	,	I
(	(	I
1996	CD	I
)	)	I
Journal	NNP	I
Of	IN	I
Biological	NNP	I
Chemistry	NNP	I
271	CD	I
(	(	I
21	CD	I
)	)	I
:12213-12220	NN	I
;	:	O
Kohlstaedt	NNP	B
,	,	I
L.	NNP	I
A.	NNP	I
,	,	I
et	FW	I
al.	NN	I
,	,	I
(	(	I
1992	CD	I
)	)	I
Science	NN	I
256	CD	I
(	(	I
5065	CD	I
)	)	I
:1783-1790	NN	I
;	:	O
Krug	NNP	B
,	,	I
M.	NNP	I
S	NNP	I
,	,	I
and	CC	I
Berger	NNP	I
,	,	I
S.	NNP	I
L.	NNP	I
(	(	I
1991	CD	I
)	)	I
Biochemistry	NN	I
30	CD	I
(	(	I
44	CD	I
)	)	I
:10614-10623	NN	I
;	:	O
Mazumder	NNP	B
,	,	I
A.	NNP	I
,	,	I
et	FW	I
al.	NN	I
,	,	I
(	(	I
1996	CD	I
)	)	I
Molecular	NNP	I
Pharmacology	NNP	I
49	CD	I
(	(	I
4	CD	I
)	)	I
:621-628	NN	I
;	:	O
Palaniappan	NNP	B
,	,	I
C.	NNP	I
,	,	I
et	FW	I
al.	NN	I
,	,	I
(	(	I
1997	CD	I
)	)	I
Journal	NNP	I
Of	IN	I
Biological	NNP	I
Chemistry	NNP	I
272	CD	I
(	(	I
17	CD	I
)	)	I
:11157-11164	NN	I
;	:	O
Rodgers	NNP	B
,	,	I
D.	NNP	I
W.	NNP	I
,	,	I
et	FW	I
al.	NN	I
,	,	I
(	(	I
1995	CD	I
)	)	I
Proceedings	NNS	I
Of	IN	I
the	DT	I
National	NNP	I
Academy	NNP	I
Of	IN	I
Sciences	NNPS	I
Of	IN	I
the	DT	I
United	NNP	I
States	NNPS	I
Of	IN	I
America	NNP	I
92	CD	I
(	(	I
4	CD	I
)	)	I
:1222-1226	NN	I
;	:	O
Sheng	NNP	B
,	,	I
N.	NNP	I
and	CC	I
Dennis	NNP	I
,	,	I
D.	NNP	I
(	(	I
1993	CD	I
)	)	I
Biochemistry	NN	I
32	CD	I
(	(	I
18	CD	I
)	)	I
:4938-4942	NN	I
;	:	O
Spence	NNP	B
,	,	I
R.	NNP	I
A.	NN	I
,	,	I
et	FW	I
al.	NN	I
,	,	I
(	(	I
1995	CD	I
)	)	I
Science	NN	I
267	CD	I
(	(	I
5200	CD	I
)	)	I
:988-993	NN	I
.	.	O
}	)	O
Furthermore	RB	O
selected	VBN	O
B-	NNP	O
and/or	JJ	O
T-cell	NNP	O
epitopes	NNS	O
can	MD	O
be	VB	O
added	VBN	O
to	TO	O
the	DT	O
Gag-polymerase	NNP	O
constructs	NNS	O
within	IN	O
the	DT	O
deletions	NNS	O
of	IN	O
the	DT	O
RT-	NNP	O
and	CC	O
INT-coding	NNP	O
sequence	NN	O
to	TO	O
replace	VB	O
and	CC	O
augment	VB	O
any	DT	O
epitopes	NNS	O
deleted	VBN	O
by	IN	O
the	DT	O
functional	JJ	O
modifications	NNS	O
of	IN	O
RT	NNP	O
and	CC	O
INT	NNP	O
.	.	O
Alternately	RB	O
,	,	O
selected	VBN	O
B-	NNP	O
and	CC	O
T-cell	NNP	O
epitopes	NNS	O
(	(	O
including	VBG	O
CTL	NNP	O
epitopes	NNS	O
)	)	O
from	IN	O
RT	NNP	O
and	CC	O
INT	NNP	O
can	MD	O
be	VB	O
included	VBN	O
in	IN	O
a	DT	O
minimal	JJ	O
VLP	NNP	O
formed	VBN	O
by	IN	O
expression	NN	O
of	IN	O
the	DT	O
synthetic	JJ	O
Gag	NNP	O
or	CC	O
synthetic	JJ	O
GagProt	NNP	O
cassette	NN	O
,	,	O
described	VBN	O
above	IN	O
.	.	O
(	(	O
For	IN	O
descriptions	NNS	O
of	IN	O
known	VBN	O
HIV	NNP	O
B-	NNP	O
and	CC	O
T-cell	NNP	O
epitopes	NNS	O
see	VBP	O
,	,	O
HIV	NNP	B
Molecular	NNP	I
Immunology	NNP	I
Database	NNP	I
CTL	NNP	I
Search	NNP	I
Interface	NNP	I
;	:	I
Los	NNP	I
Alamos	NNP	I
Sequence	NNP	I
Compendia	NNP	I
,	,	I
1987-1997	JJ	I
;	:	O
Internet	NNP	O
address	NN	O
:	:	O
http	NN	O
:	:	O
//hiv-web.lan1.gov/immunology/index.html	JJ	O
.	.	O
)	)	O
The	DT	O
resulting	VBG	O
modified	JJ	O
coding	NN	O
sequences	NNS	O
are	VBP	O
presented	VBN	O
as	IN	O
a	DT	O
synthetic	JJ	O
Gag	NNP	O
expression	NN	O
cassette	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:4	NNP	O
)	)	O
,	,	O
a	DT	O
synthetic	JJ	O
Gag-protease	NNP	O
expression	NN	O
cassette	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NOs:5	NNP	O
,	,	O
78	CD	O
and	CC	O
79	CD	O
)	)	O
,	,	O
and	CC	O
a	DT	O
synthetic	JJ	O
Gag-polymerase	NNP	O
expression	NN	O
cassette	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:6	NNP	O
)	)	O
.	.	O
Synthetic	JJ	O
expression	NN	O
cassettes	NNS	O
containing	VBG	O
codon	NN	O
modifications	NNS	O
in	IN	O
the	DT	O
reverse	NN	O
transcriptase	NN	O
region	NN	O
are	VBP	O
shown	VBN	O
in	IN	O
SEQ	NNP	O
ID	NNP	O
NOs:80	NNP	O
through	IN	O
84	CD	O
.	.	O
An	DT	O
alignment	NN	O
of	IN	O
selected	VBN	O
sequences	NNS	O
is	VBZ	O
presented	VBN	O
in	IN	O
FIG	NNP	O
.	.	O
7	CD	O
.	.	O
A	DT	O
common	JJ	O
region	NN	O
(	(	O
Gag-common	NNP	O
;	:	O
SEQ	NNP	O
ID	NNP	O
NO:9	NNP	O
)	)	O
extends	VBZ	O
from	IN	O
position	NN	O
1	CD	O
to	TO	O
position	NN	O
1262	CD	O
.	.	O
The	DT	O
synthetic	JJ	O
DNA	NN	O
fragments	NNS	O
for	IN	O
Gag	NNP	O
and	CC	O
Gag-protease	NNP	O
were	VBD	O
cloned	VBN	O
into	IN	O
the	DT	O
following	JJ	O
expression	NN	O
vectors	NNS	O
:	:	O
pCMVKm2	NN	O
,	,	O
for	IN	O
transient	JJ	O
expression	NN	O
assays	NNS	O
and	CC	O
DNA	NNP	O
immunization	NN	O
studies	NNS	O
,	,	O
the	DT	O
pCMVKm2	NN	O
vector	NN	O
was	VBD	O
derived	VBN	O
from	IN	O
pCMV6a	NN	O
(	(	O
Chapman	NNP	B
et	VBZ	I
al.	NN	I
,	,	I
Nuc	NNP	I
.	.	I
Acids	NNP	I
Res	NNP	I
.	.	I
(	(	I
1991	CD	I
)	)	I
19:3979-3986	CD	I
)	)	O
and	CC	O
comprises	VBZ	O
a	DT	O
kanamycin	NN	O
selectable	JJ	O
marker	NN	O
,	,	O
a	DT	O
ColE1	NNP	O
origin	NN	O
of	IN	O
replication	NN	O
,	,	O
a	DT	O
CMV	NNP	O
promoter	NN	O
enhancer	NN	O
and	CC	O
Intron	NNP	O
A	NNP	O
,	,	O
followed	VBN	O
by	IN	O
an	DT	O
insertion	NN	O
site	NN	O
for	IN	O
the	DT	O
synthetic	JJ	O
sequences	NNS	O
described	VBN	O
below	IN	O
followed	VBN	O
by	IN	O
a	DT	O
polyadenylation	NN	O
signal	NN	O
derived	VBN	O
from	IN	O
bovine	NN	O
growth	NN	O
hormone—the	VBP	O
pCMVKm2	NN	O
vector	NN	O
differs	NNS	O
from	IN	O
the	DT	O
pCMV-link	NN	O
vector	NN	O
only	RB	O
in	IN	O
that	DT	O
a	DT	O
polylinker	NN	O
site	NN	O
was	VBD	O
inserted	VBN	O
into	IN	O
pCMVKm2	NN	O
to	TO	O
generate	VB	O
pCMV-link	NN	O
(	(	O
FIG	NNP	O
.	.	O
14	CD	O
,	,	O
polylinker	NN	O
at	IN	O
positions	NNS	O
1646	CD	O
to	TO	O
1697	CD	O
)	)	O
;	:	O
pESN2dhfr	NN	O
(	(	O
FIG	NNP	O
.	.	O
13A	CD	O
)	)	O
and	CC	O
pCMVPLEdhfr	NN	O
(	(	O
also	RB	O
known	VBN	O
as	RB	O
pCMVIII	NN	O
as	IN	O
shown	VBN	O
in	IN	O
FIG	NNP	O
.	.	O
13B	CD	O
)	)	O
,	,	O
for	IN	O
expression	NN	O
in	IN	O
Chinese	JJ	O
Hamster	NNP	O
Ovary	NNP	O
(	(	O
CHO	NNP	O
)	)	O
cells	NNS	O
;	:	O
and	CC	O
,	,	O
pAcC13	NN	O
,	,	O
a	DT	O
shuttle	JJ	O
vector	NN	O
for	IN	O
use	NN	O
in	IN	O
the	DT	O
Baculovirus	NNP	O
expression	NN	O
system	NN	O
(	(	O
pAcC13	NN	O
,	,	O
was	VBD	O
derived	VBN	O
from	IN	O
pAcC12	NN	O
which	WDT	O
was	VBD	O
described	VBN	O
by	IN	O
Munemitsu	NNP	B
S.	NNP	I
,	,	I
et	FW	I
al.	NN	I
,	,	I
Mol	NNP	I
Cell	NNP	I
Biol	NNP	I
.	.	I
10	CD	I
(	(	I
11	CD	I
)	)	I
:5977-5982	NN	I
,	,	I
1990	CD	I
)	)	O
.	.	O
A	DT	O
restriction	NN	O
map	NN	O
for	IN	O
vector	NN	O
pCMV-link	NN	O
is	VBZ	O
presented	VBN	O
in	IN	O
FIG	NNP	O
.	.	O
14	CD	O
.	.	O
In	IN	O
the	DT	O
figure	NN	O
,	,	O
the	DT	O
CMV	NNP	O
promoter	NN	O
(	(	O
CMV	NNP	O
IE	NNP	O
ENH/PRO	NNP	O
)	)	O
,	,	O
bovine	JJ	O
growth	NN	O
hormone	NN	O
terminator	NN	O
(	(	O
BGH	NNP	O
pA	NN	O
)	)	O
,	,	O
kanamycin	FW	O
selectable	JJ	O
marker	NN	O
(	(	O
kan	NN	O
)	)	O
,	,	O
and	CC	O
a	DT	O
ColE1	NNP	O
origin	NN	O
of	IN	O
replication	NN	O
(	(	O
ColE1	NNP	O
ori	RB	O
)	)	O
are	VBP	O
indicated	VBN	O
.	.	O
A	DT	O
polycloning	NN	O
site	NN	O
is	VBZ	O
also	RB	O
indicated	VBN	O
in	IN	O
the	DT	O
figure	NN	O
following	VBG	O
the	DT	O
CMV	NNP	O
promoter	NN	O
sequences	NNS	O
.	.	O
A	DT	O
restriction	NN	O
map	NN	O
for	IN	O
vector	NN	O
pESN2dhfr	NN	O
is	VBZ	O
presented	VBN	O
in	IN	O
FIG	NNP	O
.	.	O
13A	CD	O
.	.	O
In	IN	O
the	DT	O
figure	NN	O
,	,	O
the	DT	O
CMV	NNP	O
promoter	NN	O
(	(	O
pCMV	NN	O
,	,	O
hCMVIE	NN	O
)	)	O
,	,	O
bovine	JJ	O
growth	NN	O
hormone	NN	O
terminator	NN	O
(	(	O
BGHpA	NNP	O
)	)	O
,	,	O
SV40	NNP	O
origin	NN	O
of	IN	O
replication	NN	O
(	(	O
SV40ori	NNP	O
)	)	O
,	,	O
neomycin	RB	O
selectable	JJ	O
marker	NN	O
(	(	O
Neo	NNP	O
)	)	O
,	,	O
SV40	NNP	O
polyA	NN	O
(	(	O
SV40pA	NNP	O
)	)	O
,	,	O
Adenovirus	NNP	O
2	CD	O
late	JJ	O
promoter	NN	O
(	(	O
Ad2VLP	NNP	O
)	)	O
,	,	O
and	CC	O
the	DT	O
murine	NN	O
dhfr	NN	O
gene	NN	O
(	(	O
mu	JJ	O
dhfr	NN	O
)	)	O
are	VBP	O
indicated	VBN	O
.	.	O
A	DT	O
polycloning	NN	O
site	NN	O
is	VBZ	O
also	RB	O
indicated	VBN	O
in	IN	O
the	DT	O
figure	NN	O
following	VBG	O
the	DT	O
CMV	NNP	O
promoter	NN	O
sequences	NNS	O
.	.	O
Briefly	NNP	O
,	,	O
construction	NN	O
of	IN	O
pCMVPLEdhfr	NN	O
(	(	O
pCMVIII	NN	O
)	)	O
was	VBD	O
as	IN	O
follows	VBZ	O
.	.	O
To	TO	O
construct	VB	O
a	DT	O
DHFR	NNP	O
cassette	NN	O
,	,	O
the	DT	O
EMCV	NNP	O
IRES	NNP	O
(	(	O
internal	JJ	O
ribosome	NN	O
entry	NN	O
site	NN	O
)	)	O
leader	NN	O
was	VBD	O
PCR-amplified	JJ	O
from	IN	O
pCite-4-a+	NN	O
(	(	O
Novagen	NNP	O
,	,	O
Inc.	NNP	O
,	,	O
Milwaukee	NNP	O
,	,	O
Wis.	NNP	O
)	)	O
and	CC	O
inserted	VBN	O
into	IN	O
pET-23d	NN	O
(	(	O
Novagen	NNP	O
,	,	O
Inc.	NNP	O
,	,	O
Milwaukee	NNP	O
,	,	O
Wis.	NNP	O
)	)	O
as	IN	O
an	DT	O
Xba-Nco	JJ	O
fragment	NN	O
to	TO	O
give	VB	O
pET-EMCV	NN	O
.	.	O
The	DT	O
dhfr	NN	O
gene	NN	O
was	VBD	O
PCR-amplified	VBN	O
from	IN	O
pESN2dhfr	NN	O
to	TO	O
give	VB	O
a	DT	O
product	NN	O
with	IN	O
a	DT	O
Gly-Gly-Gly-Ser	JJ	O
spacer	NN	O
in	IN	O
place	NN	O
of	IN	O
the	DT	O
translation	NN	O
stop	NN	O
codon	NN	O
and	CC	O
inserted	VBN	O
as	IN	O
an	DT	O
Nco-BamH1	JJ	O
fragment	NN	O
to	TO	O
give	VB	O
pET-E-DHFR	NN	O
.	.	O
Next	RB	O
,	,	O
the	DT	O
attenuated	VBN	O
neo	JJ	O
gene	NN	O
was	VBD	O
PCR	NNP	O
amplified	VBD	O
from	IN	O
a	DT	O
pSV2Neo	NN	O
(	(	O
Clontech	NNP	O
,	,	O
Palo	NNP	O
Alto	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
derivative	NN	O
and	CC	O
inserted	VBN	O
into	IN	O
the	DT	O
unique	JJ	O
BamH1	NNP	O
site	NN	O
of	IN	O
pET-E-DHFR	JJ	O
to	TO	O
give	VB	O
pET-E-DHFR/Neo	NN	O
(	(	O
m2	NN	O
)	)	O
.	.	O
Then	RB	O
,	,	O
the	DT	O
bovine	NN	O
growth	NN	O
hormone	NN	O
terminator	NN	O
from	IN	O
pcDNA3	NN	O
(	(	O
Invitrogen	NNP	O
,	,	O
Inc.	NNP	O
,	,	O
Carlsbad	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
was	VBD	O
inserted	VBN	O
downstream	NN	O
of	IN	O
the	DT	O
neo	JJ	O
gene	NN	O
to	TO	O
give	VB	O
pET-E-DHFR/Neo	NN	O
(	(	O
m2	NN	O
)	)	O
BGHt	NNP	O
.	.	O
The	DT	O
EMCV-dhfr/neo	NNP	O
selectable	JJ	O
marker	NN	O
cassette	NN	O
fragment	NN	O
was	VBD	O
prepared	VBN	O
by	IN	O
cleavage	NN	O
of	IN	O
pET-E-DHFR/Neo	NN	O
(	(	O
m2	NN	O
)	)	O
BGHt	NNP	O
.	.	O
The	DT	O
CMV	NNP	O
enhancer/promoter	NN	O
plus	CC	O
Intron	NNP	O
A	NNP	O
was	VBD	O
transferred	VBN	O
from	IN	O
pCMV6a	NN	O
(	(	O
Chapman	NNP	B
et	VBZ	I
al.	NN	I
,	,	I
Nuc	NNP	I
.	.	I
Acids	NNP	I
Res	NNP	I
.	.	I
(	(	I
1991	CD	I
)	)	I
19:3979-3986	NN	I
)	)	O
as	IN	O
a	DT	O
HindIII-SalI	JJ	O
fragment	NN	O
into	IN	O
pUC19	NN	O
(	(	O
New	NNP	O
England	NNP	O
Biolabs	NNP	O
,	,	O
Inc.	NNP	O
,	,	O
Beverly	NNP	O
,	,	O
Mass	NNP	O
.	.	O
)	)	O
.	.	O
The	DT	O
vector	NN	O
backbone	NN	O
of	IN	O
pUC19	NN	O
was	VBD	O
deleted	VBN	O
from	IN	O
the	DT	O
Nde1	NNP	O
to	TO	O
the	DT	O
Sap1	NNP	O
sites	NNS	O
.	.	O
The	DT	O
above	JJ	O
described	NN	O
DHFR	NNP	O
cassette	NN	O
was	VBD	O
added	VBN	O
to	TO	O
the	DT	O
construct	NN	O
such	JJ	O
that	IN	O
the	DT	O
EMCV	NNP	O
IRES	NNP	O
followed	VBD	O
the	DT	O
CMV	NNP	O
promoter	NN	O
to	TO	O
produce	VB	O
the	DT	O
final	JJ	O
construct	NN	O
.	.	O
The	DT	O
vector	NN	O
also	RB	O
contained	VBD	O
an	DT	O
ampr	JJ	O
gene	NN	O
and	CC	O
an	DT	O
SV40	NNP	O
origin	NN	O
of	IN	O
replication	NN	O
.	.	O
Selected	VBN	O
pCMVKm2	JJ	O
vectors	NNS	O
containing	VBG	O
the	DT	O
synthetic	JJ	O
expression	NN	O
cassettes	NNS	O
have	VBP	O
been	VBN	O
designated	VBN	O
as	IN	O
follows	VBZ	O
:	:	O
pCMVKm2.GagMod.SF2	NN	O
,	,	O
pCMVKm2.GagprotMod.SF2	NN	O
,	,	O
and	CC	O
pCMVKm2.GagpolMod.SF2	NN	O
,	,	O
pCMVKm2.GagprotMod.SF2.GP1	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:78	NNP	O
)	)	O
and	CC	O
pCMVKm2.GagprotMod.SF2.GP2	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:79	NNP	O
)	)	O
.	.	O
Other	JJ	O
exemplary	JJ	O
Gag-encoding	JJ	O
expressing	NN	O
cassettes	NNS	O
are	VBP	O
shown	VBN	O
in	IN	O
the	DT	O
Figures	NNS	O
and	CC	O
as	IN	O
Sequence	NNP	O
Listings	NNP	O
.	.	O
B	NNP	O
.	.	O
Modification	NN	O
of	IN	O
HIV-1	NNP	O
Gag/Hepatitis	NNP	O
C	NNP	O
Core	NNP	O
Chimeric	NNP	O
Protein	NNP	O
Nucleic	NNP	O
Acid	NNP	O
Coding	NNP	O
Sequences	NNPS	O
Generation	NNP	O
of	IN	O
Synthetic	NNP	O
Expression	NNP	O
Cassettes	NNP	O
To	TO	O
facilitate	VB	O
the	DT	O
ligation	NN	O
of	IN	O
the	DT	O
Gag	NNP	O
and	CC	O
HCV	NNP	O
core	NN	O
coding	NN	O
sequences	NNS	O
,	,	O
PCR	NNP	O
amplification	NN	O
was	VBD	O
employed	VBN	O
.	.	O
The	DT	O
synthetic	JJ	O
p55Gag	NN	O
expression	NN	O
cassette	NN	O
was	VBD	O
used	VBN	O
as	IN	O
a	DT	O
PCR	NNP	O
template	NN	O
with	IN	O
the	DT	O
following	VBG	O
primers	NNS	O
:	:	O
GAG5	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:11	NNP	O
)	)	O
and	CC	O
P55-SAL3	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:12	NNP	O
)	)	O
.	.	O
The	DT	O
PCR	NNP	O
amplification	NN	O
was	VBD	O
conducted	VBN	O
at	IN	O
55°	CD	O
C.	NNP	O
for	IN	O
25	CD	O
cycles	NNS	O
using	VBG	O
Stratagene	NNP	O
's	POS	O
Pfu	NNP	O
polymerase	NN	O
.	.	O
The	DT	O
resulting	VBG	O
PCR	NNP	O
product	NN	O
was	VBD	O
rendered	VBN	O
free	JJ	O
of	IN	O
nucleotides	NNS	O
and	CC	O
primers	NNS	O
using	VBG	O
the	DT	O
Promega	NNP	O
PCR	NNP	O
clean-up	JJ	O
kit	NN	O
and	CC	O
then	RB	O
subjected	VBD	O
to	TO	O
EcoRI	NNP	O
and	CC	O
SalI	NNP	O
digestions	NNS	O
.	.	O
For	IN	O
HCV	NNP	O
core	NN	O
coding	NN	O
sequences	NNS	O
,	,	O
the	DT	O
following	JJ	O
primers	NNS	O
were	VBD	O
used	VBN	O
with	IN	O
an	DT	O
HCV	NNP	O
template	NN	O
(	(	O
Houghton	NNP	O
,	,	O
M.	NNP	O
,	,	O
et	FW	O
al.	NN	O
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,714,596	CD	O
,	,	O
issued	VBN	O
Feb.	NNP	O
3	CD	O
,	,	O
1998	CD	O
;	:	O
Houghton	NNP	O
,	,	O
M.	NNP	O
,	,	O
et	FW	O
al.	NN	O
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,712,088	CD	O
,	,	O
issued	VBD	O
Jan.	NNP	O
27	CD	O
,	,	O
1998	CD	O
;	:	O
Houghton	NNP	O
,	,	O
M.	NNP	O
,	,	O
et	FW	O
al.	NN	O
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,683,864	CD	O
,	,	O
issued	VBD	O
Nov.	NNP	O
4	CD	O
,	,	O
1997	CD	O
;	:	O
Weiner	NNP	O
,	,	O
A.	NNP	O
J.	NNP	O
,	,	O
et	FW	O
al.	NN	O
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,728,520	CD	O
,	,	O
issued	VBN	O
Mar	NNP	O
.	.	O
17	CD	O
,	,	O
1998	CD	O
;	:	O
Weiner	NNP	O
,	,	O
A.	NNP	O
J.	NNP	O
,	,	O
et	FW	O
al.	NN	O
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,766,845	CD	O
,	,	O
issued	VBN	O
Jun	NNP	O
.	.	O
16	CD	O
,	,	O
1998	CD	O
;	:	O
Weiner	NNP	O
,	,	O
A.	NNP	O
J.	NNP	O
,	,	O
et	FW	O
al.	NN	O
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,670,152	CD	O
,	,	O
issued	VBN	O
Sep.	NNP	O
23	CD	O
,	,	O
1997	CD	O
;	:	O
all	DT	O
herein	NN	O
incorporated	VBN	O
by	IN	O
reference	NN	O
)	)	O
:	:	O
CORESAL	$	O
5	CD	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:13	NNP	O
)	)	O
and	CC	O
173CORE	CD	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:14	NNP	O
)	)	O
using	VBG	O
the	DT	O
conditions	NNS	O
outlined	VBN	O
above	IN	O
.	.	O
The	DT	O
purified	JJ	O
product	NN	O
was	VBD	O
digested	VBN	O
with	IN	O
SalI	NNP	O
and	CC	O
BamHI	NNP	O
restriction	NN	O
enzymes	NNS	O
.	.	O
The	DT	O
digested	JJ	O
Gag	NNP	O
and	CC	O
HCV	NNP	O
core	VBP	O
PCR	NNP	O
products	NNS	O
were	VBD	O
ligated	VBN	O
into	IN	O
the	DT	O
pCMVKm2	NN	O
vector	NN	O
digested	VBD	O
with	IN	O
EcoRI	NNP	O
and	CC	O
BamHI	NNP	O
.	.	O
Ligation	NN	O
of	IN	O
the	DT	O
PCR	NNP	O
products	NNS	O
at	IN	O
the	DT	O
SalI	NNP	O
site	NN	O
resulted	VBD	O
in	IN	O
a	DT	O
direct	JJ	O
fusion	NN	O
of	IN	O
the	DT	O
final	JJ	O
amino	NN	O
acid	NN	O
of	IN	O
p55Gag	NN	O
to	TO	O
the	DT	O
second	JJ	O
amino	NN	O
acid	NN	O
of	IN	O
HCV	NNP	O
core	NN	O
,	,	O
serine	NN	O
.	.	O
Amino	NNP	O
acid	VBD	O
173	CD	O
of	IN	O
core	NN	O
is	VBZ	O
a	DT	O
serine	NN	O
and	CC	O
is	VBZ	O
followed	VBN	O
immediately	RB	O
by	IN	O
a	DT	O
TAG	NNP	O
termination	NN	O
codon	NN	O
.	.	O
The	DT	O
sequence	NN	O
of	IN	O
the	DT	O
fusion	NN	O
clone	NN	O
was	VBD	O
confirmed	VBN	O
.	.	O
The	DT	O
pCMVKm2	NN	O
vector	NN	O
containing	VBG	O
the	DT	O
synthetic	JJ	O
expression	NN	O
cassette	NN	O
was	VBD	O
designated	VBN	O
as	IN	O
pCMVKm2.GagModHCVcore	NN	O
.	.	O
The	DT	O
EcoRI-BamHI	NNP	O
fragment	NN	O
of	IN	O
p55Gag-core	NN	O
173	CD	O
was	VBD	O
also	RB	O
cloned	VBN	O
into	IN	O
EcoRI-BamHI-digested	JJ	O
pAcC13	NN	O
for	IN	O
baculovirus	NN	O
expression	NN	O
.	.	O
Western	JJ	O
blots	NNS	O
confirmed	VBN	O
expression	NN	O
and	CC	O
sucrose	JJ	O
gradient	JJ	O
sedimentation	NN	O
along	IN	O
with	IN	O
electron	NN	O
microscopy	NN	O
confirmed	VBD	O
particle	NN	O
formation	NN	O
.	.	O
To	TO	O
generate	VB	O
the	DT	O
above	JJ	O
clone	NN	O
but	CC	O
containing	VBG	O
the	DT	O
synthetic	JJ	O
Gag	NNP	O
sequences	NNS	O
(	(	O
instead	RB	O
of	IN	O
wild-type	NN	O
)	)	O
,	,	O
the	DT	O
following	JJ	O
steps	NNS	O
were	VBD	O
performed	VBN	O
:	:	O
pCMVKm2-modified	JJ	O
p55Gag	NN	O
was	VBD	O
used	VBN	O
as	IN	O
template	NN	O
for	IN	O
PCR	NNP	O
amplification	NN	O
with	IN	O
MS65	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:15	NNP	O
)	)	O
and	CC	O
MS66	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:16	NNP	O
)	)	O
primers	NNS	O
.	.	O
The	DT	O
region	NN	O
amplified	VBD	O
corresponds	NNS	O
to	TO	O
the	DT	O
BspHI	NNP	O
and	CC	O
SalI	NNP	O
sites	NNS	O
at	IN	O
the	DT	O
C-terminus	NNP	O
of	IN	O
synthetic	JJ	O
Gag	NNP	O
sequence	NN	O
.	.	O
The	DT	O
amplification	NN	O
product	NN	O
was	VBD	O
digested	VBN	O
with	IN	O
BspHI	NNP	O
and	CC	O
SalI	NNP	O
and	CC	O
ligated	VBN	O
to	TO	O
SalI/BamHI	NNP	O
digested	VBD	O
pCMV-link	NN	O
along	IN	O
with	IN	O
the	DT	O
Sal/BspHI	NNP	O
fragment	NN	O
from	IN	O
pCMV-Km-p55modGag	JJ	O
,	,	O
representing	VBG	O
the	DT	O
amino	NN	O
terminal	JJ	O
end	NN	O
of	IN	O
modified	JJ	O
Gag	NNP	O
,	,	O
and	CC	O
the	DT	O
SalI/BamHI	NNP	O
fragment	NN	O
from	IN	O
pCMV-p55Gag-core173	NN	O
.	.	O
Thereafter	RB	O
,	,	O
a	DT	O
T4-blunted-SalI	JJ	O
partial/BamHI	NN	O
fragment	NN	O
was	VBD	O
ligated	VBN	O
into	IN	O
pAcC4-SmaI/BamHI	JJ	O
to	TO	O
generate	VB	O
pAcC4-p55GagMod-core173	NN	O
(	(	O
containing	VBG	O
the	DT	O
synthetic	JJ	O
sequence	NN	O
presented	VBD	O
as	IN	O
SEQ	NNP	O
ID	NNP	O
NO:7	NNP	O
)	)	O
.	.	O
C.	NNP	O
Defining	NNP	O
of	IN	O
the	DT	O
Major	NNP	O
Homology	NNP	O
Region	NNP	O
(	(	O
MHR	NNP	O
)	)	O
of	IN	O
HIV-1	NNP	O
p55Gag	IN	O
The	DT	O
Major	NNP	O
Homology	NNP	O
Region	NNP	O
(	(	O
MHR	NNP	O
)	)	O
of	IN	O
HIV-1	NNP	O
p55	NN	O
(	(	O
Gag	NNP	O
)	)	O
is	VBZ	O
located	VBN	O
in	IN	O
the	DT	O
p24-CA	JJ	O
sequence	NN	O
of	IN	O
Gag	NNP	O
.	.	O
It	PRP	O
is	VBZ	O
a	DT	O
conserved	JJ	O
stretch	NN	O
of	IN	O
20	CD	O
amino	JJ	O
acids	NNS	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:19	NNP	O
)	)	O
.	.	O
The	DT	O
position	NN	O
in	IN	O
the	DT	O
wild	JJ	O
type	JJ	O
HIV-1SF2	NNP	O
Gag	NNP	O
protein	NN	O
is	VBZ	O
from	IN	O
aa	JJ	O
286-305	JJ	O
and	CC	O
spans	VBZ	O
a	DT	O
region	NN	O
from	IN	O
nucleotides	JJ	O
856-915	CD	O
in	IN	O
the	DT	O
native	JJ	O
HIV-1SF2	NNP	O
Gag	NNP	O
DNA-sequence	NNP	O
.	.	O
The	DT	O
position	NN	O
in	IN	O
the	DT	O
synthetic	JJ	O
Gag	NNP	O
protein	NN	O
is	VBZ	O
from	IN	O
aa	JJ	O
288-307	JJ	O
and	CC	O
spans	VBZ	O
a	DT	O
region	NN	O
from	IN	O
nucleotides	NNS	O
862-921	CD	O
for	IN	O
the	DT	O
synthetic	JJ	O
Gag	NNP	O
DNA-sequence	NNP	O
.	.	O
The	DT	O
nucleotide	JJ	O
sequence	NN	O
for	IN	O
the	DT	O
MHR	NNP	O
in	IN	O
the	DT	O
synthetic	JJ	O
GagMod.SF2	NNP	O
is	VBZ	O
presented	VBN	O
as	IN	O
SEQ	NNP	O
ID	NNP	O
NO:20	NNP	O
.	.	O
Mutations	NNS	O
or	CC	O
deletions	NNS	O
in	IN	O
the	DT	O
amino	NN	O
acid	JJ	O
sequence	NN	O
of	IN	O
the	DT	O
MHR	NNP	O
can	MD	O
severely	RB	O
impair	VB	O
particle	NN	O
production	NN	O
(	(	O
Borsetti	NNP	B
,	,	I
A.	NNP	I
,	,	I
et	FW	I
al.	NN	I
,	,	I
J.	NNP	I
Virol	NNP	I
.	.	I
72	CD	I
(	(	I
11	CD	I
)	)	I
:9313-9317	NN	I
,	,	I
1998	CD	I
;	:	O
Mammano	NNP	B
,	,	I
F.	NNP	I
,	,	I
et	NN	I
al.	NN	I
,	,	I
J	NNP	I
Virol	NNP	I
68	CD	I
(	(	I
8	CD	I
)	)	I
:4927-4936	NN	I
,	,	I
1994	CD	I
)	)	O
.	.	O
Percent	NN	O
identity	NN	O
to	TO	O
the	DT	O
MHR	NNP	O
nucleotide	JJ	O
sequence	NN	O
can	MD	O
be	VB	O
determined	VBN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
using	VBG	O
the	DT	O
MacDNAsis	NNP	O
program	NN	O
(	(	O
Hitachi	NNP	O
Software	NNP	O
Engineering	NNP	O
America	NNP	O
Limited	NNP	O
,	,	O
South	NNP	O
San	NNP	O
Francisco	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
,	,	O
Higgins	NNP	O
algorithm	NN	O
,	,	O
with	IN	O
the	DT	O
following	JJ	O
exemplary	JJ	O
parameters	NNS	O
:	:	O
gap	NN	O
penalty=5	NN	O
,	,	O
no	DT	O
.	.	O
of	IN	O
top	JJ	O
diagonals=5	NN	O
,	,	O
fixed	VBN	O
gap	NN	O
penalty=5	NN	O
,	,	O
K-tuple=2	NNP	O
,	,	O
window	NN	O
size=5	NN	O
,	,	O
and	CC	O
floating	VBG	O
gap	NN	O
penalty=10	NN	O
.	.	O
D.	NNP	O
Generation	NNP	O
of	IN	O
Synthetic	NNP	O
Env	NNP	O
Expression	NNP	O
Cassettes	NNP	O
Env	NNP	O
coding	VBG	O
sequences	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
include	VBP	O
,	,	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
,	,	O
polynucleotide	VB	O
sequences	NNS	O
encoding	VBG	O
the	DT	O
following	JJ	O
HIV-encoded	JJ	O
polypeptides	NNS	O
:	:	O
gp160	NN	O
,	,	O
gp140	NN	O
,	,	O
and	CC	O
gp120	NN	O
(	(	O
see	VB	O
,	,	O
e.g.	VB	O
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,792,459	CD	O
for	IN	O
a	DT	O
description	NN	O
of	IN	O
the	DT	O
HIV-1SF2	NNP	O
(	(	O
“	NNP	O
SF2	NNP	O
”	NNP	O
)	)	O
Env	NNP	O
polypeptide	NN	O
)	)	O
.	.	O
The	DT	O
relationships	NNS	O
between	IN	O
these	DT	O
polypeptides	NNS	O
is	VBZ	O
shown	VBN	O
schematically	RB	O
in	IN	O
FIG	NNP	O
.	.	O
15	CD	O
(	(	O
in	IN	O
the	DT	O
figure	NN	O
:	:	O
the	DT	O
polypeptides	NNS	O
are	VBP	O
indicated	VBN	O
as	IN	O
lines	NNS	O
,	,	O
the	DT	O
amino	NN	O
and	CC	O
carboxy	NN	O
termini	NN	O
are	VBP	O
indicated	VBN	O
on	IN	O
the	DT	O
gp160	JJ	O
line	NN	O
;	:	O
the	DT	O
open	JJ	O
circle	NN	O
represents	VBZ	O
the	DT	O
oligomerization	NN	O
domain	NN	O
;	:	O
the	DT	O
open	JJ	O
square	NN	O
represents	VBZ	O
a	DT	O
transmembrane	NN	O
spanning	VBG	O
domain	NN	O
(	(	O
TM	NNP	O
)	)	O
;	:	O
and	CC	O
“	VB	O
c	JJ	O
”	NN	O
represents	VBZ	O
the	DT	O
location	NN	O
of	IN	O
a	DT	O
cleavage	NN	O
site	NN	O
,	,	O
in	IN	O
gp140.mut	NN	O
the	DT	O
“	NNP	O
X	NNP	O
”	NNP	O
indicates	VBZ	O
that	IN	O
the	DT	O
cleavage	NN	O
site	NN	O
has	VBZ	O
been	VBN	O
mutated	VBN	O
such	JJ	O
that	IN	O
it	PRP	O
no	RB	O
longer	RBR	O
functions	NNS	O
as	IN	O
a	DT	O
cleavage	NN	O
site	NN	O
)	)	O
.	.	O
The	DT	O
polypeptide	NN	O
gp160	NN	O
includes	VBZ	O
the	DT	O
coding	NN	O
sequences	NNS	O
for	IN	O
gp120	NN	O
and	CC	O
gp41	NN	O
.	.	O
The	DT	O
polypeptide	NN	O
gp41	NN	O
is	VBZ	O
comprised	VBN	O
of	IN	O
several	JJ	O
domains	NNS	O
including	VBG	O
an	DT	O
oligomerization	NN	O
domain	NN	O
(	(	O
OD	NNP	O
)	)	O
and	CC	O
a	DT	O
transmembrane	NN	O
spanning	VBG	O
domain	NN	O
(	(	O
TM	NNP	O
)	)	O
.	.	O
In	IN	O
the	DT	O
native	JJ	O
envelope	NN	O
,	,	O
the	DT	O
oligomerization	NN	O
domain	NN	O
is	VBZ	O
required	VBN	O
for	IN	O
the	DT	O
non-covalent	JJ	O
association	NN	O
of	IN	O
three	CD	O
gp41	NNS	O
polypeptides	NNS	O
to	TO	O
form	VB	O
a	DT	O
trimeric	JJ	O
structure	NN	O
:	:	O
through	IN	O
non-covalent	JJ	O
interactions	NNS	O
with	IN	O
the	DT	O
gp41	NN	O
trimer	NN	O
(	(	O
and	CC	O
itself	PRP	O
)	)	O
,	,	O
the	DT	O
gp120	NN	O
polypeptides	NNS	O
are	VBP	O
also	RB	O
organized	VBN	O
in	IN	O
a	DT	O
trimeric	JJ	O
structure	NN	O
.	.	O
A	DT	O
cleavage	NN	O
site	NN	O
(	(	O
or	CC	O
cleavage	VB	O
sites	NNS	O
)	)	O
exists	VBZ	O
approximately	RB	O
between	IN	O
the	DT	O
polypeptide	NN	O
sequences	NNS	O
for	IN	O
gp120	NN	O
and	CC	O
the	DT	O
polypeptide	NN	O
sequences	VBZ	O
corresponding	VBG	O
to	TO	O
gp41	VB	O
.	.	O
This	DT	O
cleavage	NN	O
site	NN	O
(	(	O
s	JJ	O
)	)	O
can	MD	O
be	VB	O
mutated	VBN	O
to	TO	O
prevent	VB	O
cleavage	NN	O
at	IN	O
the	DT	O
site	NN	O
.	.	O
The	DT	O
resulting	VBG	O
gp140	JJ	O
polypeptide	NN	O
corresponds	VBZ	O
to	TO	O
a	DT	O
truncated	JJ	O
form	NN	O
of	IN	O
gp160	NN	O
where	WRB	O
the	DT	O
transmembrane	NN	O
spanning	VBG	O
domain	NN	O
of	IN	O
gp41	NN	O
has	VBZ	O
been	VBN	O
deleted	VBN	O
.	.	O
This	DT	O
gp140	JJ	O
polypeptide	NN	O
can	MD	O
exist	VB	O
in	IN	O
both	DT	O
monomeric	JJ	O
and	CC	O
oligomeric	JJ	O
(	(	O
i.e	NN	O
.	.	O
trimeric	NN	O
)	)	O
forms	NNS	O
by	IN	O
virtue	NN	O
of	IN	O
the	DT	O
presence	NN	O
of	IN	O
the	DT	O
oligomerization	NN	O
domain	NN	O
in	IN	O
the	DT	O
gp41	NN	O
moiety	NN	O
.	.	O
In	IN	O
the	DT	O
situation	NN	O
where	WRB	O
the	DT	O
cleavage	NN	O
site	NN	O
has	VBZ	O
been	VBN	O
mutated	VBN	O
to	TO	O
prevent	VB	O
cleavage	NN	O
and	CC	O
the	DT	O
transmembrane	JJ	O
portion	NN	O
of	IN	O
gp41	NN	O
has	VBZ	O
been	VBN	O
deleted	VBN	O
the	DT	O
resulting	VBG	O
polypeptide	JJ	O
product	NN	O
is	VBZ	O
designated	VBN	O
“	RB	O
mutated	VBN	O
”	JJ	O
gp140	NN	O
(	(	O
e.g.	JJ	O
,	,	O
gp140.mut	NN	O
)	)	O
.	.	O
As	IN	O
will	MD	O
be	VB	O
apparent	JJ	O
to	TO	O
those	DT	O
in	IN	O
the	DT	O
field	NN	O
,	,	O
the	DT	O
cleavage	NN	O
site	NN	O
can	MD	O
be	VB	O
mutated	VBN	O
in	IN	O
a	DT	O
variety	NN	O
of	IN	O
ways	NNS	O
.	.	O
The	DT	O
native	JJ	O
amino	NN	O
acid	NN	O
sequence	NN	O
in	IN	O
the	DT	O
SF162	NNP	O
cleavage	NN	O
sites	NNS	O
is	VBZ	O
:	:	O
APTKAKRRVVQREKR	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:21	NNP	O
)	)	O
,	,	O
where	WRB	O
KAKRR	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:22	NNP	O
)	)	O
is	VBZ	O
termed	VBN	O
the	DT	O
“	JJ	O
second	JJ	O
”	NNP	O
site	NN	O
and	CC	O
REKR	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:23	NNP	O
)	)	O
is	VBZ	O
the	DT	O
“	NN	O
first	RB	O
site	NN	O
”	NN	O
.	.	O
Exemplary	JJ	O
mutations	NNS	O
include	VBP	O
the	DT	O
following	JJ	O
constructs	NNS	O
:	:	O
gp140.mut7.modSF162	NN	O
which	WDT	O
encodes	VBZ	O
the	DT	O
amino	NN	O
acid	JJ	O
sequence	NN	O
APTKAISSVVQSEKS	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:24	NNP	O
)	)	O
in	IN	O
the	DT	O
cleavage	NN	O
site	NN	O
region	NN	O
;	:	O
gp140.mut8.modSF162	CC	O
which	WDT	O
encodes	VBZ	O
the	DT	O
amino	NN	O
acid	JJ	O
sequence	NN	O
APTIAISSVVQSEKS	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:25	NNP	O
)	)	O
in	IN	O
the	DT	O
cleavage	NN	O
site	NN	O
region	NN	O
and	CC	O
gp140mut.modSF162	NN	O
which	WDT	O
encodes	VBZ	O
the	DT	O
amino	NN	O
acid	JJ	O
sequence	NN	O
APTKAKRRVVQREKS	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:26	NNP	O
)	)	O
.	.	O
Mutations	NNS	O
are	VBP	O
denoted	VBN	O
in	IN	O
bold	NN	O
.	.	O
The	DT	O
native	JJ	O
amino	NN	O
acid	NN	O
sequence	NN	O
in	IN	O
the	DT	O
US4	NNP	O
cleavage	NN	O
sites	NNS	O
is	VBZ	O
:	:	O
APTQAKRRVVQREKR	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:27	NNP	O
)	)	O
,	,	O
where	WRB	O
QAKRR	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:28	NNP	O
)	)	O
is	VBZ	O
termed	VBN	O
the	DT	O
“	JJ	O
second	JJ	O
”	NNP	O
site	NN	O
and	CC	O
REKR	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:23	NNP	O
)	)	O
is	VBZ	O
the	DT	O
“	NN	O
first	RB	O
site	NN	O
”	NN	O
.	.	O
Exemplary	JJ	O
mutations	NNS	O
include	VBP	O
the	DT	O
following	JJ	O
construct	NN	O
:	:	O
gp140.mut.modUS4	NN	O
which	WDT	O
encodes	VBZ	O
the	DT	O
amino	NN	O
acid	JJ	O
sequence	NN	O
APTQAKRRVVQREKS	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:29	NNP	O
)	)	O
in	IN	O
the	DT	O
cleavage	NN	O
site	NN	O
region	NN	O
.	.	O
Mutations	NNS	O
are	VBP	O
denoted	VBN	O
in	IN	O
bold	NN	O
.	.	O
E.	NNP	O
Modification	NNP	O
of	IN	O
HIV-1	NNP	O
Env	NNP	O
(	(	O
Envelope	NNP	O
)	)	O
Nucleic	NNP	O
Acid	NNP	O
Coding	NNP	O
Sequences	NNPS	O
In	IN	O
one	CD	O
embodiment	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
,	,	O
wild-type	JJ	O
Env	NNP	O
coding	NN	O
sequences	NNS	O
were	VBD	O
selected	VBN	O
from	IN	O
the	DT	O
HIV-1SF162	NNP	O
(	(	O
“	NNP	O
SF162	NNP	O
”	NNP	O
)	)	O
strain	NN	O
(	(	O
Cheng-Mayer	NNP	B
(	(	I
1989	CD	I
)	)	I
PNAS	NNP	I
USA	NNP	I
86:8575-8579	JJ	I
)	)	O
.	.	O
These	DT	O
SF162	NNP	O
sequences	NNS	O
were	VBD	O
as	IN	O
follows	VBZ	O
:	:	O
gp120	NN	O
,	,	O
SEQ	NNP	O
ID	NNP	O
NO:30	NNP	O
(	(	O
FIG	NNP	O
.	.	O
16	CD	O
)	)	O
;	:	O
gp140	NN	O
,	,	O
SEQ	NNP	O
ID	NNP	O
NO:31	NNP	O
(	(	O
FIG	NNP	O
.	.	O
17	CD	O
)	)	O
;	:	O
and	CC	O
gp160	VB	O
,	,	O
SEQ	NNP	O
ID	NNP	O
NO:32	NNP	O
(	(	O
FIG	NNP	O
.	.	O
18	CD	O
)	)	O
.	.	O
In	IN	O
another	DT	O
embodiment	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
,	,	O
wild-type	JJ	O
Env	NNP	O
coding	NN	O
sequences	NNS	O
were	VBD	O
selected	VBN	O
from	IN	O
the	DT	O
HIV-US4	NNP	O
strain	NN	O
(	(	O
Mascola	NNP	B
,	,	I
et	RB	I
al	NN	I
.	.	I
(	(	I
1994	CD	I
)	)	I
J.	NNP	I
Infect	NNP	I
.	.	I
Dis	NNP	I
.	.	I
169:48-54	JJ	I
)	)	O
.	.	O
These	DT	O
US4	NNP	O
sequences	NNS	O
were	VBD	O
as	IN	O
follows	VBZ	O
:	:	O
gp120	NN	O
,	,	O
SEQ	NNP	O
ID	NNP	O
NO:51	NNP	O
(	(	O
FIG	NNP	O
.	.	O
38	CD	O
)	)	O
;	:	O
gp140	NN	O
,	,	O
SEQ	NNP	O
ID	NNP	O
NO:52	NNP	O
(	(	O
FIG	NNP	O
.	.	O
39	CD	O
)	)	O
;	:	O
and	CC	O
gp160	VB	O
,	,	O
SEQ	NNP	O
ID	NNP	O
NO:53	NNP	O
(	(	O
FIG	NNP	O
.	.	O
40	CD	O
)	)	O
.	.	O
These	DT	O
Env	NNP	O
coding	NN	O
sequences	NNS	O
were	VBD	O
manipulated	VBN	O
to	TO	O
maximize	VB	O
expression	NN	O
of	IN	O
their	PRP$	O
gene	NN	O
products	NNS	O
.	.	O
First	RB	O
,	,	O
the	DT	O
wild-type	JJ	O
coding	NN	O
region	NN	O
was	VBD	O
modified	VBN	O
in	IN	O
one	CD	O
or	CC	O
more	JJR	O
of	IN	O
the	DT	O
following	JJ	O
ways	NNS	O
.	.	O
In	IN	O
one	CD	O
embodiment	NN	O
,	,	O
sequences	NNS	O
encoding	VBG	O
hypervariable	JJ	O
regions	NNS	O
of	IN	O
Env	NNP	O
,	,	O
particularly	RB	O
V1	NNP	O
and/or	NN	O
V2	NNP	O
were	VBD	O
deleted	VBN	O
.	.	O
In	IN	O
other	JJ	O
embodiments	NNS	O
,	,	O
mutations	NNS	O
were	VBD	O
introduced	VBN	O
into	IN	O
sequences	NNS	O
encoding	VBG	O
the	DT	O
cleavage	NN	O
site	NN	O
in	IN	O
Env	NNP	O
to	TO	O
abrogate	VB	O
the	DT	O
enzymatic	JJ	O
cleavage	NN	O
of	IN	O
oligomeric	JJ	O
gp140	NN	O
into	IN	O
gp120	JJ	O
monomers	NNS	O
.	.	O
(	(	O
See	VB	O
,	,	O
e.g.	VB	O
,	,	O
Earl	NNP	B
et	CC	I
al	NN	I
.	.	I
(	(	I
1990	CD	I
)	)	I
PNAS	NNP	I
USA	NNP	I
87:648-652	CD	I
;	:	O
Earl	NNP	B
et	FW	I
al	NN	I
.	.	I
(	(	I
1991	CD	I
)	)	I
J.	NNP	I
Virol	NNP	I
.	.	I
65:31-41	JJ	I
)	)	O
.	.	O
In	IN	O
yet	RB	O
other	JJ	O
embodiments	NNS	O
,	,	O
hypervariable	JJ	O
region	NN	O
(	(	O
s	NN	O
)	)	O
were	VBD	O
deleted	VBN	O
,	,	O
N-glycosylation	NNP	O
sites	NNS	O
were	VBD	O
removed	VBN	O
and/or	JJ	O
cleavage	NN	O
sites	NNS	O
mutated	VBD	O
.	.	O
Second	JJ	O
,	,	O
the	DT	O
HIV-1	NNP	O
codon	NN	O
usage	NN	O
pattern	NN	O
was	VBD	O
modified	VBN	O
so	RB	O
that	IN	O
the	DT	O
resulting	VBG	O
nucleic	JJ	O
acid	NN	O
coding	VBG	O
sequence	NN	O
was	VBD	O
comparable	JJ	O
to	TO	O
codon	VB	O
usage	NN	O
found	VBN	O
in	IN	O
highly	RB	O
expressed	VBN	O
human	JJ	O
genes	NNS	O
.	.	O
The	DT	O
HIV	NNP	O
codon	NN	O
usage	NN	O
reflects	VBZ	O
a	DT	O
high	JJ	O
content	NN	O
of	IN	O
the	DT	O
nucleotides	NNS	O
A	NNP	O
or	CC	O
T	NNP	O
in	IN	O
the	DT	O
codon-triplet	NN	O
.	.	O
The	DT	O
effect	NN	O
of	IN	O
the	DT	O
HIV-1	NNP	O
codon	NN	O
usage	NN	O
is	VBZ	O
a	DT	O
high	JJ	O
AT	NNP	O
content	NN	O
in	IN	O
the	DT	O
DNA	NN	O
sequence	NN	O
that	WDT	O
results	NNS	O
in	IN	O
a	DT	O
decreased	JJ	O
translation	NN	O
ability	NN	O
and	CC	O
instability	NN	O
of	IN	O
the	DT	O
mRNA	NN	O
.	.	O
In	IN	O
comparison	NN	O
,	,	O
highly	RB	O
expressed	VBN	O
human	JJ	O
codons	NNS	O
prefer	VBP	O
the	DT	O
nucleotides	NNS	O
G	NNP	O
or	CC	O
C.	NNP	O
The	DT	O
Env	NNP	O
coding	NN	O
sequences	NNS	O
were	VBD	O
modified	VBN	O
to	TO	O
be	VB	O
comparable	JJ	O
to	TO	O
codon	VB	O
usage	NN	O
found	VBN	O
in	IN	O
highly	RB	O
expressed	VBN	O
human	JJ	O
genes	NNS	O
.	.	O
FIGS	NNP	O
.	.	O
22A-22H	JJ	O
present	JJ	O
comparisons	NNS	O
of	IN	O
the	DT	O
percent	NN	O
A-T	NNP	O
content	NN	O
for	IN	O
the	DT	O
cDNAs	NN	O
of	IN	O
stable	JJ	O
versus	NN	O
unstable	JJ	O
RNAs	NNP	O
(	(	O
comparison	NN	O
window	NN	O
size=50	NN	O
)	)	O
.	.	O
Human	NNP	O
IFNγ	NNP	O
mRNA	NN	O
is	VBZ	O
known	VBN	O
to	TO	O
(	(	O
i	VB	O
)	)	O
be	VB	O
unstable	JJ	O
,	,	O
(	(	O
ii	NN	O
)	)	O
have	VBP	O
a	DT	O
short	JJ	O
half-life	NN	O
,	,	O
and	CC	O
(	(	O
iii	NN	O
)	)	O
have	VBP	O
a	DT	O
high	JJ	O
A-U	JJ	O
content	NN	O
.	.	O
Human	NNP	O
GAPDH	NNP	O
(	(	O
glyceraldehyde-3-phosphate	JJ	O
dehydrogenase	NN	O
)	)	O
mRNA	NN	O
is	VBZ	O
known	VBN	O
to	TO	O
(	(	O
i	VB	O
)	)	O
be	VB	O
a	DT	O
stable	JJ	O
RNA	NNP	O
,	,	O
and	CC	O
(	(	O
i	NN	O
)	)	O
have	VBP	O
a	DT	O
low	JJ	O
A-U	NNP	O
content	NN	O
.	.	O
In	IN	O
FIGS	NNP	O
.	.	O
22A-H	JJ	O
,	,	O
the	DT	O
percent	NN	O
A-T	NNP	O
content	NN	O
of	IN	O
these	DT	O
two	CD	O
sequences	NNS	O
are	VBP	O
compared	VBN	O
to	TO	O
the	DT	O
percent	NN	O
A-T	NNP	O
content	NN	O
of	IN	O
(	(	O
1	CD	O
)	)	O
native	JJ	O
HIV-1	NNP	O
US4	NNP	O
Env	NNP	O
gp160	NN	O
cDNA	NN	O
,	,	O
a	DT	O
synthetic	JJ	O
US4	NNP	O
Env	NNP	O
gp160	NN	O
cDNA	NN	O
sequence	NN	O
(	(	O
i.e.	FW	O
,	,	O
having	VBG	O
modified	VBN	O
codons	NNS	O
)	)	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
;	:	O
and	CC	O
(	(	O
2	CD	O
)	)	O
native	JJ	O
HIV-1	NNP	O
SF162	NNP	O
Env	NNP	O
gp160	NN	O
cDNA	NN	O
,	,	O
a	DT	O
synthetic	JJ	O
SF162	NNP	O
Env	NNP	O
gp160	NN	O
cDNA	NN	O
sequence	NN	O
(	(	O
i.e.	FW	O
,	,	O
having	VBG	O
modified	VBN	O
codons	NNS	O
)	)	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
.	.	O
FIGS	NNP	O
.	.	O
22A-H	JJ	O
show	NN	O
the	DT	O
percent	NN	O
A-T	NNP	O
content	NN	O
over	IN	O
the	DT	O
length	NN	O
of	IN	O
the	DT	O
sequences	NNS	O
for	IN	O
IFNγ	NNP	O
(	(	O
FIGS	NNP	O
.	.	O
22C	CD	O
and	CC	O
22G	CD	O
)	)	O
;	:	O
native	JJ	O
gp160	NN	O
Env	NNP	O
US4	NNP	O
and	CC	O
SF162	NNP	O
(	(	O
FIGS	NNP	O
.	.	O
22A	CD	O
and	CC	O
22E	CD	O
,	,	O
respectively	RB	O
)	)	O
;	:	O
GAPDH	NNP	O
(	(	O
FIGS	NNP	O
.	.	O
22D	CD	O
and	CC	O
22H	CD	O
)	)	O
;	:	O
and	CC	O
the	DT	O
synthetic	JJ	O
gp160	NN	O
Env	NNP	O
for	IN	O
US4	NNP	O
and	CC	O
SF162	NNP	O
(	(	O
FIGS	NNP	O
.	.	O
22B	CD	O
and	CC	O
22F	CD	O
)	)	O
.	.	O
Experiments	NNS	O
performed	VBN	O
in	IN	O
support	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
showed	VBD	O
that	IN	O
the	DT	O
synthetic	JJ	O
Env	NNP	O
sequences	NNS	O
were	VBD	O
capable	JJ	O
of	IN	O
higher	JJR	O
level	NN	O
of	IN	O
protein	JJ	O
production	NN	O
(	(	O
see	VB	O
the	DT	O
Examples	NNP	O
)	)	O
than	IN	O
the	DT	O
native	JJ	O
Env	NNP	O
sequences	NNS	O
.	.	O
The	DT	O
data	NN	O
in	IN	O
FIGS	NNP	O
.	.	O
22A-H	JJ	O
suggest	NN	O
that	IN	O
one	CD	O
reason	NN	O
for	IN	O
this	DT	O
increased	VBN	O
production	NN	O
is	VBZ	O
increased	VBN	O
stability	NN	O
of	IN	O
the	DT	O
mRNA	NN	O
corresponding	VBG	O
to	TO	O
the	DT	O
synthetic	JJ	O
Env	NNP	O
coding	NN	O
sequences	NNS	O
versus	VBP	O
the	DT	O
mRNA	NN	O
corresponding	VBG	O
to	TO	O
the	DT	O
native	JJ	O
Env	NNP	O
coding	NN	O
sequences	NNS	O
.	.	O
To	TO	O
create	VB	O
the	DT	O
synthetic	JJ	O
coding	NN	O
sequences	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
the	DT	O
gene	NN	O
cassettes	NNS	O
were	VBD	O
designed	VBN	O
to	TO	O
comprise	VB	O
the	DT	O
entire	JJ	O
coding	NN	O
sequence	NN	O
of	IN	O
interest	NN	O
.	.	O
Synthetic	JJ	O
gene	NN	O
cassettes	NNS	O
were	VBD	O
constructed	VBN	O
by	IN	O
oligonucleotide	JJ	O
synthesis	NN	O
and	CC	O
PCR	NNP	O
amplification	NN	O
to	TO	O
generate	VB	O
gene	NN	O
fragments	NNS	O
.	.	O
Primers	NNS	O
were	VBD	O
chosen	VBN	O
to	TO	O
provide	VB	O
convenient	JJ	O
restriction	NN	O
sites	NNS	O
for	IN	O
subcloning	VBG	O
.	.	O
The	DT	O
resulting	VBG	O
fragments	NNS	O
were	VBD	O
then	RB	O
ligated	VBN	O
to	TO	O
create	VB	O
the	DT	O
entire	JJ	O
desired	VBD	O
sequence	NN	O
which	WDT	O
was	VBD	O
then	RB	O
cloned	VBN	O
into	IN	O
an	DT	O
appropriate	JJ	O
vector	NN	O
.	.	O
The	DT	O
final	JJ	O
synthetic	JJ	O
sequences	NNS	O
were	VBD	O
(	(	O
i	NN	O
)	)	O
screened	VBN	O
by	IN	O
restriction	NN	O
endonuclease	NN	O
digestion	NN	O
and	CC	O
analysis	NN	O
,	,	O
(	(	O
ii	NN	O
)	)	O
subjected	VBD	O
to	TO	O
DNA	NNP	O
sequencing	VBG	O
in	IN	O
order	NN	O
to	TO	O
confirm	VB	O
that	IN	O
the	DT	O
desired	JJ	O
sequence	NN	O
had	VBD	O
been	VBN	O
obtained	VBN	O
and	CC	O
(	(	O
iii	NN	O
)	)	O
the	DT	O
identity	NN	O
and	CC	O
integrity	NN	O
of	IN	O
the	DT	O
expressed	JJ	O
protein	NN	O
confirmed	VBN	O
by	IN	O
SDS-PAGE	NNP	O
and	CC	O
Western	NNP	O
blotting	NN	O
(	(	O
See	NNP	O
,	,	O
Examples	NNP	O
.	.	O
The	DT	O
synthetic	JJ	O
coding	NN	O
sequences	NNS	O
were	VBD	O
assembled	VBN	O
at	IN	O
Chiron	NNP	O
Corp.	NNP	O
or	CC	O
by	IN	O
the	DT	O
Midland	NNP	O
Certified	NNP	O
Reagent	NNP	O
Company	NNP	O
(	(	O
Midland	NNP	O
,	,	O
Tex	NNP	O
.	.	O
)	)	O
.	.	O
Exemplary	NNP	O
modified	VBD	O
coding	VBG	O
sequences	NNS	O
are	VBP	O
presented	VBN	O
as	IN	O
synthetic	JJ	O
Env	NNP	O
expression	NN	O
cassettes	NNS	O
in	IN	O
Table	JJ	O
1A	CD	O
and	CC	O
1B	CD	O
.	.	O
The	DT	O
following	JJ	O
expression	NN	O
cassettes	NNS	O
(	(	O
i	NN	O
)	)	O
have	VBP	O
unique	JJ	O
,	,	O
terminal	JJ	O
EcoRI	NNP	O
and	CC	O
XbaI	NNP	O
cloning	VBG	O
sites	NNS	O
;	:	O
(	(	O
ii	NN	O
)	)	O
include	VBP	O
Kozak	NNP	O
sequences	NNS	O
to	TO	O
promote	VB	O
optimal	JJ	O
translation	NN	O
;	:	O
(	(	O
iii	NN	O
)	)	O
tPA	VBZ	O
signal	JJ	O
sequences	NNS	O
(	(	O
to	TO	O
direct	VB	O
the	DT	O
ENV	NNP	O
polypeptide	NN	O
to	TO	O
the	DT	O
cell	NN	O
membrane	NN	O
,	,	O
see	VBP	O
,	,	O
e.g.	FW	O
,	,	O
Chapman	NNP	B
et	VBZ	I
al.	NN	I
,	,	I
infra	NN	I
)	)	O
;	:	O
(	(	O
iv	NN	O
)	)	O
open	JJ	O
reading	VBG	O
frames	NNS	O
optimized	VBN	O
for	IN	O
expression	NN	O
in	IN	O
mammalian	JJ	O
cells	NNS	O
;	:	O
and	CC	O
(	(	O
v	NN	O
)	)	O
a	DT	O
translational	JJ	O
stop	JJ	O
signal	NN	O
codon	NN	O
.	.	O
Alignments	NNS	O
of	IN	O
the	DT	O
sequences	NNS	O
presented	VBN	O
in	IN	O
the	DT	O
above	JJ	O
tables	NNS	O
are	VBP	O
presented	VBN	O
in	IN	O
FIGS	NNP	O
.	.	O
66A	CD	O
and	CC	O
66B	CD	O
.	.	O
A	DT	O
common	JJ	O
region	NN	O
(	(	O
Env-common	NNP	O
)	)	O
extends	VBZ	O
from	IN	O
nucleotide	JJ	O
position	NN	O
1186	CD	O
to	TO	O
nucleotide	VB	O
position	NN	O
1329	CD	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:69	NNP	O
,	,	O
FIG	NNP	O
.	.	O
56	CD	O
)	)	O
relative	NN	O
to	TO	O
the	DT	O
wild-type	JJ	O
US4	NNP	O
sequence	NN	O
and	CC	O
from	IN	O
nucleotide	JJ	O
position	NN	O
1117	CD	O
to	TO	O
position	NN	O
1260	CD	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:79	NNP	O
,	,	O
FIG	NNP	O
.	.	O
57	CD	O
)	)	O
relative	NN	O
to	TO	O
the	DT	O
wild-type	JJ	O
SF162	NNP	O
sequence	NN	O
.	.	O
The	DT	O
synthetic	JJ	O
sequences	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
corresponding	VBG	O
to	TO	O
these	DT	O
regions	NNS	O
are	VBP	O
presented	VBN	O
,	,	O
as	IN	O
SEQ	NNP	O
ID	NNP	O
NO:71	NNP	O
(	(	O
FIG	NNP	O
.	.	O
58	CD	O
)	)	O
for	IN	O
the	DT	O
synthetic	JJ	O
Env	NNP	O
US4	NNP	O
common	JJ	O
region	NN	O
and	CC	O
as	IN	O
SEQ	NNP	O
ID	NNP	O
NO:72	NNP	O
(	(	O
FIG	NNP	O
.	.	O
59	CD	O
)	)	O
for	IN	O
the	DT	O
synthetic	JJ	O
Env	NNP	O
SF162	NNP	O
common	JJ	O
region	NN	O
.	.	O
Percent	NN	O
identity	NN	O
to	TO	O
this	DT	O
sequence	NN	O
can	MD	O
be	VB	O
determined	VBN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
using	VBG	O
the	DT	O
Smith-Waterman	JJ	O
search	NN	O
algorithm	NN	O
(	(	O
Time	NNP	O
Logic	NNP	O
,	,	O
Incline	NNP	O
Village	NNP	O
,	,	O
Nev.	NNP	O
)	)	O
,	,	O
with	IN	O
the	DT	O
following	JJ	O
exemplary	JJ	O
parameters	NNS	O
:	:	O
weight	NN	O
matrix=nuc4×4hb	NN	O
;	:	O
gap	CC	O
opening	VBG	O
penalty=20	NN	O
,	,	O
gap	NN	O
extension	NN	O
penalty=5	NN	O
,	,	O
reporting	VBG	O
threshold=1	NN	O
;	:	O
alignment	JJ	O
threshold=20	NN	O
.	.	O
Various	JJ	O
forms	NNS	O
of	IN	O
the	DT	O
different	JJ	O
embodiments	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
(	(	O
e.g.	JJ	O
,	,	O
constructs	NNS	O
)	)	O
may	MD	O
be	VB	O
combined	VBN	O
.	.	O
F.	NNP	O
Cloning	NNP	O
Synthetic	NNP	O
Env	NNP	O
Expression	NNP	O
Cassettes	NNP	O
of	IN	O
the	DT	O
Present	JJ	O
Invention	NNP	O
.	.	O
The	DT	O
synthetic	JJ	O
DNA	NN	O
fragments	NNS	O
encoding	VBG	O
the	DT	O
Env	NNP	O
polypeptides	NNS	O
were	VBD	O
typically	RB	O
cloned	VBN	O
into	IN	O
the	DT	O
eucaryotic	JJ	O
expression	NN	O
vectors	NNS	O
described	VBD	O
above	IN	O
for	IN	O
Gag	NNP	O
,	,	O
for	IN	O
example	NN	O
,	,	O
pCMVKm2/pCMVlink	NN	O
(	(	O
FIG	NNP	O
.	.	O
4	CD	O
)	)	O
,	,	O
pCMV6a	NN	O
,	,	O
pESN2dhfr	NN	O
(	(	O
FIG	NNP	O
.	.	O
13A	CD	O
)	)	O
,	,	O
pCMVIII	FW	O
(	(	O
FIG	NNP	O
.	.	O
13B	CD	O
;	:	O
alternately	RB	O
designated	VBN	O
as	IN	O
the	DT	O
pCMV-PL-E-dhfr/neo	JJ	O
vector	NN	O
)	)	O
.	.	O
Exemplary	JJ	O
designations	NNS	O
for	IN	O
pCMVlink	NN	O
vectors	NNS	O
containing	VBG	O
synthetic	JJ	O
expression	NN	O
cassettes	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
are	VBP	O
as	IN	O
follows	VBZ	O
:	:	O
pCMVlink.gp140.modSF162	NN	O
;	:	O
pCMVlink.gp140.-modSF162.delV2	JJ	O
;	:	O
pCMVlink.gp140.mut.modSF162	NN	O
;	:	O
pCMVlink.gp140.mut.modSF162.delV2	CC	O
;	:	O
pCMVKm2.gp140modUS4	NN	O
;	:	O
pCMVKm2.9p140.modUS4.delV2	CC	O
;	:	O
pCMVKm2.gp140.mut.modUS4	NN	O
;	:	O
and	CC	O
,	,	O
pCMVKm2.gp140.mut.modUS4.delV1/V2	NN	O
.	.	O
G.	NNP	O
Generation	NNP	O
of	IN	O
Synthetic	NNP	O
Tat	NNP	O
Expression	NNP	O
Cassettes	NNP	O
Tat	NNP	O
coding	VBG	O
sequences	NNS	O
have	VBP	O
also	RB	O
been	VBN	O
modified	VBN	O
according	VBG	O
to	TO	O
the	DT	O
teachings	NNS	O
of	IN	O
the	DT	O
present	JJ	O
specification	NN	O
.	.	O
The	DT	O
wild	JJ	O
type	NN	O
nucleotide	NN	O
sequence	NN	O
encoding	VBG	O
tat	NN	O
from	IN	O
variant	JJ	O
SF162	NNP	O
is	VBZ	O
presented	VBN	O
in	IN	O
FIG	NNP	O
.	.	O
76	CD	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:85	NNP	O
)	)	O
.	.	O
The	DT	O
corresponding	JJ	O
wild-type	JJ	O
amino	NN	O
acid	NN	O
sequence	NN	O
is	VBZ	O
presented	VBN	O
in	IN	O
FIG	NNP	O
.	.	O
77	CD	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:86	NNP	O
)	)	O
.	.	O
FIG	NNP	O
.	.	O
81	CD	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:89	NNP	O
)	)	O
shows	VBZ	O
the	DT	O
nucleotide	JJ	O
sequence	NN	O
encoding	VBG	O
the	DT	O
amino	JJ	O
terminal	NN	O
of	IN	O
the	DT	O
tat	NN	O
protein	NN	O
and	CC	O
the	DT	O
codon	NN	O
encoding	VBG	O
cystein-22	NN	O
is	VBZ	O
underlined	JJ	O
.	.	O
Other	JJ	O
exemplary	JJ	O
constructs	NNS	O
encoding	VBG	O
synthetic	JJ	O
tat	NN	O
polypeptides	NNS	O
are	VBP	O
shown	VBN	O
in	IN	O
FIGS	NNP	O
.	.	O
78	CD	O
and	CC	O
79	CD	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NOs:87	NNP	O
and	CC	O
88	CD	O
)	)	O
.	.	O
In	IN	O
one	CD	O
embodiment	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:88	NNP	O
)	)	O
,	,	O
the	DT	O
cystein	NN	O
residue	NN	O
at	IN	O
position	NN	O
22	CD	O
is	VBZ	O
replaced	VBN	O
by	IN	O
a	DT	O
glycine	NN	O
.	.	O
Caputo	NNP	B
et	CC	I
al	NN	I
.	.	I
(	(	I
1996	CD	I
)	)	I
Gene	NNP	I
Therapy	NNP	I
3:235	CD	I
have	VBP	O
shown	VBN	O
that	IN	O
this	DT	O
mutation	NN	O
affects	VBZ	O
the	DT	O
trans	NNS	O
activation	VBP	O
domain	NN	O
of	IN	O
Tat	NNP	O
.	.	O
Various	JJ	O
forms	NNS	O
of	IN	O
the	DT	O
different	JJ	O
embodiments	NNS	O
of	IN	O
the	DT	O
invention	NN	O
,	,	O
described	VBN	O
herein	NNS	O
,	,	O
may	MD	O
be	VB	O
combined	VBN	O
.	.	O
H.	NNP	O
Deposit	NNP	O
of	IN	O
Vectors	NNP	O
Selected	NNP	O
exemplary	JJ	O
constructs	NNS	O
shown	VBN	O
below	IN	O
and	CC	O
described	VBD	O
herein	NNS	O
are	VBP	O
deposited	VBN	O
at	IN	O
Chiron	NNP	O
Corporation	NNP	O
,	,	O
Emeryville	NNP	O
,	,	O
Calif.	NNP	O
,	,	O
94662-8097	CD	O
,	,	O
and	CC	O
were	VBD	O
sent	VBN	O
to	TO	O
the	DT	O
American	JJ	O
Type	NNP	O
Culture	NNP	O
Collection	NNP	O
,	,	O
10801	CD	O
University	NNP	O
Boulevard	NNP	O
,	,	O
Manassas	NNP	O
,	,	O
Va.	NNP	O
20110-2209	CD	O
on	IN	O
Dec.	NNP	O
27	CD	O
,	,	O
1999	CD	O
.	.	O
Example	RB	O
2	CD	O
Expression	NNP	O
Assays	NNP	O
for	IN	O
the	DT	O
Synthetic	NNP	O
Gag	NNP	O
,	,	O
Env	NNP	O
and	CC	O
Tat	NNP	O
Coding	NNP	O
Sequences	NNP	O
A.	NN	O
Gag	NNP	O
and	CC	O
Gag-Protease	NNP	O
Coding	NNP	O
Sequences	VBZ	O
The	DT	O
HIV-1SF2	JJ	O
wild-type	JJ	O
Gag	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:1	NNP	O
)	)	O
and	CC	O
Gag-protease	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:2	NNP	O
)	)	O
sequences	NNS	O
were	VBD	O
cloned	VBN	O
into	IN	O
expression	NN	O
vectors	NNS	O
having	VBG	O
the	DT	O
same	JJ	O
features	NNS	O
as	IN	O
the	DT	O
vectors	NNS	O
into	IN	O
which	WDT	O
the	DT	O
synthetic	JJ	O
Gag	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:4	NNP	O
)	)	O
and	CC	O
Gag-protease	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NOs:5	NNP	O
,	,	O
78	CD	O
or	CC	O
79	CD	O
)	)	O
)	)	O
sequences	NNS	O
were	VBD	O
cloned	VBN	O
.	.	O
Expression	NN	O
efficiencies	NNS	O
for	IN	O
various	JJ	O
vectors	NNS	O
carrying	VBG	O
the	DT	O
HIV-15F2	NNP	O
wild-type	NN	O
and	CC	O
synthetic	JJ	O
Gag	NNP	O
sequences	NNS	O
were	VBD	O
evaluated	VBN	O
as	IN	O
follows	VBZ	O
.	.	O
Cells	NNS	O
from	IN	O
several	JJ	O
mammalian	JJ	O
cell	NN	O
lines	NNS	O
(	(	O
293	CD	O
,	,	O
RD	NNP	O
,	,	O
COS-7	NNP	O
,	,	O
and	CC	O
CHO	NNP	O
;	:	O
all	DT	O
obtained	VBN	O
from	IN	O
the	DT	O
American	JJ	O
Type	NNP	O
Culture	NNP	O
Collection	NNP	O
,	,	O
10801	CD	O
University	NNP	O
Boulevard	NNP	O
,	,	O
Manassas	NNP	O
,	,	O
Va.	NNP	O
20110-2209	CD	O
)	)	O
were	VBD	O
transfected	VBN	O
with	IN	O
2	CD	O
μg	NNS	O
of	IN	O
DNA	NN	O
in	IN	O
transfection	NN	O
reagent	NN	O
LT1	NNP	O
(	(	O
PanVera	NNP	O
Corporation	NNP	O
,	,	O
545	CD	O
Science	NNP	O
Dr.	NNP	O
,	,	O
Madison	NNP	O
,	,	O
Wis.	NNP	O
)	)	O
.	.	O
The	DT	O
cells	NNS	O
were	VBD	O
incubated	VBN	O
for	IN	O
5	CD	O
hours	NNS	O
in	IN	O
reduced	JJ	O
serum	NN	O
medium	NN	O
(	(	O
Opti-MEM	NNP	O
,	,	O
Gibco-BRL	NNP	O
,	,	O
Gaithersburg	NNP	O
,	,	O
Md	NNP	O
.	.	O
)	)	O
.	.	O
The	DT	O
medium	NN	O
was	VBD	O
then	RB	O
replaced	VBN	O
with	IN	O
normal	JJ	O
medium	NN	O
as	IN	O
follows	VBZ	O
:	:	O
293	CD	O
cells	NNS	O
,	,	O
IMDM	NNP	O
,	,	O
10	CD	O
%	NN	O
fetal	JJ	O
calf	NN	O
serum	NN	O
,	,	O
2	CD	O
%	NN	O
glutamine	NN	O
(	(	O
BioWhittaker	NNP	O
,	,	O
Walkersville	NNP	O
,	,	O
Md	NNP	O
.	.	O
)	)	O
;	:	O
RD	NNP	O
and	CC	O
COS-7	NNP	O
cells	NNS	O
,	,	O
D-MEM	NNP	O
,	,	O
10	CD	O
%	NN	O
fetal	JJ	O
calf	NN	O
serum	NN	O
,	,	O
2	CD	O
%	NN	O
glutamine	NN	O
(	(	O
Opti-MEM	NNP	O
,	,	O
Gibco-BRL	NNP	O
,	,	O
Gaithersburg	NNP	O
,	,	O
Md	NNP	O
.	.	O
)	)	O
;	:	O
and	CC	O
CHO	NNP	O
cells	NNS	O
,	,	O
Ham	NNP	O
's	POS	O
F-12	NN	O
,	,	O
10	CD	O
%	NN	O
fetal	JJ	O
calf	NN	O
serum	NN	O
,	,	O
2	CD	O
%	NN	O
glutamine	NN	O
(	(	O
Opti-MEM	NNP	O
,	,	O
Gibco-BRL	NNP	O
,	,	O
Gaithersburg	NNP	O
,	,	O
Md	NNP	O
.	.	O
)	)	O
.	.	O
The	DT	O
cells	NNS	O
were	VBD	O
incubated	VBN	O
for	IN	O
either	DT	O
48	CD	O
or	CC	O
60	CD	O
hours	NNS	O
.	.	O
Supernatants	NNS	O
were	VBD	O
harvested	VBN	O
and	CC	O
filtered	VBN	O
through	IN	O
0.45	CD	O
μm	JJ	O
syringe	NN	O
filters	NNS	O
and	CC	O
,	,	O
optionally	RB	O
,	,	O
stored	VBD	O
at	IN	O
−20°	NNP	O
C.	NNP	O
Supernatants	NNP	O
were	VBD	O
evaluated	VBN	O
using	VBG	O
the	DT	O
Coulter	NNP	O
p24-assay	NN	O
(	(	O
Coulter	NNP	O
Corporation	NNP	O
,	,	O
Hialeah	NNP	O
,	,	O
Fla.	NNP	O
,	,	O
US	NNP	O
)	)	O
,	,	O
using	VBG	O
96-well	CD	O
plates	NNS	O
coated	VBN	O
with	IN	O
a	DT	O
murine	JJ	O
monoclonal	JJ	O
antibody	NN	O
directed	VBN	O
against	IN	O
HIV	NNP	O
core	NN	O
antigen	NN	O
.	.	O
The	DT	O
HIV-1	NNP	O
p24	NN	O
antigen	NN	O
binds	VBZ	O
to	TO	O
the	DT	O
coated	VBN	O
wells	NNS	O
.	.	O
Biotinylated	JJ	O
antibodies	NNS	O
against	IN	O
HIV	NNP	O
recognize	VBP	O
the	DT	O
bound	NN	O
p24	NN	O
antigen	NN	O
.	.	O
Conjugated	VBN	O
strepavidin-horseradish	JJ	O
peroxidase	NN	O
reacts	NNS	O
with	IN	O
the	DT	O
biotin	NN	O
.	.	O
Color	NNP	O
develops	VBZ	O
from	IN	O
the	DT	O
reaction	NN	O
of	IN	O
peroxidase	NN	O
with	IN	O
TMB	NNP	O
substrate	NN	O
.	.	O
The	DT	O
reaction	NN	O
is	VBZ	O
terminated	VBN	O
by	IN	O
addition	NN	O
of	IN	O
4NH2SO4	CD	O
.	.	O
The	DT	O
intensity	NN	O
of	IN	O
the	DT	O
color	NN	O
is	VBZ	O
directly	RB	O
proportional	JJ	O
to	TO	O
the	DT	O
amount	NN	O
of	IN	O
HIV	NNP	O
p24	NN	O
antigen	NN	O
in	IN	O
a	DT	O
sample	NN	O
.	.	O
The	DT	O
results	NNS	O
of	IN	O
these	DT	O
expression	NN	O
assays	NNS	O
are	VBP	O
presented	VBN	O
in	IN	O
Tables	NNP	O
2A	CD	O
and	CC	O
2B	CD	O
.	.	O
Tables	NNS	O
2A	CD	O
and	CC	O
2B	CD	O
shows	NNS	O
data	NNS	O
obtained	VBD	O
using	VBG	O
the	DT	O
synthetic	JJ	O
Gag-protease	NNP	O
expression	NN	O
cassette	NN	O
of	IN	O
SEQ	NNP	O
ID	NNP	O
NO:5	NNP	O
.	.	O
Similar	JJ	O
results	NNS	O
were	VBD	O
obtained	VBN	O
using	VBG	O
the	DT	O
Gag-protease	NNP	O
expression	NN	O
cassettes	NNS	O
of	IN	O
SEQ	NNP	O
ID	NNP	O
NOs:78	NNP	O
and	CC	O
79	CD	O
.	.	O
Table	JJ	O
2	CD	O
:	:	O
In	IN	O
Vitro	NNP	O
Gag	NNP	O
and	CC	O
Gagprot	NNP	O
p24	VBP	O
Expression	NNP	O
The	DT	O
data	NN	O
showed	VBD	O
that	IN	O
the	DT	O
synthetic	JJ	O
Gag	NNP	O
and	CC	O
Gag-protease	NNP	O
expression	NN	O
cassettes	NNS	O
provided	VBD	O
dramatic	JJ	O
increases	NNS	O
in	IN	O
production	NN	O
of	IN	O
their	PRP$	O
protein	NN	O
products	NNS	O
,	,	O
relative	JJ	O
to	TO	O
the	DT	O
native	JJ	O
(	(	O
HIV-1SF2	NNP	O
wild-type	NN	O
)	)	O
sequences	NNS	O
,	,	O
when	WRB	O
expressed	VBN	O
in	IN	O
a	DT	O
variety	NN	O
of	IN	O
cell	NN	O
lines	NNS	O
.	.	O
B.	NNP	O
Env	NNP	O
Coding	NNP	O
Sequences	VBZ	O
The	DT	O
HIV-SF162	NNP	O
(	(	O
“	NNP	O
SF162	NNP	O
”	NNP	O
)	)	O
wild-type	NN	O
Env	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:1-3	NNP	O
)	)	O
and	CC	O
HIV-US4	NNP	O
(	(	O
“	NNP	O
US4	NNP	O
”	NNP	O
)	)	O
wild-type	NN	O
Env	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:22-24	NNP	O
)	)	O
sequences	NNS	O
were	VBD	O
cloned	VBN	O
into	IN	O
expression	NN	O
vectors	NNS	O
having	VBG	O
the	DT	O
same	JJ	O
features	NNS	O
as	IN	O
the	DT	O
vectors	NNS	O
into	IN	O
which	WDT	O
the	DT	O
synthetic	JJ	O
Env	NNP	O
sequences	NNS	O
were	VBD	O
cloned	VBN	O
.	.	O
Expression	NN	O
efficiencies	NNS	O
for	IN	O
various	JJ	O
vectors	NNS	O
carrying	VBG	O
the	DT	O
SF162	NNP	O
and	CC	O
US4	NNP	O
wild-type	NN	O
and	CC	O
synthetic	JJ	O
Env	NNP	O
sequences	NNS	O
were	VBD	O
evaluated	VBN	O
essentially	RB	O
as	IN	O
described	VBN	O
above	IN	O
for	IN	O
Gag	NNP	O
except	IN	O
that	DT	O
cell	NN	O
lysates	VBZ	O
were	VBD	O
prepared	VBN	O
in	IN	O
40	CD	O
μl	JJ	O
lysis	NN	O
buffer	NN	O
(	(	O
1.0	CD	O
%	NN	O
NP40	NNP	O
,	,	O
0.1	CD	O
M	NNP	O
Tris	NNP	O
pH	VBZ	O
7.5	CD	O
)	)	O
and	CC	O
frozen	JJ	O
at	IN	O
−20°	NNP	O
C.	NNP	O
and	CC	O
capture	NN	O
ELISAs	NNP	O
were	VBD	O
performed	VBN	O
as	IN	O
follows	VBZ	O
.	.	O
For	IN	O
Capture	NNP	O
ELISAs	NNP	O
,	,	O
250	CD	O
ng	NN	O
of	IN	O
an	DT	O
ammonium	NN	O
sulfate	NN	O
IgG	NNP	O
cut	NN	O
of	IN	O
goat	NN	O
polyclonal	JJ	O
antibody	NN	O
to	TO	O
gp120SF2/env2-3	NN	O
was	VBD	O
used	VBN	O
to	TO	O
coat	VB	O
each	DT	O
well	NN	O
of	IN	O
a	DT	O
96-well	JJ	O
plate	NN	O
(	(	O
Corning	NNP	O
,	,	O
Corning	NNP	O
,	,	O
N	NNP	O
.	.	O
Y	NNP	O
.	.	O
)	)	O
.	.	O
Serial	JJ	O
dilutions	NNS	O
of	IN	O
gp120/SF2	NN	O
protein	NN	O
(	(	O
MID	NNP	O
167	CD	O
)	)	O
were	VBD	O
used	VBN	O
to	TO	O
set	VB	O
the	DT	O
quantitation	NN	O
curve	NN	O
from	IN	O
which	WDT	O
expression	NN	O
of	IN	O
US4	NNP	O
or	CC	O
SF162	NNP	O
gp120	VBP	O
proteins	NNS	O
from	IN	O
transfection	NN	O
supernatant	NN	O
and	CC	O
lysates	NNS	O
were	VBD	O
calculated	VBN	O
.	.	O
Samples	NNS	O
were	VBD	O
screened	VBN	O
undiluted	JJ	O
and	CC	O
,	,	O
optionally	RB	O
,	,	O
by	IN	O
serial	JJ	O
2-fold	JJ	O
dilutions	NNS	O
.	.	O
A	DT	O
human	JJ	O
polyclonal	JJ	O
antibody	NN	O
to	TO	O
HIV-1	NNP	O
gp120/SF2	NN	O
was	VBD	O
used	VBN	O
to	TO	O
detect	VB	O
bound	NN	O
gp120	FW	O
envelope	NN	O
protein	NN	O
,	,	O
followed	VBN	O
by	IN	O
horse-radish	JJ	O
peroxidase	NN	O
(	(	O
HRP	NNP	O
)	)	O
-labeled	VBD	O
goat	JJ	O
anti-human	JJ	O
IgG	NNP	O
conjugates	NNS	O
.	.	O
TME	NNP	O
(	(	O
Pierce	NNP	O
,	,	O
Rockford	NNP	O
,	,	O
Ill.	NNP	O
)	)	O
was	VBD	O
used	VBN	O
as	IN	O
the	DT	O
substrate	NN	O
and	CC	O
the	DT	O
reaction	NN	O
is	VBZ	O
terminated	VBN	O
by	IN	O
addition	NN	O
of	IN	O
4N	CD	O
H2SO4	NNP	O
.	.	O
The	DT	O
reaction	NN	O
was	VBD	O
quantified	VBN	O
by	IN	O
measuring	VBG	O
the	DT	O
optical	JJ	O
density	NN	O
(	(	O
OD	NNP	O
)	)	O
at	IN	O
450	CD	O
nm	NNS	O
.	.	O
The	DT	O
intensity	NN	O
of	IN	O
the	DT	O
color	NN	O
is	VBZ	O
directly	RB	O
proportional	JJ	O
to	TO	O
the	DT	O
amount	NN	O
of	IN	O
HIV	NNP	O
gp120	NN	O
antigen	NN	O
in	IN	O
a	DT	O
sample	NN	O
.	.	O
Purified	NNP	O
SF2	NNP	O
gp120	NN	O
protein	NN	O
was	VBD	O
diluted	VBN	O
and	CC	O
used	VBN	O
as	IN	O
a	DT	O
standard	NN	O
.	.	O
The	DT	O
results	NNS	O
of	IN	O
the	DT	O
transient	JJ	O
expression	NN	O
assays	NNS	O
are	VBP	O
presented	VBN	O
in	IN	O
Tables	NNP	O
3	CD	O
and	CC	O
4	CD	O
.	.	O
Table	JJ	O
3	CD	O
depicts	NNS	O
transient	JJ	O
expression	NN	O
in	IN	O
293	CD	O
cells	NNS	O
transfected	VBN	O
with	IN	O
a	DT	O
pCMVKm2	NN	O
vector	NN	O
carrying	VBG	O
the	DT	O
Env	NNP	O
cassette	NN	O
of	IN	O
interest	NN	O
.	.	O
Table	JJ	O
4	CD	O
depicts	NNS	O
transient	JJ	O
expression	NN	O
in	IN	O
RD	NNP	O
cells	NNS	O
transfected	VBN	O
with	IN	O
a	DT	O
pCMVKm2	NN	O
vector	NN	O
carrying	VBG	O
the	DT	O
Env	NNP	O
cassette	NN	O
of	IN	O
interest	NN	O
.	.	O
The	DT	O
data	NN	O
showed	VBD	O
that	IN	O
the	DT	O
synthetic	JJ	O
Env	NNP	O
and	CC	O
expression	NN	O
cassettes	NNS	O
provided	VBD	O
a	DT	O
significant	JJ	O
increase	NN	O
in	IN	O
production	NN	O
of	IN	O
their	PRP$	O
protein	NN	O
products	NNS	O
,	,	O
relative	JJ	O
to	TO	O
the	DT	O
native	JJ	O
(	(	O
HIV-1SF162	NNP	O
or	CC	O
US4	NNP	O
wild-type	NN	O
)	)	O
sequences	NNS	O
,	,	O
when	WRB	O
expressed	VBN	O
in	IN	O
a	DT	O
variety	NN	O
of	IN	O
cell	NN	O
lines	NNS	O
.	.	O
C.	NNP	O
CHO	NNP	O
Cell	NNP	O
Line	NNP	O
Env	NNP	O
Expression	NNP	O
Data	NNP	O
Chinese	NNP	O
hamster	NN	O
ovary	NN	O
(	(	O
CHO	NNP	O
)	)	O
cells	NNS	O
were	VBD	O
transfected	VBN	O
with	IN	O
plasmid	JJ	O
DNA	NNP	O
encoding	VBG	O
the	DT	O
synthetic	JJ	O
HIV-1	NNP	O
gp120	NN	O
or	CC	O
gp140	NN	O
proteins	NNS	O
(	(	O
e.g.	NN	O
,	,	O
pESN2dhfr	NN	O
or	CC	O
pCMVIII	NN	O
vector	NN	O
backbone	NN	O
)	)	O
using	VBG	O
Mirus	NNP	O
TransIT-LT1	NNP	O
polyamine	NN	O
transfection	NN	O
reagent	NN	O
(	(	O
Pan	NNP	O
Vera	NNP	O
)	)	O
according	VBG	O
to	TO	O
the	DT	O
manufacturers	NNS	O
instructions	NNS	O
and	CC	O
incubated	VBN	O
for	IN	O
96	CD	O
hours	NNS	O
.	.	O
After	IN	O
96	CD	O
hours	NNS	O
,	,	O
media	NNS	O
was	VBD	O
changed	VBN	O
to	TO	O
selective	JJ	O
media	NNS	O
(	(	O
F12	NNP	O
special	JJ	O
with	IN	O
250	CD	O
μg/ml	NNS	O
G418	NNP	O
)	)	O
and	CC	O
cells	NNS	O
were	VBD	O
split	JJ	O
1:5	CD	O
and	CC	O
incubated	VBD	O
for	IN	O
an	DT	O
additional	JJ	O
48	CD	O
hours	NNS	O
.	.	O
Media	NNP	O
was	VBD	O
changed	VBN	O
every	DT	O
5-7	JJ	O
days	NNS	O
until	IN	O
colonies	NNS	O
started	VBD	O
forming	VBG	O
at	IN	O
which	WDT	O
time	NN	O
the	DT	O
colonies	NNS	O
were	VBD	O
picked	VBN	O
,	,	O
plated	VBN	O
into	IN	O
96	CD	O
well	RB	O
plates	NNS	O
and	CC	O
screened	VBN	O
by	IN	O
gp120	JJ	O
Capture	NNP	O
ELISA	NNP	O
.	.	O
Positive	JJ	O
clones	NNS	O
were	VBD	O
expanded	VBN	O
in	IN	O
24	CD	O
well	RB	O
plates	NNS	O
and	CC	O
screened	VBD	O
several	JJ	O
times	NNS	O
for	IN	O
Env	NNP	O
protein	NN	O
production	NN	O
by	IN	O
Capture	NNP	O
ELISA	NNP	O
,	,	O
as	IN	O
described	VBN	O
above	IN	O
.	.	O
After	IN	O
reaching	VBG	O
confluency	NN	O
in	IN	O
24	CD	O
well	RB	O
plates	NNS	O
,	,	O
positive	JJ	O
clones	NNS	O
were	VBD	O
expanded	VBN	O
to	TO	O
T25	NNP	O
flasks	NNS	O
(	(	O
Corning	NNP	O
,	,	O
Corning	NNP	O
,	,	O
N	NNP	O
.	.	O
Y	NNP	O
.	.	O
)	)	O
.	.	O
These	DT	O
were	VBD	O
screened	VBN	O
several	JJ	O
times	NNS	O
after	IN	O
confluency	NN	O
and	CC	O
positive	JJ	O
clones	NNS	O
were	VBD	O
expanded	VBN	O
to	TO	O
T75	NNP	O
flasks	NNS	O
.	.	O
Positive	JJ	O
T75	NNP	O
clones	NNS	O
were	VBD	O
frozen	VBN	O
in	IN	O
LN2	NNP	O
and	CC	O
the	DT	O
highest	JJS	O
expressing	NN	O
clones	NNS	O
amplified	VBN	O
with	IN	O
0-5	JJ	O
μM	NN	O
methotrexate	NN	O
(	(	O
MTX	NNP	O
)	)	O
at	IN	O
several	JJ	O
concentrations	NNS	O
and	CC	O
plated	VBN	O
in	IN	O
100	CD	O
mm	JJ	O
culture	NN	O
dishes	NNS	O
.	.	O
Plates	NNS	O
were	VBD	O
screened	VBN	O
for	IN	O
colony	NN	O
formation	NN	O
and	CC	O
all	DT	O
positive	JJ	O
closed	VBN	O
were	VBD	O
again	RB	O
expanded	VBN	O
as	IN	O
described	VBN	O
above	IN	O
.	.	O
Clones	NNS	O
were	VBD	O
expanded	VBN	O
an	DT	O
amplified	JJ	O
and	CC	O
screened	VBN	O
at	IN	O
each	DT	O
step	NN	O
by	IN	O
gp120	JJ	O
capture	NN	O
ELISA	NNP	O
.	.	O
Positive	JJ	O
clones	NNS	O
were	VBD	O
frozen	VBN	O
at	IN	O
each	DT	O
methotrexate	NN	O
level	NN	O
.	.	O
Highest	NNP	O
producing	VBG	O
clones	NNS	O
were	VBD	O
grown	VBN	O
in	IN	O
perfusion	NN	O
bioreactors	NNS	O
(	(	O
3L	CD	O
,	,	O
100L	CD	O
)	)	O
for	IN	O
expansion	NN	O
and	CC	O
adaptation	NN	O
to	TO	O
low	JJ	O
serum	NN	O
suspension	NN	O
culture	NN	O
conditions	NNS	O
for	IN	O
scale-up	NN	O
to	TO	O
larger	JJR	O
bioreactors	NNS	O
.	.	O
Tables	NNS	O
5	CD	O
and	CC	O
6	CD	O
show	NN	O
Capture	NNP	O
ELISA	NNP	O
data	NNS	O
from	IN	O
CHO	NNP	O
cells	NNS	O
transfected	VBD	O
with	IN	O
pCMVIII	JJ	O
vector	NN	O
carrying	VBG	O
a	DT	O
cassette	NN	O
encoding	VBG	O
synthetic	JJ	O
HIV-US4	NNP	O
and	CC	O
SF162	NNP	O
Env	NNP	O
polypeptides	NNS	O
(	(	O
e.g.	NN	O
,	,	O
mutated	VBN	O
cleavage	NN	O
sites	NNS	O
,	,	O
modified	VBD	O
codon	JJ	O
usage	JJ	O
and/or	NN	O
deleted	VBD	O
hypervariable	JJ	O
regions	NNS	O
)	)	O
.	.	O
Thus	RB	O
,	,	O
stably	RB	O
transfected	VBD	O
CHO	NNP	O
cell	NN	O
lines	NNS	O
which	WDT	O
express	VBP	O
Env	NNP	O
polypeptides	NNS	O
(	(	O
e.g.	NN	O
,	,	O
gp120	NN	O
,	,	O
gp140-monomeric	JJ	O
,	,	O
and	CC	O
gp140-oligomeric	JJ	O
)	)	O
have	VBP	O
been	VBN	O
produced	VBN	O
.	.	O
The	DT	O
results	NNS	O
presented	VBN	O
above	IN	O
demonstrate	NN	O
the	DT	O
ability	NN	O
of	IN	O
the	DT	O
constructs	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
to	TO	O
provide	VB	O
expression	NN	O
of	IN	O
Env	NNP	O
polypeptides	NNS	O
in	IN	O
CHO	NNP	O
cells	NNS	O
.	.	O
Production	NN	O
of	IN	O
polypeptides	NNS	O
using	VBG	O
CHO	NNP	O
cells	NNS	O
provides	VBZ	O
(	(	O
i	NN	O
)	)	O
correct	VBP	O
glycosylation	NN	O
patterns	NNS	O
and	CC	O
protein	JJ	O
conformation	NN	O
(	(	O
as	IN	O
determined	VBN	O
by	IN	O
binding	VBG	O
to	TO	O
panel	NN	O
of	IN	O
MAbs	NNP	O
)	)	O
;	:	O
(	(	O
ii	NN	O
)	)	O
correct	VBP	O
binding	VBG	O
to	TO	O
CD4	NNP	O
receptor	NN	O
molecules	NNS	O
;	:	O
(	(	O
iii	NN	O
)	)	O
absence	NN	O
of	IN	O
non-mammalian	JJ	O
cell	NN	O
contaminants	NNS	O
(	(	O
e.g.	NN	O
,	,	O
insect	JJ	O
viruses	NNS	O
and/or	VBP	O
cells	NNS	O
)	)	O
;	:	O
and	CC	O
(	(	O
iv	NN	O
)	)	O
ease	NN	O
of	IN	O
purification	NN	O
.	.	O
D.	NNP	O
Tat	NNP	O
Coding	NNP	O
Sequences	VBZ	O
The	DT	O
HIV-SF162	NNP	O
(	(	O
“	NNP	O
SF162	NNP	O
”	NNP	O
)	)	O
wild-type	NN	O
Tat	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:85	NNP	O
)	)	O
sequences	NNS	O
were	VBD	O
cloned	VBN	O
into	IN	O
expression	NN	O
vectors	NNS	O
having	VBG	O
the	DT	O
same	JJ	O
features	NNS	O
as	IN	O
the	DT	O
vectors	NNS	O
into	IN	O
which	WDT	O
the	DT	O
synthetic	JJ	O
Tat	NNP	O
sequences	NNS	O
were	VBD	O
cloned	VBN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NOs:87	NNP	O
,	,	O
88	CD	O
and	CC	O
89	CD	O
)	)	O
.	.	O
Expression	NN	O
efficiencies	NNS	O
for	IN	O
various	JJ	O
vectors	NNS	O
carrying	VBG	O
the	DT	O
SF162	NNP	O
wild-type	NN	O
and	CC	O
synthetic	JJ	O
Tat	NNP	O
sequences	NNS	O
are	VBP	O
evaluated	VBN	O
essentially	RB	O
as	IN	O
described	VBN	O
above	IN	O
for	IN	O
Gag	NNP	O
and	CC	O
Env	NNP	O
using	VBG	O
capture	NN	O
ELISAs	NNP	O
with	IN	O
the	DT	O
appropriate	JJ	O
anti-tat	JJ	O
antibodies	NNS	O
and/or	VBP	O
CHO	NNP	O
cell	NN	O
assays	NNS	O
.	.	O
Expression	NN	O
of	IN	O
the	DT	O
polypeptides	NNS	O
encoded	VBN	O
by	IN	O
the	DT	O
synthetic	JJ	O
cassettes	NNS	O
is	VBZ	O
improved	JJ	O
relative	JJ	O
to	TO	O
wild	VB	O
type	NN	O
.	.	O
Example	RB	O
3	CD	O
Western	JJ	O
Blot	NNP	O
Analysis	NNP	O
of	IN	O
Expression	NNP	O
A.	NNP	O
Gag	NNP	O
and	CC	O
Gag-Protease	NNP	O
Coding	NNP	O
Sequences	NNP	O
Human	NNP	O
293	CD	O
cells	NNS	O
were	VBD	O
transfected	VBN	O
as	IN	O
described	VBN	O
in	IN	O
Example	NNP	O
2	CD	O
with	IN	O
pCMV6a-based	JJ	O
vectors	NNS	O
containing	VBG	O
native	JJ	O
or	CC	O
synthetic	JJ	O
Gag	NNP	O
expression	NN	O
cassettes	NNS	O
.	.	O
Cells	NNS	O
were	VBD	O
cultivated	VBN	O
for	IN	O
60	CD	O
hours	NNS	O
post-transfection	NN	O
.	.	O
Supernatants	NNS	O
were	VBD	O
prepared	VBN	O
as	IN	O
described	NN	O
.	.	O
Cell	NNP	O
lysates	NNS	O
were	VBD	O
prepared	VBN	O
as	IN	O
follows	VBZ	O
.	.	O
The	DT	O
cells	NNS	O
were	VBD	O
washed	VBN	O
once	RB	O
with	IN	O
phosphate-buffered	JJ	O
saline	NN	O
,	,	O
lysed	VBN	O
with	IN	O
detergent	NN	O
[	$	O
1	CD	O
%	NN	O
NP40	NNP	O
(	(	O
Sigma	NNP	O
Chemical	NNP	O
Co.	NNP	O
,	,	O
St.	NNP	O
Louis	NNP	O
,	,	O
Mo	NNP	O
.	.	O
)	)	O
in	IN	O
0.1	CD	O
M	NNP	O
Tris-HCl	NNP	O
,	,	O
pH	VBZ	O
7.5	CD	O
]	NN	O
,	,	O
and	CC	O
the	DT	O
lysate	NN	O
transferred	VBD	O
into	IN	O
fresh	JJ	O
tubes	NNS	O
.	.	O
SDS-polyacrylamide	JJ	O
gels	NNS	O
(	(	O
pre-cast	JJ	O
8-16	CD	O
%	NN	O
;	:	O
Novex	NNP	O
,	,	O
San	NNP	O
Diego	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
were	VBD	O
loaded	VBN	O
with	IN	O
20	CD	O
μl	NNS	O
of	IN	O
supernatant	NN	O
or	CC	O
12.5	CD	O
μl	NN	O
of	IN	O
cell	NN	O
lysate	NN	O
.	.	O
A	DT	O
protein	JJ	O
standard	NN	O
was	VBD	O
also	RB	O
loaded	VBN	O
(	(	O
5	CD	O
μl	NN	O
,	,	O
broad	JJ	O
size	NN	O
range	NN	O
standard	NN	O
;	:	O
BioRad	NNP	O
Laboratories	NNPS	O
,	,	O
Hercules	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
.	.	O
Electrophoresis	NN	O
was	VBD	O
carried	VBN	O
out	IN	O
and	CC	O
the	DT	O
proteins	NNS	O
were	VBD	O
transferred	VBN	O
using	VBG	O
a	DT	O
BioRad	NNP	O
Transfer	NNP	O
Chamber	NNP	O
(	(	O
BioRad	NNP	O
Laboratories	NNPS	O
,	,	O
Hercules	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
to	TO	O
Immobilon	NNP	O
P	NNP	O
membranes	NNS	O
(	(	O
Millipore	NNP	O
Corp.	NNP	O
,	,	O
Bedford	NNP	O
,	,	O
Mass	NNP	O
.	.	O
)	)	O
using	VBG	O
the	DT	O
transfer	NN	O
buffer	NN	O
recommended	VBN	O
by	IN	O
the	DT	O
manufacturer	NN	O
(	(	O
Millipore	NNP	O
)	)	O
,	,	O
where	WRB	O
the	DT	O
transfer	NN	O
was	VBD	O
performed	VBN	O
at	IN	O
100	CD	O
volts	NNS	O
for	IN	O
90	CD	O
minutes	NNS	O
.	.	O
The	DT	O
membranes	NNS	O
were	VBD	O
exposed	VBN	O
to	TO	O
HIV-1-positive	JJ	O
human	JJ	O
patient	NN	O
serum	NN	O
and	CC	O
immunostained	VBD	O
using	VBG	O
o-phenylenediamine	JJ	O
dihydrochloride	NN	O
(	(	O
OPD	NNP	O
;	:	O
Sigma	NNP	O
)	)	O
.	.	O
The	DT	O
results	NNS	O
of	IN	O
the	DT	O
immunoblotting	NN	O
analysis	NN	O
showed	VBD	O
that	IN	O
cells	NNS	O
containing	VBG	O
the	DT	O
synthetic	JJ	O
Gag	NNP	O
expression	NN	O
cassette	NN	O
produced	VBD	O
the	DT	O
expected	VBN	O
p55	NN	O
protein	NN	O
at	IN	O
higher	JJR	O
per-cell	NN	O
concentrations	NNS	O
than	IN	O
cells	NNS	O
containing	VBG	O
the	DT	O
native	JJ	O
expression	NN	O
cassette	NN	O
.	.	O
The	DT	O
Gag	NNP	O
p55	NN	O
protein	NN	O
was	VBD	O
seen	VBN	O
in	IN	O
both	DT	O
cell	NN	O
lysates	NNS	O
and	CC	O
supernatants	NNS	O
.	.	O
The	DT	O
levels	NNS	O
of	IN	O
production	NN	O
were	VBD	O
significantly	RB	O
higher	JJR	O
in	IN	O
cell	NN	O
supernatants	NNS	O
for	IN	O
cells	NNS	O
transfected	VBN	O
with	IN	O
the	DT	O
synthetic	JJ	O
Gag	NNP	O
expression	NN	O
cassette	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
.	.	O
Experiments	NNS	O
performed	VBN	O
in	IN	O
support	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
suggest	VBP	O
that	IN	O
cells	NNS	O
containing	VBG	O
the	DT	O
synthetic	JJ	O
Gag-prot	NNP	O
expression	NN	O
cassette	NN	O
produced	VBD	O
the	DT	O
expected	VBN	O
Gag-prot	NNP	O
protein	NN	O
at	IN	O
comparably	RB	O
higher	JJR	O
per-cell	NN	O
concentrations	NNS	O
than	IN	O
cells	NNS	O
containing	VBG	O
the	DT	O
native	JJ	O
expression	NN	O
cassette	NN	O
.	.	O
In	IN	O
addition	NN	O
,	,	O
supernatants	NNS	O
from	IN	O
the	DT	O
transfected	JJ	O
293	CD	O
cells	NNS	O
were	VBD	O
fractionated	VBN	O
on	IN	O
sucrose	JJ	O
gradients	NNS	O
.	.	O
Aliquots	NNS	O
of	IN	O
the	DT	O
supernatant	NN	O
were	VBD	O
transferred	VBN	O
to	TO	O
Polyclear™	VB	O
ultra-centrifuge	JJ	O
tubes	NNS	O
(	(	O
Beckman	NNP	O
Instruments	NNP	O
,	,	O
Columbia	NNP	O
,	,	O
Md	NNP	O
.	.	O
)	)	O
,	,	O
under-laid	JJ	O
with	IN	O
a	DT	O
solution	NN	O
of	IN	O
20	CD	O
%	NN	O
(	(	O
wt/wt	NN	O
)	)	O
sucrose	NN	O
,	,	O
and	CC	O
subjected	VBD	O
to	TO	O
2	CD	O
hours	NNS	O
centrifugation	NN	O
at	IN	O
28,000	CD	O
rpm	NN	O
in	IN	O
a	DT	O
Beckman	NNP	O
SW28	NNP	O
rotor	NN	O
.	.	O
The	DT	O
resulting	VBG	O
pellet	NN	O
was	VBD	O
suspended	VBN	O
in	IN	O
PBS	NNP	O
and	CC	O
layered	VBD	O
onto	IN	O
a	DT	O
20-60	JJ	O
%	NN	O
(	(	O
wt/wt	NN	O
)	)	O
sucrose	VB	O
gradient	NN	O
and	CC	O
subjected	VBN	O
to	TO	O
2	CD	O
hours	NNS	O
centrifugation	NN	O
at	IN	O
40,000	CD	O
rpm	NN	O
in	IN	O
a	DT	O
Beckman	NNP	O
SW41ti	NNP	O
rotor	NN	O
.	.	O
The	DT	O
gradient	NN	O
was	VBD	O
then	RB	O
fractionated	VBN	O
into	IN	O
approximately	RB	O
10×1	CD	O
ml	JJ	O
aliquots	NNS	O
(	(	O
starting	VBG	O
at	IN	O
the	DT	O
top	JJ	O
,	,	O
20	CD	O
%	NN	O
-end	NN	O
,	,	O
of	IN	O
the	DT	O
gradient	NN	O
)	)	O
.	.	O
Samples	NNS	O
were	VBD	O
taken	VBN	O
from	IN	O
fractions	NNS	O
1-9	CD	O
and	CC	O
were	VBD	O
electrophoresed	VBN	O
on	IN	O
8-16	CD	O
%	NN	O
SDS	NNP	O
polyacrylamide	NN	O
gels	NNS	O
.	.	O
Fraction	NNP	O
number	NN	O
4	CD	O
(	(	O
the	DT	O
peak	NN	O
fraction	NN	O
)	)	O
corresponds	VBZ	O
to	TO	O
the	DT	O
expected	VBN	O
density	NN	O
of	IN	O
Gag	NNP	O
protein	NN	O
VLPs	NNP	O
.	.	O
The	DT	O
supernatants	NNS	O
from	IN	O
293/synthetic	CD	O
Gag	NNP	O
cells	NNS	O
gave	VBD	O
much	RB	O
stronger	JJR	O
p55	NN	O
bands	NNS	O
than	IN	O
supernatants	NNS	O
from	IN	O
293/native	CD	O
Gag	NNP	O
cells	NNS	O
,	,	O
and	CC	O
,	,	O
as	IN	O
expected	VBN	O
,	,	O
the	DT	O
highest	JJS	O
concentration	NN	O
of	IN	O
p55	NN	O
in	IN	O
either	DT	O
supernatant	NN	O
was	VBD	O
found	VBN	O
in	IN	O
fraction	NN	O
4	CD	O
.	.	O
These	DT	O
results	NNS	O
demonstrate	VBP	O
that	IN	O
the	DT	O
synthetic	JJ	O
Gag	NNP	O
expression	NN	O
cassette	NN	O
provides	VBZ	O
superior	JJ	O
production	NN	O
of	IN	O
both	DT	O
p55	JJ	O
protein	NN	O
and	CC	O
VLPs	NNP	O
,	,	O
relative	JJ	O
to	TO	O
the	DT	O
native	JJ	O
Gag	NNP	O
coding	NN	O
sequences	NNS	O
.	.	O
B.	NNP	O
Env	NNP	O
Coding	NNP	O
Sequences	NNP	O
Human	NNP	O
293	CD	O
cells	NNS	O
were	VBD	O
transfected	VBN	O
as	IN	O
described	VBN	O
in	IN	O
Example	NNP	O
2	CD	O
with	IN	O
pCMVKm2-based	JJ	O
;	:	O
pCMVlink-based	JJ	O
;	:	O
p-CMVII-based	JJ	O
or	CC	O
pESN2-based	JJ	O
vectors	NNS	O
containing	VBG	O
native	JJ	O
or	CC	O
synthetic	JJ	O
Env	NNP	O
expression	NN	O
cassettes	NNS	O
.	.	O
Cells	NNS	O
were	VBD	O
cultivated	VBN	O
for	IN	O
48	CD	O
or	CC	O
60	CD	O
hours	NNS	O
post-transfection	NN	O
.	.	O
Cell	NNP	O
lysates	NNS	O
and	CC	O
supernatants	NNS	O
were	VBD	O
prepared	VBN	O
as	IN	O
described	NN	O
(	(	O
Example	NNP	O
2	CD	O
)	)	O
.	.	O
Briefly	NNP	O
,	,	O
the	DT	O
cells	NNS	O
were	VBD	O
washed	VBN	O
once	RB	O
with	IN	O
phosphate-buffered	JJ	O
saline	NN	O
,	,	O
lysed	VBN	O
with	IN	O
detergent	NN	O
[	$	O
1	CD	O
%	NN	O
NP40	NNP	O
(	(	O
Sigma	NNP	O
Chemical	NNP	O
Co.	NNP	O
,	,	O
St.	NNP	O
Louis	NNP	O
,	,	O
Mo	NNP	O
.	.	O
)	)	O
]	NN	O
in	IN	O
0.1	CD	O
M	NNP	O
Tris-HCl	NNP	O
,	,	O
pH	VBZ	O
7.5	CD	O
]	NN	O
,	,	O
and	CC	O
the	DT	O
lysate	NN	O
transferred	VBD	O
into	IN	O
fresh	JJ	O
tubes	NNS	O
.	.	O
SDS-polyacrylamide	JJ	O
gels	NNS	O
(	(	O
pre-cast	JJ	O
8-16	CD	O
%	NN	O
;	:	O
Novex	NNP	O
,	,	O
San	NNP	O
Diego	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
were	VBD	O
loaded	VBN	O
with	IN	O
20	CD	O
μl	NNS	O
of	IN	O
supernatant	NN	O
or	CC	O
12.5	CD	O
μl	NN	O
of	IN	O
cell	NN	O
lysate	NN	O
.	.	O
A	DT	O
protein	NN	O
molecular	JJ	O
weight	JJ	O
standard	NN	O
and	CC	O
an	DT	O
HIV	NNP	O
SF2	NNP	O
gp120	FW	O
positive	JJ	O
control	NN	O
protein	NN	O
(	(	O
5	CD	O
μl	NN	O
,	,	O
broad	JJ	O
size	NN	O
range	NN	O
standard	NN	O
;	:	O
BioRad	NNP	O
Laboratories	NNPS	O
,	,	O
Hercules	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
were	VBD	O
also	RB	O
loaded	VBN	O
.	.	O
Electrophoresis	NN	O
was	VBD	O
carried	VBN	O
out	IN	O
and	CC	O
the	DT	O
proteins	NNS	O
were	VBD	O
transferred	VBN	O
using	VBG	O
a	DT	O
BioRad	NNP	O
Transfer	NNP	O
Chamber	NNP	O
(	(	O
BioRad	NNP	O
Laboratories	NNPS	O
,	,	O
Hercules	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
to	TO	O
Immobilon	NNP	O
P	NNP	O
membranes	NNS	O
(	(	O
Millipore	NNP	O
Corp.	NNP	O
,	,	O
Bedford	NNP	O
,	,	O
Mass	NNP	O
.	.	O
)	)	O
using	VBG	O
the	DT	O
transfer	NN	O
buffer	NN	O
recommended	VBN	O
by	IN	O
the	DT	O
manufacturer	NN	O
(	(	O
Millipore	NNP	O
)	)	O
,	,	O
where	WRB	O
the	DT	O
transfer	NN	O
was	VBD	O
performed	VBN	O
at	IN	O
100	CD	O
volts	NNS	O
for	IN	O
90	CD	O
minutes	NNS	O
.	.	O
The	DT	O
membranes	NNS	O
were	VBD	O
then	RB	O
reacted	VBN	O
against	IN	O
polyclonal	JJ	O
goat	NN	O
anti-gp120SF2/env2-3	JJ	O
anti-sera	NN	O
,	,	O
followed	VBN	O
by	IN	O
incubation	NN	O
with	IN	O
swine	JJ	O
anti-goat	JJ	O
IgG-peroxidase	NNP	O
(	(	O
POD	NNP	O
)	)	O
(	(	O
Sigma	NNP	O
,	,	O
St.	NNP	O
Louis	NNP	O
,	,	O
Mo	NNP	O
.	.	O
)	)	O
.	.	O
Bands	NNP	O
indicative	NN	O
of	IN	O
binding	VBG	O
were	VBD	O
visualized	VBN	O
by	IN	O
adding	VBG	O
DAB	NNP	O
with	IN	O
hydrogen	NN	O
peroxide	NN	O
which	WDT	O
deposits	VBZ	O
a	DT	O
brown	JJ	O
precipitate	NN	O
on	IN	O
the	DT	O
membranes	NNS	O
.	.	O
The	DT	O
results	NNS	O
of	IN	O
the	DT	O
immunoblotting	NN	O
analysis	NN	O
showed	VBD	O
that	IN	O
cells	NNS	O
containing	VBG	O
the	DT	O
synthetic	JJ	O
Env	NNP	O
expression	NN	O
cassette	NN	O
produced	VBD	O
the	DT	O
expected	VBN	O
Env	NNP	O
gp	JJ	O
proteins	NNS	O
of	IN	O
the	DT	O
predicted	JJ	O
molecular	JJ	O
weights	NNS	O
as	IN	O
determined	VBN	O
by	IN	O
mobilities	NNS	O
in	IN	O
SDS-polyacrylamide	JJ	O
gels	NNS	O
at	IN	O
higher	JJR	O
per-cell	NN	O
concentrations	NNS	O
than	IN	O
cells	NNS	O
containing	VBG	O
the	DT	O
native	JJ	O
expression	NN	O
cassette	NN	O
.	.	O
The	DT	O
Env	NNP	O
proteins	NNS	O
were	VBD	O
seen	VBN	O
in	IN	O
both	DT	O
cell	NN	O
lysates	NNS	O
and	CC	O
supernatants	NNS	O
.	.	O
The	DT	O
levels	NNS	O
of	IN	O
production	NN	O
were	VBD	O
significantly	RB	O
higher	JJR	O
in	IN	O
cell	NN	O
supernatants	NNS	O
for	IN	O
cells	NNS	O
transfected	VBN	O
with	IN	O
the	DT	O
synthetic	JJ	O
Env	NNP	O
expression	NN	O
cassette	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
.	.	O
C.	NNP	O
Tat	NNP	O
Coding	NNP	O
Sequences	NNP	O
Human	NNP	O
293	CD	O
cells	NNS	O
are	VBP	O
transfected	VBN	O
as	IN	O
described	VBN	O
in	IN	O
Example	NNP	O
2	CD	O
with	IN	O
various	JJ	O
vectors	NNS	O
containing	VBG	O
native	JJ	O
or	CC	O
synthetic	JJ	O
Tat	NNP	O
expression	NN	O
cassettes	NNS	O
.	.	O
Cells	NNS	O
are	VBP	O
cultivated	VBN	O
and	CC	O
isolated	JJ	O
proteins	NNS	O
analyzed	VBN	O
as	IN	O
described	VBN	O
above	IN	O
.	.	O
Immunoblotting	VBG	O
analysis	NN	O
shows	NNS	O
that	WDT	O
cells	NNS	O
containing	VBG	O
the	DT	O
synthetic	JJ	O
Tat	NNP	O
expression	NN	O
cassette	NN	O
produced	VBD	O
the	DT	O
expected	VBN	O
Tat	NNP	O
proteins	NNS	O
of	IN	O
the	DT	O
predicted	JJ	O
molecular	JJ	O
weights	NNS	O
as	IN	O
determined	VBN	O
by	IN	O
mobilities	NNS	O
in	IN	O
SDS-polyacrylamide	JJ	O
gels	NNS	O
at	IN	O
higher	JJR	O
per-cell	NN	O
concentrations	NNS	O
than	IN	O
cells	NNS	O
containing	VBG	O
the	DT	O
native	JJ	O
expression	NN	O
cassette	NN	O
.	.	O
Example	RB	O
4	CD	O
Purification	NN	O
of	IN	O
Env	NNP	O
Polypeptides	NNP	O
A.	NNP	O
Purification	NNP	O
of	IN	O
Oligomeric	NNP	O
gp140	JJ	O
Purification	NNP	O
of	IN	O
oligomeric	JJ	O
gp140	NN	O
(	(	O
o-gp140	JJ	O
US4	NNP	O
)	)	O
was	VBD	O
conducted	VBN	O
essentially	RB	O
as	IN	O
shown	VBN	O
in	IN	O
FIG	NNP	O
.	.	O
60	CD	O
.	.	O
For	IN	O
the	DT	O
experiments	NNS	O
described	VBD	O
herein	JJ	O
,	,	O
o-gp140	JJ	O
refers	NNS	O
to	TO	O
oligomeric	VB	O
gp140	NN	O
in	IN	O
either	CC	O
native	JJ	O
or	CC	O
modified	VBN	O
(	(	O
e.g.	NN	O
,	,	O
optimized	VBN	O
expression	NN	O
sequences	NNS	O
,	,	O
deleted	VBN	O
,	,	O
mutated	VBN	O
,	,	O
truncated	VBN	O
,	,	O
etc	FW	O
.	.	O
)	)	O
form	NN	O
.	.	O
Briefly	NNP	O
,	,	O
concentrated	VBD	O
(	(	O
30-50×	JJ	O
)	)	O
supernatants	NNS	O
obtained	VBN	O
from	IN	O
CHO	NNP	O
cell	NN	O
cultures	NNS	O
were	VBD	O
loaded	VBN	O
onto	IN	O
an	DT	O
anion	NN	O
exchange	NN	O
(	(	O
DEAE	NNP	O
)	)	O
column	NN	O
which	WDT	O
removed	VBD	O
DNA	NNP	O
and	CC	O
other	JJ	O
serum	NN	O
proteins	NNS	O
.	.	O
The	DT	O
eluted	JJ	O
material	NN	O
was	VBD	O
loaded	VBN	O
onto	IN	O
a	DT	O
ceramic	JJ	O
hydroxyapatite	NN	O
column	NN	O
(	(	O
CHAP	NNP	O
)	)	O
which	WDT	O
bound	VBP	O
serum	NN	O
proteins	NNS	O
but	CC	O
not	RB	O
HIV	NNP	O
Env	NNP	O
proteins	VBZ	O
.	.	O
The	DT	O
flow-through	NN	O
from	IN	O
the	DT	O
DEAE	NNP	O
and	CC	O
CHAP	NNP	O
columns	NN	O
was	VBD	O
loaded	VBN	O
onto	IN	O
a	DT	O
Protein	NNP	O
A	NNP	O
column	NN	O
as	IN	O
a	DT	O
precautionary	JJ	O
step	NN	O
to	TO	O
remove	VB	O
any	DT	O
remaining	VBG	O
serum	NN	O
immunoglobulins	NNS	O
.	.	O
The	DT	O
Env	NNP	O
proteins	NNS	O
in	IN	O
the	DT	O
flow-through	JJ	O
were	VBD	O
then	RB	O
captured	VBN	O
using	VBG	O
the	DT	O
lectin	NN	O
gluvanthus	NN	O
navalis	NN	O
(	(	O
GNA	NNP	O
,	,	O
Vector	NNP	O
Labs	NNP	O
,	,	O
Burlingame	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
.	.	O
GNA	NNP	O
has	VBZ	O
high	JJ	O
affinity	NN	O
for	IN	O
mannose	JJ	O
rich	JJ	O
carbohydrates	NNS	O
such	JJ	O
as	IN	O
Env	NNP	O
.	.	O
The	DT	O
Env	NNP	O
proteins	NNS	O
were	VBD	O
then	RB	O
eluted	VBN	O
with	IN	O
GNA	NNP	O
substrate	NN	O
.	.	O
To	TO	O
remove	VB	O
other	JJ	O
highly	RB	O
glycosylated	JJ	O
proteins	NNS	O
,	,	O
a	DT	O
cation	NN	O
exchange	NN	O
column	NN	O
(	(	O
SP	NNP	O
)	)	O
was	VBD	O
used	VBN	O
to	TO	O
purify	VB	O
gp140/gp120	NN	O
.	.	O
In	IN	O
a	DT	O
final	JJ	O
step	NN	O
,	,	O
which	WDT	O
separates	VBZ	O
gp120	NN	O
from	IN	O
o-gp140	JJ	O
,	,	O
a	DT	O
gel	JJ	O
filtration	NN	O
column	NN	O
was	VBD	O
used	VBN	O
to	TO	O
separate	JJ	O
oligomers	NNS	O
from	IN	O
monomers	NNS	O
.	.	O
Sizing	VBG	O
and	CC	O
chromatography	JJ	O
analysis	NN	O
of	IN	O
the	DT	O
final	JJ	O
product	NN	O
revealed	VBD	O
that	IN	O
this	DT	O
strategy	NN	O
lead	NN	O
to	TO	O
the	DT	O
successful	JJ	O
isolation	NN	O
of	IN	O
oligomeric	JJ	O
gp140	NN	O
.	.	O
B.	NNP	O
Purification	NNP	O
of	IN	O
gp120	JJ	O
Purification	NNP	O
of	IN	O
gp120	NN	O
was	VBD	O
conducted	VBN	O
essentially	RB	O
as	IN	O
previously	RB	O
described	VBN	O
for	IN	O
other	JJ	O
Env	NNP	O
proteins	NNS	O
.	.	O
Briefly	NNP	O
,	,	O
concentrated	VBD	O
supernatants	NNS	O
obtained	VBN	O
from	IN	O
CHO	NNP	O
cell	NN	O
cultures	NNS	O
were	VBD	O
loaded	VBN	O
onto	IN	O
an	DT	O
anion	NN	O
exchange	NN	O
(	(	O
DEAF	NNP	O
)	)	O
column	NN	O
which	WDT	O
removed	VBD	O
DNA	NNP	O
and	CC	O
other	JJ	O
serum	NN	O
proteins	NNS	O
.	.	O
The	DT	O
eluted	JJ	O
material	NN	O
was	VBD	O
loaded	VBN	O
onto	IN	O
a	DT	O
ceramic	JJ	O
hydroxyapatite	NN	O
column	NN	O
(	(	O
CHAP	NNP	O
)	)	O
which	WDT	O
bound	VBP	O
serum	NN	O
proteins	NNS	O
but	CC	O
not	RB	O
HIV	NNP	O
Env	NNP	O
proteins	VBZ	O
.	.	O
The	DT	O
flow-through	NN	O
from	IN	O
the	DT	O
CHAP	NNP	O
column	NN	O
was	VBD	O
loaded	VBN	O
a	DT	O
cation	NN	O
exchange	NN	O
column	NN	O
(	(	O
SP	NNP	O
)	)	O
where	WRB	O
the	DT	O
flow-through	NN	O
was	VBD	O
discarded	VBN	O
and	CC	O
the	DT	O
bound	NN	O
fraction	NN	O
eluted	VBN	O
with	IN	O
salt	NN	O
.	.	O
The	DT	O
eluted	JJ	O
fraction	NN	O
(	(	O
s	PRP	O
)	)	O
were	VBD	O
loaded	VBN	O
onto	IN	O
a	DT	O
Suprose	NNP	O
12/Superdex	CD	O
200	CD	O
Tandem	NNP	O
column	NN	O
(	(	O
Pharmacia-Upjohn	NNP	O
,	,	O
Uppsala	NNP	O
,	,	O
Sweden	NNP	O
)	)	O
from	IN	O
which	WDT	O
purified	VBD	O
gp120	NN	O
was	VBD	O
obtained	VBN	O
.	.	O
Sizing	VBG	O
and	CC	O
chromatography	JJ	O
analysis	NN	O
of	IN	O
the	DT	O
final	JJ	O
product	NN	O
revealed	VBD	O
that	IN	O
this	DT	O
strategy	NN	O
successfully	RB	O
purified	VBN	O
gp120	NN	O
proteins	NNS	O
.	.	O
Example	RB	O
5	CD	O
Analysis	NN	O
of	IN	O
Purified	NNP	O
Env	NNP	O
Polypeptides	NNP	O
A	NNP	O
.	.	O
Analysis	NN	O
of	IN	O
o-gp140	JJ	O
It	PRP	O
is	VBZ	O
well	RB	O
documented	VBN	O
that	IN	O
HIV	NNP	O
Env	NNP	O
protein	NN	O
binds	VBZ	O
to	TO	O
CD4	NNP	O
only	RB	O
in	IN	O
its	PRP$	O
correct	JJ	O
conformation	NN	O
.	.	O
Accordingly	RB	O
,	,	O
the	DT	O
ability	NN	O
of	IN	O
o-gp140	JJ	O
US4	NNP	O
polypeptides	NNS	O
,	,	O
produced	VBN	O
and	CC	O
purified	VBN	O
as	IN	O
described	VBN	O
above	IN	O
,	,	O
to	TO	O
bind	VB	O
CD4	NNP	O
cells	NNS	O
was	VBD	O
tested	VBN	O
.	.	O
O-gp140	JJ	O
US4	NNP	O
was	VBD	O
incubated	VBN	O
for	IN	O
15	CD	O
minutes	NNS	O
with	IN	O
FITC-labeled	JJ	O
CD4	NNP	O
at	IN	O
room	NN	O
temperature	NN	O
and	CC	O
loaded	VBD	O
onto	IN	O
a	DT	O
Biosil	NNP	O
250	CD	O
(	(	O
BioRad	NNP	O
)	)	O
size	NN	O
exclusion	NN	O
column	NN	O
using	VBG	O
Waters	NNP	O
HPLC	NNP	O
.	.	O
CD4-FITC	NNP	O
has	VBZ	O
the	DT	O
longest	JJS	O
retention	NN	O
time	NN	O
(	(	O
2.67	CD	O
minutes	NNS	O
)	)	O
,	,	O
followed	VBN	O
by	IN	O
CD4-FITC-gp120	NNP	O
(	(	O
2.167	CD	O
min	NN	O
)	)	O
.	.	O
The	DT	O
shortest	JJS	O
retention	NN	O
time	NN	O
(	(	O
1.9	CD	O
min	NN	O
)	)	O
was	VBD	O
observed	VBN	O
for	IN	O
CD4-FITC-o-gp140	NNP	O
US4	NNP	O
indicating	NN	O
that	RB	O
,	,	O
as	IN	O
expected	VBN	O
,	,	O
o-gp140	JJ	O
US4	NNP	O
binds	VBZ	O
to	TO	O
CD4	NNP	O
forming	VBG	O
a	DT	O
large	JJ	O
complex	NN	O
which	WDT	O
reduces	VBZ	O
retention	NN	O
time	NN	O
on	IN	O
the	DT	O
column	NN	O
.	.	O
Thus	RB	O
,	,	O
the	DT	O
o-gp140	JJ	O
US4	NNP	O
produced	VBD	O
and	CC	O
purified	VBD	O
as	IN	O
described	VBN	O
above	IN	O
is	VBZ	O
of	IN	O
the	DT	O
correct	JJ	O
size	NN	O
and	CC	O
conformation	NN	O
.	.	O
In	IN	O
addition	NN	O
,	,	O
the	DT	O
US4	NNP	O
o-gp140	NN	O
,	,	O
purified	VBN	O
as	IN	O
described	VBN	O
above	IN	O
,	,	O
was	VBD	O
also	RB	O
tested	VBN	O
for	IN	O
its	PRP$	O
ability	NN	O
to	TO	O
bind	VB	O
to	TO	O
a	DT	O
variety	NN	O
of	IN	O
monoclonal	JJ	O
antibodies	NNS	O
with	IN	O
known	VBN	O
epitope	NN	O
specificities	NNS	O
for	IN	O
the	DT	O
CD4	NNP	O
binding	NN	O
site	NN	O
,	,	O
the	DT	O
CD4	NNP	O
inducible	JJ	O
site	NN	O
,	,	O
the	DT	O
V3	NNP	O
loop	NN	O
and	CC	O
oligomer-specific	JJ	O
gp41	NN	O
epitope	NN	O
.	.	O
O-gp140	NNP	O
bound	NN	O
strongly	RB	O
to	TO	O
these	DT	O
antibodies	NNS	O
,	,	O
indicating	VBG	O
that	IN	O
the	DT	O
purified	JJ	O
protein	NN	O
retains	VBZ	O
its	PRP$	O
structural	JJ	O
integrity	NN	O
.	.	O
B	NNP	O
.	.	O
Analysis	NN	O
of	IN	O
gp120	NN	O
As	IN	O
described	VBN	O
above	IN	O
,	,	O
CD4-FITC	NNP	O
binds	VBZ	O
gp120	NN	O
,	,	O
as	IN	O
demonstrated	VBN	O
by	IN	O
the	DT	O
decreased	JJ	O
retention	NN	O
time	NN	O
on	IN	O
the	DT	O
HPLC	NNP	O
column	NN	O
.	.	O
Thus	RB	O
,	,	O
US4	NNP	O
gp120	NN	O
purified	VBN	O
by	IN	O
the	DT	O
above	JJ	O
method	NN	O
retains	VBZ	O
its	PRP$	O
conformational	JJ	O
integrity	NN	O
.	.	O
In	IN	O
addition	NN	O
,	,	O
the	DT	O
properties	NNS	O
of	IN	O
purified	JJ	O
gp120	NN	O
can	MD	O
be	VB	O
tested	VBN	O
by	IN	O
examining	VBG	O
its	PRP$	O
integrity	NN	O
and	CC	O
identity	NN	O
on	IN	O
western	JJ	O
blots	NNS	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
,	,	O
by	IN	O
examining	VBG	O
protein	JJ	O
concentration	NN	O
,	,	O
pH	NN	O
,	,	O
conductivity	NN	O
,	,	O
endotoxin	NN	O
levels	NNS	O
,	,	O
bioburden	NN	O
and	CC	O
the	DT	O
like	JJ	O
.	.	O
US4	NNP	O
gp120	NN	O
,	,	O
purified	VBD	O
as	IN	O
described	VBN	O
above	IN	O
,	,	O
was	VBD	O
also	RB	O
tested	VBN	O
for	IN	O
its	PRP$	O
ability	NN	O
to	TO	O
bind	VB	O
to	TO	O
a	DT	O
variety	NN	O
of	IN	O
monoclonal	JJ	O
antibodies	NNS	O
with	IN	O
known	VBN	O
epitope	NN	O
specificities	NNS	O
for	IN	O
the	DT	O
CD4	NNP	O
binding	NN	O
site	NN	O
,	,	O
the	DT	O
CD4	NNP	O
inducible	JJ	O
site	NN	O
,	,	O
the	DT	O
V3	NNP	O
loop	NN	O
and	CC	O
oligomer-specific	JJ	O
gp41	NN	O
epitope	NN	O
.	.	O
The	DT	O
pattern	NN	O
of	IN	O
mAb	NN	O
binding	NN	O
to	TO	O
gp120	VB	O
indicated	JJ	O
that	IN	O
the	DT	O
purified	JJ	O
protein	NN	O
retained	VBD	O
its	PRP$	O
structural	JJ	O
integrity	NN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
the	DT	O
purified	JJ	O
gp120	NN	O
did	VBD	O
not	RB	O
bind	VB	O
the	DT	O
mAb	NN	O
having	VBG	O
the	DT	O
oligomer-specific	JJ	O
gp41	NN	O
epitope	NN	O
(	(	O
as	IN	O
expected	VBN	O
)	)	O
.	.	O
Example	RB	O
6	CD	O
Electron	NNP	O
Microscopic	NNP	O
Evaluation	NNP	O
of	IN	O
VLP	NNP	O
Production	NNP	O
The	DT	O
cells	NNS	O
for	IN	O
electron	NN	O
microscopy	NN	O
were	VBD	O
plated	VBN	O
at	IN	O
a	DT	O
density	NN	O
of	IN	O
50-70	JJ	O
%	NN	O
confluence	NN	O
,	,	O
one	CD	O
day	NN	O
before	IN	O
transfection	NN	O
.	.	O
The	DT	O
cells	NNS	O
were	VBD	O
transfected	VBN	O
with	IN	O
10	CD	O
μg	NNS	O
of	IN	O
DNA	NNP	O
using	VBG	O
transfection	NN	O
reagent	NN	O
LT1	NNP	O
(	(	O
Panvera	NNP	O
)	)	O
and	CC	O
incubated	VBN	O
for	IN	O
5	CD	O
hours	NNS	O
in	IN	O
serum-reduced	JJ	O
medium	NN	O
(	(	O
see	VB	O
Example	NNP	O
2	CD	O
)	)	O
.	.	O
The	DT	O
medium	NN	O
was	VBD	O
then	RB	O
replaced	VBN	O
with	IN	O
normal	JJ	O
medium	NN	O
(	(	O
see	VB	O
Example	NNP	O
2	CD	O
)	)	O
and	CC	O
the	DT	O
cells	NNS	O
were	VBD	O
incubated	VBN	O
for	IN	O
14	CD	O
hours	NNS	O
(	(	O
COS-7	NNP	O
)	)	O
or	CC	O
40	CD	O
hours	NNS	O
(	(	O
CHO	NNP	O
)	)	O
.	.	O
After	IN	O
incubation	NN	O
the	DT	O
cells	NNS	O
were	VBD	O
washed	VBN	O
twice	RB	O
with	IN	O
PBS	NNP	O
and	CC	O
fixed	VBN	O
with	IN	O
2	CD	O
%	NN	O
glutaraldehyde	NN	O
.	.	O
Electron	NNP	O
microscopy	NN	O
was	VBD	O
performed	VBN	O
by	IN	O
Prof.	NNP	O
T.	NNP	O
S.	NNP	O
Benedict	NNP	O
Yen	NNP	O
,	,	O
Veterans	NNP	O
Affairs	NNPS	O
,	,	O
Medical	NNP	O
Center	NNP	O
,	,	O
San	NNP	O
Francisco	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
.	.	O
Electron	NNP	O
microscopy	NN	O
was	VBD	O
carried	VBN	O
out	RP	O
using	VBG	O
a	DT	O
transmission	NN	O
electron	NN	O
microscope	NN	O
(	(	O
Zeiss	NNP	O
10c	CD	O
)	)	O
.	.	O
The	DT	O
cells	NNS	O
were	VBD	O
pre-stained	JJ	O
with	IN	O
osmium	NN	O
and	CC	O
stained	VBN	O
with	IN	O
uranium	JJ	O
acetate	NN	O
and	CC	O
lead	JJ	O
citrate	NN	O
.	.	O
The	DT	O
magnification	NN	O
was	VBD	O
100,000×	CD	O
.	.	O
FIGS	NNP	O
.	.	O
3A	CD	O
and	CC	O
3B	CD	O
show	NN	O
micrographs	NN	O
of	IN	O
CHO	NNP	O
cells	NNS	O
transfected	VBD	O
with	IN	O
pCMVKM2	NN	O
carrying	VBG	O
the	DT	O
synthetic	JJ	O
Gag	NNP	O
expression	NN	O
cassette	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:5	NNP	O
)	)	O
or	CC	O
carrying	VBG	O
the	DT	O
Gag-prot	NNP	O
expression	NN	O
cassette	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:79	NNP	O
)	)	O
.	.	O
In	IN	O
the	DT	O
figure	NN	O
,	,	O
free	JJ	O
and	CC	O
budding	JJ	O
immature	NN	O
virus-like-particles	NNS	O
(	(	O
VLP	NNP	O
)	)	O
of	IN	O
the	DT	O
expected	VBN	O
size	NN	O
(	(	O
100	CD	O
nm	NN	O
)	)	O
are	VBP	O
seen	VBN	O
for	IN	O
the	DT	O
Gag	NNP	O
expression	NN	O
cassette	NN	O
(	(	O
FIG	NNP	O
.	.	O
3A	CD	O
)	)	O
and	CC	O
both	DT	O
immature	NN	O
and	CC	O
mature	NN	O
VLPs	NNP	O
are	VBP	O
seen	VBN	O
for	IN	O
the	DT	O
Gag-prot	NNP	O
expression	NN	O
cassette	NN	O
(	(	O
FIG	NNP	O
.	.	O
38	CD	O
)	)	O
.	.	O
COS-7	NNP	O
cells	NNS	O
transfected	VBN	O
with	IN	O
the	DT	O
same	JJ	O
vector	NN	O
have	VBP	O
the	DT	O
same	JJ	O
expression	NN	O
pattern	NN	O
.	.	O
VLP	NNP	O
can	MD	O
also	RB	O
be	VB	O
found	VBN	O
intracellularly	RB	O
in	IN	O
CHO	NNP	O
and	CC	O
COS-7	NNP	O
cells	NNS	O
.	.	O
Native	JJ	O
and	CC	O
synthetic	JJ	O
Gag	NNP	O
expression	NN	O
cassettes	NNS	O
were	VBD	O
compared	VBN	O
for	IN	O
their	PRP$	O
associated	JJ	O
levels	NNS	O
of	IN	O
VLP	NNP	O
production	NN	O
when	WRB	O
used	VBN	O
to	TO	O
transfect	VB	O
human	JJ	O
293	CD	O
cells	NNS	O
.	.	O
The	DT	O
comparison	NN	O
was	VBD	O
performed	VBN	O
by	IN	O
density	NN	O
gradient	JJ	O
ultracentrifugation	NN	O
of	IN	O
cell	NN	O
supernatants	NNS	O
and	CC	O
Western-blot	JJ	O
analysis	NN	O
of	IN	O
the	DT	O
gradient	JJ	O
fractions	NNS	O
.	.	O
There	EX	O
was	VBD	O
a	DT	O
clear	JJ	O
improvement	NN	O
in	IN	O
production	NN	O
of	IN	O
VLPs	NNP	O
when	WRB	O
using	VBG	O
the	DT	O
synthetic	JJ	O
Gag	NNP	O
construct	NN	O
.	.	O
Example	RB	O
7	CD	O
Expression	NN	O
of	IN	O
Virus-Like	NNP	O
Particles	NNP	O
in	IN	O
the	DT	O
Baculovirus	NNP	O
System	NNP	O
A	NNP	O
.	.	O
Expression	NN	O
of	IN	O
Native	NNP	O
HIV	NNP	O
p55	NN	O
Gag	NNP	O
To	TO	O
construct	VB	O
the	DT	O
native	JJ	O
HIV	NNP	O
p55	NN	O
Gag	NNP	O
baculovirus	NN	O
shuttle	NN	O
vector	NN	O
,	,	O
the	DT	O
prototype	NN	O
SF2	NNP	O
HIV	NNP	O
p55	NN	O
plasmid	NN	O
,	,	O
pTM1-Gag	NN	O
(	(	O
Selby	NNP	B
M.	NNP	I
J.	NNP	I
,	,	I
et	FW	I
al.	NN	I
,	,	I
J.	NNP	I
Virol	NNP	I
.	.	I
71	CD	I
(	(	I
10	CD	I
)	)	I
:7827-7831	NN	I
,	,	I
1997	CD	I
)	)	O
,	,	O
was	VBD	O
digested	VBN	O
with	IN	O
restriction	NN	O
endonucleases	NNS	O
NcoI	NNP	O
and	CC	O
BamHI	NNP	O
to	TO	O
extract	VB	O
a	DT	O
1.5	CD	O
Kb	NNP	O
fragment	NN	O
that	WDT	O
was	VBD	O
subsequently	RB	O
subcloned	VBN	O
into	IN	O
pAcC4	NN	O
(	(	O
Bio/Technology	NNP	B
6:47-55	CD	I
,	,	I
1988	CD	I
)	)	O
,	,	O
a	DT	O
derivative	NN	O
of	IN	O
pAc436	NN	O
.	.	O
Generation	NN	O
of	IN	O
the	DT	O
recombinant	JJ	O
baculovirus	NN	O
was	VBD	O
achieved	VBN	O
by	IN	O
co-transfecting	JJ	O
2	CD	O
μg	NN	O
of	IN	O
the	DT	O
HIV	NNP	O
p55	NN	O
Gag	NNP	O
pAcC4	NN	O
shuttle	NN	O
vector	NN	O
with	IN	O
0.5	CD	O
μg	NNS	O
of	IN	O
linearized	JJ	O
,	,	O
Autographa	NNP	O
californica	NN	O
baculovirus	NN	O
(	(	O
AcNPV	NNP	O
)	)	O
wild-type	JJ	O
viral	JJ	O
DNA	NNP	O
into	IN	O
Spodoptera	NNP	O
frugiperda	NN	O
(	(	O
Sf9	NNP	O
)	)	O
cells	NNS	O
(	(	O
Kitts	NNP	B
,	,	I
P.	NNP	I
A.	NN	I
,	,	I
Ayres	NNP	I
M.	NNP	I
D.	NNP	I
,	,	I
and	CC	I
Possee	NNP	I
R.	NNP	I
D.	NNP	I
,	,	I
Nucleic	NNP	I
Acids	NNP	I
Res	NNP	I
.	.	I
18:5667-5672	CD	I
,	,	I
1990	CD	I
)	)	O
.	.	O
The	DT	O
isolation	NN	O
of	IN	O
recombinant	JJ	O
virus	NN	O
expressing	VBG	O
HIV	NNP	O
p55	NN	O
Gag	NNP	O
was	VBD	O
performed	VBN	O
according	VBG	O
to	TO	O
standard	NN	O
techniques	NNS	O
(	(	O
O'Reilly	RB	B
,	,	I
D.	NNP	I
R.	NNP	I
,	,	I
L.	NNP	I
K.	NNP	I
Miller	NNP	I
,	,	I
and	CC	I
V.	NNP	I
A.	NNP	I
Luckow	NNP	I
,	,	I
Baculovirus	NNP	I
Expression	NNP	I
Vector	NNP	I
:	:	I
A	DT	I
Laboratory	NNP	I
Manual	NNP	I
,	,	I
W.H	NNP	I
.	.	I
Freeman	NNP	I
and	CC	I
Company	NNP	I
,	,	I
New	NNP	I
York	NNP	I
,	,	I
1992	CD	I
)	)	O
.	.	O
Expression	NN	O
of	IN	O
the	DT	O
HIV	NNP	O
p55	NN	O
Gag	NNP	O
was	VBD	O
achieved	VBN	O
using	VBG	O
a	DT	O
500	CD	O
ml	NN	O
suspension	NN	O
culture	NN	O
of	IN	O
,	,	O
Sf9	NNP	O
cells	NNS	O
grown	VBN	O
in	IN	O
serum-free	JJ	O
medium	NN	O
(	(	O
Miaorella	NNP	B
,	,	I
B.	NNP	I
,	,	I
D.	NNP	I
Inlow	NNP	I
,	,	I
A.	NNP	I
Shauger	NNP	I
,	,	I
and	CC	I
D.	NNP	I
Harano	NNP	I
,	,	I
Bio/Technology	NNP	I
6:1506-1510	CD	I
,	,	I
1988	CD	I
)	)	O
that	WDT	O
had	VBD	O
been	VBN	O
infected	VBN	O
with	IN	O
the	DT	O
HIV	NNP	O
p55	NN	O
Gag	NNP	O
recombinant	NN	O
baculovirus	NN	O
at	IN	O
a	DT	O
multiplicity	NN	O
of	IN	O
infection	NN	O
(	(	O
MOI	NNP	O
)	)	O
of	IN	O
10	CD	O
.	.	O
Forty-eight	JJ	O
hours	NNS	O
post-infection	NN	O
,	,	O
the	DT	O
supernatant	NN	O
was	VBD	O
separated	VBN	O
by	IN	O
centrifugation	NN	O
and	CC	O
filtered	VBD	O
through	IN	O
a	DT	O
0.2	CD	O
μm	NN	O
filter	NN	O
.	.	O
Aliquots	NNS	O
of	IN	O
the	DT	O
supernatant	NN	O
were	VBD	O
then	RB	O
transferred	VBN	O
to	TO	O
Polyclear™	NNP	O
(	(	O
Beckman	NNP	O
Instruments	NNP	O
,	,	O
Palo	NNP	O
Alto	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
ultracentrifuge	NN	O
tubes	NNS	O
,	,	O
underlaid	JJ	O
with	IN	O
20	CD	O
%	NN	O
(	(	O
wt/wt	NN	O
)	)	O
sucrose	NN	O
,	,	O
and	CC	O
subjected	VBD	O
to	TO	O
2	CD	O
hours	NNS	O
centrifugation	NN	O
at	IN	O
24,00	CD	O
rpm	NN	O
using	VBG	O
a	DT	O
Beckman	NNP	O
SW28	NNP	O
rotor	NN	O
.	.	O
The	DT	O
resulting	VBG	O
pellet	NN	O
was	VBD	O
suspended	VBN	O
in	IN	O
Tris	NNP	O
buffer	NN	O
(	(	O
20	CD	O
mM	NN	O
Tris	NNP	O
HCl	NNP	O
,	,	O
pH	NN	O
7.5	CD	O
,	,	O
250	CD	O
mM	NN	O
NaCl	NNP	O
,	,	O
and	CC	O
2.5	CD	O
mM	NNS	O
ethylenediaminetetraacetic	JJ	O
acid	NN	O
[	NNP	O
EDTA	NNP	O
]	NNP	O
)	)	O
,	,	O
layered	VBD	O
onto	IN	O
a	DT	O
20-60	JJ	O
%	NN	O
(	(	O
wt/wt	NN	O
)	)	O
sucrose	NN	O
gradient	NN	O
,	,	O
and	CC	O
subjected	VBD	O
to	TO	O
2	CD	O
hours	NNS	O
centrifugation	NN	O
at	IN	O
40,000	CD	O
rpm	NN	O
using	VBG	O
a	DT	O
Beckman	NNP	O
SW41ti	NNP	O
rotor	NN	O
.	.	O
The	DT	O
gradient	NN	O
was	VBD	O
then	RB	O
fractionated	VBN	O
starting	VBG	O
at	IN	O
the	DT	O
top	NN	O
(	(	O
20	CD	O
%	NN	O
sucrose	NN	O
)	)	O
of	IN	O
the	DT	O
gradient	NN	O
into	IN	O
approximately	RB	O
twelve	JJ	O
0.75	CD	O
ml	JJ	O
aliquots	NNS	O
.	.	O
A	DT	O
sample	NN	O
of	IN	O
each	DT	O
fraction	NN	O
was	VBD	O
electrophoresed	VBN	O
on	IN	O
8-16	CD	O
%	NN	O
SDS	NNP	O
polyacrylamide	NN	O
gels	NNS	O
and	CC	O
the	DT	O
resulting	VBG	O
bands	NNS	O
were	VBD	O
visualized	VBN	O
after	IN	O
commassie	NN	O
staining	NN	O
(	(	O
FIG	NNP	O
.	.	O
4	CD	O
)	)	O
.	.	O
Additional	JJ	O
aliquots	NNS	O
were	VBD	O
subjected	VBN	O
to	TO	O
refractive	VB	O
index	NN	O
analysis	NN	O
.	.	O
The	DT	O
results	NNS	O
shown	VBN	O
in	IN	O
FIG	NNP	O
.	.	O
4	CD	O
indicated	VBD	O
that	IN	O
the	DT	O
p55	NN	O
Gag	NNP	O
virus-like	JJ	O
particles	NNS	O
banded	VBN	O
at	IN	O
a	DT	O
sucrose	JJ	O
density	NN	O
of	IN	O
range	NN	O
of	IN	O
1.15-1.19	JJ	O
g/ml	NN	O
with	IN	O
the	DT	O
peak	NN	O
at	IN	O
approximately	RB	O
1.17	CD	O
g/ml	NNS	O
.	.	O
The	DT	O
peak	JJ	O
fractions	NNS	O
were	VBD	O
pooled	VBN	O
and	CC	O
concentrated	VBN	O
by	IN	O
a	DT	O
second	JJ	O
20	CD	O
%	NN	O
sucrose	JJ	O
pelleting	NN	O
.	.	O
The	DT	O
resulting	VBG	O
pellet	NN	O
was	VBD	O
suspended	VBN	O
in	IN	O
1	CD	O
ml	NN	O
of	IN	O
Tris	NNP	O
buffer	NN	O
(	(	O
described	VBN	O
above	IN	O
)	)	O
.	.	O
The	DT	O
total	JJ	O
protein	JJ	O
yield	NN	O
as	IN	O
estimated	VBN	O
by	IN	O
Bicimchrominic	NNP	O
Acid	NNP	O
(	(	O
BCA	NNP	O
)	)	O
(	(	O
Pierce	NNP	O
Chemical	NNP	O
,	,	O
Rockford	NNP	O
,	,	O
Ill.	NNP	O
)	)	O
was	VBD	O
1.6	CD	O
mg.	NN	O
B	NNP	O
.	.	O
Expression	NN	O
of	IN	O
Synthetic	NNP	O
HIV	NNP	O
p55	NN	O
Gag	NNP	O
A	NNP	O
baculovirus	NN	O
shuttle	NN	O
vector	NN	O
containing	VBG	O
the	DT	O
synthetic	JJ	O
p55	NN	O
Gag	NNP	O
sequence	NN	O
was	VBD	O
constructed	VBN	O
as	IN	O
follows	VBZ	O
.	.	O
The	DT	O
synthetic	JJ	O
HIV	NNP	O
p55	NN	O
expression	NN	O
cassette	NN	O
(	(	O
Example	NNP	O
1	CD	O
)	)	O
was	VBD	O
digested	VBN	O
with	IN	O
restriction	NN	O
enzyme	NN	O
Sail	NNP	O
followed	VBN	O
by	IN	O
incubation	NN	O
with	IN	O
T4-DNA	NNP	O
polymerase	NN	O
.	.	O
The	DT	O
resulting	VBG	O
fragment	NN	O
was	VBD	O
isolated	VBN	O
(	(	O
PCR	NNP	B
Clean-Up™	NNP	I
,	,	I
Promega	NNP	I
,	,	I
Madison	NNP	I
,	,	I
Wis.	NNP	I
)	)	O
and	CC	O
then	RB	O
digested	VBD	O
with	IN	O
BamHI	NNP	O
endonuclease	NN	O
.	.	O
The	DT	O
shuttle	JJ	O
vector	NN	O
pAcC13	NN	O
(	(	O
Munemitsu	NNP	B
S.	NNP	I
,	,	I
et	FW	I
al.	NN	I
,	,	I
Mol	NNP	I
Cell	NNP	I
Biol	NNP	I
.	.	I
10	CD	I
(	(	I
11	CD	I
)	)	I
:5977-5982	NN	I
,	,	I
1990	CD	I
)	)	O
was	VBD	O
linearized	VBN	O
by	IN	O
digestion	NN	O
with	IN	O
EcoI	NNP	O
,	,	O
followed	VBN	O
by	IN	O
incubation	NN	O
with	IN	O
T4-DNA	NNP	O
polymerase	NN	O
,	,	O
and	CC	O
then	RB	O
isolated	VBD	O
(	(	O
PCR	NNP	O
Clean-Up™	NNP	O
)	)	O
.	.	O
The	DT	O
linearized	JJ	O
vector	NN	O
was	VBD	O
digested	VBN	O
with	IN	O
BamHI	NNP	O
,	,	O
treated	VBD	O
with	IN	O
alkaline	JJ	O
phosphatase	NN	O
,	,	O
and	CC	O
isolated	VBN	O
by	IN	O
size	NN	O
fragmentation	NN	O
in	IN	O
an	DT	O
agarose	JJ	O
gel	NN	O
.	.	O
The	DT	O
isolated	JJ	O
1.5	CD	O
kb	JJ	O
fragment	NN	O
was	VBD	O
ligated	VBN	O
with	IN	O
the	DT	O
prepared	JJ	O
pAcC13	NN	O
vector	NN	O
.	.	O
The	DT	O
resulting	VBG	O
clone	NN	O
was	VBD	O
designated	VBN	O
pAcC13-Modif.p55Gag	NN	O
.	.	O
The	DT	O
expression	NN	O
conditions	NNS	O
for	IN	O
the	DT	O
synthetic	JJ	O
HIV	NNP	O
p55	NN	O
VLPs	NNP	O
differed	VBD	O
from	IN	O
those	DT	O
of	IN	O
the	DT	O
native	JJ	O
p55	NN	O
Gag	NNP	O
as	IN	O
follows	VBZ	O
:	:	O
a	DT	O
culture	NN	O
volume	NN	O
of	IN	O
1	CD	O
liter	NN	O
used	VBN	O
instead	RB	O
of	IN	O
500	CD	O
ml	NN	O
;	:	O
Trichoplusia	NNP	O
ni	FW	O
(	(	O
Tn5	NNP	O
)	)	O
(	(	O
Wickham	NNP	B
,	,	I
T.	NNP	I
J.	NNP	I
,	,	I
and	CC	I
Nermerow	NNP	I
,	,	I
G.	NNP	I
R.	NNP	I
,	,	I
BioTechnology	NNP	I
Progress	NNP	I
,	,	I
9:25-30	CD	I
,	,	I
1993	CD	I
)	)	O
insect	VBP	O
cells	NNS	O
were	VBD	O
used	VBN	O
instead	RB	O
of	IN	O
Sf9	NNP	O
insect	JJ	O
cells	NNS	O
;	:	O
and	CC	O
,	,	O
an	DT	O
MOI	NNP	O
of	IN	O
3	CD	O
was	VBD	O
instead	RB	O
of	IN	O
an	DT	O
MOI	NNP	O
of	IN	O
10	CD	O
.	.	O
Experiments	NNS	O
performed	VBN	O
in	IN	O
support	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
showed	VBD	O
that	IN	O
there	EX	O
was	VBD	O
no	DT	O
appreciable	JJ	O
difference	NN	O
in	IN	O
expression	NN	O
level	NN	O
between	IN	O
the	DT	O
Sf9	NNP	O
and	CC	O
Tn5	NNP	O
insect	VBP	O
cells	NNS	O
with	IN	O
the	DT	O
native	JJ	O
p55	NN	O
clone	NN	O
.	.	O
In	IN	O
terms	NNS	O
of	IN	O
MOI	NNP	O
,	,	O
experience	NN	O
with	IN	O
the	DT	O
native	JJ	O
p55	NN	O
clone	NN	O
suggested	VBD	O
that	IN	O
an	DT	O
MOI	NNP	O
of	IN	O
10	CD	O
resulted	VBD	O
in	IN	O
higher	JJR	O
expression	NN	O
(	(	O
approximately	RB	O
2-fold	JJ	O
)	)	O
of	IN	O
VLPs	NNP	O
than	IN	O
a	DT	O
lower	JJR	O
MOI	NNP	O
.	.	O
The	DT	O
sucrose	JJ	O
pelleting	NN	O
and	CC	O
banding	NN	O
methods	NNS	O
used	VBN	O
for	IN	O
the	DT	O
synthetic	JJ	O
p55	NN	O
VLPs	NNP	O
were	VBD	O
similar	JJ	O
to	TO	O
those	DT	O
employed	VBN	O
for	IN	O
the	DT	O
native	JJ	O
p55	NN	O
VLPs	NNP	O
(	(	O
described	VBN	O
above	IN	O
)	)	O
,	,	O
with	IN	O
the	DT	O
following	JJ	O
exceptions	NNS	O
:	:	O
pelleted	VBN	O
VLPs	NNP	O
were	VBD	O
suspended	VBN	O
in	IN	O
4	CD	O
ml	NN	O
of	IN	O
phosphate	NN	O
buffered	VBN	O
saline	NN	O
(	(	O
PBS	NNP	O
)	)	O
instead	RB	O
of	IN	O
1.0	CD	O
ml	NN	O
of	IN	O
the	DT	O
Tris	NNP	O
buffer	NN	O
;	:	O
and	CC	O
four	CD	O
,	,	O
20-60	CD	O
%	NN	O
sucrose	JJ	O
gradients	NNS	O
were	VBD	O
used	VBN	O
instead	RB	O
of	IN	O
a	DT	O
single	JJ	O
gradient	NN	O
.	.	O
Also	RB	O
,	,	O
due	JJ	O
to	TO	O
the	DT	O
high	JJ	O
concentration	NN	O
of	IN	O
banded	JJ	O
VLPs	NNP	O
,	,	O
further	JJ	O
concentration	NN	O
by	IN	O
pelleting	VBG	O
was	VBD	O
not	RB	O
required	VBN	O
.	.	O
The	DT	O
peak	JJ	O
fractions	NNS	O
from	IN	O
all	DT	O
4	CD	O
gradients	NNS	O
were	VBD	O
simply	RB	O
dialyzed	VBN	O
against	IN	O
PBS	NNP	O
.	.	O
The	DT	O
approximate	JJ	O
density	NN	O
of	IN	O
the	DT	O
banded	JJ	O
VLPs	NNP	O
ranged	VBD	O
from	IN	O
1.23-1.28	JJ	O
g/ml	NN	O
.	.	O
A	DT	O
total	JJ	O
protein	JJ	O
yield	NN	O
as	IN	O
estimated	VBN	O
by	IN	O
BCA	NNP	O
was	VBD	O
46	CD	O
mg	NN	O
.	.	O
Results	NNS	O
from	IN	O
the	DT	O
sucrose	JJ	O
gradient	NN	O
banding	NN	O
of	IN	O
the	DT	O
synthetic	JJ	O
p55	NN	O
are	VBP	O
shown	VBN	O
in	IN	O
FIG	NNP	O
.	.	O
5	CD	O
.	.	O
A	DT	O
comparison	NN	O
of	IN	O
the	DT	O
total	JJ	O
amount	NN	O
of	IN	O
purified	JJ	O
HIV	NNP	O
p55	NN	O
Gag	NNP	O
from	IN	O
several	JJ	O
preparations	NNS	O
obtained	VBN	O
from	IN	O
the	DT	O
two	CD	O
baculovirus	NN	O
expression	NN	O
cassettes	VBZ	O
has	VBZ	O
been	VBN	O
summarized	VBN	O
in	IN	O
FIG	NNP	O
.	.	O
6	CD	O
.	.	O
The	DT	O
average	JJ	O
yield	NN	O
from	IN	O
the	DT	O
native	JJ	O
p55	NN	O
was	VBD	O
3.16	CD	O
mg/liter	NN	O
of	IN	O
culture	NN	O
(	(	O
n=5	UH	O
,	,	O
standard	JJ	O
deviation	NN	O
(	(	O
sd	NN	O
)	)	O
±1.07	NN	O
,	,	O
range=1.8-4.8	JJ	O
mg/L	NN	O
)	)	O
whereas	IN	O
the	DT	O
average	JJ	O
yield	NN	O
from	IN	O
the	DT	O
synthetic	JJ	O
p55	NN	O
was	VBD	O
more	JJR	O
than	IN	O
ten-fold	JJ	O
higher	JJR	O
at	IN	O
44.5	CD	O
mg/liter	NN	O
of	IN	O
culture	NN	O
(	(	O
n=2	JJ	O
,	,	O
sd=±6.4	NN	O
)	)	O
.	.	O
In	IN	O
addition	NN	O
to	TO	O
a	DT	O
higher	JJR	O
total	JJ	O
protein	JJ	O
yield	NN	O
,	,	O
the	DT	O
final	JJ	O
product	NN	O
from	IN	O
the	DT	O
synthetic	JJ	O
p55-expressed	JJ	O
Gag	NNP	O
consistently	RB	O
contained	VBD	O
lower	JJR	O
amounts	NNS	O
of	IN	O
contaminating	VBG	O
baculovirus	NN	O
proteins	NNS	O
than	IN	O
the	DT	O
final	JJ	O
product	NN	O
from	IN	O
the	DT	O
native	JJ	O
p55-expressed	JJ	O
Gag	NNP	O
.	.	O
This	DT	O
difference	NN	O
can	MD	O
be	VB	O
seen	VBN	O
in	IN	O
the	DT	O
two	CD	O
commassie-stained	JJ	O
gels	NNS	O
FIGS	NNP	O
.	.	O
4	CD	O
and	CC	O
5	CD	O
.	.	O
C.	NNP	O
Expression	NNP	O
of	IN	O
Native	NNP	O
and	CC	O
Synthetic	NNP	O
Gag-Core	NNP	O
Expression	NNP	O
of	IN	O
the	DT	O
HIV	NNP	O
p55	NN	O
Gag/HCV	NNP	O
Core	NNP	O
173	CD	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:8	NNP	O
)	)	O
was	VBD	O
achieved	VBN	O
using	VBG	O
a	DT	O
2.5	CD	O
liter	NN	O
suspension	NN	O
culture	NN	O
of	IN	O
Sf9	NNP	O
cells	NNS	O
grown	VBN	O
in	IN	O
serum-free	JJ	O
medium	NN	O
(	(	O
Miaorella	NNP	B
,	,	I
B.	NNP	I
,	,	I
D.	NNP	I
Inlow	NNP	I
,	,	I
A.	NNP	I
Shauger	NNP	I
,	,	I
and	CC	I
D.	NNP	I
Harano	NNP	I
.	.	I
1988	CD	I
Bio/Technology	NNP	I
6:1506-1510	JJ	I
)	)	O
.	.	O
The	DT	O
cells	NNS	O
were	VBD	O
infected	VBN	O
with	IN	O
an	DT	O
HIV	NNP	O
p55	NN	O
Gag/HCV	NNP	O
Core	NNP	O
173	CD	O
recombinant	NN	O
baculovirus	NN	O
.	.	O
Forty-eight	JJ	O
hours	NNS	O
post-infection	NN	O
,	,	O
the	DT	O
supernatant	NN	O
was	VBD	O
separated	VBN	O
from	IN	O
the	DT	O
cells	NNS	O
by	IN	O
centrifugation	NN	O
and	CC	O
filtered	VBD	O
through	IN	O
a	DT	O
0.2	CD	O
μm	NN	O
filter	NN	O
.	.	O
Aliquots	NNS	O
of	IN	O
the	DT	O
supernatant	NN	O
were	VBD	O
then	RB	O
transferred	VBN	O
to	TO	O
a	DT	O
Polyclear™	NNP	O
(	(	O
Beckman	NNP	O
Instruments	NNP	O
,	,	O
Palo	NNP	O
Alto	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
ultracentrifuge	NN	O
tubes	NNS	O
containing	VBG	O
30	CD	O
%	NN	O
(	(	O
wt/wt	NN	O
)	)	O
sucrose	NN	O
,	,	O
and	CC	O
subjected	VBD	O
to	TO	O
2	CD	O
hours	NNS	O
of	IN	O
centrifugation	NN	O
at	IN	O
24,000	CD	O
rpm	NN	O
in	IN	O
a	DT	O
Beckman	NNP	O
SW28	NNP	O
rotor	NN	O
and	CC	O
ultracentrifuge	NN	O
.	.	O
The	DT	O
resulting	VBG	O
pellet	NN	O
was	VBD	O
suspended	VBN	O
in	IN	O
Tris	NNP	O
buffer	NN	O
(	(	O
50	CD	O
mM	RB	O
Tris-HCl	NNP	O
,	,	O
pH	NN	O
7.5	CD	O
,	,	O
500	CD	O
mM	NN	O
NaCl	NNP	O
)	)	O
and	CC	O
layered	VBN	O
onto	IN	O
a	DT	O
30-60	JJ	O
%	NN	O
(	(	O
wt/wt	NN	O
)	)	O
sucrose	VB	O
gradient	NN	O
and	CC	O
subjected	VBN	O
to	TO	O
2	CD	O
hours	NNS	O
centrifugation	NN	O
at	IN	O
40,000	CD	O
rpm	NN	O
in	IN	O
a	DT	O
Beckman	NNP	O
SW41ti	NNP	O
rotor	NN	O
and	CC	O
ultracentrifuge	NN	O
.	.	O
The	DT	O
gradient	NN	O
was	VBD	O
then	RB	O
fractionated	VBN	O
starting	VBG	O
at	IN	O
the	DT	O
top	NN	O
(	(	O
30	CD	O
%	NN	O
)	)	O
of	IN	O
the	DT	O
gradient	NN	O
into	IN	O
approximately	RB	O
11×1.0	CD	O
ml	JJ	O
aliquots	NNS	O
.	.	O
A	DT	O
sample	NN	O
of	IN	O
each	DT	O
fraction	NN	O
was	VBD	O
electrophoresed	VBN	O
on	IN	O
8-16	CD	O
%	NN	O
SDS	NNP	O
polyacrylamide	NN	O
gels	NNS	O
and	CC	O
the	DT	O
resulting	VBG	O
bands	NNS	O
were	VBD	O
visualized	VBN	O
after	IN	O
commassie	NN	O
staining	NN	O
.	.	O
A	DT	O
subset	NN	O
of	IN	O
aliquots	NNS	O
were	VBD	O
also	RB	O
subjected	VBN	O
to	TO	O
Western	NNP	O
blot	NN	O
analysis	NN	O
using	VBG	O
monoclonal	JJ	O
antibody	NN	O
76C.5EG	CD	O
(	(	O
Steimer	NNP	B
,	,	I
K.	NNP	I
S.	NNP	I
,	,	I
et	FW	I
al.	NN	I
,	,	I
Virology	NNP	I
150:283-290	CD	I
,	,	I
1986	CD	I
)	)	O
which	WDT	O
is	VBZ	O
specific	JJ	O
for	IN	O
HIV	NNP	O
p24	NN	O
(	(	O
a	DT	O
subunit	NN	O
of	IN	O
HIV	NNP	O
p55	NN	O
)	)	O
.	.	O
The	DT	O
peak	JJ	O
fractions	NNS	O
from	IN	O
the	DT	O
sucrose	JJ	O
gradient	NN	O
were	VBD	O
pooled	VBN	O
and	CC	O
concentrated	VBN	O
by	IN	O
a	DT	O
second	JJ	O
20	CD	O
%	NN	O
sucrose	JJ	O
pelleting	NN	O
.	.	O
The	DT	O
resulting	VBG	O
pellet	NN	O
was	VBD	O
suspended	VBN	O
in	IN	O
1	CD	O
ml	NN	O
of	IN	O
buffer	NN	O
Tris	NNP	O
buffer	NN	O
and	CC	O
the	DT	O
total	JJ	O
protein	JJ	O
yield	NN	O
as	IN	O
estimated	VBN	O
by	IN	O
BCA	NNP	O
(	(	O
Pierce	NNP	O
Chemical	NNP	O
,	,	O
Rockford	NNP	O
,	,	O
Ill.	NNP	O
)	)	O
was	VBD	O
˜1.0	JJ	O
mg	NN	O
.	.	O
The	DT	O
results	NNS	O
from	IN	O
the	DT	O
SDS	NNP	O
PAGE	NNP	O
are	VBP	O
shown	VBN	O
in	IN	O
FIG	NNP	O
.	.	O
8	CD	O
and	CC	O
the	DT	O
anti-p24	JJ	O
Western	JJ	O
blot	NN	O
results	NNS	O
are	VBP	O
shown	VBN	O
in	IN	O
FIG	NNP	O
.	.	O
9	CD	O
.	.	O
Taken	VBN	O
together	RB	O
,	,	O
these	DT	O
results	NNS	O
indicate	VBP	O
that	IN	O
the	DT	O
HIV	NNP	O
p55	NN	O
Gag/HCV	NNP	O
Core	NNP	O
173	CD	O
chimeric	NN	O
VLPs	NNP	O
banded	VBD	O
at	IN	O
a	DT	O
sucrose	JJ	O
density	NN	O
similar	JJ	O
to	TO	O
that	DT	O
of	IN	O
the	DT	O
HIV	NNP	O
p55	NN	O
Gag	NNP	O
VLPs	NNP	O
and	CC	O
the	DT	O
visible	JJ	O
protein	NN	O
band	NN	O
that	WDT	O
migrated	VBD	O
at	IN	O
a	DT	O
molecular	JJ	O
weight	NN	O
of	IN	O
˜72,000	NNP	O
kd	NN	O
was	VBD	O
reactive	JJ	O
with	IN	O
the	DT	O
HIV	NNP	O
p24-specific	JJ	O
monoclonal	JJ	O
antibody	NN	O
.	.	O
An	DT	O
additional	JJ	O
immunoreactive	NN	O
band	NN	O
at	IN	O
approximately	RB	O
55,000	CD	O
kd	NNS	O
also	RB	O
appeared	VBD	O
to	TO	O
be	VB	O
reactive	JJ	O
with	IN	O
the	DT	O
anti-p24	JJ	O
antibody	NN	O
and	CC	O
may	MD	O
be	VB	O
a	DT	O
degradation	NN	O
product	NN	O
.	.	O
Although	IN	O
aliquots	NNS	O
from	IN	O
the	DT	O
above	JJ	O
preparation	NN	O
were	VBD	O
not	RB	O
tested	VBN	O
for	IN	O
reactivity	NN	O
with	IN	O
an	DT	O
HCV	NNP	O
Core-specific	NNP	O
antibody	NN	O
(	(	O
an	DT	O
anti-CD22	JJ	O
rabbit	NN	O
serum	NN	O
)	)	O
,	,	O
results	NNS	O
from	IN	O
a	DT	O
similar	JJ	O
preparation	NN	O
are	VBP	O
shown	VBN	O
in	IN	O
FIG	NNP	O
.	.	O
10	CD	O
and	CC	O
indicate	VB	O
that	IN	O
the	DT	O
main	JJ	O
HCV	NNP	O
Core-specific	NNP	O
reactivity	NN	O
migrates	NNS	O
at	IN	O
an	DT	O
approximate	JJ	O
molecular	JJ	O
weight	NN	O
of	IN	O
72,000	CD	O
kd	NN	O
which	WDT	O
is	VBZ	O
in	IN	O
accordance	NN	O
with	IN	O
the	DT	O
predicted	JJ	O
molecular	JJ	O
weight	NN	O
of	IN	O
the	DT	O
chimeric	JJ	O
protein	NN	O
.	.	O
The	DT	O
expression	NN	O
conditions	NNS	O
for	IN	O
the	DT	O
synthetic	JJ	O
HIV	NNP	O
p55	NN	O
Gag/HCV	NNP	O
Core	NNP	O
173	CD	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:8	NNP	O
)	)	O
VLPs	NNP	O
differed	VBN	O
from	IN	O
those	DT	O
of	IN	O
the	DT	O
native	JJ	O
p55	NN	O
Gag	NNP	O
and	CC	O
are	VBP	O
as	IN	O
follows	VBZ	O
:	:	O
a	DT	O
culture	NN	O
volume	NN	O
of	IN	O
1	CD	O
liter	NN	O
used	VBN	O
instead	RB	O
of	IN	O
2.5	CD	O
liters	NNS	O
,	,	O
Trichoplusia	NNP	O
ni	FW	O
(	(	O
Tn5	NNP	O
)	)	O
(	(	O
Wickham	NNP	B
,	,	I
T.	NNP	I
J.	NNP	I
,	,	I
and	CC	I
Nemerow	NNP	I
,	,	I
G.	NNP	I
R.	NNP	I
1993	CD	I
BioTechnology	NNP	I
Progress	NNP	I
,	,	I
9:25-30	CD	I
)	)	O
insect	NN	O
cells	NNS	O
were	VBD	O
used	VBN	O
instead	RB	O
of	IN	O
Sf9	NNP	O
insect	JJ	O
cells	NNS	O
and	CC	O
an	DT	O
MOI	NNP	O
of	IN	O
3	CD	O
was	VBD	O
instead	RB	O
of	IN	O
an	DT	O
MOI	NNP	O
of	IN	O
10	CD	O
.	.	O
The	DT	O
sucrose	JJ	O
pelleting	NN	O
and	CC	O
banding	NN	O
methods	NNS	O
used	VBN	O
for	IN	O
the	DT	O
synthetic	JJ	O
HIV	NNP	O
p55	NN	O
Gag/HCV	NNP	O
Core	NNP	O
173	CD	O
VLPs	NNP	O
were	VBD	O
similar	JJ	O
to	TO	O
those	DT	O
employed	VBN	O
for	IN	O
the	DT	O
native	JJ	O
HIV	NNP	O
p55	NN	O
Gag/HCV	NNP	O
Core	NNP	O
173	CD	O
VLPs	NNP	O
.	.	O
However	RB	O
,	,	O
differences	NNS	O
included	VBD	O
:	:	O
pelleted	VBN	O
VLPs	NNP	O
were	VBD	O
suspended	VBN	O
in	IN	O
1	CD	O
ml	NN	O
of	IN	O
phosphate	NN	O
buffered	VBN	O
saline	NN	O
(	(	O
PBS	NNP	O
)	)	O
instead	RB	O
of	IN	O
1.0	CD	O
ml	NN	O
of	IN	O
the	DT	O
Tris	NNP	O
buffer	NN	O
,	,	O
and	CC	O
a	DT	O
single	JJ	O
20-60	JJ	O
%	NN	O
sucrose	JJ	O
gradients	NNS	O
was	VBD	O
used	VBN	O
.	.	O
A	DT	O
comparison	NN	O
of	IN	O
the	DT	O
total	JJ	O
amount	NN	O
of	IN	O
purified	JJ	O
HIV	NNP	O
p55	NN	O
Gag/HCV	NNP	O
Core	NNP	O
173	CD	O
from	IN	O
multiple	JJ	O
preparations	NNS	O
obtained	VBN	O
from	IN	O
the	DT	O
two	CD	O
baculovirus	NN	O
expression	NN	O
cassettes	VBZ	O
showed	VBD	O
that	IN	O
there	EX	O
was	VBD	O
an	DT	O
increase	NN	O
in	IN	O
expression	NN	O
using	VBG	O
the	DT	O
synthetic	JJ	O
HIV	NNP	O
p55	NN	O
Gag/HCV	NNP	O
Core	NNP	O
173	CD	O
cassette	NN	O
.	.	O
D.	NNP	O
Alternative	NNP	O
Method	NNP	O
for	IN	O
the	DT	O
Enrichment	NNP	O
of	IN	O
HIV	NNP	O
p55	NN	O
Gag	NNP	O
VLPs	NNP	O
In	IN	O
addition	NN	O
to	TO	O
purification	NN	O
from	IN	O
the	DT	O
media	NNS	O
,	,	O
p55	NN	O
(	(	O
Gag	NNP	O
protein	RB	O
)	)	O
expressed	VBN	O
in	IN	O
baculovirus	NN	O
(	(	O
e.g.	NN	O
,	,	O
using	VBG	O
a	DT	O
synthetic	JJ	O
expression	NN	O
cassette	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
)	)	O
can	MD	O
also	RB	O
be	VB	O
purified	VBN	O
as	IN	O
virus-like	JJ	O
particles	NNS	O
from	IN	O
the	DT	O
infected	JJ	O
insect	NN	O
cells	NNS	O
.	.	O
For	IN	O
example	NN	O
,	,	O
forty-eight	JJ	O
hours	NNS	O
post	NN	O
infection	NN	O
,	,	O
the	DT	O
media	NNS	O
and	CC	O
cell	NN	O
pellet	NN	O
are	VBP	O
separated	VBN	O
by	IN	O
centrifugation	NN	O
and	CC	O
the	DT	O
cell	NN	O
pellet	NN	O
is	VBZ	O
stored	VBN	O
at	IN	O
−70°	NNP	O
C.	NNP	O
until	IN	O
future	JJ	O
use	NN	O
.	.	O
At	IN	O
the	DT	O
time	NN	O
of	IN	O
processing	NN	O
,	,	O
the	DT	O
cell	NN	O
pellet	NN	O
is	VBZ	O
suspended	VBN	O
in	IN	O
5	CD	O
volumes	NNS	O
of	IN	O
hypotonic	JJ	O
lysis	NN	O
buffer	NN	O
(	(	O
20	CD	O
mM	RB	O
Tris-HCl	NNP	O
,	,	O
pH	NN	O
8.2	CD	O
,	,	O
1	CD	O
mM	NN	O
EGTA	NNP	O
;	:	O
1	CD	O
mM	NN	O
MgCl	NNP	O
,	,	O
and	CC	O
Complete	NNP	O
Protease	NNP	O
Inhibitor®	NNP	O
(	(	O
Boehringer	NNP	O
Mannheim	NNP	O
Corp.	NNP	O
,	,	O
Indianapolis	NNP	O
,	,	O
Ind	NNP	O
.	.	O
]	NN	O
)	)	O
.	.	O
If	IN	O
needed	VBN	O
,	,	O
the	DT	O
cells	NNS	O
are	VBP	O
then	RB	O
dounced	VBN	O
8-10	JJ	O
times	NNS	O
to	TO	O
complete	VB	O
cell	NN	O
lysis	NN	O
.	.	O
The	DT	O
lysate	NN	O
is	VBZ	O
then	RB	O
centrifuged	VBN	O
at	IN	O
approximately	RB	O
1000-1500×g	JJ	O
for	IN	O
20	CD	O
minutes	NNS	O
.	.	O
The	DT	O
supernatant	NN	O
is	VBZ	O
decanted	VBN	O
into	IN	O
UltraClear™	NNP	O
tubes	NNS	O
,	,	O
underlayed	JJ	O
with	IN	O
20	CD	O
%	NN	O
sucrose	NN	O
(	(	O
w/w	NN	O
)	)	O
and	CC	O
centrifuged	VBN	O
at	IN	O
24,000	CD	O
rpm	NN	O
in	IN	O
SW28	NNP	O
buckets	NNS	O
for	IN	O
2	CD	O
hours	NNS	O
.	.	O
The	DT	O
resulting	JJ	O
pellet	NN	O
is	VBZ	O
suspended	VBN	O
in	IN	O
Tris	NNP	O
buffer	NN	O
(	(	O
20	CD	O
mM	NN	O
Tris	NNP	O
HCl	NNP	O
,	,	O
pH	NN	O
7.5	CD	O
,	,	O
250	CD	O
mM	NN	O
NaCl	NNP	O
,	,	O
and	CC	O
2.5	CD	O
mM	JJ	O
ethylene-diamine-tetraacetic	JJ	O
acid	NN	O
(	(	O
EDTA	NNP	O
)	)	O
with	IN	O
0.1	CD	O
%	NN	O
IGEPAL	NNP	O
detergent	NN	O
(	(	O
Sigma	NNP	O
Chemical	NNP	O
,	,	O
St.	NNP	O
Louis	NNP	O
,	,	O
Mo	NNP	O
.	.	O
)	)	O
and	CC	O
250	CD	O
units/ml	NN	O
of	IN	O
benzonase	NN	O
(	(	O
American	JJ	O
International	NNP	O
Chemical	NNP	O
,	,	O
Inc.	NNP	O
,	,	O
Natick	NNP	O
,	,	O
Mass	NNP	O
.	.	O
)	)	O
and	CC	O
incubated	VBN	O
at	IN	O
4°	CD	O
C.	NNP	O
for	IN	O
at	IN	O
least	JJS	O
30	CD	O
minutes	NNS	O
.	.	O
The	DT	O
suspension	NN	O
is	VBZ	O
subsequently	RB	O
layered	VBN	O
onto	IN	O
a	DT	O
20-60	JJ	O
%	NN	O
sucrose	JJ	O
gradient	NN	O
and	CC	O
spun	NN	O
at	IN	O
40,000	CD	O
rpm	NN	O
using	VBG	O
an	DT	O
SW41ti	NNP	O
rotor	NN	O
for	IN	O
20-24	JJ	O
hours	NNS	O
.	.	O
After	IN	O
ultracentrifugation	NN	O
,	,	O
the	DT	O
sucrose	JJ	O
gradient	NN	O
is	VBZ	O
fractionated	VBN	O
and	CC	O
aliquots	NNS	O
run	VBP	O
on	IN	O
SDS	NNP	O
PAGE	NNP	O
to	TO	O
identify	VB	O
peak	JJ	O
fractions	NNS	O
.	.	O
The	DT	O
peak	JJ	O
fractions	NNS	O
are	VBP	O
dialyzed	VBN	O
against	IN	O
PBS	NNP	O
and	CC	O
measured	VBN	O
for	IN	O
protein	NN	O
content	NN	O
.	.	O
Negatively	RB	O
stained	VBN	O
electron	NN	O
mircographs	NN	O
typically	RB	O
show	VBP	O
non-enveloped	JJ	O
VLPs	NNP	O
somewhat	RB	O
smaller	JJR	O
in	IN	O
diameter	NN	O
(	(	O
80-120	JJ	O
nm	NN	O
)	)	O
than	IN	O
the	DT	O
budded	JJ	O
VLPs	NNP	O
.	.	O
HIV	NNP	O
Gag	NNP	O
VLPs	NNP	O
prepared	VBD	O
in	IN	O
this	DT	O
manner	NN	O
are	VBP	O
also	RB	O
capable	JJ	O
of	IN	O
generating	VBG	O
Gag-specific	NNP	O
CTL	NNP	O
responses	NNS	O
in	IN	O
mice	NN	O
.	.	O
Example	JJ	O
8	CD	O
In	IN	O
Vivo	NNP	O
Immunogenicity	NNP	O
of	IN	O
Synthetic	NNP	O
Gag	NNP	O
Expression	NNP	O
Cassettes	NNP	O
A.	NNP	O
Immunization	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
possibly	RB	O
improved	VBN	O
immunogenicity	NN	O
of	IN	O
the	DT	O
synthetic	JJ	O
Gag	NNP	O
expression	NN	O
cassettes	NNS	O
,	,	O
a	DT	O
mouse	NN	O
study	NN	O
was	VBD	O
performed	VBN	O
.	.	O
The	DT	O
plasmid	NN	O
DNA	NNP	O
,	,	O
pCMVKM2	NN	O
carrying	VBG	O
the	DT	O
synthetic	JJ	O
Gag	NNP	O
expression	NN	O
cassette	NN	O
,	,	O
was	VBD	O
diluted	VBN	O
to	TO	O
the	DT	O
following	JJ	O
final	JJ	O
concentrations	NNS	O
in	IN	O
a	DT	O
total	JJ	O
injection	NN	O
volume	NN	O
of	IN	O
100	CD	O
μl	NNS	O
:	:	O
20	CD	O
μg	NN	O
,	,	O
2	CD	O
μg	NN	O
,	,	O
0.2	CD	O
μg	NN	O
,	,	O
and	CC	O
0.02	CD	O
μg	NN	O
.	.	O
To	TO	O
overcome	VB	O
possible	JJ	O
negative	JJ	O
dilution	NN	O
effects	NNS	O
of	IN	O
the	DT	O
diluted	JJ	O
DNA	NNP	O
,	,	O
the	DT	O
total	JJ	O
DNA	NNP	O
concentration	NN	O
in	IN	O
each	DT	O
sample	NN	O
was	VBD	O
brought	VBN	O
up	RP	O
to	TO	O
20	CD	O
μg	NNS	O
using	VBG	O
the	DT	O
vector	NN	O
(	(	O
pCMVKM2	NN	O
)	)	O
alone	RB	O
.	.	O
As	IN	O
a	DT	O
control	NN	O
,	,	O
plasmid	JJ	O
DNA	NN	O
of	IN	O
the	DT	O
native	JJ	O
Gag	NNP	O
expression	NN	O
cassette	NN	O
was	VBD	O
handled	VBN	O
in	IN	O
the	DT	O
same	JJ	O
manner	NN	O
.	.	O
Twelve	NNP	O
groups	NNS	O
of	IN	O
four	CD	O
Balb/c	NNP	O
mice	NN	O
(	(	O
Charles	NNP	O
River	NNP	O
,	,	O
Boston	NNP	O
,	,	O
Mass	NNP	O
.	.	O
)	)	O
were	VBD	O
intramuscularly	RB	O
immunized	VBN	O
(	(	O
50	CD	O
μl	NN	O
per	IN	O
leg	NN	O
,	,	O
intramuscular	JJ	O
injection	NN	O
into	IN	O
the	DT	O
tibialis	JJ	O
anterior	NN	O
)	)	O
according	VBG	O
to	TO	O
the	DT	O
schedule	NN	O
in	IN	O
Table	JJ	O
7	CD	O
.	.	O
B.	NNP	O
Humoral	NNP	O
Immune	NNP	O
Response	NNP	O
The	DT	O
humoral	JJ	O
immune	NN	O
response	NN	O
was	VBD	O
checked	VBN	O
with	IN	O
an	DT	O
anti-HIV	JJ	O
Gag	NNP	O
antibody	NN	O
ELISAs	NNP	O
(	(	O
enzyme-linked	JJ	O
immunosorbent	NN	O
assays	NNS	O
)	)	O
of	IN	O
the	DT	O
mice	NN	O
sera	NN	O
0	CD	O
and	CC	O
4	CD	O
weeks	NNS	O
post	NN	O
immunization	NN	O
(	(	O
groups	NNS	O
5-12	RB	O
)	)	O
and	CC	O
,	,	O
in	IN	O
addition	NN	O
,	,	O
6	CD	O
and	CC	O
8	CD	O
weeks	NNS	O
post	NN	O
immunization	NN	O
,	,	O
respectively	RB	O
,	,	O
2	CD	O
and	CC	O
4	CD	O
weeks	NNS	O
post	RB	O
second	JJ	O
immunization	NN	O
(	(	O
groups	NNS	O
1-4	RB	O
)	)	O
.	.	O
The	DT	O
antibody	NN	O
titers	NNS	O
of	IN	O
the	DT	O
sera	NN	O
were	VBD	O
determined	VBN	O
by	IN	O
anti-Gag	JJ	O
antibody	NN	O
ELISA	NNP	O
.	.	O
Briefly	NNP	O
,	,	O
sera	NN	O
from	IN	O
immunized	JJ	O
mice	NNS	O
were	VBD	O
screened	VBN	O
for	IN	O
antibodies	NNS	O
directed	VBN	O
against	IN	O
the	DT	O
HIV	NNP	O
p55	NN	O
Gag	NNP	O
protein	NN	O
.	.	O
ELISA	NNP	O
microtiter	NN	O
plates	NNS	O
were	VBD	O
coated	VBN	O
with	IN	O
0.2	CD	O
μg	NNS	O
of	IN	O
HIV-1SF2	NNP	O
p24-Gag	JJ	O
protein	NN	O
per	IN	O
well	RB	O
overnight	JJ	O
and	CC	O
washed	VBD	O
four	CD	O
times	NNS	O
;	:	O
subsequently	RB	O
,	,	O
blocking	VBG	O
was	VBD	O
done	VBN	O
with	IN	O
PBS-0.2	NNP	O
%	NN	O
Tween	NNP	O
(	(	O
Sigma	NNP	O
)	)	O
for	IN	O
2	CD	O
hours	NNS	O
.	.	O
After	IN	O
removal	NN	O
of	IN	O
the	DT	O
blocking	VBG	O
solution	NN	O
,	,	O
100	CD	O
μl	NN	O
of	IN	O
diluted	VBN	O
mouse	NN	O
serum	NN	O
was	VBD	O
added	VBN	O
.	.	O
Sera	NN	O
were	VBD	O
tested	VBN	O
at	IN	O
1/25	CD	O
dilutions	NNS	O
and	CC	O
by	IN	O
serial	JJ	O
3-fold	JJ	O
dilutions	NNS	O
,	,	O
thereafter	RB	O
.	.	O
Microtiter	NN	O
plates	NNS	O
were	VBD	O
washed	VBN	O
four	CD	O
times	NNS	O
and	CC	O
incubated	VBN	O
with	IN	O
a	DT	O
secondary	JJ	O
,	,	O
peroxidase-coupled	JJ	O
anti-mouse	NN	O
IgG	NNP	O
antibody	NN	O
(	(	O
Pierce	NNP	O
,	,	O
Rockford	NNP	O
,	,	O
Ill.	NNP	O
)	)	O
.	.	O
ELISA	NNP	O
plates	NNS	O
were	VBD	O
washed	VBN	O
and	CC	O
100	CD	O
μl	NN	O
of	IN	O
3,3′,5,5′-tetramethyl	JJ	O
benzidine	NN	O
(	(	O
TMB	NNP	O
;	:	O
Pierce	NNP	O
)	)	O
was	VBD	O
added	VBN	O
per	IN	O
well	RB	O
.	.	O
The	DT	O
optical	JJ	O
density	NN	O
of	IN	O
each	DT	O
well	NN	O
was	VBD	O
measured	VBN	O
after	IN	O
15	CD	O
minutes	NNS	O
.	.	O
The	DT	O
titers	NNS	O
reported	VBN	O
are	VBP	O
the	DT	O
reciprocal	NN	O
of	IN	O
the	DT	O
dilution	NN	O
of	IN	O
serum	NN	O
that	WDT	O
gave	VBD	O
a	DT	O
half-maximum	JJ	O
optical	JJ	O
density	NN	O
(	(	O
O.	NNP	O
D.	NNP	O
)	)	O
.	.	O
The	DT	O
ELISA	NNP	O
results	NNS	O
are	VBP	O
presented	VBN	O
in	IN	O
Table	JJ	O
8	CD	O
.	.	O
The	DT	O
results	NNS	O
of	IN	O
the	DT	O
mouse	NN	O
immunizations	NNS	O
with	IN	O
plasmid-DNAs	JJ	O
show	NN	O
that	IN	O
the	DT	O
synthetic	JJ	O
expression	NN	O
cassettes	NNS	O
provide	VBP	O
a	DT	O
clear	JJ	O
improvement	NN	O
of	IN	O
immunogenicity	NN	O
relative	NN	O
to	TO	O
the	DT	O
native	JJ	O
expression	NN	O
cassettes	NNS	O
.	.	O
Also	RB	O
,	,	O
the	DT	O
second	JJ	O
boost	NN	O
immunization	NN	O
induced	VBD	O
a	DT	O
secondary	JJ	O
immune	NN	O
response	NN	O
after	IN	O
two	CD	O
weeks	NNS	O
(	(	O
groups	NNS	O
1-3	RB	O
)	)	O
.	.	O
C.	NNP	O
Cellular	NNP	O
Immune	NNP	O
Response	NNP	O
The	DT	O
frequency	NN	O
of	IN	O
specific	JJ	O
cytotoxic	JJ	O
T-lymphocytes	NNS	O
(	(	O
CTL	NNP	O
)	)	O
was	VBD	O
evaluated	VBN	O
by	IN	O
a	DT	O
standard	JJ	O
chromium	NN	O
release	NN	O
assay	NN	O
of	IN	O
peptide	NN	O
pulsed	VBN	O
Balb/c	NNP	O
mouse	NN	O
CD4	NNP	O
cells	NNS	O
.	.	O
Gag	NNP	O
expressing	VBG	O
vaccinia	NN	O
virus	NN	O
infected	VBD	O
CD-8	NNP	O
cells	NNS	O
were	VBD	O
used	VBN	O
as	IN	O
a	DT	O
positive	JJ	O
control	NN	O
(	(	O
vvGag	NN	O
)	)	O
.	.	O
Briefly	NNP	O
,	,	O
spleen	JJ	O
cells	NNS	O
(	(	O
Effector	NNP	O
cells	NNS	O
,	,	O
E	NNP	O
)	)	O
were	VBD	O
obtained	VBN	O
from	IN	O
the	DT	O
BALB/c	NNP	O
mice	NN	O
immunized	RB	O
,	,	O
as	IN	O
described	VBN	O
above	IN	O
(	(	O
Table	JJ	O
8	CD	O
)	)	O
were	VBD	O
cultured	VBN	O
,	,	O
restimulated	VBN	O
,	,	O
and	CC	O
assayed	VBD	O
for	IN	O
CTL	NNP	O
activity	NN	O
against	IN	O
Gag	NNP	O
peptide-pulsed	JJ	O
target	NN	O
cells	NNS	O
as	IN	O
described	NN	O
(	(	O
Doe	NNP	B
,	,	I
B.	NNP	I
,	,	I
and	CC	I
Walker	NNP	I
,	,	I
C.	NNP	I
M.	NNP	I
,	,	I
AIDS	NNP	I
10	CD	I
(	(	I
7	CD	I
)	)	I
:793-794	NN	I
,	,	I
1996	CD	I
)	)	O
.	.	O
The	DT	O
HIV-1SF2	NNP	O
Gag	NNP	O
peptide	NN	O
used	VBN	O
was	VBD	O
p7g	JJ	O
SEQ	NNP	O
ID	NNP	O
NO:10	NNP	O
.	.	O
Cytotoxic	NNP	O
activity	NN	O
was	VBD	O
measured	VBN	O
in	IN	O
a	DT	O
standard	JJ	O
51Cr	CD	O
release	NN	O
assay	NN	O
.	.	O
Target	NN	O
(	(	O
T	NNP	O
)	)	O
cells	NNS	O
were	VBD	O
cultured	VBN	O
with	IN	O
effector	NN	O
(	(	O
E	NNP	O
)	)	O
cells	NNS	O
at	IN	O
various	JJ	O
E	NN	O
:	:	O
T	NNP	O
ratios	NNS	O
for	IN	O
4	CD	O
hours	NNS	O
and	CC	O
the	DT	O
average	JJ	O
cpm	NN	O
from	IN	O
duplicate	NN	O
wells	NNS	O
was	VBD	O
used	VBN	O
to	TO	O
calculate	VB	O
percent	NN	O
specific	JJ	O
51Cr	CD	O
release	NN	O
.	.	O
The	DT	O
results	NNS	O
are	VBP	O
presented	VBN	O
in	IN	O
Table	JJ	O
9	CD	O
.	.	O
Cytotoxic	NNP	O
T-cell	NNP	O
(	(	O
CTL	NNP	O
)	)	O
activity	NN	O
was	VBD	O
measured	VBN	O
in	IN	O
splenocytes	NNS	O
recovered	VBN	O
from	IN	O
the	DT	O
mice	NNS	O
immunized	VBN	O
with	IN	O
HIV	NNP	O
Gag	NNP	O
DNA	NNP	O
(	(	O
compare	JJ	O
Effector	NNP	O
column	NN	O
,	,	O
Table	NNP	O
9	CD	O
,	,	O
to	TO	O
immunization	NN	O
schedule	NN	O
,	,	O
Table	NNP	O
8	CD	O
)	)	O
.	.	O
Effector	NNP	O
cells	NNS	O
from	IN	O
the	DT	O
Gag	NNP	O
DNA-immunized	NNP	O
animals	NNS	O
exhibited	VBD	O
specific	JJ	O
lysis	NN	O
of	IN	O
Gag	NNP	O
p7g	JJ	O
peptide-pulsed	JJ	O
SV-BALB	NNP	O
(	(	O
MHC	NNP	O
matched	VBN	O
)	)	O
targets	NNS	O
cells	NNS	O
indicative	JJ	O
of	IN	O
a	DT	O
CTL	NNP	O
response	NN	O
.	.	O
Target	NN	O
cells	NNS	O
that	WDT	O
were	VBD	O
peptide-pulsed	JJ	O
and	CC	O
derived	VBN	O
from	IN	O
an	DT	O
MHC-unmatched	JJ	O
mouse	NN	O
strain	NN	O
(	(	O
MC57	NNP	O
)	)	O
were	VBD	O
not	RB	O
lysed	VBN	O
(	(	O
Table	JJ	O
9	CD	O
;	:	O
MC/p7g	NNP	O
)	)	O
.	.	O
The	DT	O
results	NNS	O
of	IN	O
the	DT	O
CTL	NNP	O
assays	VBZ	O
show	NN	O
increased	VBD	O
potency	NN	O
of	IN	O
synthetic	JJ	O
Gag	NNP	O
expression	NN	O
cassettes	NNS	O
for	IN	O
induction	NN	O
of	IN	O
cytotoxic	JJ	O
T-lymphocyte	NNP	O
(	(	O
CTL	NNP	O
)	)	O
responses	NNS	O
by	IN	O
DNA	NNP	O
immunization	NN	O
.	.	O
Example	JJ	O
9	CD	O
In	IN	O
Vivo	NNP	O
Immunization	NNP	O
with	IN	O
Env	NNP	O
Polypeptides	NNP	O
A.	NNP	O
Immunogenicity	NNP	O
Study	NNP	O
of	IN	O
US4	NNP	O
o-gp140	JJ	O
in	IN	O
Ras-3c	NNP	O
Adjuvant	NNP	O
System	NNP	O
Studies	NNPS	O
have	VBP	O
been	VBN	O
conducted	VBN	O
using	VBG	O
rabbits	NNS	O
immunized	VBN	O
with	IN	O
US4	NNP	O
o-gp140	JJ	O
purified	VBD	O
as	IN	O
described	VBN	O
above	IN	O
.	.	O
Studies	NNS	O
are	VBP	O
also	RB	O
underway	RB	O
in	IN	O
animals	NNS	O
to	TO	O
determine	VB	O
immunogenicity	NN	O
of	IN	O
US4	NNP	O
gp120	NN	O
,	,	O
SF162	NNP	O
o-gp140	NN	O
and	CC	O
SF162	NNP	O
gp120	NN	O
.	.	O
Two	CD	O
rabbits	NNS	O
(	(	O
#	#	O
1	CD	O
and	CC	O
#	#	O
2	CD	O
)	)	O
were	VBD	O
immunized	VBN	O
intramuscularly	RB	O
at	IN	O
0	CD	O
,	,	O
4	CD	O
,	,	O
12	CD	O
and	CC	O
24	CD	O
weeks	NNS	O
with	IN	O
50	CD	O
μg	NNS	O
of	IN	O
US4	NNP	O
o-gp140	NN	O
in	IN	O
the	DT	O
Ribi™	NNP	O
adjuvant	NN	O
system	NN	O
(	(	O
RAS-3c	NNP	O
)	)	O
,	,	O
(	(	O
Ribi	NNP	O
Immunochem	NNP	O
,	,	O
Hamilton	NNP	O
,	,	O
Mont	NNP	O
.	.	O
)	)	O
containing	VBG	O
2	CD	O
%	NN	O
Squalene	NNP	O
,	,	O
0.2	CD	O
%	NN	O
Tween	NNP	O
80	CD	O
,	,	O
and	CC	O
one	CD	O
or	CC	O
more	JJR	O
bacterial	JJ	O
cell	NN	O
wall	NN	O
components	NNS	O
from	IN	O
the	DT	O
group	NN	O
consisting	VBG	O
of	IN	O
monophosphorylipid	NN	O
A	NNP	O
(	(	O
MPL	NNP	O
,	,	O
Ribi	NNP	O
Immunochem	NNP	O
,	,	O
Hamilton	NNP	O
,	,	O
Mont	NNP	O
.	.	O
)	)	O
.	.	O
In	IN	O
each	DT	O
experiment	NN	O
described	VBD	O
herein	JJ	O
,	,	O
o-gp140	JJ	O
can	MD	O
be	VB	O
native	JJ	O
,	,	O
mutated	VBD	O
and/or	RB	O
modified	VBN	O
.	.	O
Antibody	NN	O
responses	NNS	O
directed	VBN	O
against	IN	O
the	DT	O
US4	NNP	O
o-gp140	JJ	O
protein	NN	O
were	VBD	O
measured	VBN	O
by	IN	O
ELISA	NNP	O
.	.	O
Results	NNS	O
are	VBP	O
shown	VBN	O
in	IN	O
Table	JJ	O
10	CD	O
.	.	O
The	DT	O
avidities	NNS	O
of	IN	O
antibodies	NNS	O
directed	VBN	O
against	IN	O
the	DT	O
US4	NNP	O
o-gp140	JJ	O
protein	NN	O
were	VBD	O
measured	VBN	O
in	IN	O
a	DT	O
similar	JJ	O
ELISA	NNP	O
format	NN	O
employing	VBG	O
successive	JJ	O
washes	NNS	O
with	IN	O
increasing	VBG	O
concentrations	NNS	O
of	IN	O
ammonium	NN	O
isothiocynate	NN	O
.	.	O
Results	NNS	O
are	VBP	O
shown	VBN	O
in	IN	O
Table	JJ	O
11	CD	O
.	.	O
These	DT	O
results	NNS	O
show	VBP	O
that	IN	O
US4	NNP	O
o-gp140	NN	O
is	VBZ	O
highly	RB	O
immunogenic	JJ	O
and	CC	O
able	JJ	O
to	TO	O
induce	VB	O
substantial	JJ	O
antibody	NN	O
responses	NNS	O
after	IN	O
only	RB	O
one	CD	O
or	CC	O
two	CD	O
immunizations	NNS	O
.	.	O
B.	NNP	O
Immunogenicity	NNP	O
of	IN	O
US4	NNP	O
o-gp140	JJ	O
in	IN	O
MF59-Based	JJ	O
Adjuvants	NNS	O
Groups	NNP	O
of	IN	O
4	CD	O
rabbits	NNS	O
were	VBD	O
immunized	VBN	O
intramuscularly	RB	O
at	IN	O
0	CD	O
,	,	O
4	CD	O
,	,	O
12	CD	O
and	CC	O
24	CD	O
weeks	NNS	O
with	IN	O
various	JJ	O
doses	NNS	O
of	IN	O
US4	NNP	O
o-gp140	JJ	O
protein	NN	O
in	IN	O
three	CD	O
different	JJ	O
MF59-based	JJ	O
adjuvants	NNS	O
(	(	O
MF59	NNP	O
is	VBZ	O
described	VBN	O
in	IN	O
International	NNP	O
Publication	NNP	O
No	NNP	O
.	.	O
WO	$	O
90/14837	CD	O
and	CC	O
typically	RB	O
contains	VBZ	O
5	CD	O
%	NN	O
Squalene	NNP	O
,	,	O
0.5	CD	O
%	NN	O
Tween	NNP	O
80	CD	O
,	,	O
and	CC	O
0.5	CD	O
%	NN	O
Span	NNP	O
85	CD	O
)	)	O
.	.	O
Antibody	NN	O
titers	NNS	O
were	VBD	O
measured	VBN	O
post-third	JJ	O
by	IN	O
ELISA	NNP	O
using	VBG	O
SF2	NNP	O
gp120	NN	O
to	TO	O
coat	VB	O
the	DT	O
plates	NNS	O
.	.	O
QHC	NNP	O
is	VBZ	O
a	DT	O
quill-based	JJ	O
adjuvant	NN	O
(	(	O
Iscotek	NNP	O
,	,	O
Uppsala	NNP	O
,	,	O
Sweden	NNP	O
)	)	O
.	.	O
Results	NNS	O
are	VBP	O
shown	VBN	O
in	IN	O
Table	JJ	O
12	CD	O
.	.	O
Thus	RB	O
,	,	O
adjuvanted	VBD	O
o-gp140	JJ	O
generated	JJ	O
antigen-specific	JJ	O
antibodies	NNS	O
.	.	O
Further	RB	O
,	,	O
the	DT	O
antibodies	NNS	O
were	VBD	O
shown	VBN	O
to	TO	O
increased	VBN	O
in	IN	O
avidity	NN	O
over	IN	O
time	NN	O
.	.	O
C.	NNP	O
Neutralizing	NNP	O
Antibodies	NNP	O
Neutralizing	NNP	O
antibodies	VBZ	O
post-third	JJ	O
immunization	NN	O
were	VBD	O
measured	VBN	O
against	IN	O
HIV-1	NNP	O
SF2	NNP	O
in	IN	O
a	DT	O
T-cell	NNP	O
line	NN	O
adapted	VBN	O
virus	NN	O
(	(	O
TCLA	NNP	O
)	)	O
assay	VBP	O
and	CC	O
against	IN	O
PBMC-grown	NNP	O
HIV-1	NNP	O
variants	NNS	O
SF2	NNP	O
,	,	O
SF162	NNP	O
and	CC	O
119	CD	O
using	VBG	O
the	DT	O
CCR5+	NNP	O
CEMx174	NNP	O
LTR-GFP	NNP	O
reporter	NN	O
cell	NN	O
line	NN	O
,	,	O
5.25	CD	O
(	(	O
provided	VBN	O
by	IN	O
N.	NNP	O
Landau	NNP	O
,	,	O
Salk	NNP	O
Institute	NNP	O
,	,	O
San	NNP	O
Diego	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
as	IN	O
target	NN	O
cells	NNS	O
.	.	O
Results	NNS	O
are	VBP	O
shown	VBN	O
in	IN	O
Table	JJ	O
13	CD	O
.	.	O
The	DT	O
above	JJ	O
studies	NNS	O
in	IN	O
rabbits	NNS	O
indicate	VBP	O
that	IN	O
the	DT	O
US4	NNP	O
o-gp140	JJ	O
protein	NN	O
is	VBZ	O
highly	RB	O
immunogenic	JJ	O
.	.	O
When	WRB	O
administered	VBN	O
with	IN	O
adjuvant	NN	O
,	,	O
this	DT	O
protein	NN	O
was	VBD	O
able	JJ	O
to	TO	O
induce	VB	O
substantial	JJ	O
antibody	NN	O
responses	NNS	O
after	IN	O
only	RB	O
one	CD	O
or	CC	O
two	CD	O
immunizations	NNS	O
.	.	O
Moreover	RB	O
,	,	O
the	DT	O
adjuvanted	JJ	O
o-gp140	JJ	O
protein	NN	O
was	VBD	O
able	JJ	O
to	TO	O
generate	VB	O
antigen-specific	JJ	O
antibodies	NNS	O
which	WDT	O
increased	VBD	O
in	IN	O
avidity	NN	O
after	IN	O
successive	JJ	O
immunizations	NNS	O
,	,	O
and	CC	O
substantial	JJ	O
neutralizing	NN	O
activity	NN	O
against	IN	O
T-cell	NNP	O
line	NN	O
adapted	VBD	O
HIV-1.Neutralizing	NNP	O
activity	NN	O
was	VBD	O
also	RB	O
observed	VBN	O
against	IN	O
PBMC-grown	NNP	O
primary	JJ	O
HIV	NNP	O
strains	NNS	O
,	,	O
including	VBG	O
the	DT	O
difficult	JJ	O
to	TO	O
neutralize	VB	O
CCR5	NNP	O
co-receptor	NN	O
(	(	O
R5	NNP	O
)	)	O
-utilizing	VBG	O
isolates	NNS	O
,	,	O
SF162	NNP	O
and	CC	O
119	CD	O
.	.	O
Example	JJ	O
10	CD	O
In	IN	O
Vivo	NNP	O
Immunogenicity	NNP	O
of	IN	O
Synthetic	NNP	O
Env	NNP	O
Expression	NNP	O
Cassettes	VBZ	O
A	DT	O
.	.	O
General	NNP	O
Immunization	NNP	O
Methods	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
immunogenicity	NN	O
of	IN	O
the	DT	O
synthetic	JJ	O
Env	NNP	O
expression	NN	O
cassettes	NNS	O
,	,	O
studies	NNS	O
using	VBG	O
guinea	NN	O
pigs	NNS	O
,	,	O
rabbits	NNS	O
,	,	O
mice	NN	O
,	,	O
rhesus	NN	O
macaques	NNS	O
and	CC	O
baboons	NNS	O
were	VBD	O
performed	VBN	O
.	.	O
The	DT	O
studies	NNS	O
were	VBD	O
structured	VBN	O
as	IN	O
follows	VBZ	O
:	:	O
DNA	NN	O
immunization	NN	O
alone	RB	O
(	(	O
single	JJ	O
or	CC	O
multiple	JJ	O
)	)	O
;	:	O
DNA	NNP	O
immunization	NN	O
followed	VBN	O
by	IN	O
protein	NN	O
immunization	NN	O
(	(	O
boost	NN	O
)	)	O
;	:	O
DNA	NNP	O
immunization	NN	O
followed	VBN	O
by	IN	O
Sindbis	NNP	O
particle	NN	O
immunization	NN	O
;	:	O
immunization	NN	O
by	IN	O
Sindbis	NNP	O
particles	NNS	O
alone	RB	O
.	.	O
B.	NNP	O
Humoral	NNP	O
Immune	NNP	O
Response	NNP	O
The	DT	O
humoral	JJ	O
immune	NN	O
response	NN	O
was	VBD	O
checked	VBN	O
in	IN	O
serum	NN	O
specimens	NNS	O
from	IN	O
immunized	JJ	O
animals	NNS	O
with	IN	O
an	DT	O
anti-HIV	JJ	O
Env	NNP	O
antibody	NN	O
ELISAs	NNP	O
(	(	O
enzyme-linked	JJ	O
immunosorbent	NN	O
assays	NNS	O
)	)	O
at	IN	O
various	JJ	O
times	NNS	O
post-immunization	NN	O
.	.	O
The	DT	O
antibody	NN	O
titers	NNS	O
of	IN	O
the	DT	O
sera	NN	O
were	VBD	O
determined	VBN	O
by	IN	O
anti-Env	JJ	O
antibody	NN	O
ELISA	NNP	O
as	IN	O
described	VBN	O
above	IN	O
.	.	O
Briefly	NNP	O
,	,	O
sera	NN	O
from	IN	O
immunized	VBN	O
animals	NNS	O
were	VBD	O
screened	VBN	O
for	IN	O
antibodies	NNS	O
directed	VBN	O
against	IN	O
the	DT	O
HIV	NNP	O
gp120	NN	O
or	CC	O
gp140	NN	O
Env	NNP	O
protein	NN	O
.	.	O
Wells	NNP	O
of	IN	O
ELISA	NNP	O
microtiter	NN	O
plates	NNS	O
were	VBD	O
coated	VBN	O
overnight	JJ	O
with	IN	O
the	DT	O
selected	VBN	O
Env	NNP	O
protein	NN	O
and	CC	O
washed	VBD	O
four	CD	O
times	NNS	O
;	:	O
subsequently	RB	O
,	,	O
blocking	VBG	O
was	VBD	O
done	VBN	O
with	IN	O
PBS-0.2	NNP	O
%	NN	O
Tween	NNP	O
(	(	O
Sigma	NNP	O
)	)	O
for	IN	O
2	CD	O
hours	NNS	O
.	.	O
After	IN	O
removal	NN	O
of	IN	O
the	DT	O
blocking	VBG	O
solution	NN	O
,	,	O
100	CD	O
μl	NN	O
of	IN	O
diluted	VBN	O
mouse	NN	O
serum	NN	O
was	VBD	O
added	VBN	O
.	.	O
Sera	NN	O
were	VBD	O
tested	VBN	O
at	IN	O
1/25	CD	O
dilutions	NNS	O
and	CC	O
by	IN	O
serial	JJ	O
3-fold	JJ	O
dilutions	NNS	O
,	,	O
thereafter	RB	O
.	.	O
Microtiter	NN	O
plates	NNS	O
were	VBD	O
washed	VBN	O
four	CD	O
times	NNS	O
and	CC	O
incubated	VBN	O
with	IN	O
a	DT	O
secondary	JJ	O
,	,	O
peroxidase-coupled	JJ	O
anti-mouse	NN	O
IgG	NNP	O
antibody	NN	O
(	(	O
Pierce	NNP	O
,	,	O
Rockford	NNP	O
,	,	O
Ill.	NNP	O
)	)	O
.	.	O
ELISA	NNP	O
plates	NNS	O
were	VBD	O
washed	VBN	O
and	CC	O
100	CD	O
μl	NN	O
of	IN	O
3,3′	CD	O
,	,	O
5,5′-tetramethyl	JJ	O
benzidine	NN	O
(	(	O
TMB	NNP	O
;	:	O
Pierce	NNP	O
)	)	O
was	VBD	O
added	VBN	O
per	IN	O
well	RB	O
.	.	O
The	DT	O
optical	JJ	O
density	NN	O
of	IN	O
each	DT	O
well	NN	O
was	VBD	O
measured	VBN	O
after	IN	O
15	CD	O
minutes	NNS	O
.	.	O
Titers	NNS	O
are	VBP	O
typically	RB	O
reported	VBN	O
as	IN	O
the	DT	O
reciprocal	NN	O
of	IN	O
the	DT	O
dilution	NN	O
of	IN	O
serum	NN	O
that	WDT	O
gave	VBD	O
a	DT	O
half-maximum	JJ	O
optical	JJ	O
density	NN	O
(	(	O
O.D	NNP	O
.	.	O
)	)	O
.	.	O
Example	JJ	O
11	CD	O
DNA-immunization	NN	O
of	IN	O
Baboons	NNP	O
Using	NNP	O
Synthetic	NNP	O
Gag	NNP	O
Expression	NNP	O
Cassettes	NNP	O
A.	NNP	O
Baboons	NNP	O
Four	NNP	O
baboons	NNS	O
were	VBD	O
immunized	VBN	O
3	CD	O
times	NNS	O
(	(	O
weeks	NNS	O
0	CD	O
,	,	O
4	CD	O
and	CC	O
8	CD	O
)	)	O
bilaterally	RB	O
,	,	O
intramuscular	JJ	O
into	IN	O
the	DT	O
quadriceps	NNS	O
using	VBG	O
1	CD	O
mg	JJ	O
pCMVKM2.GagMod.SF2	NN	O
plasmid-DNA	NN	O
(	(	O
Example	NNP	O
1	CD	O
)	)	O
.	.	O
The	DT	O
animals	NNS	O
were	VBD	O
bled	VBN	O
two	CD	O
weeks	NNS	O
after	IN	O
each	DT	O
immunization	NN	O
and	CC	O
a	DT	O
p24	NN	O
antibody	NN	O
ELISA	NNP	O
was	VBD	O
performed	VBN	O
with	IN	O
isolated	JJ	O
plasma	NN	O
.	.	O
The	DT	O
ELISA	NNP	O
was	VBD	O
performed	VBN	O
essentially	RB	O
as	IN	O
described	VBN	O
in	IN	O
Example	NNP	O
5	CD	O
except	IN	O
the	DT	O
second	JJ	O
antibody-conjugate	NN	O
was	VBD	O
an	DT	O
anti-human	JJ	O
IgG	NNP	O
,	,	O
g-chain	NN	O
specific	NN	O
,	,	O
peroxidase	NN	O
conjugate	NN	O
(	(	O
Sigma	NNP	O
Chemical	NNP	O
Co.	NNP	O
,	,	O
St.	NNP	O
Louis	NNP	O
,	,	O
Md	NNP	O
.	.	O
63178	CD	O
)	)	O
used	VBN	O
at	IN	O
a	DT	O
dilution	NN	O
of	IN	O
1:500	CD	O
.	.	O
Fifty	NNP	O
μg/ml	NNP	O
yeast	NNP	O
extract	NN	O
was	VBD	O
added	VBN	O
to	TO	O
the	DT	O
dilutions	NNS	O
of	IN	O
plasma	NN	O
samples	NNS	O
and	CC	O
antibody	NN	O
conjugate	NN	O
to	TO	O
reduce	VB	O
non-specific	JJ	O
background	NN	O
due	JJ	O
to	TO	O
preexisting	VBG	O
yeast	JJ	O
antibodies	NNS	O
in	IN	O
the	DT	O
baboons	NNS	O
.	.	O
The	DT	O
antibody	NN	O
titer	NN	O
results	NNS	O
are	VBP	O
presented	VBN	O
in	IN	O
Table	JJ	O
14	CD	O
.	.	O
In	IN	O
Table	NNP	O
14	CD	O
,	,	O
pre-bleed	JJ	O
data	NNS	O
are	VBP	O
given	VBN	O
as	IN	O
Immunization	NNP	O
No	NNP	O
.	.	O
0	CD	O
;	:	O
data	NNS	O
for	IN	O
bleeds	NNS	O
taken	VBN	O
2	CD	O
weeks	NNS	O
post-first	JJ	O
immunization	NN	O
are	VBP	O
given	VBN	O
as	IN	O
Immunization	NNP	O
No	NNP	O
.	.	O
1	CD	O
;	:	O
data	NNS	O
for	IN	O
bleeds	NNS	O
taken	VBN	O
2	CD	O
weeks	NNS	O
post-second	JJ	O
immunization	NN	O
are	VBP	O
given	VBN	O
as	IN	O
Immunization	NNP	O
No	NNP	O
.	.	O
2	CD	O
;	:	O
and	CC	O
,	,	O
data	NNS	O
for	IN	O
bleeds	NNS	O
taken	VBN	O
2	CD	O
weeks	NNS	O
post-third	JJ	O
immunization	NN	O
are	VBP	O
given	VBN	O
as	IN	O
Immunization	NNP	O
No	NNP	O
.	.	O
3	CD	O
.	.	O
Further	RB	O
,	,	O
lymphoproliferative	JJ	O
responses	NNS	O
to	TO	O
p24	VB	O
antigen	NN	O
were	VBD	O
also	RB	O
observed	VBN	O
in	IN	O
baboons	NNS	O
221	CD	O
and	CC	O
222	CD	O
two	CD	O
weeks	NNS	O
post-fourth	JJ	O
immunization	NN	O
(	(	O
at	IN	O
week	NN	O
14	CD	O
)	)	O
,	,	O
and	CC	O
enhanced	VBD	O
substantially	RB	O
post-boosting	VBG	O
with	IN	O
VLP	NNP	O
(	(	O
at	IN	O
week	NN	O
44	CD	O
and	CC	O
76	CD	O
)	)	O
.	.	O
Such	JJ	O
proliferation	NN	O
results	NNS	O
are	VBP	O
indicative	JJ	O
of	IN	O
induction	NN	O
of	IN	O
T-helper	NNP	O
cell	NN	O
functions	NNS	O
.	.	O
B.	NNP	O
Rhesus	NNP	O
Macaques	NNP	O
The	DT	O
improved	JJ	O
potency	NN	O
of	IN	O
the	DT	O
codon-modified	JJ	O
gag	NN	O
expression	NN	O
plasmid	NN	O
observed	VBN	O
in	IN	O
mouse	NN	O
and	CC	O
baboon	NN	O
studies	NNS	O
was	VBD	O
confirmed	VBN	O
in	IN	O
rhesus	NN	O
macaques	NNS	O
.	.	O
Four	CD	O
of	IN	O
four	CD	O
macaques	NNS	O
had	VBD	O
detectable	JJ	O
Gag-specific	NNP	O
CTL	NNP	O
after	IN	O
two	CD	O
or	CC	O
three	CD	O
1	CD	O
mg	NN	O
doses	NNS	O
of	IN	O
modified	JJ	O
gag	NN	O
plasmid	NN	O
.	.	O
In	IN	O
contrast	NN	O
,	,	O
in	IN	O
a	DT	O
previous	JJ	O
study	NN	O
,	,	O
only	RB	O
one	CD	O
of	IN	O
four	CD	O
macaques	NNS	O
given	VBN	O
1	CD	O
mg	JJ	O
doses	NNS	O
of	IN	O
plasmid-DNA	NN	O
encoding	VBG	O
the	DT	O
wild-type	JJ	O
HIV-1SF2	NNP	O
Gag	NNP	O
showed	VBD	O
strong	JJ	O
CTL	NNP	O
activity	NN	O
that	WDT	O
was	VBD	O
not	RB	O
apparent	JJ	O
until	IN	O
after	IN	O
the	DT	O
seventh	JJ	O
immunization	NN	O
.	.	O
Further	JJ	O
evidence	NN	O
of	IN	O
the	DT	O
potency	NN	O
of	IN	O
the	DT	O
modified	JJ	O
gag	NN	O
plasmid	NN	O
was	VBD	O
the	DT	O
observation	NN	O
that	WDT	O
CTL	NNP	O
from	IN	O
two	CD	O
of	IN	O
the	DT	O
four	CD	O
rhesus	NN	O
macaques	NNS	O
reacted	VBD	O
with	IN	O
three	CD	O
nonoverlapping	VBG	O
Gag	NNP	O
peptide	NN	O
pools	NNS	O
,	,	O
suggesting	VBG	O
that	IN	O
as	RB	O
many	JJ	O
as	IN	O
three	CD	O
different	JJ	O
Gag	NNP	O
peptides	NNS	O
are	VBP	O
recognized	VBN	O
and	CC	O
indicating	VBG	O
that	IN	O
the	DT	O
CTL	NNP	O
response	NN	O
is	VBZ	O
polyclonal	JJ	O
.	.	O
Additional	JJ	O
quantification	NN	O
and	CC	O
specificity	NN	O
studies	NNS	O
are	VBP	O
in	IN	O
progress	NN	O
to	TO	O
further	RBR	O
characterize	VB	O
the	DT	O
T	NNP	O
cell	NN	O
responses	NNS	O
to	TO	O
Gag	NNP	O
in	IN	O
the	DT	O
plasmid-immunized	JJ	O
rhesus	NN	O
macaques	NNS	O
.	.	O
DNA	NNP	O
immunization	NN	O
of	IN	O
macaques	NNS	O
with	IN	O
the	DT	O
modified	VBN	O
gag	NN	O
plasmid	NN	O
did	VBD	O
not	RB	O
result	VB	O
in	IN	O
significant	JJ	O
antibody	NN	O
responses	NNS	O
,	,	O
with	IN	O
only	RB	O
two	CD	O
of	IN	O
four	CD	O
animals	NNS	O
seroconverting	VBG	O
at	IN	O
low	JJ	O
titers	NNS	O
.	.	O
In	IN	O
contrast	NN	O
,	,	O
in	IN	O
the	DT	O
same	JJ	O
study	NN	O
the	DT	O
majority	NN	O
of	IN	O
macaques	NNS	O
in	IN	O
groups	NNS	O
immunized	VBN	O
with	IN	O
p55Gag	JJ	O
protein	NN	O
seroconverted	VBD	O
and	CC	O
had	VBD	O
strong	JJ	O
Gag-specific	NNP	O
antibody	NN	O
titers	NNS	O
.	.	O
These	DT	O
data	NNS	O
suggest	VBP	O
that	IN	O
a	DT	O
prime-boost	JJ	O
strategy	NN	O
(	(	O
DNA-prime	JJ	O
and	CC	O
protein-boost	NN	O
)	)	O
could	MD	O
be	VB	O
very	RB	O
promising	VBG	O
for	IN	O
the	DT	O
induction	NN	O
of	IN	O
a	DT	O
strong	JJ	O
CTL	NNP	O
and	CC	O
antibody	NN	O
response	NN	O
.	.	O
In	IN	O
sum	NN	O
,	,	O
these	DT	O
results	NNS	O
demonstrate	VBP	O
that	IN	O
the	DT	O
synthetic	JJ	O
Gag	NNP	O
plasmid	NN	O
DNA	NNP	O
is	VBZ	O
immunogenic	JJ	O
in	IN	O
non-human	JJ	O
primates	NNS	O
.	.	O
When	WRB	O
similar	JJ	O
experiments	NNS	O
were	VBD	O
carried	VBN	O
out	RP	O
using	VBG	O
wild-type	JJ	O
Gag	NNP	O
plasmid	NN	O
DNA	NNP	O
no	DT	O
such	JJ	O
induction	NN	O
of	IN	O
anti-p24	JJ	O
antibodies	NNS	O
was	VBD	O
observed	VBN	O
after	IN	O
four	CD	O
immunizations	NNS	O
.	.	O
Example	JJ	O
12	CD	O
DNA-	JJ	O
and	CC	O
Protein	NNP	O
Immunizations	NNP	O
of	IN	O
Animals	NNP	O
Using	NNP	O
Env	NNP	O
Expression	NNP	O
Cassettes	NNP	O
and	CC	O
Polypeptides	NNP	O
A	NNP	O
.	.	O
Guinea	NNP	O
Pigs	NNP	O
Groups	NNP	O
comprising	VBG	O
six	CD	O
guinea	NN	O
pigs	NNS	O
each	DT	O
were	VBD	O
immunized	VBN	O
intramuscularly	RB	O
at	IN	O
0	CD	O
,	,	O
4	CD	O
,	,	O
and	CC	O
12	CD	O
weeks	NNS	O
with	IN	O
plasmid	JJ	O
DNAs	NNP	O
encoding	VBG	O
the	DT	O
gp120.modUS4	NN	O
,	,	O
gp140.modUS4	NN	O
,	,	O
gp140.modUS4.delV1	NN	O
,	,	O
gp140.modUS4.delV2	NN	O
,	,	O
gp140.modUS4.delV1/V2	NN	O
,	,	O
or	CC	O
gp160.modUS4	NN	O
coding	VBG	O
sequences	NNS	O
of	IN	O
the	DT	O
US4-derived	JJ	O
Env	NNP	O
.	.	O
The	DT	O
animals	NNS	O
were	VBD	O
subsequently	RB	O
boosted	VBN	O
at	IN	O
18	CD	O
weeks	NNS	O
with	IN	O
a	DT	O
single	JJ	O
intramuscular	NN	O
dose	NN	O
of	IN	O
US4	NNP	O
o-gp140.mut.modUS4	JJ	O
protein	NN	O
in	IN	O
MF59	NNP	O
adjuvant	NN	O
.	.	O
Anti-gp120	JJ	O
SF2	NNP	O
antibody	NN	O
titers	NNS	O
(	(	O
geometric	JJ	O
mean	NN	O
titers	NNS	O
)	)	O
were	VBD	O
measured	VBN	O
at	IN	O
two	CD	O
weeks	NNS	O
following	VBG	O
the	DT	O
third	JJ	O
DNA	NNP	O
immunization	NN	O
and	CC	O
at	IN	O
two	CD	O
weeks	NNS	O
after	IN	O
the	DT	O
protein	NN	O
boost	NN	O
.	.	O
Results	NNS	O
are	VBP	O
shown	VBN	O
in	IN	O
Table	JJ	O
15	CD	O
.	.	O
These	DT	O
results	NNS	O
demonstrate	VBP	O
the	DT	O
usefulness	NN	O
of	IN	O
the	DT	O
synthetic	JJ	O
constructs	NNS	O
to	TO	O
generate	VB	O
immune	JJ	O
responses	NNS	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
,	,	O
the	DT	O
advantage	NN	O
of	IN	O
providing	VBG	O
a	DT	O
protein	NN	O
boost	NN	O
to	TO	O
enhance	VB	O
the	DT	O
immune	JJ	O
response	NN	O
following	VBG	O
DNA	NNP	O
immunization	NN	O
.	.	O
B.	NNP	O
Rabbits	NNP	O
Rabbits	NNP	O
were	VBD	O
immunized	VBN	O
intramuscularly	RB	O
and	CC	O
intradermally	RB	O
using	VBG	O
a	DT	O
Bioject	NNP	O
needless	JJ	O
syringe	NN	O
with	IN	O
plasmid	JJ	O
DNAs	NNP	O
encoding	VBG	O
the	DT	O
following	JJ	O
synthetic	JJ	O
SF162	NNP	O
Env	NNP	O
polypeptides	NNS	O
:	:	O
gp120.modSF162	NN	O
,	,	O
gp120.modSF162.delV2	NN	O
,	,	O
gp140.modSF162	NN	O
,	,	O
gp140.modSF162.delV2	NN	O
,	,	O
gp140.mut.modSF162	NN	O
,	,	O
gp140.mut.modSF162.delV2	NN	O
,	,	O
gp160.modSF162	NN	O
,	,	O
and	CC	O
gp160.modSF162.delV2	NN	O
.	.	O
Approximately	RB	O
1	CD	O
mg	NNS	O
of	IN	O
plasmid	NN	O
DNA	NNP	O
(	(	O
pCMVlink	NN	O
)	)	O
carrying	VBG	O
the	DT	O
synthetic	JJ	O
Env	NNP	O
expression	NN	O
cassette	NN	O
was	VBD	O
used	VBN	O
to	TO	O
immunize	VB	O
the	DT	O
rabbits	NNS	O
.	.	O
Rabbits	NNS	O
were	VBD	O
immunized	VBN	O
with	IN	O
plasmid	JJ	O
DNA	NN	O
at	IN	O
0	CD	O
,	,	O
4	CD	O
,	,	O
and	CC	O
12	CD	O
weeks	NNS	O
.	.	O
At	IN	O
two	CD	O
weeks	NNS	O
after	IN	O
the	DT	O
third	JJ	O
immunization	NN	O
all	DT	O
of	IN	O
the	DT	O
constructs	NNS	O
were	VBD	O
shown	VBN	O
to	TO	O
have	VB	O
generated	VBN	O
significant	JJ	O
antibody	NN	O
titers	NNS	O
in	IN	O
the	DT	O
test	NN	O
animals	NNS	O
.	.	O
Further	RB	O
,	,	O
rabbits	NNS	O
immunized	VBN	O
with	IN	O
constructs	NNS	O
containing	VBG	O
deletions	NNS	O
of	IN	O
the	DT	O
V2	NNP	O
region	NN	O
generally	RB	O
generated	VBD	O
similar	JJ	O
antibody	NN	O
titers	NNS	O
relative	VBP	O
to	TO	O
rabbits	NNS	O
immunized	VBN	O
with	IN	O
the	DT	O
companion	NN	O
construct	NN	O
still	RB	O
containing	VBG	O
the	DT	O
V2	NNP	O
region	NN	O
.	.	O
The	DT	O
nucleic	JJ	O
acid	NN	O
immunizations	NNS	O
are	VBP	O
followed	VBN	O
by	IN	O
protein	NN	O
boosting	VBG	O
with	IN	O
o-gp140.modSF162.delV2	JJ	O
(	(	O
0.1	CD	O
mg	NN	O
of	IN	O
purified	JJ	O
protein	NN	O
)	)	O
at	IN	O
24	CD	O
weeks	NNS	O
after	IN	O
the	DT	O
initial	JJ	O
immunization	NN	O
.	.	O
Results	NNS	O
are	VBP	O
shown	VBN	O
in	IN	O
Table	JJ	O
16	CD	O
.	.	O
All	DT	O
constructs	NNS	O
are	VBP	O
highly	RB	O
immunogenic	JJ	O
and	CC	O
generate	JJ	O
substantial	JJ	O
antigen	NN	O
binding	VBG	O
antibody	NN	O
responses	NNS	O
after	IN	O
only	RB	O
2	CD	O
immunizations	NNS	O
in	IN	O
rabbits	NNS	O
.	.	O
C.	NNP	O
Baboons	NNP	O
Groups	NNP	O
of	IN	O
four	CD	O
baboons	NNS	O
were	VBD	O
immunized	VBN	O
intramuscularly	RB	O
with	IN	O
1	CD	O
mg	JJ	O
doses	NNS	O
of	IN	O
DNA	NNP	O
encoding	VBG	O
different	JJ	O
forms	NNS	O
of	IN	O
synthetic	JJ	O
US4	NNP	O
gp140	NN	O
(	(	O
see	VB	O
the	DT	O
following	VBG	O
table	NN	O
)	)	O
at	IN	O
0	CD	O
,	,	O
4	CD	O
,	,	O
8	CD	O
,	,	O
12	CD	O
,	,	O
28	CD	O
,	,	O
and	CC	O
44	CD	O
weeks	NNS	O
.	.	O
The	DT	O
animals	NNS	O
were	VBD	O
also	RB	O
boosted	VBN	O
twice	RB	O
with	IN	O
US4	NNP	O
o-gp140	JJ	O
protein	NN	O
(	(	O
gp140.mut.modUS4	NN	O
)	)	O
at	IN	O
44	CD	O
and	CC	O
76	CD	O
weeks	NNS	O
using	VBG	O
MF59	NNP	O
as	IN	O
adjuvant	NN	O
.	.	O
Results	NNS	O
are	VBP	O
shown	VBN	O
in	IN	O
Table	JJ	O
17	CD	O
.	.	O
The	DT	O
results	NNS	O
in	IN	O
Table	JJ	O
17	CD	O
demonstrate	NN	O
the	DT	O
usefulness	NN	O
of	IN	O
the	DT	O
synthetic	JJ	O
constructs	NNS	O
to	TO	O
generate	VB	O
immune	JJ	O
responses	NNS	O
in	IN	O
primates	NNS	O
such	JJ	O
as	IN	O
baboons	NNS	O
.	.	O
In	IN	O
addition	NN	O
,	,	O
all	DT	O
animals	NNS	O
showed	VBD	O
evidence	NN	O
of	IN	O
antigen-specific	JJ	O
(	(	O
Env	NNP	O
antigen	NN	O
)	)	O
lymphopro-liferative	JJ	O
responses	NNS	O
.	.	O
D.	NNP	O
Rhesus	NNP	O
Macaques	NNP	O
Two	CD	O
rhesus	NN	O
macaques	NNS	O
(	(	O
designated	VBN	O
H445	NNP	O
and	CC	O
J408	NNP	O
)	)	O
were	VBD	O
immunized	VBN	O
with	IN	O
1	CD	O
mg	NN	O
of	IN	O
DNA	NNP	O
encoding	VBG	O
SF162	NNP	O
gp140	NN	O
with	IN	O
a	DT	O
deleted	JJ	O
V2	NNP	O
region	NN	O
(	(	O
SF162.9p140.delV2	NNP	O
)	)	O
by	IN	O
intramuscular	NN	O
(	(	O
IM	NNP	O
)	)	O
and	CC	O
intradermal	JJ	O
(	(	O
ID	NNP	O
)	)	O
routes	VBZ	O
at	IN	O
0	CD	O
,	,	O
4	CD	O
,	,	O
8	CD	O
,	,	O
and	CC	O
28	CD	O
weeks	NNS	O
.	.	O
Approximately	RB	O
100	CD	O
μg	NNS	O
of	IN	O
the	DT	O
protein	NN	O
encoded	VBN	O
by	IN	O
the	DT	O
SF162	NNP	O
.	.	O
gp140mut.delV2	NN	O
construct	NN	O
was	VBD	O
also	RB	O
administered	VBN	O
in	IN	O
MF59	NNP	O
by	IN	O
IM	NNP	O
delivery	NN	O
at	IN	O
28	CD	O
weeks	NNS	O
.	.	O
ELISA	NN	O
titers	NNS	O
are	VBP	O
shown	VBN	O
in	IN	O
FIG	NNP	O
.	.	O
61	CD	O
.	.	O
Neutralizing	VBG	O
antibody	NN	O
activity	NN	O
is	VBZ	O
shown	VBN	O
Tables	NNP	O
18	CD	O
and	CC	O
19	CD	O
.	.	O
Neutralizing	VBG	O
antibody	NN	O
activity	NN	O
was	VBD	O
determined	VBN	O
against	IN	O
a	DT	O
variety	NN	O
of	IN	O
primary	JJ	O
HIV-1	NNP	O
isolates	NNS	O
in	IN	O
a	DT	O
primary	JJ	O
lymphocyte	NN	O
or	CC	O
“	VB	O
PBMC-based	JJ	O
”	NNS	O
assay	VBP	O
(	(	O
see	VB	O
the	DT	O
following	JJ	O
tables	NNS	O
)	)	O
.	.	O
Further	RB	O
,	,	O
the	DT	O
phenotypic	NN	O
co-receptor	NN	O
usage	NN	O
for	IN	O
each	DT	O
of	IN	O
the	DT	O
primary	JJ	O
isolates	NNS	O
is	VBZ	O
indicated	VBN	O
.	.	O
As	IN	O
can	MD	O
be	VB	O
seen	VBN	O
in	IN	O
the	DT	O
tables	NNS	O
neutralizing	VBG	O
antibodies	NNS	O
were	VBD	O
detected	VBN	O
against	IN	O
every	DT	O
isolate	NN	O
tested	VBN	O
,	,	O
including	VBG	O
the	DT	O
HIV-1	NNP	O
primary	JJ	O
isolates	NNS	O
(	(	O
i.e.	FW	O
,	,	O
SF128A	NNP	O
,	,	O
92US660	CD	O
,	,	O
92HT593	CD	O
,	,	O
92US657	CD	O
,	,	O
92US714	CD	O
,	,	O
91US056	CD	O
,	,	O
and	CC	O
91US054	CD	O
)	)	O
.	.	O
Lymphoproliferative	JJ	O
activity	NN	O
(	(	O
LPA	NNP	O
)	)	O
was	VBD	O
also	RB	O
determined	VBN	O
by	IN	O
antigenic	JJ	O
stimulation	NN	O
followed	VBN	O
by	IN	O
uptake	NN	O
of	IN	O
3H-thymidine	JJ	O
in	IN	O
these	DT	O
animals	NNS	O
and	CC	O
is	VBZ	O
shown	VBN	O
in	IN	O
Table	JJ	O
20	CD	O
.	.	O
Experiment	JJ	O
1	CD	O
was	VBD	O
performed	VBN	O
at	IN	O
14	CD	O
weeks	NNS	O
post	RB	O
third	JJ	O
DNA	NNP	O
immunization	NN	O
and	CC	O
Experiment	NNP	O
2	CD	O
was	VBD	O
performed	VBN	O
at	IN	O
2	CD	O
weeks	NNS	O
post	RB	O
fourth	JJ	O
DNA	NNP	O
immunization	NN	O
using	VBG	O
DNA	NNP	O
and	CC	O
protein	NN	O
.	.	O
For	IN	O
gp120ThaiE	NN	O
,	,	O
gp120SF2	NN	O
and	CC	O
US4	NNP	O
o-gp140	NN	O
,	,	O
appropriate	JJ	O
background	NN	O
values	NNS	O
were	VBD	O
used	VBN	O
to	TO	O
calculate	VB	O
Stimulation	NNP	O
Indices	NNP	O
(	(	O
S.	NNP	O
I.	NNP	O
;	:	O
Antigenic	NNP	O
stimulation	NN	O
CPM/Background	NNP	O
CPM	NNP	O
)	)	O
.	.	O
As	IN	O
can	MD	O
be	VB	O
seen	VBN	O
by	IN	O
the	DT	O
results	NNS	O
presented	VBD	O
in	IN	O
Table	JJ	O
20	CD	O
lymphoproliferative	JJ	O
responses	NNS	O
to	TO	O
o-gp140.US4	JJ	O
antigen	NN	O
were	VBD	O
also	RB	O
in	IN	O
all	DT	O
four	CD	O
animals	NNS	O
at	IN	O
both	DT	O
experimental	JJ	O
time	NN	O
points	NNS	O
.	.	O
Such	JJ	O
proliferation	NN	O
results	NNS	O
are	VBP	O
indicative	JJ	O
of	IN	O
induction	NN	O
of	IN	O
T-helper	NNP	O
cell	NN	O
functions	NNS	O
.	.	O
The	DT	O
results	NNS	O
presented	VBN	O
above	JJ	O
demonstrate	NN	O
that	IN	O
the	DT	O
synthetic	JJ	O
gp140.modSF162.delV2	NN	O
DNA	NNP	O
and	CC	O
protein	NN	O
are	VBP	O
immunogenic	JJ	O
in	IN	O
non-human	JJ	O
primates	NNS	O
.	.	O
Example	JJ	O
13	CD	O
In	IN	O
Vitro	NNP	O
Expression	NNP	O
of	IN	O
Recombinant	NNP	O
Sindbis	NNP	O
RNA	NNP	O
and	CC	O
DNA	NNP	O
Containing	NNP	O
the	DT	O
Synthetic	NNP	O
Gag	NNP	O
or	CC	O
Env	NNP	O
Expression	NNP	O
Cassettes	VBZ	O
A	DT	O
.	.	O
Synthetic	JJ	O
Gag	NNP	O
Expression	NNP	O
Cassettes	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
expression	NN	O
efficiency	NN	O
of	IN	O
the	DT	O
synthetic	JJ	O
Gag	NNP	O
expression	NN	O
cassette	NN	O
in	IN	O
Alphavirus	NNP	O
vectors	NNS	O
,	,	O
the	DT	O
synthetic	JJ	O
Gag	NNP	O
expression	NN	O
cassette	NN	O
was	VBD	O
subcloned	VBN	O
into	IN	O
both	DT	O
plasmid	JJ	O
DNA-based	JJ	O
and	CC	O
recombinant	JJ	O
vector	NN	O
particle-based	JJ	O
Sindbis	NNP	O
virus	NN	O
vectors	NNS	O
.	.	O
Specifically	RB	O
,	,	O
a	DT	O
cDNA	NN	O
vector	NN	O
construct	NN	O
for	IN	O
in	IN	O
vitro	JJ	O
transcription	NN	O
of	IN	O
Sindbis	NNP	O
virus	NN	O
RNA	NNP	O
vector	NN	O
replicons	NNS	O
(	(	O
pRSIN-luc	NN	O
;	:	O
Dubensky	NNP	B
,	,	I
et	FW	I
al.	NN	I
,	,	I
J	NNP	I
Virol	NNP	I
.	.	I
70:508-519	CD	I
,	,	I
1996	CD	I
)	)	O
was	VBD	O
modified	VBN	O
to	TO	O
contain	VB	O
a	DT	O
PmeI	NNP	O
site	NN	O
for	IN	O
plasmid	JJ	O
linearization	NN	O
and	CC	O
a	DT	O
polylinker	NN	O
for	IN	O
insertion	NN	O
of	IN	O
heterologous	JJ	O
genes	NNS	O
.	.	O
A	DT	O
polylinker	NN	O
was	VBD	O
generated	VBN	O
using	VBG	O
two	CD	O
oligonucleotides	NNS	O
that	WDT	O
contain	VBP	O
the	DT	O
sites	NNS	O
XhoI	NNP	O
,	,	O
PmlI	NNP	O
,	,	O
ApaI	NNP	O
,	,	O
NarI	NNP	O
,	,	O
XbaI	NNP	O
,	,	O
and	CC	O
NotI	NNP	O
(	(	O
XPANXNF	NNP	O
,	,	O
SEQ	NNP	O
ID	NNP	O
NO:17	NNP	O
,	,	O
and	CC	O
XPANXNR	NNP	O
,	,	O
SEQ	NNP	O
ID	NNP	O
NO:18	NNP	O
)	)	O
.	.	O
The	DT	O
plasmid	JJ	O
pRSIN-luc	NN	O
(	(	O
Dubensky	NNP	O
et	FW	O
al.	NN	O
,	,	O
supra	NN	O
)	)	O
was	VBD	O
digested	VBN	O
with	IN	O
XhoI	NNP	O
and	CC	O
NotI	NNP	O
to	TO	O
remove	VB	O
the	DT	O
luciferase	NN	O
gene	NN	O
insert	NN	O
,	,	O
blunt-ended	JJ	O
using	VBG	O
Klenow	NNP	O
and	CC	O
dNTPs	NN	O
,	,	O
and	CC	O
purified	VBD	O
from	IN	O
an	DT	O
agarose	JJ	O
get	NN	O
using	VBG	O
GeneCleanII	NNP	O
(	(	O
Biol0l	NNP	O
,	,	O
Vista	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
.	.	O
The	DT	O
oligonucleotides	NNS	O
were	VBD	O
annealed	VBN	O
to	TO	O
each	DT	O
other	JJ	O
and	CC	O
ligated	VBN	O
into	IN	O
the	DT	O
plasmid	NN	O
.	.	O
The	DT	O
resulting	VBG	O
construct	NN	O
was	VBD	O
digested	VBN	O
with	IN	O
NotI	NNP	O
and	CC	O
SacI	NNP	O
to	TO	O
remove	VB	O
the	DT	O
minimal	JJ	O
Sindbis	NNP	O
3′-end	JJ	O
sequence	NN	O
and	CC	O
A40	NNP	O
tract	NN	O
,	,	O
and	CC	O
ligated	VBD	O
with	IN	O
an	DT	O
approximately	RB	O
0.4	CD	O
kbp	JJ	O
fragment	NN	O
from	IN	O
PKSSIN-BV	NNP	O
(	(	O
WO	NNP	O
97/38087	CD	O
)	)	O
.	.	O
This	DT	O
0.4	CD	O
kbp	FW	O
fragment	NN	O
was	VBD	O
obtained	VBN	O
by	IN	O
digestion	NN	O
of	IN	O
pKSSIN-BV	NN	O
with	IN	O
NotI	NNP	O
and	CC	O
SacI	NNP	O
,	,	O
and	CC	O
purification	NN	O
after	IN	O
size	NN	O
fractionation	NN	O
from	IN	O
an	DT	O
agarose	JJ	O
gel	NN	O
.	.	O
The	DT	O
fragment	NN	O
contained	VBD	O
the	DT	O
complete	JJ	O
Sindbis	NNP	O
virus	NN	O
3′-end	CD	O
,	,	O
an	DT	O
A40	NNP	O
tract	NN	O
and	CC	O
a	DT	O
PmeI	NNP	O
site	NN	O
for	IN	O
linearization	NN	O
.	.	O
This	DT	O
new	JJ	O
vector	NN	O
construct	NN	O
was	VBD	O
designated	VBN	O
SINBVE	NNP	O
.	.	O
The	DT	O
synthetic	JJ	O
HIV	NNP	O
Gag	NNP	O
coding	VBG	O
sequence	NN	O
was	VBD	O
obtained	VBN	O
from	IN	O
the	DT	O
parental	JJ	O
plasmid	NN	O
by	IN	O
digestion	NN	O
with	IN	O
EcoRI	NNP	O
,	,	O
blunt-ending	NN	O
with	IN	O
Klenow	NNP	O
and	CC	O
dNTPs	NN	O
,	,	O
purification	NN	O
with	IN	O
GeneCleanII	NNP	O
,	,	O
digestion	NN	O
with	IN	O
Sail	NNP	O
,	,	O
size	NN	O
fractionation	NN	O
on	IN	O
an	DT	O
agarose	JJ	O
gel	NN	O
,	,	O
and	CC	O
purification	NN	O
from	IN	O
the	DT	O
agarose	JJ	O
gel	NN	O
using	VBG	O
GeneCleanII	NNP	O
.	.	O
The	DT	O
synthetic	JJ	O
Gag	NNP	O
coding	VBG	O
fragment	NN	O
was	VBD	O
ligated	VBN	O
into	IN	O
the	DT	O
SINBVE	NNP	O
vector	NN	O
that	WDT	O
had	VBD	O
been	VBN	O
digested	VBN	O
with	IN	O
XhoI	NNP	O
and	CC	O
PmlI	NNP	O
.	.	O
The	DT	O
resulting	VBG	O
vector	NN	O
was	VBD	O
purified	VBN	O
using	VBG	O
GeneCleanII	NNP	O
and	CC	O
designated	VBN	O
SINBVGag	NNP	O
.	.	O
Vector	NNP	O
RNA	NNP	O
replicons	NNS	O
may	MD	O
be	VB	O
transcribed	VBN	O
in	IN	O
vitro	NN	O
(	(	O
Dubensky	NNP	O
et	FW	O
al.	NN	O
,	,	O
supra	NN	O
)	)	O
from	IN	O
SINBVGag	NNP	O
and	CC	O
used	VBN	O
directly	RB	O
for	IN	O
transfection	NN	O
of	IN	O
cells	NNS	O
.	.	O
Alternatively	RB	O
,	,	O
the	DT	O
replicons	NNS	O
may	MD	O
be	VB	O
packaged	VBN	O
into	IN	O
recombinant	JJ	O
vector	NN	O
particles	NNS	O
by	IN	O
co-transfection	NN	O
with	IN	O
defective	JJ	O
helper	NN	O
RNAs	NNP	O
or	CC	O
using	VBG	O
an	DT	O
alphavirus	NN	O
packaging	NN	O
cell	NN	O
line	NN	O
as	IN	O
described	NN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
in	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
Nos	NNP	O
.	.	O
5,843,723	CD	O
and	CC	O
5,789,245	CD	O
,	,	O
and	CC	O
then	RB	O
administered	VBN	O
in	IN	O
vivo	NN	O
as	IN	O
described	NN	O
.	.	O
The	DT	O
DNA-based	JJ	O
Sindbis	NNP	O
virus	NN	O
vector	NN	O
pDCMVSIN-beta-gal	JJ	O
(	(	O
Dubensky	NNP	B
,	,	I
et	FW	I
al.	NN	I
,	,	I
J.	NNP	I
Virol	NNP	I
.	.	I
70:508-519	CD	I
,	,	I
1996	CD	I
)	)	O
was	VBD	O
digested	VBN	O
with	IN	O
Sail	NNP	O
and	CC	O
XbaI	NNP	O
,	,	O
to	TO	O
remove	VB	O
the	DT	O
beta-galactosidase	JJ	O
gene	NN	O
insert	NN	O
,	,	O
and	CC	O
purified	VBD	O
using	VBG	O
GeneCleanII	NNP	O
after	IN	O
agarose	JJ	O
gel	JJ	O
size	NN	O
fractionation	NN	O
.	.	O
The	DT	O
HIV	NNP	O
Gag	NNP	O
gene	NN	O
was	VBD	O
inserted	VBN	O
into	IN	O
the	DT	O
pDCMVSIN-beta-gal	JJ	O
by	IN	O
digestion	NN	O
of	IN	O
SINBVGag	NNP	O
with	IN	O
SalI	NNP	O
and	CC	O
XhoI	NNP	O
,	,	O
purification	NN	O
using	VBG	O
GeneCleanII	NNP	O
of	IN	O
the	DT	O
Gag-containing	NNP	O
fragment	NN	O
after	IN	O
agarose	JJ	O
gel	JJ	O
size	NN	O
fractionation	NN	O
,	,	O
and	CC	O
ligation	NN	O
.	.	O
The	DT	O
resulting	VBG	O
construct	NN	O
was	VBD	O
designated	VBN	O
pDSIN-Gag	NN	O
,	,	O
and	CC	O
may	MD	O
be	VB	O
used	VBN	O
directly	RB	O
for	IN	O
in	IN	O
vivo	JJ	O
administration	NN	O
or	CC	O
formulated	VBN	O
using	VBG	O
any	DT	O
of	IN	O
the	DT	O
methods	NNS	O
described	VBD	O
herein	NN	O
.	.	O
BHK	NNP	O
and	CC	O
293	CD	O
cells	NNS	O
were	VBD	O
transfected	VBN	O
with	IN	O
recombinant	JJ	O
Sindbis	NNP	O
vector	NN	O
RNA	NNP	O
and	CC	O
DNA	NNP	O
,	,	O
respectively	RB	O
.	.	O
The	DT	O
supernatants	NNS	O
and	CC	O
cell	NN	O
lysates	NNS	O
were	VBD	O
tested	VBN	O
with	IN	O
the	DT	O
Coulter	NNP	O
p24	NN	O
capture	NN	O
ELISA	NNP	O
(	(	O
Example	NNP	O
2	CD	O
)	)	O
.	.	O
BHK	NNP	O
cells	NNS	O
were	VBD	O
transfected	VBN	O
by	IN	O
electroporation	NN	O
with	IN	O
recombinant	JJ	O
Sindbis	NNP	O
RNA	NNP	O
.	.	O
The	DT	O
expression	NN	O
of	IN	O
p24	NN	O
(	(	O
in	IN	O
ng/ml	NN	O
)	)	O
is	VBZ	O
presented	VBN	O
in	IN	O
Table	JJ	O
21	CD	O
.	.	O
In	IN	O
the	DT	O
table	NN	O
,	,	O
SINGag	NNP	O
#	#	O
1	CD	O
and	CC	O
2	CD	O
represent	NN	O
duplicate	NN	O
measurements	NNS	O
,	,	O
and	CC	O
SINβgal	NNP	O
represents	VBZ	O
a	DT	O
negative	JJ	O
control	NN	O
.	.	O
Supernatants	NNS	O
and	CC	O
lysates	NNS	O
were	VBD	O
collected	VBN	O
24	CD	O
h	JJ	O
post	NN	O
transfection	NN	O
.	.	O
293	CD	O
cells	NNS	O
were	VBD	O
transfected	VBN	O
using	VBG	O
LT-1	NNP	O
(	(	O
Example	NNP	O
2	CD	O
)	)	O
with	IN	O
recombinant	JJ	O
Sindbis	NNP	O
DNA	NNP	O
.	.	O
Synthetic	JJ	O
pCMVKM2GagMod.SF2	NN	O
was	VBD	O
used	VBN	O
as	IN	O
a	DT	O
positive	JJ	O
control	NN	O
.	.	O
Supernatants	NNS	O
and	CC	O
lysates	NNS	O
were	VBD	O
collected	VBN	O
48	CD	O
h	JJ	O
post	NN	O
transfection	NN	O
.	.	O
The	DT	O
expression	NN	O
of	IN	O
p24	NN	O
(	(	O
in	IN	O
ng/ml	NN	O
)	)	O
is	VBZ	O
presented	VBN	O
in	IN	O
Table	JJ	O
22	CD	O
.	.	O
The	DT	O
results	NNS	O
presented	VBD	O
in	IN	O
Tables	NNP	O
21	CD	O
and	CC	O
22	CD	O
demonstrate	NN	O
that	WDT	O
Gag	NNP	O
proteins	VBZ	O
can	MD	O
be	VB	O
efficiently	RB	O
expressed	VBN	O
from	IN	O
both	DT	O
DNA	NNP	O
and	CC	O
RNA-based	JJ	O
Sindbis	NNP	O
vector	NN	O
systems	NNS	O
using	VBG	O
the	DT	O
synthetic	JJ	O
Gag	NNP	O
expression	NN	O
cassette	NN	O
(	(	O
p55Gag.mod	NN	O
)	)	O
.	.	O
B	NNP	O
.	.	O
Synthetic	JJ	O
Env	NNP	O
Expression	NNP	O
Cassettes	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
expression	NN	O
efficiency	NN	O
of	IN	O
the	DT	O
synthetic	JJ	O
Env	NNP	O
expression	NN	O
cassette	NN	O
in	IN	O
Alphavirus	NNP	O
vectors	NNS	O
,	,	O
synthetic	JJ	O
Env	NNP	O
expression	NN	O
cassettes	NNS	O
were	VBD	O
subcloned	VBN	O
into	IN	O
both	DT	O
plasmid	JJ	O
DNA-based	JJ	O
and	CC	O
recombinant	JJ	O
vector	NN	O
particle-based	JJ	O
Sindbis	NNP	O
virus	NN	O
vectors	NNS	O
as	IN	O
described	VBN	O
above	IN	O
for	IN	O
Gag	NNP	O
.	.	O
The	DT	O
synthetic	JJ	O
HIV	NNP	O
Env	NNP	O
coding	VBG	O
sequence	NN	O
was	VBD	O
obtained	VBN	O
from	IN	O
the	DT	O
parental	JJ	O
plasmid	NN	O
by	IN	O
digestion	NN	O
with	IN	O
SalI	NNP	O
and	CC	O
XbaI	NNP	O
,	,	O
size	NN	O
fractionation	NN	O
on	IN	O
an	DT	O
agarose	JJ	O
gel	NN	O
,	,	O
and	CC	O
purification	NN	O
from	IN	O
the	DT	O
agarose	JJ	O
gel	NN	O
using	VBG	O
GeneCleanII	NNP	O
.	.	O
The	DT	O
synthetic	JJ	O
Env	NNP	O
coding	VBG	O
fragment	NN	O
was	VBD	O
ligated	VBN	O
into	IN	O
the	DT	O
SINBVE	NNP	O
vector	NN	O
that	WDT	O
had	VBD	O
been	VBN	O
digested	VBN	O
with	IN	O
XhoI	NNP	O
and	CC	O
XbaI	NNP	O
.	.	O
The	DT	O
resulting	VBG	O
vector	NN	O
was	VBD	O
purified	VBN	O
using	VBG	O
GeneCleanII	NNP	O
and	CC	O
designated	VBN	O
SINBVEnv	NNP	O
.	.	O
Vector	NNP	O
RNA	NNP	O
replicons	NNS	O
may	MD	O
be	VB	O
transcribed	VBN	O
in	IN	O
vitro	NN	O
(	(	O
Dubensky	NNP	O
et	FW	O
al.	NN	O
,	,	O
supra	NN	O
)	)	O
from	IN	O
SINBVEnv	NNP	O
and	CC	O
used	VBN	O
directly	RB	O
for	IN	O
transfection	NN	O
of	IN	O
cells	NNS	O
.	.	O
Alternatively	RB	O
,	,	O
the	DT	O
replicons	NNS	O
may	MD	O
be	VB	O
packaged	VBN	O
into	IN	O
recombinant	JJ	O
vector	NN	O
particles	NNS	O
by	IN	O
co-transfection	NN	O
with	IN	O
defective	JJ	O
helper	NN	O
RNAs	NNP	O
or	CC	O
using	VBG	O
an	DT	O
alphavirus	NN	O
packaging	NN	O
cell	NN	O
line	NN	O
and	CC	O
administered	VBD	O
as	IN	O
described	VBN	O
above	IN	O
for	IN	O
Gag	NNP	O
.	.	O
The	DT	O
DNA-based	JJ	O
Sindbis	NNP	O
virus	NN	O
vector	NN	O
pDCMVSIN-beta-gal	JJ	O
(	(	O
Dubensky	NNP	B
,	,	I
et	FW	I
al.	NN	I
,	,	I
J.	NNP	I
Virol	NNP	I
.	.	I
70:508-519	CD	I
,	,	I
1996	CD	I
)	)	O
was	VBD	O
digested	VBN	O
with	IN	O
Sail	NNP	O
and	CC	O
XbaI	NNP	O
,	,	O
to	TO	O
remove	VB	O
the	DT	O
beta-galactosidase	JJ	O
gene	NN	O
insert	NN	O
,	,	O
and	CC	O
purified	VBD	O
using	VBG	O
GeneCleanII	NNP	O
after	IN	O
agarose	JJ	O
gel	JJ	O
size	NN	O
fractionation	NN	O
.	.	O
The	DT	O
HIV	NNP	O
Env	NNP	O
gene	NN	O
was	VBD	O
inserted	VBN	O
into	IN	O
the	DT	O
pDCMVSIN-beta-gal	JJ	O
by	IN	O
digestion	NN	O
of	IN	O
SINBVEnv	NNP	O
with	IN	O
XbaI	NNP	O
and	CC	O
XhoI	NNP	O
,	,	O
purification	NN	O
using	VBG	O
GeneCleanII	NNP	O
of	IN	O
the	DT	O
Env-containing	NNP	O
fragment	NN	O
after	IN	O
agarose	JJ	O
gel	JJ	O
size	NN	O
fractionation	NN	O
,	,	O
and	CC	O
ligation	NN	O
.	.	O
The	DT	O
resulting	VBG	O
construct	NN	O
was	VBD	O
designated	VBN	O
pDSIN-Env	NN	O
,	,	O
and	CC	O
may	MD	O
be	VB	O
used	VBN	O
directly	RB	O
for	IN	O
in	IN	O
vivo	JJ	O
administration	NN	O
or	CC	O
formulated	VBN	O
using	VBG	O
any	DT	O
of	IN	O
the	DT	O
methods	NNS	O
described	VBD	O
herein	NN	O
.	.	O
BHK	NNP	O
and	CC	O
293	CD	O
cells	NNS	O
were	VBD	O
transfected	VBN	O
with	IN	O
recombinant	JJ	O
Sindbis	NNP	O
vector	NN	O
RNA	NNP	O
and	CC	O
DNA	NNP	O
,	,	O
respectively	RB	O
.	.	O
The	DT	O
supernatants	NNS	O
and	CC	O
cell	NN	O
lysates	NNS	O
were	VBD	O
tested	VBN	O
by	IN	O
capture	NN	O
ELISA	NNP	O
.	.	O
BHK	NNP	O
cells	NNS	O
were	VBD	O
transfected	VBN	O
by	IN	O
electroporation	NN	O
with	IN	O
recombinant	JJ	O
Sindbis	NNP	O
RNA	NNP	O
.	.	O
The	DT	O
expression	NN	O
of	IN	O
Env	NNP	O
(	(	O
in	IN	O
ng/ml	NN	O
)	)	O
is	VBZ	O
presented	VBN	O
in	IN	O
Table	JJ	O
23	CD	O
.	.	O
In	IN	O
the	DT	O
table	NN	O
,	,	O
the	DT	O
Sindbis	NNP	O
RNA	NNP	O
containing	VBG	O
synthetic	JJ	O
Env	NNP	O
expression	NN	O
cassettes	NNS	O
are	VBP	O
indicated	VBN	O
and	CC	O
βgal	JJ	O
represents	VBZ	O
a	DT	O
negative	JJ	O
control	NN	O
.	.	O
Supernatants	NNS	O
and	CC	O
lysates	NNS	O
were	VBD	O
collected	VBN	O
24	CD	O
h	JJ	O
post	NN	O
transfection	NN	O
.	.	O
293	CD	O
cells	NNS	O
were	VBD	O
transfected	VBN	O
using	VBG	O
LT-1	NNP	O
mediated	JJ	O
transfection	NN	O
(	(	O
PanVera	NNP	O
)	)	O
with	IN	O
recombinant	JJ	O
Sindbis	NNP	O
DNA	NNP	O
containing	VBG	O
synthetic	JJ	O
expression	NN	O
cassettes	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
and	CC	O
βgal	JJ	O
sequences	NNS	O
as	IN	O
a	DT	O
negative	JJ	O
control	NN	O
.	.	O
Supernatants	NNS	O
and	CC	O
lysates	NNS	O
were	VBD	O
collected	VBN	O
48	CD	O
h	JJ	O
post	NN	O
transfection	NN	O
.	.	O
The	DT	O
expression	NN	O
of	IN	O
Env	NNP	O
(	(	O
in	IN	O
ng/ml	NN	O
)	)	O
is	VBZ	O
presented	VBN	O
in	IN	O
Table	JJ	O
24	CD	O
.	.	O
The	DT	O
results	NNS	O
presented	VBD	O
in	IN	O
Tables	NNP	O
23	CD	O
and	CC	O
24	CD	O
demonstrated	VBD	O
that	IN	O
Env	NNP	O
proteins	NNS	O
can	MD	O
be	VB	O
efficiently	RB	O
expressed	VBN	O
from	IN	O
both	DT	O
DNA	NNP	O
and	CC	O
RNA-based	JJ	O
Sindbis	NNP	O
vector	NN	O
systems	NNS	O
using	VBG	O
the	DT	O
synthetic	JJ	O
Env	NNP	O
expression	NN	O
cassettes	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
.	.	O
Example	RB	O
14	CD	O
A	NNP	O
.	.	O
In	IN	O
vivo	JJ	O
Immunization	NN	O
with	IN	O
Gag-containing	NNP	O
DNA	NNP	O
and/or	VBZ	O
Sindbis	NNP	O
Particles	NNP	O
CB6F1	NNP	O
mice	NN	O
were	VBD	O
immunized	VBN	O
intramuscularly	RB	O
at	IN	O
0	CD	O
and	CC	O
4	CD	O
weeks	NNS	O
with	IN	O
plasmid	JJ	O
DNA	NNP	O
and/or	NN	O
Sindbis	NNP	O
vector	NN	O
RNA-containing	JJ	O
particles	NNS	O
each	DT	O
containing	VBG	O
GagMod.SF2	NNP	O
sequences	NNS	O
as	IN	O
indicated	VBN	O
in	IN	O
Table	JJ	O
25	CD	O
.	.	O
Animals	NNS	O
were	VBD	O
challenged	VBN	O
with	IN	O
recombinant	JJ	O
vaccinia	NN	O
expressing	VBG	O
SF2	NNP	O
Gag	NNP	O
at	IN	O
3	CD	O
weeks	NNS	O
post	RB	O
second	JJ	O
immunization	NN	O
(	(	O
at	IN	O
week	NN	O
7	CD	O
)	)	O
.	.	O
Spleens	NNS	O
were	VBD	O
removed	VBN	O
from	IN	O
the	DT	O
immunized	JJ	O
and	CC	O
challenged	VBD	O
animals	NNS	O
5	CD	O
days	NNS	O
later	RB	O
for	IN	O
a	DT	O
standard	JJ	O
51C	CD	O
release	NN	O
assay	NN	O
for	IN	O
CTL	NNP	O
activity	NN	O
.	.	O
Values	NNS	O
shown	VBN	O
in	IN	O
Table	JJ	O
25	CD	O
indicate	VBP	O
the	DT	O
results	NNS	O
from	IN	O
the	DT	O
spleens	NNS	O
of	IN	O
three	CD	O
mice	NNS	O
from	IN	O
each	DT	O
group	NN	O
.	.	O
The	DT	O
boxed	JJ	O
values	NNS	O
in	IN	O
Table	JJ	O
25	CD	O
indicate	NN	O
that	IN	O
all	DT	O
groups	NNS	O
of	IN	O
mice	NNS	O
receiving	VBG	O
immunizations	NNS	O
with	IN	O
pCMVKm2.GagMod.SF2	JJ	O
DNA	NNP	O
and/or	NN	O
SindbisGagMod.SF2	NNP	O
virus	NN	O
particles	NNS	O
either	CC	O
alone	RB	O
or	CC	O
in	IN	O
combinations	NNS	O
showed	VBD	O
antigen-specific	JJ	O
CTL	NNP	O
activity	NN	O
.	.	O
B	NNP	O
.	.	O
In	IN	O
Vivo	NNP	O
Immunization	NNP	O
with	IN	O
Env-Containing	NNP	O
DNA	NNP	O
and/or	VBZ	O
Sindbis	NNP	O
Particles	NNP	O
Balb/C	NNP	O
mice	NN	O
were	VBD	O
immunized	VBN	O
intramuscularly	RB	O
at	IN	O
0	CD	O
and	CC	O
4	CD	O
weeks	NNS	O
(	(	O
as	IN	O
shown	VBN	O
in	IN	O
the	DT	O
following	JJ	O
table	NN	O
)	)	O
with	IN	O
plasmid	NN	O
DNA	NNP	O
and/or	VBZ	O
Sindbis-virus	NNP	O
RNA-containing	NNP	O
particles	VBZ	O
each	DT	O
containing	VBG	O
gp120.modUS4	NN	O
sequences	NNS	O
.	.	O
Treatment	NNP	O
regimes	NNS	O
and	CC	O
antibody	NN	O
titers	NNS	O
are	VBP	O
shown	VBN	O
in	IN	O
Table	JJ	O
26	CD	O
.	.	O
Antibody	NN	O
titers	NNS	O
were	VBD	O
determined	VBN	O
by	IN	O
ELISA	NNP	O
using	VBG	O
gp120	JJ	O
SF2	NNP	O
protein	NN	O
to	TO	O
coat	VB	O
the	DT	O
plates	NNS	O
.	.	O
As	IN	O
can	MD	O
be	VB	O
seen	VBN	O
from	IN	O
the	DT	O
data	NNS	O
presented	VBN	O
above	IN	O
,	,	O
all	DT	O
of	IN	O
the	DT	O
mice	NN	O
generally	RB	O
demonstrated	VBN	O
substantial	JJ	O
immunological	JJ	O
responses	NNS	O
by	IN	O
bleed	NN	O
number	NN	O
2	CD	O
.	.	O
For	IN	O
Env	NNP	O
,	,	O
the	DT	O
best	JJS	O
results	NNS	O
were	VBD	O
obtained	VBN	O
using	VBG	O
either	CC	O
(	(	O
i	NN	O
)	)	O
50	CD	O
μg	NN	O
of	IN	O
gp120.modUS4	NN	O
DNA	NN	O
for	IN	O
the	DT	O
first	JJ	O
immunization	NN	O
followed	VBN	O
by	IN	O
a	DT	O
second	JJ	O
immunization	NN	O
using	VBG	O
50	CD	O
μg	NN	O
of	IN	O
gp120.modUS4	NN	O
DNA	NNP	O
,	,	O
or	CC	O
(	(	O
ii	NN	O
)	)	O
25	CD	O
μg	NN	O
of	IN	O
gp120.modUS4	NN	O
DNA	NN	O
for	IN	O
the	DT	O
first	JJ	O
immunization	NN	O
followed	VBN	O
by	IN	O
a	DT	O
second	JJ	O
immunization	NN	O
using	VBG	O
107	CD	O
pfus	NN	O
of	IN	O
Sindbis	NNP	O
.	.	O
The	DT	O
results	NNS	O
presented	VBN	O
above	JJ	O
demonstrate	NN	O
that	IN	O
the	DT	O
Env	NNP	O
and	CC	O
Gag	NNP	O
proteins	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
are	VBP	O
effective	JJ	O
to	TO	O
induce	VB	O
an	DT	O
immune	JJ	O
response	NN	O
using	VBG	O
Sindbis	NNP	O
vector	NN	O
systems	NNS	O
which	WDT	O
include	VBP	O
the	DT	O
synthetic	JJ	O
Env	NNP	O
(	(	O
e.g.	NN	O
,	,	O
gp120.modUS4	NN	O
)	)	O
or	CC	O
Gag	NNP	O
expression	NN	O
cassettes	NNS	O
.	.	O
Example	JJ	O
15	CD	O
Co-Transfection	NN	O
of	IN	O
Env	NNP	O
and	CC	O
Gag	NNP	O
as	IN	O
Monocistronic	NNP	O
and	CC	O
Bicistronic	NNP	O
Constructs	NNP	O
DNA	NNP	O
constructs	VBZ	O
encoding	VBG	O
(	(	O
i	NN	O
)	)	O
wild-type	NN	O
US4	NNP	O
and	CC	O
SF162	NNP	O
Env	NNP	O
polypeptides	NNS	O
,	,	O
(	(	O
ii	NN	O
)	)	O
synthetic	JJ	O
US4	NNP	O
and	CC	O
SF162	NNP	O
Env	NNP	O
polypeptides	NNS	O
(	(	O
gp160.modUS4	NN	O
,	,	O
gp160.modUS4.delV1/V2	NN	O
,	,	O
gp160.modSF162	NN	O
,	,	O
and	CC	O
gp120.modSF162.delV2	NN	O
)	)	O
,	,	O
and	CC	O
(	(	O
iii	NN	O
)	)	O
SF2-gag	NNP	O
polypeptide	NN	O
(	(	O
i.e.	FW	O
,	,	O
the	DT	O
Gag	NNP	O
coding	NN	O
sequences	NNS	O
obtained	VBN	O
from	IN	O
the	DT	O
SF2	NNP	O
variant	NN	O
or	CC	O
optimized	VBN	O
sequences	NNS	O
corresponding	VBG	O
to	TO	O
the	DT	O
gagSF2-gag.modSF2	NN	O
)	)	O
were	VBD	O
prepared	VBN	O
.	.	O
These	DT	O
monocistronic	JJ	O
constructs	NNS	O
were	VBD	O
co-transfected	JJ	O
into	IN	O
293T	CD	O
cells	NNS	O
in	IN	O
a	DT	O
transient	JJ	O
transfection	NN	O
protocol	NN	O
using	VBG	O
the	DT	O
following	JJ	O
combinations	NNS	O
:	:	O
gp160.modUS4	NN	O
;	:	O
gp160.modUS4	NN	O
and	CC	O
gag.modSF2	NN	O
;	:	O
gp160.modUS4.delV1/V2	NN	O
;	:	O
gp160.modUS4.delV1/V2	NN	O
and	CC	O
gag.modSF2	NN	O
;	:	O
gp160.modSF162	NN	O
and	CC	O
gag.modSF2	NN	O
;	:	O
gp120.modSF162.delV2	NN	O
and	CC	O
gag.modSF2	NN	O
;	:	O
and	CC	O
gag.modSF2	VB	O
alone	RB	O
.	.	O
Further	RB	O
several	JJ	O
bicistronic	JJ	O
constructs	NNS	O
were	VBD	O
made	VBN	O
where	WRB	O
the	DT	O
coding	NN	O
sequences	NNS	O
for	IN	O
Env	NNP	O
and	CC	O
Gag	NNP	O
were	VBD	O
under	IN	O
the	DT	O
control	NN	O
of	IN	O
a	DT	O
single	JJ	O
CMV	NNP	O
promoter	NN	O
and	CC	O
,	,	O
between	IN	O
the	DT	O
two	CD	O
coding	NN	O
sequences	NNS	O
,	,	O
an	DT	O
IRES	NNP	O
(	(	O
internal	JJ	O
ribosome	NN	O
entry	NN	O
site	NN	O
(	(	O
EMCV	NNP	O
TRES	NNP	O
)	)	O
;	:	O
Kozak	NNP	B
,	,	I
M.	NNP	I
,	,	I
Critical	NNP	I
Reviews	NNP	I
dn	NN	I
Biochemistry	NNP	I
and	CC	I
Molecular	NNP	I
Biology	NNP	I
27	CD	I
(	(	I
45	CD	I
)	)	I
:385-402	NN	I
,	,	I
1992	CD	I
;	:	O
Witherell	NNP	B
,	,	I
G.	NNP	I
W.	NNP	I
,	,	I
et	FW	I
al.	NN	I
,	,	I
Virology	NNP	I
214:660-663	CD	I
,	,	I
1995	CD	I
)	)	O
sequence	NN	O
was	VBD	O
introduced	VBN	O
after	IN	O
the	DT	O
Env	NNP	O
coding	NN	O
sequence	NN	O
and	CC	O
before	IN	O
the	DT	O
Gag	NNP	O
coding	NN	O
sequence	NN	O
.	.	O
Those	DT	O
constructs	NNS	O
were	VBD	O
as	IN	O
follows	VBZ	O
:	:	O
gp160.modUS4.gag.modSF2	NN	O
,	,	O
SEQ	NNP	O
ID	NNP	O
NO:73	NNP	O
(	(	O
FIG	NNP	O
.	.	O
61	CD	O
)	)	O
;	:	O
gp160.modUSF162.gag.modSF2	NN	O
,	,	O
SEQ	NNP	O
ID	NNP	O
NO:74	NNP	O
(	(	O
FIG	NNP	O
.	.	O
62	CD	O
)	)	O
;	:	O
gp160.modUS4.delV1/V2.gag.modSF2	NN	O
,	,	O
SEQ	NNP	O
ID	NNP	O
NO:75	NNP	O
(	(	O
FIG	NNP	O
.	.	O
63	CD	O
)	)	O
;	:	O
and	CC	O
gp160.modSF162.delV2.gag.modSF2	VB	O
,	,	O
SEQ	NNP	O
ID	NNP	O
NO:76	NNP	O
(	(	O
FIG	NNP	O
.	.	O
64	CD	O
)	)	O
.	.	O
Supernatants	NNS	O
from	IN	O
cell	NN	O
culture	NN	O
were	VBD	O
filtered	VBN	O
through	IN	O
0.45	CD	O
μm	JJ	O
filters	NNS	O
then	RB	O
ultracentrifuged	VBD	O
for	IN	O
2	CD	O
hours	NNS	O
at	IN	O
24,000	CD	O
rpm	NN	O
(	(	O
140,000×g	CD	O
)	)	O
in	IN	O
an	DT	O
SW28	NNP	O
rotor	NN	O
through	IN	O
a	DT	O
20	CD	O
%	NN	O
sucrose	JJ	O
cushion	NN	O
.	.	O
The	DT	O
pelleted	JJ	O
materials	NNS	O
were	VBD	O
suspended	VBN	O
and	CC	O
layered	VBN	O
on	IN	O
a	DT	O
20-60	JJ	O
%	NN	O
sucrose	JJ	O
gradient	NN	O
and	CC	O
spun	NN	O
for	IN	O
2	CD	O
hours	NNS	O
at	IN	O
40,000	CD	O
rpm	NN	O
(	(	O
285,000×g	CD	O
)	)	O
in	IN	O
an	DT	O
SW41Ti	NNP	O
rotor	NN	O
.	.	O
Gradients	NNS	O
were	VBD	O
fractionated	VBN	O
into	IN	O
1.0	CD	O
ml	NN	O
samples	NNS	O
.	.	O
A	DT	O
total	NN	O
of	IN	O
9-10	JJ	O
fractions	NNS	O
were	VBD	O
typically	RB	O
collected	VBN	O
from	IN	O
each	DT	O
DNA	NNP	O
transfection	NN	O
group	NN	O
.	.	O
The	DT	O
fractions	NNS	O
were	VBD	O
tested	VBN	O
for	IN	O
the	DT	O
presence	NN	O
of	IN	O
the	DT	O
Env	NNP	O
and	CC	O
Gag	NNP	O
proteins	NNS	O
(	(	O
across	IN	O
all	DT	O
fractions	NNS	O
)	)	O
.	.	O
These	DT	O
results	NNS	O
demonstrated	VBD	O
that	IN	O
the	DT	O
appropriate	JJ	O
proteins	NNS	O
were	VBD	O
expressed	VBN	O
in	IN	O
the	DT	O
transfected	JJ	O
cells	NNS	O
(	(	O
i.e.	FW	O
,	,	O
if	IN	O
an	DT	O
Env	NNP	O
coding	NN	O
sequence	NN	O
was	VBD	O
present	JJ	O
the	DT	O
corresponding	JJ	O
Env	NNP	O
protein	NN	O
was	VBD	O
detected	VBN	O
;	:	O
if	IN	O
a	DT	O
Gag	NNP	O
coding	VBG	O
sequence	NN	O
was	VBD	O
present	JJ	O
the	DT	O
corresponding	JJ	O
Gag	NNP	O
protein	NN	O
was	VBD	O
detected	VBN	O
)	)	O
.	.	O
Virus	NNP	O
like	IN	O
particles	NNS	O
(	(	O
VLPs	NNP	O
)	)	O
were	VBD	O
known	VBN	O
to	TO	O
be	VB	O
present	JJ	O
through	IN	O
a	DT	O
selected	VBN	O
range	NN	O
of	IN	O
sucrose	JJ	O
densities	NNS	O
.	.	O
Chimeric	NNP	O
virus	NN	O
like	IN	O
particles	NNS	O
(	(	O
VLPs	NNP	O
)	)	O
were	VBD	O
formed	VBN	O
using	VBG	O
all	PDT	O
the	DT	O
tested	JJ	O
combinations	NNS	O
of	IN	O
constructs	NNS	O
containing	VBG	O
both	DT	O
Env	NNP	O
and	CC	O
Gag	NNP	O
.	.	O
Significantly	RB	O
more	JJR	O
protein	NN	O
was	VBD	O
found	VBN	O
in	IN	O
the	DT	O
supernatant	NN	O
collected	VBN	O
from	IN	O
the	DT	O
cells	NNS	O
transfected	VBN	O
with	IN	O
“	NNP	O
gp160.modUS4.delV1/V2	NN	O
and	CC	O
gag.modSF2	NN	O
”	NN	O
than	IN	O
in	IN	O
all	PDT	O
the	DT	O
other	JJ	O
supernatants	NNS	O
.	.	O
Western	JJ	O
blot	NN	O
analysis	NN	O
was	VBD	O
also	RB	O
performed	VBN	O
on	IN	O
sucrose	JJ	O
gradient	JJ	O
fractions	NNS	O
from	IN	O
each	DT	O
transfection	NN	O
.	.	O
The	DT	O
results	NNS	O
show	VBP	O
that	IN	O
bicistronic	JJ	O
plasmids	NNS	O
gave	VBD	O
lower	JJR	O
amounts	NNS	O
of	IN	O
VLPs	NNP	O
than	IN	O
the	DT	O
amounts	NNS	O
obtained	VBN	O
using	VBG	O
co-transfection	NN	O
with	IN	O
monocistronic	JJ	O
plasmids	NNS	O
.	.	O
In	IN	O
order	NN	O
to	TO	O
verify	VB	O
the	DT	O
production	NN	O
of	IN	O
chimeric	JJ	O
VLPs	NNP	O
by	IN	O
these	DT	O
cell	NN	O
lines	NNS	O
the	DT	O
following	JJ	O
electron	NN	O
microscopic	NN	O
analysis	NN	O
was	VBD	O
carried	VBN	O
out	RP	O
.	.	O
293T	CD	O
cells	NNS	O
were	VBD	O
plated	VBN	O
at	IN	O
a	DT	O
density	NN	O
of	IN	O
60-70	JJ	O
%	NN	O
confluence	NN	O
in	IN	O
100	CD	O
mm	NN	O
dishes	NNS	O
on	IN	O
the	DT	O
day	NN	O
before	IN	O
transfection	NN	O
.	.	O
The	DT	O
cells	NNS	O
were	VBD	O
transfected	VBN	O
with	IN	O
10	CD	O
μg	NNS	O
of	IN	O
DNA	NN	O
in	IN	O
transfection	NN	O
reagent	NN	O
LT1	NNP	O
(	(	O
Panvera	NNP	O
Corporation	NNP	O
,	,	O
545	CD	O
Science	NNP	O
Dr.	NNP	O
,	,	O
Madison	NNP	O
,	,	O
Wis.	NNP	O
)	)	O
.	.	O
The	DT	O
cells	NNS	O
were	VBD	O
incubated	VBN	O
overnight	NN	O
in	IN	O
reduced	JJ	O
serum	NN	O
medium	NN	O
(	(	O
opti-MEM	JJ	O
,	,	O
Gibco-BRL	NNP	O
,	,	O
Gaithersburg	NNP	O
,	,	O
Md	NNP	O
.	.	O
)	)	O
.	.	O
The	DT	O
medium	NN	O
was	VBD	O
replaced	VBN	O
with	IN	O
10	CD	O
%	NN	O
fetal	JJ	O
calf	NN	O
serum	NN	O
,	,	O
2	CD	O
%	NN	O
glutamine	NN	O
in	IN	O
IMDM	NNP	O
in	IN	O
the	DT	O
morning	NN	O
of	IN	O
the	DT	O
next	JJ	O
day	NN	O
and	CC	O
the	DT	O
cells	NNS	O
were	VBD	O
incubated	VBN	O
for	IN	O
65	CD	O
hours	NNS	O
.	.	O
Supernatants	NNS	O
and	CC	O
lysates	NNS	O
were	VBD	O
collected	VBN	O
for	IN	O
analysis	NN	O
as	IN	O
described	VBN	O
above	IN	O
(	(	O
see	VB	O
Example	NNP	O
2	CD	O
)	)	O
.	.	O
The	DT	O
fixed	VBN	O
,	,	O
transfected	VBD	O
293T	CD	O
cells	NNS	O
and	CC	O
purified	VBD	O
ENV-GAG	NNP	O
VLPs	NNP	O
were	VBD	O
analyzed	VBN	O
by	IN	O
electron	NN	O
microscopy	NN	O
.	.	O
The	DT	O
cells	NNS	O
were	VBD	O
fixed	VBN	O
as	IN	O
follows	VBZ	O
.	.	O
Cell	NNP	O
monolayers	NNS	O
were	VBD	O
washed	VBN	O
twice	RB	O
with	IN	O
PBS	NNP	O
and	CC	O
fixed	VBN	O
with	IN	O
2	CD	O
%	NN	O
glutaraldehyde	NN	O
.	.	O
For	IN	O
purified	VBN	O
VLPs	NNP	O
,	,	O
gradient	NN	O
peak	NN	O
fractions	NNS	O
were	VBD	O
collected	VBN	O
and	CC	O
concentrated	VBN	O
by	IN	O
ultracentrifugation	NN	O
(	(	O
24,000	CD	O
rpm	NN	O
)	)	O
for	IN	O
2	CD	O
hours	NNS	O
.	.	O
Electron	NNP	O
microscopic	NN	O
analysis	NN	O
was	VBD	O
performed	VBN	O
by	IN	O
Prof.	NNP	O
T.	NNP	O
S.	NNP	O
Benedict	NNP	O
Yen	NNP	O
(	(	O
Veterans	NNP	O
Affairs	NNPS	O
,	,	O
Medical	NNP	O
Center	NNP	O
,	,	O
San	NNP	O
Francisco	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
.	.	O
Electron	NNP	O
microscopy	NN	O
was	VBD	O
carried	VBN	O
out	RP	O
using	VBG	O
a	DT	O
transmission	NN	O
electron	NN	O
microscope	NN	O
(	(	O
Zeiss	NNP	O
10c	CD	O
)	)	O
.	.	O
The	DT	O
cells	NNS	O
were	VBD	O
pre-stained	JJ	O
with	IN	O
osmium	NN	O
and	CC	O
stained	VBN	O
with	IN	O
uranium	JJ	O
acetate	NN	O
and	CC	O
lead	JJ	O
citrate	NN	O
.	.	O
Immunostaining	NN	O
was	VBD	O
performed	VBN	O
to	TO	O
visualize	VB	O
envelope	NN	O
on	IN	O
the	DT	O
VLP	NNP	O
.	.	O
The	DT	O
magnification	NN	O
was	VBD	O
100,000×	CD	O
.	.	O
FIGS	NNP	O
.	.	O
65A-65F	JJ	O
show	NN	O
micrographs	NN	O
of	IN	O
293T	CD	O
cells	NNS	O
transfected	VBN	O
with	IN	O
the	DT	O
following	JJ	O
constructs	NNS	O
:	:	O
FIG	NNP	O
.	.	O
65A	CD	O
,	,	O
gag.modSF2	NN	O
;	:	O
FIG	NNP	O
.	.	O
65B	CD	O
,	,	O
gp160.modUS4	NN	O
;	:	O
FIG	NNP	O
.	.	O
65C	CD	O
,	,	O
gp160.modUS4.delV1/V2.gag.modSF2	NN	O
(	(	O
bicistronic	JJ	O
Env	NNP	O
and	CC	O
Gag	NNP	O
)	)	O
;	:	O
FIGS	NNP	O
.	.	O
65D	CD	O
and	CC	O
65E	CD	O
,	,	O
gp160.modUS4.delV1/V2	NN	O
and	CC	O
gag.modSF2	NN	O
;	:	O
and	CC	O
FIG	NNP	O
.	.	O
65F	CD	O
,	,	O
gp120.modSF162.delV2	NN	O
and	CC	O
gag.modSF2	NN	O
.	.	O
In	IN	O
the	DT	O
figures	NNS	O
,	,	O
free	JJ	O
and	CC	O
budding	JJ	O
immature	NN	O
virus-like-particles	NNS	O
(	(	O
VLPs	NNP	O
)	)	O
of	IN	O
the	DT	O
expected	VBN	O
size	NN	O
(	(	O
approximately	RB	O
100	CD	O
nm	NNS	O
)	)	O
decorated	VBN	O
with	IN	O
the	DT	O
Env	NNP	O
protein	NN	O
were	VBD	O
seen	VBN	O
.	.	O
In	IN	O
sum	NN	O
,	,	O
gp160	NN	O
polypeptides	NNS	O
incorporate	VBP	O
into	IN	O
Gag	NNP	O
VLPs	NNP	O
when	WRB	O
constructs	NNS	O
were	VBD	O
co-transfected	JJ	O
into	IN	O
cells	NNS	O
.	.	O
The	DT	O
efficiency	NN	O
of	IN	O
incorporation	NN	O
is	VBZ	O
2-3	JJ	O
fold	NN	O
higher	JJR	O
when	WRB	O
constructs	NNS	O
encoding	VBG	O
V-deleted	JJ	O
Env	NNP	O
polypeptides	NNS	O
from	IN	O
high	JJ	O
synthetic	JJ	O
expression	NN	O
cassettes	NNS	O
are	VBP	O
used	VBN	O
.	.	O
Although	IN	O
preferred	JJ	O
embodiments	NNS	O
of	IN	O
the	DT	O
subject	JJ	O
invention	NN	O
have	VBP	O
been	VBN	O
described	VBN	O
in	IN	O
some	DT	O
detail	NN	O
,	,	O
it	PRP	O
is	VBZ	O
understood	JJ	O
that	IN	O
obvious	JJ	O
variations	NNS	O
can	MD	O
be	VB	O
made	VBN	O
without	IN	O
departing	VBG	O
from	IN	O
the	DT	O
spirit	NN	O
and	CC	O
the	DT	O
scope	NN	O
of	IN	O
the	DT	O
invention	NN	O
as	IN	O
defined	VBN	O
by	IN	O
the	DT	O
appended	JJ	O
claims	NNS	O
.	.	O
Claims	NNS	O
(	(	O
14	CD	O
)	)	O
Priority	NN	O
Applications	NNP	O
(	(	O
6	CD	O
)	)	O
Applications	NNPS	O
Claiming	NNP	O
Priority	NNP	O
(	(	O
2	CD	O
)	)	O
Related	VBN	O
Parent	NN	O
Applications	NNP	O
(	(	O
1	CD	O
)	)	O
Related	VBN	O
Child	NNP	O
Applications	NNP	O
(	(	O
1	CD	O
)	)	O
Publications	NNPS	O
(	(	O
2	CD	O
)	)	O
Family	RB	O
ID=26812261	NNP	O
Family	NNP	O
Applications	NNP	O
(	(	O
5	CD	O
)	)	O
Family	NNP	O
Applications	NNP	O
Before	NNP	O
(	(	O
3	CD	O
)	)	O
Family	NNP	O
Applications	NNP	O
After	IN	O
(	(	O
1	CD	O
)	)	O
Country	NN	O
Status	NNP	O
(	(	O
5	CD	O
)	)	O
Families	NNPS	O
Citing	VBG	O
this	DT	O
family	NN	O
(	(	O
99	CD	O
)	)	O
Citations	NNPS	O
(	(	O
86	CD	O
)	)	O
Family	RB	O
Cites	VBZ	O
Families	NNS	O
(	(	O
105	CD	O
)	)	O
Patent	NN	O
Citations	NNP	O
(	(	O
103	CD	O
)	)	O
Non-Patent	JJ	O
Citations	NNP	O
(	(	O
192	CD	O
)	)	O
Also	RB	O
Published	VBN	O
As	IN	O
Similar	JJ	O
Documents	NNP	O
Legal	NNP	O
Events	NNP	O
Year	NNP	O
of	IN	O
fee	JJ	O
payment	NN	O
:	:	O
4	CD	O
